<SEC-DOCUMENT>0001213900-24-093266.txt : 20241101
<SEC-HEADER>0001213900-24-093266.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101105928
ACCESSION NUMBER:		0001213900-24-093266
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		137
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NewGenIvf Group Ltd
		CENTRAL INDEX KEY:			0001981662
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281964
		FILM NUMBER:		241417742

	BUSINESS ADDRESS:	
		STREET 1:		13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
		CITY:			BANGKOK
		STATE:			W1
		ZIP:			0000
		BUSINESS PHONE:		852-2861-1666

	MAIL ADDRESS:	
		STREET 1:		1/F, PIER 2, CENTRAL
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASPAC I Mini Acquisition Corp.
		DATE OF NAME CHANGE:	20230614
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea0219447-f1a4_newgen.htm
<DESCRIPTION>AMENDMENT NO. 4 TO FORM F-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:24 UTC 2024 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nivf="http://www.newgenivf.com/20240630" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true">As filed with the
Securities and Exchange Commission on October 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt"><b>Registration No.
333-281964</b></span></p><div>

</div><p style="margin: 0"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
DC 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-42"><span style="font-size: 10pt"><b>Amendment
No. 4</b></span></ix:nonNumeric></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form
<span style="-sec-ix-hidden: hidden-fact-0">F-1</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-62"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEWGENIVF
GROUP LIMITED</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact
name of registrant as specified in its charter)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-76"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British Virgin Islands</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8090</b></span></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not Applicable</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State or other jurisdiction of<br/> incorporation or organization)</i></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary Standard Industrial<br/> Classification Code Number)</i></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer<br/> Identification Number)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wing
Fung Alfred Siu</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-119"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1/F,
Pier 2, Central</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-34089"><ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-34090">Hong
Kong</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-34091">999077</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel:
<ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-34092">+1 (212)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-34093">537-4406</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address,
including zip code, and telephone number,</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>including
area code, of registrant&#8217;s principal executive offices)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-143"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cogency
</b></span><b><span style="font-size: 10pt">Global Inc.</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-34094">122
East 42nd Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-34095">18th Floor</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-34096">New
York</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressStateOrProvince" id="ixv-34097">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-34098">10168</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-34099">(212)</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-34100">947-7200</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 10pt"><i>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b><i>Copies to:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Darrin M. Ocasio,
Esq.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Matthew Siracusa,
Esq.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Sichenzia Ross
Ference Carmel LLP</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>1185 Avenue of
the America, 31st Fl.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>New York, NY
10036</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Telephone: +1-212-930-9700</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Approximate
date of commencement of proposed sale to the public:</b> As soon as practicable after the effective date hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If any of the securities
being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check
the following box. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If this form is
a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Emerging growth
company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="ixv-246"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging
growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="ixv-254"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting
pursuant to said Section 8(a), may determine.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt; color: Red"><b>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt; color: Red">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%"><span style="font-size: 10pt; color: Red"><b>PRELIMINARY PROSPECTUS</b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt; color: Red"><b>SUBJECT TO COMPLETION</b></span></td>
    <td style="width: 33%; text-align: right"><span style="font-size: 10pt; color: Red"><b>DATED OCTOBER 31, 2024</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt; color: Red">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>139,425,259 Class
A Ordinary Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_001.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NewGenIvf Group
Limited</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
                                            prospectus relates to the resale by the selling shareholders identified in this prospectus
                                            (&#8220;Selling Shareholders&#8221;) of up to 139,425,259 Class A Ordinary Shares, no par
                                            value per share (&#8220;Ordinary Shares&#8221;), consisting of (i) 86,704,087 Ordinary Shares
                                            issuable upon the conversion of (x) the senior convertible note (the &#8220;Initial Note&#8221;)
                                            issued on August 12, 2024, (y) the senior convertible note (the &#8220;First Mandatory Additional
                                            Note&#8221;) issued on August 28, 2024 and (y) the Additional Notes (as defined below), (ii)
                                            22,085,003 Ordinary Shares issuable upon the conversion of the senior convertible notes (the
                                            &#8220;Exchange Notes&#8221;, and together with the Initial Note, the First Mandatory Additional
                                            Note and the Additional Notes, the &#8220;Notes&#8221;) exchanged on August 8, 2024, (iii)
                                            19,871,935 Ordinary Shares that are issuable upon the exercise of Series A warrants to purchase
                                            Ordinary Shares (the &#8220;Series A Warrants&#8221;), (iv) 180,722 Ordinary Shares that
                                            are issuable upon the exercise of Series B warrants to purchase Ordinary Shares (the &#8220;Series
                                            B Warrants&#8221;), (v) 3,253,012 Ordinary Shares that are issuable upon the exercise of
                                            Series C warrants to purchase Ordinary Shares (the &#8220;Exchange Warrants&#8221; and together
                                            with the Series A Warrants and the Series B Warrants, the &#8220;Warrants&#8221;) and (vi)
                                            7,330,500 Ordinary Shares. The Notes and the Warrants were all issued in private placements
                                            to certain Selling Shareholders, see &#8220;<i>Item 7. Recent Sales of Unregistered Securities</i>&#8221;&#160;on
                                            page II-1 of &#160;this prospectus.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
                                            Selling Shareholders are identified in the table commencing on page 85. No Ordinary Shares
                                            are being registered hereunder for sale by us. We will not receive any proceeds from the
                                            sale of the Ordinary Shares by the Selling Shareholders, but will receive proceeds from the
                                            exercise of the Warrants if the Warrants are exercised for cash, which proceeds will be used
                                            for working capital and other general corporate purposes. All net proceeds from the sale
                                            of the Ordinary Shares covered by this prospectus will go to the Selling Shareholders (see
                                            &#8220;<i>Use of Proceeds</i>&#8221;). The Selling Shareholders are offering their securities
                                            to further enhance liquidity in the public trading market for our equity securities in the
                                            United States. Unlike an initial public offering, any sale by the Selling Shareholders of
                                            the Ordinary Shares is not being underwritten by any investment bank. The Selling Shareholders
                                            may sell all or a portion of the Ordinary Shares from time to time in market transactions
                                            through any market on which our Ordinary Shares are then traded, in negotiated transactions
                                            or otherwise, and at prices and on terms that will be determined by the then prevailing market
                                            price or at negotiated prices directly or through a broker or brokers, who may act as agent
                                            or as principal or by a combination of such methods of sale (see &#8220;<i>Plan of Distribution</i>&#8221;).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
Ordinary Shares currently trade on The Nasdaq Global Market under the symbol &#8220;NIVF.&#8221; The last reported closing price of our
Ordinary Shares on October 30, 2024 was $0.837. The Company&#8217;s common stock may be delisted by Nasdaq on November 20, 2024 for failing
to comply with the minimum market value of listed securities set forth in Nasdaq Listing Rule 5450(b)(2)(A). The Company&#8217;s common
stock may also be delisted by Nasdaq on November 20, 2024 for failing to comply with the minimum market value of publicly held shares
set forth in Nasdaq Listing Rule 5450(b)(2)(C). See &#8220;Prospectus Summary &#8211; Nasdaq Deficiency&#8221; and &#8220;Risk Factors&#8221;
regarding this possibility of delisting.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are not a &#8220;controlled company&#8221; as defined under the Listing Rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;),
but we qualify as a &#8220;foreign private issuer,&#8221; as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or
the Securities Act, and are eligible for reduced public company reporting requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
Group Limited (&#8220;NewGenIvf,&#8221; &#8220;Company,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) is a British
Virgin Islands holding company with our operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary,
NewGenIvf Limited) and in Asia (Hong Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure,
investors are purchasing equity interests in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests
in our Cayman Islands and Asian operating subsidiaries. Substantially all of NewGenIvf&#8217;s operations and assets are based in Thailand,
Cambodia and Kyrgyzstan.&#160;As a result, its businesses and operations are subject to the changing economic conditions prevailing from
time to time in such countries.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>Investing
in our Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See &#8220;<i>Risk Factors</i>&#8221;
starting on page 20 to read about the factors you should consider before buying the Ordinary Shares.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>Neither
the Securities and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved
these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>The date of this
prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>TABLE OF CONTENTS</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 90%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_001"><span style="font-size: 10pt">About this Prospectus</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_002"><span style="font-size: 10pt">Glossary of Defined Terms</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_003"><span style="font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_004"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_005"><span style="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#s_001">Management</a></td>
    <td style="text-align: center">46</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#s_002">Related Party Transactions&#160;</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_006"><span style="font-size: 10pt">Listing Details</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_007"><span style="font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_008"><span style="font-size: 10pt">Dividend Policy</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#aa_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results
    of Operations</a></td>
    <td style="text-align: center">53</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="#aa_002">Business</a></p>


</td>
    <td style="text-align: center">70</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_009"><span style="font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_010"><span style="font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center">88</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_011"><span style="font-size: 10pt">Description of Share Capital</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_012"><span style="font-size: 10pt">Taxation</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_013"><span style="font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_014"><span style="font-size: 10pt">Experts</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_015"><span style="font-size: 10pt">Expenses</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_016"><span style="font-size: 10pt">Enforceability of Civil Liabilities</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#a_017"><span style="font-size: 10pt">Where You Can Find Additional Information</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><a href="#a_018"><span style="font-size: 10pt">Material Changes</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">100</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>You
should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. Neither we nor any of the Selling Shareholders have authorized anyone to provide you with different information.
Neither we nor any of the Selling Shareholders are making an offer of these securities in any jurisdiction where the offer is not permitted.
You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other
than the date of the applicable document. Since the date of this prospectus, our business, financial condition, results of operations
and prospects may have changed.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
investors outside of the United States: Neither we nor any of the Selling Shareholders have done anything that would permit this offering
or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United
States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of
this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
this prospectus, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to NewGenIvf Group Limited
and its wholly owned subsidiary, NewGenIvf Limited, a Cayman Islands company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
reporting currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus
to &#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports
generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy
or completeness of the information. Although we believe that these sources are reliable, we have not independently verified the information
contained in such publications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the United
States of America, or U.S. GAAP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
number of Ordinary Shares currently issued and outstanding was 10,149,386 as of September 4, 2024. No new shares are being issued by
the Company pursuant to this offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>ABOUT
THIS PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
prospectus describes the general manner in which the Selling Shareholders identified in this prospectus may offer from time to time up
to 139,425,259 Ordinary Shares. If necessary, the specific manner in which the Ordinary Shares may be offered and sold will be described
in a supplement to this prospectus, which supplement may also add, update or change any of the information contained in this prospectus.
To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement, you should rely
on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement
in another document having a later date&#8212;for example, any prospectus supplement&#8212;the statement in the document having the later
date modifies or supersedes the earlier statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>GLOSSARY
OF DEFINED TERMS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
this prospectus, unless otherwise indicated or the context otherwise requires, references to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;ASCA&#8221;
means A SPAC&#160;I Acquisition Corp., a British Virgin Islands business company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;A
SPAC&#160;I Mini Acquisition Corp.&#8221; means A SPAC&#160;I Mini Acquisition Corp., a British Virgin Islands business company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Business
Combination&#8221; means the transactions contemplated by the Merger Agreement, pursuant to which (i)&#160;ASCA reincorporated to the
British Virgin Islands by merging with and into the Company; and (ii)&#160;Merger Sub merged with and into Legacy NewGenIvf, resulting
in Legacy NewGenIvf being a wholly-owned subsidiary of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;BVI&#8221;
means British Virgin Islands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;BVI
Act&#8221; means BVI Business Companies Act (As Revised).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Class
A Ordinary Share&#8221; means Class A ordinary shares of the Company, no par value per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Class
B Ordinary Share&#8221; means (x) the Company&#8217;s Class B ordinary shares with no par value per share, and (y) any shares into which
such ordinary shares shall have been changed or any shares resulting from a reclassification of such ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Closing&#8221;
means the consummation of the Business Combination, which occurred on April 3, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Company&#8221;
means NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Legacy
NewGenIvf&#8221; means NewGenIvf Limited, a Cayman Islands exempted company, which became a wholly owned subsidiary of ASCA upon the
Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Merger
Agreement&#8221; means the Merger Agreement entered into on February 15, 2023, and as amended on June 12, 2023 and December 6, 2023,
between ASCA, A SPAC&#160;I Mini Acquisition Corp., Merger Sub, Legacy NewGenIvf, and certain shareholders of Legacy NewGenIvf, pursuant
to which the Reincorporation Merger and Acquisition Merger were consummated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Merger
Sub&#8221; means A SPAC&#160;I Mini Sub Acquisition Corp., a Cayman Islands exempted company and former wholly-owned subsidiary of A
SPAC&#160;I Mini Acquisition Corp.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Memorandum
and Articles of Association&#8221; means the Company&#8217;s Amended and Restated Memorandum and Articles of Association, as and restated
on September 23, 2024.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;NewGenIvf&#8221;
means NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination, unless the
context so requires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Ordinary
Shares&#8221; means the Class A Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Preferred
Shares&#8221; means preferred shares of the Company, no par value per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Reincorporation
Merger&#8221; means the first step of the Business Combination which occurred pursuant to the Merger Agreement, in which ASCA reincorporated
to the British Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the &#8220;Risk Factors&#8221; section and the financial statements and related notes appearing at the end of this prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Unless
the context otherwise requires, all references in this Prospectus Summary to &#8220;NewGenIvf,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
and &#8220;us&#8221; refer to Legacy NewGenIvf and its subsidiaries as they existed prior to the Closing if described in relation to
a date prior to April 3, 2024. Any references to &#8220;NewGenIvf,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; with
respect to the present time, a future time, or a date after April 3, 2024 refers to NewGenIvf, a British Virgin Islands company, and
its subsidiaries, whose existence continued after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are an assisted reproductive services (&#8220;ARS&#8221;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand
in 2014, we have established ourself as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and
Kyrgyzstan positions us to take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&#8220;CIC&#8221;),
from 2014 to 2022, there was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing
trend towards later maternal age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&#160;million in
2014 to 833.2&#160;million in 2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific
countries such as China, India, and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8
thousand in 2017 to 184.9 thousand in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">According
to CIC, the prevalence of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand,
India and China was about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%,
representing an annual growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%.
Infertility is increasingly gaining society&#8217;s attention as individuals are more openly discussing their struggles. Despite the
prevalence of infertility, access to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs
of treatment, and limited availability or capacity of fertility medical care are some of the main challenges in the fertility marketplace
in Asia-Pacific region. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have
children. We believe that we can help address some of these key challenges of Asia-Pacific fertility industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>History and Development of the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Prior
to the Business Combination, on April&#160;29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin
Islands business company, specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,
share purchase, recapitalization, reorganization or similar business combination with one or more target businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>The Business
Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
February&#160;15, 2023, ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221;
and the transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC&#160;I Mini Acquisition Corp., Merger
Sub, NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf.
Pursuant to the Merger Agreement, the Business Combination was effected in two steps: (i)&#160;ASCA was reincorporated to the British
Virgin Islands by merging with and into A SPAC&#160;I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;);
and (ii)&#160;Merger Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the
Company (such second step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination, together
with its subsidiaries is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221;
or &#8220;us,&#8221; unless the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
</div><div>
</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
June&#160;12, 2023, the parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;),
pursuant to which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the
&#8220;Loan&#8221;) to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA
to consummate a business combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees
and expenses, and other purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing
of the Acquisition Merger. In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan
from NewGenIvf, ASCA agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s
failure to deliver audited financial statements by no later than February&#160;28, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
December 6, 2023, the parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;)
which amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following
the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf
and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii)
provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary
Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible
assets immediately after the consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
April 3, 2024, the Business Combination was consummated with the Company as the surviving entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>NewGenIvf&#8217;s Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i)
in vitro fertilization (&#8220;IVF&#8221;) treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and
ancillary caring services. Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>IVF treatment service: </b>For the&#160;years ended December&#160;31,
    2023 and 2022, we generated approximately 78.3% and 47.4%, of its revenue from IVF treatments services. We primarily provide our
    clients with conventional IVF/intracytoplasmic sperm injection (&#8220;ICSI&#8221;) and embryo transfer services. As technology has
    progressively advanced, we have been able to, through technologies and facilities provided by MicroSort technology, help fulfill
    the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases. IVF treatment involves the performance
    of a series of medical treatment and procedures that are not separately distinct and only brings benefits to clients when embryo
    is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
    The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Surrogacy and ancillary caring services: </b>We also generate revenue
    from surrogacy services and related ancillary caring services in Kyrgyzstan. For the&#160;years ended December&#160;31, 2023 and
    2022, we generated approximately 21.7% and 52.6%, of our revenue from surrogacy and ancillary caring services. For surrogacy services,
    NewGenIvf conducts implantation of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides a &#8220;success
    guarantee&#8221; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this optional program,
    patients pay additional fees of approximately 40% of the original price and can have repeated attempts of IVF cycles, egg donation
    services and/or surrogacy services until the procedures are successful. The additional costs to NewGenIvf are generally limited and
    amount to approximately 30% of the original costs because NewGenIvf&#8217;s clinics, together with the patients, can choose suitable
    egg donors and surrogate mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary caring
    services including regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy
    and ancillary caring services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services provide
    infertile couples with an alternative method of having children.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the&#160;years ended December&#160;31, 2023 and 2022, NewGenIvf&#8217;s revenue was US$5,136,153 and US$5,944,190, and its net income
was US$108,418&#160;and US$135,847, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Market Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">According
to CIC, NewGenIvf&#8217;s core market for fertility services is substantial and growing rapidly, driven by, among other things, societal
and cultural shifts, such as people starting families later in life and other health-related challenges which could impact couples&#8217;
and individuals&#8217; ability to have children. In addition, NewGenIvf believes that continued overall de-stigmatization of infertility
will help drive better access to, and stronger demand for, fertility treatment services, thereby further enabling the expansion of NewGenIvf&#8217;s
addressable market. According to CIC, the market size of fertility treatments in Asia Pacific was increasing steadily and the potential
size of the Asia fertility market is expected to reach US$37.4&#160;billion by 2030. NewGenIvf believes its market opportunity is substantial
and is continuing to grow as a result of the rising demand for fertility services, the lack of adequate offerings in the market and the
increasing awareness of the challenges of infertility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Competitive Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that the following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific,
and have differentiated it from its competitors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Broad-range
ARS Provider Offering Comprehensive Fertility Treatment Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
almost a decade of experience in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf
has reinforced its long-standing position through expanding its service offerings and locations to address the evolving clients&#8217;
needs or requests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
comprehensive fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia)
and surrogacy services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services
but with a relatively low cost, as compared with the US market. According to CIC, the average cost per IVF cycle in the US is around
US$12,000 (excluding medication), which is 65% higher than that of Asia-Pacific market. Meanwhile, the average cost per IVF cycle by
NewGenIvf is around US$7,000 (excluding medication). Each of NewGenIvf&#8217;s clinics in Thailand, Cambodia, and Kyrgyzstan has its
own specialty, and together, NewGenIvf is able to provide more flexibility and options to its patients. For example, NewGenIvf&#8217;s
Thailand clinic focus on IVF and related ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The
clinic in Cambodia specializes in providing both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in
2019, which broadened NewGenIvf&#8217;s services by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan
to offer surrogacy services. As of December 31, 2023, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few
companies in Kyrgyzstan that is licensed to offer surrogacy services in Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
attributes its track record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing
it to meet patients&#8217; increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has extensive experience serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has
personnel speaking multiple languages, including nurses, facilitators, and translators, who are familiar with the health condition and
culture of Asia-Pacific patients from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit
from market growth driven by Asia-Pacific patients travelling to its clinics for treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Attractive Market
with Significant Demand and Fast Growth</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
operates in the ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential.
According to CIC, during the&#160;years ended December&#160;31, 2021 and 2022, the ARS market in Asia Pacific has experienced growth
underpinned by long-term demographic and social trends. These trends include a rising demand for fertility services, the lack of adequate
offerings in the market and the increasing awareness of the challenges of infertility, according to CIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">According
to CIC, the Asia Pacific ARS market is a large, multi-billion dollar industry growing at a strong pace of approximately 15% in 2022 as
increased awareness and acceptance of IVF and surrogacy services continue to drive demand. Additionally, according to CIC, the market
is underserved as a substantial percentage of patients in need of ARS treatments go untreated. The industry also remains constrained
in capacity, thereby creating challenges in providing access to ARS to the volume of patients in need. According to CIC, as of December&#160;31,
2022, there were more than 213&#160;million infertile couples in Asia Pacific. While there have been substantial increases in the use
of ARS, according to CIC, only approximately 1.47&#160;million ARS cycles, including IVF, and other fertility treatments, were performed
in Asia Pacific in 2022. This amounts to less than 1.1% of the infertile couples in Asia Pacific being treated and only 0.7% having a
child though ARS in 2022, indicating significant unmet demand for ARS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Asia-Pacific
fertility markets, in particular India and China, present a vast opportunity for ARS providers in the region. China&#8217;s ARS market
has been driven by an increasing rate of infertility, the implementation of the Three-Child Policy in May&#160;2021, a decreasing number
of couples at childbearing age and increasing affordability and awareness of ARS, according to CIC.&#160;China&#8217;s ARS market size
in 2021 and 2022 was US$2,105&#160;million and US$2,069&#160;million, respectively, and is expected to further grow to US$2.3&#160;billion
in 2023, according to CIC.&#160;India&#8217;s ARS market size increased from US$1.2&#160;billion in 2021 to US$1.5&#160;billion in 2022,
and is expected to grow further to US$1.6&#160;billion in 2023, according to CIC.&#160;NewGenIvf believes that its existing market presence
and reputation in Thailand, Cambodia, and Kyrgyzstan well positions it to capitalize on the fast-growing Asia-Pacific fertility market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">According
to CIC, the significant entry barriers in Asia-Pacific ARS industry are expected to continue to constrain supply in the industry. The
industry is heavily regulated and a significant number of stringent requirements must be satisfied in order to obtain relevant licenses
to conduct IVF, egg donation and surrogacy procedures in the relevant countries. NewGenIvf believes that such barriers to entry can help
it maintain its market position in Asia Pacific as the fertility market in the region continues to expand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Built
on years of experience, NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners
to approach NewGenIvf to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly
held in the PRC to approach potential business partners and establish new partnerships by entering into agency agreements with each agent.
NewGenIvf has become a significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each
agency agreement has a maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&#8217;s
services by word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment
fees upon the completion of client&#8217;s treatment. Normally, agents provide potential clients&#8217; contact information to the sales
team of NewGenIvf, who then approach potential clients and provide consultation on services. Overall, approximately 50% of NewGenIvf&#8217;s
patients are referrals from agents, among which approximately 80% are referrals from China and the remaining 20% from India, whereas
the remaining 50% of NewGenIvf&#8217;s patients are patients who contact NewGenIvf directly through its websites from social media promotions.
With its partnerships in various countries, NewGenIvf believes it is able to better benefit from the growing market opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Exclusively Licensed Technology for
Family Planning and Access to Mature Fertility Technologies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual
patient&#8217;s needs. These technologies include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>MicroSort Technology: </i>NewGenIvf holds an exclusive license granted
    by a division of the Genetics and IVF Institute, to use MicroSort technology in Thailand and Cambodia, which is a form of pre-conception
    gender selection technology for humans. MicroSort technology aims to separate male sperm cells based on which gender chromosome they
    contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same gender chromosome.
    The technology ultimately helps couples choose the gender of their future child by choosing semen samples that predominately contain
    sperm with the&#160;X chromosome for a female or Y chromosome for a male. Traditionally and naturally, gender selection occurs after
    conception, meaning after the eggs are fertilized. As a result, some fertilized eggs will go unused. However, with MicroSort technology,
    NewGenIvf is able to increase the ratio of male or female embryos, based on the patient&#8217;s preference. Eggs are more likely
    to be fertilized according to the preferences of the parents. Other improvements that MicroSort treatment could help achieve include
    prevention of certain gender-related hereditary diseases. As of December 31, 2023, NewGenIvf was one of the only seven exclusive
    license holders of MicroSort technology world-wide.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Screening (&#8220;PGS&#8221;)</i>: PGS is
    used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too
    few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid
    embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf
    by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Next-Generation Sequencing (&#8220;NGS&#8221;)</i>: NGS is a high-throughput
    technology for determining the sequence of deoxyribonucleic acid (&#8220;DNA&#8221;) or ribonucleic acid (&#8220;RNA&#8221;) to study
    genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by
    using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands
    of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and
    data output.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Diagnosis (&#8220;PGD&#8221;)</i>: Similar
    to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for
    individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic
    fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check
    the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help
    women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt
    to screen for healthy embryos ahead of time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Well Established Brand with Reliable
Reputation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
founders of NewGenIvf entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility
treatments. The founders of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia
and Kyrgyzstan. Since then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&#160;Kong,
India, Thailand, Australia and Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
benefits from the favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated
in one of the biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular
tourist attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue
to benefit from, the convenience of its locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has developed a relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical
facilities in Asia. Under this model, NewGenIvf&#8217;s medical facilities have established standardized operating procedures to select
the treatment process according to each patient&#8217;s profile. NewGenIvf&#8217;s medical and operational personnel are organized into
specialized teams according to the different stages of the treatment process and different patient profiles. When patients are initially
admitted or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf
believes is better suited after taking into account the patient&#8217;s diagnosis and preferences. NewGenIvf believes that this model
allows each team to improve its efficiency and arrange suitable physicians for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
physicians of NewGenIvf have also developed and employed an operating model that seeks to increase the effectiveness of physicians by
utilizing standardized workflows and operating procedures with teams of supporting nurses and medical assistants. This helps to increase
the number of IVF treatment cycles that physicians can perform while providing treatment customized based on patient conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
its established client service history, accumulated experience as well as its continuous upgrades and development of treatment models,
NewGenIvf believes that it will be able to better monetize its brands through its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Experienced
Management Team</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
NewGenIvf management team has considerable experience in the ARS market and the broader healthcare industry. A considerable number of
NewGenIvf&#8217;s management are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts
in their respective fields. NewGenIvf&#8217;s Chief Executive Officer, Mr.&#160;Alfred Siu, has more than 13&#160;years of experience
in the fertility service market. Dr.&#160;Wiphawee Luangtangvarodom had over 8&#160;years of experience as an obstetrician and gynecologist.
NewGenIvf&#8217;s two lab supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&#160;years of experience
in the embryologist field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf
is also led by other members of the professional management team, who are intimately involved in the operational and financial management
of NewGenIvf&#8217;s Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims
to become a leader in the Asia Pacific ARS market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
vision is to provide tailored ARS solutions to fulfil patients&#8217; dreams of becoming a parent. To realize this vision, NewGenIvf
plans to adopt the following strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Offer Broad
Fertility Services for Fertility Tourists across Asia Pacific</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to provide broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions.
According to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction
of the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&#160;To
address these needs, NewGenIvf plans to offer its customers a &#8220;hassle-free&#8221;, seamless and integrated ARS and hospitality
arrangement experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for
traveling patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup
services. NewGenIvf plans to enhance its customers&#8217; experience by entering into exclusive cooperation arrangements with local premium
hospitality providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Furthermore,
NewGenIvf expects the easing of COVID-19 travel restrictions to contribute to an increase in tourists seeking fertility services. According
to CIC, the COVID-19 pandemic led to a delay in many patients&#8217; plans for fertility treatments, with travel restrictions and border
closures impacting their ability to access care. On May&#160;5, 2023, the WHO Director-General Dr.&#160;Tedros Adhanom Ghebreyesus announced
that COVID-19 no longer constituted a public health emergency of international concern. The pent-up demand for these services is expected
to be released with the lifting of the travel restrictions, leading to a surge in patients seeking fertility treatment. NewGenIvf&#8217;s
believes that its strategy of offering a comprehensive approach to fertility treatments will help it capture a share of the growing market
for fertility tourism in Asia Pacific.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Continue to Invest in Laboratories
and Facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes laboratories and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf
currently operates two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its
existing laboratories. NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and
expansion, which it believes will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency,
scalability, and client experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to develop advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science
and experiments relating to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its
data on patient treatment protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment
protocols to increase ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions
to discover ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to
expand the services it provides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has accumulated experience in treating patients over 40&#160;years old with premature ovarian failure and patients who have had recurrent
ARS implementation failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the
follicles. NewGenIvf is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated
sperm analysers, time lapsed incubators, non-invasive preimplantation genetic testing (&#8220;PGT&#8221;) of cell-free DNA in spent media,
automated systems for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement
therapy to reconstruct oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to
increase the number of oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough
developments in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells
for creation of functional gametes, but these techniques are not yet ready for human clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also intends to develop clinically customised interior design concepts for its medical facilities, including improved service rooms,
consultation rooms, reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Increase Brand Awareness and Market
Share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to maintain and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient
numbers, NewGenIvf plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS
industry in Asia Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives,
and establishing its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile,
NewGenIvf intends to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental
health services, which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg
donation and surrogacy. These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive
strategy to expand its market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional
market share of the growingly ARS market in Asia-Pacific.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Expand Service Reach Through Acquisitions
and Partnerships</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Leveraging
its reputation and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through
strategic acquisitions and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only
allow NewGenIvf to diversify its client base, but also allow it to benefit from potential economies of scale and increasing efficiency
through consolidation. NewGenIvf could also leverage the acquired or acquiring company&#8217;s customer base, reputation and expertise
to further improve its offerings and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional
licenses and locally recognized brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through
partnerships with other IVF clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, NewGenIvf plans to explore expanding its client base by offering its fertility services as part of corporate benefit programs
in Asia. NewGenIvf believes that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly
in companies with a large number of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits,
NewGenIvf can increase its market reach, enhance its brand reputation, and drive client growth. NewGenIvf&#8217;s broad range of fertility
services, including IVF and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment
landscape, which could make them more attractive to potential employees. Additionally, by offering these services, companies can help
address the growing concern of delayed childbearing, which is becoming more common among women according to CIC.&#160;NewGenIvf plans
to collaborate with potential corporate clients to develop customized fertility benefit programs that cater to their specific needs,
and to provide comprehensive support and counselling throughout the process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Meanwhile,
NewGenIvf also intends to attract more clients by establishing its &#8220;home country gynecologist partnership program&#8221;. Under
the program, NewGenIvf may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements
to be spent overseas. Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf
partners with, in their home countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
had entered into a non-binding term sheet dated June 3, 2024 (the &#8220;Term Sheet&#8221;) with COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;)
for a proposed reverse merger (the &#8220;Proposed Transaction&#8221;). However, on September 21, 2024, COVIRIX withdrew from the Proposed
Transaction, as such the Proposed Transaction was terminated with no cost to the Company.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Business Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">With
a focus on providing fertility treatments to fulfil couples and individuals&#8217; dreams of raising children, NewGenIvf offers mainly
two services, namely: (i)&#160;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary
caring services. The following table sets forth NewGenIvf&#8217;s revenue by service offerings and as a percentage of total revenue for
the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">IVF Treatment Service</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">78.3</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,819,163</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">47.4</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Surrogacy
    and Ancillary Caring Services</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">21.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">3,125,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">52.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total
    Revenue</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>IVF Treatment Service</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
primarily provides its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort
technology, help fulfill the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">IVF
treatments that NewGenIvf provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor,
male factor, unexplained infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within
a laboratory environment. Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances
for success. Follicles are retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due
to the number of follicles retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular
fluid and combined with sperm and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment
designed to mimic the condition of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred
to the uterine cavity. According to CIC, the average clinical pregnancy success rates, using 5-day incubation, averaged approximately
64.6% (with no PGT) for IVF, with live birth rate at approximately 28.7%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
a long-standing IVF treatments provider in Asia-Pacific, NewGenIvf had completed over 4,000 cycles of IVF treatments from 2014 to 2023.
For the&#160;years ended December&#160;31, 2023 and 2022, the revenue from NewGenIvf&#8217;s IVF treatments was US$4,021,696 and US$2,819,163,
respectively, representing 78.3% and 47.4%&#160;of its total revenue in the corresponding periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">IVF Treatments Process</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
typical IVF treatment process mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment
process, NewGenIvf also provides support services such as nutrition guidance and psychological counselling. The flow chart below shows
the stages involved in a typical IVF treatment process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_002.jpg" style="height: 311px; width: 780px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">At
the pre-IVF treatment stage, clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological
and andrological diseases, if needed. At the initial consultation, a physician reviews the clients&#8217; detailed medical history to
collect more information relating to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which
may include, among other things, blood pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male
fertility test. The physician will then design treatment plans based on the client&#8217;s medical history and results of the tests.
If the client is satisfied with treatment plan and the test results are acceptable to the physician, the physician will prescribe medications
and start stimulation treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
first step of the cycle is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation,
clients are monitored on a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size,
an additional antagonist drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time.
After another few&#160;days of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17
mm, the final injection of a human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation
process and is for the maturation of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs
with a minor surgical procedure called Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner
collects the sperms for fertilizing the eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized
embryos are cultured in the laboratory for two to six&#160;days. Embryos that grow well are biopsied and tested by PGT to detect potential
genetic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
final step is to transfer the embryos into the uterus using a catheter. Within eight&#160;days after the embryo transfer, a blood test
can be conducted to detect whether the implantation was successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">MicroSort Technology</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">MicroSort
technology is a preconception process developed by the Genetics and IVF Institute, Inc. that aims to improve the chances that the baby
to be conceived will be of the desired gender and prevents certain gender-related hereditary diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Semen
samples usually contain equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&#160;X chromosome
(which will produce a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After
the washing, the sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm
cells are analyzed one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce.
The sperm containing the&#160;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing
the Y chromosome. The flow cytometer uses a special software to identify&#160;X&#160;and Y chromosome sperm based on their fluorescence
signature. The sperm carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting
in an enriched sperm sample ready for use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
holds an exclusive license granted by a division of the Genetics and IVF Institute, MicroSort International, to use the MicroSort technology
in Thailand and Cambodia. MicroSort licenses for NewGenIvf&#8217;s operation in Thailand and Cambodia are each provided under a lease
and service agreement. In April 2019, First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to
use MicroSort equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International
to use MicroSort equipment in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;). Pursuant to the Lease and Services
Agreements, First Fertility PGS and Phnom Penh Center each has the exclusive right to utilize the MicroSort equipment and to market and
sell MicroSort sperm sorting services in Thailand and Cambodia, respectively. MicroSort International is responsible for the maintenance
of MicroSort equipment and technical and engineering support. The term of each Lease and Service Agreements is initially from 2019 to
2024, which shall be automatically renewed for one year unless a written notice of at&#160;least 180 days prior to the intended termination
date is provided. The consideration under each of the Lease and Services Agreements is US$9,000 per month after six months from the effective
date of the agreements. MicroSort International was entitled to a down payment of US$15,000 per agreement and the aggregated amounts
received by it under the agreements was US$328,500. During the term of each lease and service agreement, MicroSort grants NewGenIvf the
exclusive right in that country to utilize the MicroSort equipment and market MicroSort services. The term of each lease and service
agreement is initially from 2019 to 2024, which shall be automatically renewed for one year unless a written notice at least 180&#160;days
prior to the intended termination date is provided. The flow chart below shows the process involved in MicroSort:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_003.jpg"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Preimplantation Genetic Screening</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">PGS
is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too
few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos
that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving
a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Next-Generation
Sequencing</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NGS
is a high-throughput technology for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated
with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional
Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with
NGS reduces time and cost associated with sequencing and increases the coverage quality and data output.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Preimplantation Genetic Diagnosis</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Similar
to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual
genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis,
where carrier status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes
for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy.
Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Surrogacy and Ancillary Caring
Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also generated revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of
embryos from biological parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including
regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring
services is recognized when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method
of having children. In general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg
donation and surrogacy, after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor
egg quality of aged female clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
compared to other countries, Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&#160;surrogacy
is legal and regulated, which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child
relationship can be requested before the child&#8217;s birth; and (ii)&#160;the costs of operation and surrogate mother is favourable,
given the cost of living in Kyrgyzstan is relatively low.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition to the regular surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate
the application of infants&#8217; passports and visas as supplemental services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the&#160;years ended December&#160;31, 2023 and 2022, the revenue from NewGenIvf&#8217;s surrogacy and ancillary caring services was
US$1,114,457 and US$3,125,027, respectively, representing 21.7% and 52.6% of its total revenue in the corresponding periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
flow chart below shows the stages involved in a typical surrogacy process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_004.jpg"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
Kyrgyzstan, NewGenIvf also provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services
include: (i)&#160;maternity caring service, and (ii)&#160;documentation service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Network of Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, NewGenIvf had one marketing and sales support office located in Hong&#160;Kong and three clinics located in Thailand,
in Cambodia, and in Kyrgyzstan, respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless
one-stop experience to its clients. Set out below is an illustration of the locations of NewGenIvf&#8217;s clinics and marketing and
sales office:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_005.jpg"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth the approximate aggregate average gross floor area (&#8220;<b>G.F.A.</b>&#8221;) of each of NewGenIvf&#8217;s
clinics that were under lease and actively used for client service as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">As
    of <br/> December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td style="font-style: italic; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-style: italic; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">(Square
    Feet)</span></td><td style="padding-bottom: 1.5pt; font-style: italic"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"><span style="font-size: 10pt">Thailand</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><span style="font-size: 10pt">First Fertility
    PGS Center Co., Ltd. <br/> (&#8220;<b>First Fertility PGS Center</b>&#8221;)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">14,750</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">First Fertility Phnom Penh
    Center <br/> (&#8220;<b>Phnom Penh Center</b>&#8221;)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">18,567</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">First Fertility Bishkek
    Limited Liability Company <br/> (&#8220;<b>First Fertility Bishkek</b>&#8221;)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,368</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-size: 10pt">Aggregate
    G.F.A</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">35,685</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
increase the scale of NewGenIvf&#8217;s operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for
its second clinic Erawan Consultation Clinic in May&#160;2023. Consisting of approximately 2,500 sq. ft., Erawan Consultation Clinic
is expected to open in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
</div><div>
</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Currently,
IVF treatments are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy
services are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&#8217;s clinics:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">IVF <br/> Treatments</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Surrogacy <br/>
    Services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">Thailand</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="padding-left: 0.125in; width: 68%; text-align: left"><span style="font-size: 10pt">First Fertility PGS Center</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#8730;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Phnom Penh Center</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">First Fertility Bishkek</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#215;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#8730;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#215;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth a breakdown of revenue from services performed at NewGenIvf&#8217;s medical centers for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">34,038</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">0.7</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Thailand</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,356,903</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">26.4</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">505,609</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">8.5</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">621,619</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">12.1</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">377,608</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Kyrgyzstan</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">3,123,593</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">60.8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5,060,973</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">85.1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(206,238,254)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total
    Revenue</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Thailand Clinic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, NewGenIvf had one clinic in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility
treatment solutions including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT,
hysteroscopy, sperm analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized into
specialized teams according to the different stages of the IVF treatment process and different patient profiles. When clients are admitted,
they are assigned to a team which NewGenIvf believes is better suited the clients after taking into account the clients&#8217; diagnosis
and preferences. Furthermore, NewGenIvf also provides related value-added services such as nutrition guidance, psychological counselling,
acupuncture, and translation interpreters to supplement the IVF treatment. NewGenIvf prides itself on providing quality and customized
treatment to its clients on a&#160;day-to-day basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, the clinic in Thailand had six nurses, 8 full time lab physicians and embryologists, 14 administrative staff, totaling
28 staff members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Cambodia Clinic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has one clinic, Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with one Cambodian physician, three embryologists, five
nurses and twelve other staff, and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates
under a license issued by Cambodia MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the
exclusive use of such license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">After
eight&#160;years of development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia.
According to CIC, it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its
establishment, Phnom Penh Center achieved more than 1,600 IVF treatment cycles as of December 31, 2023. As of December 31, 2023, Phnom
Penh Center&#8217;s IVF philosophy concentrates on three key points in the treatment process: the mother&#8217;s wellbeing, the technology
used to assist mothers deliver a strong and healthy baby and the medical science used to ensure every chance of success for women in
various age spectrums.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Clinic in Kyrgyzstan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
established First Fertility Bishkek in October&#160;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate
candidates at a relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained
the license to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities
licensed to offer surrogacy services in Kyrgyzstan as of December&#160;31, 2023, according to CIC.&#160;In addition, NewGenIvf also provide
related ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity
caring service, and (ii)&#160;documentation service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Physicians
at First Fertility Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery,
and postnatal care. First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos.
NewGenIvf hires local physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists
in Thailand. Some personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such
operations from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, First Fertility Bishkek had one full-time physician, one embryologist, two nurses, and ten other staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Professionals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Licensed Physicians</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, NewGenIvf contracted with five licensed physicians, among which one was based in Cambodia and the other four were
based in Thailand. Most of NewGenIvf&#8217;s physicians had over 10&#160;years of experience or above. The following table summarises
the number and types of such licensed physicians as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licensed physician</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Licenses
    and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Effective Period</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Mr.&#160;Keut Serey</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Decision on permission for beauty treatment operation</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">December&#160;14, 2022&#160;&#8211; December&#160;14, 2026</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">The Ministry of Health of Cambodia</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Dr Patsama Vichinsartvichai</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Medical Facility Operating License number 288006</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">August&#160;12, 2022&#160;&#8211; December&#160;31, 2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">The Ministry of Health of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Number 30920 Medical Practitioner License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2004&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">The Ministry of Health of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Number 26443/2556 Reproductive Medicine Diploma</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2013&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Certificate number obscured OB-Gyn License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">October&#160;13, 2010&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Dr Keatthisak Boonsimma</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Number 31801 Medical Practitioner License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2005&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Number 22624/2554 OB-Gyn License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2014&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Number 40962/2563 Reproductive Medicine Diploma</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2020&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; width: 20%"><span style="font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Licensed physician</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Licenses and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Effective Period</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: center"><span style="font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Dr Seree Teerapong</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 15231/2564 Reproductive Medicine License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2021&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 4576/2533 OB-Gyn License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;12, 1990&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 11544 (replacement) Medical Practitioner License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;12, 1984&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Dr Wiphawee Luangtangvarodom</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 38347/2562 OB-Gyn License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">August&#160;1, 2019&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 43217/2564 Reproductive Medicine License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2021&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Number 48510 Medical Practitioner License</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2014&#160;&#8211; Indefinite</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Agreements with Physicians</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
enters into independent physician agreements or employment contracts with its physicians. The terms and conditions and the format of
the agreements NewGenIvf enters into with each of its physicians vary, depending on the physician&#8217;s seniority and practise nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the&#160;years ended December&#160;31, 2023 and 2022, the majority of NewGenIvf&#8217;s clients were from China (including mainland China
and Hong Kong). The number of Thai and Cambodian local patients generally increased in 2022 and 2023 compared with earlier years due
to the impact of COVID-19 on international travel. NewGenIvf enters into a service agreement with each of its customers that outline,
among other things, the scope of services, service fees, payment terms and rights, responsibilities and obligations of each party. Customers
are not entitled to enjoy the relevant services until outstanding amounts have been settled pursuant to the relevant contract. Sales
to individual consumers did not vary significantly and none of the customers contribute more than 10% of NewGenIvf&#8217;s revenue for
the&#160;years ended December&#160;31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth a breakdown of NewGenIvf&#8217;s total customers by major countries (determined by the passports they provided
to NewGenIvf for registration) and as a percentage of the total customers for the periods indicated<sup>(1)</sup>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="30" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">First
    <br/> Fertility <br/> PGS <br/> Center</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Phnom
    <br/> Penh <br/> Center</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">First
    <br/> Fertility <br/> PGS <br/> Center</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Phnom
    <br/> Penh <br/> Center</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China<sup>(2)</sup></span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">34</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">87</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">121</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">42</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">66</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">117</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">183</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 10pt">72</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">India</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">16</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">16</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">16</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">16</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Thailand</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">103</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">103</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">36</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">25</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">28</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">11</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">9</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">31</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">40</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">184</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">103</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">287</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">147</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">254</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Customers of First Fertility Bishkek are the same customers of Phnom
    Penh Center.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Include customers from mainland China and Hong&#160;Kong.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Include customers from Philippines, Singapore, USA, Korea, Nigeria
    and UK.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition to significant customers using NewGenIvf&#8217;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf
also has customers who only use its relatively insignificant services, such as check-ups services, blood test services and other minor
services (the latter category of customers are referred to as &#8220;consultation customers&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Sales and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the&#160;years ended December&#160;31, 2023 and 2022, NewGenIvf promoted brand awareness through its sales teams and, in many cases,
through cooperating with third-party agencies and partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
sales teams have broad experience in fertility services and are responsible for identifying potential clients and managing the overall
sales process. NewGenIvf&#8217;s sales team primarily relies on social media marketing, word-of-mouth referrals, recognition of its brand,
printed advertisements and marketing events. NewGenIvf spends marketing expenses on placing advertisements through popular social media
platforms, maintaining the official website of NewGenIvf and sending information through its official accounts on social media platforms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Supply and Procurement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
procurement is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&#160;31,
2023 and 2022, one and four suppliers individually contributed more than 10% of the Group&#8217;s trade payable, in aggregate accounting
for 30.6% and 69.8% of the Group&#8217;s trade payables, respectively. For the year ended December&#160;31, 2023 and 2022, nil and two
vendors contributed more than 10% of total purchases of the Group, in aggregate accounting for nil and 55.3% of the Group&#8217;s total
purchases, respectively. NewGenIvf&#8217;s procurement team is experienced in selecting cost-effective supplies as well as selecting
reliable suppliers. NewGenIvf&#8217;s major suppliers are pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that it is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            value and comprehensiveness of the solutions;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">treatment
                                            that is effective and achieves desired outcomes;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">clients&#8217;
                                            experience, including dedicated patient education, clinical guidance and emotional support;
                                            and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">access
                                            to a network of high-quality fertility specialists.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
competes primarily with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably
robust and integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&#8217;s competitors may compete
in a variety of ways, including by providing better services, having established local connections, fulfilling evolving client needs,
as well as conducting brand promotions and other marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
NewGenIvf may introduce new ancillary services and other companies may introduce similar fertility services as NewGenIvf&#8217;s, NewGenIvf
may become subject to additional competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December 31, 2023, in addition to its clinics, NewGenIvf leased one property in Hong&#160;Kong with an aggregate square footage of
approximately 8,000 for its administration support offices. NewGenIvf also operates its medical facilities as described above in &#8220;&#8212;&#160;Network
of Facilities&#8221; above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>C. Organizational Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following is a list of our principal subsidiaries and consolidated affiliated entities as of the date of this prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 26%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid; width: 20%"><span style="font-size: 10pt"><b>Place of Formation</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1.5pt solid; width: 52%"><span style="font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Legacy NewGenIvf</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Cayman Islands</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Wholly-owned subsidiary</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">FFPGS (HK) Ltd</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Hong Kong</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Legacy NewGenIvf</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">First Fertility Bishkek LLC</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Legacy NewGenIvf</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">First Fertility PGS Center Limited</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Well Image Limited HK</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">First Fertility Phnom Penh Ltd</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Kingdom of Cambodia</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Legacy NewGenIvf</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Med Holdings Limited</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Well Image Limited HK</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Well Image Limited HK</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Hong Kong</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Indirect subsidiary, wholly owned by Legacy NewGenIvf</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>D. Property, Plants and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company leases the premises for its principal executive office located at 36/39-36/40, 13th Floor, PS Tower, Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district, Watthana District, Bangkok 10110, Thailand. This property contains approximately 14,750 square feet. The
Company leases one property in Hong&#160;Kong with an aggregate square footage of approximately 8,000 for its administration support
offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company also leases several premises to operate its clinics in various countries. In Kyrgyzstan, the Company operates the First Fertility
Bishkek Limited Liability Company, which premises have an aggregate area of 2,368 square feet. In Cambodia, the Company operates the
First Fertility Phnom Penh Center, which premises have an aggregate area of 18,567 square feet. In Thailand, the Company operates a clinic
named First Fertility PGS Center Co., Ltd., which premises have an aggregate area of 14,750 square feet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company also leases premises located in Thailand for its anticipated Erawan Consultation Clinic clinic, with an aggregate area of approximately
2,500 square feet. This property is used as the Company&#8217;s second clinic in Thailand, which is expected to open in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Nasdaq Deficiency</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
October 8, 2024, the Company received a deficiency letter (&#8220;Bid Price Deficiency Letter&#8221;) from the Listing Qualifications
Department (the &#8220;Staff&#8221;) of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price
requirement under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Price Rule&#8221;). The Bid Price Deficiency Letter stated that,
for the preceding 30 consecutive business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum closing bid price
of $1 per share pursuant to the Minimum Bid Price Rule. The Company has an initial compliance period of 180 calendar days, or until April
7, 2025 to regain compliance with the Minimum Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price
of the Company&#8217;s Class A Ordinary Shares is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the
Company written confirmation of compliance with this requirement, as applicable. If the Company does not regain compliance with the above
requirements by April 7, 2025, the Company will receive written notification that its securities are subject to delisting. The Company
may be eligible for additional time to regain compliance, which will require the Company to submit to Nasdaq written notice of its intent
to cure the deficiency ahead of April 7, 2025. The Company intends to monitor the minimum bid price of its Class A Ordinary Shares and
may, if appropriate, consider available options to regain compliance with the Nasdaq requirements.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
May 24, 2024, the Company received a deficiency letter (&#8220;MVLS Deficiency Letter&#8221;) from the Staff of Nasdaq notifying the
Company that, for the preceding 35 consecutive business days, the Class A Shares did not meet the minimum $50,000,000 Market Value
of Listed Securities requirement (&#8220;MVLS Requirement&#8221;) for continued listing on Nasdaq pursuant to Nasdaq Listing Rules
5450(b)(2)(A) (the &#8220;MVLS Requirement,&#8221; and the Company&#8217;s non-compliance with this requirement, the &#8220;MVLS
Deficiency&#8221;). In accordance with Nasdaq Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar
days, or until November 20, 2024 (the &#8220;Compliance Date&#8221;), to regain compliance with the MVLS Requirement. If, at any
time before the Compliance Date, the MVLS for the Class A Shares is at least $50,000,000 for a minimum of ten consecutive business
days, the Staff will provide the Company written confirmation of compliance with the MVLS Requirement. In the event the Company does
not regain compliance with the above requirement prior to the expiration of the compliance period, it will receive written
notification that its securities are subject to delisting.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 24, 2024, the Company
received a deficiency letter (&#8220;MVPHS Deficiency Letter&#8221;) from the Staff of Nasdaq notifying the Company that, for the preceding
35 consecutive business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum $15,000,000 Market Value of Publicly
Held Shares (&#8220;MVPHS&#8221;) requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C) (the &#8220;MVPHS
Requirement,&#8221; and the Company&#8217;s non-compliance with this requirement, the &#8220;MVPHS Deficiency&#8221;). In accordance
with Nasdaq Rule 5810(c)(3)(D), the Company has until the Compliance Date to regain compliance with the MVPHS Requirement. If, at any
time before the Compliance Date, the MVPHS for the Class A Shares is at least $15,000,000 for a minimum of ten consecutive business days,
the Staff will provide the Company written confirmation of compliance with the MVPHS Requirement. In the event the Company does not regain
compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification that its
securities are subject to delisting. Alternatively, the Company may apply to transfer the Company&#8217;s securities to The Nasdaq Capital
Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Capitalization and Indebtedness</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below is the Company&#8217;s capitalization and indebtedness as
of August 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">US$</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and Cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157,680</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">EQUITY AND LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,494</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,415,970</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(715,745</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total capitization</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(7,872,541</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Statements of indebtedness as of August 31,
2024</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">US$</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">Accounts payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,607,833</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Other payables, accruals and advance receipt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,217,195</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,373</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Amount with related companies/parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,996</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liabilities, operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Loan&#160;&#160;to New Gen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">560,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Customer deposit received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,219</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">486,705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,134,796</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liabilities, operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,096</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Lease liabilities, finance lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453,861</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Convertible Promissory Note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,930,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Discount on convertible note</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,497,957</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Indebtedness</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,632,753</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<b>Dilution</b>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following information is presented as of August 31, 2024:<span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Existing shareholder</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31/8/2024</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Total comprehensive income attributable to the shareholders of the company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(247,106</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Earning per share - diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic and diluted weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,149,386</td><td style="text-align: left">&#160;</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Implications
of being a &#8220;Foreign Private Issuer&#8221;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to &#8220;foreign private issuers,&#8221;
and under those requirements, we file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements
that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain
respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue
quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies or individual executive
compensation information that is as detailed as that required of U.S. domestic reporting companies. We also have four months after the
end of each fiscal year to file our annual report with the SEC and are not required to file current reports as frequently or promptly
as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt from the requirements to report transactions
in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign
private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition,
as a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise
required under the rules of Nasdaq for domestic U.S. issuers and are not required to be compliant with all Nasdaq rules as of the date
of our initial listing on Nasdaq as would domestic U.S. issuers. These exemptions and leniencies will reduce the frequency and scope
of information and protections available to you in comparison to those applicable to a U.S. domestic reporting company. We intend to
take advantage of the exemptions available to us as a foreign private issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Summary of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Investing
in our Ordinary Shares involves significant risks. You should carefully consider all of the information in this prospectus before making
an investment in our shares. Below please find a summary of the principal risks we face, organized under relevant headings. These risks
are discussed more fully in the section titled &#8220;<i>Risk Factors</i>&#8221; and in Part I, Item 3, D. Risk Factors in our most recent
Annual Report on Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 6pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks
                                            Related to NewGenIvf&#8217;s Business and Industry</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to continue
    operating as a going concern.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fertility market in
    which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations
    could be materially and adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf has a limited
    operating history with its current platform of solutions, which makes it difficult to predict its future prospects, financial performance
    and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s marketing
    efforts depend significantly on its ability to receive positive references from its existing clients.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If NewGenIvf is unable
    to attract new clients, its business, financial condition and results of operations would be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s business
    depends on its ability to maintain its existing client demographics. Any failure to do so would harm its business, financial condition
    and results of operations.</span></td></tr>
  </table><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to offer high-quality support, its reputation could
    suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s failure to effectively develop and expand its marketing
    and sales capabilities could harm its ability to increase its client base and achieve broader market acceptance of solutions NewGenIvf
    provides.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may experience net losses and may not sustain profitability
    in the future.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s future revenue may not grow at the rates it historically
    has, or at all.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s quarterly and annual results may fluctuate significantly
    and may not fully reflect the underlying performance of NewGenIvf&#8217;s business.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If the estimates and assumptions NewGenIvf uses to determine the size
    of the target markets for its services are inaccurate, its future growth rate may be impacted and its business would be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may not be able to successfully manage its growth, and if
    NewGenIvf is not able to grow efficiently, its business, financial condition and results of operations could be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf&#8217;s new solutions and services are not adopted by
    its clients, or if it fails to innovate and develop new offerings that are adopted by its clients, its revenue and results of operations
    may be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to adapt and respond effectively to the changing
    medical landscape, changing regulations, changing client needs, requirements or preferences, its offerings may become less competitive.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to maintain and enhance its brand, its ability to
    expand its client base will be impaired and its business, financial condition and results of operations may suffer.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf fails to retain and motivate members of its management
    team or other key employees, or fails to attract additional qualified personnel to support its operations, its business and future
    growth prospects could be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To successfully market and sell its services and products in Asia-Pacific
    markets, NewGenIvf must address many international business risks with which NewGenIvf has limited experience.</span></td></tr>
</table>

<p style="margin: 0">&#160;&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Ethical, legal and social concerns related to the use of assisted reproductive
    technology could reduce demand for the fertility services provided by the medical facilities in NewGenIvf&#8217;s network, and thus
    may adversely affect the business, financial conditions and results of operations of the medical facilities in its network.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf is reliant on revenue from international clients.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fluctuations in exchange rates could have a material and adverse effect
    on NewGenIvf&#8217;s results of operations and the value of your investment.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Governmental control of currency conversion may limit NewGenIvf&#8217;s
    ability to utilize NewGenIvf&#8217;s net revenue effectively and affect the value of your investment.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Substantially all of NewGenIvf&#8217;s assets and operations are located
    in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal and regulatory uncertainties in such countries.</span></td>
    </tr>
</table><p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Failure to comply with the terms of future financing arrangements could
    result in default, which could have an adverse effect on NewGenIvf&#8217;s cash flow and liquidity.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf requires a significant amount of capital to fund its operations
    and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may
    be materially and adversely affected.</span></td>
    </tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The defects in certain leased property interests and failure to register
    certain lease agreements may materially and adversely affect NewGenIvf&#8217;s business, financial condition, results of operations,
    and prospects. </span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf currently has no insurance coverage for its operations.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may not be successful in adapting to technological developments,
    which may affect its business and results of operations.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If its computer systems, or those of its providers, specialty pharmacies
    or other downstream vendors lag, fail or suffer security breaches, NewGenIvf may incur a material disruption of its services, which
    could materially impact its business and the results of operations.</span></td>
    </tr>

<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may not be able to comply with the filing deadlines for reports
    that we file pursuant to the Exchange Act,, and our failure to timely file such reports may have material adverse consequences on
    our business.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are unable to continue to meet the listing requirements of Nasdaq,
    our Class A Ordinary Shares will be delisted</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to NewGenIvf&#8217;s
Relationships with Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s business depends on its ability to maintain its network
    of high-quality fertility specialists and other healthcare providers. If NewGenIvf is unable to do so, its future growth would be
    limited and its business, financial condition and results of operations would be harmed.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The medical facilities and professionals in NewGenIvf&#8217;s network
    could become the subject of litigation, allegations and other claims, and NewGenIvf is not insured against these liabilities.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The assisted reproductive medical facilities in NewGenIvf&#8217;s network
    have limited control over the quality of the pharmaceuticals, medical equipment, medical consumables and other supplies used in its
    operations, and cannot guarantee that the products in use are not defective or counterfeit. NewGenIvf also has no control over independent
    sub-contractors and cannot guarantee the services thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf loses its relationship with one or more key pharmaceutical
    manufacturers, its business and results of operations could be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf has engaged in transactions with related parties, and such
    transactions present potential conflicts of interest that could have an adverse effect on its business and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf may be subject to claims and allegations relating to intellectual
    property and other causes.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Certain
                                    data and information in this prospectus relied on by NewGenIvf were obtained from third-party data
                                    and polls. These metrics were not independently verified by NewGenIvf and may not be accurate.</span></p>
</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf operates in a highly regulated industry and must comply with
    a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf&#8217;s
    business may have a material and adverse impact on NewGenIvf&#8217;s business, financial condition, and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in NewGenIvf&#8217;s effective tax rate or tax liability may
    have an adverse effect on its results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s reported financial results may be adversely affected
    by changes in accounting principles generally accepted in relevant jurisdictions.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s reported financial results may be adversely affected
    by changes in accounting principles generally accepted in relevant jurisdictions.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If NewGenIvf&#8217;s estimates or judgments relating to its critical
    accounting policies prove to be incorrect, its results of operations could be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">NewGenIvf
                                    is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance
                                    with such laws can subject it to criminal or civil liability and harm its business, financial condition
                                    and results of operations.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 3pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>THE OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
prospectus relates to the resale by the Selling Shareholders identified in this prospectus of up to 139,425,259 Ordinary Shares. All
of the Ordinary Shares, when sold, will be sold by these Selling Shareholders. The Selling Shareholders may sell their Ordinary Shares
from time to time at prevailing market prices. We will not receive any proceeds from the sale of the Ordinary Shares by the Selling Shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 35%"><span style="font-size: 10pt">Ordinary Shares currently issued and outstanding </span></td>
    <td style="width: 2%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 63%; text-align: justify"><span style="font-size: 10pt">10,149,386 Class A Ordinary Shares </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Ordinary Shares offered by the Selling Shareholders </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Up
                                    to 139,425,259 Class A Ordinary Shares, which includes (i) 108,789,090 shares underlying the Notes
                                    (as defined below) and (ii) 23,305,669 shares underlying the Warrants (as defined below).</span></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>Ordinary Shares after this offering</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">149,574,645 Class A Ordinary Shares</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Use of proceeds </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We will not receive any proceeds from the sale of the Ordinary Shares
    by the Selling Shareholders, but will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash,
    which proceeds will be used for working capital and other general corporate purposes. All net proceeds from the sale of the Ordinary
    Shares covered by this prospectus will go to the Selling Shareholders (see &#8220;<i>Use of Proceeds</i>&#8221;). </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Risk factors</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">You should read the &#8220;<i>Risk Factors</i>&#8221; section starting
    on page 20 of this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Nasdaq symbol</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#8220;NIVF&#8221; (Class A Ordinary Shares); &#8220;NIVFW&#8221; (Warrants to purchase Class A
    Ordinary Shares).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white">The
number of Class A Ordinary Shares issued and outstanding is </span><span style="font-size: 10pt">10,149,386 <span style="background-color: white">as
of September 4, 2024. </span>No new Class A Ordinary Shares will be issued by us under this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>RISK
FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Investing
in our Class A Ordinary Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors
described under the caption &#8220;<i>Risk Factors</i>&#8221; in any applicable prospectus supplement and any risk factors set forth
in our other filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended,
or the Exchange Act, before making a decision about investing in our Ordinary Shares. The risks and uncertainties we have described are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
affect our operations. If any risks actually occur, our business, financial condition and results of operations may be materially and
adversely affected. In such an event, the trading price of our Ordinary Shares could decline and you could lose part or all of your investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Additionally,
we are also subject to the following risk factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Risks Related
to NewGenIvf&#8217;s Business and Industry</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may not
be able to continue operating as a going concern.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
of December&#160;31, 2023, the Company had bank balance of $54,104 and may have challenge to settle its obligations when payment become
due. The Company is always closely monitoring the market opportunities and is currently in the process of exercising various fundraising
projects with various potential investors to improve the Company&#8217;s cash flow position for its operation and short-term payables.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">One
fundraising project was completed on April 3, 2024. As of April 4, 2024, the Company settled $2 million to any payment with respect to
accounts payable, but not, directly or indirectly, for (i) except for expenses relating to the Business Combination, the satisfaction
of any indebtedness of the Company or any of its Subsidiaries, (ii) the redemption or repurchase of any securities of the Company or
any of its Subsidiaries, or (iii) the settlement of any outstanding litigation as at December 31, 2023. The Company secured funding subsequent
to year-end with total of $2 million, and that the Company received $2 million funding to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company can make no assurance that required financings will be available for the amounts needed, or on terms commercially acceptable
to the Company, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial
and liquidity shortfall, there would likely be a material adverse effect on the Company and its financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
consolidated financial statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate.&#160;
If the going concern basis was not appropriate for these consolidated financial statements, then adjustments would be necessary in the
carrying value of the assets and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments
could be material.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The fertility
market in which NewGenIvf participates is competitive, and if NewGenIvf does not continue to compete effectively, its results of operations
could be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
market for NewGenIvf&#8217;s solutions is competitive and is likely to attract increased competition, which could make it hard for it
to succeed. NewGenIvf faces significant competition from other fertility companies and other players in the fertility market. Some of
NewGenIvf&#8217;s competitors are more established, have a longer operating history and a larger client base, benefit from greater brand
recognition and have substantially greater financial, technical and marketing resources than NewGenIvf does. NewGenIvf&#8217;s competitors
may compete with NewGenIvf in a variety of ways, including seeking to develop or integrating solutions and services that may become more
efficient or appealing to NewGenIvf&#8217;s existing and potential clients, achieving superior clinical outcomes, having access to a
network of more high-quality fertility specialists, establishing more comprehensive data reporting and sharing systems, conducting brand
promotions and other marketing activities, and making investments in and acquisitions of NewGenIvf&#8217;s business partners. While NewGenIvf
believes that one of its key competitive advantages is its ability to provide a broad range of services, and NewGenIvf does not believe
any competitors have developed a similar broad range services in Asia Pacific at this time, current or future competitors may be successful
in doing so in the future. If current or future competitors are successful at developing a similar broad range of services, NewGenIvf&#8217;s
financial performance may be negatively impacted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, NewGenIvf believes that there is growing awareness of the demand for fertility services. As the fertility services field gains
more attention, more competitors may be drawn into the market. NewGenIvf also could be adversely affected if NewGenIvf fails to identify
or effectively respond to changes in market dynamics. As a result of any of these factors, NewGenIvf may not be able to continue to compete
successfully against its current or future competitors, and this competition could result in the decrease in its clients base and market
share and the failure of its platform to continue to maintain market acceptance, which would materially and adversely affect its business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
has a limited operating history with its current platform of solutions, which makes it difficult to predict its future prospects, financial
performance and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
predecessor entity of the Company prior to the Business Combination in April of 2024, NewGenIvf Limited, a Cayman Islands exempted company,
was established in 2019, and although it launched its fertility services in 2014, has a limited operating history. As a result of its
limited operating history with its current platform of solutions, as well as a limited amount of time serving a majority of its client
base, its ability to accurately forecast its future results of operations, key operating data, net revenue, cash flows, and operating
margins is limited and subject to a number of uncertainties, including its ability to plan for and model future growth. NewGenIvf&#8217;s
historical revenue growth should not be considered indicative of its future performance. Further, in future periods, its revenue growth
could slow or decline for a number of reasons, including risks, challenges and uncertainties that NewGenIvf has encountered and may continue
to encounter that are frequently experienced by companies at an early stage, slowing demand for its solutions and fertility services
in general, changes in utilization trends by its clients, general economic slowdown, an increase in unemployment, an increase in competition,
changes to health care trends and regulations, changes to science relating to the fertility market, a decrease in the growth of the fertility
market, or its failure, for any reason, to continue to take advantage of growth opportunities. If NewGenIvf&#8217;s assumptions regarding
these risks and uncertainties and its future revenue growth are incorrect or change, or if it does not address these risks successfully,
its operating and financial results could differ materially from its expectations, and its business could suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
marketing efforts depend significantly on its ability to receive positive references from its existing clients.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
marketing efforts depend significantly on its ability to call on its current clients to provide positive references to new, potential
clients. Given its limited number of long-term clients, the loss or dissatisfaction of any client could substantially harm its brand
and reputation, inhibit the market adoption of its offering and impair its ability to attract new clients and maintain existing clients.
Any of these consequences could have an adverse effect on its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>As a public
reporting company, we are subject to filing deadlines for reports that we file pursuant to the Exchange Act, and our failure to timely
file such reports may have material adverse consequences on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In
the past, we have not been able to, and may continue to be unable to produce timely financial statements, and file these financial statements
as part of a periodic report in a timely manner with the SEC. For example, we failed to timely file with the SEC the requisite Form 20-F
for the year ended December 31, 2023. Consequently, we were not compliant with the periodic reporting requirements under the Exchange
Act at such time. We cannot guarantee that in the future our reporting will always be timely. Our failure to timely file future periodic
reports with the SEC could subject us to enforcement action by the SEC and shareholder lawsuits and could eventually result in the delisting
of our Class A Ordinary Shares from Nasdaq, regulatory sanctions from the SEC, and/or the breach of covenants in our credit facilities
or of any preferred equity or debt securities we may issue in the future, any of which could have a material adverse impact on our operations
and your investment in our Class A Ordinary Shares, and our ability to register with the SEC public offerings of our securities for our
benefit or the benefit of our security holders. Additionally, our failure to file our past periodic reports and future periodic reports
has resulted in and could result in investors not receiving adequate information regarding us with which to make investment decisions.
As a result, investors may not have access to current or timely financial information about our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If we are
unable to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">On
October 8, 2024, the Company received a deficiency letter (&#8220;Bid Price Deficiency Letter&#8221;) from the Listing Qualifications
Department (the &#8220;Staff&#8221;) of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price
requirement under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Price Rule&#8221;). The Bid Price Deficiency Letter stated that,
for the preceding 30 consecutive business days, the Company&#8217;s Class A Ordinary Shares did not meet the minimum closing bid price
of $1 per share pursuant to the Minimum Bid Price Rule. The Company has an initial compliance period of 180 calendar days, or until April
7, 2025 to regain compliance with the Minimum Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price
of the Company&#8217;s Class A Ordinary Shares is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the
Company written confirmation of compliance with this requirement, as applicable. If the Company does not regain compliance with the above
requirements by April 7, 2025, the Company will receive written notification that its securities are subject to delisting. The Company
may be eligible for additional time to regain compliance, which will require the Company to submit to Nasdaq written notice of its intent
to cure the deficiency ahead of April 7, 2025. The Company intends to monitor the minimum bid price of its Class A Ordinary Shares and
may, if appropriate, consider available options to regain compliance with the Nasdaq requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On May 24, 2024, the Company
received a MVLS Deficiency Letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of Nasdaq notifying the Company
that, for the preceding 35 consecutive business days, the Class A Shares did not meet the minimum MVLS Requirement for continued listing
on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A). In accordance with Nasdaq Rule 5810(c)(3)(C), the Company has been provided
an initial period of 180 calendar days, or until November 20, 2024, the Compliance Date, to regain compliance with the MVLS Requirement.
If, at any time before the Compliance Date, the MVLS for the Class A Shares is at least $50,000,000 for a minimum of ten consecutive
business days, the Staff will provide the Company written confirmation of compliance with the MVLS Requirement. In the event the Company
does not regain compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification
that its securities are subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">On
                                            May 24, 2024, the Company received a MVPHS Deficiency Letter from the Staff of Nasdaq notifying
                                            the Company that, for the preceding 35 consecutive business days, the Company&#8217;s Class
                                            A Ordinary Shares did not meet the minimum $15,000,000 MVPHS Requirement for continued listing
                                            on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C) . In accordance with Nasdaq Rule
                                            5810(c)(3)(D), the Company has until the Compliance Date to regain compliance with the MVPHS
                                            Requirement. If, at any time before the Compliance Date, the MVPHS for the Class A Shares
                                            is at least $15,000,000 for a minimum of ten consecutive business days, the Staff will provide
                                            the Company written confirmation of compliance with the MVPHS Requirement. In the event the
                                            Company does not regain compliance with the above requirement prior to the expiration of
                                            the compliance period, it will receive written notification that its securities are subject
                                            to delisting. Alternatively, the Company may apply to transfer the Company&#8217;s securities
                                            to The Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">If
we are unable to achieve and maintain compliance with such listing standards or other Nasdaq listing requirements in the future, our
Class A Ordinary Shares could be delisted from Nasdaq. A delisting of our Class A Ordinary Shares and our inability to list on another
national securities market could negatively impact us by: (i) reducing the liquidity and market price of our Class A Ordinary Shares;
(ii) reducing the number of investors willing to hold or acquire our Class A Ordinary Shares, which could negatively impact our ability
to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradable securities,
thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our
employees.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
is unable to attract new clients, its business, financial condition and results of operations would be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
increase its revenue, NewGenIvf must continue to attract new clients. NewGenIvf&#8217;s ability to do so depends in large part on the
success of its sales and marketing efforts, and the success of references through existing clients. Potential clients may seek out other
options; therefore, NewGenIvf must demonstrate that its solutions are valuable and superior to alternatives. If NewGenIvf fails to provide
high-quality solutions and convince clients of the benefits of its model and value proposition, NewGenIvf may not be able to attract
new clients. If the markets for NewGenIvf&#8217;s solutions decline or grow more slowly than it expects, or if the number of clients
that contract with it for its solutions declines or fails to increase as it expects, its financial results could be harmed. As the markets
in which NewGenIvf participate mature, fertility solutions and services evolve and competitors begin to enter into the market and introduce
differentiated solutions or services that are perceived to compete with its solutions, particularly if such competing solutions are adopted
by its competitors, its ability to sell its solutions could be impaired. As a result of these and other factors, NewGenIvf may be unable
to attract new clients, which would have an adverse effect on its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
business depends on its ability to maintain its existing client demographics. Any failure to do so would harm its business, financial
condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
part of its growth strategy, NewGenIvf is focused on maintaining its services within its existing client demographics. NewGenIvf mainly
competes with mid-level private clinics and hospitals, which have improved and developed their services and equipment over the&#160;years.
In addition to private clinics and hospitals already existing, foreign medical companies may also enter the markets where NewGenIvf operates.
Such foreign medical companies may be well-placed to compete with NewGenIvf due to their larger network size, reputation as global players
and access to more advanced technology and financial resources. The expansion of existing competitors in the industry may erode NewGenIvf&#8217;s
existing market share or decrease its traditional client pool. There can be no assurance that NewGenIvf will be able to compete effectively
and therefore its future business growth may suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>A significant
reduction in the utilization of NewGenIvf&#8217;s solutions could have an adverse effect on its business, financial condition and results
of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
significant reduction in the number of clients using NewGenIvf&#8217;s solutions could adversely affect its business, financial condition
and results of operations. Factors that could contribute to a reduction in the use of its solutions include: general economic downturn
that results in adverse financial conditions; regulatory changes; failure to adapt and respond effectively to changing medical landscape,
changing regulations, changing client needs, requirements or preferences; negative publicity, through social media or otherwise and news
coverage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to offer high-quality support, its reputation could suffer.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
relies on its client account management personnel and the patient navigators (the &#8220;PNs&#8221;) to resolve client issues and help
clients realize the full benefits that its solutions and services provide. High-quality support is also important for the renewal and
expansion of its services to existing clients. The importance of its support functions will increase as NewGenIvf expands its business
and pursue new clients. If NewGenIvf does not help its clients quickly resolve issues and provide effective ongoing supports, its ability
to maintain and expand its offerings to existing and new clients could suffer, and its reputation with existing or potential clients
could suffer. Further, to the extent that NewGenIvf is unsuccessful in hiring, training and retaining adequate PNs and client account
management personnel, its ability to provide adequate and timely support to its clients would be negatively impacted, and its clients&#8217;
satisfaction with its solutions and services would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
failure to effectively develop and expand its marketing and sales capabilities could harm its ability to increase its client base and
achieve broader market acceptance of solutions NewGenIvf provides.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
ability to increase its client base and achieve broader market acceptance of solutions it provides will depend to a significant extent
on its ability to expand its marketing and sales capabilities. NewGenIvf plans to continue expanding its direct sales force and to dedicate
significant resources to sales and marketing programs, including direct sales, inside sales, targeted direct marketing, advertising,
digital marketing, e-newsletter and conference sponsorships. All of these efforts will require it to invest significant financial and
other resources. Its business and results of operations could be harmed if its sales and marketing efforts do not generate significant
increases in revenue. NewGenIvf may not achieve anticipated revenue growth from expanding its sales and marketing efforts if it is unable
to hire, develop, integrate and retain talented and effective sales personnel, if its new and existing sales personnel, on the whole,
are unable to achieve desired productivity levels in a reasonable period of time, or if its sales and marketing programs are not effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may experience net losses and may not sustain profitability in the future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
experienced significant revenue decrease from 2019 to 2020, due to the impact of COVID-19. NewGenIvf is not certain whether it will obtain
sufficient levels of sales to sustain its growth or maintain profitability in the future. NewGenIvf also expects its costs and expenses
to increase in future periods, which could negatively affect its future results of operations if its revenue does not increase accordingly.
In particular, NewGenIvf intends to continue to incrementally expand its sales and client account management teams to educate potential
clients and drive new client adoption. NewGenIvf also expects to incur additional costs as it introduces new solutions and services to
enhance its comprehensive fertility offering. NewGenIvf will also face increased compliance costs associated with growth, the expansion
of its client base and being a public company. NewGenIvf&#8217;s efforts to grow its business may be costlier than it expects, and NewGenIvf
may not be able to increase its revenue enough to offset its increased operating expenses. NewGenIvf may incur significant losses in
the future for a number of reasons, including the other risks described herein, and unforeseen expenses, difficulties, complications
and delays, and other unknown events. If NewGenIvf is unable to sustain profitability, the value of its business and common stock may
significantly decrease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
future revenue may not grow at the rates it historically has, or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has experienced growth since its business operations started in 2014. Revenue and NewGenIvf&#8217;s client base may not grow at the same
rates they historically have, or they may decline in the future. NewGenIvf&#8217;s future growth will depend, in part, on its ability
to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">continue
                                            to attract new clients and/or maintain existing clients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">price
                                            its solutions and services effectively so that it is able to attract new clients, expand
                                            sales to its existing clients and maintain profitability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">provide
                                            its clients with client support that meets their needs, including through dedicated PNs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maintain successful collection of applicable receivable balances;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">retain and maintain relationships with high-quality and respected fertility
    specialists;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">attract and retain highly qualified personnel to support all clients;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increase awareness of its brand and successfully compete with other
    competitors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may not successfully accomplish all or any of these objectives, which may affect its future revenue, and which makes it difficult for
it to forecast its future results of operations. In addition, if the assumptions that NewGenIvf uses to plan its business are incorrect
or change in reaction to changes in its market, it may be difficult for it to maintain profitability. NewGenIvf&#8217;s shareholders
should not rely on its revenue for any prior quarterly or annual periods as any indication of its future revenue or revenue growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, NewGenIvf expects to continue to expend substantial financial and other resources on:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sales and marketing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">technology infrastructure, including systems architecture, scalability,
    availability, performance and security; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">general administration, including increased legal and accounting expenses
    associated with being a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
investments may not result in increased revenue growth in its business. If NewGenIvf is unable to increase its revenue at a rate sufficient
to offset the expected increase in its costs, its business, financial position, and results of operations will be harmed, and NewGenIvf
may not be able to maintain profitability over the long term. Additionally, NewGenIvf may encounter unforeseen operating expenses, difficulties,
complications, delays and other unknown factors that may result in losses in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
its revenue growth does not meet its expectations in future periods, NewGenIvf may not maintain profitability in the future, its business,
financial position and results of operations may be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of NewGenIvf&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
quarterly and annual results of operations, including the levels of NewGenIvf&#8217;s revenues, expenses, net (loss)/income and other
key metrics, may vary significantly in the future due to a variety of factors, some of which are outside of NewGenIvf&#8217;s control,
and period-to-period comparisons of NewGenIvf&#8217;s operating results may not be meaningful, especially given NewGenIvf&#8217;s limited
operating history. Accordingly, the results for any one fiscal quarter or any one fiscal year are not necessarily an indication of future
performance. Fluctuations in quarterly and/or annual financial results may adversely affect the price of NewGenIvf&#8217;s ordinary shares.
Factors that may cause fluctuations in NewGenIvf&#8217;s quarterly and annual financial results include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">NewGenIvf&#8217;s
                                            ability to attract new customers and maintain relationships with existing customers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes
                                            in NewGenIvf&#8217;s products and services offered and introduction of new services and products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            amount and timing of operating expenses related to marketing and the maintenance and expansion
                                            of NewGenIvf&#8217;s business, operations and infrastructure;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general
                                            economic, industry and market conditions; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            timing of expenses related to the development or acquisition of technologies or businesses.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If the estimates
and assumptions NewGenIvf uses to determine the size of the target markets for its services are inaccurate, its future growth rate may
be impacted and its business would be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Market
opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may
not prove to be accurate. Market opportunity estimates and growth forecasts included in this prospectus, including those NewGenIvf has
generated itself, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate,
including the risks described in this prospectus. Even if the markets in which NewGenIvf competes achieve the forecasted growth, its
business could fail to grow at similar rates, if at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
estimates of the market opportunity for its services are based on the assumption that the purpose-built, data-driven and disruptive fertility
services platform with the plan design NewGenIvf offers will be attractive to clients. Clients may pursue alternatives or may not see
the value in providing enhanced fertility-related services. In addition, NewGenIvf believes that it is expanding the size of the fertility
market as NewGenIvf enhances demand and increase awareness for fertility services. If these assumptions prove inaccurate, or if the increase
in awareness of fertility services attracts potential competitors to the market and results in greater competition, NewGenIvf&#8217;s
business, financial condition and results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is difficult to predict the demand for NewGenIvf&#8217;s solutions, the entry of competitive solutions or the future growth rate and
size of the fertility market. The expansion of the fertility market depends on a number of factors, including, but not limited to: the
continued trend of individuals starting families later in life, increase in the number of single mothers by choice, adoption of non-traditional
paths to parenthood and continued de-stigmatization of infertility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
there is a reduction in demand caused by a lack of client acceptance, weakening economic conditions, data security or privacy concerns,
governmental regulation, competing offerings or otherwise, the market for its solutions and services might not continue to develop or
might develop more slowly than NewGenIvf expects, which would adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may not be able to successfully manage its growth, and if NewGenIvf is not able to grow efficiently, its business, financial condition
and results of operations could be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
usage of its solutions grows, NewGenIvf will need to devote additional resources to improving and maintaining its infrastructure. In
addition, NewGenIvf will need to appropriately scale its internal business systems and its client account management and services personnel
to serve its growing client base. Any failure of or delay in these efforts could result in reduced client satisfaction, resulting in
decreased sales to new clients and lower renewal and utilization rates by existing clients, which could hurt its revenue growth and its
reputation. Even if NewGenIvf is successful in these efforts, they will require the dedication of management time and attention. NewGenIvf
could also face inefficiencies or service disruptions as a result of its efforts to scale its internal infrastructure. NewGenIvf cannot
be sure that the expansion and improvements to its internal infrastructure will be effectively implemented on a timely basis, and such
failures could harm its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf&#8217;s
new solutions and services are not adopted by its clients, or if it fails to innovate and develop new offerings that are adopted by its
clients, its revenue and results of operations may be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
date, NewGenIvf has derived a substantial majority of its revenue from sales of its fertility services. As NewGenIvf operates in an evolving
industry, its long-term results of operations and continued growth will depend on its ability to successfully develop and market new
successful solutions and services to its clients. If its existing clients do not value and/or are not willing to make additional payments
for such new solutions or services, it could adversely affect its business, financial condition and results of operations. If NewGenIvf
is unable to predict clients&#8217; preferences, if the markets in which NewGenIvf participates change, including in response to government
regulation, or if NewGenIvf is unable to modify its solutions and services on a timely basis, NewGenIvf may lose clients. Its results
of operations would also suffer if its innovations were not responsive to the needs of the clients, appropriately timed with market opportunity
or effectively brought to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to adapt and respond effectively to the changing medical landscape, changing regulations, changing client needs, requirements or
preferences, its offerings may become less competitive.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
market in which NewGenIvf competes is subject to a changing medical landscape and changing regulations, as well as changing client needs,
requirements and preferences. The success of its business will depend, in part, on its ability to adapt and respond effectively to these
changes on a timely basis. NewGenIvf&#8217;s business strategy may not effectively respond to these changes, and NewGenIvf may fail to
recognize and position itself to capitalize upon market opportunities. NewGenIvf may not have sufficient advance notice and resources
to develop and effectively implement an alternative strategy. There may be scientific or clinical changes that require it to change its
solutions or that make its solutions less competitive in the marketplace. If there are sensitivities to its model or its existing competitors
and new entrants create new disruptive business models and/or develop new solutions that clients prefer to its solutions, NewGenIvf may
lose clients, and its results of operations, cash flows and/or prospects may be adversely affected. The future performance of NewGenIvf&#8217;s
business will depend in large part on its ability to design and implement market appropriate strategic initiatives, some of which will
occur over several&#160;years in a dynamic industry. If these initiatives of NewGenIvf do not result in met objectives, NewGenIvf&#8217;s
results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to maintain and enhance its brand, its ability to expand its client base will be impaired and its business, financial condition
and results of operations may suffer.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
growth of NewGenIvf&#8217;s business partially depends on the recognition of NewGenIvf&#8217;s brand and reputation. NewGenIvf believes
that maintaining and enhancing its brand is important to support the marketing and sale of its existing and future solutions to new clients
and expand sales of its solutions to existing clients. NewGenIvf also believes that the importance of brand recognition will increase
as competition in its market increases. Successfully maintaining and enhancing its brand will depend largely on the effectiveness of
its marketing efforts, its ability to provide reliable services that continue to meet the needs of its clients at competitive prices,
its ability to maintain its clients&#8217; trust, its ability to continue to develop new solutions, and its ability to successfully differentiate
its platform from competitive solutions and services. NewGenIvf&#8217;s brand promotion activities may not generate client awareness
or yield increased revenue, and even if they do, any increased revenue may not offset the expenses NewGenIvf incurs in building its brand.
If NewGenIvf fails to successfully promote and maintain its brand, its business, financial condition and results of operations may suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
fails to retain and motivate members of its management team or other key employees, or fails to attract additional qualified personnel
to support its operations, its business and future growth prospects could be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
success and future growth depend largely upon the continued services of its management team and its other key employees. From time to
time, there may be changes in its executive management team or other key employees resulting from the hiring or departure of these personnel.
Its executive officers and other key employees are employed on an at-will basis, which means that these personnel could terminate their
employment with it at any time. The loss of one or more of its executive officers, or the failure by its executive team to effectively
work with its employees and lead its company, could harm its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, to execute its growth plan, NewGenIvf must attract and retain highly qualified personnel. Competition for these personnel is
intense, especially for experienced medical officers and scientific staffs and sales and client account management personnel. There is
no guarantee NewGenIvf will be able to attract such personnel or that competition among potential employers will not result in increased
salaries or other benefits. From time to time, NewGenIvf has experienced, and NewGenIvf expects to continue to experience, difficulty
in hiring and retaining employees with appropriate qualifications. Many of the companies with which NewGenIvf competes for experienced
personnel have greater resources than NewGenIvf has. If NewGenIvf hires employees from competitors or other companies, their former employers
may attempt to assert that these employees or NewGenIvf has breached their legal obligations, resulting in a diversion of its time and
resources. In addition, prospective and existing employees often consider the value of the equity awards they receive in connection with
their contribution to the company. If the perceived value of its equity awards declines, experiences significant volatility, or increases
such that prospective employees believe there is limited upside to the value of its equity awards, it may adversely affect its ability
to recruit and retain key employees. If NewGenIvf fails to attract new personnel or fails to retain and motivate its current personnel,
its business and future growth prospects could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Furthermore,
in order to attract and retain key personnel and employees, the compensation amounts for NewGenIvf&#8217;s executive officers may change
significantly after consummation of the Business Combination, although there are currently no agreements in place relating to any such
post Business Combination compensation arrangements. As a result, NewGenIvf&#8217;s expenses associated with the compensation may increase,
which may also have an adverse effect on its results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>To successfully
market and sell its services and products in Asia-Pacific markets, NewGenIvf must address many international business risks with which
NewGenIvf has limited experience.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
business is subject to risks in connection with changes in international, national and local economic and market conditions, including
the effects of global financial crises, effects of terrorist acts and war and global pandemics. Such economic changes could negatively
impact infertile couples&#8217; abilities to pay for fertility treatments around the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
strategy is to increase its international presence in Asia-Pacific countries and its international sales are subject to a number of risks,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased competition as a result of more products and procedures receiving
    regulatory approval or otherwise free to market in international markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">longer accounts receivable payment cycles and difficulties in collecting
    accounts receivable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reduced or varied protection for intellectual property rights in some
    countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">export restrictions, trade regulations, and foreign tax laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fluctuations in currency exchange rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">foreign certification and regulatory clearance or approval requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>   <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">customs clearance and shipping delays;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">political, social, and economic instability abroad, terrorist attacks,
    and security concerns in general;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">preference for locally provided services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potentially adverse tax consequences, including the complexities of
    foreign value-added tax systems;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the burdens of complying with a wide variety of foreign laws and different
    legal standards; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased financial accounting and reporting burdens and complexities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
one or more of these risks are realized, its business, financial condition and results of operations could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Ethical,
legal and social concerns related to the use of assisted reproductive technology could reduce demand for the fertility services provided
by the medical facilities in NewGenIvf&#8217;s network, and thus may adversely affect the business, financial conditions and results
of operations of the medical facilities in its network.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Patient
sentiment and distrust of the use of assisted reproductive technology may lead to less demand for fertility services. Assisted reproductive
technologies, including genetic testing, technologies used for surrogacy and egg donation and gender selection, have raised ethical,
legal and social issues regarding privacy and the appropriate uses of the resulting information. Government authorities could, for social
or other purposes, limit or regulate the use of assisted reproductive technology to certain conditions. Similarly, these concerns may
lead patients to refuse to use, or physicians to be reluctant to order, assisted reproductive services even if permissible. These and
other ethical, legal and social concerns may limit market acceptance of fertility services or reduce patient demand for such services,
either of which could have a material adverse effect on the business, financial condition and results of operations of the medical facilities
in NewGenIvf&#8217;s network, and NewGenIvf itself.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
is reliant on revenue from international clients.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Fertility
services revenue from international clients are an important part of NewGenIvf&#8217;s revenue, though NewGenIvf is expanding rapidly
into the local markets. The number of international clients travelling to Thailand, Cambodia and Kyrgyzstan to seek fertility services
may, however, be affected by a number of factors, including the economic status of the foreign client&#8217;s country of origin, the
relative exchange rate of the client&#8217;s home currency to the relevant authorities, which may affect the cost of treatment, natural
disasters, pandemics like COVID-19, and political tension or acts of terrorism in such countries and the region. For example, the COVID-19
has had resulted in a number of countries declaring a state of emergency and a number of countries, including the countries in Asian
Pacific, imposing extensive travel restrictions, which in turn caused a decrease in the numbers of internal clients traveling to Thailand,
Cambodia or Kyrgyzstan for treatments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
events could cause a postponement or a reduction in the number of clients traveling to Thailand, Cambodia or Kyrgyzstan, and could in
turn affect revenues from international clients, which is the significant contributor in terms of volume. A decline in the medical tourism
industry may have a material adverse effect on NewGenIvf&#8217;s financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Fluctuations
in exchange rates could have a material and adverse effect on NewGenIvf&#8217;s results of operations and the value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
reporting currency is U.S.&#160;dollars. The functional currency of NewGenIvf and its subsidiaries include Hong&#160;Kong dollar (&#8220;HK$&#8221;),
Thai baht (&#8220;THB&#8221;), Cambodian riel (&#8220;KHR&#8221;) and United&#160;States dollar (&#8220;USD&#8221;). Accordingly, fluctuations
in the value of HK$, THB and KHR relative to the USD could affect its results of operations due to translational remeasurements. As its
international operations expand, an increasing portion of its revenue and operating expenses may be denominated in non- HK$, THB or KHR
currencies. Accordingly, NewGenIvf&#8217;s revenue and operating expenses will become increasingly subject to fluctuations due to changes
in foreign currency exchange rates. If NewGenIvf is not able to successfully hedge against the risks associated with currency fluctuations,
NewGenIvf&#8217;s business, financial condition and results of operations could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Governmental
control of currency conversion may limit NewGenIvf&#8217;s ability to utilize NewGenIvf&#8217;s net revenue effectively and affect the
value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenue and expenses for its businesses are substantially denominated in &#160;THB, which are currently not freely convertible currencies.
A portion of such revenue must be converted into other currencies in order to meet its foreign currency obligations. For example, NewGenIvf&#8217;s
subsidiaries will need to obtain foreign currency to make payments of declared dividends, if any, on its shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the existing foreign exchange regulations in Thailand, NewGenIvf will be able to make current account foreign exchange transactions.
However, in the future, governments may take measures, at its discretion, to restrict access to foreign currencies for capital account
and current account transactions under certain circumstances. If such measures are implemented, NewGenIvf may not be able to pay dividends
in foreign currencies to holders of its shares. Foreign exchange transactions under its capital account are subject to significant foreign
exchange controls and require certain approvals. These limitations could affect our ability to obtain foreign exchange through offshore
financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
value of the THB against the U.S.&#160;dollar and other currencies fluctuates, and is subject to changes resulting from policies of the
Thailand and other governments, and depends to a large extent on domestic and international economic and political developments as well
as supply and demand in the local market. For example, the Bank of Thailand, which is the central bank of Thailand, is responsible for
formulating and implementing monetary policies in the country to maintain the price stability and promote economic stability and sustainable
growth. The Bank of Thailand imposes (four) measures in preventing THB fluctuation. Those are measures to limit THB liquidity, to curb
capital inflows, to limit the flows on Non-resident Bank Account and Non-resident Baht for Securities, and to limit the flows on Non-Deliverable
Forward transactions. With an increased floating range of the THB&#8217;s value against foreign currencies and a more market-oriented
mechanism for determining the mid-point exchange rates, the THB may further appreciate or depreciate significantly in value against the
U.S.&#160;dollar or other foreign currencies in the long-term, depending on the fluctuation of the basket of currencies against which
it is currently valued, or it may be permitted to enter into a full float, which may also result in a significant appreciation or depreciation
of the THB against the U.S.&#160;dollar or other foreign currencies. It cannot be assured that THB will not experience significant appreciation
or depreciation against the U.S.&#160;dollar or other foreign currencies in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Furthermore,
NewGenIvf is also currently required to obtain approvals before converting significant sums of foreign currencies into THB. All of these
factors could materially and adversely affect its business, results of operations, financial condition and prospects, and could reduce
the value of, and dividends payable on, its shares in foreign currency terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sales of
a substantial number of our securities in the public market by the Selling Securityholders and/or by our existing securityholders could
cause the price of our Ordinary Shares to decrease significantly.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Selling Securityholders can resell, under this prospectus, up to 139,425,259 Ordinary Shares. The securities being offered in this prospectus
represent a substantial percentage of our issued and outstanding Ordinary Shares, and the sale of such securities in the public market
by the Selling Securityholders, or the perception that those sales might occur, could depress the market price of our Ordinary Shares,
and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that
such sales may have on the prevailing market price of our Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Substantially
all of NewGenIvf&#8217;s assets and operations are located in Thailand, Cambodia and Kyrgyzstan and they are subject to economic, legal
and regulatory uncertainties in such countries.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Substantially
all of NewGenIvf&#8217;s operations and assets are based in Thailand, Cambodia and Kyrgyzstan.&#160;As a result, its businesses and operations
are subject to the changing economic conditions prevailing from time to time in such countries. Since 2020, Thailand&#8217;s economy
has been experiencing a slowdown. According to the National Economic and Social Development Board of Thailand (the &#8220;NESDB&#8221;)
the GDP growth rate of Thailand declined to minus 6.1% in 2020 and slightly recovered to 1.6% in 2021 and 2.6% in 2022. Under such conditions,
the NESDB projected that Thailand&#8217;s economy will only grow by 3.0% to 4.0% in 2023,&#160;&#160;lower than the previously growth
in historical&#160;years. Meanwhile, Cambodia&#8217;s post-pandemic economic recovery has gained momentum, but remains uneven. Traditional
growth drivers, especially manufacturing and agricultural commodities exports, have fully recovered. However, while travel and tourism
have improved, the sector remains well below pre-COVID-19 levels. The subsequent impact also caused the vendors and customers preference
change, lower the willingness travelling to Kyrgyzstan for surrogacy services. The economy is projected to grow, underpinned by merchandise
exports and domestic economic activity. Foreign direct investment, while diversified, remains affected by China&#8217;s related COVID-19
policies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also derives a substantial portion of its revenue from Chinese clients and as such, its maintenance of PRC-sourced revenues and access
to new and existing clients from the PRC are also subject to the economic conditions of China. However, the near-term growth prospects
of the PRC economy are unclear due to the uncertain effects of ongoing economic stress caused by policies to contain the COVID-19 pandemic,
trade and national security policies, and the elevated levels of private and public indebtedness, among others. According to the National
Statistics Bureau of the PRC, growth rate of China&#8217;s GDP for the year 2022 slowed down to 3.0% on a year-on-year basis compared
to the growth rate of approximately 8.4% for the year 2021. In the second quarter of 2023, China&#8217;s GDP grew only 0.8% on a quarter
basis, a significant slowdown from the 2.2% quarter growth registered in the first quarter of 2023. A prolonged downturn in the PRC economy
generally could materially and adversely affect NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Factors
that may adversely affect the economy and conditions in such countries include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">political instability (e.g., Thailand&#8217;s national election in
    May&#160;2023);&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">global economic conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exchange rate fluctuations and the exchange control policy of the banks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a prolonged period of inflation or increase in regional interest rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in taxation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in government policies affecting import and export volumes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decline in tourism;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">natural disasters, including tsunamis, earthquakes, fires, floods,
    drought and similar events;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a potential recurrence or outbreak of avian influenza, severe acute
    respiratory syndrome or other infectious or contagious diseases like COVID-19 in Asian countries, and governmental policies to address
    such outbreak;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">scarcity of credit or other financing, resulting in lower demand for
    products and services provided by companies in the region;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increases in oil prices and other commodity prices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">decreased consumer confidence;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other external recessions or potential economic downturns in the United&#160;States,
    Asia or other parts of the world; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">other regulatory, political or economic developments in or affecting
    the countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
economic conditions in Thailand, Cambodia, Kyrgyzstan and China are also affected by global economic conditions. The global credit markets
have experienced, and may continue to experience, volatility and liquidity disruptions, which have resulted in the consolidation, failure
or near failure of a number of institutions in the banking and insurance industries. There remains a concern that a return of the debt
crisis in Europe, the political unrest in the Middle East and Eastern Europe as well as rumors or threats or actual terrorist attacks
or conflicts in the Middle East, Southeast Asia, Eastern Europe or other regions will impinge upon the health of the global financial
system. These or other such events could adversely affect NewGenIvf&#8217;s business, financial condition, results of operations and
prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is no assurance that the economies and social conditions of Thailand, Cambodia, Kyrgyzstan and China will meet current projections or
improve in the future. Any instability or economic downturn could have a material adverse effect on NewGenIvf&#8217;s business, financial
condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Failure to
comply with the terms of future financing arrangements could result in default, which could have an adverse effect on NewGenIvf&#8217;s
cash flow and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may from time to time enter into credit facilities and debt financing arrangements containing financial and other covenants that could,
among other things, restrict NewGenIvf&#8217;s business and operations. If NewGenIvf breaches any of these covenants, including the failure
to maintain certain financial ratios, NewGenIvf&#8217;s lenders may be entitled to accelerate NewGenIvf&#8217;s debt obligations. Any
default under the credit facility could result in the repayment of these loans prior to maturity as well as the inability to obtain additional
financing, which in turn may have a material adverse effect on NewGenIvf&#8217;s cash flow and liquidity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable
terms, its business, financial condition, and prospects may be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
requires a significant amount of capital and resources for its operations and continued growth. NewGenIvf expects to make significant
investments to fund operations, laboratory upgrades, among other things, which may significantly increase NewGenIvf&#8217;s net cash
used in operating activities. In addition, NewGenIvf will continue to invest in laboratory and facilities which are fundamental to NewGenIvf&#8217;s
business operation and future growth. However, NewGenIvf cannot assure you that these investments will generate the optimal returns,
if at all. To date, NewGenIvf has historically funded its cash requirements primarily through operational, capital contributions from
its shareholders and short-term or long-term borrowings. If these resources are insufficient to satisfy NewGenIvf&#8217;s cash requirements,
NewGenIvf may seek to raise funds through additional equity offering or debt financing or additional bank facilities. NewGenIvf&#8217;s
ability to obtain additional capital in the future, however, is subject to a number of uncertainties, including those relating to its
future business development, financial condition, and results of operations, general market conditions for financing activities by companies
in its industry, and macro-economic and other conditions in Thailand, Cambodia, Kyrgyzstan and globally. If NewGenIvf cannot obtain sufficient
capital on acceptable terms to meet its capital needs, NewGenIvf may not be able to execute its growth strategies, and NewGenIvf&#8217;s
business, financial condition, and prospects may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The defects
in certain leased property interests and failure to register certain lease agreements may materially and adversely affect NewGenIvf&#8217;s
business, financial condition, results of operations, and prospects. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
leases premises in Thailand, Cambodia and Kyrgyzstan in various locations. With respect to property leased by First Fertility PGS Center
in Thailand, the lessors did not have or provide NewGenIvf with property ownership certificates or other documents evidencing their rights
to lease such premises to First Fertility PGS Center. Therefore, NewGenIvf cannot assure that it will not be subject to any challenges,
lawsuits, or other actions taken against First Fertility PGS Center with respect to its leased premises for which the relevant lessors
do not have valid title or right to lease. If First Fertility PGS Center&#8217;s lessors&#8217; right to lease premises is successfully
challenged by any third party, First Fertility PGS Center&#8217;s lease agreements may not be enforceable and NewGenIvf may be forced
to vacate the premises and relocate to a different location. Under such circumstances, NewGenIvf expects to incur relocation costs of
up to THB3 million and expects that there would not be material business interruption costs, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the failure of the lessor to provide sufficient legal evidence of its right to lease the premises has prevented First Fertility
PGS Center from registering the clinic with the Bangkok Metropolitan Authority (&#8220;BMA&#8221;) as required under the Public Health
Act B.E. 2535 (1992) (the &#8220;PHA&#8221;). Under Section 71 of the PHA, First Fertility PGS Center and its directors are subject to
imprisonment of up to 6 (six) months and a fine of up to THB50,000, or both. The BMA could also order First Fertility PGS Center to stop
operating the clinic which would require relocation of the clinic if First Fertility PGS Center could not make the necessary registration.
Under such circumstances, First Fertility PGS Center expects to incur relocation costs of up to THB3 million and expects that there would
not be material business interruption costs, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Only
one of NewGenIvf&#8217;s directors or officers, namely Ms. Fong, Hei Yue Tina, is also a director of First Fertility PGS Center. NewGenIvf
believes that if First Fertility PGS Center&#8217;s directors, including Ms.&#160;Fong, are found guilty of the above offence and subject
to imprisonment, the resulting impact on NewGenIvf&#8217;s business, results of operations and financial conditions would be limited,
as Ms. Fong has limited involvement in the day-to-day management of First Fertility PGS Center&#8217;s operations and Mr. Siu, Wing Fung
Alfred and the other directors and officers of NewGenIvf and its subsidiaries would be able to keep operating the group&#8217;s and First
Fertility PGS Center&#8217;s activities with limited disruptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, NewGenIvf has not registered the lease agreements of First Fertility Bishkek in Kyrgyzstan with the relevant government authorities.
The enforceability of the lease of property may therefore be subject to restrictions under relevant laws and regulations and NewGenIvf
may be forced to vacate the premises and relocate to a different premise. Under such circumstances, NewGenIvf expects to incur relocation
costs of up to USD150,000 and expects that there would not be material business interruption costs, if any. Meanwhile, First Fertility
Bishkek may be required to pay a penalty for the late registration of the lease agreement with a lease term of 3 or more years, the maximum
amount of which is KGS3060 ($35).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
currently has no insurance coverage for its operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
assisted reproductive medical facilities in NewGenIvf&#8217;s network are exposed to potential liabilities that are inherent to the provision
of services. Medical and other liabilities may not be fully covered by insurance and the medical facilities may face claims in excess
of the insurance coverage or claims which are not covered by insurance due to other policy limitations or exclusions or where the medical
facilities in NewGenIvf&#8217;s network have failed to comply with the terms of the policy. Any uninsured risks may result in substantial
costs and the diversion of resources, which could adversely affect its results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
insurance industries in Thailand, Cambodia and Kyrgyzstan are still at early stages of development, and insurance companies in Thailand,
Cambodia and Kyrgyzstan currently offer limited business-related insurance products. NewGenIvf does not currently maintain insurance.
NewGenIvf cannot assure you that the medical facilities in its network will be able to obtain and/or maintain medical liability insurance
on acceptable terms or without substantial premium increases or at all in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, as NewGenIvf&#8217;s business expands, the cost for each medical facility in its network and NewGenIvf to maintain an adequate
level of insurance may become increasingly high. NewGenIvf cannot ensure that the medical facilities in its network will be able to locate
or purchase appropriate insurance to cover the expanding operations in time, on commercially reasonable terms or at all. Any significant
uninsured loss could have material and adverse effects on the financial condition and results of operations of the medical facilities
in NewGenIvf&#8217;s network, and thus may affect its business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Moreover,
NewGenIvf does not currently maintain professional malpractice liability insurance for its physicians and nurses. As a result, NewGenIvf
may be subject to medical disputes and claims arising under relevant laws from time to time, which could cause substantial damage to
NewGenIvf if not covered by professional malpractice liability insurance. Any dispute with clients, or any legal proceeding involving
the physicians of the medical facilities or medical professionals, regardless of its merit or eventual outcome, could result in significant
legal costs and financial and/or reputational damages to the medical facilities and NewGenIvf and materially and adversely affect the
business, financial condition and results of operations of the medical facilities in NewGenIvf&#8217;s network, and further affect its
business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may not be successful in adapting to technological developments, which may affect its business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is possible that new technologies could be developed or scientific advances made by NewGenIvf&#8217;s competitors, or elsewhere and licensed
to NewGenIvf&#8217;s competitors, which cannot be replicated by NewGenIvf without significant capital expenditure or at all, or that
replace or reduce the requirement for assisted reproductive services, ultrasound or specialized diagnostics. The consequences for NewGenIvf
of the development of new technologies could include lower or loss of revenues, loss of market position and reduced prospects of NewGenIvf.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If its computer
systems, or those of its providers, specialty pharmacies or other downstream vendors lag, fail or suffer security breaches, NewGenIvf
may incur a material disruption of its services, which could materially impact its business and the results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
businesses in Thailand, Cambodia and Kyrgyzstan are increasingly dependent on critical, complex and interdependent information technology
systems to support business processes as well as internal and external communications. NewGenIvf&#8217;s success is therefore dependent
in part on its ability to secure, integrate, develop, redesign and enhance its (or contract with vendors to provide) technology systems
that support its business strategy initiatives and processes in a compliant, secure, and cost and resource efficient manner. If NewGenIvf
or its providers, specialty pharmacies or other downstream vendors have an issue with its or their respective technology systems, it
may result in a disruption to its operations or downstream disruption to its relationships with its clients or its selective network
of high-quality fertility specialists. Additionally, if NewGenIvf chooses to insource any of the services currently handled by a third
party, it may result in technological or operational disruptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, despite the implementation of security measures, its internal computer systems, and those of its provider clinics, specialty
pharmacies or other downstream vendors, are potentially vulnerable to damage from malicious intrusion, malware, computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. While NewGenIvf is not aware that it has experienced
any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in its operations,
it could result in a material disruption to its ability to operate and deliver its solutions. In addition, to the extent that any disruption
or security breach were to result in a loss or inappropriate disclosure of confidential information, NewGenIvf could incur liability.
See &#8220;&#8212;<i>&#160;Risks Related to Government Regulation&#160;&#8212;&#160;NewGenIvf operates in a highly regulated industry
and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits
applicable to NewGenIvf&#8217;s business may have a material and adverse impact on NewGenIvf&#8217;s business, financial condition, and
results of operations&#160;&#8212;&#160;Data Protection and Breaches</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Risks Related to NewGenIvf&#8217;s
Relationships with Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
business depends on its ability to maintain its network of high-quality fertility specialists and other healthcare providers. If NewGenIvf
is unable to do so, its future growth would be limited and its business, financial condition and results of operations would be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
performance and success is dependent upon its continued ability to maintain a credentialed network of high-quality fertility specialists,
including its senior management team, other key employees, as well as research and development and operation maintenance personnel, many
of whom are difficult to replace. Fertility specialists could refuse to contract, demand higher payments or take other actions that could
result in higher medical costs, less attractive service for its clients or difficulty meeting regulatory or accreditation requirements.
Identifying high-quality fertility specialists, credentialing and negotiating contracts with them and evaluating, monitoring and maintaining
its network, requires significant time and resources. Competition in the healthcare industry for qualified employees is intense. NewGenIvf
may need to offer higher compensation and other benefits in order to attract and retain key personnel in the future, which could increase
NewGenIvf&#8217;s compensation expenses, including stock-based compensation. NewGenIvf&#8217;s continued ability to compete effectively
depends on NewGenIvf&#8217;s ability to attract new employees and to retain and motivate NewGenIvf&#8217;s existing employees. If NewGenIvf
is not successful in maintaining its relationships with top fertility specialists, these fertility specialists may refuse to renew their
contracts with it, and potential competitors may be effective in onboarding these or other high-quality fertility specialists to create
a similarly high-quality network. There may be additional shifts in the fertility specialty provider space as the fertility market matures,
and high-quality fertility specialists may become more demanding in re-negotiating to remain in its network. Its ability to develop and
maintain satisfactory relationships with high-quality fertility specialists also may be negatively impacted by other factors not associated
with it, such as regulatory changes impacting providers or consolidation activity among hospitals, physician groups and healthcare providers.
In addition, certain organizations of physicians, such as practice management companies (which group together physician practices for
administrative efficiency), may change the way in which healthcare providers do business with it and may compete directly with it, which
could adversely affect its business, financial condition and results of operations. NewGenIvf intends to grant, and may continue to grant,
options and other types of awards, which may result in increased share-based compensation expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
Share Incentive Award will allow NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents
and to encourage them to acquire a proprietary interest in the company&#8217;s growth and performance. Competition for highly skilled
personnel and agents is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating,
or retaining qualified personnel and agents to fulfill NewGenIvf&#8217;s current or future needs. NewGenIvf believes that the granting
of share-based awards is of significant importance to NewGenIvf&#8217;s ability to attract and retain agents, key personnel and employees,
and NewGenIvf will continue to grant share-based awards in the future. As a result, NewGenIvf&#8217;s expenses associated with share-based
compensation may increase, which may have an adverse effect on NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Meanwhile,
the retirement or loss of certain specialists, scientific staff or other key personnel, the activities of competitors, the introduction
of a competing service that is perceived to be superior to the services provided by NewGenIvf, or other events which impact NewGenIvf&#8217;s
reputation could adversely affect NewGenIvf&#8217;s relationships with fertility specialists. For example, one specialist who was previously
engaged by NewGenIvf brought a lawsuit against NewGenIvf regarding disputed remuneration, which resulted in a settlement for NewGenIvf
to compensate the specialist with a sum of approximately US$98,000. Also, fertility specialists&#8217; relationship with NewGenIvf could
affect their behaviors in recommending NewGenIvf&#8217;s services or referring patients to NewGenIvf, which could in turn adversely impact
the number of patients treated by NewGenIvf and adversely impact on its financial performance, market position and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the perceived value of NewGenIvf&#8217;s solutions and its reputation may be negatively impacted if the services provided by
fertility specialists or other healthcare providers are not satisfactory to NewGenIvf&#8217;s clients, including as a result of error
that could result in litigation. For example, if fertility specialist or other healthcare provider releases sensitive information of
its clients, it could incur additional expenses and give rise to litigation against NewGenIvf. Any such issue with one of its providers
may expose it to public scrutiny, adversely affect its brand and reputation, expose it to litigation or regulatory action, and otherwise
make its operations vulnerable. Further, if its services result in less than favorable outcomes, this could cause it to fail to meet
its contractually guaranteed specified service metrics, and NewGenIvf could be obligated to provide the client with a fee reduction or
a second chance for free, depending on their contract terms. The failure to maintain its selective network of high-quality fertility
specialists or the failure of those specialists to meet and exceed its clients&#8217; expectation, may result in a loss of or inability
to grow or maintain its client base, which could adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The medical
facilities and professionals in NewGenIvf&#8217;s network could become the subject of litigation, allegations and other claims, and NewGenIvf
is not insured against these liabilities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
relies on the physicians and other medical professionals of the assisted reproductive medical facilities in its network to make proper
clinical decisions regarding the diagnosis and treatment of clients. However, NewGenIvf does not have full and direct control over every
step of clinical activities undertaken at each of the medical facilities. In addition, physicians and medical professionals outside NewGenIvf&#8217;s
network may introduce patients to NewGenIvf and conduct medical treatments and/or procedures for such patients in NewGenIvf&#8217;s facilities.
NewGenIvf enters into independent contractor agreements with such physicians and medical professionals and treats such patients as NewGenIvf&#8217;s
own patients. As such, NewGenIvf will have to bear any liabilities arising from their medical treatments and/or procedures conducted
in NewGenIvf&#8217;s facilities. Any incorrect clinical decision or malpractice on the part of physicians and other medical professionals
(including those from outside of its network), or any failure by the medical facilities in its network to properly manage their clinical
activities may result in unsatisfactory treatment outcomes, patient injury or even death, which could lead to disputes with patients
and/or their families or the medical professionals, including those from outside its network. In its experience, moreover, clients of
fertility treatments tend to be more demanding on the medical services received. In addition, the relevant laws governing medical disputes
and claims grant claimants liberal rights in bringing claims against physicians and other medical professionals practicing in the jurisdiction.
As a result, the medical facilities in its network may be subject to medical disputes and claims arising under relevant laws, from time
to time, which could generate substantial damages imposed on such facilities if not covered by professional liability insurance. Any
dispute with its patients and/or their families or the medical professionals, including those from outside its network, or any legal
proceeding involving the physicians of the medical facilities or medical professionals, including those from outside its network, regardless
of its merit or eventual outcome, could result in significant legal costs and reputational damage to the medical facilities and materially
and adversely affect the business, financial condition and results of operations of the medical facilities in its network, and further
affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>The assisted
reproductive medical facilities in NewGenIvf&#8217;s network have limited control over the quality of the pharmaceuticals, medical equipment,
medical consumables and other supplies used in its operations, and cannot guarantee that the products in use are not defective or counterfeit.
NewGenIvf also has no control over independent sub-contractors and cannot guarantee the services thereof.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
assisted reproductive medical facilities in NewGenIvf&#8217;s network procure a variety of pharmaceuticals, medical equipment, consumables
and other supplies in NewGenIvf&#8217;s operations from third-party suppliers. As the medical facilities in NewGenIvf&#8217;s network
do not engage in the direct manufacture of such supplies, NewGenIvf cannot assure you that such supplies are free of defects and meet
relevant quality standards or, in the case of imported supplies, verify the origin of such products. In addition, there may be counterfeit
pharmaceutical products manufactured without proper licenses or approvals or fraudulently mislabeled with respect to their content or
manufacturer in the pharmaceutical markets. In some cases these products are very similar in appearance to the authentic products. The
quality control checks and processes may not be able to identify all counterfeit pharmaceutical products in the inventory. Any sale of
such products by the medical facilities in NewGenIvf&#8217;s network, regardless of its knowledge as to their authenticity, may subject
the medical facilities to administrative sanctions, civil claims, negative publicity or reputational damage. NewGenIvf cannot assure
you that the medical facilities in our network will be able to successfully claim full indemnity from such manufacturers of counterfeit
pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also cannot assure you that the medical facilities in our network will not encounter incidents relating to defective products, or that
such incidents will not materially and adversely affect our network of medical facilities. If the products provided by NewGenIvf&#8217;s
suppliers are defective, of poor quality or are otherwise unsafe or ineffective, the medical facilities in NewGenIvf&#8217;s network
could be subject to liability claims, complaints or adverse publicity, any of which would materially and &#160;adversely affect its results
of operations and reputation. NewGenIvf cannot assure you that the medical facilities in NewGenIvf&#8217;s network will find suitable
replacement suppliers on commercially acceptable terms or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
suppliers are also subject to extensive laws, rules and regulations. If any suppliers violate applicable laws, rules and regulations,
NewGenIvf&#8217;s reputation or procurement may be materially and adversely affected. In addition, the medical facilities in NewGenIvf&#8217;s
network may be exposed to reputational damages or even liabilities for defective goods provided by the suppliers or negative publicity
associated with any suppliers, and the business and results of operations of the medical facilities in NewGenIvf&#8217;s network and
NewGenIvf could suffer as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Independent
sub-contractors and/or agents that work with NewGenIvf are also subject to extensive laws, rules, and regulations. If any sub-contractor
and/or agent violates any applicable laws, rules, regulations or breaches any agreements, NewGenIvf&#8217;s reputation may be materially
and adversely affected and NewGenIvf may be penalized by regulatory or other parties. In addition, NewgenIvf&#8217;s clients may engage
Newgen&#8217;s sub-contractors and/or agents for ongoing services or additional services following the termination of contracts with
NewGenIvf. NewGenIvf has no control over the services provided by sub-contractors and cannot assure the quality of such services or ensure
compliance with applicable laws, rules and regulations. In addition, the services provided by independent sub-contractors may expose
NewGenIvf to public scrutiny, adversely affect its brand and reputation, expose it to litigation or regulatory action, and otherwise
make its operations vulnerable if such independent sub-contractors fail to meet their contractual obligations or to comply with applicable
laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf
loses its relationship with one or more key pharmaceutical manufacturers, its business and results of operations could be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
maintains contractual relationships with select pharmaceutical manufacturers in Thailand, Cambodia and Kyrgyzstan. The consolidation
of pharmaceutical manufacturers, the shortages of drugs provided by such manufacturers, the termination or material alteration of its
contractual relationships, or its failure to renew such contracts could have a material adverse effect on its business and results of
operations. Adoption of new laws, rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations,
relating to any of these programs could materially adversely affect its business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
has engaged in transactions with related parties, and such transactions present potential conflicts of interest that could have an adverse
effect on its business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has entered into a number of transactions with related parties. NewGenIvf may in the future enter into additional transactions with its
related parties. Interests of these related parties may not necessarily be aligned with NewGenIvf&#8217;s or The Company&#8217;s interests
and the interests of its other shareholders. For example, conflicts of interest may arise in connection with decisions regarding the
transaction arrangements which may be less favorable to NewGenIvf than similar arrangements negotiated with unaffiliated third parties.
Conflicts of interest may also arise in connection with the exercise of contractual remedies, such as the treatment of events of default.
As a result, those related party transactions, individually or in the aggregate, may have an adverse effect on NewGenIvf&#8217;s business
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
may be subject to claims and allegations relating to intellectual property and other causes.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may from time to time receive claims that NewGenIvf infringes on the intellectual property rights of others. Moreover, NewGenIvf may
be subject to claims by third parties who maintain that NewGenIvf&#8217;s service providers&#8217; technology infringes third-party&#8217;s
intellectual property rights. If NewGenIvf fails to successfully defend against such claim or does not prevail in such litigation, it
could be required to modify, redesign or cease operating, pay monetary amounts as damages or enter into royalty or licensing arrangements
with the valid intellectual property holders. Any royalty or licensing arrangements that NewGenIvf may seek in such circumstances may
not be available to it on commercially reasonable terms or at all. Also, if NewGenIvf acquires technology licenses from third parties,
NewGenIvf&#8217;s exposure to infringement actions may increase because NewGenIvf must rely upon these third parties to verify the origin
and ownership of such technology. This exposure to liability could result in disruptions in NewGenIvf&#8217;s business that could materially
and adversely affect NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Some
of NewGenIvf&#8217;s employees may previously employed at other companies, including NewGenIvf&#8217;s competitors. NewGenIvf may hire
additional personnel to expand its development team and technical support team as its business grows. To the extent these employees were
involved in the development of content or technology similar to NewGenIvf&#8217;s at their former employers, NewGenIvf may become subject
to claims that these employees or NewGenIvf has appropriated these employees&#8217; former employers&#8217; proprietary information or
intellectual properties. If NewGenIvf fails to successfully defend such claims against itself, NewGenIvf may be exposed to liabilities
which could have a material adverse effect on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is currently not a party to any material legal or administrative proceedings but may subject to legal or administrative actions for defamation,
negligence, copyright and trademark infringement, unfair competition, breach of service terms, or other purported injuries resulting
from the content NewGenIvf provides or the nature of NewGenIvf&#8217;s services. Such legal and administrative actions, with or without
merits, may be expensive and time-consuming and may result in significant diversion of resources and management attention from NewGenIvf&#8217;s
business operations. Furthermore, such legal or administrative actions may adversely affect NewGenIvf&#8217;s brand image and reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Certain data
and information in this prospectus relied on by NewGenIvf were obtained from third-party data and polls. These metrics were not independently
verified by NewGenIvf and may not be accurate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
numbers and information in this prospectus were obtained and provided from numerous sources including management data, third-party data
or numbers generally estimated by calculating infertile couples, fertility tourism number, etc. to generally assess potential customer
numbers in Asia-Pacific countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
metrics were not independently verified. Such databases, third-party information, and calculations may not accurately reflect actual
statistics or numbers and NewGenIvf does not have access to specific rating numbers. Similarly, any statistical data in any third-party
publications also include projections based on a number of assumptions. If any one or more of the assumptions underlying the market data
is later found to be incorrect, actual results may differ from the projections based on these assumptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Risks Related
to Government Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite
approvals, licenses, or permits applicable to NewGenIvf&#8217;s business may have a material and adverse impact on NewGenIvf&#8217;s
business, financial condition, and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
operations of NewGenIvf are subject to various laws, rules and regulations at the national, regional and local levels in Thailand, Cambodia,
Kyrgyzstan and other applicable jurisdictions. Such laws and regulations mainly relate to (i)&#160;the licensing of local and foreign
medical professionals, nursing professionals, medical technology professionals, pharmaceutical professions and other applicable licensing;
(ii)&#160;the licensing, registration, and accreditation of medical facilities, laboratories, including but not limited to the licensing,
registration, and accreditation of persons performing related activities; (iii)&#160;the privacy and security of confidential patient
medical records; (iv)&#160;the corporate practice of medicine; (v)&#160;healthcare fraud and abuse laws; (vi)&#160;the donation and transplantation
of human cells, tissues and organs; (vii)&#160;potential prohibition on surrogacy or providing intermediary assistance in surrogacy;
and (viii)&#160;licensing and approval of the accommodation provided as parts of the services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has attempted to structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its
clients and vendors, but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or
enforcement initiatives, or that the relevant authorities in each jurisdiction could impose higher standards or requirements, which NewGenIvf
may have difficulty to adhere to, e.g. Medical Facilities Act B.E. 2541 (1998)&#160;and Protection of a Child Born by Medically Assisted
Reproductive Technology Act B.E. 2558 (2015)&#160;for Thailand jurisdiction, Law on Reproduction Rights and on Guarantees of Their Realization
of July&#160;4, 2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and Temporary Regulation on Procedure of Licensing
Private Medical Activity approved by the resolution of government of April&#160;4, 2017 No. 203 for Kyrgyz Republic. NewGenIvf in the
future may become involved in governmental investigations, audits, reviews and assessments. Any determination by a court or agency that
NewGenIvf&#8217;s solutions or services violate, or cause its clients to violate, applicable laws, regulations or other requirements
could subject it or its clients to civil, criminal, or administrative penalties. Such a determination also could require it to change
or terminate portions of its business, disqualify it from serving clients that do business with government entities, or cause it to refund
some or all of its service fees or otherwise compensate its clients. In addition, failure to satisfy laws, regulations or other requirements
could adversely affect demand for its solutions and could force it to expend significant capital, research and development and other
resources to address the failure. Even an unsuccessful challenge by regulatory and other authorities or parties could be expensive and
time-consuming, could result in loss of business, exposure to adverse publicity, and injury to its reputation and could adversely affect
its ability to retain and attract clients. If NewGenIvf fails to comply with applicable laws, regulations and other requirements, its
business, financial condition and results of operations could be adversely affected. Such non-compliance could also require significant
investment to address and may prove costly. There are several additional state statutes, regulations, guidance and contractual provisions
related to or impacting the healthcare industry that may apply to its business activities directly or indirectly, including, but not
limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Licensing and Licensed Personnel. </i></b>Many countries have
    licensure or registration requirements for entities acting as a medical services provider. The scope of these laws differs from country
    to country, and the application of such laws to the activities of fertility treatment is often unclear. Given the nature and scope
    of the solutions and services that NewGenIvf provides, it is required to maintain the License to Operate Medical Facility Business
    (Sor.Por.7), the License to Manage Medical Facility Business (Sor.Por.19), License to Certify the Standard of Service relating to
    Medically Assisted Reproductive Technology (KorThorPhor.9), and personnel licenses, i.e., license of medical professionals, nursing
    professionals, medical technology professionals, pharmaceutical professions and other applicable licenses in Thailand, Approval on
    Opening of Medical Clinic, Approval on Opening of Pharmacy and relevant approvals to conduct IVF, embryo implant and/or transfer
    activities issued by the Ministry of Health of Cambodia (&#8220;Cambodia MOH&#8221;) in Cambodia and licenses to carry out private
    medical activities (including diagnostics and treatment gynecological diseases, supervision of pregnant women before childbirth,
    IVF in outpatient and&#160;day hospital conditions (for four (4) beds)) in Kyrgyzstan, respectively, and to ensure that such licenses
    and registrations are in good standing on an annual basis. NewGenIvf is licensed, has licensure applications pending before appropriate
    regulatory bodies, is exempt from licensure or registration, or is otherwise authorized under such laws in those countries in which
    it provides its services. These licenses require it to comply with the rules and regulations of the governmental bodies that issued
    such licenses. NewGenIvf&#8217;s failure to comply with such rules and regulations could result in criminal and/ or administrative
    penalties, the suspension of a license, or the loss of a license, all of which could negatively impact its business. First Fertility
    PGS had provided arrangements of accommodation without additional charges for its patients without a tourism license in Thailand,
    all of which was subsequently ceased in early 2023. Pursuant to the Tourism Business and Guide Act 2551 (2008) of Thailand, a maximum
    fine of THB500,000 may be imposed on First Fertility PGS as a result of the above activity without a tourism license in Thailand.
    NewGenIvf is unable to predict, however, how its services may be viewed by regulators over time, how these laws and regulations will
    be interpreted, or the full extent of their applicable. If a regulatory authority in any country determines that the nature of its
    business requires that NewGenIvf be licensed under applicable laws, it may need to restructure its business or it may need to comply
    with any related requirements, such as obtaining relevant license, paying additional regulatory fees and/or penalties for previous
    non-compliance with relevant licensing requirements, which could adversely affect its results of operation. Additionally, in extreme
    case, NewGenIvf may need to cease operations until it is able to obtain appropriate licensure, which may adversely affect its revenue
    for a period of time that it cannot estimate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Patients&#8217; Right Protection. </i></b>There has been an increased
    awareness of patients&#8217; rights in Thailand, Cambodia and Kyrgyzstan, especially with the issuance of the Constitution of the
    Kingdom of Thailand, the Act on Court Proceedings for Consumer Cases B.E. 2551 (2008)&#160;(as amended), National Health Act B.E.
    2550 (2007), and other applicable laws in Thailand, the Civil Code dated December&#160;8, 2017 as amended by the Law on Implementation
    of the Civil Code dated May&#160;31, 2011, Law on Management of Donation and Transplantation of Human Cells, Tissues, and Organs
    (2016)&#160;and Sub-Decree No. 61 on the Code of Medical Ethics (2003) in Cambodia and Constitution of Kyrgyzstan of May&#160;5,
    2021, Civil Code, Part&#160;I of May&#160;8, 1996 No. 15, Law on Health Protection of Civilians of Kyrgyzstan of January&#160;9,
    2005 No. 6, Law on Reproduction Rights and on Guarantees of their Realization of July&#160;4, 2015 No. 148, Law on status of medical
    worker of May 28, 2013 No. 81 and other relevant applicable laws in Kyrgyzstan, which enables consumers and patients to file suits
    more easily against healthcare service providers. Furthermore, treatment of more complex medical conditions has no guaranteed positive
    outcome, which subjects it to an increased likelihood of medical malpractice suits. Such lawsuits could result in hefty compensation
    payments or damage to NewGenIvf&#8217;s reputation, which may have a material adverse effect on its business, financial condition,
    results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Meanwhile,
Thailand is considering enacting a Patient Protection Bill &#160;(the &#8220;Bill&#8221;). The Bill, if issued, is intended to alleviate
disputes between patients and healthcare providers, which have an impact on the healthcare system in Thailand as a whole. The compensation
outlined in the Bill will assist patients in claiming damages, thereby fostering a positive relationship between patients and healthcare
providers. Consequently, the rate of disputes is expected to decrease. The provisions under the Bill would require healthcare providers
to compensate patients in a timely manner, sometimes without requiring proof of wrongdoing. The Bill also contemplates setting up a patient
protection fund for damages to patients pursuant to which healthcare providers have to make mandatory contributions according to the
rules determined by a patient protection committee. Failure by it to comply with applicable rules and regulations could result in penalties,
the loss of regulatory permits and damage to NewGenIvf&#8217;s business reputation, each of which could have a material adverse effect
on its financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Furthermore,
the Protection of A Child Born By Medically Assisted Reproductive Technology Act B.E. 2558 (2015)&#160;of Thailand was promulgated with
the intention to appropriately designate the legitimate parenthood status of a child born using medically assisted reproductive technology
and regulate any medical scientific research on embryology and medically assisted reproductive technologies to prevent the misuse of
medically assisted reproductive technologies. NewGenIvf is therefore under the supervision of a Committee of the Protection for Children
Born through Medically Assisted Reproductive Technology, which is a committee established to control, inspect, supervise and formulate
various policies relating to such acts. In Cambodia and Kyrgyzstan, all health establishments, including private medical clinics, are
under the supervision of the Cambodia MOH and the Ministry of Health of Kyrgyzstan, respectively, which each governs and regulates the
operation of medical clinics and activities of medical practitioners in respective countries. In particular, the Medical Council of Cambodia,
Cambodian Council of Nurses, Cambodian Midwives Council and the Pharmaceutical Council of Cambodia, all assist the Cambodia MOH to supervise
and monitor the practice of health professionals in Cambodia. IVF/embryo implant/transfer activities are subject to an approval by the
Cambodia MOH.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Privacy and Security Requirements. </i></b>There are numerous
    laws and regulations related to the privacy and security of health information in each country. In particular, regulations promulgated
    pursuant to the Personal Data Protection Act B.E. 2562 (2019)&#160;of Thailand (&#8220;PDPA&#8221;), Law on Data of Personal Character
    of April&#160;14, 2008 No. 58 of Kyrgyzstan (&#8220;Data Protection Law&#8221;), as well as Regulation of Registration of Personal
    Data Holders (Owners) approved by the Resolution of the Cabinet of Ministers of KR of November&#160;18, 2022, Offences Code No. 128
    of October&#160;28, 2021 of Kyrgyzstan establish privacy and security standards in each country that limit the collection, use, and/
    or disclosure of certain individually identifiable health information, whether directly or indirectly (excluding the information
    of the deceased person) and require the implementation of administrative, physical and technological safeguards to protect the privacy
    of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information.
    The privacy regulations established under the PDPA and Data Protection Law also provide patients with rights related to understanding
    and controlling how their protected health information is collected, used and/ or disclosed. As a provider of services to entities
    subject to the PDPA and Data Protection Law, NewGenIvf is directly subject to certain provisions of the regulations. To the extent
    permitted by applicable privacy regulations and contracts with its clients, NewGenIvf is permitted to use and disclose protected
    health information to perform its services and for other limited purposes, but other uses and disclosures, such as marketing communications,
    require written authorization from the patient or must meet an exception specified under the privacy regulations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">NewGenIvf
also has downstream entities which provide it with services and are also subject to applicable regulations. If NewGenIvf or any of its
downstream entities are unable to properly protect the privacy and security of protected health information entrusted to it, it could
be found to have breached its contracts with its clients and be subject to investigation by the relevant supervision institution, i.e.,
the Office of the Personal Data Protection Committee of Thailand (the Government Authority under the PDPA), the Cambodia MOH and the
State Data Protection Agency under the Cabinet of Ministers of Kyrgyzstan (the &#8220;Agency&#8221;). In the event the Office of the
Personal Data Protection Committee or the Agency finds that NewGenIvf has failed to comply with applicable privacy and security standards,
it could face civil, criminal, and/ or administrative penalties. In addition, the Office of the Personal Data Protection Committee performs
compliance audits in order to proactively enforce the privacy and security standards. The Office of the Personal Data Protection Committee
has become an increasingly active regulator and has signaled its intention to continue this trend. The Office of the Personal Data Protection
Committee has the discretion to impose penalties and may require companies to enter into resolution agreements and corrective action
plans which impose ongoing compliance requirements. The Office of the Personal Data Protection Committee&#8217;s enforcement activity,
or audit related to incident regarding it or its downstream entity, can result in financial liability and reputational harm, and responses
to such enforcement activity can consume significant internal resources. Although NewGenIvf has implemented and maintain policies, processes
and compliance program infrastructure to assist it in complying with these laws and regulations and its contractual obligations, NewGenIvf
cannot provide assurance regarding how these laws and regulations will be interpreted, enforced or applied to its operations. In associated
with enforcement activities and potential contractual liabilities, its ongoing efforts to comply with evolving laws and regulations might
also require it to make costly system purchases and/or modifications or otherwise divert significant resources to compliance initiatives
from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Other Privacy and Security Requirements. </i></b>In addition,
    numerous other laws govern the collection, dissemination, use, access to and confidentiality of personal information. For example,
    the Law on E-Commerce of Cambodia (2019)&#160;places an obligation on those who electronically store private information to use all
    means to ensure that the information is protected by security safeguards in every reasonable circumstance to avoid the loss, access,
    use, modification, leakage, or disclosure of the information, except with the consent of the data owner or other lawfully authorized
    party. The Law on E-Commerce also prohibits individuals from dishonestly accessing, downloading, copying, extracting, leaking, deleting,
    modifying, or otherwise interfering with data stored by other persons. Applicable laws are contributing to increased enforcement
    activity and may also be subject to interpretation by various courts and other governmental authorities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Certain
of NewGenIvf&#8217;s solutions and services involve the transmission and storage of client data in various jurisdictions, which subjects
the operation of those solutions and services to privacy or data protection laws and regulations in those jurisdictions. While NewGenIvf
believes those solutions and services comply with current regulatory and security requirements in the jurisdictions in which it provides
these solutions and services, there can be no assurance that such requirements will not change or that it will not otherwise be subject
to legal or regulatory actions. The laws and regulations are rapidly evolving and changing, and could have an adverse impact on its operations.
These laws and regulations are subject to uncertainty in how they may be interpreted and enforced by government authorities and regulators.
The costs of compliance with, and the other burdens imposed by, these and other laws or regulatory actions may increase its operational
costs, prevent it from providing its solutions, and/or impact its ability to invest in or jointly develop its solutions. NewGenIvf also
may face audits or investigations by one or more government agencies relating to its compliance with these laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">An
adverse outcome under any such investigation or audit could result in fines, penalties, other liability, or could result in adverse publicity
or a loss of reputation, and adversely affect NewGenIvf&#8217;s business. Any failure or perceived failure by it or by NewGenIvf&#8217;s
solutions to comply with these laws and regulations may subject it to legal or regulatory actions, damage its reputation or adversely
affect its ability to provide its solutions in the jurisdiction that has enacted the applicable law or regulation. Moreover, if these
laws and regulations change, or are interpreted and applied in a manner that is inconsistent with its policies and processes or the operation
of its solutions NewGenIvf may need to expend resources in order to change its business operations, policies and processes or the manner
in which it provides its solutions. This could adversely affect NewGenIvf&#8217;s business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Data Protection and Breaches. </i></b>In recent&#160;years, there
    have been a number of well-publicized data breaches involving the improper dissemination of personal information of individuals both
    within and outside of the healthcare industry. Pursuant to the applicable data protection law of Thailand, the PDPA requires businesses
    to notify the data subjects and/or the government authorities upon the occurrence of a data breach. The laws are not consistent,
    and compliance in the event of a widespread data breach is costly. Each country also constantly amending existing laws, requiring
    attention to frequently changing regulatory requirements. Most countries require holders of personal information to maintain safeguards
    and take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals.
    In some countries, these laws are limited to electronic data, but they increasingly are enacting or considering stricter and broader
    requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">Despite
NewGenIvf&#8217;s security management efforts with respect to physical and technological safeguards, employee training, vendor (and sub-vendor)
controls and contractual relationships, its infrastructure, data or other operation centers and systems used in its business operations,
including the internet and related systems of its vendors (including vendors to whom NewGenIvf outsources data hosting, storage and processing
functions) are vulnerable to, and may from time to time experience, unauthorized access to data and/or breaches of confidential information
due to a variety of causes. Techniques used to obtain unauthorized access to or compromise systems change frequently, are becoming increasingly
sophisticated and complex, and are often not detected until after an incident has occurred. As a result, NewGenIvf might not be able
to anticipate these techniques, implement adequate preventive measures, or immediately detect a potential compromise. If its security
measures, some of which are managed by third parties, or the security measures of its service providers or vendors, are breached or fail,
it is possible that unauthorized or illegal access to or acquisition, disclosure, use or processing of personal information, confidential
information, or other sensitive client or employee data, including protected health information, may occur. A security breach or failure
could result from a variety of circumstances and events, including third-party action, human negligence or error, malfeasance, employee
theft or misuse, phishing and other social engineering schemes, computer viruses, attacks by computer hackers, failures during the process
of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, and
catastrophic events. If NewGenIvf&#8217;s security measures, or those of its service providers or vendors, were to be breached or fail,
its reputation could be severely damaged, adversely affecting client or investor confidence. As a result, clients may curtail their use
of or stop using its offering and its business may suffer. In addition, NewGenIvf could face litigation, damages for contract breach,
penalties and regulatory actions for violation of laws or regulations applicable to data protection and significant costs for remediation
and for measures to prevent future occurrences. In addition, any potential security breach could result in increased costs associated
with liability for stolen assets or information, repairing system damage that may have been caused by such breaches, incentives offered
to clients or other business partners in an effort to maintain the business relationships after a breach and implementing measures to
prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees
and engaging third-party experts and consultants. Negative publicity may also result from real, threatened or perceived security breaches
affecting it or its industry or clients, which could cause it to lose clients or partners and adversely affect its operations and future
prospects. NewGenIvf may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not
be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage
that could result from a security incident.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Fraud and Abuse Laws. </i></b>NewGenIvf may be impacted directly
    and indirectly by certain fraud and abuse laws, including the Act Supplementing the Constitution Relating to the Prevention and Suppression
    of Corruption B.E. 2561 (2018)&#160;of Thailand, the Penal Code of Thailand, the Criminal Code of Cambodia, the Offences Code of
    October&#160;28, 2021 No. 128 of Kyrgyzstan, the Criminal Code of October&#160;28, 2021, No. 17 of Kyrgyzstan and the Law on prevention
    of corruption of August&#160;8, 2021 No. 153 of Kyrgyzstan. Because the solutions and services NewGenIvf provides are not reimbursed
    by government healthcare payors, such fraud and abuse laws generally do not directly apply to its business, however, some laws may
    be applicable. The laws, regulations and other requirements in this area are both broad and vague and judicial interpretation can
    also be inconsistent. NewGenIvf reviews its practices with regulatory experts in an effort to comply with all applicable laws, regulatory
    and other requirements. However, NewGenIvf is unable to predict how these laws, regulations and other requirements will be interpreted
    or the full extent of their application, particularly to services that are not directly reimbursed by healthcare programs. Any determination
    by a regulatory authority that any of NewGenIvf&#8217;s activities or those of its clients or vendors violate any of these laws or
    regulations could subject NewGenIvf to civil or criminal penalties, require it to enter into corporate integrity agreements or similar
    agreements with ongoing compliance obligations, disqualify it from providing services to clients and/or have an adverse impact on
    its business, financial condition and results of operations. Even an unsuccessful challenge by a regulatory authority of NewGenIvf&#8217;s
    activities could result in adverse publicity and could require a costly response from it.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Consumer Protection Laws. </i></b>Consumer protection laws are
    being applied increasingly by the Office of the Consumer Protection Board in Thailand and by the Cambodia Ministry of Health to regulate
    the collection, use, storage and disclosure of personal or health information, through websites or otherwise, and, in Cambodia, by
    the Consumer Protection Competition and Fraud Repression Directorate-General, to regulate the presentation of website content. Courts
    may also adopt the standards for fair information practices, which concern consumer notice, choice, security and access.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Restrictions on Communication. </i></b>Communications with NewGenIvf&#8217;s
    clients increasingly may be subject to and restricted by laws and regulations governing communications via telephone, fax, text,
    and email. NewGenIvf also uses email and social media platforms as marketing tools. For example, NewGenIvf maintains social media
    accounts. As laws and regulations rapidly evolve to govern the use of these platforms and devices, the failure by it, its employees
    or third parties acting at its direction to abide by applicable laws and regulations in the use of these platforms and devices could
    adversely impact its business, financial condition and results of operations or subject it to fines or other penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b><i>&#9679;</i></b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Advertisement Laws. </i></b>NewGenIvf&#8217;s advertisement and
    announcements, in particular, the messages releasing on the Internet related to medical facilities may subject to the laws and regulations
    of relevant jurisdictions (and potential prohibition in Cambodia on commercial advertisement of private medical services).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
example, in Thailand, NewGenIvf shall apply for and obtain the approval and/ or pre-approval from the relevant authority for the images,
and text used in advertisements or announcements which shall be in accordance with the Medical Facility Act B.E. 2541 (1998)&#160;(and
its amendments) and the Notification of the Department of Health Services Support on Rules, Procedures, Conditions, and Costs of Advertisements
or Announcements of Healthcare Facilities B.E. 2562 (2019)&#160;(and its amendments) and the Operational Manual for Approval of Advertisements
or Announcements relating to Healthcare Facilities. If such approval was not obtained by NewGenIvf, it could lead to significant liabilities
and consequences, which could adversely impact NewGenIvf&#8217;s business, financial condition and results of operations or subject its
sales and marketing director to personal liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
Cambodia, Prakas 028 on Advertisement of Private Medical, Paramedical and Medical Aid Practices dated August&#160;23, 2004 issued by
the Cambodia MOH prohibits commercial advertising of private medical services. Advertisement of private health care services is only
allowed for any advertisements within the professional framework not affecting the ethics of private medical services and such advertisement
requires a permit from the Cambodia MOH.&#160;In addition, the Royal Government of Cambodia has recently issued Sub-Decree 232 on the
Management of Commercial Advertisements of Goods and Services on November&#160;4, 2022 to provide the legal framework for the management
of commercial advertising of goods and services for all types, forms and means in Cambodia. In light of this Sub-Decree, in addition
to the permit requirement of the Cambodia MOH, a person wishing to advertise their goods and/or services in Cambodia may also apply for
a compliance certificate from the Ministry of Commerce, which certifies that advertising text or content complies with the Law on Consumer
Protection or other applicable regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-size: 10pt">For
Kyrgyzstan, the Law on Advertisements of December&#160;24, 1998, No. 155 requires that if the activities of the advertiser subject to
licensing, the advertisement of such advertiser must include the license number and the name of the authority that issued the license,
except for radio advertising, where it is sufficient to state &#8220;licensed activity&#8221; on the territory of Kyrgyzstan. In advertising
goods (including works and services), and other objects of advertising, cost indicators must be stated in the national currency. There
are also other requirements established in relation to size, frequency, cost and other features of advertisements via different types
of media.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">New
laws and regulations relevant to the fertility services may be introduced in the future, or the current applicable regulations may otherwise
be amended or replaced requiring the assisted reproductive medical facilities in its network to conduct business with additional oversight
and regulatory compliance. If NewGenIvf fails to obtain the necessary licenses, permits and approvals, NewGenIvf may be subject to fines,
confiscation of revenues generated from incompliance operations, or the suspension of relevant operations. NewGenIvf may also experience
adverse publicity arising from such non-compliance with government regulations that negatively impacts its brand. NewGenIvf may experience
difficulties or failures in obtaining the necessary approvals, licenses, and permits for new spaces or new service offerings. If NewGenIvf
fails to obtain the material licenses, NewGenIvf&#8217;s business activities could be severely delayed. In addition, there can be no
assurance that NewGenIvf will be able to obtain, renew, and/or convert all of the approvals, licenses, and permits required for its existing
business operations upon their expiration in a timely manner, in a cost-efficient manner or at all, which could adversely affect NewGenIvf&#8217;s
business operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, considerable uncertainties exist in relation to the interpretation and implementation of existing and future laws and regulations
governing NewGenIvf&#8217;s business activities. NewGenIvf could be found not in compliance with any future laws and regulations or of
the laws and regulations currently in effect due to changes in the relevant authorities&#8217; interpretation of those laws and regulations.
It is possible that different interpretations or enforcement of these regulations could subject the current or past practices to allegations
of impropriety or illegality or require the medical facilities in its network to implement changes in the facilities, equipment, personnel
or services, or increase capital expenditure and operating expenses. If NewGenIvf fails to complete, obtain, or maintain any of the required
licenses or approvals or make the necessary filings, NewGenIvf may be subject to various penalties, such as confiscation of unlawful
gains, the imposition of fines, revocation of licenses, and the discontinuation or restriction of NewGenIvf&#8217;s operations. Any such
penalties or changes in policies, regulations, or enforcement by government authorities may disrupt NewGenIvf&#8217;s operations and
materially and adversely affect NewGenIvf&#8217;s business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Legal or
regulatory restriction, government regulation, industry standards and other requirements create risks and challenges with respect to
NewGenIvf&#8217;s compliance efforts and its business strategies and could adversely impact NewGenIvf&#8217;s business and limited the
growth of NewGenIvf&#8217;s operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
healthcare industry is highly regulated and subject to frequently changing laws, regulations, industry standards and other requirements.
Many healthcare laws and regulations are complex, and their application to specific solutions, services and relationships may not be
clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the solutions and services that
NewGenIvf provides, and these laws and regulations may be applied to its solutions and services in ways that NewGenIvf does not anticipate.
Efforts to reform or revise aspects of the healthcare industry or to revise or create additional legal or and regulatory requirements
could impact its operations, the use of its solutions and services, and its ability to market new solutions and services, or could create
unexpected liabilities for it. NewGenIvf also may be impacted by laws, industry standards and other requirements that are not specific
to the healthcare industry, such as consumer protection laws and payment card industry standards. These requirements may impact its operations
and, if not followed, could result in fines, penalties and other liabilities and adverse publicity and injury to its reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is a risk that existing or future laws may be interpreted in a manner that is not consistent with the healthcare industry&#8217;s current
practices and could have an adverse effect on NewGenIvf&#8217;s business, financial condition, results of operations and growth prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Any litigation
against NewGenIvf could be costly and time-consuming to defend and could harm its business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has in the past and may in the future become subject to regulatory actions, litigation, disputes, or claims of various types, legal proceedings
and claims that arise in the ordinary course of business, such as claims brought by its clients or vendors in connection with commercial
disputes or employment claims made by its current or former employees, as well as claims brought by relevant regulatory authorities or
NewGenIvf&#8217;s competitors, patients, employees, or other third parties against NewGenIvf. NewGenIvf is unable to predict the outcome
of any of these legal proceedings. Such regulatory actions, disputes, allegations, complaints, or legal proceedings may damage NewGenIvf&#8217;s
reputation, evolve into litigation, or otherwise have a material adverse impact on NewGenIvf&#8217;s reputation and business. Such proceedings
might result in substantial costs, regardless of the outcome, and may significantly divert management&#8217;s attention and resources
from operating NewGenIvf&#8217;s business, which might seriously harm its business, financial condition and results of operations. Insurance
might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims, and might
not continue to be available on terms acceptable to it. A claim brought against it that is uninsured or underinsured could result in
unanticipated costs, potentially harming its business, financial condition and results of operations. The outcomes of actions NewGenIvf
institutes may not be successful or favorable to NewGenIvf. Lawsuits against NewGenIvf may also generate negative publicity that significantly
harms NewGenIvf&#8217;s reputation, which may adversely affect NewGenIvf&#8217;s client base. NewGenIvf may also need to pay damages
or settle lawsuits with a substantial amount of cash.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Acquisitions,
strategic investments, partnerships, or alliances could be difficult to identify, pose integration challenges, divert the attention of
management, disrupt NewGenIvf&#8217;s business, dilute stockholder value, and adversely affect its business, financial condition and
results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
may in the future seek to acquire or invest in businesses, joint ventures, products and services, or technologies that it believes could
complement or expand its platform, enhance its technical capabilities, or otherwise offer growth opportunities. Any such acquisition
or investment may divert the attention of management and cause NewGenIvf to incur various expenses in identifying, investigating and
pursuing suitable opportunities, whether or not the transactions are completed, and may result in unforeseen operating difficulties and
expenditures. In particular, NewGenIvf may encounter difficulties assimilating or integrating the businesses, technologies, products
and services, personnel or operations of the acquired companies, particularly if the key personnel of the acquired company choose not
to work for it, they are operationally difficult to integrate, or NewGenIvf has difficulty retaining the clients of any acquired business
due to changes in ownership, management or otherwise. These transactions may also disrupt its business, divert its resources, and require
significant management attention that would otherwise be available for development of its existing business and may not benefit NewGenIvf&#8217;s
business strategy, may not generate sufficient revenues to offset the associated acquisition costs or may not otherwise result in the
intended benefits. Any such transactions that NewGenIvf is able to complete may not result in any synergies or other benefits it had
expected to achieve, which could result in impairment charges that could be substantial. In addition, NewGenIvf may not be able to find
and identify desirable acquisition targets or business opportunities or be successful in entering into an agreement with any particular
strategic partner. These transactions could also result in dilutive issuances of equity securities or the incurrence of debt, which could
adversely affect its results of operations. In addition, if the resulting business from such a transaction fails to meet NewGenIvf&#8217;s
expectations, or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations
may be adversely affected or it may be exposed to unknown risks or liabilities. Even when NewGenIvf identifies an appropriate acquisition
or investment target, it may not be able to negotiate the terms of the acquisition or investment successfully, obtain financing for the
proposed transaction, or integrate the relevant businesses into its existing business and operations. Strategic investments or acquisitions
will involve risks commonly encountered in business relationships, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in assimilating and integrating the operations, personnel,
    systems, data, technologies, products and services of the acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability of the acquired technologies, products or businesses to achieve
    expected levels of revenue, profitability, productivity or other benefits;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in retaining, training, motivating and integrating key
    personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">diversion of management&#8217;s time and resources from NewGenIvf&#8217;s
    normal daily operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in maintaining uniform standards, controls, procedures
    and policies within the combined organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulties in retaining relationships with customers, employees and
    suppliers of the acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">risks of entering markets in which NewGenIvf have limited or no prior
    experience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory risks, including remaining in good standing with existing
    regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with
    oversight over an acquired business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assumption of contractual obligations that contain terms that are not
    beneficial to NewGenIvf, require it to license or waive intellectual property rights or increase its risk for liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to further successfully develop the acquired technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">liability for activities of the acquired business before the acquisition,
    including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities and other known and
    unknown liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential disruptions to NewGenIvf&#8217;s ongoing businesses; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unexpected costs and unknown risks and liabilities associated with
    strategic investments or acquisitions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Even
if the transaction is consummated, NewGenIvf may only have limited control over the companies in which it only has minority stake, it
cannot ensure that these companies will always comply with applicable laws and regulations in their business operations. Non-compliance
of regulatory requirements by NewGenIvf&#8217;s investees may cause substantial harm to NewGenIvf&#8217;s reputations and the value of
NewGenIvf&#8217;s investment. In addition, if the resulting business from such a transaction fails to meet NewGenIvf&#8217;s expectations,
or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations may be
adversely affected or it may be exposed to unknown risks or liabilities. If NewGenIvf is unable to effectively address these challenges,
its ability to execute acquisitions as a component of its long-term strategy will be impaired, which could have an adverse effect on
its growth. As a result of the above, NewGenIvf&#8217;s strategies may not be successfully implemented beyond the current markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Any
investment might not achieve the synergies, operational or financial benefits it expects and may adversely impact NewGenIvf&#8217;s operating
results. In addition, NewGenIvf cannot assure you that any future investment in or acquisition of new businesses or technology will lead
to the successful development of new or enhanced products and services or that any new or enhanced products and services, if developed,
will achieve market acceptance, or prove to be profitable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Changes in
NewGenIvf&#8217;s effective tax rate or tax liability may have an adverse effect on its results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
effective tax rate could increase due to several factors, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in the relative amounts of income before taxes in the various
    jurisdictions in which NewGenIvf operates that have differing statutory tax rates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in tax laws, tax treaties, and regulations or the interpretation
    of them;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes to its assessment about its ability to realize its deferred
    tax assets that are based on estimates of its future results, the prudence and feasibility of possible tax planning strategies, and
    the economic and political environments in which NewGenIvf does business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the outcome of future tax audits, examinations, or administrative appeals;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">limitations or adverse findings regarding its ability to do business
    in some jurisdictions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Any
of these developments could have an adverse effect on its results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf&#8217;s
reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Accounting
principles generally accepted in Thailand, Cambodia and Kyrgyzstan are subject to interpretation by the relevant supervision institutions,
and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations
could have a significant effect on NewGenIvf&#8217;s reported results of operations and could affect the reporting of transactions already
completed before the announcement of a change. The adoption of new or revised accounting principles may require it to make changes to
its systems, processes and control, which could have a significant effect on its reported financial results, cause unexpected financial
reporting fluctuations, retroactively affect previously reported results or require it to make costly changes to its operational processes
and accounting systems upon or following the adoption of these standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>If NewGenIvf&#8217;s
estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect
the amounts reported in NewGenIvf&#8217;s consolidated financial statements and accompanying notes appearing elsewhere in this prospectus.
NewGenIvf bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances,
as provided in the section titled &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
of NewGenIvf&#160;&#8212;&#160;Critical Accounting Policies, Judgments and Estimates</i>.&#8221; The results of these estimates form
the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenue and expenses that
are not readily apparent from other sources. Significant estimates and judgments used in preparing NewGenIvf&#8217;s consolidated financial
statements include those related to the determination of fair value of its Class A Ordinary Shares and Warrants and revenue recognition
relating to services rendered but for which no claim has yet been reported, among other things. NewGenIvf&#8217;s results of operations
may be adversely affected if its assumptions change or if actual circumstances differ from those in its assumptions, which could cause
its results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price
of its Class A Ordinary Shares and Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>NewGenIvf
is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it
to criminal or civil liability and harm its business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is subject to the Anti-Money Laundering Act B.E. 2542 (1999)&#160;of Thailand, the Act Supplementing the Constitution Relating to the
Prevention and Suppression of Corruption B.E. 2561 (2018)&#160;of Thailand, and the Penal Code of Thailand, domestic bribery laws, and
other anticorruption and anti-money laundering laws in the countries in which it conducts activities. Anti-corruption and anti-bribery
laws have been enforced aggressively in recent&#160;years and are interpreted broadly to generally prohibit companies, their employees
and their third-party intermediaries from authorizing, offering, or providing, directly or indirectly, improper payments or benefits
to recipients in the public or private sector. If NewGenIvf expands its business and sales and to the public sector, it may engage with
business partners and third-party intermediaries to market its services and to obtain for it the necessary permits, licenses, and other
regulatory approvals. In addition, NewGenIvf or its third-party intermediaries may have direct or indirect interactions with officials
and employees of government agencies or state-owned or affiliated entities. NewGenIvf can be held liable for the corrupt or other illegal
activities of these third-party intermediaries, its employees, representatives, contractors, partners and agents, even if it does not
explicitly authorize such activities. Detecting, investigating, and resolving actual or alleged violations of anti-corruption laws can
require a significant diversion of time, resources, and attention from senior management. In addition, noncompliance with anti-corruption,
anti-bribery, or anti-money laundering laws could subject it to whistleblower complaints, investigations, prosecution, enforcement actions,
sanctions, settlements, fines, damages, other civil or criminal penalties or injunctions, suspension or debarment from contracting with
certain persons, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas or investigations are
launched, or governmental or other sanctions are imposed, or if NewGenIvf does not prevail in any possible civil or criminal proceeding,
its business, financial condition and results of operations could be harmed. In addition, responding to any action will likely result
in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional
fees, which could adversely affect its business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-size: 10pt">For
more information about our SEC filings, please see &#8220;<i>Where You Can Find More Information</i>&#8221; and &#8220;<i>Incorporation
by Reference</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Some
of the statements made under &#8220;<i>Prospectus Summary</i>,&#8221; &#8220;<i>Risk Factors</i>,&#8221; &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i>,&#8221; &#8220;<i>Business</i>&#8221; and elsewhere in this
prospectus constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; &#8220;intends&#8221; or &#8220;continue,&#8221; or the negative
of these terms or other comparable terminology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our
                                            planned level of revenues and capital expenditures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to market and sell our products and services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our plans to continue to invest in research and development to develop
    technology for both existing and new products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain our relationships with suppliers, manufacturers
    and other partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain or protect the validity of our intellectual
    property and know-how;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to retain key executive members;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to internally develop and protect new inventions and intellectual
    property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to expose and educate the industry about the use of our
    services and products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our expectations regarding our tax classifications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">interpretations of current laws and the passages of future laws; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of the coronavirus (COVID-19) pandemic and resulting government
    actions on us, our manufacturers, suppliers and facilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our
or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &#8220;<i>Risk
Factors</i>&#8221; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="s_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth information regarding our executive officers and directors as of the date of this prospectus.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 35%; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 55%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors, Chief Executive
    Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hei Yue Tina Fong</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chief Marketing Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hok Man Jefferson Au</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yip Eng Jeremy Foo</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ho Fai Chung</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Wing
Fung Alfred Siu</i></b><i>.&#160;</i>NewGenIvf&#8217;s co-founder, Mr. Wing Fung Alfred Siu, has served as the Chairman of the Board
and the Chief Executive Officer of NewGenIvf (before the Closing, Legacy NewGenIvf) since 2019. Prior to establishing Legacy NewGenIvf
in 2019, Mr.&#160;Siu served as a director of First Fertility PGS Center Co., Ltd. since 2014. Mr.&#160;Siu received his master&#8217;s
degree in science and bachelor&#8217;s degree in science from Stanford University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Hei
Yue Tina Fong.&#160;</i></b>Ms. Fong has served as a Director and the Chief Marketing Officer of NewGenIvf (before the Closing, Legacy
NewGenIvf) since 2019. Prior to establishing NewGenIvf in 2019, Ms. Fong served as a director of First Fertility PGS Center Co., Ltd.
since 2014. Ms. Fong received her bachelor&#8217;s degree in marketing from Indiana University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ho
Fai Chung</i></b>. Mr. Chung has served as NewGenIvf&#8217;s Chief Financial Officer since October 10, 2024. Mr. Chung has over 30 years
of working experience in Asia. He is a certified public accountant in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.
Chung served as Financial Controller of King City Limited, a Hong Kong beauty salon, from January 2024 to May 2024. In this role, Mr.
Chung evaluated and implemented the company&#8217;s sales system; set up employment contracts for staff members; set up the staff appraisal
system for salary review, performance evaluation, and staff productivity; and set up a new management account format for the company
for better evaluation of its business metrics. Prior to this role, Mr. Chung was the Accounting Manager at Beauty Land Holdings Ltd,
another Hong Kong beauty salon, from May of 2017 to November of 2023. As Accounting Manager, Mr. Chung built up effective management
tools to monitor and control all of the financial and accounting functions of the company and developed business strategies with the
General Manager in order to achieve the company&#8217;s financial goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.
Chung started his career in an accountancy firm, Price Waterhouse (&#8220;PwC&#8221;), in Hong Kong. After five full years of working
exposure in PwC, Mr. Chung joined a number of companies to take up regionalfinancial control as well as general management jobs in businesses
including fashion, office products, telecommunications/internet and advertising. He had worked and based in China,Taiwan, Singapore and
Malaysia before and had extensive regional financial controlling exposure in Asia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Born
in Hong Kong, Mr. Chung holds a Bachelor of Law degree from University of London and a Master&#8217;s degree in Accounting and Finance
from Lancaster University (UK). Mr. Chung also holds a Master&#8217;s degree in International and Public Affairs from Hong Kong University.
He is a certified public accountant in the U.S.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Hok
Man Jefferson Au</i></b>. Mr. Au has served as NewGenIvf&#8217;s independent director since April 3, 2024. Mr. Au has served as the Assistant
Financial Controller and the Company Secretary at Coolpoint Innonism Holding Limited since May 2017 and a director of JWMG CPA Limited,
Certified Public Accountants since August 2014. He previously worked as the audit supervisor at Clement C.W. Chan &amp; Co., Certified
Public Accountants from September 2010 to March 2014. Mr. Au obtained his honours diploma in accounting from Hong Kong Shue Yan University
(formerly known as Hong Kong Shue Yan College) and received his Master of Science in professional accountancy from the University of
London. Mr. Au is a member of the Hong Kong Institute of Certified Public Accountants and an associate of the Association of Chartered
Certified Accountants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yip
Eng Jeremy Foo. </i></b>Mr. Foo has served as NewGenIvf&#8217;s independent director since April 3, 202. Mr. Foo has been a freelance
organizational development and learning consultant since 2007. Mr. Foo previously served as the head of human capital practice of Changi
Airports International, or CAI, from 2008 to 2011. Prior to joining CAI, Mr. Foo served as the head of institute of management and allied
health sciences of National Healthcare Group, or NHG, from 2005 to 2007. Prior to joining NHG, Mr. Foo served as the head of Ministry
of Defence, Singapore, or MINDEF, and served as CEO of MINDEF centre for management development, from 1998 to 2005. Prior to joining
MINDEF, Mr. Foo worked in key senior positions covering strategic and operations planning, sea command, and naval leadership and professional
development of Republic of Singapore Navy from 1979 to 1998. Mr. Foo obtained his Bachelor of Science from National University of Singapore
and his Postgraduate Certificate in Business Administration from University of Leicester.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Election of Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our
executive officers are appointed by, and serve at the discretion of, the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.
Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong are husband and wife. Other than as disclosed in this prospectus, none of the directors
or executive officers has a family relationship as defined in Item 401 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Involvement in Certain
Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To
the best of our knowledge, none of our directors or executive officers has, during the past ten years, been involved in any legal proceedings
described in subparagraph (f) of Item 401 of Regulation S-K. Our directors and officers have not been involved in any transactions with
us or any of our affiliates or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Diversity Matrix
of Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table provides the diversity statistics of the Board, as required by Rule 5606 of the Nasdaq Listing Rules:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Board Diversity Matrix as at the
    date of this prospectus</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Country of Principal Executive Offices:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thailand</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign Private Issuer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Disclosure Prohibited Under Home Country Law</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Number of Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Female</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Male</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-Binary</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Did Not <br/>
    Disclose <br/>
    Gender</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Part I: Gender Identity</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Directors</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">3</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Part II: Demographic Background</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Underrepresented Individual in Home Country Jurisdiction</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">LGBTQ+</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Did Not Disclose Demographic Background</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>B. Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
following table sets forth the amount of compensation, including base salary, discretionary bonus, equity compensation, contractual benefits
and contributions to defined contribution plans, which was paid, earned and/or accrued during the fiscal years ended December 31, 2023
and 2022, for each of the officers and directors for Legacy NewGenIvf prior to the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023<br/> Compensation<br/> US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022<br/> Compensation<br/> US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Directors and Officers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wing Fung Alfred Siu</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">125,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Hei Yue Tina Fong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">250,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">240,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><b>Committees
of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
established three committees under the Board: an audit committee (&#8220;Audit Committee&#8221;), a Compensation Committee (&#8220;Compensation
Committee&#8221;) and a nominating and corporate governance committee (&#8220;Nominating and Corporate Governance Committee). We have
adopted a charter for each of the three committees. Each committee&#8217;s members and functions are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Audit
Committee</i>. Our Audit Committee consists of Mr. Hok Man Jefferson Au and Mr. Yip Eng Jeremy Foo. We have determined that all of these
individuals satisfy the &#8220;independence&#8221; requirements of NASDAQ Rule 5605 and Rule 10A-3 under the Exchange Act. Our Board
has determined that Mr. Hok Man Jefferson Au qualifies as an audit committee financial expert and has the accounting or financial management
expertise as required under Item 407(d)(5)(ii) and (iii) of Regulation S-K. The audit committee will oversee our accounting and financial
reporting processes and the audits of the financial statements of our company. The Audit Committee will be responsible for, among other
things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            clear hiring policies for employees or former employees of the independent auditors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending to the Board for approval, the appointment, reappointment or removal of
                                            the independent auditor, after considering its annual performance evaluation of the independent
                                            auditor;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                            the remuneration and terms of engagement of the independent auditor and pre-approving all
                                            auditing and non-auditing services permitted to be performed by the Company&#8217;s independent
                                            auditors at least annually;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            a written report from the Company&#8217;s independent auditor describing matters relating
                                            to its independence and quality control procedures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            with the independent registered public accounting firm any audit problems or difficulties
                                            and management&#8217;s response;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                            with the Company&#8217;s independent auditor, among other things, the audits of the financial
                                            statements, including whether any material information should be disclosed, in addition to
                                            issues regarding accounting and auditing principles and practices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and approving all proposed related party transactions, as defined in Item&#160;404 of Regulation&#160;S-K
                                            under the Securities Act;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending the financial statements for inclusion within the Company&#8217;s quarterly
                                            earnings releases and to the Board for inclusion in its annual reports;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                            the annual audited financial statements with management and the independent registered public
                                            accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            policies with respect to risk assessment and risk management;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            the adequacy and effectiveness of the Company&#8217;s accounting and internal control policies
                                            and procedures and any special steps taken to monitor and control major financial risk exposures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            reviewing and reassessing the adequacy of the committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                            annual audit plans, and undertaking an annual performance evaluation of the internal audit
                                            function;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            and overseeing procedures for the handling of complaints and whistleblowing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
                                            separately and periodically with management, the internal auditors and the independent registered
                                            public accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
                                            compliance with the Company&#8217;s code of business conduct and ethics, including reviewing
                                            the adequacy and effectiveness of its procedures to ensure proper compliance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
                                            periodically to the Board; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other matters that are specifically delegated to the Company&#8217;s Audit Committee by the
                                            Board from time to time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of
the audit committee&#8217;s current charter is available at our corporate website at www.newgenivf.com.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Compensation
Committee</i>. Our Compensation Committee (&#8220;Compensation Committee&#8221;) consists of Mr. Wing Fung Alfred Siu, Ms. Hei Yue Tina
Fong, and Mr. Yip Eng Jeremy Foo. The Chairman of the Compensation Committee is Mr. Siu. The Company has determined that Mr. Foo satisfies
the &#8220;independence&#8221; requirements of Rule&#160;5605(c)(2)&#160;of the Nasdaq Stock Market Listing Rules. The Compensation Committee
assists the Board in reviewing and approving compensation structure, including all forms of compensation relating to the Company&#8217;s
directors and executive officers. The Company&#8217;s Chief Executive Officer may not be present at any committee meeting during which
their compensation is deliberated upon. The Compensation Committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and evaluating the Company&#8217;s executive compensation and benefits policies generally;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending any incentive compensation or equity plans, programs or other similar arrangements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            reviewing and reassessing the adequacy of the Compensation Committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
                                            compensation consultant, legal counsel or other adviser only after taking into consideration
                                            all factors relevant to that person&#8217;s independence from management;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
                                            periodically to the Board; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other matters that are specifically delegated to the Compensation Committee by the Board
                                            from time to time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A
copy of the Compensation Committee&#8217;s current charter is available at our corporate website at: www.newgenivf.com.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Nominating
and Corporate Governance Committee</i>. The Company&#8217;s Nominating and Corporate Governance Committee consist of Mr. Wing Fung Alfred
Siu, Ms. Hei Yue Tina Fong, and Mr. Hok Man Jefferson Au. The Chairman of the Nominating and Corporate Governance Committee is Mr. Siu.
The Company has determined that Mr. Au satisfies the &#8220;independence&#8221; requirements of Rule&#160;5605(c)(2)&#160;of the Nasdaq
Stock Market Listing Rules. The Nominating and Corporate Governance Committee assists the Board of Directors in selecting individuals
qualified to become the Company&#8217;s directors and in determining the composition of the Board of Directors and its committees. The
Nominating and Corporate Governance Committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            nominees to the Board for election or re-election to the Board, or for appointment to fill
                                            any vacancy or newly created directorships on the Board;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            periodically with the Board the current composition of the Board with regards to characteristics
                                            such as judgment, experience, expertise, diversity and background;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the Board of criteria with respect to nomination or appointment of members of its Board
                                            of Directors and chairs and members of its committees or other corporate governance matters
                                            as may be required pursuant to any SEC or Nasdaq Stock Market Listing Rules, or otherwise
                                            considered desirable and appropriate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the Board the names of directors to serve as members of the Audit Committee and the Compensation
                                            Committee, as well as of the Nominating and Corporate Governance Committee itself;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
                                            and reassessing the adequacy of the committee charter;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                            compliance with the corporate governance guidelines and code of business conduct and ethics;
                                            and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                            and leading the self-evaluation of the Board in its performance and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
                                            as a whole.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A
copy of the Nominating and Corporate Governance Committee&#8217;s current charter is available at our corporate website at www.newgenivf.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Duties and Functions
of Directors</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under
the laws of the British Virgin Islands, the Company&#8217;s directors owe fiduciary duties to the Company, including duty to act honestly
and in good faith in what the directors believe to be in the best interests of the company, duty to exercise powers for a proper purpose
and directors shall not act, or agree to act, in a matter that contravenes the BVI Companies Act or the Memorandum and Articles of Association,
duty to exercise the care, diligence and skill that a reasonable director would exercise in the circumstances, and duty to avoid conflicts
of interest. In fulfilling their duty of care to the Company, the Company&#8217;s directors must ensure compliance with the Company&#8217;s
Memorandum and Articles of Association, as amended and restated from time to time. The Company has the right to seek damages if a duty
owed by its directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in the Company&#8217;s
name if a duty owed by the Company&#8217;s directors is breached. The functions and powers of the Board include, among other things,
(i)&#160;convening shareholder meetings at such times and in such manner and places as the director considers necessary or desirable,
(ii)&#160;declaring dividends, (iii)&#160;appointing directors or officers and determining their terms of offices and responsibilities,
and (iv)&#160;approving the transfer of shares of the Company, including the registering of such shares in the Company&#8217;s share
register.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Terms of Directors
and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Company&#8217;s officers are elected by and serve at the discretion of the Board. Each director holds office for the term fixed by the
resolution of shareholders or the resolution of directors appointing him until such time as his successor takes office or until the earlier
of his death, resignation or removal from office by resolution of directors with or without cause or by resolution of shareholders for
cause. The directors may at any time appoint any person to be a director either to fill a vacancy or as an addition to the existing directors.
Where the directors appoint a person as director to fill a vacancy, the term shall not exceed the term that remained when the person
who has ceased to be a director ceased to hold office. A vacancy in relation to directors occurs if a director dies or otherwise ceases
to hold office prior to the expiration of his term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Interested Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A
director may, subject to any separate requirements for Audit Committee approval under applicable laws or applicable Nasdaq Stock Market
Listing Rules, vote on a matter relating to the transaction in which he or she is interested, provided that the interest of any directors
in such transaction is disclosed by him or her to all other directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Director Agreements&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
have entered into director agreements with our directors, which require us to maintain director and officer liability insurance for our
directors, provide reimbursements for business related travel and accommodation and other reasonable expenses, and an annual remuneration
of between $20,000 to $25,000 for our independent directors, and $240,000&#160;&#160;for our executive directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As
of December 31, 2023, Legacy NewGenIvf had 70 full-time employees, of which 63 are based in Thailand, Cambodia and Kyrgyzstan. NewGenIvf
aims to attract and retain employees with the skills, and experience necessary to implement its growth strategy. The following table
sets forth the number of its employees in Thailand, Cambodia and Kyrgyzstan by function as of December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Function</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> employees</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Thailand</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Medical professionals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Administrative staff and others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Sub-total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Medical professionals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Administrative staff and others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Sub-total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Medical professionals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Administrative staff and others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Sub-total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Hong&#160;Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Administrative staff and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">70</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
believe that we maintain a good working relationship with our employees and we have not experienced any significant labor disputes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except
as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares as
of the date of this annual report by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and executive officers; and</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our principal shareholders who beneficially own more than 5% of our total outstanding
                                            ordinary shares;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
calculations in the table below are based on 10,149,386 Class A Ordinary Shares outstanding as of May 10, 2024.&#160;Unless otherwise
indicated, each person has sole investment and voting power with respect to all shares shown as beneficially owned. The term &#8220;beneficial
owner&#8221; of securities refers to any person who, even if not the record owner of the securities, has or shares the underlying benefits
of ownership. These benefits include the power to direct the voting or the disposition of the securities or to receive the economic benefit
of ownership of the securities. A person also is considered to be the &#8220;beneficial owner&#8221; of securities that the person has
the right to acquire within 60 days by option or other agreement. Beneficial owners include persons who hold their securities through
one or more trustees, brokers, agents, legal representatives or other intermediaries, or through companies in which they have a &#8220;controlling
interest&#8221;, which means the direct or indirect power to direct the management and policies of the entity. The Company&#8217;s directors
and executive officers do not have different voting rights than other shareholders of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Five Percent Holders other than our Directors and Officers</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Chardan Capital Markets, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,569,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15.46</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">A SPAC Holdings Group Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">655,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Future Yield Holdings Limited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kit Yee Sze</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wing Fung Alfred Siu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,779,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.53</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hei Yue Tina Fong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,326,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.92</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hok Man Jefferson Au</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yip Eng Jeremy Foo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chiu, Wai Yip Raymond</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All Directors and Executive Officers as Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,105,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40.45</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="s_002"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>RELATED
PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Related Party Transactions</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A
summary of related parties of the Company is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 49%">&#160;</td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seazen Resources Investment Limited</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders and directors<sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harcourt Limited</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A related company<sup>(2)</sup></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
                                            Fong is the spouse of Mr. Siu.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            directors and shareholders of Harcourt Limited are Mr. Wing Fung Alfred Siu and Ms. Hei Yue
                                            Tina Fong.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Transaction with Seazen Resources Investment
Limited</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the year ended December 31, 2022, Legacy NewGenIvf had consideration receivables from Seazen Resources Investment Limited, representing
the unsettled consideration for Legacy NewGenIvf&#8217;s shares. For the years ended December 31, 2022 and 2023, the largest amount outstanding
was US$319,872. As of the date of this prospectus, the balance of loans receivable from Seazen Resources Investment Limited is US$ Nil.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately,
Legacy NewGenIvf borrowed money from Seazen Resources Investment Limited in May 2020 primarily for its general working capital purposes.
The maximum borrowing was HKD5,000,000. The borrowing carried fixed interest at 18.0% per annum. Interest expense on the borrowing was
US$45,988 and US$Nil during the year ended December 31, 2022 and 2023, respectively. As at December 31, 2023, the amount outstanding
was nil.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Transaction with
Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically,
certain amount of cash provided by operating activities was distributed to Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong, resulting
in amount due from them. As of the date of this prospectus, the aggregate balance of amount due from Mr. Siu and Ms. Fong was US$354,285
and US$2,240,872, respectively. For the years ended December 31, 2022 and 2023, the largest amount due from Mr. Siu, Wing Fung Alfred
and Ms. Fong, Hei Yue Tina was US$2,240,872, and US$2,240,872, respectively. Mr. Siu and Ms.&#160;Fong intend to continue to repay the
remaining outstanding amounts due pursuant to the terms and conditions of the repayment agreement dated August 14, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
addition, NewGenIvf also recorded remuneration to its directors, Mr. Siu and Ms. Fong. The remuneration to Mr. Siu, Wing Fung Alfred
was US$100,000, US$120,000 and US$125,000 during the year ended December 31, 2021, 2022 and 2023, respectively. The remuneration to Ms.
Fong, Hei Yue Tina was US$100,000, US$120,000 and US$125,000 during the year ended December 31, 2021, 2022 and 2023, respectively. The
remuneration during the years ended December 31, 2021, 2022 and 2023 was all in the nature of the fair value of the services provided
by Mr. Siu and Ms. Fong and was recorded as noncash operating expense and additional paid-in capital. Mr. Siu Wing Fung also entered
into agreement to waive the balance of due from the Company US$88,151 in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Transaction with
Harcourt Limited</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically,
NewGenIvf borrowed money from Harcourt Limited without interest for normal operating use in 2022 and 2023. For the years ended December
31, 2022 and 2023, the largest amount outstanding was US$110,773. As of December 31, 2022 and 2023, the borrowings payable to Harcourt
Limited were US$110,773 and US$ Nil, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>LISTING
DETAILS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
Ordinary Shares currently trade on Nasdaq under the symbol &#8220;NIVF.&#8221; As of the date of this prospectus, our only listed class
of securities are our Ordinary Shares. All of our Ordinary Shares, including those to be offered by the Selling Shareholders pursuant
to this prospectus, have the same rights and privileges. For more information, see &#8220;<i>Description of Share Capital&#8212;Ordinary
Shares</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>USE
OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
                                            will not receive any proceeds from the sale of the Ordinary Shares by the Selling Shareholders,
                                            but will receive proceeds from the exercise of the Warrants if the Warrants are exercised
                                            for cash, which proceeds will be used for working capital and other general corporate purposes.
                                            All net proceeds from the sale of the Ordinary Shares will go to the Selling Shareholders.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>DIVIDEND
POLICY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
have not declared or paid any cash dividend on our Ordinary Shares as of the date of this prospectus. We currently intend to retain any
future earnings and do not expect to pay any dividends in the near future. Any further determination to pay dividends on our ordinary
shares would be at the discretion of our Board of Directors, subject to applicable laws, and would depend on our financial condition,
results of operations, capital requirements, general business conditions, and other factors that our Board of Directors may deem relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>
</div><div><a id="aa_001"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>The
following discussion and analysis of our results of operations and financial condition should be read together with ou consolidated financial
statements and the notes thereto and other financial information, which are included elsewhere in this registration statement. Our financial
statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). In addition,
our financial statements and the financial information included in this registration statement reflect our organizational transactions
and have been prepared as if our current corporate structure had been in place throughout the relevant periods.<b>&#160;</b></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>This
section contains forward-looking statements. These forward-looking statements are subject to various factors, risks and uncertainties
that could cause actual results to differ materially from those reflected in these forward-looking statements. Further, as a result of
these factors, risks and uncertainties, the forward-looking events may not occur. Relevant factors, risks and uncertainties include,
but are not limited to, those discussed in the section entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and elsewhere in this
registration statement. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management&#8217;s
beliefs and opinions as of the date of this registration statement. We are not obligated to publicly update or revise any forward -looking
statements, whether as a result of new information, future events or otherwise. See &#8220;Cautionary Note Regarding Forward-Looking
Statements.&#8221;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is an assisted reproductive services (&#8220;ARS&#8221;) provider in Asia Pacific. Since the establishment of its first clinic in Thailand
in 2014, it has established itself as a long-standing ARS provider in the region. NewGenIvf&#8217;s mission is to assist couples and
individuals across Asia Pacific, regardless of fertility challenges that they may face, to fulfil their dreams of building families and
to increase their access to fertility treatments. Its strategic presence in Thailand, Cambodia, and Kyrgyzstan positions the company
to take advantage of opportunities across Asia Pacific.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is still in the early stage of materializing its long-term objective of building a comprehensive, sophisticated and high-end ARS platform
for its clients and providing personalized solutions based on NewGenIvf&#8217;s brands and client-generated services. NewGenIvf plans
to offer full fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities updates,
increase its brand awareness and market share, as well as expand service reach through acquisitions and partnerships, which NewGenIvf
believes will help expand its client base and enhance expertise attraction, and in turn strengthen NewGenIvf&#8217;s monetization capabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Key Factors Affecting NewGenIvf&#8217;s
Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
results of operation are principally affected by the following factors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Regulatory environment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
ARS market in Asia-Pacific region is highly regulated. The implementation and enforcement of laws, regulations and government policies
in Thailand, Cambodia, Kyrgyzstan and other applicable jurisdictions significantly impact the design, pricing and sale of fertility services
and cost of compliance for clinics across Asia Pacific. Medical facilities providing fertility services generally must be filed and registered
with the relevant supervision institutions and such filing and registration must be renewed periodically. Any change in laws, regulations
or policies in relation to such filing or registration could affect NewGenIvf&#8217;s ability and plans to launch new services and renew
registration for existing services. The regulatory framework for medical facilities and services, especially those involving ARS, is,
and will continue, evolving. Any changes in the applicable regulatory frameworks in the jurisdictions where NewGenIvf operates may materially
affect its financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Growth and competitive landscape
of Asia Pacific&#8217;s ARS market</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenue has historically been primarily derived from clients in Asia Pacific. As such, NewGenIvf&#8217;s financial performance and future
growth depend primarily on the demand for ARS, as well as changes in its competitive landscape, in Asia Pacific. Population growth, infertility
rates, and demand for facility treatments in the region will ultimately determine the demand for NewGenIvf&#8217;s services. According
to CIC, infertility is increasingly becoming prevalent globally, primarily driven by increasing average age of first birth, as well as
various lifestyle and environmental factors. Driven by an increased infertility rate and growing demand for children without birth defects,
resulting from improving living standards and improved awareness about birth defects and prevention, the global ARS market is expected
to continue to grow. Furthermore, according to CIC, a growing number of governments around the world has granted legal recognition to
same-sex marriages, which brings more desires for having children to form a complete family. According to CIC, because of the fertility
rate and recent government incentive policies, such as the Three-child Policy of China in 2021, the ARS market increased significantly
in Asia Pacific. Leveraging its status as a long-standing ARS provider in Asia Pacific, NewGenIvf expects to continue to be well positioned
to capture the expected growth in the demand for ARS in the area.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
date, NewGenIvf holds an exclusive license granted by a division of the Genetics and IVF Institute to use MicroSort technology in Thailand
and Cambodia, which is a form of pre-conception gender selection technology for humans. While NewGenIvf expects to benefit from first-mover
advantages for this technology in the two regions, market entry by potential competitors or faster-than-expected development of potential
competitors may affect its market position and demand for its services and cause downward pricing pressure on its treatments, which may
in turn materially and adversely affect its results of operations. Meanwhile, ARS market could also be affected by the macroeconomic
environment and geopolitical events. Uncertainty in the macroeconomic environment, resulting from a range of events and trends, including
the rise in global inflation and interest rates, supply chain disruptions, geopolitical pressures, including the unknown impact of current
and future trade regulations, changes in Asian-Pacific relations, fluctuation in foreign exchange rates, and associated global economic
conditions may result in volatility in ARS market and NewGenIvf&#8217;s operating performance. For example, NewGenIvf derives a substantial
portion of its revenue from Chinese clients and as such, its failure to maintain PRC-sourced revenues and access to new and existing
clients from the PRC could materially and adversely affect its results of operations and competitive position. However, the near-term
growth prospects of the PRC economy are unclear due to the uncertain effects of ongoing economic stress caused by policies to contain
the COVID-19 pandemic, trade and national security policies, and the elevated levels of private and public indebtedness, among others.
According to the National Statistics Bureau of the PRC, growth rate of China&#8217;s GDP for the year 2022 slowed down to 3.0% on a year-on-year
basis compared to the growth rate of approximately 8.4% for the year 2021. In the second quarter of 2023, China&#8217;s GDP grew only
0.8% on a quarter basis, a significant slowdown from the 2.2% quarter growth registered in the first quarter of 2023. A prolonged downturn
in the PRC economy generally could materially and adversely affect NewGenIvf&#8217;s results of operations and there is a significant
likelihood that NewGenIvf&#8217;s actual results over the time periods and under the scenarios covered by the projections would be different.
However, China&#8217;s GDP in the third quarter of 2023 grew 4.9% on a year-on-year basis and grew 1.3% on a quarter-by-quarter basis.
NewGenIvf believes that if there is a recovery of the PRC economy, it might increase the demand for NewgenIvf&#8217;s services and therefore
in turn affect NewGenIvf&#8217;s results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Fluctuation
of costs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
costs primarily include clinic costs, cost of goods sold, selling and marketing expenses and general and administrative expenses, details
of which are set out below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinic costs.&#160;</i>NewGenIvf&#8217;s
    clinic costs primarily consisted of sub-contracting charges, office supplies and staff salaries and bonus, most of which are recognized
    during the provision of surrogacy services. Its clinic costs represented approximately 55.7%, 65.7% of its revenue for the&#160;years
    ended December 31, 2023 and 2022, respectively. As NewGenIvf gradually expands the scale of its operation and presence in Asia Pacific,
    its clinic costs is expected to increase in the foreseeable future, which will affect its profitability.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost of goods sold.&#160;</i>NewGenIvf&#8217;s
    cost of goods sold primarily consisted of purchase and direct cost for IVF treatment services and surrogacy and ancillary caring
    services, most of which are recognized during the provision of IVF treatment services. Its cost of goods sold represented approximately
    11.6% and 8.5% of the revenue for the&#160;years ended December&#160;31, 2023 and 2022, respectively. NewGenIvf expects its cost
    of goods sold to increase in the foreseeable future as it gradually grows its revenues and expand its sales network.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling and marketing
    expenses.&#160;</i>NewGenIvf&#8217;s selling and marketing expenses primarily consisted of social media expense. Its selling and
    marketing expenses represented approximately 0.4% and 0.6% of its revenue for the&#160;years ended December 31, 2023 and 2022, respectively.
    NewGenIvf expects its selling and marketing expenses to increase as it plans to expand its sales and scale its operation in Asia-Pacific.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General and administrative
    expenses.&#160;</i>NewGenIvf&#8217;s general and administrative expenses primarily consisted of depreciation in operating lease right-of-use
    (&#8220;ROU&#8221;) assets, l and staff salaries</span><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif">and
    director fees. Its general and administrative expenses represented approximately 24.5% and 18.4% of its revenue for the&#160;years
    ended December 31, 2023 and 2022, respectively. NewGenIvf expects its general and administrative expenses to increase in line with
    its expansion plan.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
expects its cost structure to evolve as it develops and expands its business. As NewGenIvf continues to develop new services and technologies,
NewGenIvf expects to incur additional costs in relation to its raw materials procurement, production and sales and marketing, among other
things. Moreover, to support NewGenIvf&#8217;s business growth, it expects to increase its headcount, particularly for its lab and nurse
team, and incur higher staff costs as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Ability to maintain trust of clients
and reputation in the industry</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
success of NewGenIvf&#8217;s business will depend to a large extent on its ability to gain broad acceptance of its services from clients.
Reputation is crucial in keeping existing clients and attracting new clients. NewGenIvf&#8217;s reputation depends on a number of factors,
including for example the success, effectiveness, quality and pricing of its services, service offerings of its competitors, the effectiveness
of its marketing efforts to drive awareness and the demand for fertility services, which eventually will affect its ability to maintain
clients and attract new clients. Therefore, NewGenIvf&#8217;s success will depend to a large extent on its ability to maintain its reputation
in the industry and its clients&#8217; trust, which would affect the number of its clients and treatment cycles that will in turn affect
its revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
believes that the medical facilities in its network are increasingly recognized among clients, for their service quality, technological
expertise and patient experience. NewGenIvf also hopes to keep its clients by providing discounts in treatment services and via the &#8220;success
guarantee&#8221; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan, which provides treatments to clients
until a success is achieved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Based
on its increasingly recognized reputation, NewGenIvf believes that there is substantial opportunity to continue to grow its revenue through
attracting new clients. NewGenIvf&#8217;s addressable market is couples who want to have children, egg freezing patients, LGBT groups
and couples with genetic abnormalities, particularly those in Asia Pacific. NewGenIvf believes that its current client base represents
a small percentage of its total market opportunity. NewGenIvf intends to attract new clients by, among other things, making significant
investments in sales and marketing to engage, educate and drive awareness of the unmet need of fertility treatment among its potential
clients and by its customer-reference discounts mechanism. Additionally, NewGenIvf believes that its expanding presence has resulted
in a heightened awareness of the need to offer fertility services and the value it provides to its clients, which it believes will help
facilitate its growth. In addition, NewGenIvf is continuously utilizing its established client relationships to evaluate other potential
services that could benefit its clients and simultaneously drive its growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>International traveling conditions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
revenue from international clients is a critical component of NewGenIvf&#8217;s revenue. International traveling to Thailand, Cambodia
and Kyrgyzstan may be affected by a number of factors, including local and global political, economic and cultural conditions. Furthermore,
an outbreak, or threatened outbreak, of any severe contagious disease may also in turn significantly reduce the demand of traveling.
For example, the COVID-19 pandemic has had resulted in a number of countries declaring a state of emergency and a number of countries,
including the countries in Asian Pacific, imposing extensive travel restrictions. NewGenIvf&#8217;s revenue in the year 2021 was significantly
adversely affected due to the impact from COVID-19 travel restrictions. In addition, a Chinese crime thriller, <i>No More Bets</i>, which
has grossed more than $500 million at the international box office since its August 2023 release and which tells the harrowing story
of characters being lured and kidnapped into a violent scam ring in an unnamed Southeast Asian country after accepting lucrative overseas
job offers, and the continuing social media coverage may have brought fears and safety concerns to Chinese tourists of being scammed
and kidnapped in Thailand&#160;and&#160;Cambodia. In addition, in October 2023, a 14-year-old with a gun opened fire in a luxury shopping
mall in downtown Bangkok, killing two people and injuring five in one of Thailand&#8217;s most popular tourist destinations. These conditions
may cause NewGenIvf difficulty in attracting clients from the PRC to travel to Thailand, Cambodia and Kyrgyzstan for NewGenIvf&#8217;s
services, which could materially and adversely affect NewGenIvf&#8217;s operations and financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Given
the uncertainty of the local and global conditions and the countries&#8217; future policy regarding international traveling, all of which
are beyond NewGenIvf&#8217;s control, NewGenIvf&#8217;s results of operation may be materially and adversely affected by any changes
in international travelling conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Key Components of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenues were derived from two types of services: IVF treatment services and surrogacy and ancillary caring services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth NewGenIvf&#8217;s revenue for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,686,902</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,138,622</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth a breakdown of NewGenIvf&#8217;s revenue by the types of services, in absolute amounts and as percentages
of total revenue, for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IVF
    treatment services<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">78.3</span></td><td style="width: 1%; text-align: left"/><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,819,163</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">47.4</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Surrogacy
    and ancillary caring services</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">21.7</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">3,125,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">52.6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total
    revenues</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include an insignificant
    amount of revenue derived from consultation customers who used NewGenIvf&#8217;s non-IVF treatment and insignificant services, such
    as check-ups services, blood test services and other minor services.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the fiscal year ended December 31, 2023, the Company&#8217;s revenue was $5,136,153. For the fiscal year ended December 31, 2023, the
Company&#8217;s revenue was $5,944,190.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
generated revenue from facilities located in various geographic regions. The following table sets forth a breakdown of NewGenIvf&#8217;s
revenue based on the locations where the revenue originated, in absolute amounts and as percentages of total revenue, for the periods
indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">34,038</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">0.7</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,123,593</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">60.8</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,060,973</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">85.1</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">621,619</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">12.1</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">377,608</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,356,903</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">26.4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">505,609</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">8.5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total
    revenues</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-size: 10pt">100.0</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
revenue results are affected by, among others, changes in sales price and the fluctuation of foreign currency rates with US dollars.
A 5% change in sales price would cause 5% change in NewGenIvf&#8217;s revenue. Based on the breakdown of the revenue contribution in
terms of currencies used by customers for 2023, a 5% change in foreign currency rates with US dollars would cause approximately 1.3%
change in NewGenIvf&#8217;s revenue. NewGenIvf&#8217;s average sales revenue from IVF treatment services per each IVF Customer (as defined
below) was approximately&#160;US$ 14,951 in 2023 and average sales revenue from surrogacy and related ancillary caring services per each
Surrogacy Customer was approximately US$10,926 in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">For
the year ended December 31, 2023, NewGenIvf served 357 customers using IVF treatment services and surrogacy and ancillary caring services,
and recorded average revenue per such significant customer of approximately US$14,386.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>IVF treatment
services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf
generated revenue from IVF treatment services provided at facilities that NewGenIvf operated in Thailand and Cambodia. In addition, NewGenIvf
also recognized revenues from IVF treatments included in surrogacy services performed in Kyrgyzstan. NewGenIvf&#8217;s revenue from IVF
treatment service amounted to US$2,819,163 and US$4,021,696, representing approximately 78.3% and 47.4% of its total revenues in 2023
and 2022, respectively. The number of IVF treatment service customers (the &#8220;IVF Customers&#8221;), which includes surrogacy and
ancillary caring service customers who also use IVF treatment services, was approximately 269 in 2023, and the average sales revenue
from IVF treatment services per each IVF Customer was approximately US$14,951 in 2023.</span><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">IVF
treatment involves the performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits
to client when embryo is successfully implanted, either in the client or a surrogate mother. Therefore, revenue from IVF treatment is
recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced by a written IVF report indicating
successful embryo implantation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Surrogacy and ancillary caring services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
also generated revenue from surrogacy and related ancillary caring services provided at facilities that NewGenIvf operated in Kyrgyzstan.
NewGenIvf&#8217;s revenue from surrogacy and ancillary caring services amounted to US$1,114,457 and US$3,125,027, representing approximately
21.7% and 52.6% of its total revenues in 2023 and 2022, respectively. The decrease in revenue from 2022 to 2023 was primarily attributed
to the departure of an agent in mid-2023, which agent had who introduced us customers for surrogacy and ancillary caring services, thus
less income arising from surrogacy and ancillary caring services was generated. The number of surrogacy and related ancillary caring
service customers (the &#8220;Surrogacy Customers&#8221;) was approximately 102 in 2023 and the average sales revenue from surrogacy
and related ancillary caring services per each Surrogacy Customer was approximately US$10,926 in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
surrogacy and ancillary caring services, embryo from intending parents is implanted in the surrogate mother sub-contracted by NewGenIvf.
During the pregnancy period of the surrogate mother, NewGenIvf provides ancillary caring services including maternity caring services
such as regular body check and provision of vitamins, supplements and medicines to surrogate mothers, documentation service, and hotel
accommodation services. Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother
gives birth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Cost of revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth NewGenIvf&#8217;s cost of revenue for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Cost of revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,047,970</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,205,940</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth a breakdown of NewGenIvf&#8217;s cost of revenue by the nature of the cost, in absolute amounts and as percentages
of total cost of revenues, for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the Year ended December&#160;31,</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost of revenues</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of goods sold</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">594,984</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2</span></td>
    <td style="width: 1%"/>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">502,969</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinic
    costs</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,859,384</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82.8</span></td>
    <td/>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,903,452</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88.6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    cost of revenues</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,454,368</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,406,421</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Cost
of goods sold. </i>Cost of goods sold primarily consisted of purchase and direct cost for IVF treatment services and surrogacy and ancillary
caring services. NewGenIvf&#8217;s cost of goods was mostly recognized during the provision of IVF treatment services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Clinic
costs. </i>Clinic costs primarily consisted of sub-contracting charges, office supplies and staff salaries and bonus. The largest portion
of clinic costs was sub-contracting charges, representing fees paid to agents who recruited surrogate mothers and assisted in the documentation,
consulting and medical treatment arrangement throughout treatment procedure. NewGenIvf&#8217;s clinic costs of goods were mostly recognized
during the provision of surrogacy services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Gross profit and gross margin</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth NewGenIvf&#8217;s gross profit in absolute amounts for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Gross profit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">638,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">932,682</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth NewGenIvf&#8217;s gross profit in absolute amounts and its gross margin as percentages of total revenues,
for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Gross profit</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,681,785</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">32.7</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,537,769</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">25.9</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Revenues</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
expects that gross profit and gross margin will continue to be affected by various factors including the geographic locations where treatments
are performed, as well as the pricing with its clients, agent subcontracting charges and the costs of the supplies provided by major
pharmaceutical companies, all of which are negotiated separately.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Operating expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
operating expenses consist primarily of selling and marketing expenses and general and administrative expenses. NewGenIvf&#8217;s selling
and marketing expenses are primarily social media expenses. NewGenIvf&#8217;s general and administrative expenses mainly include depreciation
in operating lease ROU assets, loss on disposal of plant and equipment and staff salaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Other income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
other income consists primarily of waiver of related party balance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Interest expense</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
interest expense is incurred in relation to its interest-bearing borrowing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Taxation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Cayman Islands</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is incorporated in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition,
upon payment of dividends to shareholders, no Cayman Islands withholding tax will be imposed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Hong&#160;Kong</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the two-tiered profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong profits tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime
will continue to be taxed at a flat rate of 16.5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Accordingly,
the Hong&#160;Kong profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5%
on the remaining estimated assessable profits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Thailand</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
companies incorporated in Thailand are taxed on worldwide income. A company incorporated outside of Thailand is taxed on its profits
arising from or in consequence of the business carried on in Thailand. The Thailand corporate income tax rate is 20%. A foreign company
not carrying on business in Thailand is subject to a final withholding tax on certain types of assessable income (e.g., interest, dividends,
royalties, rentals, and service fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%,
while other rates may apply under the provisions of a double tax treaty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Cambodia</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
standard rate of corporate income tax for companies and permanent establishments in Cambodia who are classified as medium and large taxpayers
is 20%. For companies and permanent establishments who are classified as small taxpayers, the corporate income tax rates are progressive
rates from 0% to 20%. In view of the annual turnover of the company, which ranges from KHR1 billion to KHR6 billion for service and commercial
sectors, the company is considered a medium-sized company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is subject to a corporate income tax on its aggregate annual income earned worldwide. Non-resident legal entities carrying out business
activities through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that
permanent establishments. Profit tax is calculated at a rate of 10% of aggregate annual income less allowed deductions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Six month period ending June 30, 2024 Compared with Six month
period ending June 30, 2023&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months <br/>
    Ended <br/>
    June 30, <br/>
    2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months <br/>
    Ended <br/>
    June 30, <br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,686,902</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,138,622</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,047,970</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,205,940</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">638,932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">932,682</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,732</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,887</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,223,284</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(926,618</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,266,171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(287,686</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(293,489</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,528</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(120,162</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,463</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,571</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Income (loss) before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(387,781</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(295,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(83,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(387,781</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(378,787</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: net loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,762</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net income (loss) attributable to the shareholders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(396,543</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(307,897</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">270,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,894</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117,545</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(340,893</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: total comprehensive loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive income attributable to the shareholders
    of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(195,990</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">279,682</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Earning per share&#160;&#8211;&#160;basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.51</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic and diluted weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,149,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">601,830</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Year Ended December&#160;31, 2023 Compared with Year Ended December&#160;31,
2022&#160;</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Year ended<br/>
    December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold"><span style="font-size: 10pt">Revenues</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Cost of revenues</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(3,454,368</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(4,406,421</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Gross profit</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">1,681,785</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">1,537,769</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Operating expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Selling and marketing expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(18,030</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(36,194</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">General and administrative expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,259,364</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,094,962</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Auditors fees</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(362,149</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(7,908</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif"><b>Total
    operating expenses</b></span></span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">(1,639,543</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">(1,139,064</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Operating income</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">42,242</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">398,705</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Other income (expenses), net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Other income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">111,837</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">23,019</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Interest income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">518</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">21</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Interest expense</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(46,179</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(77,757</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total other income (expenses), net</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">66,176</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">(54,717</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Income before taxes</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">108,418</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">343,988</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Provision for income taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(208,141</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Net income</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">108,418</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">135,847</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: net loss attributable to non-controlling interests</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(21,775</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(322,820</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Net income attributable to the shareholders of the
    Company</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">130,193</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 10pt">458,667</span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Other comprehensive (loss) income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(22,704</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,920</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total comprehensive income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">85,714</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">133,927</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Less: Total comprehensive loss attributable to non-controlling interests</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(27,621</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(323,458</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Total comprehensive income attributable to the shareholders of the Company</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">113,335</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">457,385</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">(Loss) earning per share&#160;&#8211;&#160;basic and diluted</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">0.18</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">0.80</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Basic and diluted weighted average shares outstanding</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">615,135</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">575,930</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s revenue
for the six months ended June 30, 2024 was $2,686,902 and was $2,138,622 for the six months ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s revenue
decreased by approximately 13.6% from US$5,944,190 in the fiscal year ended December 31, 2022 to US$5,136,153 in the fiscal year ended
December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>IVF treatment
services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s
IVF treatment service revenue increased by approximately 42.7% from US$2,819,163 in 2022 to US$4,021,696 in 2023. This increase was primarily
the result of our continued expansion of clinics in Thailand which focus on IVF services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Surrogacy and
ancillary caring services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf&#8217;s
surrogacy and ancillary caring services revenue decreased by approximately 64.3% from US$3,125,027 in 2022 to US$1,114,457 in 2023. This
decrease was primarily the result of temporary caesura of surrogacy business.</span><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cost of revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s cost of
revenues increased by approximately 69.82% from (1,205,940) for the six month period ending June 30, 2023 was to (2,047,970) for the
six month period ending June 30, 2023. The reason for this increase was increased agency services costs involving in subcontracting follow-up
services.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s cost of
revenue decreased by approximately 21.6% from US$4,406,421 in the fiscal year ended December 31, 2022 to US$3,454,368 in the fiscal year
ended December 31, 2023.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cost of goods
sold</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s cost of
goods sold increased by approximately 18.3% from US$502,969 in the fiscal year ended December 31, 2022 to US$594,984 in the fiscal year
ended December 31, 2023, primarily attributed to the stocking arrangements prepared for 2023 exceed the original estimated demand, due
to the local top management reported on board until in the middle of the year, and the procurement strategy was not immediately carried
on time, which also caused procurement costs to double year-on-year.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Clinic costs</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s clinic
costs decreased by approximately 26.7% from US$3,903,452 in the fiscal year ended December 31, 2022 to US$2,859,384 in the fiscal year
ended December 31, 2023, primarily due to the relocation arrangement, certain daily operating schedules stopped, resulting in the clinic&#8217;s
service being temporarily suspended in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Gross profit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s gross
profit for the six months ended June 30, 2024 was $638,932, compared to its gross profit of $932,682 for the six months ended June 30,
2023, representing a 31.50% increase from the six months ended June 30, 2023. This increase was due primarily to business difficulties
in the six months ended June 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s gross
profit increased by approximately 9.4% from US$1,537,769 in the fiscal year ended December 31, 2022 to US$1,681,785 in the fiscal year
ended December 31, 2023, primarily attributable to a reorganizing of our cooperation model with subcontractors and the increased efficiency
of our marketing services, resulting in a decrease in unit service costs per customer, directly leading to increases in gross profit
margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s gross
margin increased from 25.9% in the fiscal year ended December 31, 2022 to 32.7% in the fiscal year ended December 31, 2023.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Operating expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s operating
expenses were ($926,618) and ($1,266,171) for the six month period ended June 30, 2024 and the six month period ended June 30, 2023,
respectively. This represents a decrease of 26.82% from the six month period ended June 30, 2023, primarily attributable to a one-time
legal and professional fee in connection with NewGenIvf&#8217;s de-SPAC merger, in the amount of $735,826 and recognized in the six months
period ended June 30, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s operating
expenses increased by approximately 43.9% from US$1,139,064 in the fiscal year ended December 31, 2022 to US$1,639,543 in the fiscal
year ended December 31, 2023, primarily attributable to auditor fees of US$362,149 incurred in 2022 being recognised in 2023 and listing
legal and professional fees of US$183,527, other than these old fees incurred, there is the similar level with last year.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Other income</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s other
income increased decreased from $8,528 to $7,146 from the six month period ended June 30, 2023 to the six month period ended June 30,
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s other
income increased from US$23,019 in the fiscal year ended December 31, 2022 to US$111,837 in the fiscal year ended December 31, 2023,
primarily attributable to a waiving amount due to director from the company which is about US$88,151.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Interest expense</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s interest
expense increased by approximately 1,048.45%, from US($10,463) in the six month period ended June 30, 2023 to US($120,162) in the six
month period ended June 30, 2024 as a result of an interest charged of $67,500 and a discount on issuance of a promissory note of $52,500
on debt financing from February 29, 2024 with a principal loan $2,000,000.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s interest
expense decreased by approximately 40.6%, from US$77,757 in 2022 to US$46,179 in 2023 as a result of less interest expenses on bank and
other borrowings in 2023.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Provision
                                            for income taxes</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s provision
for income taxes increased by approximately 100% from US$(10,463) in the six months ended June 30, 2023 to US$Nil in the six month period
ended June 30, 2024 as a result of 100% allowance from deferred tax assets on net operating loss.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>NewGenIvf&#8217;s
provision for income taxes decreased by approximately 100% from US$208,141 in 2022 to US$Nil in 2023 as a result of no assessable income
generated from Thailand, Kyrgyzstan and Cambodia.&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Net income </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
net income decreased by approximately 20% from US$135,847 in 2022 to US$108,418 in 2023 as a result of a listing project carried out
during in 2023 and a relocation of our operating clinic in Thailand, to cause the increase cost and salary of recruiting and training
loacl talents. There is an additional auditor fees for the year, which is amounting to US$362,149.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Liquidity
                                            and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Cash flows and working capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s principal
sources of liquidity have been cash flows generated from its business operations. As of June 30, 2024 NewGenIvf had US$184,109 in cash
and cash equivalents. As of December&#160;31, 2023 and 2022, NewGenIvf had US$54,104 and U$27,556, respectively, in cash and cash equivalents.
NewGenIvf had working capital (defined as total current assets deducted by total current liabilities) of a deficit of US$5,327,124 as
of June 30, 2024. NewGenIvf had working capital of a surplus of US$79,000 and deficit of US$157,027, respectively, as of December&#160;31,
2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Over
the years, certain amount of cash provided by operating activities was distributed to NewGenIvf&#8217;s primary shareholders, Mr. Siu,
Wing Fung Alfred and Ms. Fong, Hei Yue Tina. As of December 31, 2023, NewGenIvf does not owe any amounts to shareholders. Nevertheless,
NewGenIvf is able to generate sufficient cash flow from its business operations to operate and grow its business.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
continually seeks to monetize from positive cash flow contracts and increase revenue from its operating activities. NewGenIvf monitors
its current and expected liquidity requirements to help ensure that it maintains sufficient cash balances to meet its existing and reasonably
likely long-term liquidity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
intends to finance its future working capital requirements and capital expenditures from cash generated from operating activities, in
addition to funds raised from financing activities. NewGenIvf may, however, require additional cash due to changing business conditions
or other future developments, including any investments or acquisitions it may decide to pursue. If its existing cash is insufficient
to meet its requirements, NewGenIvf may seek to issue debt or equity securities or obtain additional credit facilities. Financing may
be unavailable in the amounts NewGenIvf needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including
convertible debt securities, would dilute NewGenIvf&#8217;s earnings per share. The incurrence of debt would divert cash for working
capital and capital expenditures to service debt obligations and could result in operating and financial covenants that restrict NewGenIvf&#8217;s
operations and its ability to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing
as required, its business operations and prospects may suffer. Please see &#8220;<i>Risk Factors &#8212; Risks Relating to NewGenIvf&#8217;s
Business and Industry&#160;&#8212; NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf
cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely
affected</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table presents NewGenIvf&#8217;s selected consolidated cash flow data for the periods indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the&#160;Six Months&#160;Ended
    <br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2023</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(387,781</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(378,787</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation of plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,619</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,731</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Provision of expected credit loss allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">612</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(165,568</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,515</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,451</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loan to A SPAC I</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(140,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deposit, prepayment and other receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,771,406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,770,371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,681</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,250,900</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,714</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(89,702</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.05pt; padding-left: 0.05pt">Net cash provided by/(used in) operating
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,209,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,702,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchase of plant and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,393</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchase of intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,056</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,449</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,446</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,317</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other borrowings, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">560,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amount with related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">605,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,530,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Subscription receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,892,956</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,308</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible promissory note</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,380,990</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in)/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,352,923</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,713,863</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease)/increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(154,677</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of foreign currency translation on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,724</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">184,109</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">77,294</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Supplementary cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(120,162</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Listing fee paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675,826</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">US$</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,209,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,702,849</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,449</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash provided by/(used in) financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,352,923</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,713,863</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net increase/(decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(154,677</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Effect of foreign currency translation on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,724</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents, end of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,294</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Year ended <br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="font-weight: bold; font-style: italic"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Net cash (used in)/provided
    by operating activities</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(1,766,135</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,710,901</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Net cash used in investing activities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(69,848</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(94,452</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Net cash provided by/(used in)
    financing activities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,881,493</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,633,781</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Net increase/(decrease) in cash
    and cash equivalents</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">45,510</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(17,332</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Effect of foreign currency translation
    on cash and cash equivalents</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(18,962</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">16,124</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Cash and cash equivalents, beginning
    of year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">27,556</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">28,764</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Cash and cash equivalents, end
    of year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">54,104</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">27,556</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Operating activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was US$4,209,695 for the six month period ended June 30, 2024. The difference between NewGenIvf&#8217;s net profit of US$(387,781)
for the six month period ended June 30, 2024 and the net cash used in operating activities was primarily attributable to accounts payable
$1,771,406 and accrued liabilities and other payables $2,770,371.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in operating activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf&#8217;s net
profit of US$108,418 for the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to
refund of payment from clients from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized
in the book of 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash provided by operating activities was US$1,710,901 for the year ended December&#160;31, 2022. The difference between NewGenIvf&#8217;s
net income of US$135,847 for the year ended December 31, 2022 and the net cash provided by operating activities was primarily attributable
to (i)&#160;adjustments for depreciation and amortization of US$303,944, (ii)&#160;changes in contract liabilities of US$548,010 and
(iii) changes in directors&#8217; remuneration of US$240,000, partially offset by operating lease liabilities of US$175,132.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Investing activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities in the six month period ending on June 30, 2024 was ($11,449), primarily representing NewGenIvf&#8217;s additional equipment
and improvement at its Thailand clinic.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in investing activities in 2023 was US$69,848, primarily representing purchase of plant and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in investing activities in 2022 was US$94,452, primarily representing purchase of plant and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Financing activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in financing
activities in the six month period ending on June 30, 2024 was (4,352,923), primarily representing the settlement made on subscription
receivable in amount $8,892,956 and a debt financing by a convertible promissory note in the amount of $3,380,990 on February 29, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities in 2023 was US$1,881,493, primarily representing amounts from shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Net
cash used in financing activities in 2022 was US$1,633,781, primarily representing amounts due from related parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Contractual Obligations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following table sets forth NewGenIvf&#8217;s main contractual obligations and commitments as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">US$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;current portion</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"/><td style="width: 9%; text-align: right"><span style="font-size: 10pt">207,128</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"/><td style="width: 9%; text-align: right"><span style="font-size: 10pt">184,651</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">118,979</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">242,187</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">326,107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">426,838</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Off-Balance Sheet Commitments and
Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
has not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties, nor any
derivative contracts that are indexed to its shares and classified as shareholder&#8217;s equity or that are not reflected in its consolidated
financial statements. Furthermore, NewGenIvf does not have any retained or contingent interest in assets transferred to an unconsolidated
entity that serves as credit, liquidity or market risk support to such entity. NewGenIvf does not have any variable interest in any unconsolidated
entity that provides financing, liquidity, market risk or credit support to it or engages in leasing, hedging or product development
services with it.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Holding Company Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
Group Limited is a holding company with no material operations of its own. NewGenIvf Group Limited conducts all of its operations through
its subsidiaries. As a result, NewGenIvf Group Limited&#8217;s ability to pay dividends depends upon dividends paid by its subsidiaries.
If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt
may restrict their ability to pay dividends to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
Group Limited is permitted under BVI law to provide funding to its subsidiaries in Hong&#160;Kong, Thailand, Cambodia and Kyrgyzstan
through loans or capital contributions without restrictions on the amount of the funds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition, the Company&#8217;s subsidiaries are currently permitted to pay dividends to the Company in accordance with relevant laws and
regulations. Payment of dividends requirements in a company incorporated under the laws of Thailand is governed by the Civil and Commercial
Code of Thailand. For example, the company may not declare dividends if the company has incurred losses, the company must appropriate
to a reserved fund at each dividend contribution of dividend of at least one-twentieth of the profits until the fund reaches one-tenth
of the capital, or the dividends payment must be made to the shareholders within one (1)&#160;month from the dividend declaration date.
On the capital remittance or payment of dividends to the shareholders from outside of Thailand, it is regulated by the regulations issued
by the Bank of Thailand, including the Exchange Control Act B.E. 2485 (1942). The fund remittance from Thailand to a foreign jurisdiction
may require an approval from the Bank of Thailand or require notifying the Bank of Thailand for such transfer, depending on the types
of the remittance transactions, through the commercial bank in the country. For a company incorporated under the laws of Kyrgyzstan,
under Kyrgyz regulations of dividends (net profit), the dividends can be paid once a year depending on the results of the financial year
of the company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Quantitative and Qualitative Disclosure
about Market Risk</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Accounts receivable</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
order to minimize the credit risk, NewGenIvf&#8217;s management team monitors and ensures that follow-up action is taken to recover overdue
debts. NewGenIvf considers the probability of default upon initial recognition of the asset and whether there has been a significant
increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit
risk, NewGenIvf compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date
of initial recognition. It considers available reasonable and supportive forwarding-looking information, such as GDP growth rate and
nominal GDP per capita. Based on the impairment assessment performed by NewGenIvf, the directors considered the loss allowance for account
receivables as of December&#160;31, 2023 and December&#160;31, 2022 is $19 and $26, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and cash equivalents</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings. The credit
risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating
agencies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Deposits
and other receivables, amount due from shareholders and loan to A SPAC I</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
assessed the impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal
credit rating and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial
recognition. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and
other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and Nil, respectively. The
loss allowance for deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2022 is $141, $17,059
and Nil, respectively. The loss allowance for deposits and other receivables and amount due from shareholders as of December&#160;31,
2021 was $115 and $6,312 and Nil, respectively.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Cash flow
interest rate risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
is exposed to cash flow interest rate risk through the changes in interest rates related mainly to its variable-rates bank balances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
currently does not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk.
The directors monitor NewGenIvf&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sensitivity
analysis</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
sensitivity analysis below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period
and had been applied to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is
used when reporting interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably
possible change in interest rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
interest rates had been 1% higher or lower and all other variables were held constant, NewGenIvf&#8217;s post tax loss for the&#160;years
ended December&#160;31, 2023 and 2022 would have increased or decreased by approximately US$122 and US$275, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Foreign currency
risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Foreign
currency risk is the risk that the holding of foreign currency assets will affect NewGenIvf&#8217;s financial position as a result of
a change in foreign currency exchange rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
monetary assets and liabilities are mainly denominated in HK$ and THB which are the same as the functional currencies of the relevant
group entities. Hence, in the opinion of the directors of NewGenIvf, the currency risk of US$ is considered insignificant. NewGenIvf
currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related
foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need arise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Economic and political risks</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
operations are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, NewGenIvf&#8217;s business, financial condition, and
results of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
operations in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks not typically associated
with companies in North America and Western Europe. These include risks associated with, among other things, the political, economic
and legal environment and foreign currency exchange. NewGenIvf&#8217;s results may be adversely affected by changes in the political
and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies with respect to laws and regulations,
anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Travel restriction risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">International
clients contribute a large portion of NewGenIvf&#8217;s revenue. International clients need to travel to Thailand, Cambodia and Kyrgyzstan
for treatment services, where NewGenIvf&#8217;s operations are mainly conducted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">International
traveling to Thailand, Cambodia and Kyrgyzstan may be affected by a number of factors, including local and global political and economic
conditions. Furthermore, an outbreak, or threatened outbreak, of any severe contagious disease may also in turn significantly reduce
the demand of traveling or cause extensive travel restrictions. NewGenIvf&#8217;s results may be materially and adversely affected if
travel restriction was imposed or difficulties in cross-border flow arose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Inflation risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Management
of NewGenIvf monitors changes in prices levels. Historically inflation has not materially impacted NewGenIvf&#8217;s consolidated financial
statements; however, significant increases in the price of labor that cannot be passed to NewGenIvf&#8217;s customers could adversely
impact its results of operations.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Critical Accounting Policies, Judgments
and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
prepares its financial statements in conformity with U.S.&#160;GAAP, which requires NewGenIvf to make judgments, estimates and assumptions.
NewGenIvf continually evaluates these estimates and assumptions based on the most recently available information, its historical experience
and various other assumptions that NewGenIvf&#8217;s management believes to be reasonable under the circumstances. Since the use of estimates
is an integral component of the financial reporting process, actual results could differ from its expectations as a result of changes
in NewGenIvf&#8217;s estimates. Some of NewGenIvf&#8217;s accounting policies require a higher degree of judgment than others in their
application and require NewGenIvf to make significant accounting estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
selection of critical accounting policies, the judgments and other uncertainties affecting application of those policies and the sensitivity
of reported results to changes in conditions and assumptions are factors that should be considered when reviewing NewGenIvf&#8217;s financial
statements. NewGenIvf&#8217;s management believes the following accounting policies involve the most significant judgments and estimates
used in the preparation of their financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Foreign currency translation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
consolidated financial statements are presented in United&#160;States dollar, which is the reporting currency of NewGenIvf. The functional
currency of NewGenIvf and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are HK$. Med Holdings and FFC use THB as their
functional currencies. First Fertility Phnom Penh Limited uses KHR as its functional currency and First Fertility Bishkek LLC uses USD
as its functional currency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect NewGenIvf&#8217;s financial
condition in terms of reporting in USD.&#160;See &#8220;<i>Note&#160;2 &#8212; Summary of Significant Accounting Policies</i>&#8221;
for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Revenue recognition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires it to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. NewGenIvf derives revenue principally from provision of IVF treatment and surrogacy and ancillary
caring services. Revenue from contracts with customers is recognized using the following five steps:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
its contracts with customers;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
its performance obligations under those contracts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
the transaction prices of those contracts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
the transaction prices to its performance obligations in those contracts; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred
to the client in an amount that reflects the consideration expected in exchange for those services.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements
also identify the scope of services, service fees and payment terms. Agreements are acknowledged and signed by both parties. All the
contracts have commercial substance, and it is probable that NewGenIvf will collect considerations from its customers for service component.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
derives its revenues from two types of services: (1)&#160;IVF treatment services, and (2)&#160;surrogacy and ancillary caring services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Revenue from IVF treatment services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">IVF
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted in the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. NewGenIvf collects payment from customer in advance for IVF treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Revenue from surrogacy and ancillary
caring services</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf
provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted
by NewGenIvf. During pregnancy period, NewGenIvf provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. NewGenIvf collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Lease</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenIvf
adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842). Lease terms used to calculate the present value of lease payments generally do
not include any options to extend, renew, or terminate the lease, as NewGenIvf does not have reasonable certainty at lease inception
that these options will be exercised. NewGenIvf generally considers the economic life of its operating lease ROU assets to be comparable
to the useful life of similar owned assets. NewGenIvf has elected the short-term lease exception, therefore operating lease ROU assets
and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee.
The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there </span><span style="font-size: 10pt">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">were
approximately $0.38 million ROU assets and approximately $0.43 million in lease liabilities based on the present value of the future
minimum rental payments of leases, respectively. NewGenIvf&#8217;s management believes that using an incremental borrowing rate of the
Hong Kong Dollar Best Lending Rate (&#8220;BLR&#8221;) minus 0.125% was the most indicative rate of NewGenIvf&#8217;s borrowing cost
for the calculation of the present value of the lease payments; the rate used by NewGenIvf was 5.0%.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were approximately $0.28 </span><span style="font-size: 10pt">&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">million
ROU assets and approximately $0.33 million in lease liabilities based on the present value of the future minimum rental payments of leases,
respectively. NewGenIvf&#8217;s management believes that using an incremental borrowing rate of the Hong Kong Dollar Best Lending Rate
(&#8220;BLR&#8221;) minus 0.125%</span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">was the most indicative
rate of NewGenIvf&#8217;s borrowing cost for the calculation of the present value of the lease payments; the rate used by NewGenIvf was
5.0%.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
instruments</i></b></span><span style="font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">NewGenIvf&#8217;s
financial instruments, including cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities
and amounts due from (to) shareholders, have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820,
&#8220;Fair Value Measurements and Disclosures&#8221; requires disclosing the fair value of financial instruments held by NewGenIvf.
ASC Topic&#160;825, &#8220;Financial Instruments&#8221; defines fair value and establishes a three-level valuation hierarchy for disclosures
of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated
balance sheets for cash and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts
due from (to) shareholders each qualify as financial instruments and are a reasonable estimate of their fair values because of the short
period between the origination of such instruments and their expected realization and their current market rate of interest. NewGenIvf
analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities
from Equity&#8221; and ASC&#160;815. See &#8220;<i>Note&#160;2 &#8212; Summary of Significant Accounting Policies</i>&#8221; for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Recent accounting pronouncements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures. &#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="aa_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an assisted reproductive
services (&#8220;ARS&#8221;) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourself as a long-standing ARS provider in this region. Our strategic presence in Thailand, Cambodia, and Kyrgyzstan positions us to
take advantage of opportunities across Asia-Pacific. According to China Insights Consultancy (&#8220;CIC&#8221;), from 2014 to 2022,
there was a rising number of women in the key ARS-targeted age group (ages 15 to 49) in Asia Pacific and a growing trend towards later
maternal age. The number of married women of reproductive age in Asia Pacific has risen from 816.4&#160;million in 2014 to 833.2&#160;million
in 2022. Additionally, according to CIC, there was increasing social acceptance of ARS use in Asia Pacific countries such as China, India,
and Thailand during the same period. For example, the number of ARS users in China has risen from 136.8 thousand in 2017 to 184.9 thousand
in 2022 approximately and that in Japan has risen from 98.0 thousand in 2017 to 128.5 thousand in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the
prevalence of infertility in Asia-Pacific developing countries is substantial. For example, the infertility rate in Thailand, India and
China was about 15.4%, 13.8% and 17.8%, respectively, in 2022. In India, the infertility rate in 2020 was approximately 13.1%, representing
an annual growth of 2.6%. The infertility rate in China was around 17.6% in 2020, representing an annual growth of 0.6%. Infertility
is increasingly gaining society&#8217;s attention as individuals are more openly discussing their struggles. Despite the prevalence of
infertility, access to treatment is often limited in the Asia Pacific region. According to CIC, financial challenges, costs of treatment,
and limited availability or capacity of fertility medical care are some of the main challenges in the fertility marketplace in Asia-Pacific
region. Religious, social and cultural roadblocks can also prevent hopeful couples from realizing their dream to have children. We believe
that we can help address some of these key challenges of Asia-Pacific fertility industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>History and Development of the Company</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Business
Combination, on April&#160;29, 2021, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), was incorporated as a British Virgin Islands business
company, specifically a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
recapitalization, reorganization or similar business combination with one or more target businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Business Combination</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;15, 2023,
ASCA entered into the Merger Agreement (as amended on June 12, 2023 and December 6, 2023, the &#8220;Merger Agreement,&#8221; and the
transactions contemplated thereunder, the &#8220;Business Combination&#8221;) with A SPAC&#160;I Mini Acquisition Corp., Merger Sub,
NewGenIvf Limited, a Cayman Islands exempted company (&#8220;Legacy NewGenIvf&#8221;) and certain shareholders of Legacy NewGenIvf. Pursuant
to the Merger Agreement, the Business Combination was effected in two steps: (i)&#160;ASCA was reincorporated to the British Virgin Islands
by merging with and into A SPAC&#160;I Mini Acquisition Corp. (such transaction, the &#8220;Reincorporation Merger&#8221;); and (ii)&#160;Merger
Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second
step in isolation, the &#8220;Acquisition Merger&#8221;). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as &#8220;NewGenIvf,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221;
unless the context otherwise requires.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&#160;12, 2023,
the parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the &#8220;First Amendment&#8221;), pursuant
to which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the &#8220;Loan&#8221;)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA&#8217;s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed
to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf&#8217;s failure to deliver audited
financial statements by no later than February&#160;28, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 6, 2023, the
parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the &#8220;Second Amendment&#8221;) which
amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf&#8217;s board of directors following
the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf
and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii)
provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary
Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible
assets immediately after the consummation of the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 3, 2024, the
Business Combination was consummated with the Company as the surviving entity.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NewGenIvf&#8217;s Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization
(&#8220;IVF&#8221;) treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary caring services.
Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>IVF treatment service: </b>For the&#160;years
    ended December&#160;31, 2023 and 2022, we generated approximately 78.3% and 47.4%, of its revenue from IVF treatments services. We
    primarily provide our clients with conventional IVF/intracytoplasmic sperm injection (&#8220;ICSI&#8221;) and embryo transfer services.
    As technology has progressively advanced, we have been able to, through technologies and facilities provided by MicroSort technology,
    help fulfill the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases. IVF treatment involves
    the performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to clients
    when embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed
    in clinic. The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Surrogacy and ancillary caring services: </b>We also generate
    revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. For the&#160;years ended December&#160;31, 2023
    and 2022, we generated approximately 21.7% and 52.6%, of our revenue from surrogacy and ancillary caring services. For surrogacy
    services, NewGenIvf conducts implantation of embryos from biological parents in surrogate mothers. In addition, NewGenIvf provides
    a &#8220;success guarantee&#8221; program for egg donation services in Cambodia and surrogacy services in Kyrgyzstan. Under this
    optional program, patients pay additional fees of approximately 40% of the original price and can have repeated attempts of IVF cycles,
    egg donation services and/or surrogacy services until the procedures are successful. The additional costs to NewGenIvf are generally
    limited and amount to approximately 30% of the original costs because NewGenIvf&#8217;s clinics, together with the patients, can
    choose suitable egg donors and surrogate mothers to limit the additional costs. During the pregnancy period, NewGenIvf provides ancillary
    caring services including regular body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from
    surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth. Surrogacy services
    provide infertile couples with an alternative method of having children.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&#160;years ended
December&#160;31, 2023 and 2022, NewGenIvf&#8217;s revenue was US$5,136,153 and US$5,944,190, and its net income was US$108,418&#160;and
US$135,847, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, NewGenIvf&#8217;s
core market for fertility services is substantial and growing rapidly, driven by, among other things, societal and cultural shifts, such
as people starting families later in life and other health-related challenges which could impact couples&#8217; and individuals&#8217;
ability to have children. In addition, NewGenIvf believes that continued overall de-stigmatization of infertility will help drive better
access to, and stronger demand for, fertility treatment services, thereby further enabling the expansion of NewGenIvf&#8217;s addressable
market. According to CIC, the market size of fertility treatments in Asia Pacific was increasing steadily and the potential size of the
Asia fertility market is expected to reach US$37.4&#160;billion by 2030. NewGenIvf believes its market opportunity is substantial and
is continuing to grow as a result of the rising demand for fertility services, the lack of adequate offerings in the market and the increasing
awareness of the challenges of infertility.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competitive Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that
the following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and
have differentiated it from its competitors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Broad-range ARS Provider Offering Comprehensive
Fertility Treatment Services</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With almost a decade of
experience in the fertility market, NewGenIvf has built a reputation in the IVF industry in Asia-Pacific. NewGenIvf has reinforced its
long-standing position through expanding its service offerings and locations to address the evolving clients&#8217; needs or requests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s comprehensive
fertility treatment offerings in Thailand, Cambodia, and Kyrgyzstan, primarily including IVF, egg donation (in Cambodia) and surrogacy
services (in Kyrgyzstan), make it convenient for clients in Asia-Pacific market to have access to various fertility services but with
a relatively low cost, as compared with the US market. According to CIC, the average cost per IVF cycle in the US is around US$12,000
(excluding medication), which is 65% higher than that of Asia-Pacific market. Meanwhile, the average cost per IVF cycle by NewGenIvf
is around US$7,000 (excluding medication). Each of NewGenIvf&#8217;s clinics in Thailand, Cambodia, and Kyrgyzstan has its own specialty,
and together, NewGenIvf is able to provide more flexibility and options to its patients. For example, NewGenIvf&#8217;s Thailand clinic
focus on IVF and related ancillary services including HIV sperm washing, egg freezing, and chromosome screening. The clinic in Cambodia
specializes in providing both IVF services and egg donation services. NewGenIvf opened the clinic in Kyrgyzstan in 2019, which broadened
NewGenIvf&#8217;s services by being legally qualified/received approval letter from The Ministry of Health of Kyrgyzstan to offer surrogacy
services. As of December 31, 2023, NewGenIvf was the one of the few ARS providers in Kyrgyzstan and one of the few companies in Kyrgyzstan
that is licensed to offer surrogacy services in Kyrgyzstan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf attributes its
track record of success to its experienced physicians and its ability to provide comprehensive ARS services, allowing it to meet patients&#8217;
increasing demand for advanced, high-end, and sophisticated ARS, a higher standard and a wider range of advanced services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has extensive
experience serving Asia-Pacific patients and a deep understanding of their general profiles. In particular, NewGenIvf has personnel speaking
multiple languages, including nurses, facilitators, and translators, who are familiar with the health condition and culture of Asia-Pacific
patients from different countries in the region. NewGenIvf believes that it is therefore well-positioned to benefit from market growth
driven by Asia-Pacific patients travelling to its clinics for treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Attractive Market with Significant Demand
and Fast Growth</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf operates in
the ARS market in Asia Pacific, positioning it to leverage on an attractive market with compelling underlying growth potential. According
to CIC, during the&#160;years ended December&#160;31, 2021 and 2022, the ARS market in Asia Pacific has experienced growth underpinned
by long-term demographic and social trends. These trends include a rising demand for fertility services, the lack of adequate offerings
in the market and the increasing awareness of the challenges of infertility, according to CIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the
Asia Pacific ARS market is a large, multi-billion dollar industry growing at a strong pace of approximately 15% in 2022 as increased
awareness and acceptance of IVF and surrogacy services continue to drive demand. Additionally, according to CIC, the market is underserved
as a substantial percentage of patients in need of ARS treatments go untreated. The industry also remains constrained in capacity, thereby
creating challenges in providing access to ARS to the volume of patients in need. According to CIC, as of December&#160;31, 2022, there
were more than 213&#160;million infertile couples in Asia Pacific. While there have been substantial increases in the use of ARS, according
to CIC, only approximately 1.47&#160;million ARS cycles, including IVF, and other fertility treatments, were performed in Asia Pacific
in 2022. This amounts to less than 1.1% of the infertile couples in Asia Pacific being treated and only 0.7% having a child though ARS
in 2022, indicating significant unmet demand for ARS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Asia-Pacific fertility
markets, in particular India and China, present a vast opportunity for ARS providers in the region. China&#8217;s ARS market has been
driven by an increasing rate of infertility, the implementation of the Three-Child Policy in May&#160;2021, a decreasing number of couples
at childbearing age and increasing affordability and awareness of ARS, according to CIC.&#160;China&#8217;s ARS market size in 2021 and
2022 was US$2,105&#160;million and US$2,069&#160;million, respectively, and is expected to further grow to US$2.3&#160;billion in 2023,
according to CIC.&#160;India&#8217;s ARS market size increased from US$1.2&#160;billion in 2021 to US$1.5&#160;billion in 2022, and is
expected to grow further to US$1.6&#160;billion in 2023, according to CIC.&#160;NewGenIvf believes that its existing market presence
and reputation in Thailand, Cambodia, and Kyrgyzstan well positions it to capitalize on the fast-growing Asia-Pacific fertility market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to CIC, the
significant entry barriers in Asia-Pacific ARS industry are expected to continue to constrain supply in the industry. The industry is
heavily regulated and a significant number of stringent requirements must be satisfied in order to obtain relevant licenses to conduct
IVF, egg donation and surrogacy procedures in the relevant countries. NewGenIvf believes that such barriers to entry can help it maintain
its market position in Asia Pacific as the fertility market in the region continues to expand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Built on years of experience,
NewGenIvf has established a strong reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each agency agreement has
a maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf&#8217;s services
by word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees
upon the completion of client&#8217;s treatment. Normally, agents provide potential clients&#8217; contact information to the sales team
of NewGenIvf, who then approach potential clients and provide consultation on services. Overall, approximately 50% of NewGenIvf&#8217;s
patients are referrals from agents, among which approximately 80% are referrals from China and the remaining 20% from India, whereas
the remaining 50% of NewGenIvf&#8217;s patients are patients who contact NewGenIvf directly through its websites from social media promotions.
With its partnerships in various countries, NewGenIvf believes it is able to better benefit from the growing market opportunities.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exclusively Licensed Technology for Family
Planning and Access to Mature Fertility Technologies</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that
its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient&#8217;s
needs. These technologies include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>MicroSort Technology: </i>NewGenIvf holds an exclusive license
    granted by a division of the Genetics and IVF Institute, to use MicroSort technology in Thailand and Cambodia, which is a form of
    pre-conception gender selection technology for humans. MicroSort technology aims to separate male sperm cells based on which gender
    chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the
    same gender chromosome. The technology ultimately helps couples choose the gender of their future child by choosing semen samples
    that predominately contain sperm with the&#160;X chromosome for a female or Y chromosome for a male. Traditionally and naturally,
    gender selection occurs after conception, meaning after the eggs are fertilized. As a result, some fertilized eggs will go unused.
    However, with MicroSort technology, NewGenIvf is able to increase the ratio of male or female embryos, based on the patient&#8217;s
    preference. Eggs are more likely to be fertilized according to the preferences of the parents. Other improvements that MicroSort
    treatment could help achieve include prevention of certain gender-related hereditary diseases. As of December 31, 2023, NewGenIvf
    was one of the only seven exclusive license holders of MicroSort technology world-wide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Screening (&#8220;PGS&#8221;)</i>: PGS
    is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or
    too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid
    embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf
    by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Next-Generation Sequencing (&#8220;NGS&#8221;)</i>: NGS is a
    high-throughput technology for determining the sequence of deoxyribonucleic acid (&#8220;DNA&#8221;) or ribonucleic acid (&#8220;RNA&#8221;)
    to study genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at
    once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing
    thousands of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality
    and data output.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Preimplantation Genetic Diagnosis (&#8220;PGD&#8221;)</i>: Similar
    to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for
    individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic
    fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check
    the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help
    women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt
    to screen for healthy embryos ahead of time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Well Established Brand with Reliable Reputation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia and Kyrgyzstan. Since
then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong&#160;Kong, India, Thailand,
Australia and Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf benefits from
the favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated in one
of the biggest shopping malls of the city, the clinic is located in close proximity to various transportation facilities and popular
tourist attractions, such as the Erawan Shrine. In this regard, NewGenIvf believes that its business has benefited from, and will continue
to benefit from, the convenience of its locations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has developed
a relatively replicable and scalable operating model that supports high productivity at its assisted reproductive medical facilities
in Asia. Under this model, NewGenIvf&#8217;s medical facilities have established standardized operating procedures to select the treatment
process according to each patient&#8217;s profile. NewGenIvf&#8217;s medical and operational personnel are organized into specialized
teams according to the different stages of the treatment process and different patient profiles. When patients are initially admitted
or would like to seek additional medical services later on, they are assigned to one of the optimal medical teams, which NewGenIvf believes
is better suited after taking into account the patient&#8217;s diagnosis and preferences. NewGenIvf believes that this model allows each
team to improve its efficiency and arrange suitable physicians for patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The physicians of NewGenIvf
have also developed and employed an operating model that seeks to increase the effectiveness of physicians by utilizing standardized
workflows and operating procedures with teams of supporting nurses and medical assistants. This helps to increase the number of IVF treatment
cycles that physicians can perform while providing treatment customized based on patient conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With its established client
service history, accumulated experience as well as its continuous upgrades and development of treatment models, NewGenIvf believes that
it will be able to better monetize its brands through its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Experienced Management Team</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NewGenIvf management
team has considerable experience in the ARS market and the broader healthcare industry. A considerable number of NewGenIvf&#8217;s management
are physicians or laboratory technicians who possess extensive experience in the ARS industry and are experts in their respective fields.
NewGenIvf&#8217;s Chief Executive Officer, Mr.&#160;Alfred Siu, has more than 13&#160;years of experience in the fertility service market.
Dr.&#160;Wiphawee Luangtangvarodom had over 8&#160;years of experience as an obstetrician and gynecologist. NewGenIvf&#8217;s two lab
supervisors, Ms. Anussara Phinyong, and Ms. Araya Boonchaisitthipong, each had over eight&#160;years of experience in the embryologist
field. These individuals have extensive experience in managing assisted reproductive medical facilities. NewGenIvf is also led by other
members of the professional management team, who are intimately involved in the operational and financial management of NewGenIvf&#8217;s
Group. Leveraging their experience, NewGenIvf believes that it is well positioned to expand its network and aims to become a leader in
the Asia Pacific ARS market.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Strategies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s vision
is to provide tailored ARS solutions to fulfil patients&#8217; dreams of becoming a parent. To realize this vision, NewGenIvf plans to
adopt the following strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Offer Broad Fertility Services for Fertility
Tourists across Asia Pacific</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to provide
broad fertility services for fertility tourists seeking high quality, cost effective and comprehensive fertility solutions. According
to CIC, the demand for fertility tourism is driven by a variety of factors including the prevalence of infertility, the introduction
of the Three-Child policy in China, the improved understanding of assisted reproductive technology and increased affordability of ARS.&#160;To
address these needs, NewGenIvf plans to offer its customers a &#8220;hassle-free&#8221;, seamless and integrated ARS and hospitality
arrangement experience. To complement its fertility services, NewGenIvf intends to integrate its offerings with additional services for
traveling patients, most of whom are first-time fertility tourists, such as translation service, hotel arrangement and airport pickup
services. NewGenIvf plans to enhance its customers&#8217; experience by entering into exclusive cooperation arrangements with local premium
hospitality providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, NewGenIvf
expects the easing of COVID-19 travel restrictions to contribute to an increase in tourists seeking fertility services. According to
CIC, the COVID-19 pandemic led to a delay in many patients&#8217; plans for fertility treatments, with travel restrictions and border
closures impacting their ability to access care. On May&#160;5, 2023, the WHO Director-General Dr.&#160;Tedros Adhanom Ghebreyesus announced
that COVID-19 no longer constituted a public health emergency of international concern. The pent-up demand for these services is expected
to be released with the lifting of the travel restrictions, leading to a surge in patients seeking fertility treatment. NewGenIvf&#8217;s
believes that its strategy of offering a comprehensive approach to fertility treatments will help it capture a share of the growing market
for fertility tourism in Asia Pacific.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Continue to Invest in Laboratories and Facilities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes laboratories
and treatment facilities are critical to supporting its future research, development and clients experience. NewGenIvf currently operates
two laboratories that offer IVF services, one in Thailand and one in Cambodia, and plans to continue to scale up its existing laboratories.
NewGenIvf plans to continue to invest in upgrading its laboratories and facilities to complement its growth and expansion, which it believes
will help NewGenIvf maintain an edge over its competitors with regard to technology, operational efficiency, scalability, and client
experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to develop
advanced facilities for its existing laboratories, which will be conducting research on ARS related basic science and experiments relating
to emerging technologies to improve ARS success rates and lower costs. NewGenIvf also plans to correlate its data on patient treatment
protocols to the embryo physiologic data and the pregnancy success rate-related data to identify better treatment protocols to increase
ARS success rates. NewGenIvf intends to continue to actively promote technological cooperation with tertiary institutions to discover
ways to improve its IVF success rates. Furthermore, NewGenIvf seeks to actively deploy the technology that it possesses to expand the
services it provides.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has accumulated
experience in treating patients over 40&#160;years old with premature ovarian failure and patients who have had recurrent ARS implementation
failure, by, for the example, injecting platelet rich plasma into the ovaries to stimulate and support growth of the follicles. NewGenIvf
is also implementing certain technological advancements relevant to the ARS industry, including microfluidics, automated sperm analysers,
time lapsed incubators, non-invasive preimplantation genetic testing (&#8220;PGT&#8221;) of cell-free DNA in spent media, automated systems
for oocyte/embryo vitrification to reduce reagent consumption and decrease labor intensity, mitochondria replacement therapy to reconstruct
oocytes by nuclear transfer of polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to increase the number of
oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough developments
in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells for creation
of functional gametes, but these techniques are not yet ready for human clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also intends
to develop clinically customised interior design concepts for its medical facilities, including improved service rooms, consultation
rooms, reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Increase Brand Awareness and Market Share</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf intends to maintain
and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient numbers, NewGenIvf
plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS industry in Asia
Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives, and establishing
its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile, NewGenIvf intends
to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental health services,
which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg donation and surrogacy.
These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive strategy to expand its
market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional market share of the
growingly ARS market in Asia-Pacific.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expand Service Reach Through Acquisitions and Partnerships</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leveraging its reputation
and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through strategic acquisitions
and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only allow NewGenIvf to diversify
its client base, but also allow it to benefit from potential economies of scale and increasing efficiency through consolidation. NewGenIvf
could also leverage the acquired or acquiring company&#8217;s customer base, reputation and expertise to further improve its offerings
and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional licenses and locally recognized
brands. For the global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through partnerships with other IVF clinics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NewGenIvf
plans to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf
believes that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with
a large number of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf
can increase its market reach, enhance its brand reputation, and drive client growth. NewGenIvf&#8217;s broad range of fertility services,
including IVF and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape,
which could make them more attractive to potential employees. Additionally, by offering these services, companies can help address the
growing concern of delayed childbearing, which is becoming more common among women according to CIC.&#160;NewGenIvf plans to collaborate
with potential corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide
comprehensive support and counselling throughout the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meanwhile, NewGenIvf also
intends to attract more clients by establishing its &#8220;home country gynecologist partnership program&#8221;. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent
overseas. Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners
with, in their home countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf had entered
into a non-binding term sheet dated June 3, 2024 (the &#8220;Term Sheet&#8221;) with COVIRIX Medical Pty Ltd (&#8220;COVIRIX&#8221;)
for a proposed reverse merger (the &#8220;Proposed Transaction&#8221;). However, on September 21, 2024, COVIRIX withdrew from the Proposed
Transaction, as such the Proposed Transaction was terminated with no cost to the Company.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Model</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a focus on providing
fertility treatments to fulfil couples and individuals&#8217; dreams of raising children, NewGenIvf offers mainly two services, namely:
(i)&#160;IVF treatment service, comprising traditional IVF and egg donation; and (ii)&#160;surrogacy and ancillary caring services. The
following table sets forth NewGenIvf&#8217;s revenue by service offerings and as a percentage of total revenue for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">IVF Treatment Service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,021,696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">78.3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,819,163</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">47.4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy and Ancillary Caring Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,457</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,125,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,944,190</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>IVF Treatment Service</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles
are retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with
sperm and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic
the condition of the fallopian tubes. Once the embryos develop, typically over a 3-to-5-day period, they are transferred to the uterine
cavity. According to CIC, the average clinical pregnancy success rates, using 5-day incubation, averaged approximately 64.6% (with no
PGT) for IVF, with live birth rate at approximately 28.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a long-standing IVF
treatments provider in Asia-Pacific, NewGenIvf had completed over 4,000 cycles of IVF treatments from 2014 to 2023. For the&#160;years
ended December&#160;31, 2023 and 2022, the revenue from NewGenIvf&#8217;s IVF treatments was US$4,021,696 and US$2,819,163, respectively,
representing 78.3% and 47.4%&#160;of its total revenue in the corresponding periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IVF Treatments Process</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A typical IVF treatment
process mainly includes two stages, the pre-IVF treatment stage and the IVF treatment stage. During the IVF treatment process, NewGenIvf
also provides support services such as nutrition guidance and psychological counselling. The flow chart below shows the stages involved
in a typical IVF treatment process:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the pre-IVF treatment
stage, clients attend an initial consultation, undergo pre-IVF tests, and undergo treatment for gynaecological and andrological diseases,
if needed. At the initial consultation, a physician reviews the clients&#8217; detailed medical history to collect more information relating
to the potential cause of their infertility. The client then undergoes various pre-IVF tests, which may include, among other things,
blood pressure, hormone level, ultrasound, infectious disease screening, uterine evaluation and male fertility test. The physician will
then design treatment plans based on the client&#8217;s medical history and results of the tests. If the client is satisfied with treatment
plan and the test results are acceptable to the physician, the physician will prescribe medications and start stimulation treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first step of the
cycle is to boost egg production through injecting synthetic hormones. Over about one week of ovarian stimulation, clients are monitored
on a regular basis with blood test and transvaginal ultrasound. If follicles have reached at least 10 mm in size, an additional antagonist
drug will be added into the daily injection schedule. This is used to prevent ovulation before ovum pickup time. After another few&#160;days
of ovarian simulation, if follicle growth is consistent and majority of follicles are around 16 mm to 17 mm, the final injection of a
human chorionic gonadotropin will be administered. The trigger injection is the final step of the stimulation process and is for the
maturation of the eggs in the follicles before they are collected. The next major step is to retrieve the eggs with a minor surgical
procedure called Trans Vaginal Follicle Aspiration conducted under anaesthesia. At the same time the male partner collects the sperms
for fertilizing the eggs in the laboratory by a process known as intracytoplasmic sperm injection. The fertilized embryos are cultured
in the laboratory for two to six&#160;days. Embryos that grow well are biopsied and tested by PGT to detect potential genetic diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final step is to transfer
the embryos into the uterus using a catheter. Within eight&#160;days after the embryo transfer, a blood test can be conducted to detect
whether the implantation was successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MicroSort Technology</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroSort technology is
a preconception process developed by the Genetics and IVF Institute, Inc. that aims to improve the chances that the baby to be conceived
will be of the desired gender and prevents certain gender-related hereditary diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Semen samples usually
contain equal amounts of sperm carrying the Y chromosome (which will produce a boy), and sperm carrying the&#160;X chromosome (which
will produce a girl). During the MicroSort process, the sperm sample is washed to remove seminal liquid and nonmotile cells. After the
washing, the sample is stained with a special fluorescent material that attaches to the DNA contained in the sperm. The stained sperm
cells are analyzed one by one by a flow cytometer, in which cells pass through a laser to make the stain attach to the DNA fluoresce.
The sperm containing the&#160;X chromosome (which have more DNA and therefore more stain) will shine brighter than the sperm containing
the Y chromosome. The flow cytometer uses a special software to identify&#160;X&#160;and Y chromosome sperm based on their fluorescence
signature. The sperm carrying the chromosome that will produce the desired gender are separated from the rest of the sample -resulting
in an enriched sperm sample ready for use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf holds an exclusive
license granted by a division of the Genetics and IVF Institute, MicroSort International, to use the MicroSort technology in Thailand
and Cambodia. MicroSort licenses for NewGenIvf&#8217;s operation in Thailand and Cambodia are each provided under a lease and service
agreement. In April 2019, First Fertility PGS entered into a Lease and Services Agreement with MicroSort International to use MicroSort
equipment in Thailand and in March 2019, Phnom Penh Center entered into a Lease and Services Agreement with MicroSort International to
use MicroSort equipment in Cambodia (together, the &#8220;Lease and Services Agreements&#8221;). Pursuant to the Lease and Services Agreements,
First Fertility PGS and Phnom Penh Center each has the exclusive right to utilize the MicroSort equipment and to market and sell MicroSort
sperm sorting services in Thailand and Cambodia, respectively. MicroSort International is responsible for the maintenance of MicroSort
equipment and technical and engineering support. The term of each Lease and Service Agreements is initially from 2019 to 2024, which
shall be automatically renewed for one year unless a written notice of at&#160;least 180 days prior to the intended termination date
is provided. The consideration under each of the Lease and Services Agreements is US$9,000 per month after six months from the effective
date of the agreements. MicroSort International was entitled to a down payment of US$15,000 per agreement and the aggregated amounts
received by it under the agreements was US$328,500. During the term of each lease and service agreement, MicroSort grants NewGenIvf the
exclusive right in that country to utilize the MicroSort equipment and market MicroSort services. The term of each lease and service
agreement is initially from 2019 to 2024, which shall be automatically renewed for one year unless a written notice at least 180&#160;days
prior to the intended termination date is provided. The flow chart below shows the process involved in MicroSort:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preimplantation Genetic Screening</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PGS is used in parallel
with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in
a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher
chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation
rate of 70.9% and reducing miscarriage rates by 26.6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next-Generation Sequencing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NGS is a high-throughput
technology for determining the sequence of deoxyribonucleic acid DNA or RNA to study genetic variation associated with diseases or other
biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing
determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time
and cost associated with sequencing and increases the coverage quality and data output.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preimplantation Genetic Diagnosis</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to PGS, PGD is
also used in parallel with an IVF treatment cycle. But PGD is a more enhanced process than PGS since it scans for individual genes. PGD
is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic fibrosis, where carrier
status has been documented in each of the parents. By using this technique, physicians are able to check the genes or chromosomes for
a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help women achieve a healthy pregnancy.
Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Surrogacy and Ancillary Caring Services</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf also generated
revenue from surrogacy services and related ancillary caring services in Kyrgyzstan. NewGenIvf conducts implantation of embryos from
biological parents in surrogate mothers. During the pregnancy period, NewGenIvf provides ancillary caring services including regular
body check and provision of vitamins, supplements and medicines to surrogate mothers. Revenue from surrogacy and ancillary caring services
is recognized when the surrogate mother gives birth. Surrogacy services provide infertile couples with an alternative method of having
children. In general, NewGenIvf provides certain discount to clients if they wish to pursue additional services such as egg donation
and surrogacy, after several cycles of IVF treatments failures due to medical reasons including, but not limited to, the poor egg quality
of aged female clients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compared to other countries,
Kyrgyzstan has the following features that allow NewGenIvf to operates its surrogacy services: (i)&#160;surrogacy is legal and regulated,
which means that there are less restrictions on either intended parents or surrogate mothers, and a parent-child relationship can be
requested before the child&#8217;s birth; and (ii)&#160;the costs of operation and surrogate mother is favourable, given the cost of
living in Kyrgyzstan is relatively low.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regular
surrogacy services, NewGenIvf is also able to assist the clients with birth certificate applications and facilitate the application of
infants&#8217; passports and visas as supplemental services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&#160;years ended
December&#160;31, 2023 and 2022, the revenue from NewGenIvf&#8217;s surrogacy and ancillary caring services was US$1,114,457 and US$3,125,027,
respectively, representing 21.7% and 52.6% of its total revenue in the corresponding periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The flow chart below shows
the stages involved in a typical surrogacy process:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Kyrgyzstan, NewGenIvf
also provides ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity
caring service, and (ii)&#160;documentation service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Network of Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
NewGenIvf had one marketing and sales support office located in Hong&#160;Kong and three clinics located in Thailand, in Cambodia, and
in Kyrgyzstan, respectively. The integration of the medical facilities in Thailand help NewGenIvf provide a more seamless one-stop experience
to its clients. Set out below is an illustration of the locations of NewGenIvf&#8217;s clinics and marketing and sales office:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the approximate aggregate average gross floor area (&#8220;<b>G.F.A.</b>&#8221;) of each of NewGenIvf&#8217;s clinics that were
under lease and actively used for client service as of December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>As of <br/>
    December&#160;31, <br/>
    2023</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>(Square Feet)</i></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b><i>Thailand</i></b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="width: 89%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">First Fertility PGS Center Co., Ltd.
    <br/>
    (&#8220;<b>First Fertility PGS Center</b>&#8221;)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">14,750</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b><i>Cambodia</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">First Fertility Phnom Penh Center <br/>
    (&#8220;<b>Phnom Penh Center</b>&#8221;)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">18,567</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b><i>Kyrgyzstan</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">First Fertility Bishkek Limited Liability Company
    <br/>
    (&#8220;<b>First Fertility Bishkek</b>&#8221;)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,368</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Aggregate G.F.A</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">35,685</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To increase the scale
of NewGenIvf&#8217;s operations, NewGenIvf expanded its Thailand fertility services by leasing a new property for its second clinic Erawan
Consultation Clinic in May&#160;2023. Consisting of approximately 2,500 sq. ft., Erawan Consultation Clinic is expected to open in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, IVF treatments
are performed in its Thailand and Cambodia clinics, egg donation services are provided in its Cambodia clinic, and surrogacy services
are provided in its Kyrgyzstan clinic. The following table summarises the services available at NewGenIvf&#8217;s clinics:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>IVF <br/>
    Treatments</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Surrogacy <br/>
    Services</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Thailand</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="width: 68%; padding-left: 9pt"><span style="font-size: 10pt">First Fertility PGS Center</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Cambodia</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Phnom Penh Center</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#215;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td><span style="font-size: 10pt"><b><i>Kyrgyzstan</i></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CEEEFE">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">First Fertility Bishkek</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#215;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#8730;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#8730;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yes</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#215;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth a breakdown of revenue from services performed at NewGenIvf&#8217;s medical centers for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Thailand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,356,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">505,609</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">621,619</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,608</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,123,593</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,060,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total Revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,136,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,944,190</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Thailand Clinic</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
NewGenIvf had one clinic in Thailand. At the clinic in Thailand, NewGenIvf offers its clients customized fertility treatment solutions
including IVF/ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening by PGT, hysteroscopy, sperm
analysis, sorting, washing and freezing, and egg freezing. Its medical and operational personnel are organized into specialized teams
according to the different stages of the IVF treatment process and different patient profiles. When clients are admitted, they are assigned
to a team which NewGenIvf believes is better suited the clients after taking into account the clients&#8217; diagnosis and preferences.
Furthermore, NewGenIvf also provides related value-added services such as nutrition guidance, psychological counselling, acupuncture,
and translation interpreters to supplement the IVF treatment. NewGenIvf prides itself on providing quality and customized treatment to
its clients on a&#160;day-to-day basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
the clinic in Thailand had six nurses, 8 full time lab physicians and embryologists, 14 administrative staff, totaling 28 staff members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cambodia Clinic</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf has one clinic,
Phnom Penh Center, in Cambodia. Phnom Penh Center is staffed with one Cambodian physician, three embryologists, five nurses and twelve
other staff, and offers similar IVF treatments as in Thailand and egg donation services. Phnom Penh Center operates under a license issued
by Cambodia MOH for the Cambodian physician, who has entered into an agreement with Phnom Penh Center for the exclusive use of such license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After eight&#160;years
of development since its opening in 2015, Phnom Penh Center has become one of the long-standing ARS providers in Cambodia. According
to CIC, it was the first to use conventional IVF technology which led to a successful birth in 2016 in Cambodia. Since its establishment,
Phnom Penh Center achieved more than 1,600 IVF treatment cycles as of December 31, 2023. As of December 31, 2023, Phnom Penh Center&#8217;s
IVF philosophy concentrates on three key points in the treatment process: the mother&#8217;s wellbeing, the technology used to assist
mothers deliver a strong and healthy baby and the medical science used to ensure every chance of success for women in various age spectrums.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinic in Kyrgyzstan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf established
First Fertility Bishkek in October&#160;2019 in Kyrgyzstan for its surrogacy services, as Kyrgyzstan has supply of surrogate candidates
at a relatively low cost and a more friendly legal environment for surrogacy services. In 2020, First Fertility Bishkek obtained the
license to provide ARS and surrogacy services, becoming one of the few facilities licensed to offer ARS and one of the facilities licensed
to offer surrogacy services in Kyrgyzstan as of December&#160;31, 2023, according to CIC.&#160;In addition, NewGenIvf also provide related
ancillary fertility services when carrying out surrogacy services. These ancillary fertility services include: (i)&#160;maternity caring
service, and (ii)&#160;documentation service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians at First Fertility
Bishkek have expertise in sourcing surrogate mothers, techniques of embryo transfers, prenatal care, baby delivery, and postnatal care.
First Fertility Bishkek also collaborates closely with Phnom Penh Center in arranging shipment of frozen embryos. NewGenIvf hires local
physicians and local staff. NewGenIvf also provides training for newly admitted Kyrgyzstan physicians and embryologists in Thailand.
Some personnel who had relevant experience in Kyrgyzstan had also been sent from Cambodia to Kyrgyzstan to help manage such operations
from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
First Fertility Bishkek had one full-time physician, one embryologist, two nurses, and ten other staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Professionals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Licensed Physicians</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
NewGenIvf contracted with five licensed physicians, among which one was based in Cambodia and the other four were based in Thailand.
Most of NewGenIvf&#8217;s physicians had over 10&#160;years of experience or above. The following table summarises the number and types
of such licensed physicians as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licensed physician</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licenses and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Effective Period</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Cambodia</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Mr.&#160;Keut Serey</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Decision on permission for beauty treatment operation</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">December&#160;14, 2022&#160;&#8211; December&#160;14, 2026</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">The Ministry of Health of Cambodia</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dr Patsama Vichinsartvichai</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Facility Operating License number 288006</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August&#160;12, 2022&#160;&#8211; December&#160;31, 2023</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">The Ministry of Health of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 30920 Medical Practitioner License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2004&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">The Ministry of Health of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 26443/2556 Reproductive Medicine Diploma</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2013&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Certificate number obscured OB-Gyn License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October&#160;13, 2010&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dr Keatthisak Boonsimma</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 31801 Medical Practitioner License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2005&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Royal Thai College of Obstetricians and Gynaecologists of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 22624/2554 OB-Gyn License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2014&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 40962/2563 Reproductive Medicine Diploma</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2020&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licensed physician</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licenses and<br/>
    Approvals</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Effective Period</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Issuing<br/>
    Authority</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dr Seree Teerapong</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 15231/2564 Reproductive Medicine License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2021&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 4576/2533 OB-Gyn License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;12, 1990&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 11544 (replacement) Medical Practitioner License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;12, 1984&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dr Wiphawee Luangtangvarodom</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 38347/2562 OB-Gyn License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August&#160;1, 2019&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 43217/2564 Reproductive Medicine License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July&#160;1, 2021&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Number 48510 Medical Practitioner License</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">April&#160;1, 2014&#160;&#8211; Indefinite</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Medical Council of Thailand</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Agreements with Physicians</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf enters into
independent physician agreements or employment contracts with its physicians. The terms and conditions and the format of the agreements
NewGenIvf enters into with each of its physicians vary, depending on the physician&#8217;s seniority and practise nature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Customers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&#160;years ended
December&#160;31, 2023 and 2022, the majority of NewGenIvf&#8217;s clients were from China (including mainland China and Hong Kong).
The number of Thai and Cambodian local patients generally increased in 2022 and 2023 compared with earlier years due to the impact of
COVID-19 on international travel. NewGenIvf enters into a service agreement with each of its customers that outline, among other things,
the scope of services, service fees, payment terms and rights, responsibilities and obligations of each party. Customers are not entitled
to enjoy the relevant services until outstanding amounts have been settled pursuant to the relevant contract. Sales to individual consumers
did not vary significantly and none of the customers contribute more than 10% of NewGenIvf&#8217;s revenue for the&#160;years ended December&#160;31,
2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth a breakdown of NewGenIvf&#8217;s total customers by major countries (determined by the passports they provided to NewGenIvf for
registration) and as a percentage of the total customers for the periods indicated<sup>(1)</sup>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">First <br/> Fertility <br/> PGS
    <br/> Center</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Phnom <br/> Penh <br/> Center</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">First <br/> Fertility <br/> PGS
    <br/> Center</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Phnom <br/> Penh <br/> Center</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-size: 10pt">China<sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">87</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">121</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">117</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>India</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Thailand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Others<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">103</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">287</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">107</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">147</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">254</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Customers of First Fertility Bishkek are the same customers of Phnom
    Penh Center.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Include customers from mainland China and Hong&#160;Kong.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Include customers from Philippines, Singapore, USA, Korea, Nigeria
    and UK.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to significant
customers using NewGenIvf&#8217;s IVF treatment services and surrogacy and ancillary caring services, NewGenIvf also has customers who
only use its relatively insignificant services, such as check-ups services, blood test services and other minor services (the latter
category of customers are referred to as &#8220;consultation customers&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&#160;years ended
December&#160;31, 2023 and 2022, NewGenIvf promoted brand awareness through its sales teams and, in many cases, through cooperating with
third-party agencies and partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s sales
teams have broad experience in fertility services and are responsible for identifying potential clients and managing the overall sales
process. NewGenIvf&#8217;s sales team primarily relies on social media marketing, word-of-mouth referrals, recognition of its brand,
printed advertisements and marketing events. NewGenIvf spends marketing expenses on placing advertisements through popular social media
platforms, maintaining the official website of NewGenIvf and sending information through its official accounts on social media platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Supply and Procurement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf&#8217;s procurement
is mainly for medications, laboratory media and reagents, laboratory consumables, and blood test reagents. As of December&#160;31, 2023
and 2022, one and four suppliers individually contributed more than 10% of the Group&#8217;s trade payable, in aggregate accounting for
30.6% and 69.8% of the Group&#8217;s trade payables, respectively. For the year ended December&#160;31, 2023 and 2022, nil and two vendors
contributed more than 10% of total purchases of the Group, in aggregate accounting for nil and 55.3% of the Group&#8217;s total purchases,
respectively. NewGenIvf&#8217;s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers.
NewGenIvf&#8217;s major suppliers are pharmaceutical companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf believes that
it is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the value and comprehensiveness of the solutions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">treatment that is effective and achieves desired outcomes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clients&#8217; experience, including dedicated patient education,
    clinical guidance and emotional support; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">access to a network of high-quality fertility specialists.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf&#8217;s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf&#8217;s, NewGenIvf may become subject
to additional competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
in addition to its clinics, NewGenIvf leased one property in Hong&#160;Kong with an aggregate square footage of approximately 8,000 for
its administration support offices. NewGenIvf also operates its medical facilities as described above in &#8220;&#8212;&#160;Network
of Facilities&#8221; above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SELLING
SHAREHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
139,425,259 Ordinary Shares being offered by the Selling Shareholders are those issuable to the Selling Shareholders upon conversion
of the Notes and exercise of the Warrants previously issued to the Selling Shareholders as a result of various transactions that have
occurred, which details are set forth below. We are registering the Ordinary Shares in order to permit the Selling Shareholders to offer
the Ordinary Shares for resale from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Other
than the relationships described herein, to our knowledge, the Selling Shareholders have not had any material relationship with us within
the past three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Any
Selling Shareholders that are affiliates of broker-dealers and any participating broker-dealers would be deemed to be &#8220;underwriters&#8221;
within the meaning of the Securities Act, and any commissions or discounts given to any such Selling Shareholders or broker-dealer may
be regarded as underwriting commissions or discounts under the Securities Act. To our knowledge, none of the Selling Shareholders listed
below are broker-dealers or affiliates of broker-dealers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
table below lists the Selling Shareholders and other information regarding the beneficial ownership (as determined under Section 13(d)
of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the Ordinary Shares by each of the Selling
Shareholders. The second column lists the number of Ordinary Shares beneficially owned by each Selling Shareholder, based on its ownership
of the Ordinary Shares, Notes and Warrants, as of August 27, 2024, assuming conversion of the Notes and exercise of the Warrants held
by each such Selling Shareholder on that date but taking account of any limitations on conversion and exercise set forth therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
fourth column lists the Ordinary Shares being offered by this prospectus by the Selling Shareholders and does not take in account any
limitations on (i) conversion of the Notes set forth therein or (ii) exercise of the Warrants set forth therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
accordance with the terms of a registration rights agreement with the holders of the Notes and the Warrants, this prospectus generally
covers the resale of the sum of (i) 250% of the maximum number of Ordinary Shares issued or issuable pursuant to the Notes, including
payment of interest on the Notes through the fifty-four (54) month anniversary of the issuance date of such Notes, and (ii) 100% of the
maximum number of Ordinary Shares issued or issuable upon exercise of the Warrants, in each case, determined as if the outstanding Notes
(including interest on the Notes through the fifty-four (54) month anniversary of the issuance date of such Notes) and Warrants were
converted or exercised (as the case may be) in full (without regard to any limitations on conversion or exercise contained therein solely
for the purpose of such calculation) at the $0.509 alternate conversion price of the Notes or the exercise price of the Warrants then
in effect (as the case may be) calculated as of the trading day immediately preceding the date this registration statement was initially
filed with the SEC. Because the conversion price and alternate conversion price of the Notes and the exercise price of the Warrants may
be adjusted, the number of shares that will actually be issued may be more or less than the number of shares being offered by this prospectus.
The fourth column assumes the sale of all of the shares offered by the Selling Shareholders pursuant to this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the terms of the Notes and the Warrants, a Selling Shareholder may not convert the Notes or exercise the Warrants to the extent (but
only to the extent) such Selling Shareholder or any of its affiliates would beneficially own a number of shares of our Ordinary Shares
which would exceed 4.99% of the outstanding shares of the Company (the &#8220;Maximum Percentage&#8221;). The number of shares in the
second column reflects these limitations. The Selling Shareholder may sell all, some or none of their shares in this offering. See &#8220;Plan
of Distribution.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
explained below under &#8220;<i>Plan of Distribution</i>,&#8221; we have agreed with the Selling Shareholders to bear certain expenses
(other than broker discounts and commissions, if any) in connection with the registration statement, which includes this prospectus.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">The
following table sets forth details regarding the offering of certain Selling Shareholders&#8217; Ordinary Shares pursuant to this registration
statement.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Name of Selling Shareholders</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
    <br/> Shares <br/> Beneficially <br/> Owned<br/> Prior to <br/> Offering<sup>(1)(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage&#160;of
    <br/> Ordinary Shares Beneficially Owned <br/>
    Prior to<br/>
    Offering<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt"><sup>&#160;</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">Maximum
    <br/> Number of <br/> Ordinary<br/>
    Shares <br/> to be <br/>
    Sold<br/> Pursuant to<br/>
    this<br/> Prospectus</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
    <br/> Shares Beneficially Owned<br/> Immediately<br/> After Sale of <br/> Maximum<br/> Number&#160;of Shares <br/> in this<br/> Offering<sup>(1)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage&#160;of<br/>
    Ordinary Shares Beneficially Owned Immediately<br/> After <br/>
    Sale of<br/> Maximum<br/> Number&#160;of Shares<br/> in this<br/> Offering<sup>(1)(2)(4)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAK
    Opportunities VI LLC<sup>(6)</sup></span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">533,053</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4.99</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132,094,759
                                            </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"><sup>(5)</sup>&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hei
    Yue Tina Fong<sup>(7)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,326,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22.92</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,326,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wing
    Fung Alfred Siu <sup>(8)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,779,500</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">17.53</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,779,500</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chardan
    Capital Markets LLC <sup>(9)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,569,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">15.46</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,500,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">69,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">69,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    Yield Holdings Limited <sup>(10)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">750,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.39</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">750,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    SPAC (Holdings) GROUP Corp <sup>(10) (11)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">655,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.45</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">655,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chung
    Mei Investment Limited <sup>(10) (12)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">260,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2.56</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">260,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abuzzal
    Abusaeri <sup>(10) (13)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">0.20</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Ignatius Brebeck <sup>(10) (14)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">0.20</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hoang
    Giang Nguyen <sup>(10) (15)</sup></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">0.20</span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
                                            ownership is determined in accordance with SEC rules and generally includes voting or investment
                                            power with respect to securities. Ordinary Shares subject to options or warrants currently
                                            exercisable, or exercisable within 60 days of September 4, 2024, are counted as outstanding
                                            for computing the percentage of the Selling Shareholder holding such options or warrants
                                            but are not counted as outstanding for computing the percentage of any other Selling Shareholder.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The applicable
    percentage of beneficial ownership is calculated based on the total number of Ordinary Shares issued and outstanding, being 10,149,386
    shares as of September 4, 2024, and 149,574,645 shares that will be outstanding after this offering. </span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This column
    lists the number of our Ordinary Shares beneficially owned by this Selling Shareholder as of September 4, 2024 after giving effect
    to the Maximum Percentage (as defined in the paragraph above). Without regard to the Maximum Percentage, as of September 4, 2024,
    this Selling Shareholder would beneficially own an aggregate of 132,094,759 of our Ordinary Shares, consisting of (i) 108,789,090
    shares underlying the Notes held by this Selling Shareholder, which includes (v) 8,997,594 shares underlying the Initial Note, (w)
    4,089,815 shares underlying the First Mandatory Additional Note, (x) 12,269,446 shares underlying the Second Mandatory Additional
    Note (as defined below), (y) 61,347,231 shares underlying the Additional Notes and (z) 22,085,003 shares underlying the Exchange
    Notes, all of which shares are being registered for resale under this prospectus, (ii) 19,871,935 shares underlying the Series A
    Warrants held by this Selling Shareholder, currently exercisable at an exercise price of $0.913, all of which shares are being registered
    for resale under this prospectus, (iii) 180,722 shares underlying the Series B Warrants held by this Selling Shareholder, the exercise
    price of the Series B Warrants was prepaid, except for a nominal exercise price of $0.001 per share, all of which shares are being
    registered for resale under this prospectus and (iv) 3,253,012 shares underlying the Exchange Warrants held by this Selling Shareholder,
    currently exercisable at an exercise price of $$0.913, all of which shares are being registered for resale under this prospectus.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Represents
                                            the amount of shares that will be held by the Selling Shareholder after completion of this
                                            offering based on the assumptions that (a) all Ordinary Shares, including all Ordinary Shares
                                            underlying the Notes and Warrants, registered for sale by the registration statement of which
                                            this prospectus is part of will be sold, and (b) no other shares of Ordinary Shares are acquired
                                            or sold by the Selling Shareholder prior to completion of this offering. However, the Selling
                                            Shareholder is not obligated to sell all or any portion of the Ordinary Shares offered pursuant
                                            to this prospectus.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">In
                                            accordance with the terms of the Registration Rights Agreement (as defined below) with this
                                            Selling Shareholder, for purposes of the calculations of Ordinary Shares to be sold by this
                                            Selling Shareholder pursuant to the prospectus we are assuming (i) an event of default under
                                            the Notes has not occurred and the issuance of 250% of the Ordinary Shares underlying the
                                            Notes, assuming that (x) all Additional Notes issuable under the Securities Purchase Agreement
                                            (as defined below) have been issued and (y) the Notes, including payment of 14.75% interest
                                            on the Notes through the fifty-four (54) month anniversary of the issuance date of such Notes,
                                            are converted in full at an Alternate Conversion Price (as defined below) of $0.509 per share,
                                            without regard to any limitations set forth therein and (ii) the issuance of the maximum
                                            amount of Ordinary Shares underlying the Warrants, exercised in full at the applicable exercise
                                            price without regard to any limitations set forth therein.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Selling Shareholder, JAK Opportunities VI LLC (&#8220;JAK VI&#8221;), is wholly-owned by
                                            ATW Opportunities Master Fund II, L.P. (the &#8220;Fund&#8221;). ATW Partners Opportunities
                                            Management, LLC serves as the investment manager to the Fund (the &#8220;Adviser&#8221;).
                                            The Fund and the Adviser may be deemed to have shared voting and dispositive power with respect
                                            to the shares of common stock beneficially owned by the Selling Shareholderand may be deemed
                                            to be the beneficial owner of these shares. Antonio Ruiz-Gimenez and Kerry Propper serve
                                            as the managing members of the Adviser (the &#8220;Managing Members&#8221;). The Managing
                                            Members, in their capacity as Managing Members of the Adviser, may also be deemed to have
                                            investment discretion and voting power over the shares of common stock beneficially owned
                                            by the Selling Shareholder. The Fund, the Adviser and the Managing Members each disclaim
                                            any beneficial ownership of such holdings. The address of this Selling Shareholderis c/o
                                            ATW Partners Opportunities Management, LLC, 1 Pennsylvania Plaza, Suite 4810, New York, NY
                                            10119.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The number of ordinary shares being registered for Hei Yue Fong Tina
    represents the 2,326,000 Ordinary Shares Ms. Fong received as part of the closing payment pursuant to the merger agreement between
    A SPAC I Acquisition Corp and NewgenIVF Limited dated February 15, 2023 and as amended on June 12, 2023, December 6, 2023, March
    1, 2024 and March 28, 2024, and pursuant to the Amended and Restated Registration Rights Agreement dated April 3, 2024. The mailing
    address of Hei Yue Tina Fong is Flat D1, 20/F, Block D, 43 Stubbs Road, Evergreen Villa Mid-levels, Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The number of ordinary shares being registered for Wing Fung Alfred
    Siu represents the&#160;&#160;1,779,500 Ordinary Shares Mr. Siu received as part of the closing payment pursuant to the merger agreement
    between A SPAC I ACquisition Corp and NewgenIVF Limited, entered into on February 15, 2023 and as amended on June 12, 2023, December
    6, 2023, March 1, 2024 and March 28, 2024, and pursuant to the Amended and Restated Registration Rights Agreement dated April 3,
    2024. The mailing address of Wing Fung Alfred Siu is Flat D1, 20/F, Block D, 43 Stubbs Road, Evergreen Villa Mid-levels, Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Steven Urbach, in its capacity as the CEO of Chardan Capital Markets
    LLC, has the power to vote and the power to direct the disposition of all securities held by Chardan Capital Markets LLC. The number
    of Ordinary Shares being registered for Chardan Capital Market LLC represents the 1,500,000 Ordinary Shares for the deferred underwriting
    commission pursuant to the acknowledgement agreement dated March 1, 2024 and the Amended and Restated Registration Rights Agreement
    dated April 3, 2024. The mailing address of Chardan Capital Market LLC is 17 State Street, 21ST Floor, New York, New York, 10004.
    </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The number of Ordinary Shares being registered for Future Yield Holdings
    Limited, A SPAC (Holdings) Group Corp., Chung Mei Investment Limited, Abuzzal Abusaeri, John Ignatius Brebeck, and Hoang Giang Nguyen,
    represents the aggregate of 1,725,000 founder shares originally issued to the Sponsor, A SPAC (Holdings) Acquisition Corp. prior
    to the initial public offering of A SPAC I Acquisition Corp, and pursuant to the terms of the Amended and Restated Registration Rights
    Agreement dated April 3, 2024. The mailing address of Future Yield Holdings Limited is Sea Meadow House, Blackburne Highway, (P.O.
    Box 116), Road Town, Tortola, British Virgin Islands. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The mailing address of A SPAC (Holdings) Group Corp is Ritter House,
    Wickhams Cay II, PO Box 3170, Road Town, Tortola VG1110, British Virgin Islands.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The mailing address of Chung Mei Investment Limited is 11/F, Chung
    Mei Centre, 15B Hing Yip Street, Kwun Tong, Kowloon, Hong Kong.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The mailing address of Abuzzal Abusaeri is JL. Cipete Raya No.9 (Victoria
    Townhouse) no Unit B6 kel.Cipete Selatan, kec.Cilandak, RT/RW 8/4, Kota Jakarta Selatan, 12410, Indonesia.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The mailing address of John Ignatius Brebeck is 1821 E 5th St, Apr7,
    Long Beach, CA 90702-2015, USA.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The mailing address of Hoang Giang Nguyen is A1707, 88 Lang Ha Street,
    Dong Da District, Ho Noi City, Vietnam.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PLAN
OF DISTRIBUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are registering the Ordinary Shares previously issued and the Ordinary Shares issuable upon conversion of the Notes and exercise of the
Warrants, to permit the resale of these Ordinary Shares by the holders of these securities from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Shareholders of the Ordinary Shares, although we will receive the
exercise price of any Warrants not exercised by the Selling Shareholders on a cashless exercise basis. We will bear all fees and expenses
incident to our obligation to register the Selling Shareholders&#8217; Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Selling Shareholders may sell all or a portion of the Ordinary Shares held by them and offered hereby from time to time directly or through
one or more underwriters, broker-dealers or agents. If the Ordinary Shares are sold through underwriters or broker-dealers, the Selling
Shareholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The Ordinary Shares may be sold
in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the
time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant
to one or more of the following methods:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">on
                                            any national securities exchange or quotation service on which the securities may be listed
                                            or quoted at the time of sale;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in the over-the-counter market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">in
                                    transactions other than on these exchanges or systems or in the over-the-counter market;</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer
    solicits purchasers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">through
        the writing or settlement of options, whether such options are listed on an options exchange or otherwise;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares
    as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer
    for its account;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable
    exchange;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">privately negotiated transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales made after
    the date this registration statement is declared effective by the SEC;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">broker-dealers may agree with the selling securityholders to sell a
    specified number of such shares at a stipulated price per share;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a combination of any such methods of sale; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any other method permitted pursuant to applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Selling Shareholders may also sell Ordinary Shares under Rule 144 promulgated under the Securities Act, if available, rather than under
this prospectus. In addition, the Selling Shareholders may transfer the Ordinary Shares by other means not described in this prospectus.
If the Selling Shareholders affect such transactions by selling Ordinary Shares to or through underwriters, broker-dealers or agents,
such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling
Shareholders or commissions from purchasers of the Ordinary Shares for whom they may act as an agent or to whom they may sell as principal
(which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary
in the types of transactions involved). In connection with sales of the Ordinary Shares or otherwise, the Selling Shareholders may enter
into hedging transactions with broker-dealers, which may in turn engage in short sales of the Ordinary Shares in the course of hedging
in positions they assume. The Selling Shareholders may also sell Ordinary Shares short and deliver Ordinary Shares covered by this prospectus
to close out short positions and to return borrowed shares in connection with such short sales. The Selling Shareholders may also loan
or pledge Ordinary Shares to broker-dealers that in turn may sell such shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
                                            Selling Shareholders may pledge or grant a security interest in some or all of the Notes,
                                            Warrants or Ordinary Shares owned by them and, if they default in the performance of their
                                            secured obligations, the pledgees or secured parties may offer and sell the Ordinary Shares
                                            from time to time pursuant to this prospectus or any amendment to this prospectus under Rule
                                            424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the
                                            list of Selling Shareholders to include the pledgee, transferee or other successors in interest
                                            as Selling Shareholders under this prospectus. The Selling Shareholders also may transfer
                                            and donate the Ordinary Shares in other circumstances in which case the transferees, donees,
                                            pledgees or other successors in interest will be the selling beneficial owners for purposes
                                            of this prospectus. To the extent required by the Securities Act and the rules and regulations
                                            thereunder, the Selling Shareholders and any broker-dealer participating in the distribution
                                            of the shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities
                                            Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer
                                            may be deemed to be underwriting commissions or discounts under the Securities Act. At the
                                            time a particular offering of the shares is made, a prospectus supplement, if required, will
                                            be distributed which will set forth the aggregate amount of Ordinary Shares being offered
                                            and the terms of the offering, including the name or names of any broker-dealers or agents,
                                            any discounts, commissions and other terms constituting compensation from the Selling Shareholders
                                            and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
the securities laws of some states, the Ordinary Shares may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some states, the Ordinary Shares may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
can be no assurance that any Selling Shareholder will sell any or all of the Ordinary Shares registered pursuant to the registration
statement, of which this prospectus forms a part.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Selling Shareholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange
Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange
Act, which may limit the timing of purchases and sales of any of the shares by the Selling Shareholders and any other participating person.
To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Ordinary Shares
to engage in market-making activities with respect to the shares. All of the foregoing may affect the marketability of the Ordinary Shares
and the ability of any person or entity to engage in market-making activities with respect to the Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
will pay all expenses of the registration of the Ordinary Shares, estimated to be $59,938 in total, including, without limitation, SEC
filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that a Selling Shareholder
will pay all underwriting discounts and selling commissions if any. We will indemnify the Selling Shareholders against liabilities, including
some liabilities under the Securities Act in accordance with the Registration Rights Agreement, or the Selling Shareholders will be entitled
to contribution. We may be indemnified by the Selling Shareholders against civil liabilities, including liabilities under the Securities
Act, that may arise from any written information furnished to us by the Selling Shareholders specifically for use in this prospectus,
in accordance with the related registration rights agreements or we may be entitled to contribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Once
sold under the registration statement, of which this prospectus forms a part, the Ordinary Shares will be freely tradable in the hands
of persons other than our affiliates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>DESCRIPTION
OF SHARE CAPITAL</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Class A and
Class B Ordinary Shares</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>General</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><span style="font-size: 10pt">The
Memorandum and Articles of Association authorize the issuance of a maximum of 200,000,000 Class A Ordinary Shares, 200,000 Class B Ordinary
Shares and 1,000,000 preferred shares with no par value (&#8220;Preferred Shares&#8221;). As of September 4, 2024, we have 10,149,386
shares &#160;of Class A Ordinary Shares outstanding, no Class B Ordinary Shares outstanding, and no Preferred Shares outstanding. All
of our outstanding Class A Ordinary Shares at the time of the closing of this offering, will be, validly issued, and fully paid. Our
Class A Ordinary Shares and Class B Ordinary Shares are not redeemable and are not subject to any preemptive right.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Dividends<i>.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
holders of our Class A Ordinary Shares and Class B Ordinary Shares are entitled to an equal share, for each share held, in any dividend
paid by the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Voting Rights</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to the rights of the Preferred Shares&#8217; holders, in respect of all matters subject to a member&#8217;s vote, each Class A Ordinary
Share and Class B Ordinary Share is entitled to one vote at a meeting of the members or on any resolution of members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Distributions</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
holders of the Class A Ordinary Shares and Class B Ordinary Shares each have a right to an equal share with each other in the distribution
of the surplus assets of the Company on the Company&#8217;s liquidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Preferred
Shares</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to applicable law and the Memorandum and Articles of Association, the Board of Directors may issue Preferred Shares with such preferred
rights as they shall determine. The rights, privileges, restrictions and conditions attaching to the Preferred Shares shall be stated
in the Memorandum and Articles of Association, which shall be amended accordingly prior to the issue of such Preferred Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>TAXATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>The
following is a general summary of the material U.S. federal income tax consequences relevant to an investment in our Ordinary Shares.
The discussion is not intended to be, nor should it be construed as, legal or tax advice to any particular prospective purchaser. The
discussion is based on laws and relevant interpretations thereof as of the date of this annual report, all of which are subject to change
or different interpretations, possibly with retroactive effect. The discussion does not address U.S. state or local tax laws. You should
consult your own tax advisors with respect to the consequences of acquisition, ownership and disposition of our Ordinary Shares.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed),
administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing
interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of
all potential U.S.&#160;federal income tax considerations that may apply to a securityholder of the Company as a result of the ownership
and disposition of the Company Securities. In addition, this discussion does not address all aspects of U.S.&#160;federal income taxation
that may be relevant to particular holders nor does it take into account the individual facts and circumstances of any particular holder
that may affect the U.S.&#160;federal income tax consequences to such holder, and accordingly, is not intended to be, and should not
be construed as, tax advice. This discussion does not address the U.S.&#160;federal 3.8% Medicare tax imposed on certain net investment
income or any aspects of U.S.&#160;federal taxation other than those pertaining to the income tax, nor does it address any tax consequences
arising under any U.S.&#160;state and local, or non-U.S.&#160;tax laws, or, except as discussed here, any tax reporting obligations of
a holder of the Company Securities. Holders should consult their own tax advisors regarding such tax consequences in light of their particular
circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">No
ruling has been requested or will be obtained from the IRS regarding the U.S.&#160;federal income tax consequences discussed below; thus,
there can be no assurance that the IRS will not challenge the U.S.&#160;federal income tax treatment described below or that, if challenged,
such treatment will be sustained by a court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">This
summary is limited to considerations relevant to U.S.&#160;Holders that hold the Company Securities as &#8220;capital assets&#8221; within
the meaning of section 1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S.&#160;federal
income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment
under the U.S.&#160;tax laws, such as, for example:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">banks or other financial institutions, underwriters, or insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">traders in securities who elect to apply a mark-to-market method of
    accounting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">real estate investment trusts and regulated investment companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">tax-exempt organizations, qualified retirement plans, individual retirement
    accounts, or other tax- deferred accounts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expatriates or former citizens or long-term residents of the United&#160;States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">subchapter S corporations, partnerships or other pass-through entities
    or investors in such entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any holder that is not a U.S.&#160;Holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">dealers or traders in securities, commodities or currencies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">grantor trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons subject to the alternative minimum tax;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">U.S.&#160;persons whose &#8220;functional currency&#8221; is not the
    U.S.&#160;dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who receive stock of the Company through the issuance of restricted
    share under an incentive plan or through a tax-qualified retirement plan or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">U.S.&#160;shareholders of controlled foreign corporations, as those
    terms are defined in Sections 951(b)&#160;and 957(a), respectively;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">persons who own (directly or through attribution) 5% or more (by vote
    or value) of the outstanding Class A Ordinary Shares (excluding treasury shares);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">holders holding ASCA securities, or, after the Business Combination,
    the Company Securities, as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221;
    as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
used in this prospectus, the term &#8220;U.S.&#160;Holder&#8221; means a beneficial owner of the Company Securities, that is, for U.S.&#160;federal
income tax purposes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an individual who is a citizen or resident of the United&#160;States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a corporation (or other entity that is classified as a corporation
    for U.S.&#160;federal income tax purposes) that is created or organized in or under the laws of the United&#160;States or any State
    thereof or the District of Columbia;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an estate the income of which is subject to U.S.&#160;federal income
    tax regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a trust (i)&#160;if a court within the United&#160;States is able to
    exercise primary supervision over the administration of the trust and one or more U.S.&#160;persons have the authority to control
    all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to
    be treated as a U.S.&#160;person for U.S.&#160;federal income tax purposes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S.&#160;federal income tax
purposes, holds the Company Securities, the U.S.&#160;federal income tax treatment of a partner in such partnership will generally depend
on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership
should consult their own tax advisors with regard to the U.S.&#160;federal income tax consequences of ownership and disposition of the
Company Securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">THIS
SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES OF
OWNERSHIP AND DISPOSITION OF THE COMPANY SECURITIES.&#160;IN ADDITION, THE U.S.&#160;FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS
OF THE COMPANY SECURITIES MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND
INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S.&#160;FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE.&#160;HOLDERS
OF THE COMPANY SECURITIES SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND
DISPOSITION OF THE COMPANY SECURITIES, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&#160;FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Distribution on the Class A Ordinary
Shares</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to the PFIC rules discussed below &#8220;&#8212;&#160;Passive Foreign Investment Company Status,&#8221; the gross amount of any distribution
on the Class A Ordinary Shares that is made out of the Company&#8217;s current and accumulated earnings and profits (as determined for
U.S.&#160;federal income tax purposes) will generally be taxable to a U.S.&#160;Holder as ordinary dividend income on the date such distribution
is actually or constructively received by such U.S.&#160;Holder. Any such dividends paid to corporate U.S.&#160;Holders generally will
not qualify for the dividends-received deduction that may otherwise be allowed under the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Dividends
received by non-corporate U.S.&#160;Holders, including individuals, from a &#8220;qualified foreign corporation&#8221; may be eligible
for reduced rates of taxation, provided that certain holding period requirements and other conditions are satisfied. For these purposes,
a non-U.S.&#160;corporation will be treated as a qualified foreign corporation with respect to dividends paid by that corporation on
shares that are readily tradable on an established securities market in the United&#160;States. U.S.&#160;Treasury Department guidance
indicates that shares listed on Nasdaq will be considered readily tradable on an established securities market in the United&#160;States.
Even if the Class A Ordinary Shares are listed on Nasdaq, there can be no assurance that the Class A Ordinary Shares will be considered
readily tradable on an established securities market in future&#160;years. Non-corporate U.S.&#160;Holders that do not meet a minimum
holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4)
of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation regardless
of the Company&#8217;s status as a qualified foreign corporation. In addition, the rate reduction will not apply to dividends if the
recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property.
This disallowance applies even if the minimum holding period has been met. Finally, the Company will not constitute a qualified foreign
corporation for purposes of these rules if it is a PFIC for the taxable year in which it pays a dividend or for the preceding taxable
year. See the discussion below under &#8220;&#8212;&#160;Passive Foreign Investment Company Status.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
amount of any dividend paid in foreign currency will be the U.S.&#160;dollar value of the foreign currency distributed by the Company,
calculated by reference to the exchange rate in effect on the date the dividend is includible in the U.S.&#160;Holder&#8217;s income,
regardless of whether the payment is in fact converted into U.S.&#160;dollars on the date of receipt. Generally, a U.S.&#160;Holder should
not recognize any foreign currency gain or loss if the foreign currency is converted into U.S.&#160;dollars on the date the payment is
received. However, any gain or loss resulting from currency exchange fluctuations during the period from the date the U.S.&#160;Holder
includes the dividend payment in income to the date such U.S.&#160;Holder actually converts the payment into U.S.&#160;dollars will be
treated as ordinary income or loss. That currency exchange income or loss (if any) generally will be income or loss from U.S.&#160;sources
for foreign tax credit limitation purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">To
the extent that the amount of any distribution made by the Company on the Class A Ordinary Shares exceeds the Company&#8217;s current
and accumulated earnings and profits for a taxable year (as determined under U.S.&#160;federal income tax principles), the distribution
will first be treated as a tax-free return of capital, causing a reduction in the adjusted basis of the U.S.&#160;Holder&#8217;s the
Class A Ordinary Shares, and to the extent the amount of the distribution exceeds the U.S.&#160;Holder&#8217;s tax basis, the excess
will be taxed as capital gain recognized on a sale or exchange as described below under &#8220;&#8212;&#160;Sale, Exchange, Redemption
or Other Taxable Disposition of the Company Securities.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Sale, Exchange, Redemption or Other
Taxable Disposition of the Company Securities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Subject
to the discussion below under &#8220;&#8212;&#160;Passive Foreign Investment Company Status,&#8221; a U.S.&#160;Holder will generally
recognize gain or loss on any sale, exchange, redemption, or other taxable disposition of the Class A Ordinary Shares and the Warrants
in an amount equal to the difference between the amount realized on the disposition and such U.S.&#160;Holder&#8217;s adjusted tax basis
in such the Class A Ordinary Shares or Warrants. Any gain or loss recognized by a U.S.&#160;Holder on a taxable disposition of the Class
A Ordinary Shares or Warrants will generally be capital gain or loss and will be long-term capital gain or loss if the holder&#8217;s
holding period in the Class A Ordinary Shares or Warrants exceeds one year at the time of the disposition. Preferential tax rates may
apply to long-term capital gains of non-corporate U.S.&#160;Holders (including individuals). The deductibility of capital losses is subject
to limitations. Any gain or loss recognized by a U.S.&#160;Holder on the sale or exchange of the Class A Ordinary Shares or the Warrants
will generally be treated as U.S.&#160;source gain or loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Exercise or
Lapse of a Warrant</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Except
as discussed below with respect to the cashless exercise of a Warrant, a U.S.&#160;Holder generally will not recognize gain or loss upon
the acquisition of an ordinary share of the Company on the exercise of a Warrant for cash. A U.S.&#160;Holder&#8217;s tax basis in an
ordinary share received upon exercise of the Warrant generally will be an amount equal to the sum of the U.S.&#160;Holder&#8217;s tax
basis in the Warrant exchanged therefor and the exercise price. The U.S.&#160;Holder&#8217;s holding period for an ordinary share received
upon exercise of the Warrant will begin on the date following the date of exercise (or possibly the date of exercise) of the Warrants
and will not include the period during which the U.S.&#160;Holder held the Warrants. If a Warrant is allowed to lapse unexercised, a
U.S.&#160;Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
tax consequences of a cashless exercise of a warrant are not clear under current tax law. A cashless exercise may be tax-free, either
because the exercise is not a gain realization event or because the exercise is treated as a recapitalization for U.S.&#160;federal income
tax purposes. In either tax-free situation, a U.S.&#160;Holder&#8217;s basis in the Class A Ordinary Shares received would equal the
holder&#8217;s basis in the Warrant. If the cashless exercise were treated as not being a gain recognition event, a U.S.&#160;Holder&#8217;s
holding period in the Class A Ordinary Shares would be treated as commencing on the date following the date of exercise (or possibly
the date of exercise) of the Warrant. If the cashless exercise were treated as a recapitalization, the holding period of the Class A
Ordinary Share would include the holding period of the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">It
is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In
such event, a U.S.&#160;Holder would recognize gain or loss with respect to the portion of the exercised Warrants treated as surrendered
to pay the exercise price of the Warrants (the &#8220;surrendered warrants&#8221;). The U.S.&#160;Holder would recognize capital gain
or loss with respect to the surrendered warrants in an amount generally equal to the difference between (i)&#160;the fair market value
of the Class A Ordinary Shares that would have been received with respect to the surrendered warrants in a regular exercise of the Warrants
and (ii)&#160;the sum of the U.S.&#160;Holder&#8217;s tax basis in the surrendered warrants and the aggregate cash exercise price of
such warrants (if they had been exercised in a regular exercise). In this case, a U.S.&#160;Holder&#8217;s tax basis in the Class A Ordinary
Shares received would equal the U.S.&#160;Holder&#8217;s tax basis in the Warrants exercised plus (or minus) the gain (or loss) recognized
with respect to the surrendered warrants. A U.S.&#160;Holder&#8217;s holding period for the Class A Ordinary Shares would commence on
the date following the date of exercise (or possibly the date of exercise) of the Warrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Due
to the absence of authority on the U.S.&#160;federal income tax treatment of a cashless exercise, there can be no assurance which, if
any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly,
U.S.&#160;Holders should consult their tax advisors regarding the tax consequences of a cashless exercise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Passive Foreign
Investment Company Status</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
adverse U.S.&#160;federal income tax consequences could apply to a U.S.&#160;Holder if the Company or any of its subsidiaries is treated
as a PFIC for any taxable year during which the U.S.&#160;Holder holds the Company Securities. A non-U.S.&#160;corporation will be classified
as a PFIC for any taxable year (a)&#160;if at least 75% of its gross income in a taxable year, including its pro rata share of the gross
income of any entity in which it is considered to own at least 25% of the interest by value, is passive income, or (b)&#160;if at least
50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly
over the year, including its pro rata share of the assets of any entity in which it is considered to own at least 25% of the interest
by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and
royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive
assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company is not a PFIC in the 2024 taxable year, such U.S.&#160;Holder would likely recognize gain (but not loss if the Reincorporation
Merger qualifies as a &#8220;reorganization&#8221;) upon the exchange of ASCA securities for The Company securities pursuant to the Reincorporation
Merger. The gain (or loss) would be computed as described above under &#8220;&#8212;&#160;If the Reincorporation Merger Does Not Qualify
as a Reorganization.&#8221; Any such gain recognized by such U.S.&#160;Holder on the exchange of ASCA securities for The Company securities
would be allocated ratably over the U.S.&#160;Holder&#8217;s holding period for the ASCA securities. Such amounts allocated for the current
taxable year and any taxable year prior to the first taxable year in which ASCA was a PFIC would be treated as ordinary income, and not
as capital gain, in the U.S.&#160;Holder&#8217;s taxable year, and such amounts allocated to each other taxable year beginning with the
year that ASCA became a PFIC would be taxed at the highest tax rate in effect for each year to which the gain was allocated, together
with a special interest charge on the tax attributable to each such year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Whether
the Company is a PFIC for any taxable year is a factual determination that depends on, among other things, the composition of the Company&#8217;s
income and assets, the market value of its assets, and potentially the composition of the income and assets of one or more of the Company&#8217;s
subsidiaries and the market value of their assets in that year. Whether a Company subsidiary is a PFIC for any taxable year is likewise
a factual determination that depends on, among other things, the composition of the subsidiary&#8217;s income and assets and the market
value of such assets in that year. One or more changes in these factors may cause the Company and/or one or more of its subsidiaries
to become a PFIC for a taxable year even though it has not been a PFIC for one or more prior taxable years. Whether the Company or a
subsidiary is treated as a PFIC for U.S.&#160;federal income tax purposes is a factual determination that must be made annually at the
close of each taxable year and, thus, is subject to significant uncertainty. Moreover, there can be no assurance that the Company will
timely provide a PFIC annual information statement for 2024 or going forward. The failure to provide such information on an annual basis
could preclude U.S.&#160;Holders from making or maintaining a &#8220;qualified electing fund&#8221; election under Section&#160;1295
of the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company were determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S.&#160;Holder
of Class A Ordinary Shares, the U.S.&#160;Holder did not make a valid &#8220;mark-to-market&#8221; election, such U.S.&#160;Holder generally
will be subject to special rules&#160;with respect to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any gain recognized by the U.S.&#160;Holder on the sale or other disposition
    of the Company Securities (including a redemption treated as a sale or exchange); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any &#8220;excess distribution&#8221; made to the U.S.&#160;Holder
    (generally, any distributions to such U.S.&#160;Holder during a taxable year of the U.S.&#160;Holder that are greater than 125% of
    the average annual distributions received by such U.S.&#160;Holder in respect of the Class A Ordinary Shares during the three preceding
    taxable&#160;years of such U.S.&#160;Holder or, if shorter, such U.S.&#160;Holder&#8217;s holding period for such ordinary shares).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Under
these rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the U.S.&#160;Holder&#8217;s gain or excess distribution will be allocated
    ratably over the U.S.&#160;Holder&#8217;s Company Securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to the U.S.&#160;Holder&#8217;s taxable year in
    which the U.S.&#160;holder recognized gain or received the excess distribution, or to the period in the U.S.&#160;Holder&#8217;s
    holding period before the first&#160;day of the Company&#8217;s first taxable year in the Company is a PFIC, will be taxed as ordinary
    income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amount allocated to other taxable&#160;years (or portions thereof)
    of the U.S.&#160;Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable
    to the&#160;U.S.&#160;Holder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the interest charge generally applicable to underpayments of tax will
    be imposed in respect of the tax attributable to each such other taxable year of the U.S.&#160;Holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Although
a determination as to the Company&#8217;s PFIC status will be made annually, an initial determination that the Company is a PFIC will
generally apply for subsequent&#160;years to a U.S.&#160;Holder who held Company Securities while the Company was a PFIC, whether or
not the Company meets the test for PFIC status in those subsequent&#160;years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
a U.S.&#160;Holder, at the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S.&#160;Holder
may make a mark-to-market election with respect to such shares for such taxable year. If the U.S.&#160;Holder makes a valid mark-to-market
election for the first taxable year of the U.S.&#160;Holder in which the U.S.&#160;Holder holds (or is deemed to hold) the Class A Ordinary
Shares and for which the Company is determined to be a PFIC, such holder generally will not be subject to the PFIC rules&#160;described
above in respect to the Class A Ordinary Shares as long as such shares continue to be treated as marketable stock. Instead, in general,
the U.S.&#160;Holder will include as ordinary income each year that the Company is treated as a PFIC the excess, if any, of the fair
market value of its Class A Ordinary Shares at the end of its taxable year over the adjusted basis in its Class A Ordinary Shares. The
U.S.&#160;Holder also will be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of its Class A
Ordinary Shares over the fair market value of its Class A Ordinary Shares at the end of its taxable year (but only to the extent of the
net amount of previously recognized income as a result of the mark-to-market election). The U.S.&#160;Holder&#8217;s adjusted tax basis
in its Class A Ordinary Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale
or other taxable disposition of the Class A Ordinary Shares in a taxable year in which the Company is treated as a PFIC will be treated
as ordinary income. Special tax rules may also apply if a U.S.&#160;Holder makes a mark-to-market election for a taxable year after the
first taxable year in which the U.S.&#160;Holder holds (or is deemed to hold) its Class A Ordinary Shares and for which the Company is
treated as a PFIC.&#160;Currently, a mark-to-market election may not be made with respect to the Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
mark-to-market election is available only for stock that is regularly traded on a national securities exchange that is registered with
the SEC, including Nasdaq (on which the Company Securities are traded), or on a foreign exchange or market that the IRS determines has
rules&#160;sufficient to ensure that the market price represents a legitimate and sound fair market value. Such stock generally will
be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at
least 15&#160;days during each calendar quarter, but no assurances can be given in this regard with respect to the Class A Ordinary Shares.
U.S.&#160;Holders should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election
in respect of the Class A Ordinary Shares under their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">If
the Company is a PFIC and, at any time, has a foreign subsidiary that is classified as a PFIC, U.S.&#160;Holders generally would be deemed
to own a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge
described above if the Company were to receive a distribution from, or dispose of all or part of the Company&#8217;s interest in, the
lower-tier PFIC (even though such U.S.&#160;Holder would not receive the proceeds of those distributions or dispositions) or the U.S.&#160;Holders
otherwise were deemed to have disposed of an interest in the lower-tier PFIC.&#160;A mark-to-market election generally would not be available
with respect to such lower-tier PFIC.&#160;U.S.&#160;Holders are urged to consult their own tax advisors regarding the tax issues raised
by lower-tier PFICs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
U.S.&#160;Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S.&#160;Holder, may have to file an
IRS Form&#160;8621 (whether or not a mark-to-market election is or has been made) with such U.S.&#160;Holder&#8217;s U.S.&#160;federal
income tax return and provide any such other information as may be required by the U.S.&#160;Treasury Department. Failure to do so, if
required, will extend the statute of limitations until such required information is furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
rules&#160;dealing with PFICs and mark-to-market elections are very complex and are affected by various factors in addition to those
described above. Accordingly, U.S.&#160;Holders of Company Securities should consult their own tax advisors concerning the application
of the PFIC rules&#160;to the Company Securities under the U.S. Holders&#8217; particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>Information Reporting and Backup
Withholding</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
general, information reporting requirements may apply to dividends received by U.S.&#160;Holders of the Class A Ordinary Shares (including
constructive dividends), and the proceeds received on sale or other taxable disposition of the Class A Ordinary Shares or Warrants effected
within the United&#160;States (and, in certain cases, outside the United&#160;States), in each case, other than U.S.&#160;Holders that
are exempt recipients (such as corporations). Backup withholding (currently at a rate of 24%) may apply to such amounts if the U.S.&#160;Holder
fails to provide an accurate taxpayer identification number (generally on an IRS Form&#160;W-9 provided to the paying agent or the U.S.&#160;Holder&#8217;s
broker) or is otherwise subject to backup withholding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
U.S.&#160;Holders holding specified foreign financial assets with an aggregate value in excess of the applicable dollar threshold are
required to report information to the IRS relating to the Company Securities, subject to certain exceptions (including an exception for
the Company Securities held in accounts maintained by U.S.&#160;financial institutions), by attaching a complete IRS Form&#160;8938,
Statement of Specified Foreign Financial Assets, with their tax return, for each year in which they hold the Company Securities. In addition
to these requirements, U.S.&#160;Holders may be required to annually file FinCEN Report 114 (Report of Foreign Bank and Financial Accounts)
with the U.S.&#160;Department of Treasury. U.S.&#160;Holders should consult their own tax advisors regarding information reporting requirements
relating to their ownership of the Company Securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against
a holder&#8217;s U.S.&#160;federal income tax liability, if any, provided the required information is timely furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>This summary
does not contain a detailed description of all the United States federal income tax consequences that may be applicable to you in light
of your particular circumstances and, except as set forth below with respect to PRC tax considerations, does not address the effects
of any state, local or non-United States tax laws. If you are considering the purchase, ownership or disposition of our Ordinary Shares,
you should consult your own tax advisors concerning the United States federal income tax consequences to you in light of your particular
situation as well as any consequences arising under the laws of any other taxing jurisdiction.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>LEGAL
MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Certain
legal matters as to U.S. federal securities law concerning this offering will be passed upon for us by Sichenzia Ross Ference Carmel
LLP, New York, New York. Certain legal matters as to BVI law will be passed upon for us by Ogier. Sichenzia Ross Ference Carmel LLP may
rely upon Ogier with respect to matters governed by BVI law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
financial statements of NewGenIvf Limited as of December 31, 2023 and for the year then ended included in this prospectus have been so
included in reliance on the report of Onestop Assurance PAC, an independent registered public accounting firm, given on the authority
of said firm as an expert in auditing and accounting. The financial statements of NewGenIvf Limited as of December 31, 2022 and 2021and
for the years then ended included in this prospectus have been so included in reliance on the report of WWC, P.C., an independent registered
public accounting firm, given on the authority of said firm as an expert in auditing and accounting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>EXPENSES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following are the estimated expenses of the issuance and distribution of the securities being registered under the registration statement
of which this prospectus forms a part, all of which will be paid by us. With the exception of the SEC registration fee, all amounts are
estimates and may change:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-size: 10pt">SEC registration fee</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">13,938.37</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Printer fees and expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Legal fees and expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">40,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Miscellaneous</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">59,938</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">This
                                            is an estimate.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>ENFORCEABILITY
OF CIVIL LIABILITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are incorporated under the laws of the British Virgin Islands with limited liability. We are incorporated in the British Virgin Islands
because of certain benefits associated with being a British Virgin Islands company, such as political and economic stability, an effective
judicial system, a favorable tax system, the absence of exchange control or currency restrictions and the availability of professional
and support services. However, the British Virgin Islands has a less developed body of securities laws as compared to the United States
and provides protections for investors to a lesser extent. In addition, British Virgin Islands companies may not have standing to sue
before the federal courts of the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Substantially
all of our assets are located outside the United States. In addition, a majority of our directors and officers are nationals and/or residents
of countries other than the United States, and all or a substantial portion of such persons&#8217; assets are located outside the United
States. As a result, it may be difficult for investors to effect service of process within the United States upon us or such persons
or to enforce against them or against us, judgments obtained in United States courts, including judgments predicated upon the civil liability
provisions of the securities laws of the United States or any state thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
have appointed Cogency Global Inc., as our agent to receive service of process with respect to any action brought against us in the United
States District Court for districts in the State of New York under the federal securities laws of the United States or of any State of
the United States or any action brought against us in the Supreme Court of the State of New York under the securities laws of the State
of New York.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">There
is no statutory enforcement in the British Virgin Islands of judgments obtained in the U.S., however, the courts of the British Virgin
Islands will in certain circumstances recognize such a foreign judgment and treat it as a cause of action in itself which may be sued
upon as a debt at common law so that no retrial of the issues would be necessary, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the U.S. court issuing the judgment had jurisdiction in the matter
    and the company either submitted to such jurisdiction or was resident or carrying on business within such jurisdiction and was duly
    served with process;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the judgment is final and for a liquidated sum;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the judgment given by the U.S. court was not in respect of penalties,
    taxes, fines or similar fiscal or revenue obligations of the company;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in obtaining judgment there was no fraud on the part of the person
    in whose favor judgment was given or on the part of the court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recognition or enforcement of the judgment in the British Virgin Islands
    would not be contrary to public policy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the proceedings pursuant to which judgment was obtained were not contrary
    to natural justice.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">The British
Virgin Islands courts are unlikely:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">to recognize or enforce against the Company, judgments of courts of
    the U.S. based on certain civil liability provisions of U.S. securities laws where that liability is in respect of penalties, taxes,
    fines or similar fiscal or revenue obligations of the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">to impose liabilities against the Company, in original actions brought
    in the British Virgin Islands, based on certain civil liability provisions of U.S. securities laws that are penal in nature.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
have filed with the SEC a registration statement on Form&#160;F-1 under the Securities Act relating to this registration of the Ordinary
Shares to be sold by the Selling Shareholders, or the Registration Statement. This prospectus, which is part of the Registration Statement,
does not contain all of the information contained in the Registration Statement. The rules&#160;and regulations of the SEC allow us to
omit certain information from this prospectus that is included in the Registration Statement. Statements made in this prospectus concerning
the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but
are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the Registration Statement,
you may read the document itself for a complete description of its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the
SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at <i>www.sec.gov</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
are not currently subject to the information reporting requirements of the Exchange Act. In connection with when the Registration Statement
is declared effective by the SEC, we will become subject to the information reporting requirements of the Exchange Act that are applicable
to foreign private issuers. Accordingly, we will be required to file or furnish reports and other information with the SEC. Those other
reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt
from the rules&#160;under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and
principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly, and current reports and financial statements
with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However,
we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual
report on Form&#160;20-F containing financial statements audited by an independent registered public accounting firm, and intend to submit
to the SEC, on Form&#160;6-K, unaudited interim financial information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">We
maintain a corporate website at www.newgenivf.com. Information contained on, or that can be accessed through, our website does not constitute
a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post
on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations,
including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>MATERIAL
CHANGES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Except
as otherwise described in our Annual Report on Form&#160;20-F for the fiscal year ended December&#160;31, 2023, and our current reports
on Form&#160;6-K filed or submitted under the Exchange Act and incorporated by reference herein and as disclosed in this prospectus,
no reportable material changes have occurred since December&#160;31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>139,425,259 Ordinary Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b><img alt="" src="image_006.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>NewGenIvf
Group Limited</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>PROSPECTUS</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>PART II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>INFORMATION NOT
REQUIRED IN PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 6. Indemnification
of Directors, Officers and Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">British
Virgin Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to
public policy, such as to provide indemnification against willful default, civil fraud or the consequences of committing a crime. Under
our Memorandum and Articles of Association, we may indemnify its directors, officers and liquidators against all expenses, including
legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with civil, criminal,
administrative or investigative proceedings to which they are party or are threatened to be made a party by reason of their acting as
our director, officer or liquidator. To be entitled to indemnification, these persons must have acted honestly and in good faith with
a view to the best interest of the registrant and, in the case of criminal proceedings, they must have had no reasonable cause to believe
their conduct was unlawful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Insofar
as indemnification for liabilities arising under the&#160;Securities Act of 1933&#160;may be permitted to directors, officers or persons
controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the&#160;Securities Act&#160;and is therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 7. Recent
Sales of Unregistered Securities</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Set
forth below are the sales of all securities by the Company since the closing of the Business Combination which were not registered under
the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance
on Section&#160;4(a)(2)&#160;of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
April 3, 2024, the date of Closing, the Company issued to certain investors 295,000 Ordinary Shares which were converted from the ordinary
shares of Legacy NewGenIvf pursuant to the terms of the Securities Purchase Agreement by and between A SPAC I Mini Acquisition Corp.
and certain investors named therein (the &#8220;February Buyers&#8221;) on February 29, 2024. Pursuant to this Securities Purchase Agreement,
A SPAC I Mini Acquisition Corp agreed to issue and sell to the February Buyers, in a private placement, an aggregate of up to $3,500,000
principal amount of convertible notes, consisting of one or more tranches: (i) an initial tranche of an aggregate principal amount of
promissory notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500, and (ii) subsequent tranches
of an aggregate principal amount of promissory notes of up to $1,750,000 and including an original issue discount of up to aggregate
$122,500. The closing of the Initial Tranche took place on April 3, 2024. The Company also closed on a subsequent tranche of the aforementioned
promissory notes in the principal amount of $250,000 by issuing and selling to the February Buyers shortly after the closing of the Business
Combination, resulting in an aggregate principal amount of notes of $2,000,000 sold to the February Buyers. The form of these promissory
notes is included as Exhibit 4.2 of the Form 6-K filed on April 4, 2024. The aforementioned Securities Purchase Agreement is included
as Exhibit 4.1 of the Form 6-K filed on April 4, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><span style="text-decoration:underline">2024 Debt Financing</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
August 7, 2024, the Company entered into a Securities Purchase Agreement (&#8220;Securities Purchase Agreement&#8221;) with certain investors
named therein (collectively, the &#8220;Buyers&#8221;), pursuant to which, amongst other things: (i) the Company agreed to sell, at an
initial closing (and such initial closing, the &#8220;Initial Closing&#8221;), (a) a senior convertible note (the &#8220;Initial Note&#8221;)
in the aggregate original principal amount not exceeding $1,100,000, convertible into Ordinary Shares pursuant to its terms, (b) a warrant
to purchase 1,325,301 Ordinary Shares (such warrant, the &#8220;Series A Warrant&#8221;), and (c) a warrant to purchase 180,722 Ordinary
Shares (the &#8220;Series B Warrant&#8221;); and (ii) the Company may require each Buyer (or each Buyer may require the Company, as applicable)
to participate in the sale of (a) one or more additional convertible notes (which aggregate original principal amount for all additional
convertible notes shall not exceed $9,500,000) (the &#8220;Additional Notes&#8221;) and (b) related Warrants. Subject to the satisfaction
or waiver of the certain conditions to closing set forth in the Securities Purchase Agreement, the Company may require that the Buyers
purchase (i) an Additional Note in the aggregate principal amount of $500,000 (the &#8220;First Mandatory Additional Note&#8221;) and
(ii) an Additional Note in the aggregate principal amount of $1,500,000 (the &#8220;Second Mandatory Additional Note&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
connection with the issuance and sale of the Notes, the Series A Warrants and the Series B Warrants, the Company entered into a registration
rights agreement with the Buyers (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company agrees to provide certain
registration rights with respect to such securities. The Securities Purchase Agreement is filed as Exhibit 4.1 of the Company&#8217;s
current report on Form 6-K dated August 16, 2024 and is incorporated by reference herein. The Initial Note is filed as Exhibit 10.25
of this registration statement.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Additionally,
in connection with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders
of its convertible promissory notes (the &#8220;Existing Notes&#8221; and each of such amendment and exchange agreements, an &#8220;Amendment
and Exchange Agreement&#8221;), pursuant to which the Company exchanged the Existing Notes by issuing, among other things, (i) senior
convertible notes in the aggregate principal amount of $2,700,000 (the &#8220;Exchange Notes&#8221;, and, together with the Initial Note
and the Additional Notes, the &#8220;Notes&#8221;) and (b) a series of warrants to initially acquire up to a certain number of Ordinary
Shares to the holders of the Existing Notes set forth therein (the &#8220;Exchange Warrants&#8221; and the Series A Warrants and the
Series B Warrants, the &#8220;Warrants&#8221;). The Exchange Notes are in substantially similar form to the Initial Notes, which are
discussed further below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
                                            Exchange Warrants expire nine years after the issuance date and are initially exercisable
                                            for an aggregate of 3,253,012 Ordinary Shares, subject to adjustment as provided therein.
                                            The Exchange Warrants may be exercised at any time after the exchange date, subject to the
                                            Maximum Percentage (as defined below). The initial exercise price of the Exchange Warrants
                                            is $0.913 per share, subject to adjustment as provided therein. If at the time of exercise
                                            of the Exchange Warrants, there is no effective registration statement registering our Ordinary
                                            Shares underlying such warrants, such warrants may be exercised on a cashless basis pursuant
                                            to their terms. The form of the Amendment and Exchange Agreement, the form of Exchange Notes,
                                            and the form of Exchange Warrants are filed as Exhibits 4.2, 4.3, and 4.4 to the Form 6-K
                                            dated August 16, 2024, and are incorporated herein by reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">A
holder may not convert any portion of the Notes and/or exercise any portion of the Warrants to the extent that, after giving effect to
such conversion and/or exercise, as applicable, such holder (together with certain related parties) would beneficially own in excess
of 4.99%, or the &#8220;Maximum Percentage&#8221;, of our Ordinary Shares outstanding immediately after giving effect to such conversion
and/or exercise, as applicable. The Maximum Percentage may be raised or lowered to any other percentage not in excess of 9.99%, at the
option of the holder, except that any increase will only be effective upon 61 days&#8217; prior notice to us.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Initial Closing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
August 12, 2024, the Company and the Buyers consummated the Initial Closing. The Initial Note sold in connection with the Securities
Purchase Agreement bears an interest rate of 14.75% per annum and is convertible into the Company&#8217;s Ordinary Shares as follows:
the Conversion Amount (as defined below) into validly issued, fully paid and non-assessable Ordinary Shares at the Conversion Rate (as
defined below); subject to adjustment as provided therein. No fractional Ordinary Shares are issuable upon any such conversion. A holder
may convert the Initial Notes at any time after the initial issuance date of such Initial Note; subject to the Maximum Percentage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
form of the Initial Note is included as Exhibit A of the Securities Purchase Agreement filed as Exhibit 4.1 in the Form 6-K dated August
15, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Conversion
Amount&#8221; means 110% of the sum of (A) the portion of the principal of the Initial Note to be converted, redeemed or otherwise with
respect to which such determination is being made, (B) accrued and unpaid interest with respect to such aggregate principal amount owed
on the Initial Note (and as reduced pursuant to redemption, conversion or otherwise, the &#8220;Principal&#8221;), (C) the Make-Whole
Amount (as defined below), if any, (D) accrued and unpaid Late Charges (as defined below) with respect to the Principal on the Initial
Note, Make-Whole Amount and Interest, and (E) any other unpaid amounts pursuant to the Transaction Documents (as defined in the Securities
Purchase Agreement), if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Conversion
Rate&#8221; means the amount of Ordinary Shares issuable upon conversion of any Conversion Amount pursuant to the Initial Note determined
by dividing (x) such Conversion Amount by (y) the Conversion Price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Conversion
Price&#8221; means, as of any Conversion Date or other date of determination, $0.83, subject to adjustment as provided in the Initial
Note.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Late
Charge&#8221; means a late charge incurred and payable by the Company in an amount equal to interest on such amount at the rate of eighteen
percent (18%) per annum from the date such amount was due until the same is paid in full.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Make-Whole
Amount&#8221; means, as of any given date and as applicable, in connection with any conversion, redemption or other repayment under the
Initial Note, an amount equal to the amount of additional interest that would accrue under the Initial Note at the interest rate then
in effect assuming for calculation purposes that the outstanding Principal of the Initial Note as of the Closing Date remained outstanding
through and including the maturity date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">At
the Initial Closing, the Company also sold to the Buyers Series A Warrants to purchase an aggregate 1,325,301 Ordinary Shares and Series
B Warrants to purchase an aggregate 180,722 Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Series
A Warrants</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">The
Series A Warrants expire nine years after the issuance date and are initially be exercisable for an aggregate of 1,325,301 Ordinary Shares
(the &#8220;Series A Warrant Shares&#8221;), subject to adjustment as provided therein. If immediately after any Additional Closing Date
(as defined in the Securities Purchase Agreement) (each an &#8220;Adjustment Date&#8221;), the aggregate number of Ordinary Shares then
issuable upon exercise of the Series A Warrant is less than the Maximum Eligibility Number (as defined below) immediately after such
Adjustment Date the aggregate number of Ordinary Shares issuable upon exercise of the Series A Warrant will automatically increase to
such Maximum Eligibility Number (in each case, without regard to any limitations on exercise contained therein and without regard to
any prior exercises of such Series A Warrant). The Series A Warrants may be exercised at any time after the issuance date, subject to
the Maximum Percentage. The initial exercise price of the Series A Warrants is $0.913 per share, subject to adjustment as provided therein.
If at the time of exercise of the Series A Warrants, there is no effective registration statement registering the shares of our Ordinary
Shares underlying such warrants, such warrants may be exercised on a cashless basis pursuant to their terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Maximum
Eligibility Number&#8221; means as of any time of determination, the number of Series A Warrant Shares then in effect (subject to adjustment
as provided therein), but shall automatically increase on each Additional Closing Date, by such aggregate number of Ordinary Shares equal
to the Additional Share Amount (as defined below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Additional
Share Amount&#8221; means, with respect to any given Additional Closing (as defined in the Securities Purchase Agreement), such aggregate
number of Ordinary Shares equal to 100% of the quotient of (x) the sum of (I) the aggregate principal amount of Additional Notes purchased
by such holder at such Additional Closing and (II) the Make-Whole Amount with respect to such Additional Notes purchased by such holder
at such Additional Closing, divided by (y) the applicable Additional Share Price (as defined below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#8220;Additional
Share Price&#8221; means the lower of (i) the exercise price then in effect and (ii) (x) the lower of the Conversion Price as of such
Additional Closing Date and (y) the VWAP of the Ordinary Shares as of the Trading Day immediately prior to such applicable Additional
Closing Date</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Series
B Warrants</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Series B Warrants expire nine years after the issuance date and are initially be exercisable for an aggregate of 180,722 Ordinary Shares,
subject to adjustment as provided therein. The Series B Warrants may be exercised at any time on or after February 12, 2025 (the &#8220;Initial
Exercise Eligibility Date&#8221;), subject to the Maximum Percentage. If on the Initial Exercise Eligibility Date, the Ordinary Shares
then issuable upon exercise of the Series B Warrants is not equal to the quotient of $150,000 divided by the Closing Bid Price (as defined
therein) of the Ordinary Shares as of the Trading Day ended immediately prior to the Initial Exercise Eligibility Date (the &#8220;Adjusted
Warrant Number&#8221;), on the Initial Exercise Eligibility Date the Ordinary Shares then issuable upon exercise of the Series B Warrant
will automatically adjust to the Adjusted Warrant Number. The initial exercise price of the Series B Warrants were a prepaid, except
for a nominal exercise price of $0.001 per share, subject to adjustment as provided therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
form of the Series A Warrant and form of the Series B Warrant are included as Exhibit B of the Securities Purchase Agreement included
as Exhibit 4.1 in the Form 6-K filed on August 16, 2024, which is incorporate herein by reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><i>Second Tranche</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">On
August 28, 2024, the Company closed on the second tranche of the 2024 Debt Financing pursuant to the terms of the Securities Purchase
Agreement. Under the second tranche, the Company sold the First Mandatory Additional Note in the aggregate principal amount of $500,000.
The First Mandatory Additional Note is in substantially similar form to the Initial Note. Upon issuance of the First Mandatory Additional
Note, the number of Ordinary Shares issuable upon exercise of the Series A Warrant automatically increased to 2,172,959. The First Mandatory
Additional Note is included as Exhibit 4.1 in the Form 6-K filed on August 30, 2024.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
Company may receive up to approximately $29,483,257 in additional net proceeds from the 2024 Debt Financing if (i) all remaining Additional
Notes in the aggregate principal amount of $9,000,000 (the &#8220;Remaining Additional Notes&#8221;) issuable pursuant to the Securities
Purchase Agreement are sold and (ii) the Series A Warrants are increased by 17,698,976 assuming that (A) all Remaining Additional Notes
are sold and (B) an Additional Share Price is equal to $0.509 and (iii) all of the Warrants are exercised in full, based on the following
assumptions: (w) approximately $8,370,000 in net proceeds are received from the sale of Remaining Additional Notes, assuming that all
Remaining Additional Notes are sold, (x) approximately $18,143,076 in net proceeds are received from the exercise of the Series A Warrants,
assuming that the Series A Warrants are exercised in full at an exercise price of $0.913 and the number of Ordinary Shares issuable upon
exercise of the Series A Warrants equals 19,871,935, (y) approximately $181 in net proceeds are received from the exercise of the Series
B Warrants, assuming that the Series B Warrants are exercised in full at an exercise price of $0.001 per share, and (z) approximately
$2,970,000 in net proceeds are received from the exercise of the Exchange Warrants, assuming that the Exchange Warrants are exercised
in full at an exercise price of $0.913. The foregoing is subject to adjustment as set forth in the respective Notes and Warrants, as
applicable.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Financial Statement
Schedules:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company&#8217;s financial statements and related notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 8. Exhibits
and Financial Statement Schedules</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023_aspac1miniacq.htm#T702">Amended
    and Restated Memorandum and Articles of Association of PubCo (incorporated by reference to Annex B of PubCo&#8217;s registration
    statement on Form F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.2***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024083415/ea021568301ex3-2_newgen.htm"><span style="font-size: 10pt">Amended and Restated Memorandum and Articles of Association of the Company dated September 23, 2024.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-1_newgen.htm">Specimen
    Class A Ordinary Share Certificate of the Company (incorporated by reference to Exhibit 2.1 of the report on Form 20-F filed with
    the Securities and Exchange Commission on April 9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex2-2_newgen.htm">Specimen
    Warrant Certificate of the Company (incorporated by reference to Exhibit 2.2 of the report on Form 20-F filed with the Securities
    and Exchange Commission on April 9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex4-2.htm">Warrant
    Agreement, dated February 14, 2022, by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by reference
    to Exhibit 4.2 to ASCA&#8217;s Current Report on Form 6-K filed with the Securities and Exchange Commission on February 18, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390023087023/ff42023a1ex4-7_aspac1.htm">Form
    of Assumption of Warrant Agreement (incorporated by reference to Exhibit 4.7 to the Company&#8217;s registration statement on Form
    F-4 (File No. 333-275208), filed with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">5.1***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024088185/ea021748001ex5-1_newgen.htm">Opinion
    of Ogier</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex2-1_aspac1acq.htm">Merger
    Agreement, dated as of February 15, 2023, by and among ASCA, NewGenIvf Limited, certain shareholders of NewGenIvf Limited, A SPAC
    I Mini Acquisition Corp., and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current
    Report on Form 6-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023048612/ea180200ex2-1_aspac1acq.htm">First
    Amendment to the Merger Agreement, dated June 12, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini
    Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current Report
    on Form 6-K filed with the Securities and Exchange Commission on June 13, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023093702/ea189487ex2-1_aspac1acq.htm">Second
    Amendment to the Merger Agreement, dated December 6, 2023, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I
    Mini Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current
    Report on Form 6-K filed with the Securities and Exchange Commission on December 6, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex2-1_aspac1.htm">Third
    Amendment to the Merger Agreement, dated March 1, 2024, by and among ASCA, NewGenIvf Limited, Principal Shareholders, A SPAC I Mini
    Acquisition Corp. and A SPAC I Mini Sub Acquisition Corp. (incorporated by reference to Exhibit 2.1 to ASCA&#8217;s Current Report
    on Form 6-K filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.5</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000110465922025006/tm225054d14_ex10-5.htm">Stock
    Escrow Agreement, dated February 14, 2022 by and between ASCA and Continental Stock Transfer &amp; Trust Company (incorporated by
    reference to Exhibit 10.5 to ASCA&#8217;s Current Report on Form 6-K filed with the Securities and Exchange Commission on February
    18, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-1_aspac1acq.htm">Voting
    and Support Agreement, dated as of February 15, 2023, by and among A SPAC I Acquisition Corp., A SPAC I Mini Acquisition Corp., NewGenIvf
    Limited, and certain shareholders of NewGenIvf Limited (incorporated by reference to Exhibit 10.1 to ASCA&#8217;s Current Report
    on Form 6-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390023012495/ea173753ex10-2_aspac1acq.htm">Form
    of Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to ASCA&#8217;s Current Report on
    Form 6-K filed with the Securities and Exchange Commission on February 16, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-8_newgen.htm">Form
    of Lock-Up Agreement (incorporated by reference to exhibit 4.8 of the Company&#8217;s report on Form 20-F filed with the SEC on April
    9, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm">Securities
    Purchase Agreement, dated February 29, 2024, by and among ASCA, The Company, Legacy NewGenIvf, the Buyers and Merger Sub (incorporated
    by reference to Exhibit 10.1 to ASCA&#8217;s Current Report on Form 6-K filed with the Securities and Exchange Commission on March
    6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm">Form
    of Note between The Company and the Buyers (incorporated by reference to Exhibit 10.2 to ASCA&#8217;s Current Report on Form 6-K
    filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-3_aspac1.htm">Acknowledgement
    Agreement, dated March 1, 2024, by and among ASCA, Legacy NewGenIvf and Chardan (incorporated by reference to Exhibit 10.3 to ASCA&#8217;s
    Current Report on Form 6-K filed with the Securities and Exchange Commission on March 6, 2024)</a></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.12</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-19_aspac1.htm">Power
    Generator Lease Contract, dated January 10, 2021, between BD &amp; H TECH Co., LTD. and First Fertility Phnom Penh Ltd (English Translation)
    (incorporated by reference to Exhibit 10.19 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed
    with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-20_aspac1.htm">Property
    Lease Contract, dated June 22, 2020, between SOK HEANG and First Fertility Phnom Penh Ltd (English Translation) (incorporated by
    reference to Exhibit 10.20 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-21_aspac1.htm">MicroSort
    Lease and Services Agreement, dated March 29, 2019, between First Fertility Phnom Penh Ltd and MicroSort International (incorporated
    by reference to Exhibit 10.21 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-22_aspac1.htm">Management
    and Administrative Services Agreement, dated November 1, 2022, between First Fertility PGS Center Ltd and Med Holdings Ltd (incorporated
    by reference to Exhibit 10.22 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-23_aspac1.htm">MicroSort
    Lease and Services Agreement, dated April, 8, 2019, between First Fertility PGS Center Ltd. and MicroSort International (incorporated
    by reference to Exhibit 10.23 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.17</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-24_aspac1.htm">Medical
    Consulting Service Agreement, dated January 1, 2021, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated
    by reference to Exhibit 10.24 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.18</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-25_aspac1.htm">Receivables
    Purchase Agreement, dated December, 28, 2022, between First Fertility PGS Center Ltd and Mr. Siu, Wing Fung Alfred (incorporated
    by reference to Exhibit 10.25 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.19</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-26_aspac1.htm">Master
    Services Agreement, dated December 21, 2022, between First Fertility PGS Center Ltd and First Fertility Phnom Penh Ltd (incorporated
    by reference to Exhibit 10.26 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed with the Securities
    and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.20</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000101376223007357/ff42023ex10-27_aspac1.htm">Form
    of Agreement for Storage of Embryos, Eggs, and Sperms Service between First Fertility PGS Center Ltd and Reproductive Expert Co Ltd
    (incorporated by reference to Exhibit 10.27 to the Company&#8217;s registration statement on Form F-4 (File No. 333-275208), filed
    with the Securities and Exchange Commission on October 27, 2023)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.21</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1981662/000121390024031644/ea020344201ex4-21_newgen.htm">Form
    of NewGenIvf Group Limited 2024 Share Incentive Plan (incorporated by reference to exhibit 4.21 of the Company&#8217;s report on
    Form 20-F filed with the SEC on April 9, 2024)</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.22</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-1_aspac1.htm">Securities
    Purchase Agreement between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by
    reference to Exhibit 4.1 of the Company&#8217;s current report on Form 6-K filed with the SEC on April 4, 2024)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1868775/000121390024020466/ea0201275ex10-2_aspac1.htm">Form
    of Note between A SPAC I Mini Acquisition Corp. and JAK Opportunities VI LLC dated February 29, 2024 (incorporated by reference to
    Exhibit 4.2 of the Company&#8217;s current report on Form 6-K filed with the SEC on April 4, 2024)</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.24</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024069887/ea021151801ex4-1_newgen.htm">Securities
    Purchase Agreement between the Company and certain buyers dated August 7, 2024 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s
    current report on Form 6-K filed with the SEC on August 16, 2024)</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.25***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024083415/ea021568301ex10-25_newgen.htm"><span style="font-size: 10pt">Form of Note between the Company and JAK Opportunities VI LLC dated August 7, 2024</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.26</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024074614/ea021297701ex4-1_newgen.htm">Form
    of Note between the Company and JAK Opportunities VI LLC dated August 28, 2024 (incorporated by reference to Exhibit 4.1 of the Company&#8217;s
    current report on Form 6-K filed with the SEC on August 30, 2024)</a>&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024070853/ea021122901ex16-1_newgen.htm">Letter
    from WWC, P.C. regarding Item 16F of Form 20-F (incorporated by reference to Exhibit 16.1 of the Company&#8217;s annual report on
    Form 20-F filed with the SEC on August 20, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024070853/ea021122901ex8-1_newgen.htm">List
    of Subsidiaries (incorporated by reference to Exhibit 8.1 of the Company&#8217;s annual report on Form 20-F filed with the SEC on
    August 20, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024088185/ea021748001ex23-1_newgen.htm"><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">Consent Letter from WWC, P.C.</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="ea021944701ex23-2_newgen.htm"><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">Consent Letter from Onestop Assurance PAC</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024088185/ea021748001ex5-1_newgen.htm"><span style="font-family: Times New Roman, Times, Serif">Consent
    of Ogier (included in Exhibit 5.1)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024076330/ea0212927-f1_newgen.htm#sig_006"><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">Power of Attorney</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024070853/ea021122901ex97-1_newgen.htm">Clawback
    Policy of the Company. (incorporated by reference to Exhibit 97.1 of the Company&#8217;s annual report on Form 20-F filed with the
    SEC on August 20, 2024)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1981662/000121390024083415/ea021568301ex-fee_newgen.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Table</span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To be filed via an amendment</span></td></tr>
  </table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">***</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Previously filed. </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Item 9. Undertakings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The undersigned Registrant hereby undertakes:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To file, during any period in which offers or sales are being made,
    a post-effective amendment to this registration statement:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">i.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any prospectus required by section 10(a)(3)&#160;of the
    Securities Act of 1933;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">ii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus any facts or events arising after the
    effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
    aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
    any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
    was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
    prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent
    no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table
    in the effective registration statement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">iii.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any material information with respect to the plan of distribution
    not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining any liability under the Securities
    Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To remove from registration by means of a post-effective amendment
    any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To file a post-effective amendment to the registration statement to
    include any financial statements required by Item 8.A. of Form&#160;20-F at the start of any delayed offering or throughout a continuous
    offering. Financial statements and information otherwise required by Section&#160;10(a)(3)&#160;of the Act need not be furnished,
    provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant
    to this paragraph (a)(4)&#160;and other information necessary to ensure that all other information in the prospectus is at least
    as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form&#160;F-3,
    a post-effective amendment need not be filed to include financial statements and information required by Section&#160;10(a)(3)&#160;of
    the Act or Rule&#160;3-19 of this chapter if such financial statements and information are contained in periodic reports filed with
    or furnished to the Commission by the registrant pursuant to section 13 or section 15(d)&#160;of the Securities Exchange Act of 1934
    that are incorporated by reference in the Form&#160;F-3.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That for purposes of determining any liability under the Securities
    Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A
    and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1)&#160;or (4), or 497(h)&#160;under the
    Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That for the purpose of determining any liability under the Securities
    Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement
    relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona
    fide</i> offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities
    Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
    or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification
    is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
    against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
    person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has
    been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification
    by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form&#160;F-1 and has duly caused this registration statement on Form&#160;F-1 to be signed on its behalf by the undersigned,
thereunto duly authorized, on October 31, 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-size: 10pt"><b>NEWGENIVF GROUP LIMITED</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 36%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 60%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap"><span style="font-size: 10pt"><i>/s/ Wing Fung Alfred Siu</i></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following
persons in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 38%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt"><i>/s/ Wing Fung Alfred Siu</i></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer and Director, </span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">October 31, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ <i>*</i></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director, Chief Marketing Officer</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">October 31, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Hei Yue Tina Fong</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ <i>*</i></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Independent Director</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">October 31, 2024</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Hok Man Jefferson Au</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">/s/ <i>*</i></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Independent Director</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">October 31, 2024</span></td></tr>
  <tr>
    <td style="border-top: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt">Yip Eng Jeremy Foo</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ <i>*</i></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">October 31, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">Ho Fai Chung</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">* /s/
    Wing Fung Alfred Siu</span></td>
    <td style="width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 60%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Wing Fung Alfred Siu</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Attorney-in-fact</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURE OF
AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Pursuant
to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America of NewGenIvf
Group Limited, has signed this registration statement in New York, NY on October 25, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt"><b>COGENCY GLOBAL INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt"><i>/s/ Colleen A. De Vries</i></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-size: 10pt">Colleen A. De Vries</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Senior Vice President on behalf of Cogency Global Inc.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>


</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 90%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDITED
    CONSOLIDATED FINANCIAL STATEMENTS</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif">Report
    of Independent Registered Public Accounting Firm (PCAOB ID: 1171)</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif">Report
    of Independent Registered Public Accounting Firm (PCAOB ID: 6732)</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    Balance Sheets as of December&#160;31, 2023 and 2022</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    Statements of Operations and Comprehensive Income (Loss) for the&#160;Years Ended December&#160;31, 2023, 2022 and 2021</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    Statements of Changes in Shareholders&#8217; Equity (Deficit) for the&#160;Years Ended December&#160;31, 2023, 2022 and 2021</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    Statements of Cash Flows for the&#160;Years Ended December&#160;31, 2023, 2022 and 2021</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt"><a href="#f_007"><span style="font-family: Times New Roman, Times, Serif">Notes
    to the Consolidated Financial Statements</span></a></span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
    CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001a">Unaudited
    Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-36</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002a">Unaudited
    Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the&#160;Six Months Ended June 30, 2024 and 2023</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-37</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003a">Unaudited
    Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) for the&#160;Six Months Ended June 30, 2024
    and 2023</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-38</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004a">Consolidated
    Statements of Cash Flows for the&#160;Six Months Ended June 30, 2024 and 2023</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-39</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005a">Notes
    to the Consolidated Financial Statements</a></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-40</span></td></tr>

</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 115; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>





</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">To:</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Board of Directors and Shareholders of NewGenIvf Limited</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Opinion on the
Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">We
have audited the accompanying consolidated balance sheets of NewGenIvf Limited and its subsidiaries (collectively the &#8220;Company&#8221;)
as of December&#160;31, 2021 and 2022, and the related consolidated statements of operations and comprehensive income (loss), changes
in shareholders&#8217; equity (deficit), and cash flows in each of the&#160;years for the two-year&#160;period ended December&#160;31,
2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2022, and the results of its
operations and its cash flows for each of the&#160;years in the two-year&#160;period ended December&#160;31, 2022, in conformity with
accounting principles generally accepted in the United&#160;States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Restatement
of Previously Issued Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">As
discussed in Note&#160;2, the Company has restated its consolidated financial statements as of December&#160;31, 2021 and 2022, and for
the years then ended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Correction of
errors in the classification of subscription receivable</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">The
Company had previously erroneously presented subscription receivable as an asset; that classification was incorrect. According to Article
5-02.29 of Regulation S-X, subscription receivable should be presented as a deduction from equity rather than an asset. The Company has
reassessed the classification of subscription receivable and has determined that it should be deducted from equity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Recognition
of directors&#8217; remuneration for principal shareholders</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">The
Company has previously recorded no directors&#8217; remuneration to Mr.&#160;Siu Wing Fung, Alfred and Ms. Fong Hei Yue, Tina, who are
concurrently directors and principal shareholders of the Company. The absent of cost recognition was incorrect. According to SAB Topics
1:B and 5.T., principal shareholders not receiving compensation for their time and effort serving as directors are making a capital contribution
to the Company. The Company has reassessed the fair value of services rendered by these directors and has determined that it should be
recorded as an operating expense and additional paid-in&#160;capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Emphasis of
Matter &#8212; Going Concern</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December&#160;31,
2021, the Company had a working capital deficit and shareholders&#8217; deficit, accordingly, these factors gave rise to substantial
doubt that the Company would continue as a going concern. As of December&#160;31, 2022, the Company had an improvement in its capital
position where the Company had net positive shareholders&#8217; equity position, but the Company still had a working capital deficit;
accordingly, the Company had not alleviated the substantial doubt that it would continue as a going concern. Management closely monitors
the Company&#8217;s financial position and result of operations and has prepared a plan that includes raising additional capital and
implementing improvements to increase profitability to address this substantial doubt. Details of this plan are also found in Note 1.
These financial statements do not include any adjustments that might result from the outcome of this uncertainly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Basis for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose
of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>/s/&#160;WWC,
P.C.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">WWC, P.C.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Certified Public
Accountants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">PCAOB ID No.1171</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">San Mateo, California</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">September&#160;28,
2023</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We have served
as the Company&#8217;s auditor since 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>



</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">To:</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            Board of Directors and Shareholders of Newgenivf Limited</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Opinion on the
Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Newgenivf Limited and its subsidiaries (collectively, the &#8220;Company&#8221;)
as of December 31, 2023, the related consolidated statements of operations and comprehensive income, shareholders&#8217; equity, and
cash flows for the year ended December 31, 2023, and the related notes to the consolidated financial statements and schedule (collectively,
the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in
conformity with accounting principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Material Uncertainty
relating to Going Concern</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company had bank balance of $54,104 as of December 31, 2023 and for the year ended December 31, 2023,
the Company had operating cash outflows of $1,766,135. </span><span style="font-size: 10pt">This raises substantial doubt about its ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified in respect
of this matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Basis for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">/s/&#160;Onestop Assurance
PAC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">We have served as
the Company&#8217;s auditor since 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">Singapore</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">August 16, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND&#160;2022<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">ASSETS</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Current assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="font-size: 10pt">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-34101">54,104</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-34102">27,556</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Accounts receivable, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34103">9,374</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34104">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Inventories</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34105">126,264</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34106">46,910</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Deposits, prepayment, other receivables and deferred
    IPO cost, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34107">517,429</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34108">70,285</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Loan to A SPAC I</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:LoanToASPAC" scale="0" unitRef="usd" id="ixv-34109">140,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due from shareholders</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-34110">354,285</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-34111">2,240,872</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; font-weight: bold; text-align: left"><span style="font-size: 10pt">Total current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-34112">1,201,456</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-34113">2,398,623</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Non-current assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Plant and equipment, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34114">162,157</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34115">122,673</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Right-of-use assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34116">283,847</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34117">383,670</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34118">446,004</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34119">506,343</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">TOTAL ASSETS</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-34120">1,647,460</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-34121">2,904,966</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Current liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Accounts payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-34122">172,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-34123">104,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Accrued liabilities and other payables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34124">241,613</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34125">289,777</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Contract liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34126">7,937</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34127">1,360,168</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due to a related party</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34128">110,773</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Operating lease liabilities, current</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34129">207,128</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34130">184,651</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Finance lease liabilities, current</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34131">6,446</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34132">18,758</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Taxes payable</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-34133">486,706</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-34134">486,872</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34135">1,122,456</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34136">2,555,650</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Non-current liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Operating lease liabilities, non-current</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34137">118,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34138">242,187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Finance lease liabilities, non-current</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34139">6,446</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total non-current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-34140">118,979</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-34141">248,633</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-34142">1,241,435</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-34143">2,804,283</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Shareholders&#8217; equity</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-size: 10pt">Ordinary shares, $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-34144"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-34145">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-34146"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-34147">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34148"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34149">698,123</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34150"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34151">601,830</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34152">6,981</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34153">6,018</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Subscription receivable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34154">2,967,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34155">319,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Additional paid-in capital</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34156">4,324,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34157">1,458,941</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Accumulated deficit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-34158">461,351</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-34159">591,544</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Accumulated other comprehensive (loss) income</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34160">7,288</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-34161">9,570</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Equity attributable to the shareholders of the Company</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-34162">896,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-34163">563,113</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-34164">490,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-34165">462,430</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">Total shareholders&#8217; equity</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34166">406,025</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34167">100,683</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-34168">1,647,460</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-34169">2,904,966</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these consolidated financial statements.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Revenues</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34170">5,136,153</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34171">5,944,190</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34172">4,118,120</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Cost of revenues</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-34173">3,454,368</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-34174">4,406,421</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-34175">3,093,340</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Gross profit</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-34176">1,681,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-34177">1,537,769</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-34178">1,024,780</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Operating expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Selling and marketing expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-34179">18,030</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-34180">36,194</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-34181">24,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">General and administrative expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-34182">1,259,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-34183">1,094,962</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-34184">801,329</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Audit fees</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-34185">362,149</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-34186">7,908</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Total operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-34187">1,639,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-34188">1,139,064</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-34189">826,022</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Operating income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-34190">42,242</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-34191">398,705</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-34192">198,758</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Other income (expenses), net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Other income, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-34193">111,837</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-34194">23,019</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-34195">45,652</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Interest income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-34196">518</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-34197">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-34198">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Interest expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-34199">46,179</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-34200">77,757</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-34201">88,289</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Total other
    income (expenses), net</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-34202">66,176</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-34203">54,717</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-34204">42,574</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Income before taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34205">108,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34206">343,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34207">156,184</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Provision for income taxes</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34208">208,141</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34209">294,716</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Net income (loss)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34210">108,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34211">135,847</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34212">138,532</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: net loss attributable
    to non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34213">21,775</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34214">322,820</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34215">137,999</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0in"><span style="font-size: 10pt">Net income
    (loss) attributable to the shareholders of the Company</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd" id="ixv-34216">130,193</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd" id="ixv-34217">458,667</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-34218">533</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Other comprehensive income (loss)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Foreign currency translation
    adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34219">22,704</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34220">1,920</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34221">7,751</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Total comprehensive income (loss)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" unitRef="usd" id="ixv-34222">85,714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" unitRef="usd" id="ixv-34223">133,927</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-34224">130,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: total comprehensive loss
    attributable to non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34225">27,621</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34226">323,458</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34227">136,396</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">Total
    comprehensive income attributable to the shareholders of the Company</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-34228">113,335</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-34229">457,385</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-34230">5,615</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Earning per share&#160;&#8211;&#160;basic and diluted</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-34231"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-34232">0.18</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-34233"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-34234">0.80</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-34235"><ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-34236">0.00</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Basic and diluted weighted average shares outstanding</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-34237"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-34238">615,135</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-34239"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-34240">575,930</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-34241"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-34242">560,000</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these consolidated financial statements.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT)<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023,&#160;2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of<br/> shares</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary<br/>
    shares</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Subscription<br/>
    receivable</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional
    <br/>
    paid-in <br/>
    capital</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    deficit</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    other<br/> comprehensive<br/> income/(loss)</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    attributable<br/> to the<br/> shareholders<br/> of the<br/> Company</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-
    controlling<br/>
    interests</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td><td style="font: bold 9pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    January&#160;1, 2021</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34243">560,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34244">5,600</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34245">57,821</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34246">1,049,678</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34247">4,704</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34248">981,553</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34249">2,576</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34250">984,129</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34251">533</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34252">533</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34253">137,999</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34254">138,532</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation&#160;adjustment</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34255">6,148</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34256">6,148</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34257">1,603</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34258">7,751</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Directors&#8217;
    remuneration</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34259">200,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34260">200,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34261">200,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December&#160;31, 2021</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34262">560,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34263">5,600</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34264">257,821</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34265">1,050,211</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34266">10,852</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34267">775,938</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34268">138,972</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34269">914,910</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    January&#160;1, 2022</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34270">560,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34271">5,600</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34272">257,821</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34273">1,050,211</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34274">10,852</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34275">775,938</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34276">138,972</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34277">914,910</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    income (loss)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34278">458,667</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34279">458,667</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34280">322,820</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34281">135,847</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation&#160;adjustment</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34282">1,282</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34283">1,282</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34284">638</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34285">1,920</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Directors&#8217;
    remuneration</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34286">240,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34287">240,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd" id="ixv-34288">240,000</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of shares</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c38" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-34289">41,830</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34290">418</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"/><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" sign="-" unitRef="usd" id="ixv-34291">319,872</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34292">961,120</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34293">641,666</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34294">641,666</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December&#160;31, 2022</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34295">601,830</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34296">6,018</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$&#160;</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34297">319,872</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34298">1,458,941</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34299">591,544</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34300">9,570</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34301">563,113</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34302">462,430</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34303">100,683</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    January&#160;1, 2023</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34304">601,830</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34305">6,018</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34306">319,872</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34307">1,458,941</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34308">591,544</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34309">9,570</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34310">563,113</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34311">462,430</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34312">100,683</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    (loss) income</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34313">130,193</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34314">130,193</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34315">21,775</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34316">108,418</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation&#160;adjustment</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34317">16,858</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34318">16,858</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34319">5,846</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34320">22,704</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Settlement
    of subscription receivable</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34321">219,628</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34322">219,628</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34323">219,628</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of shares</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-34324">96,293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34325">963</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" sign="-" unitRef="usd" id="ixv-34326">2,866,856</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-34327">2,865,893</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December&#160;31, 2023</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34328">698,123</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34329">6,981</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34330">2,967,100</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34331">4,324,834</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34332">461,351</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34333">7,288</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34334">896,076</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34335">490,051</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34336">406,025</ix:nonFraction></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
CONSOLIDATED STATEMENTS OF CASH FLOWS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Net income (loss)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34337">108,418</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34338">135,847</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34339">138,532</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Adjustments to reconcile net (loss)
    income to net cash provided by operating activities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Depreciation of plant and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-34340">31,173</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-34341">100,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-34342">166,709</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Amortization of right-of-use assets</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-34343">198,535</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-34344">203,411</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-34345">175,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Loss on disposal of plant and equipment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-34346">114,013</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Provision of expected credit loss allowance</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-34347">625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-34348">10,777</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-34349">6,717</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Interest expense</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-34350">46,179</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Waiver of related party balance</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nivf:WaiverOfRelatedPartyBalance" scale="0" unitRef="usd" id="ixv-34351">88,151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Directors&#8217; remuneration</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-34352">240,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-34353">200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Legal and professional fee</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd" id="ixv-34354">27,320</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Provision for income taxes</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeTaxExpense" scale="0" unitRef="usd" id="ixv-34355">208,141</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Changes in operating assets and
    liabilities:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Accounts receivable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-34356">1,166</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-34357">129,922</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd" id="ixv-34358">56,183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Inventories</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-34359">80,665</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-34360">7,219</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-34361">1,352</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deposit and other receivables, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-34362">448,266</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-34363">15,197</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-34364">10,987</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Accounts payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-34365">71,362</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-34366">58,752</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd" id="ixv-34367">60,989</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Accrued liabilities and other payables</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-34368">51,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-34369">190,689</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-34370">79,853</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Contract liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" sign="-" unitRef="usd" id="ixv-34371">1,352,231</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34372">548,010</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34373">812,158</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Operating lease liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-34374">230,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-34375">175,132</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-34376">148,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Finance lease liabilities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInFinanceReceivables" scale="0" unitRef="usd" id="ixv-34377">19,476</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInFinanceReceivables" scale="0" unitRef="usd" id="ixv-34378">19,476</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Tax paid</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" sign="-" unitRef="usd" id="ixv-34379">12,170</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-34380">290,887</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Net cash (used in) provided
    by operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34381">1,766,135</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-34382">1,710,901</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-34383">1,433,002</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Purchase of plant and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34384">69,848</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34385">94,452</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34386">16,575</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Net cash used in investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34387">69,848</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34388">94,452</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34389">16,575</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in"><span style="font-size: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Amount due from A SPAC I</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nivf:ProceedsFromAmountDueFromASPACI" scale="0" unitRef="usd" id="ixv-34390">140,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Finance lease</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-34391">9,317</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-34392">19,476</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-34393">17,221</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Other borrowings, net</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd" id="ixv-34394">128,204</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd" id="ixv-34395">512,821</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Issuance of shares</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-34396">192,308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Interest paid</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nivf:PaymentofInterest" scale="0" unitRef="usd" id="ixv-34397">24,704</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Amount with related parties</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-34398">1,863,206</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd" id="ixv-34399">1,742,509</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd" id="ixv-34400">2,039,969</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Net cash provided by (used in)
    financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-34401">1,881,493</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34402">1,633,781</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34403">1,544,369</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Net increase/(decrease) in cash and cash equivalents</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-34404">45,510</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-34405">17,332</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-34406">127,942</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Effect of foreign currency translation on cash and
    cash equivalents</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-34407">18,962</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34408">16,124</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34409">50,514</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Cash and cash equivalents, beginning
    of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34410">27,556</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34411">28,764</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34412">106,192</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"><span style="font-size: 10pt">Cash and cash equivalents, end
    of year</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34413">54,104</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34414">27,556</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34415">28,764</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 0in"><span style="font-size: 10pt">Supplementary cash flow information:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Taxes paid</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-34416">12,170</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-34417">3,829</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">Interest paid</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-34418">24,704</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-34419">55,469</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-34420">65,582</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these consolidated financial statements.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c11_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-22749"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION
AND PRINCIPAL ACTIVITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">NewGenIvf
Limited (the &#8220;Company&#8221; or the &#8220;Group&#8221;) was incorporated under the laws of the Cayman Islands on January&#160;16,
2019 as an investment holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
following is an organization chart of the Company and its subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><img alt="" src="fin_001.jpg"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-22770"><span style="font-size: 10pt">As
of December&#160;31, 2023, the Company&#8217;s subsidiaries are detailed in the table as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_2" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 22%; padding-right: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c98" name="nivf:SubsidiariesBackground" id="ixv-22801"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34421">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c98" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22813"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c99" name="nivf:SubsidiariesBackground" id="ixv-22821"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34422">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c99" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22833"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c100" name="nivf:SubsidiariesBackground" id="ixv-22841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure">49</ix:nonFraction>%*</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c100" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22853"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c101" name="nivf:SubsidiariesBackground" id="ixv-22861"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34424">74</ix:nonFraction>%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c101" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22873"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c102" name="nivf:SubsidiariesBackground" id="ixv-22881"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34425">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c102" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22893"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION
AND PRINCIPAL ACTIVITIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c11_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c11_cont_1"><ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_3" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 23%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c103" name="nivf:SubsidiariesBackground" id="ixv-22964"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></p></ix:nonNumeric></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34426">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><ix:nonNumeric contextRef="c103" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-22976"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></ix:nonNumeric></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">Where less than <ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-34427">50</ix:nonFraction>% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">Note:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">According
to the Foreign Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required
to be owned by Thai nationals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">With
reference to the capital structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;)
of Med Holdings and FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have
the same rights and status in all respects except for the distribution of profits by way of dividends with details as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed <ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PolicyholderDividendsRateOnPolicyEarnings" scale="-2" unitRef="pure" id="ixv-34428">15</ix:nonFraction>% of the total amount of dividends declared from time to time;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">After
                                            allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed
                                            equally amongst the holders of ordinary shares according to their shareholding ratio;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            holders of preferred shares shall be entitled to dividends only in respect of the&#160;years
                                            for which the Company has declared a dividend payment, and there shall be no cumulative dividends;
                                            and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(d)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Dividends
                                            allocated to the holders of preferred shares in each year shall be limited at the rate as
                                            stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred
                                            shares.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Based
upon the management&#8217;s judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board
meeting, the Company accounts for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings
and FFC by exercising its majority voting power in any board meetings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION
AND PRINCIPAL ACTIVITIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Group reorganization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Pursuant
to a group reorganization (the &#8220;group reorganization&#8221;) to rationalize the structure of the Company and its subsidiary companies
(herein collectively referred to as the &#8220;Group&#8221;) in preparation for the listing of its shares, the Company becomes the holding
company of the Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests
were also ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and
comprehensive income, consolidated statements of changes in shareholders&#8217; equity and consolidated statements of cash flows are
prepared as if the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023,
or since the respective dates of incorporation/establishment of the relevant entity, where this is a shorter period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
consolidated balance sheets as of December&#160;31, 2023 and 2022 present the assets and liabilities of the aforementioned companies
now comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
movement in the Company&#8217;s authorized share capital and the number of ordinary shares outstanding and issued in the Company are
also detailed in Note&#160;10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December&#160;31,
2023, the Company had bank balance of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-34429">54,104</ix:nonFraction> and may have challenge to settle its obligations when payment become due. The Company is
always closely monitoring the market opportunities and is currently in the process of exercising various fundraising projects with various
potential investors to improve the Company&#8217;s cash flow position for its operation and short-term payables. One fundraising project
was completed on April 3, 2024. As of April 4, 2024, the Company settled $<ix:nonFraction contextRef="c97" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" unitRef="usd" id="ixv-34430">2</ix:nonFraction> million to any payment with respect to accounts payable,
but not, directly or indirectly, for (i) except for expenses relating to the Business Combination, the satisfaction of any indebtedness
of the Company or any of its Subsidiaries, (ii) the redemption or repurchase of any securities of the Company or any of its Subsidiaries,
or (iii) the settlement of any outstanding litigation as at December 31, 2023. The Company secured funding subsequent to year-end with
total of $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherSecuredFinancings" scale="6" unitRef="usd" id="ixv-34431">2</ix:nonFraction> million, and that the Company received $<ix:nonFraction contextRef="c11" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" unitRef="usd" id="ixv-34432">2</ix:nonFraction> million funding to date. Please refer to <i>Note 20 &#8211; Subsequent Events</i>
for further information. The Company can make no assurance that required financings will be available for the amounts needed, or on terms
commercially acceptable to the Company, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient
to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Company and its financial statements.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-23112"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_ConsolidationPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-23119"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Principles of consolidation
and basis of preparation</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c11_cont_2" id="_ConsolidationPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company&#160;balances and transactions have been eliminated in consolidation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Management
has prepared the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted
in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_2" id="_SignificantAccountingPoliciesTextBlock-c11_cont_1"><ix:nonNumeric contextRef="c11" continuedAt="_UseOfEstimates-c11_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-23172"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Use of estimates</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates
required to be made by management include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ
from those estimates, and as such, differences may be material to the consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-23183"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Foreign currency
translation</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency
of the Company. The functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong
dollar (&#8220;HK$&#8221;). Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom
Penh Limited uses Cambodian riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States
dollar (&#8220;USD&#8221;) as its functional currency.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial
condition in terms of reporting in USD.&#160;<ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="ixv-34433">The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c11_cont_1"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c11_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34434">7.8000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34435">7.8000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34436">7.8000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34437">7.8000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34438">7.8000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34439">7.8000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34440">34.2265</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c122" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34441">34.6153</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c123" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34442">33.1964</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34443">34.7867</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c122" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34444">35.1428</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c123" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34445">32.1003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c124" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34446">4,080.0304</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c125" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34447">4,114.3335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c126" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34448">4,068.9577</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c124" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34449">4,105.4181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c125" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34450">4,083.7043</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c126" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34451">4,065.8164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34452">7.0971</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c128" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34453">6.9091</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-34454">6.3551</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34455">7.0835</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c128" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34456">6.4569</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-34457">6.4368</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation></ix:continuation><div>



</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_3" id="_SignificantAccountingPoliciesTextBlock-c11_cont_2"><ix:nonNumeric contextRef="c11" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-23524"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Cash and cash equivalents</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original
maturities of three&#160;months or less that are readily convertible to known amounts of cash and which are subject to an insignificant
risk of changes in value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c11_cont_1" escape="true" name="nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" id="ixv-23535"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Deposits, prepayment,
other receivables and deferred IPO cost, net</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c11_cont_2" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers,
prepaid expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deferred
IPO costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the Initial Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-23551"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Plant and equipment,
net</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Plant
and equipment are stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the
straight-line&#160;method. The Company typically applies a salvage value of <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-34458">0</ix:nonFraction>%. <ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment-c11_cont_1" escape="true" name="nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" id="ixv-34459">The estimated useful lives of the plan and equipment
are as follows:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment-c11_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 25%; padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34460">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c131" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34461">5</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c133" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34462">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c134" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34463">10</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c135" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34464">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c136" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34465">5</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34466">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c138" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-34467">5</ix:nonNumeric>&#160;years</span></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c11_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss
are included in the Company&#8217;s results of operations. The costs of maintenance and repairs are expensed as incurred. Significant
renewals and betterments that extend the useful life of an assets are capitalized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-23609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c11_cont_2" id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company evaluates the long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of assets may not be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies,
or if the Company has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present
if the carrying amount of an asset is less than its expected future undiscounted cash flows.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">If
an asset is considered impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value
of the asset. Assets to be disposed of are reported lower the carrying amount or fair value less cost to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_4" id="_SignificantAccountingPoliciesTextBlock-c11_cont_3"><ix:nonNumeric contextRef="c11" continuedAt="_InventoryPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-23661"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Inventories</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_InventoryPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Inventories
are stated at the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value
is based on the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and
obsolete inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes
the basis for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory
would not be reversed if market conditions improve.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_DebtPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-23672"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Other borrowings</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DebtPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Other
borrowings are recognized initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized
cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements
of operations over the period of the borrowings using the effective interest method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_StockholdersEquityPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:StockholdersEquityPolicyTextBlock" id="ixv-23683"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Ordinary shares</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_StockholdersEquityPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s ordinary shares are stated at par value of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-34468">0.01</ix:nonFraction> per ordinary share. The difference between the consideration received,
net of issuance cost, and the par value is recorded in additional paid-in&#160;capital.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-23694"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenue recognition</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606
had been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its contracts with customers;</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its performance obligations under those contracts;</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine
                                            the transaction prices of those contracts;</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate
                                            the transaction prices to its performance obligations in those contracts; and</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize
                                            revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
                                            when promised services are transferred to the client in an amount that reflects the consideration
                                            expected in exchange for those services.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The
agreements also identify the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties.
All the contracts have commercial substance, and it is probable that the Company will collect considerations from its customers for service
component.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>



</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenue recognition
(cont.)</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_5" id="_SignificantAccountingPoliciesTextBlock-c11_cont_4"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company derives its revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary
caring services.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
IVF treatment</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized
in laboratory to become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the
performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to customer when
embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation. The Company collects
payment from customer in advance for IVF treatment. The amount of revenue recognized from contract liabilities to the Company&#8217;s
result of operations can be found in Note&#160;8 below.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
surrogacy and ancillary caring services</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother
contracted by the Company. During pregnancy period, the Company provides ancillary caring services including regular body check and provision
of vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="nivf:RevenueRate" scale="-2" unitRef="pure" id="ixv-34469">40</ix:nonFraction>% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result
of operations can be found in Note&#160;8 below.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
related assets and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to
the revenue cycle are as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Account receivables,
net</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable, net are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected
credit loss is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the
accounts receivable balances, current general economic conditions, future expectations and customer specific quantitative and qualitative
factors that may affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence
for the Company to reasonably estimate the amount of probable loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenue recognition
(cont.)</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_6" id="_SignificantAccountingPoliciesTextBlock-c11_cont_5"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Contract liabilities</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
liabilities represent considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under
the contract. These amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Expected
credit loss</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c11_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">ASU
No.&#160;2016-13, Financial Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments
requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using
this methodology will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to
recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments
of other financial assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates
of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows
due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the
effective interest rate of the financial asset.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_PostemploymentBenefitPlansPolicy-c11_cont_1" escape="true" name="us-gaap:PostemploymentBenefitPlansPolicy" id="ixv-23927"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Retirement benefits</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PostemploymentBenefitPlansPolicy-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Retirement
benefits in the form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated
to wages as part of cost of revenues.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-23938"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Segment information</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources
and assess performance. The Company operates and manages in <ix:nonFraction contextRef="c11" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-34470">one</ix:nonFraction> operating segment. The Company defines its CODM as Mr.&#160;Siu Wing
Fund Alfred, the Company&#8217;s Chief Executive Officer. Since the Company operates in <ix:nonFraction contextRef="c104" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-34471">one</ix:nonFraction> operating segment, all required financial
segment information can be found in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers
as of December&#160;31, 2023, 2022 and 2021 by geographical area are presented in Note&#160;13.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_7" id="_SignificantAccountingPoliciesTextBlock-c11_cont_6"><ix:nonNumeric contextRef="c11" continuedAt="_LesseeLeasesPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-23985"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Leases</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c11_cont_2" id="_LesseeLeasesPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company measured the lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the
present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not
have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life
of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease
exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-108">twelve</span>&#160;months or less.
Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense
is recognized on a straight-line&#160;basis over the lease term.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2023 and 2022, there were $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34472">283,847</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34473">383,670</ix:nonFraction>&#160;million right of use (&#8220;ROU&#8221;) assets and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="0" unitRef="usd" id="ixv-34474">326,107</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="0" unitRef="usd" id="ixv-34475">426,838</ix:nonFraction> lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s
management believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate
(&#8220;BLR&#8221;) minus <ix:nonFraction contextRef="c11" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure" id="ixv-34476">0.125</ix:nonFraction>%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present
value of the lease payments; the rate used by the Company was <ix:nonFraction contextRef="c105" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-34477">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-34478">5.0</ix:nonFraction>% respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_IncomeTaxPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-24002"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c11_cont_2" id="_IncomeTaxPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company recognizes deferred income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated
financial statements or tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences
between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will
be in effect when the differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred
tax asset is not realizable or recoverable in the future.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company determines that the tax position is more likely than not to be sustained and records the largest amount of benefit that is more
likely than not to be realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain
tax positions in income tax expense.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-24018"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Comprehensive Income</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company presents comprehensive income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states
that all items that are required to be recognized under accounting standards as components of comprehensive income be reported in the
consolidated financial statements. The components of comprehensive income were the net income for the&#160;years and the foreign currency
translation adjustments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_8" id="_SignificantAccountingPoliciesTextBlock-c11_cont_7"><ix:nonNumeric contextRef="c11" continuedAt="_EarningsPerSharePolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-24066"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Earnings per share</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is
measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period.
Diluted EPS presents the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise
of options and or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the
potentially dilutive effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities
(i.e., those that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially
dilutive securities that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="nivf_RelatedPartiesPolicyTextBlock-c11_cont_1" escape="true" name="nivf:RelatedPartiesPolicyTextBlock" id="ixv-24077"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Related parties</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_RelatedPartiesPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC&#160;850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-24088"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Commitments and
contingencies</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such
contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments including historical and the specific facts and circumstances of each matter.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="nivf_NonControllingInterestsPolicyTextBlock-c11_cont_1" escape="true" name="nivf:NonControllingInterestsPolicyTextBlock" id="ixv-24099"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Non-controlling&#160;interests</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_NonControllingInterestsPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_ConcentrationRiskCreditRisk-c11_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-24110"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Concentration of
risks</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_2" id="_ConcentrationRiskCreditRisk-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
credit risk</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_3" id="_ConcentrationRiskCreditRisk-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable.
The Company places cash and cash equivalents with financial institutions with high credit ratings and quality.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_4" id="_ConcentrationRiskCreditRisk-c11_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable primarily comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers,
and generally does not require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts
primarily based upon the factors surrounding the credit risk of specific customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Concentration of
risks (cont.)</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c11_cont_9" id="_SignificantAccountingPoliciesTextBlock-c11_cont_8"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_5" id="_ConcentrationRiskCreditRisk-c11_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
customers</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_6" id="_ConcentrationRiskCreditRisk-c11_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, two and Nil customers which individually contributed more than <ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34479">10</ix:nonFraction>% of trade receivable, accounted
for <ix:nonFraction contextRef="c107" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34480">96.3</ix:nonFraction>% and <span style="-sec-ix-hidden: hidden-fact-109">Nil</span> of the Company&#8217;s trade receivable respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_7" id="_ConcentrationRiskCreditRisk-c11_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">None
of the customers contributed more than <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34481"><ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34482"><ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34483">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of revenue for&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_8" id="_ConcentrationRiskCreditRisk-c11_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Concentration
of suppliers</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c11_cont_9" id="_ConcentrationRiskCreditRisk-c11_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, one and four suppliers which individually contributed more than <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34484">10</ix:nonFraction>% of trade payable, accounted for
<ix:nonFraction contextRef="c113" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34485">30.6</ix:nonFraction>% and <ix:nonFraction contextRef="c114" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34486">69.8</ix:nonFraction>% of the Company&#8217;s trade payable respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c11_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">For
the year ended December&#160;31, 2023, 2022 and 2021, Nil, two and two vendors which contributed more than 10% of total purchases of
the Company, accounted for <span style="-sec-ix-hidden: hidden-fact-110">Nil</span>, <ix:nonFraction contextRef="c116" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34487">55.3</ix:nonFraction>% and <ix:nonFraction contextRef="c117" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-34488">35.6</ix:nonFraction>% of the Company&#8217;s total purchases respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c11_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-24213"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Financial instruments</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c11_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and
deferred IPO cost, net, loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders,
have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements
and Disclosures&#8221; requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial
Instruments&#8221; defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash
and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related
parties each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation
hierarchy are defined as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c11_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical
                                            assets or liabilities in active markets.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c11_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar
                                            assets and liabilities in active markets and information that are observable for the asset
                                            or liability, either directly or indirectly, for substantially the financial instrument&#8217;s
                                            full term</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c11_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c11_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant
                                            to the fair value measurement.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c11_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities
from Equity&#8221; and ASC&#160;815.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c11_cont_9"><ix:nonNumeric contextRef="c11" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c11_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-24296"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements adopted </span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c11" continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="ixv-24307"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements not yet adopted</span></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_2" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in
ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for
all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report
a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions
about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and
depletion expense, to be disclosed under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure
requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective
for years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively.
Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial
statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_3" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
December 2023, FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements
to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU
2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit)
from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable
statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling
items within certain categories that are equal to or greater than a specified quantitative threshold of <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-34489">5</ix:nonFraction>%. ASU 2023-09 also requires
disclosure of, on an annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state,
and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual
jurisdiction equal to or greater than <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-34490">5</ix:nonFraction>% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective
for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact
of the update on the Company&#8217;s consolidated financial statements and related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c11_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Save
for elsewhere disclosed, the Company does not believe other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income
(loss) and statement of cash flows.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:AccountsAndNontradeReceivableTextBlock" id="ixv-24354"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 3 &#8212;&#160;ACCOUNTS
RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-24362"><span style="font-size: 10pt">Accounts
receivable, net consists of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accounts receivable</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-34491">9,393</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-34492">13,026</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: allowance for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-34493">19</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-34494">26</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34495">9,374</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34496">13,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c11_cont_1" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="ixv-24452"><span style="font-size: 10pt">As
of the end of each of the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based
on the invoice date is as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Within 90&#160;days</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34497">9,374</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34498">13,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34499">9,374</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34500">13,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock-c11_cont_1" escape="true" name="nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" id="ixv-24523"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34501">26</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34502">286</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of expected credit losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-34503">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-34504">260</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34505">19</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34506">26</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-24615"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-24623"><span style="font-size: 10pt">Inventories
consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Medicines, consumables and reagents for clinical and laboratory
    analyses</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-34507">126,264</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-34508">46,910</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34509">126,264</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34510">46,910</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-24720"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;DEPOSITS,
PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfOtherCurrentAssetsTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-24728"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred IPO cost, net consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfOtherCurrentAssetsTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Other receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-34511">15,910</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-34512">30,295</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deposits</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositAssets" scale="0" unitRef="usd" id="ixv-34513">123,008</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositAssets" scale="0" unitRef="usd" id="ixv-34514">40,131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Prepayment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-34515">4,848</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deferred initial public offering &#8220;IPO&#8221;
    cost</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-34516">373,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: allowance for expected
    credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-34517">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-34518">141</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34519">517,429</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34520">70,285</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock-c11_cont_1" escape="true" name="nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" id="ixv-24890"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-34521">141</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-34522">115</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of provision (Provision)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" scale="0" unitRef="usd" id="ixv-34523">127</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" scale="0" sign="-" unitRef="usd" id="ixv-34524">30</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Effect of currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" scale="0" unitRef="usd" id="ixv-34525">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-34526">14</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-34527">141</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-25024"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;PLANT
AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_PropertyPlantAndEquipmentTextBlock-c11_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-25032"><span style="font-size: 10pt">Plant
and equipment, net consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">At cost:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Building improvement</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34528">92,438</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34529">72,519</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Furniture and fixtures</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34530">250,493</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34531">246,682</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Medical instruments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34532">844,809</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34533">791,514</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34534">142,936</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34535">142,936</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34536">150,688</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34537">146,432</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34538">1,481,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-34539">1,400,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34540">1,319,207</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34541">1,277,410</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34542">162,157</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34543">122,673</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Depreciation
expenses for the&#160;years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-34544">31,173</ix:nonFraction> and $<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-34545">100,533</ix:nonFraction>, respectively. Loss on disposal of assets
for the year ended December&#160;31, 2023 and 2022 was $<span style="-sec-ix-hidden: hidden-fact-114">Nil</span> and $<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd" id="ixv-34546">114,013</ix:nonFraction>, respectively, due to moving of clinic to new location in First
Fertility PGS Center Limited in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-hidden: hidden-fact-116">No</span></span>
impairment loss was recorded for the&#160;years ended December&#160;31, 2023, and 2022.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF
LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-25272"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;ACCRUED
LIABILTIES AND OTHER PAYABLES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-25280"><span style="font-size: 10pt">Accrued
liabilities and other payables consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c11_cont_2" id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accrued expenses</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34547">43,633</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34548">22,345</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Other tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-34549">3,180</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Withholding tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-34550">7,349</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-34551">82,240</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Compensation payable (Note&#160;1)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">144,015</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">117,935</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-34554">46,616</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-34555">64,077</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34556">241,613</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34557">289,777</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-25439"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;CONTRACT
LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="ixv-25447"><span style="font-size: 10pt">Contract
liabilities consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c11_cont_2" id="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34558">1,360,168</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34559">812,158</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Additions</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-34560">112,006</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-34561">1,360,168</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Recognized to revenue during the
    year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-34562">122,662</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-34563">812,158</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Refund
    to customers (Note 1)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:ContractWithCustomerRefundLiability" scale="0" unitRef="usd">1,341,575</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at
    end of year</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34565">7,937</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34566">1,360,168</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-25611"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has various operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The
Company&#8217;s management believes that the interest rate of <ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-34567">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-34568">5</ix:nonFraction>% was the most indicative rate of the Company&#8217;s borrowing
cost for the calculation of the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, the right-of-use&#160;assets totaled $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34569">283,847</ix:nonFraction>, and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34570">383,670</ix:nonFraction>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock-c11_cont_1" escape="true" name="nivf:ScheduleOfLeaseLiabilitiesTableTextBlock" id="ixv-25627"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, lease liabilities consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;current
    portion</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34571">207,128</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34572">184,651</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34573">118,979</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34574">242,187</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-34575">326,107</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-34576">426,838</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_LeaseCostTableTextBlock-c11_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-25717"><span style="font-size: 10pt">Other
lease information is as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LeaseCostTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-34577">0.92</ix:nonNumeric>&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-34578">1.91</ix:nonNumeric>&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-34579">5</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-34580">5</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Short term lease cost</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-34581">114,937</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-34582">89,380</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c11_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-25807"><span style="font-size: 10pt">The
following is a schedule of future minimum payments under operating leases as of December&#160;31, 2023:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Not later than 1 year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-34583">240,835</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between 1 to 2&#160;years</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-34584">111,613</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between
    2 to 3&#160;years</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-34585">10,373</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total lease payments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-34586">362,821</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: imputed
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-34587">36,714</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total operating
    lease liabilities, net of interest</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-34588">326,107</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-25918"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Ordinary shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
at December&#160;31, 2023, the Company is authorized to issue <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-34589">5,000,000</ix:nonFraction> ordinary shares. Each ordinary share is entitled to <ix:nonNumeric contextRef="c11" name="us-gaap:CommonStockVotingRights" id="ixv-34590">one</ix:nonNumeric> vote.
The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
equity of the Company as of December&#160;31, 2023 and 2022 represents <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34591">698,123</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34592">601,830</ix:nonFraction> ordinary shares amounting to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34593">6,981</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34594">6,018</ix:nonFraction>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="ixv-25945"><span style="font-size: 10pt"><i>Subscription
receivables</i></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<ix:continuation continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_2" id="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34595">319,872</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">2,866,856</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">319,872</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd">219,628</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34599">2,967,100</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34600">319,872</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_3" id="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional <ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-34601">41,830</ix:nonFraction> ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-34602">961,538</ix:nonFraction>, of which other borrowings of $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherBorrowings" scale="0" unitRef="usd" id="ixv-34603">641,025</ix:nonFraction> and $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherBorrowings" scale="0" unitRef="usd" id="ixv-34604">641</ix:nonFraction> settlement was offset with consideration as partial settlement and $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34605">319,872</ix:nonFraction> was subscription receivable due from Seazen.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfStockholdersEquityTableTextBlock-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0%"/><td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On January&#160;18, 2023, the Company received $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="usd" id="ixv-34606">192,308</ix:nonFraction> from Seazen, reducing the subscription receivable by $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34607">192,308</ix:nonFraction>. On January 10, 2023, the Company issued and allotted additional <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-34608">27,293</ix:nonFraction> ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34609">812,573</ix:nonFraction>. On December 4, 2023, the Company issued and allotted additional <ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-34610">69,000</ix:nonFraction> shares to DoubleClick Services Limited at $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-34611">2,054,283</ix:nonFraction>. Among the subscription receivable during the year, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34612">27,320</ix:nonFraction> was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_1" escape="true" name="nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock" id="ixv-26080"><span style="font-size: 10pt"><i>Additional paid-in
capital</i></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<ix:continuation continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_2" id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34613">1,458,941</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34614">257,821</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    remuneration <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" scale="0" unitRef="usd">240,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="nivf:IssuanceOfSharesAdditionalpaidincapital" scale="0" unitRef="usd">2,865,893</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="nivf:IssuanceOfSharesAdditionalpaidincapital" scale="0" unitRef="usd">961,120</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34618">4,324,834</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34619">1,458,941</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_3" id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-size: 10pt">The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionAmount" scale="0" unitRef="usd" id="ixv-34620">120,000</ix:nonFraction> and $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionAmount" scale="0" unitRef="usd" id="ixv-34621">120,000</ix:nonFraction> for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="0" unitRef="usd" id="ixv-34622">240,000</ix:nonFraction> increase in paid-in capital.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-size: 10pt">On August 15, 2022, the Company issued <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-34623">41,830</ix:nonFraction> ordinary shares to Seazen, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="0" unitRef="usd" id="ixv-34624">961,120</ix:nonFraction>. On January 10, 2023, the Company issued <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-34625">27,293</ix:nonFraction> ordinary shares to professional party for consulting service of <ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-34626">10</ix:nonNumeric> years, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34627">812,300</ix:nonFraction>. On December 4, 2023, the Company issued additional <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-34628">69,000</ix:nonFraction> shares to DoubleClick Services Limited for consulting service of <ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-34629">10</ix:nonNumeric> years, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34630">2,053,593</ix:nonFraction>.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_CompensationAndEmployeeBenefitPlansTextBlock-c11_cont_1" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-26217"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE
BENEFIT PLANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>HK SAR</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-34631">5</ix:nonFraction>%
of the employees&#8217; basic salaries on monthly basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE
BENEFIT PLANS (cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_CompensationAndEmployeeBenefitPlansTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Thailand</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company is obliged to make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession
had been determined by the Government which saw the standard amount <span style="-sec-ix-hidden: hidden-fact-124">THB750</span> per month per person reduced to <span style="-sec-ix-hidden: hidden-fact-125">THB450</span> per month per person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cambodia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Every
business employing one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;)
for the Occupational Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension
Scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Once
registered, the business must pay to the NSSF:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-34632">0.8</ix:nonFraction>% of each worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-34633">0.40</ix:nonFraction> and $<ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-34634">2.40</ix:nonFraction> per month per worker) for the Occupational Risk Scheme.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c188" decimals="3" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-34635">2.6</ix:nonFraction>% of a worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-34636">1.30</ix:nonFraction> and $<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-34637">7.80</ix:nonFraction> per month per worker) for the Health Care Scheme.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of <ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-34638">2</ix:nonFraction>% (total of <ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="nivf:ContributableWageTotalRate" scale="-2" unitRef="pure" id="ixv-34639">4</ix:nonFraction>%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-123">KHR400,000</span> (approximately $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-34640">100</ix:nonFraction>) up to <span style="-sec-ix-hidden: hidden-fact-122">KHR1,200,000</span> (approximately $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-34641">300</ix:nonFraction>).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-34642">15</ix:nonFraction>%
and <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-34643">8</ix:nonFraction>%, respectively of the employees&#8217; basic salaries on monthly basis.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_IncomeTaxDisclosureTextBlock-c11_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-26336"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION
FOR INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cayman Islands</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">NewGenIvf
Limited was incorporated in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law.
In addition, upon payment of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>HK SAR</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" name="nivf:ProfitTaxDescription" id="ixv-26360"><span style="font-size: 10pt">Under
the two-tiered&#160;profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates
regime will continue to be taxed at a flat rate of 16.5%.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accordingly,
the HK SAR profits tax is calculated at <ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-34644">8.25</ix:nonFraction>% on the first HK$<ix:nonFraction contextRef="c195" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" unitRef="hkd" id="ixv-34645">2</ix:nonFraction>&#160;million of the estimated assessable profits and at <ix:nonFraction contextRef="c11" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" scale="-2" unitRef="pure" id="ixv-34646">16.5</ix:nonFraction>% on the
remaining estimated assessable profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Thailand</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
companies incorporated in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from
or in consequence of the business carried on in Thailand. The corporate income tax (CIT) rate is <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" scale="-2" unitRef="pure" id="ixv-34647">20</ix:nonFraction>%. A foreign company not carrying
on business in Thailand is subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends,
royalties, rentals, and service fees) paid from or in Thailand. The rate of tax is generally <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" unitRef="pure" id="ixv-34648">15</ix:nonFraction>%, except for dividends, which is <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-34649">10</ix:nonFraction>%,
while other rates may apply under the provisions of a double tax treaty (DTT).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION
FOR INCOME TAXES (cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c11_cont_2" id="_IncomeTaxDisclosureTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cambodia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">The
standard rate of corporate income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and
large taxpayers is <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-34650">20</ix:nonFraction>%. For companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive
rates from <ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-34651">0</ix:nonFraction>% to <ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-34652">20</ix:nonFraction>%. In view of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-143">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-144">KHR6</span>&#160;billion
for service and commercial sectors, the company shall consider as the medium-sized&#160;company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
company is subject to a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying
out business activities through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities
of that permanent establishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Profit
tax is calculated at a rate of <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" unitRef="pure" id="ixv-34653">10</ix:nonFraction>% of aggregate annual income less allowed deductions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-26440"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the provisions for income taxes for the year ended December&#160;31, 2023, and 2022 were as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"><td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34654">196,116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34655">11,323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34656">702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34657">208,141</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>




</div><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION
FOR INCOME TAXES (cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c11_cont_2"><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-26537"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income before taxes</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34658">108,418</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34659">343,988</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34660">156,184</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax expenses (credit) at the effective
    tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd" id="ixv-34661">10,732</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-34662">124,591</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd" id="ixv-34663">36,755</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-taxable income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" sign="-" unitRef="usd" id="ixv-34664">39,173</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-deductible expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-34665">369,101</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-34666">114,656</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on late penalty provision</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-34667">145,295</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-34668">28,441</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect
    on utilization of tax losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" sign="-" unitRef="usd" id="ixv-34669">36,369</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" sign="-" unitRef="usd" id="ixv-34670">1,990</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income taxes</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34671">208,141</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34672">294,716</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Deferred tax asset,
net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-26792"><span style="font-size: 10pt">Significant
components of deferred tax assets, net were as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred tax assets:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">&#8211; Net operating
    loss carry forward</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-34673">28,441</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-34674">28,441</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, the Company had net operating loss carry forward of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-34675">164,721</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-34676">297,207</ix:nonFraction>. The Company believes it
is less likely than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry
forward. As a result, the Company provided <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="nivf:PercentageOfAllowanceOnDeferredTaxAssets" scale="-2" unitRef="pure" id="ixv-34677">100</ix:nonFraction>% allowance on deferred tax assets on net operating loss.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="nivf_DissagregattedRevenuesTextBlock-c11_cont_1" escape="true" name="nivf:DissagregattedRevenuesTextBlock" id="ixv-26914"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED
REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ixv-26922"><span style="font-size: 10pt">The
Company&#8217;s main business operations are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring
services.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the year ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">IVF treatment service</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34678">4,021,696</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34679">2,819,163</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34680">3,199,683</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Surrogacy,
    ancillary caring and other services</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34681">1,114,457</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34682">3,125,027</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34683">918,437</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34684">5,136,153</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34685">5,944,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34686">4,118,120</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>



</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED
REVENUES (cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation id="nivf_DissagregattedRevenuesTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><ix:nonNumeric contextRef="c11" continuedAt="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c11_cont_1" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-27079"><span style="font-size: 10pt"><b>Geographical information</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<ix:continuation id="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers originated from</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34687">34,038</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34688">3,123,593</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34689">5,060,973</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34690">3,110,483</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34691">621,619</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34692">377,608</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34693">313,737</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34694">1,356,903</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34695">505,609</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34696">693,900</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34697">5,136,153</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34698">5,944,190</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34699">4,118,120</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_DisaggregationOfRevenueTableTextBlock-c11_cont_1" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-27255"><span style="font-size: 10pt">The
revenue information above is based on the locations where the revenue originated.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisaggregationOfRevenueTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 10pt">Long-lived assets located at</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34700">584</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34701">22,513</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34702">20,835</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34703">137,472</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34704">229,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34705">332,799</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34706">307,948</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34707">254,745</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34708">238,744</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34709">446,004</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34710">506,343</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34711">592,378</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s long-lived&#160;assets consist of plant and equipment, net and operating leases right-of-use&#160;assets, net.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_ConcentrationRiskDisclosureTextBlock-c11_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-27435"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">A.
Credit risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Accounts receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
order to minimize the credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover
overdue debts. The Company considers the probability of default upon initial recognition of asset and whether there has been a significant
increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit
risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date
of initial recognition. It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and
nominal GDP per capita. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account
receivables as of December&#160;31, 2023 and 2022 is $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" unitRef="usd" id="ixv-34712">19</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" unitRef="usd" id="ixv-34713">26</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS
(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">A.
Credit risk (cont.)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c11_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cash and cash equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Deposits and
other receivables, amount due from shareholders and loan to A SPAC I</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company assessed the impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on
internal credit rating and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk
since initial recognition. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for
deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34714">14</ix:nonFraction>, $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34715">17,818</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-149">Nil</span>, respectively.
The loss allowance for deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2022 is $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34716">141</ix:nonFraction>,
$<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34717">17,059</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-150">Nil</span>, respectively. The loss allowance for deposits and other receivables and amount due from shareholders as of December&#160;31,
2021 was $<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34718">115</ix:nonFraction> and $<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34719">6,312</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-151">Nil</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">B.&#160;Interest
risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cash flow interest
rate risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company is exposed to cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank
balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company currently does not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest
rate risk. The directors monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should
the need arises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Sensitivity
analysis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
sensitivity analysis below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period
and had been applied to the exposure to interest rates for financial instruments in existence at that date. <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure" id="ixv-34720">1</ix:nonFraction>% increase or decrease is
used when reporting interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably
possible change in interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">If
interest rates had been <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="nivf:InterestRateOtherVariablesPercentage" scale="-2" unitRef="pure" id="ixv-34721">1</ix:nonFraction>% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;years
ended December&#160;31, 2023, 2022 and 2021 would have increased or decreased by approximately $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-34722">541</ix:nonFraction>, $<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-34723">275</ix:nonFraction> and $<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-34724">287</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">B. Interest risk
(cont.)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c11_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Foreign currency
risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Foreign
currency risk is the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result
of a change in foreign currency exchange rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s monetary assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional
currencies of the relevant group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered
insignificant. The Company currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors
monitor the related foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">C.
Economic and political risks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s operations are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial
condition, and results of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia
and Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s operations in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s
results may be adversely affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes
in governmental policies with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad,
and rates and methods of taxation, among other things.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">D.
Inflation risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Management
monitors changes in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements;
however, significant increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the
Company&#8217;s results of operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c11_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-27655"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED
PARTY BALANCES AND TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-27663"><span style="font-size: 10pt">The
summary of amount due from and due to related parties as the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Relationship</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due from shareholders consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><span style="font-size: 10pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c236" id="ix_10_fact" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction"><span style="font-size: 10pt">Shareholders and directors (note 1)</span></ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-34725">354,285</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-34726">2,240,872</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due to a related party consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Harcourt Limited</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c238" id="ix_11_fact" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction"><span style="font-size: 10pt">A related company (note&#160;2)</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-152; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueToRelatedParties" scale="0" unitRef="usd" id="ixv-34727">110,773</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24pt"><span style="font-size: 10pt">Note</span></td><td style="text-align: left"/></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_3" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholders" scale="0" unitRef="usd" id="ixv-34728">354,285</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholders" scale="0" unitRef="usd" id="ixv-34729">2,240,872</ix:nonFraction>, respectively.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c11_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><ix:footnote id="ix_8_footnote" xml:lang="en-US"><span style="font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock-c11_cont_1" escape="true" name="nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" id="ixv-27847"><span style="font-size: 10pt">The
balance due from shareholders consist of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Due from shareholders</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholder" scale="0" unitRef="usd" id="ixv-34730">372,103</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholder" scale="0" unitRef="usd" id="ixv-34731">2,257,931</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: allowance
    for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" scale="0" unitRef="usd" id="ixv-34732">17,818</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" scale="0" unitRef="usd" id="ixv-34733">17,059</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34734">354,285</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-34735">2,240,872</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>



</div><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED
PARTY BALANCES AND TRANSACTIONS&#160;(cont.)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c11_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_SummaryOfValuationAllowanceTextBlock-c11_cont_1" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-27973"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>


<ix:continuation id="_SummaryOfValuationAllowanceTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34736">17,059</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34737">6,312</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-34738">759</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-34739">10,747</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34740">17,818</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-34741">17,059</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c11" continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c11_cont_1" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-28063"><span style="font-size: 10pt">In
addition to the transactions and balances detailed elsewhere in these consolidated financial statements, the Company had the following
transactions with related parties:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c11_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Mr.&#160;Siu Wing Fung, Alfred</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34742">125,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34743">120,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34744">100,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Ms. Fong Hei Yue, Tina</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34745">125,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34746">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-34747">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Waiver of related party balance
    of Mr. Siu Wing Fung, Alfred</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-34748">88,151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-28185"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;LOAN
TO A SPAC&#160;I</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">On
June&#160;12, 2023, NewGenIvf Limited (the &#8220;Company&#8221;) and A SPAC&#160;I Acquisition Corp (&#8220;A SPAC&#160;I&#8221;) entered
into a First Amendment to Merger Agreement, pursuant to which the Company agreed to provide non-interest&#160;bearing loans in an aggregate
principal amount of up to $<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34749">560,000</ix:nonFraction> (the &#8220;Loan&#8221;) to A SPAC&#160;I to fund amounts required to further extend the period of
time available for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative
and operational expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Company. The Loan will only become repayable
upon the closing of the Acquisition Merger. As of December 31, 2023, $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherShortTermDebt" scale="0" unitRef="usd" id="ixv-34750">140,000</ix:nonFraction> was outstanding under the loan. The Company completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to A SPAC I was eliminated
in the subsequent period.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="nivf:ImpactOfCovid19TextBlock" id="ixv-28198"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;<span style="text-transform: uppercase">IMPACT
OF&#160;</span>COVID-19</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
COVID-19&#160;has negatively impacted the global economy, disrupted consumer spending and global supply chains, and created significant
volatility and disruption of financial markets. The Company experienced some resulting disruptions to the Company&#8217;s business operations,
and the Company expected the COVID-19&#160;pandemic could have a material adverse impact on the Company&#8217;s business and financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Due
to the ongoing recession caused by the COVID-19, the Company&#8217;s business is likely to be adversely impacted. The effects of recession
can also increase economic instability with vendors and customers.</span></p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>NEWGENIVF LIMITED<br/>
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br/>
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021<br/>
(Stated in US Dollars)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-28240"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;<span style="text-transform: uppercase">CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December 31, 2023 and 2022, the Company was not a party to any legal or administrative proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Fertility Bishkek LLC (&#8220;FFB&#8221;), the Company incorporated in Kyrgyzstan, did not report the current year tax </span><span style="font-size: 10pt">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">to
the tax authority till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of December 31, 2023.
Since FFB had no profit for the year ended December 31, 2023, the tax department may not issue tax return at current tax position. The
tax return is not yet filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible
amount of tax penalty. The contingent tax penalty is reasonably possible and estimated at $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="0" unitRef="usd" id="ixv-34751">486,706</ix:nonFraction>. Thus, no provision was made. Except
the potential tax issue, the Company concludes that there was no contingent liability, either individually or in the aggregate, that
could have resulted in an unfavorable outcome with a material adverse effect on the Company&#8217;s results of operations, consolidated
financial condition, or cash flows.</span></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-28261"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 19 &#8212;&#160;<span style="text-transform: uppercase">segment
information</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company uses the management approach to determine reportable operating segments. The management approach considers the internal organization
and reporting used by the Company&#8217;s CODM, specifically the Group&#8217;s CEO and CFO, for making decisions, allocating resources
and assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company does not distinguish revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses
by nature as a whole. Based on the management&#8217;s assessment, the Group determines that it has only <ix:nonFraction contextRef="c11" decimals="0" format="ixt-sec:numwordsen" name="nivf:NumberOfOperatingSegment" scale="0" unitRef="pure" id="ixv-34752">one</ix:nonFraction> operating segment and therefore
<ix:nonFraction contextRef="c11" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" unitRef="pure" id="ixv-34753">one</ix:nonFraction> reportable segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be
found in these consolidated financial statements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c11" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-28280"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">NOTE
20 &#8212;&#160;SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements
were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have
required adjustment or disclosure in the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Convertible note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
February 29, 2024, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), A SPAC I Mini Acquisition Corp. (the then name of NewGenIvf Group
Limited), NewGenIvf Limited (&#8220;NewGenIvf&#8221;, the &#8220;Company&#8221;), A SPAC I Mini Sub Acquisition Corp. (the &#8220;Merger
Sub&#8221;), and certain buyers named therein led by JAK Opportunities VI LLC (collectively, the &#8220;Buyers&#8221; or &#8220;JAK&#8221;)
entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;), pursuant to which the NewGenIvf Group
Limited agreed to issue and sell to JAK, in a private placement, an aggregate of up to $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34754">3,500,000</ix:nonFraction> principal amount of convertible notes
(the &#8220;Notes&#8221;), consisting of one or more tranches: (i) an initial tranche (the &#8220;Initial Tranche&#8221;) of an aggregate
principal amount of Notes of up to $<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34755">1,750,000</ix:nonFraction> and including an original issue discount of up to aggregate $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="0" unitRef="usd" id="ixv-34756">122,500</ix:nonFraction>, and (ii) subsequent
tranches of an aggregate principal amount of Notes of up to $<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34757">1,750,000</ix:nonFraction> and including an original issue discount of up to aggregate $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="0" unitRef="usd" id="ixv-34758">122,500</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, JAK received a certain amount of ordinary shares of the NewGenIvf Group Limited (the &#8220;Commitment Shares&#8221;),
which were converted from the Company ordinary shares issued to JAK in February 2024 and equaled <ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-34759">295,000</ix:nonFraction> ordinary shares of the NewGenIvf
Group Limited, as well as an additional <ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-34760">100,000</ix:nonFraction> ordinary shares of the NewGenIvf Group Limited, which were converted from the Company
ordinary shares transferred by another shareholder of the Company to JAK in March 2024. In addition, a subsequent tranche of the Notes
in the principal amount of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34761">250,000</ix:nonFraction> was issued and sold to JAK shortly after the closing of the Business Combination. As such, as of
April 4, 2024, an aggregate principal amount of Notes of $<ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd" id="ixv-34762">2,000,000</ix:nonFraction> were issued and sold to JAK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Business combination
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp. After the combination, the combined company
will be named &#8220;NewGenIvf Group Limited&#8221; (&#8220;NewGenIvf Group&#8221;) and its shares and warrants are expected to begin
trading on the Nasdaq Capital Market under the tickers &#8220;NIVF&#8221;, and &#8220;NIVFW&#8221;, respectively, on April 4, 2024.</span></p></ix:nonNumeric><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="fin_001a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF JUNE 30, 2024 AND 31 DECEMBER&#160;2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-34763">184,109</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-34764">54,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34765">172,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-34766">9,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34767">102,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-34768">126,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deposits, prepayment and other receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34769">703,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-34770">517,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loan to A SPAC I</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:LoanToASPAC" scale="0" unitRef="usd" id="ixv-34771">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Due from shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-34772">354,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-34773">1,163,306</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-34774">1,201,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34775">159,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-34776">162,157</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34777">272,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-34778">283,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-34779">1,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Deposits, prepayment and other receivables, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34780">910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34781">434,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-34782">446,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-34783">1,597,677</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-34784">1,647,460</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-34785">1,940,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-34786">172,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34787">3,014,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34788">241,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34789">37,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34790">7,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Due to a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34791">48,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Due to shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueToShareholders" scale="0" unitRef="usd" id="ixv-34792">762,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34793">199,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34794">207,128</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Finance lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-34795">6,446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-34796">486,705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-34797">486,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34798">6,490,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-34799">1,122,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34800">114,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-34801">118,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Convertible promissory note</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="0" unitRef="usd" id="ixv-34802">3,383,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-34803">3,497,957</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-34804">118,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-34805">9,988,387</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-34806">1,241,435</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares, $<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-34807"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-34808">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-34809">100,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-34810">5,000,000</ix:nonFraction> shares authorized as of June 30, 2024 and December 31, 2023; <ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34811"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34812">10,149,386</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-34813"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34814">698,123</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2024 and December&#160;31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34815">101,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-34816">6,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34817">7,473,791</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-34818">2,967,100</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34819">57,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-34820">4,324,834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-34821">857,894</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-34822">461,351</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-34823">193,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34824">7,288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Equity attributable to the shareholders of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-34825">7,979,105</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-34826">896,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-34827">411,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-34828">490,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34829">8,390,710</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34830">406,025</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-34831">1,597,677</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-34832">1,647,460</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_002a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>COMPREHENSIVE INCOME (LOSS)<br/>
FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34833">2,686,902</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-34834">2,138,622</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-34835">2,047,970</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-34836">1,205,940</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-34837">638,932</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-34838">932,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-34839">56,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-34840">2,887</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-34841">869,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-34842">1,223,284</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-34843">926,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-34844">1,266,171</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-34845">287,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-34846">293,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-34847">7,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-34848">8,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-34849">12,921</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-34850">364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-34851">120,162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="0" unitRef="usd" id="ixv-34852">10,463</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-34853">100,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-34854">1,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Income (loss) before taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34855">387,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34856">295,060</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-34857">83,727</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34858">387,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34859">378,787</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: net loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34860">8,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34861">70,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net income (loss) attributable to the shareholders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-34862">396,543</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-34863">307,897</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34864">270,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34865">37,894</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-34866">117,545</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" sign="-" unitRef="usd" id="ixv-34867">340,893</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: total comprehensive loss attributable to non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34868">78,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34869">61,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive income attributable to the shareholders
    of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-34870">195,990</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" unitRef="usd" id="ixv-34871">279,682</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Earning per share&#160;&#8211;&#160;basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-34872"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-34873">0.04</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-34874"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-34875">0.51</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic and diluted weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-34876"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-34877">10,149,386</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-34878"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-34879">601,830</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_003a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EQUITY (DEFICIT)<br/>
FOR THE SIX MONTHS ENDED JUNE 30, 2024 and&#160;2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ordinary<br/>
    shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Subscription<br/>
    receivable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional
    <br/> paid-in <br/> capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    other<br/> comprehensive<br/> income/(loss)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<br/>
    attributable<br/> to the<br/> shareholders<br/> of the<br/> Company</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-
    controlling<br/> interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December 31, 2022</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34880">601,830</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34881">6,018</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34882">319,872</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34883">1,458,941</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34884">591,544</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34885">9,570</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34886">563,113</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34887">462,430</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34888">100,683</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34889">307,897</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34890">307,897</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34891">70,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34892">378,787</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation&#160;adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34893">28,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34894">28,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34895">9,679</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34896">37,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Subscription
    receivables</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34897">192,308</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34898">192,308</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd" id="ixv-34899">192,308</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    June&#160;30, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34900">601,830</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34901">6,018</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34902">127,564</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34903">1,458,941</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34904">899,441</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34905">37,785</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34906">475,739</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34907">523,641</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34908">47,902</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-34909">698,123</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34910">6,981</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34911">2,967,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34912">4,324,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34913">461,351</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34914">7,288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34915">896,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34916">490,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34917">406,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34918">396,543</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34919">396,543</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-34920">8,762</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34921">387,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation&#160;adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34922">191,791</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34923">191,791</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34924">78,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-34925">270,236</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Business
    combination</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c81" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-34926">9,451,263</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" sign="-" unitRef="usd" id="ixv-34927">94,513</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-34928">4,506,691</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-34929">4,267,013</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" sign="-" unitRef="usd" id="ixv-34930">8,762</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-34931">8,670,429</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-34932">8,761</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-34933">8,679,190</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    June&#160;30, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">10,149386</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34934">101,494</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34935">7,473,791</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34936">57,821</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34937">857,894</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-34938">193,265</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34939">7,979,105</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34940">411,605</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-34941">8,390,710</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="fin_004a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br/>
FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the&#160;Six Months&#160;Ended
    <br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>2023</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34942">387,781</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-34943">378,787</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation of plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-34944">12,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-34945">19,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-34946">4,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-34947">84,731</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Provision of expected credit loss allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" unitRef="usd" id="ixv-34948">612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-34949">165,568</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-34950">81,515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-34951">22,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-34952">22,451</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loan to A SPAC I</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd" id="ixv-34953">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-34954">140,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deposit, prepayment and other receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-34955">25,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-34956">1,406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-34957">1,771,406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-34958">51,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-34959">2,770,371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-34960">19,681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-34961">29,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" sign="-" unitRef="usd" id="ixv-34962">1,250,900</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-34963">12,714</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-34964">89,702</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" unitRef="usd" id="ixv-34965">83,561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.05pt; padding-left: 0.05pt">Net cash provided by/(used in) operating
    activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-34966">4,209,695</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34967">1,702,849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchase of plant and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-34968">10,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchase of intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-34969">1,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34970">11,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-34971">6,446</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" unitRef="usd" id="ixv-34972">9,317</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other borrowings, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd" id="ixv-34973">560,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amount with related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-34974">605,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-34975">1,530,872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Subscription receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:SubscriptionReceivables" scale="0" sign="-" unitRef="usd" id="ixv-34976">8,892,956</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="nivf:SubscriptionReceivables" scale="0" unitRef="usd" id="ixv-34977">192,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible promissory note</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-34978">3,380,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash (used in)/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-34979">4,352,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-34980">1,713,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease)/increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-34981">154,677</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-34982">11,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of foreign currency translation on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34983">284,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34984">38,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34985">54,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34986">27,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34987">184,109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-34988">77,294</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Supplementary cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-34989">120,162</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-34990">837</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Listing fee paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="0" unitRef="usd" id="ixv-34991">675,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_005a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-30615"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited (the &#8220;Company&#8221;
or the &#8220;Group&#8221;) was incorporated under the laws of the Cayman Islands on January&#160;16, 2019 as an investment holding company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is an organization chart of the
Company and its subsidiaries:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<img alt="" src="fin_002.jpg" style="width: 650px; height: 355px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-34992">As of June&#160;30, 2024, the Company&#8217;s
subsidiaries are detailed in the table as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_2" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 22%; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c259" name="nivf:SubsidiariesBackground" id="ixv-30652"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c259" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34993">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c259" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30660"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c260" name="nivf:SubsidiariesBackground" id="ixv-30667"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c260" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34994">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c260" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30675"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c261" name="nivf:SubsidiariesBackground" id="ixv-30682"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c261" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34995">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c261" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30690"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c262" name="nivf:SubsidiariesBackground" id="ixv-30697"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c262" decimals="2" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure">49</ix:nonFraction>%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c262" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30705"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><ix:nonNumeric contextRef="c263" name="nivf:SubsidiariesBackground" id="ixv-30712"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34997">74</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c263" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30720"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><ix:nonNumeric contextRef="c264" name="nivf:SubsidiariesBackground" id="ixv-30727"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company<br/> &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34998">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c264" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30735"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></ix:nonNumeric></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL
ACTIVITIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_3" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><ix:nonNumeric contextRef="c265" name="nivf:SubsidiariesBackground" id="ixv-30795"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company<br/> &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></ix:nonNumeric></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c265" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-34999">100</ix:nonFraction>%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c265" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-30803"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></ix:nonNumeric></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<ix:continuation id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than <ix:nonFraction contextRef="c258" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-35000">50</ix:nonFraction>% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></ix:footnote></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to the Foreign
Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required to be owned
by Thai nationals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;) of Med Holdings and
FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have the same rights and
status in all respects except for the distribution of profits by way of dividends with details as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PolicyholderDividendsRateOnPolicyEarnings" scale="-2" unitRef="pure" id="ixv-35001">15</ix:nonFraction>% of the total amount of dividends declared from time to time;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After allocation of dividends
    as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to
    their shareholding ratio;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of preferred
    shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and
    there shall be no cumulative dividends; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends allocated to
    the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall
    be paid to the holders of preferred shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the management&#8217;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL
ACTIVITIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Group reorganization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to a group reorganization
(the &#8220;group reorganization&#8221;) to rationalize the structure of the Company and its subsidiary companies (herein collectively
referred to as the &#8220;Group&#8221;) in preparation for the listing of its shares, the Company becomes the holding company of the
Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests were also
ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and comprehensive
income, consolidated statements of changes in shareholders&#8217; equity and consolidated statements of cash flows are prepared as if
the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023, or since the respective
dates of incorporation/establishment of the relevant entity, where this is a shorter period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited condensed
consolidated balance sheets as of June&#160;30, 2024 and 2023 present the assets and liabilities of the aforementioned companies now
comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The movement in the Company&#8217;s
authorized share capital and the number of ordinary shares outstanding and issued in the Company are also detailed in Note&#160;10.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-30899"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-30904"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_2" id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared
the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the
United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-30946"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant estimates required to be made by management
include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ from those estimates, and as such,
differences may be material to the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-30953"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited uses Cambodian
riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States dollar (&#8220;USD&#8221;)
as its functional currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations and comprehensive income
as other comprehensive income or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="ixv-35002">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c281" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35003">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c282" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35004">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35005">7.8000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35006">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c282" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35007">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35008">7.8000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35009">36.8454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35010">35.3081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35011">34.2265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35012">34.4021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35013">34.3864</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35014">34.7867</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c285" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35015">4,112.3016</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35016">4,132.8226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35017">4,080.0304</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c285" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35018">4,075.4046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35019">4,058.1179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35020">4,105.4181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35021">7.2674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35022">6.4586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-35023">7.0971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35024">7.2142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35025">6.4077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="4" format="ixt:num-dot-decimal" name="nivf:ForeignCurrencyExchangeRateTranslation" scale="0" unitRef="pure" id="ixv-35026">7.0835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-31174"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_1" escape="true" name="nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" id="ixv-31181"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, prepayment, other receivables and
deferred IPO cost, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_2" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, prepayment, other
receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers, prepaid
expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-31191"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Plant and equipment, net</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are
stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of <ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-35027">0</ix:nonFraction>%. <ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment-c0_cont_1" escape="true" name="nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" id="ixv-35028">The estimated useful lives of the plan and equipment are as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c289" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35029">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c290" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35030">5</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c292" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35031">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c293" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35032">10</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c294" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35033">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c295" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35034">5</ix:nonNumeric>&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c296" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35035">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="c297" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-35036">5</ix:nonNumeric>&#160;years</span></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-31235"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2" id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-31276"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete
inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes the basis
for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory would not
be reversed if market conditions improve.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-31283"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityPolicyTextBlock" id="ixv-31290"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_StockholdersEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at par value of $<ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-35037">0.01</ix:nonFraction> per ordinary share. The difference between the consideration received, net of issuance cost,
and the par value is recorded in additional paid-in&#160;capital.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-31297"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC
Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts
    with customers;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance
    obligations under those contracts;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction
    prices of those contracts;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction
    prices to its performance obligations in those contracts; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when
    each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the
    client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into
service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties. All the contracts have
commercial substance, and it is probable that the Company will collect considerations from its customers for service component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Revenue recognition (cont.)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its
revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. The Company collects payment from customer in advance for IVF treatment.
The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can be found in Note&#160;8 below.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company.
During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins, supplements
and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where a baby is born,
therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother gives birth. The
Company collects approximately <ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="nivf:RevenueRate" scale="-2" unitRef="pure" id="ixv-35038">40</ix:nonFraction>% of contract sum upfront, and remaining contract sum is collected in installments across pregnancy
period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can
be found in Note&#160;8 below.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets
and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Revenue recognition (cont.)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of
credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due
to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective
interest rate of the financial asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PostemploymentBenefitPlansPolicy-c0_cont_1" escape="true" name="us-gaap:PostemploymentBenefitPlansPolicy" id="ixv-31483"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PostemploymentBenefitPlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-31490"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources and assess performance.
The Company operates and manages in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-35039">one</ix:nonFraction> operating segment. The Company defines its CODM as Mr.&#160;Siu Wing Fund Alfred, the Company&#8217;s
Chief Executive Officer. Since the Company operates in <ix:nonFraction contextRef="c266" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-35040">one</ix:nonFraction> operating segment, all required financial segment information can be found
in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers as of June 30, 2024 and 2023
by geographical area are presented in Note&#160;13.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-31528"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-155">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, there were $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-35041">272,474</ix:nonFraction> and $ <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-35042">283,847</ix:nonFraction> million&#160;right of use (&#8220;ROU&#8221;) assets and $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="0" unitRef="usd" id="ixv-35043">313,393</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="0" unitRef="usd" id="ixv-35044">326,107</ix:nonFraction>
lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s management
believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#8220;BLR&#8221;)
minus <ix:nonFraction contextRef="c0" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" unitRef="pure" id="ixv-35045">0.125</ix:nonFraction>%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present value of the
lease payments; the rate used by the Company was <ix:nonFraction contextRef="c8" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-35046">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-35047">5.0</ix:nonFraction>% respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-31539"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the
differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not
realizable or recoverable in the future.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions
in income tax expense.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-31549"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-31588"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or
loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents
the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and
or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive
effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those
that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive
securities that were in-the-money&#160;that were outstanding during the six months ended June 30, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_RelatedPartiesPolicyTextBlock-c0_cont_1" escape="true" name="nivf:RelatedPartiesPolicyTextBlock" id="ixv-31595"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_RelatedPartiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-31602"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of
business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to
a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency
if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nivf_NonControllingInterestsPolicyTextBlock-c0_cont_1" escape="true" name="nivf:NonControllingInterestsPolicyTextBlock" id="ixv-31609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_NonControllingInterestsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-31616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks (cont.)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_5" id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_6" id="_ConcentrationRiskCreditRisk-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and two customers which individually contributed more than <ix:nonFraction contextRef="c267" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35048"><ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35049">10</ix:nonFraction></ix:nonFraction>% of trade receivable, accounted for <ix:nonFraction contextRef="c269" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35050">15</ix:nonFraction>% and
<ix:nonFraction contextRef="c270" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35051">96.3</ix:nonFraction>% of the Company&#8217;s trade receivable respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_7" id="_ConcentrationRiskCreditRisk-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than <ix:nonFraction contextRef="c271" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35052"><ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35053">10</ix:nonFraction></ix:nonFraction>% of revenue for&#160;six months ended June 30, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_8" id="_ConcentrationRiskCreditRisk-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_9" id="_ConcentrationRiskCreditRisk-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and four suppliers which individually contributed more than <ix:nonFraction contextRef="c273" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35054"><ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35055">10</ix:nonFraction></ix:nonFraction>% of trade payable, accounted for <ix:nonFraction contextRef="c275" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35056">13.6</ix:nonFraction>% and
<ix:nonFraction contextRef="c276" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35057">30.6</ix:nonFraction>% of the Company&#8217;s trade payable respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the six months ended
June 30, 2024 and 2023, one and one vendors which contributed more than <ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35058"><ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35059">10</ix:nonFraction></ix:nonFraction>% of total purchases of the Company, accounted for <ix:nonFraction contextRef="c279" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35060">15.3</ix:nonFraction>% and
<ix:nonFraction contextRef="c280" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-35061">21.5</ix:nonFraction>% of the Company&#8217;s total purchases respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-31690"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net,
loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that
approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221;
requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221;
defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents,
accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify
as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such
instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined
as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs
    to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are
    observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-31759"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements adopted </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2019, the FASB
issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,
and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB issued ASU 2019-05,
Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair value option to
be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until December 15,
2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected
credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial
asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets
measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures
such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected
to be collected by using an allowance for expected credit losses. The Company already adopted the new standard and the Company recognizes
the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="ixv-31766"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements not yet adopted</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November 2023, the FASB
issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in ASU 2023-07 improve financial
reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable
investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit
or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources.
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed
under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure requirements. The amendments in ASU
2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December
15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that
the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3" id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2023, FASB issued
Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU 2023-09&#8221;). The amendments
in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure
of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations,
to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income
tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain
categories that are equal to or greater than a specified quantitative threshold of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-35062">5</ix:nonFraction>%. ASU 2023-09 also requires disclosure of, on an
annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions,
including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to
or greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-35063">5</ix:nonFraction>% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods
beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update
on the Company&#8217;s consolidated financial statements and related disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsAndNontradeReceivableTextBlock" id="ixv-31802"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 &#8212;&#160;ACCOUNTS RECEIVABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-35064">Accounts receivable, net consists of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-35065">172,493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd" id="ixv-35066">9,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-35067">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-35068">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35069">172,475</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35070">9,374</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="ixv-35071">As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35072">172,475</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35073">9,374</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35074">172,475</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-35075">9,374</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" id="ixv-35076">The movement of allowances for expected credit
loss is as follow:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35077">19</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35078">26</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal (provision) of provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-35079">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-35080">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35081">18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35082">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-31965"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;INVENTORIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-35083">Inventories consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-35084">102,825</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd" id="ixv-35085">126,264</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-35086">102,825</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-35087">126,264</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-32035"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES
AND DEFERRED IPO COST, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-35088">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-35089">359,035</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-35090">15,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositAssets" scale="0" unitRef="usd" id="ixv-35091">131,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositAssets" scale="0" unitRef="usd" id="ixv-35092">123,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Prepayment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-35093">213,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-35094">4,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-35095">373,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-35096">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-35097">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-35098">703,897</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-35099">517,429</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" id="ixv-35100">The movement of allowances for expected credit
loss is as follow:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-35101">14</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-35102">141</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal of provision (Provision)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" scale="0" unitRef="usd" id="ixv-35103">127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-35104">14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowancesForExpectedCreditLoss" scale="0" sign="-" unitRef="usd" id="ixv-35105">14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-32217"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;PLANT AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-35106">Plant and equipment, net consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35107">85,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35108">92,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35109">247,229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35110">250,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35111">765,081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35112">844,809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35113">142,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35114">142,936</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35115">138,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35116">150,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35117">1,379,482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-35118">1,481,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-35119">1,219,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-35120">1,319,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-35121">159,931</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-35122">162,157</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation expenses for the&#160;six
months ended June 30, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-35123">12,619</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-35124">19,461</ix:nonFraction>, respectively. No loss on disposal of assets for the six months ended June
30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-hidden: hidden-fact-163">No</span></span> impairment loss was recorded for the&#160;six
months ended June&#160;30, 2024, and 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-32362"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;ACCRUED LIABILTIES AND OTHER PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-35125">Accrued liabilities and other payables consist
of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_2" id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-35126">183,071</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-35127">43,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-35128">4,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-35129">7,349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">14,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" unitRef="usd">144,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued legal and professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-35132">2,699,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">--</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-35133">114,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-35134">46,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-35135">315,696</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-35136">241,613</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"/> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-32461"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;CONTRACT LIABILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="ixv-35137">Contract liabilities consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c0_cont_2" id="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-35138">7,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-35139">1,360,168</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-35140">37,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" scale="0" unitRef="usd" id="ixv-35141">112,006</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Recognized to revenue during the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-35142">7,937</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" sign="-" unitRef="usd" id="ixv-35143">122,662</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:ContractWithCustomerRefundLiability" scale="0" unitRef="usd">1,341,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-35145">37,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-35146">7,937</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<ix:continuation id="_ContractWithCustomerAssetAndLiabilityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"/> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_11_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-32573"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has various
operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#8217;s management
believes that the interest rate of <ix:nonFraction contextRef="c307" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-35147">6.6</ix:nonFraction>% and <ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-35148">5</ix:nonFraction>% was the most indicative rate of the Company&#8217;s borrowing cost for the calculation
of the present value of the lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024 and December 31, 2023, the
right-of-use&#160;assets totaled $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="nivf:OperatingLeaseRightOfUseAssets" scale="0" unitRef="usd" id="ixv-35149">272,474</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:OperatingLeaseRightOfUseAssets" scale="0" unitRef="usd" id="ixv-35150">296,742</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfLeaseLiabilitiesTableTextBlock" id="ixv-35151">As of June&#160;30, 2024 and December 31,2023,
lease liabilities consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-35152">199,297</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-35153">207,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-35154">114,096</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-35155">118,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-35156">313,393</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-35157">326,107</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-35158">Other lease information is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c8" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-35159">0.67</ix:nonNumeric>years</td><td style="width: 1%; text-align: left"/><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-35160">0.92</ix:nonNumeric>years</td><td style="width: 1%; text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-35161">5</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-35162">5</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-35163">100,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="0" unitRef="usd" id="ixv-35164">114,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-35165">The following is a schedule
of future minimum payments under operating leases as of June 30, 2024:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-35166">199,654</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-35167">79,079</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Between 2 to 3&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-35168">35,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-35169">313,751</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-35170">358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities, net
    of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-35171">313,393</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-32757"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Ordinary shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As at June&#160;30, 2024,
the Company is authorized to issue <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-35172">5,000,000</ix:nonFraction> ordinary shares. Each ordinary share is entitled to <ix:nonNumeric contextRef="c0" name="us-gaap:CommonStockVotingRights" id="ixv-35173">one</ix:nonNumeric> vote. The holders of ordinary shares
are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 3, 2024, the Company
completed the business combination with A SPAC I Acquisition Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity of the Company
as of June&#160;30, 2024 and December 31, 2023 represents <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35174">10,149,386</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-35175">698,123</ix:nonFraction> ordinary shares amounting to $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-35176">101,494</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-35177">6,981</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="ixv-32774"><i>Subscription receivables</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_2" id="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35178">2,967,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35179">319,872</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">2,866,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" scale="0" unitRef="usd">219,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-35182">4,506,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35183">7,473,791</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35184">2,967,100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_3" id="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"/> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_12_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional <ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-35185">41,830</ix:nonFraction> ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-35186">961,538</ix:nonFraction>, of which other borrowings of $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherBorrowings" scale="0" unitRef="usd" id="ixv-35187">641,025</ix:nonFraction> and $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherBorrowings" scale="0" unitRef="usd" id="ixv-35188">641</ix:nonFraction> settlement was offset with consideration as partial settlement and $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35189">319,872</ix:nonFraction> was subscription receivable due from Seazen.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"/> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January&#160;18, 2023, the Company received $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmountOfRegulatoryAssistanceReceived1" scale="0" unitRef="usd" id="ixv-35190">192,308</ix:nonFraction> from Seazen, reducing the subscription receivable by $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35191">192,308</ix:nonFraction>. On January 10, 2023, the Company issued and allotted additional <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-35192">27,293</ix:nonFraction> ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35193">812,573</ix:nonFraction>. On December 4, 2023, the Company issued and allotted additional <ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-35194">69,000</ix:nonFraction> shares to DoubleClick Services Limited at $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-35195">2,054,283</ix:nonFraction>. Among the subscription receivable during the year, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35196">27,320</ix:nonFraction> was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock" id="ixv-32875"><i>Additional paid-in capital</i></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_2" id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-35197">4,324,834</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c314" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-35198">1,458,941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c316" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="nivf:IssuanceOfSharesAdditionalpaidincapital" scale="0" unitRef="usd">2,865,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c315" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" scale="0" unitRef="usd" id="ixv-35200">4,267,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-35201">57,821</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-35202">4,324,834</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"/> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><ix:footnote id="ix_13_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares" id="ixv-35203">41,830</ix:nonFraction> ordinary shares to Seazen, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAdditionalCapital" scale="0" unitRef="usd" id="ixv-35204">961,120</ix:nonFraction>. On January 10, 2023, the Company issued <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-35205">27,293</ix:nonFraction> ordinary shares to professional party for consulting service of <ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-35206">10</ix:nonNumeric> years, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35207">812,300</ix:nonFraction>. On December 4, 2023, the Company issued additional <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-35208">69,000</ix:nonFraction> shares to DoubleClick Services Limited for consulting service of <ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-35209">10</ix:nonNumeric> years, increasing the additional paid-in capital by $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd" id="ixv-35210">2,053,593</ix:nonFraction>.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-32955"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE BENEFIT PLANS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c318" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-35211">5</ix:nonFraction>% of the employees&#8217;
basic salaries on monthly basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE BENEFIT PLANS (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><ix:continuation id="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession had been determined
by the Government which saw the standard amount <span style="-sec-ix-hidden: hidden-fact-173">THB750</span> per month per person reduced to <span style="-sec-ix-hidden: hidden-fact-174">THB450</span> per month per person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once registered, the business
must pay to the NSSF:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c320" decimals="3" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-35212">0.8</ix:nonFraction>% of each worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c321" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-35213">0.40</ix:nonFraction> and $<ix:nonFraction contextRef="c322" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-35214">2.40</ix:nonFraction> per month per worker) for the Occupational Risk Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to <ix:nonFraction contextRef="c323" decimals="3" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-35215">2.6</ix:nonFraction>% of a worker&#8217;s monthly average wages (between $<ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-35216">1.30</ix:nonFraction> and $<ix:nonFraction contextRef="c325" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-35217">7.80</ix:nonFraction> per month per worker) for the Health Care Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of <ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="nivf:ContributableWageRate" scale="-2" unitRef="pure" id="ixv-35218">2</ix:nonFraction>% (total of <ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="nivf:ContributableWageTotalRate" scale="-2" unitRef="pure" id="ixv-35219">4</ix:nonFraction>%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-172">KHR400,000</span> (approximately $<ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-35220">100</ix:nonFraction>) up to <span style="-sec-ix-hidden: hidden-fact-171">KHR1,200,000</span> (approximately $<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitRef="usd" id="ixv-35221">300</ix:nonFraction>).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at <ix:nonFraction contextRef="c329" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-35222">15</ix:nonFraction>% and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ManagementAndServiceFeesRate" scale="-2" unitRef="pure" id="ixv-35223">8</ix:nonFraction>%, respectively
of the employees&#8217; basic salaries on monthly basis.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-33046"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION FOR INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cayman Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" name="nivf:ProfitTaxDescription" id="ixv-35224">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived
from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the HK SAR
profits tax is calculated at <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-35225">8.25</ix:nonFraction>% on the first HK$<ix:nonFraction contextRef="c330" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" unitRef="hkd" id="ixv-35226">2</ix:nonFraction>&#160;million of the estimated assessable profits and at <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" scale="-2" unitRef="pure" id="ixv-35227">16.5</ix:nonFraction>% on the remaining estimated
assessable profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" scale="-2" unitRef="pure" id="ixv-35228">20</ix:nonFraction>%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" unitRef="pure" id="ixv-35229">15</ix:nonFraction>%, except for dividends, which is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-35230">10</ix:nonFraction>%, while other rates may apply under
the provisions of a double tax treaty (DTT).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION FOR INCOME TAXES (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard rate of corporate
income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and large taxpayers is <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-35231">20</ix:nonFraction>%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from <ix:nonFraction contextRef="c331" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-35232">0</ix:nonFraction>% to <ix:nonFraction contextRef="c332" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-35233">20</ix:nonFraction>%. In
view of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-185">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-186">KHR6</span>&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Profit tax is calculated
at a rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" unitRef="pure" id="ixv-35234">10</ix:nonFraction>% of aggregate annual income less allowed deductions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-35235">Significant components of
the provisions for income taxes for the six months ended June 30, 2024, and 2023 were as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-35236">83,727</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-35237">83,727</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION FOR INCOME TAXES (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-33213"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Income/(loss) before taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-35238">387,781</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-35239">295,060</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax expenses/(credit) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-35240">69,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-35241">114,645</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="0" sign="-" unitRef="usd" id="ixv-35242">509</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-35243">42,924</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" unitRef="usd" id="ixv-35244">206,496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Tax effect on utilization of tax losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" unitRef="usd" id="ixv-35245">26,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" sign="-" unitRef="usd" id="ixv-35246">8,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-35247">83,727</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax asset, net</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-35248">Significant components of deferred tax assets,
net were as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-35249">28,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-35250">28,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-35251">28,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-35252">28,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, the Company had net operating loss carry forward of $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-35253">164,721</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-35254">164,721</ix:nonFraction>. The Company believes it is less likely
than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As
a result, the Company provided <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:PercentageOfAllowanceOnDeferredTaxAssets" scale="-2" unitRef="pure" id="ixv-35255">100</ix:nonFraction>% allowance on deferred tax assets on net operating loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="nivf_DissagregattedRevenuesTextBlock-c0_cont_1" escape="true" name="nivf:DissagregattedRevenuesTextBlock" id="ixv-33360"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED REVENUES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ixv-35256">The Company&#8217;s main business operations
are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35257">2,380,576</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35258">1,869,987</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy, ancillary caring and other
    services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c341" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35259">306,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35260">268,635</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35261">2,686,902</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35262">2,138,622</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED REVENUES (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="nivf_DissagregattedRevenuesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-33445"><b>Geographical information</b></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35263">3,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35264">1,267,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35265">1,426,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35266">306,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35267">270,655</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c348" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35268">1,109,516</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35269">441,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35270">2,686,902</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-35271">2,138,622</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenueTableTextBlock-c0_cont_1" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-35272">The revenue information above is based on the
locations where the revenue originated.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisaggregationOfRevenueTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35273">1,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35274">584</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35275">132,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35276">137,472</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35277">300,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35278">307,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35279">434,371</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-35280">446,004</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-33582"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounts receivable</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of
June 30, 2024 and December&#160;31, 2023 is $<span style="-sec-ix-hidden: hidden-fact-188">Nil</span> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" unitRef="usd" id="ixv-35281">19</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS (cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash and cash equivalents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company assessed the
impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating
and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables,
due from shareholders and loan to A SPAC I as of June 30, 2024 is $<ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-35282">14</ix:nonFraction>, $<span style="-sec-ix-hidden: hidden-fact-189">Nil</span> and $ <span style="-sec-ix-hidden: hidden-fact-190">Nil</span>, respectively. The loss allowance for deposits
and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-35283">14</ix:nonFraction>, $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" scale="0" unitRef="usd" id="ixv-35284">17,818</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-191">Nil</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">B.&#160;Interest
risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash flow interest rate risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure" id="ixv-35285">1</ix:nonFraction>% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably possible change
in interest rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If interest rates had been
<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nivf:InterestRateOtherVariablesPercentage" scale="-2" unitRef="pure" id="ixv-35286">1</ix:nonFraction>% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;six months ended June
30, 2024 and 2023 would have increased or decreased by approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-35287">1,202</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPensionPlanObligations" scale="0" unitRef="usd" id="ixv-35288">773</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. Interest risk (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result of a change in foreign
currency exchange rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s monetary
assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional currencies of the relevant
group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company
currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related
foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">C. Economic and
political risks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">D. Inflation risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements; however,
significant increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the Company&#8217;s
results of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-33742"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED PARTY BALANCES AND TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-35289">The summary of amount due from and due to related
parties as the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c354" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-35290">Shareholders and directors (note 1)</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-35291">354,285</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c354" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-35292">Shareholders and directors (note 1)</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-35293">221,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock-c0_cont_1" escape="true" name="nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" id="ixv-35294">The balance due from shareholders consist of
the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Due (to) from shareholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholder" scale="0" sign="-" unitRef="usd" id="ixv-35295">221,203</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:DueFromShareholder" scale="0" unitRef="usd" id="ixv-35296">372,103</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" scale="0" unitRef="usd" id="ixv-35297">17,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="nivf:OtherReceivablesNet" scale="0" sign="-" unitRef="usd" id="ixv-35298">221,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nivf:OtherReceivablesNet" scale="0" unitRef="usd" id="ixv-35299">354,285</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED PARTY BALANCES AND TRANSACTIONS&#160;(cont.)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_SummaryOfValuationAllowanceTextBlock-c0_cont_1" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-35300">The movement of allowances for expected credit
loss is as follow:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_SummaryOfValuationAllowanceTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35301">17,818</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35302">17,059</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-35303">759</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Revised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nivf:AllowanceForExpectedCreditLossRevised" scale="0" unitRef="usd" id="ixv-35304">17,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-35305">17,818</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-35306">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Mr.&#160;Siu Wing
    Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c357" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-35307">95,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-35308">60,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-35309">95,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="nivf:TransactionsWithRelatedParties" scale="0" unitRef="usd" id="ixv-35310">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NEWGENIVF GROUP LIMITED<br/>
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2024 AND 2023<br/>
(Stated in US Dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-34042"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;<span style="text-transform: uppercase">CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2024 and
2023, the Company was not a party to any legal or administrative proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">First Fertility Bishkek
LLC (&#8220;FFB&#8221;), the Company incorporated in Kyrgyzstan, did not report the current year tax &#160;&#160;to the tax authority
till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of June 30, 2024. Since FFB had no profit
for the six months ended June 30, 2024, the tax department may not issue tax return at current tax position. The tax return is not yet
filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible amount of tax penalty.
The contingent tax penalty is reasonably possible and estimated at $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="0" unitRef="usd" id="ixv-35311">486,706</ix:nonFraction>. Thus, no provision was made. Except the potential tax issue,
the Company concludes that there was no contingent liability, either individually or in the aggregate, that could have resulted in an
unfavorable outcome with a material adverse effect on the Company&#8217;s results of operations, consolidated financial condition, or
cash flows.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-34055"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;<span style="text-transform: uppercase">segment
information</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company uses the management
approach to determine reportable operating segments. The management approach considers the internal organization and reporting used by
the Company&#8217;s CODM, specifically the Group&#8217;s CEO and CFO, for making decisions, allocating resources and assessing performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses by nature as a whole.
Based on the management&#8217;s assessment, the Group determines that it has only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="nivf:NumberOfOperatingSegment" scale="0" unitRef="pure" id="ixv-35312">one</ix:nonFraction> operating segment and therefore <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" unitRef="pure" id="ixv-35313">one</ix:nonFraction> reportable
segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be found in these
consolidated financial statements.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-34068"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC Topic
855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of events that occur after
the balance sheet date but before consolidated financial statements are issued, the Company evaluated all events or transactions that
occurred after June 30, 2024, up through the date the Company</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 180; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">F-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="nivf:LoanToASPAC" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-2" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-4" name="nivf:LoanToASPAC" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-5" name="us-gaap:OtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="nivf:DueToShareholders" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-10" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="us-gaap:ConvertibleDebtNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="us-gaap:ProfessionalFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-13" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-14" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-15" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-16" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-17" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-18" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-20" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-22" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-24" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-25" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-26" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-27" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-29" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-30" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-31" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-32" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-33" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-34" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-35" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-36" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-37" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-38" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-39" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-40" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-41" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-42" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-46" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-47" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-48" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-49" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-50" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-51" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-52" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-53" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-54" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-55" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-56" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-57" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-58" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-59" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-60" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-61" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-62" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-63" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c66" id="hidden-fact-64" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c67" id="hidden-fact-65" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-66" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c70" id="hidden-fact-67" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c66" id="hidden-fact-68" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c67" id="hidden-fact-69" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-70" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c69" id="hidden-fact-71" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c66" id="hidden-fact-72" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-73" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c69" id="hidden-fact-74" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c70" id="hidden-fact-75" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c72" id="hidden-fact-76" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-77" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-78" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-79" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c85" id="hidden-fact-80" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-81" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-82" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-83" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-84" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c88" decimals="INF" id="hidden-fact-86" name="us-gaap:CommonStockSharesOutstanding" unitRef="shares">10149386</ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-87" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-88" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-89" name="us-gaap:InterestExpenseDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-90" name="us-gaap:InterestExpenseDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-91" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-92" name="nivf:WaiverOfRelatedPartyBalance" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-93" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-94" name="us-gaap:LegalFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-95" name="us-gaap:LegalFees" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-96" name="us-gaap:OtherNoncashIncomeTaxExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-97" name="us-gaap:OtherNoncashIncomeTaxExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-98" name="us-gaap:IncreaseDecreaseInFinanceReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-99" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-100" name="nivf:ProceedsFromAmountDueFromASPACI" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-101" name="nivf:ProceedsFromAmountDueFromASPACI" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-102" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-103" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-104" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-105" name="nivf:PaymentofInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-106" name="nivf:PaymentofInterest" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-107" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c2" id="hidden-fact-108" name="us-gaap:LesseeOperatingLeaseTermOfContract">P12M</ix:nonNumeric>
<ix:nonFraction contextRef="c108" id="hidden-fact-109" name="us-gaap:ConcentrationRiskPercentage1" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-110" name="us-gaap:ConcentrationRiskPercentage1" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-111" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-112" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-113" name="nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-114" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-115" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-116" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-117" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-118" name="us-gaap:ContractWithCustomerRefundLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-119" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c176" id="hidden-fact-120" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:footnote id="ix_4_footnote" xml:lang="en-US">On January 18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald FAN and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Subscription Receivables-->
<ix:nonFraction contextRef="c180" id="hidden-fact-121" name="nivf:StockIssuedDuringPeriodValueDirectorsRemuneration" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c193" decimals="0" id="hidden-fact-122" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">1200000</ix:nonFraction>
<ix:nonFraction contextRef="c192" decimals="0" id="hidden-fact-123" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">400000</ix:nonFraction>
<ix:nonFraction contextRef="c184" decimals="0" id="hidden-fact-124" name="us-gaap:SpecialAssessmentBond" unitRef="thb">750</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="0" id="hidden-fact-125" name="us-gaap:SpecialAssessmentBond" unitRef="thb">450</ix:nonFraction>
<ix:nonFraction contextRef="c198" id="hidden-fact-126" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c200" id="hidden-fact-127" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c202" id="hidden-fact-128" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-129" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-130" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-131" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-132" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-133" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-134" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-135" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-136" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-137" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-138" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-139" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-140" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-141" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-142" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c157" decimals="-9" id="hidden-fact-143" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="khr">1000000000</ix:nonFraction>
<ix:nonFraction contextRef="c156" decimals="-9" id="hidden-fact-144" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="khr">1000000000</ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-145" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c212" id="hidden-fact-146" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c222" id="hidden-fact-147" name="us-gaap:AssetsNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c223" id="hidden-fact-148" name="us-gaap:AssetsNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-149" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-150" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-151" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c239" id="hidden-fact-152" name="nivf:DueToRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c247" id="hidden-fact-153" name="nivf:TransactionsWithRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c248" id="hidden-fact-154" name="nivf:TransactionsWithRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c8" id="hidden-fact-155" name="us-gaap:LesseeOperatingLeaseTermOfContract">P12M</ix:nonNumeric>
<ix:nonFraction contextRef="c299" id="hidden-fact-156" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-157" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-158" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-159" name="nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-160" name="nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c301" id="hidden-fact-161" name="nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-162" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-163" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-164" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-165" name="us-gaap:ContractWithCustomerRefundLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c311" id="hidden-fact-166" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c311" id="hidden-fact-167" name="nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c312" id="hidden-fact-168" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c315" id="hidden-fact-169" name="nivf:IssuanceOfSharesAdditionalpaidincapital" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c316" id="hidden-fact-170" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c328" decimals="0" id="hidden-fact-171" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">1200000</ix:nonFraction>
<ix:nonFraction contextRef="c327" decimals="0" id="hidden-fact-172" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="kzt">400000</ix:nonFraction>
<ix:nonFraction contextRef="c319" decimals="0" id="hidden-fact-173" name="us-gaap:SpecialAssessmentBond" unitRef="thb">750</ix:nonFraction>
<ix:nonFraction contextRef="c8" decimals="0" id="hidden-fact-174" name="us-gaap:SpecialAssessmentBond" unitRef="thb">450</ix:nonFraction>
<ix:nonFraction contextRef="c333" id="hidden-fact-175" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c335" id="hidden-fact-176" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c336" id="hidden-fact-177" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c337" id="hidden-fact-178" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c338" id="hidden-fact-179" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-180" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-181" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-182" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-183" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-184" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" decimals="-9" id="hidden-fact-185" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="khr">1000000000</ix:nonFraction>
<ix:nonFraction contextRef="c307" decimals="-9" id="hidden-fact-186" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="khr">6000000000</ix:nonFraction>
<ix:nonFraction contextRef="c344" id="hidden-fact-187" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-188" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-189" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c353" id="hidden-fact-190" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-191" name="us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c355" id="hidden-fact-192" name="us-gaap:OtherReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c356" id="hidden-fact-193" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-194" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-195" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c301" id="hidden-fact-196" name="nivf:AllowanceForExpectedCreditLossRevised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-197" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-35515">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-35516">0001981662</ix:nonNumeric>
<ix:nonNumeric contextRef="c132" name="nivf:PropertyPlantAndEquipmentEstimatedUsefulLive" id="ixv-35517">the lesser of useful life or term of lease</ix:nonNumeric><!--From Schedule of Estimated Useful Lives of the Plant and Equipment with text 'the lesser of useful life or term of lease'-->
<ix:nonNumeric contextRef="c291" name="nivf:PropertyPlantAndEquipmentEstimatedUsefulLive" id="ixv-35518">the lesser of useful life or term of lease</ix:nonNumeric><!--From Schedule of Estimated Useful Lives of the Plant and Equipment with text 'the lesser of useful life or term of lease'-->
</ix:hidden>
<ix:references><link:schemaRef xlink:href="nivf-20240630.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact ix_2_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact hidden-fact-118" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact hidden-fact-120 hidden-fact-167 ix_17_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-121 ix_7_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_8_fact ix_9_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_12_fact" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_13_fact ix_14_fact" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-165 ix_15_fact" toRefs="ix_11_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-166 ix_16_fact" toRefs="ix_12_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-169 ix_18_fact" toRefs="ix_13_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SupplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:VendorTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:VendorTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-15</xbrli:startDate>
    <xbrli:endDate>2022-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-18</xbrli:startDate>
    <xbrli:endDate>2023-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-04</xbrli:startDate>
    <xbrli:endDate>2023-12-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-15</xbrli:startDate>
    <xbrli:endDate>2022-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-10</xbrli:startDate>
    <xbrli:endDate>2023-01-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-04</xbrli:startDate>
    <xbrli:endDate>2023-12-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFiifyqnzc90xzUGes+z8h8yG+N9tEDBSR0=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-29</xbrli:startDate>
    <xbrli:endDate>2024-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:TranchesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:TranchesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-29</xbrli:startDate>
    <xbrli:endDate>2024-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:OneVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:OneVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001981662</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="thb">
  <xbrli:measure>iso4217:THB</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="kzt">
  <xbrli:measure>iso4217:KZT</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="hkd">
  <xbrli:measure>iso4217:HKD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="khr">
  <xbrli:measure>iso4217:KHR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>2
<FILENAME>ea021944701ex23-2_newgen.htm
<DESCRIPTION>CONSENT LETTER FROM ONESTOP ASSURANCE PAC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; padding-bottom: 4pt"><IMG SRC="ex23-2_001.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.75pt; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><B>Onestop
                                            Assurance PAC</B></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Co.
                                            Registration No.: 201823302D</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>10
                                            Anson Road #06-15</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>International
                                            Plaza</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Singapore,
                                            079903</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Email:
                                            audit@onestop-ca.com</B></FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Website:
                                            www.onestop-ca.com</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 340.35pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.5pt 0pt 55.25pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the inclusion in this Registration Statement on Form
F-1 of NewGenIvf Group Limited of our report dated August 16, 2024, relating to the consolidated balance sheet of NewGenIvf Limited and
its subsidiaries as of December 31, 2023, and the related consolidated statement of operations and comprehensive income, changes in shareholder&rsquo;s
equity, and cash flows for the years ended December 31, 2023 and the related notes. We also consent to the reference to us under the heading
&ldquo;Experts&rdquo; in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">/s/ OneStop Assurance PAC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex23-2_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 387.45pt; margin-bottom: 0pt">Singapore<BR>
 October 31, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P +(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^^QKEP?EC
MB([DW&,#UP(F/O5*_N$GMI(/+21W,9VDS>4-LJ.69TC5\)M+81225QT)ISSB
MWM_.=8C@@$QL./F .#M<G ()VC"X.XA<N..UCQ3H]C ]S<ZSIMI'!)"]P]]X
MBTJ"UBMQ<1+-)-NG!6,1%E7"LV\J-N3BNW#X:K6LZ4%&;:5*3C.<55?P*<8-
M2DN:UXIQE*Z2U.&KC<-@7"KB,=A\+&7O2EFF<Y1E'U6"4I.O.&*K86LXTDN>
M7+4C)):2BVF_FF^^)/QA\<^/?&/A?X06O@+PSX:^'FHVVA:_XV\<V6KZU'K/
MB.33+?4+[0])T6QN=/EC&CK>V(GO9-3F-PTSA+.(1$O/KUQ^USX0TB^\6IJ'
MP9\>PZ):3:L_A72O"GB3PYJ?B"ULXFGNK/3=6N-:UM+&[:U25[9KC2Y?/E1+
M91&TPGC9^RG)%K5E\9?&T,32^&?%_P :_%FO>%M0C1DM=:TRUM-%\.G7;6'S
M)':#4[S2;FYCE9466*-)?+2-P3]-WDUBFE:M'97L,]X;*^=_],M9YDF%M+)$
M\L;W&^/9)L**$9MX&XCBO>S#'2IXRE@<-EV61PE/#4</C:CR['5*U:K4^JTZ
MM66,KU9RPU>3JU7.3C3C2E;V%&*46?CF08+&<2<,X;BS%\:<>4,VS&IQ+FU)
MRXFHY+@<MHX6KFU#*,#AN&51QF$SC+:#P6%Q=*KC76P^84*BGF%>>$K2I*E\
M-?B'IGQ*\&^%/'.BVQAT7Q?H>G>(=*6>X)N(EU*S$TEE- ]O&T5U:RF:">,9
M5'1R" 0I[U+UI658X=QW8DS)M,:F-G5@-AWY9=A'RXR#GH#\=?LC366D_LU?
M!:=Y[>)Y/#$$8EU2^5)%N%NKX2)$I4/=SQPPR2,4A_>;L[8XU+GZRL]4L]1>
M-K&:*ZC\UHY)K>:+;"ZQDE9HQ^]4D,QC!7H021\RKYN>Y>L!G&:8;"4IRP6$
MSK.,%"4^9\E#!9AC\/1A*5[SE&E2I0YI34YSAS./O-2_0>$N(*N:\.</U<VQ
M.44L_P QR#)<RG@<+F^ K8Z:>6Y?B,;BL7AX5%"E+&5)U:RI8>C&FH5I1PRC
M&-/DWO,[  L!TS^F<?TY[=LAD((&WDYXSZ?AG]*HBZC$K1%0H4X,A.% )VJ2
MQPN6?:H3.22,$Y!H-WS&JJJLQ;B25%)4!B6'EM*<8' V\\YQR1Y$HRU2IS3<
M6TW:RNFT[W:\[;GUTHU8/DJ2I4YN+K_$N948ZRLF]4HWO*UUOYJ^&8\%,'Z_
MX@4C.1GY<D>^,_I^-1;S\N"64]&4Y (!SG."/3H>3R!D9=(1M ;/('0;F/(Q
M@=?KZ<]AFI2MRJ;5];[]-U;35>0.\8J46JJG;D2<;-O975MW;7L/#L?X5_[[
MQ_-13@V3C _[Z!_2JN43&3\Q*C&X _,P4 $D#)8@*#C<Q !)(%/C<,^U0V58
MJX)&Z,[2?G!(.#P%*[LY&/E!().SLH2DMG)+1>;N]E<$ZKLY0IPUVY[OY)M:
M]MTRS36;:I(&<8X_''O3JBF8I&6!4$%!EF"CYG5>I[G. .Y( Y--*[2WNTK#
M:NFE)1;5E)V2CYMO2RW=].XCR2#&R+>#CD/C&1W^4]._X>O#@[$<J V<;0V>
M^#S@8QUY'-5'#.5P"O9B&3"Y!() ?=AC@#"D GJ ,TXN(EP?F.5!(W8!8A5)
MX) R0"<' ^8X&324HR<H)2C**?,TFW'L^J?E9._;4S<ZJYDZ,%"FN9UO:-QF
MDKMK6RTZ[(L>9R1MY'3YAS^G^<CU%*')*@KM+9XSG& 3Z#T]JH"Z7>P9$4!0
MQE$@,1&Y4.V3:-S;F50I5=S$*""1B6*<.\ $9Q(9 260["JL5! <_?4$C;D@
M?> [0N6ZM5J/;1P5G=75W[-63W>J?;0K]Y&:I25)5)1=96FK^R6KLKZNVB=M
M2]1115EA1110 4444 ?%O[1%K-XT\:_"'X4:A?7^G^"_%FJ^-=1\76^D7%Q9
MWFLZ=X(\/S:Y::%]IMY8I[:TU#5$M#J$D<CM-91W%D4_TDSP;.F_LH_L[Z=)
M:+;?"#P4/L[->VZR6,TKI:NC!;C$JLAN)0=LR--N(<EF8Y)J?M!R:QX/\:?"
M3XM:=X:UKQAH_@#5_%<'BG0_#=K)?^(%T;QCI$FC-J^G:?%&[ZHVCSM;7.H:
M;&(Y9=,DNKF.<-9^3<=!X:_:9^%GC#7-)\.:%-XT&I>()B--^V_#OQ_96WFS
MQ2%OM6I7V@0:79*A#Q-'>7,*J<>7(\I5&^KE/-/[-PM;+J=3ZK0A[;$8BG4E
M35"$9N=>O)TFJJK4X_O(3ET4>5Q<7S?AS7 F(XPXNPG&W]E5,SI\6X>ED,\\
M5*O-Y1B<BX36 P^%I8G)<?&M&6>5,YY'&N\3*MB)476Y*6'IT/'-<\'CXV?&
MOQ+\(M3U74O"WP>^#WAKP)J2^!/"5Q)H=OXNUOQ;9:K<VR:QJFF/8W=KH_AU
M+!HK31+)5M[C4%M[^>9([62PNO6++]G#X,^ _M'BGPS\/M#TWQ#I=G=)8ZS%
M)J!NE.H:=<:?)*UQ<SZA<323)>26KN\F"9B[F-=S)YAJWBBX^"G[1'Q'\6>(
MO"?C?6?!_P 1_#W@.#3=;\(>%]4\4?V?K_@Z'Q';ZEIVLZ;HEO?:A:6EY%?V
MUU:ZD8/+,]Q'8F %9+A.EU_]JOPG>:!J&G>'/A_\9-7UJ>SEATG28_A7XWTX
MZGJ,@VVU@U_JV@V^GV<5S,5B>[N9XT@C=Y DCJL;^E6_MZ=/ 8; O$U<HE'#
M5\5!XN5.BU.=&KC:U62JQE6FYI^U==S?*DG)+FM\[0Q_A[3H\38OCC%9=B.)
ML3G'&2IXK%87.<RQN3X2&=YWEW"& R9RR+%+ 8662X/!X6E@\MPD\-*525:6
M'Q->3JO$_9]^&7@3XE_LK? ^V\;^%=&\7)IOA:VN=/M-?MS=0"ZN9-2MGD=2
MDD;,(E86[&W/V>6*.=7$R1RIG>,/ASX=^!/Q%^#/BSX6:=;^#8/%?Q&T7X>>
M-/#^B7%Y#X:UC3/$6@^)Y+6^GT61VM/[0TRXL89H+^W<33M%LG$#/DR_"+XR
M?#'X)?#KP-\)?%WB&XN/&/@CPII^E^)=&\-:#XB\63:3K02X>]T>[NO"6G:Y
MI]MJ<%Q<362V%Q>1W4MS$K(B+,%IWB/QW!^T)X_^$_AWX?\ AWQC'X<\"_$/
M2_B)XL\:^)?"GB#PIHEHFE:+XFCM/#.GQ^)=-TF[U37=2U'4;=+F&TB>+2[2
M&>])N5@:%]<1]??$N;5:DX++,1CN(,14=1P^K3IXNCG]>7LY5I<LG7JK#U<-
MR1YIU.25%^]&,N;#XKA+$\#<*Y;@J?#V)\0YTO#G*I4\EP>(P_$-/BK+:/#5
M?%91F/\ 9V7SQN78?"X++N(YX[#8V67X2A@LM]IC<;*E4G0/KWQM/J5IX0\2
MWFDW']G:A:Z-J-Y:7BK!*;>6TL'N8G-O<H\,ZM(JDP,%,BG8CHQ61?D3PE\7
M?'IT/Q#\/_&7B&TLOB=X8N/!WB&SU^PTJWM-.\<?#WQ-XDTW2X?$NFZ5<&:)
M1:&]N-+U2TM;UVM-2BM@;ATN5W?6?C?1;[7?"_B+0]/D@BO-6TJYT^VDN[B6
MTMXIKBU-E(SW$<%PR%8W>6,"%@\HCC9HU8R#Q7XE? K4/B!I?PRUAM1L?#'Q
M \ >(?"VHQZMI!_T&\T>"_TA/$7A:;=#&T^A:S;V4EQ!8SQ3)8ZS'87Z&0VQ
M$GS^6U,!*C4IXMQ_>XAPA63DI4(PLU)1NXU8WC.$[J]/F3C[S5_TGC;!<33K
MX;-\DI8C$2R?)J4Y8=8B4*?$D<VJT<MQ."FG)0PM7AY599K&>&5&MB8T)4*\
MZL*T8KV*?XE>#= U :!K?B*RM[^%M(M[B><3);1W>M"9=*@N;OR%L[.ZU(P@
M6UM-,C32SPPQAGEA,C8/BYX"OX;J>S\3Z+)'9^)T\$/(=06+'BTW!M'T#$T4
M>-5$P?RK3YI)X?+GC!CFB9O$+G]GUY_&WQ)UIK3P]XETSXC>(_"'BM)-?N=3
M>3PYJ'AC3+*S@%MI7G2Z??JDEH^H:<4%BMG>/"YA9K>.<9/C;]FEO$WB3XE7
M^F^(;/3=%\7_ /"/>+?#.DPZ>/,\-_%_1;&WTNU\>6\T4UOO+Z=IMO'<Z<54
MW-S!/<M=1RS[8]UE_#]>=*-7'UHRG"#J5.5<E.3=!3]R-IIWJU-)/2.'J2M:
M43DQ6>>(6$P=:&%X:A)4LTQ^#P\55<Y?5Z-+/Z>%FY3G*4HJID>'QDFG*K*E
MQ!EV'3=;+LPY^\^(WQA-KK/@3P)X1U2RB\0^//'&I>$3J-S;SW1T6#PWI,^O
M^([XVCPQQ7%[;VEM%96MM)<PJ+R_CG:<K9/#-W6@V.O^&M?O]1UGQO<ZOX53
M1'F33-5ALYM1T[4+24K=W;ZG;VUD\D$D+.%MG@81%"6D&Y57S_6?@]JEYH7P
MNNTU2QF\>?#3Q!!XMOM4E@:&QU_6[W2;_3_&"W2PNLMG;Z_;ZMJDT4:/<#3[
MB.P0K>0VB%\.Y^#&K^+O&OQ"\3Z[=6V@VGCGX7V_@BVL-*U?5+UK/5+N369=
M7\0VYF>TMH)-0MK^RB6UBLA-:'2HY!J$S7!$"=/*JD7A<-C'AJ=&$_K-;V-.
MM.NH8FG!1A[2$Y0C5H*4XRIN-2,+-M2;;ZZU3C&ECLXQT\B>,IU\YX=H\.8/
MZ]5IK!4)\+U<?F?MO93C*NGFM*\WBE5A%RC3@XT_=/9'^-_PVBL=6U2X\3Z9
M;Z=H>GRZUJ5Y/)<010Z#%-)"=?B6XM89;W14D18+C4M/CN[2VO)!!)+Y8^T'
M*U_XJ>&_$7A7QG#X+\46A\0:/X4'B&*2&"2:>UM;JS>_TK6(+*^MH(]1TVX2
MWG:.8$0S^2\092ZN/!Y_V:]<D^&.L>"K.R\%V>OR_".Z^$MCXEDDU2ZDO-.N
M;6&R::=I7NI](TMT%SJ%]HT/]HO>ZA)%*VIQF/<]VS^!GCS3_%VN>)DN?!L4
M&L? W1OA/:VB7NLHMOK=A/KP.HM,=*,4FBI%KSFWA%LMRSV4,1D1+HO;Z0R[
M(Z515(YHINE4A.-.7(U44)TI-/EBTU./M$E>ZLN9)Z'+B,]\1L3S9=7X-IJC
MCJ-?"5<11Q%>$J'UG#8ZG&K&<:D)1E1J?59J47J[V=D^;NO@Y\78]2\!_"!O
M&WB"SO/&OQ+\,6>N:?!Y4=E)JEU=:9<:I-%96UI:&,/:6L$JRQ1X?RHYIP/+
MB85F^.OBK<^(_&7@GX;^!O%=MX?N/&6E>.;U?$<FC7FI&WN/"ALK*QAM[.XC
ML+>5+K4YKMIW>^MRD6FJL:S#48IH,$? +QC<?!?X5>$;;Q#HOA[XE?"B;09O
M#7C"UMKR^L;8Z9;C1=9E:W\FQNECU?0+C6+7[ MQY<<U[;B2XG2)F;OYOACJ
M]K\3_AIXETJ;23X5\%^'_$NAW5E<SWJ:Q<7OB+^Q7BO8&^RR0L+0Z"B31SLC
MS?VA<W F1X1#,XQR2&(Q5:-2\U'&^QBXIPYX1K?59M3C*#]H_8QC"RM+VCDW
MRQOP9?+Q$Q'#/#F!QN6WJ/#<$QS><\1*%:K'%97D-#B53J4JE.=)RS;^VJ[=
M.4'1A4C2H<D804(_&7C;Q#;^-/A=\(],U2VM/$/C32=?UCQ%XEBLDGDM="\'
M:5:+J\^E:;,7MXI[[Q!JNCV*M+<3_8HKEI%CFDCC*]/87T_PY_X3;7?%_CJ/
M4O!FE6\&M"74X(8KOPS9V%B8_$$E[>V\1-S9Q%5NT"P121*6BY.\R9OCOX>7
MFH^-O 'Q%\-7UE'XD\ 1^(;,V&I+<+8ZWX=\4I;Q:[I<]U;EI;-S/8:?J-I<
M+;7:_;-/@BEM_*D>:'RO4O@CXOUJ'X^W;2:!97/Q?\,V'AWP_I.HZAJNH:7X
M=,^GWEAXBO;SY6AFBUE+M;U+>'3[<Q3V<5O),WG&ZAYL.\!B\'A4\12PZG@\
M'5Q;E3IJI5KU<R<,2X2E!R@XX-\T%2BX1A&48QC)Z^SBGQ/@LXS"K3RNIF&(
MIYEF\,@K?6L2J5#A>/#[>1N=*%7V%>IB>(Z?]G5GB(SK^RKPK2J.,=?==/\
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MS\K1!&'D@Y=2")02YPV!@C'.3S@XISV"R!1))OV/'(NY/XXP,$@. P+A7P>
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*6<I291110;'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &* ]T# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,^(/\
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MH@,5Y&)J\SY3[#+,*J4.9K5EA1@8IV*/2EKC/8"BBB@ HHHH **** "BBB@
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M6?+S=PQ1VQ111<K7J&:***+W"]] HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BB@=>: M<#Z]JO:79-=W:G&5!Z52"F0A!
MR2>E=[X:TL1(K%>3S7+BJO)&R/5RW#>VJ7>R-_1['R8URH&!6X.E1Q1A%QBI
M:\7=W9]DDEH@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@+!1110%@HHHH **** "BBB@ HHHH **** L%%%% !1110 4444 %%%%
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MKN/^$*C_ +S4?\(5'_>:CZW /[)K'#_A1^%=Q_PA4?\ >:C_ (0J/^\U'UN
M?V36.'_"C\*[C_A"H_[S4?\ "%1_WFH^MP#^R:QP_P"%'X5W'_"%1_WFH_X0
MJ/\ O-1];@']DUCA_P */PKN/^$*C_O-1_PA4?\ >:CZW /[)K'#_A17<?\
M"%Q_WC1_PA<?]XT?6X#_ +(K6.'R%;C/-=/X9TK>PD<<GI6FO@N-2#@G'O72
M:7I0M0G'"US5<0I+0[\!ESHRO4+]E;B&-<#%7:11P*6O//H$':EHQ12ZC"BB
MBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&_Y[BC_A.M&_Y[BO'MJ;SR  .E(%!7../4"G[5B><UUT1[%_PG6C?\]Q2?\
M"=:-_P ]Q7C^T9&X!<>O>DVC/('X4>U8_P"V*[Z(]A_X3K1_^?@4?\)UH_\
MSW%>/;1GH*7:.>!1[9B_MBO?H>UZ=XIT[5+L6UM*&D(SCVK; ZUX_P" @/\
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MJ[E__A9TG_/D?SH_X6=)_P ^1_.J'_"M]5_Y[14?\*WU7_GM%2M .3*^Y?\
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MNL&?(C_W17A6E$G5;5L\&09%>[P_ZB/_ '16U#8]O)-(R):2BBND^B%HHHH
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MX21/]PUZ_P"M=E'X3ZW*/X'S%I:2EK4]@**** "BBB@ HHHH **** "BBB@
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MJ5_:>'M>YW6:,_YQ7G__  L*7(_T;KTH_P"%A2_\^P]*/JM47]J89=3T#/\
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M&Y!(QY?]:JWFM1W-M+$ W*@#VJJ<I-DSITDG8RK'_C_BZ_C4=QQ/)]:?8?\
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ML-+CN]6^R2-@(O.VDUJQCL;P0PHX7U)JM:WL]M>-=*!N9CQ[4_4=0DU*8-(
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MU4Y %/KBK5?:RYF=5*GR1L( :,4M%8FHF*,&EHH"PF*,'UI:*5@$QFDQ3J*
M$Q1BEHI@%%%% !24M!H 2EI** "BD)QUII('?]:!#\T9IF]?4?G1O7U_6@7,
MB'4#BRE.<<4W3S_H$/TJIK+S1VIGA^=4Y>,=Z-&DFFM!/-\@?[B8Z"JTL',C
M6I*;E?[WZT%U'(-0#:'$C'K2CI48=<\4\8YQ3N.Z:T%HHI:!H2BEHH 0@TM%
M% "8HI:* "BBB@!,48I:* "DI:* $I:** "DI:* $Q1BEHH 2EHHH **** "
MDQ[4M% "<T<TM% "49I,<]:6BP@S128]Z7% !1FBD/0YH&))_JGY_A-9>@?\
M>DG.?WAZ5<OA+]D8P]0,X]:Q_#<ES.LSO%Y46\X4U:2L)WZ'19YHIHZ4M18-
M1<TE&/>C'O0%WV%HS28]Z4#WH!!1110,.:.:*6@!**6B@ Q1110 F*,4M% !
MBBBB@!**6DH$%!-)1G/2@&+VI.:!G-&/>@>POX4G-&/>C'O0*_D+111BD,**
M,44P"DI>:CF#F)O+.&[4(#/L_P#D*7#'TK4KF=,FNY]6E0J5"GYR>]=(!@54
MD"%)I0<T@I:D+#<<TZDQGO1CWH$VQ>/2BDQ[T8]Z+!=BT4F/>C'O18-1:*3'
MO2YI6 3-!S2\44P"BEHI6&)S12T4P$HI:* $HI:* $HQ2T4 )BC%+10 F*,4
MM%%@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%!H 2CO10: *FJ.T
M>FW#H<,(S@^G%>*MK^K^84_M"7CONKVG5@#I5R.WEG^5>*:/9)J6K-;,,#)V
MGUK"K?H?/YM.HI14!1K^K$X%_*/JU*=?U<<?;Y1[[JOOX8G6QSL F,NT%NBC
MUJ!?#-X9MD<L+;N?.S\N!UK#WCQW'$+6[*QU[5V _P!-F _WNM']O:MC"W\I
M] &Z5=3PG>29/GP[?7/6HQX:O0Y21HHE'\>>M%Y$VQ3ZLK_V_JXR#?39';=2
M#7M8(YO9@3_M58C\,WIB=V:-<?P$\FFR^'+R.P:Y8*BK_">IH;DM0MB5JVR+
M_A(-7)0?;9<Y'\5>SZ.[RZ5;O(Q9R@))KP<$DC'52,_G7NVBG_B3VA]4%;TI
M71Z^35:E1RYC0/%**;UIPZ5N?1+8****!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ''>)/&<FA7Z0"U+H1G=FL;_
M (67,1G[$?SJA\0P/[<ASR=O2N1QG[PQBN25629\ECLPQ%.HXQ9WO_"S)?\
MGR/YT?\ "S)0"?L3?G7!<>E.BC>:18XDW.W %1[61S/,L3I9G=CXERE<_8B/
MQH/Q-?\ Y\F^E<7=:?<V1'VJ+:3T%,M[2ZNF*P1,9!U '2GSR*_M#%^9V_\
MPLN0_P#+H<>E(OQ)= 0M@1GG@BN&DADCD,;JWF#J,5'S_=H]I)$O,,6=Z?B9
M*!G[$0!UYH_X6=)C/V,UP]O;S7,GEQ(2Q'./2E-M<+;_ &AXV\MFV]/2CVDB
MO[1Q?<[C_A9DN>+(D?6C_A9DO_/D?SK@B#D[E.?>DX]*/:R(_M3$KJ=__P +
M,E_Y\C^=.@^)$LUQ'$;0J'8#)KS_ (]*GL?^0A;]!^\'\Z:JRN:4LSQ$II-Z
M'O4,GF1!^F1FI15>U_X]T!_NBIE/6NN.J/L8.\+CJ6FCI3J92"BBB@ HHHH
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MV4#!]*Y8Z%?YVA,CMS49TF\6+<8^AVX'6GS,ZU6J+[)U4=U82LY61/,!)D+
M<BBQN]"DA=I$4-O*C([>M<NVC7B!5"DDCD#J:0Z/>>9L*$<8'O[T<S*^L3?V
M31L[^V7Q1)+O$4#C8A XK8LX[:%(M/\ M"3MN>3/IDYKE+#3S>ZD+(G:R\9-
M27=N=)U,PK,>.'D] :.9F<*KMK$T/$[VP,*Q%&E'W]OI6!CY1Q\N<M]*W)=#
ML5\G;?EGN!N7=GGO5>VTAK@-)/)Y1+^6%/>I:N95*;J2;1F#V-2V7&HVX/\
MST7^=6M3TZ*R8".3-5K+)O[?/42+_.I2U,80<)I'O-O_ ,>T?^Z*E'>HK?\
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M;T4T]3WLHHSIN3DB]WI:3O2UTGT(4444 %%%% !1110 4444 %%%% !1110
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MHP/2EHH 3 ]*-H/4"EHH"PFU1V%+BBB@5@HHHH&%%%% !1110 4444 %%%%
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- A # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)P*
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M?E'TSS7:Z?9QZ?906< (BAC"*#Z 5;HJ"@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]*** ,B714
M:X:>WN;BV9SEQ$>&/J13/["$DB-=7ES<HIW>6[#:3[@5L]:/I5<[,'0A>]@[
M>F*6BBI-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 449%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "B
MBB@ HHHH **** "C-0W%Q#;1^9,X5<XR?6H?[2L\D>>I(7=QZ4 7*#TK/_MB
MSV@K+N) / [$XS4POH9;>26W/G[.-J<DF@"P30#6-INK7%Q9W$]W9O$8=QPO
M.0/3WK,?QK!*%>""8+MW'<O7Z<TXQ<GH1.:@KLZ[-%9.DZ];:S),EO',AAQN
M\Q<#FM:D6%%&:* "BBB@ HHHH **** "C-!Z5DQ:SYGBB?1O)(\JV6X\W/7)
M(QC\* -:BBB@ HHHH **** "BBB@ I#TI::P)^E  *.]<%XA\0ZWH^J- 'C,
M+?-&2G:LL>.-9/\ RTB_[XKICA9R7,CRZF9T:<W"5[H]2R:,^U>7?\)OK/\
MSTB_[XH_X3?6?^>D7_?%5]3J$?VOA_/[CU'/L:,^U>7'QOK6/]9%_P!\4G_"
M<:U_STB_[XH^IU _M?#^?W'J6:,FO+?^$WUKG]Y%Q_L4O_";ZU_STB_[XH^I
MU _M?#^?W'J.31FO+O\ A-]9_P">D7_?%'_"<:S_ ,](O^^*7U2H']L8?S/4
M<^U&:\M_X3?6O^>D7_?%'_"<:T?^6D7_ 'Q3^J5 _M?#^?W'J631FO+?^$WU
MK_GI%_WQ1_PF^M9QYD?_ 'Q1]4J!_:^'\_N/4L^U&:\M_P"$WUK_ )Z1?]\4
M#QQK7_/2+_OBCZI4#^U\/YGJ631DUY=_PF^L_P#/2+_OBC_A-]:_YZ1?]\4?
M5*@?VOA_,]1R:,FO+O\ A-]9_P">D7_?%'_"<:R>DD7_ 'Q1]3J!_:^'\_N/
M4<FC\*\N_P"$XUD=9(O^^*/^$XUG_GI%_P!\4?4ZH?VOA_/[CU'/M17EO_"<
M:S_STB_[XH_X3C6<?ZR/_OBAX.H"S;#O:_W'J6/>CI7F\'B;Q-<@&&(,#WV4
MZ?Q%XIME+2P;5'4^76?U>5[71M]?A:_*_N/1L^U&:\M'CC6O^>D?XI1_PF^M
M?\](O^^*T^J5#'^U\.N_W'J=%%(2 ,DX%<AZXM%,CECE0/&ZNC=&4Y!IS,J*
M69@JCJ3VH 6BF1S1R@F.17 ."5.:?0 4444 %%%123QQ/&CN%+G"^YH 2>WC
MN%42#(5@P^HJD=%M.<*XR",!CQGJ15\3Q-C$BG(R,'M1Y\6,^8O3=P>U%A71
M071K5=W^M8,H4AGXP.@J:/3TMK62&V9HB^2&ZE3VJ>.Y@E1725&5ONG/6G>?
M#C_6IZ=:=F%T9>C:=>6D$R7TZR[V;"*,* 3_ #KA+VW_ +/U"\M&_P"61)&?
M[I.17J 96&0P(/<5S7B6"(WEDQC3<[A6..2/>M:/QG+B_P"']Q-X.M/(T7[0
MP^>Y8R9]NU=!D9Q4<:I%&JH J@8  Z57FNBSF&W422=S_"OUK"3M<Z5HD3S7
M4, 7S7"[C@#UI\<J2J"C!A[5FR6P@*7$C>;(IRS$XX]JELY(IYI)(?\ 4X ]
M 6J$W<$]31HK,O=1>TNXX_*#1E<NV>12?VS")EB9'$A;;CJ,UH4:E)D4F:IO
ML-S)YA;L!@T#2N7:*IHD#OM4/TZY-.FMXUA=ANR!_>- 6+7:N6M?^2GW_P#V
M#(O_ $,UTT9_=K]!7,VO_)3[_P#[!D7_ *&::$=51112 **** "BBB@ HHHH
M *0]*6D- '.^+-'&JZ4[(O[^$;D(')]17EG3((Y[U[F1G(Q7EGC#1_[-U3SH
MUQ!.=PP.A[BO0P=77D9\]F^%T56/S.?HHH/2O3/G+%W3-,GU:[-M;,HD"[OF
MZ'%5)4:"5XW&&1BK#W%=#X*<1Z[)(>0L#'\JFU+2EN_%UMY0S!?8F]L=6KFE
M5Y:CB]K'H1PJJ4(SCO<S'\/7L3V*-L5KP_)D].,\U!;Z1>76I2V$"AI8F(=L
M_*N.YKM-5GCN-8T&2/[@F<*!Z 8K)WM#IOB>:,[9/M.S=W )'^-91K2:_KN=
M,\'3C*W];&7>>&Y[2VEN/MMG*(AEUC?)%2Q^%+E[>*5[VTB,J[E1W()%<^0H
M4\'WKM]5T-]6@THK=V\3"V5=LIP2?:KG*<+7>YC0ITZO,U';I<Y:]TN\L+Q;
M6:+,K8V;3G?GT-:B^$;W:JRW5I%*PRL+R$-^72MK$2^)]'TPEI7L8B'=AU..
M/Y5QNHRR3:E<RNY:3S&.[)XYXQZ4HU9ST3L%2C1HWE)-ZV)3I%\-4&G&!A<D
M\+QR/7/I6D?"5R,J+^Q,@&3&).16G?:G_9\VAZG(AD9K<K)ZD&L^XT"VOUDN
M]$NEG/+-;O\ ?7O256;WT+>'IQ327,^U^AF:;HUWJL\B0*BI$<22.?E6K=WX
M9O+>U>XAFM[I(_O^0V2OO5@DV_@,;,H9;HI+C@D>AJ/P<Q371$O"2QNKJ.A
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MJ0*X&#2?'#6V+G4]LJM(P\MAAFQ\HY'W2>W:E72?&9GN&>\1BKNT#NXRN1P
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M.;^RL/V/*?\ A#-6[1BE_P"$,U?_ )Y+7JN*,4_K=0/[*P_9GE7_  AFK?\
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M/$7]AZ+%J(:Z_>&2?R]O)Q0![+_PKCP;_P!"WI__ 'Z%'_"M_!O_ $+>G_\
M?H5F_P#"1>/O^A.MO_ T?X4?\)%X^_Z$ZV_\#1_A0!I?\*W\&_\ 0N6'_?NC
M_A6_@W_H7+#_ +]UF_\ "1>/O^A.MO\ P-'^%'_"1>/O^A.MO_ T?X4 :7_"
MM_!O_0MZ?_WZ%'_"N/!H_P"9;T__ +]"LW_A(O'W_0G6W_@:/\*/^$B\??\
M0G6W_@:/\* . ^.?A30-"\)6<^E:3:VDS705GB3!(QG%>S>&R3X:TO/7[+'_
M .@BO#?C3JGB:^\*V::SH,-A +D%9$N-^3CIBO<O#?\ R+&E_P#7K'_Z"* -
M2BBB@ KDOB6YC\ ZE(/X55L>N&%=;7(?$_\ Y)WJO^XO_H0JHJ[2)D[19Y+X
MC\:KK%L3=^'EN)1;%%E29EVC'IFO:/!'_(DZ+Z?94_#BOFG4VC$.))KA3Y7
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MS )1<%MJL "F!Q^>:CMY?%LT4):*TBW*"Q;JO3/'YUU)YXH'6@#-TE=64O\
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )F @8# 2(  A$! Q$!_\0
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M[N8C+8["M'1_$MIK/A^35XX+F".+>LL4R;71D^\,=Z\V\'^*[/P+K>K^&?%
M:PEGOY+FWNY%Q',KG(RW]37I^I/;R^&KZ6U:-XGM9&5H\8;*GGB@!/#>OV?B
M?0;;5[ 2"VN 2@E7#<$@Y'X5)KNM6OA_29=2O Y@B*AMBY/) '\ZY3X,?\DI
MT?Z2?^AM5WXH?\B#?_[\7_HQ: -+Q3XKL/".DIJ%_'/)%)*L2K"@9BS=!@D5
MGZAX^M]'@6ZU;1=7LK,D!KF2%61,]VVL2!7._&]E3P/8,S *-1@))[<]:O\
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M8*#C!]^]:\LD=M;O)(0D42%F/8*!FO$M?M[FRATKXG;&%R-1\R<>EFQVJ#[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1112N 44447 ****+@%%%%%P"BBBF 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M QUWH5R1D=17/SR74$S1/-)D=#NZBNBJAJ5IY\.]!\Z_J*F2NC2G))ZF1]IF
M_P">TG_?1H^TS?\ /:3_ +Z-145C<ZK(D-Q.?^6TG_?1H^T3?\]I/^^C4=%%
MPY42?:)O^>TG_?1H\^;_ )[2?]]&HZ*+A9$GVB;_ )[2?]]&CSYO^>TG_?1J
M.B@+(D\^;_GJ_P#WT://F_YZO_WT:CHHN%D/\Z7_ )ZO_P!]&CSI?^>K_P#?
M1IE% 60_SI?^>K_]]&CSI?\ GJ__ 'T:910%D/\ .E_YZ/\ ]]&CSI?^>C_]
M]&F44!9&OI5TS@PR,2PY4GO6IVKEHI#'*LBG!4\>]=+!,L\*R+T(K6+NCEJ1
MLR6BBBK,Q*RK_P Z&7<LC;&Z<]#6K44\*SQ,A[]/K6=2+E'3<J+L]3#^T3?\
M]7_.C[1-_P ]7_[ZIKHT<A1NH[TVO.<I+2YUI(D\^8_\M7_[Z-'GRC_EJ_\
MWT:CHI<[[CY42>?+_P ]7_[Z-'GR_P#/5_\ OHU'12YGW"R)//E_YZO_ -]&
MCSY?^>K_ /?1J.BB[[A9#_.E_P">C_\ ?1H\Z7_GH_\ WT:911S,+(?YTO\
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MV4S:;;R'J4%6J@LX?(LXHO[B@'ZU/7$]R@HHHI %%%% !1110 4444 %%%%
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M_P!*D;_B6+IWS(IPHS\W^]S^%0R?#BRD,S?;KDS-%;I%,Q#/$T/W6R>I/?-
M&W:>)[*]O[NR1)4N;9D#1.H4NK#*NO/W?>H6\8Z6-*FU8&1M-BF,+7*IE<@X
M+>NT'C-3OX=BD\3VVO2S,;B&S:T9 H"R G.3[U1_X0FR7P[+X?6:8:7+,9#$
M/O;2VXIG^[F@"SJ7BNTTR[MK>:WN6-U<1VT+JHVN[@D8R>1QR:J3>/-,MS?B
M>"ZB:Q6)KA2@RHD) P,Y/2K^L^&X-8;2"9G@&F727,00#DJ, 'VQ6;J/@6TU
M+5=0U%[J>.YNF@>-U _<M%]TCUSGG/% &Q/KUC!K-EI4CL)[Q&>([<*<#."?
M[V.0*KV?BO3KV^O[&,RK>61_>0R+M+KTWIG[R^XIFJ^%XM6MD$ER\=W'<I<Q
MW48 9&7'0>A''T-,U7PC::K%"9)I(;NWF,L-W"=LB9.2N>ZGH1TH FL/%>GZ
MG<7$-HLSR6LY@E4J R$#EMN<[>>N*HR>/M-3PPOB$6]V]AE@SJ@)4JQ7YAGC
MD58G\(VMU?V=]+*PNK24NLZ*%=U.1L8CJO/?TJL/ EJ/ \WA;[5+Y$I;=/M&
M_!<O].IQ0!H7WB>UT^:U2YMKA5NIHX(9,#:S/T&<_G5C1M>LM;2=K5G#03O
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M'. H]34&E:SIVMV(O=,O(;JV)($D39&1UH OT50;5;$0K*+A&5BP7;SN*]<
M=<4^;4+2W$?G3HOF2"%<GJYZ+]: +E% Z44 %%%-)% #J*J6NH6E]&'MITD4
ME@,'N#@_D:L,P52S$  $DGL* 'T54@OK:Z7=%,"I8!<\;C[>M+9WUO?0F6VF
M65 [(2/4'!% %JBD'2EH **** "BBB@ HHHH **** "BBJ\]W#!(%DE 8C<%
MZG'K@=O>@"Q13(IHYHA)%(KHW1E.0:?0 44UV5%+,P '4D\57BOK6>\FM(Y5
M:>)59T!Z!NAH M44@Z57DO(([V*T:0">569%_O =: +-%(#Q2T %%&110 44
MR22.-2SNJJ.I)Q3ATH 6BBC- !1110 4444 <O8> ?#NF>*KCQ):V934IRQ9
M]Y*@M]X@= 36]/:K<21,Y^2-MVS'#'&!GZ5:JC>7\=G+;PE2TURY2)!WP,DG
MT % &=:>&8+.>U>.9S%:S2R0Q%1A-_51[#M1!X;CM[80174@'VB2=N!AM^<@
MCVR<>E:,6JV,Y7RKF-BREQ@]0#@G\^*IZ;XBLK]&+.('621-DC==AP3GICC-
M %./P?;I926OVJ1E>WCMPQ R%1BP_4U#-X5DN[J9+B:,V4CN^Q4VLI8Y)!SU
MR 3D<UOG4+<Q3/'(KO'%YNT'DK@X/T..M5M/UVROK..=9-C-$LIC/WE#<#ZT
M )=Z'#>:5<V3.$-R%$DJ* 6QCG]*B_X1NU&5$DFQK@73+GK(!C.?3VJZFJ64
MS!8KJ-G;. #D\'!_7BI)+VUCN!;R2J)68*JDXRQY ^M &?#X=MXO#IT;S7:,
MC'F$#=USFJ]UX3M[Q[QY+B3==& N0 ,>5T_.K&F^)+*^LHYW86[/OQ&YYPK;
M2?I[U;_M>P(&+J,Y4.,'JOJ/;@\T 0V.A6UA"L4?(176-F4%E#')&?QJM%X;
M@A13!.\;QS":(?PHP&#A>P(ZBK&H:_9V.GRW:.LX1%<JC<E6( -78;VWG.$E
M5B'\LCN& R10!E6?AB"TO8KE;AW:.&2%00,8=MQ/YTEEX6M;&"R2*5_,M(Y(
MDD(ZJY).1^-36GB*RN3.LKBW:*YDM_WAX)49)STZ&K7]KV'F;!=1[RNX+GDK
MC.<=QCO0!AKX3EMIU2TGC2U!5@K1Y8%<X;.>O)JR/"L1:5WNY6DD2)2Q ZQD
ME3^O-::ZSIS,$%W$22HX/=NGYTLNJV<-U-;R3;&A19'+< *QP.?K0!#I^B6V
MFONC^<"5Y5+@%E9SEL'T]JIQ>%8(GB=9WW1M<,/E&,R_>_G6F-4LFE,2W*&0
M9W(#EAC&<C\1^=,AUBPF@283!58MMW<$[3@GZ9% &>OA6S%M+;F60I-'$DP!
MP7$?"\]J(_"T$4MJPN'V6HG$:D#I+G/\ZM7.O6D,EFD;+,+FX6WW1MPK$%AS
M]*MR:A:I/Y+3*LG3!XYQG'UP#0!F:;X6M--4*CM*/+C1A* P/E_=(]#5W1M*
MBT?3ELHI&D569@S#GYF+']32QZSITR&2.[B*;%?.>JL< CV)XHT_5(]0N;Z%
M$*FUE$3$]SM#?UH T1THHHH HZOI5GK>EW.FW\7FVEPFR5,XR/J*H^&?"FD^
M$=+.G:/ 8H"Y=MS%F9CW)-;E-) !)X YS0!RVG^&;FSN]*F>>)A9273N #\W
MFD$8^F*+CPO<2W#D20^6^IK>G<#DJ ?E_6MM=8TYU+"^M]NTOG>,;1U/T'>I
M!J=B>1=P_P#?8^E &!:>'=2C.VYU!I( LJ+&C$;-S94@^H'%7+_1;FZOS*ER
M4A%DT"C<21+V?TXJ^^KZ>C$-=Q8"ER<\!0<9)[#/%/\ [2L2K-]JBP#M)#=#
MC/\ +F@#%?P_>M9PA;R1;J-%#2"0E68#&2IZY/7UIXT?4A<;C=IM-U#/\N<
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M2K\_01<K3;#Q/;7$3M=XMF625 3]TB,\G/TJT=?TU?+!GYD=508)R6&5_,4
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M*SCXN3RW=+*0B.TBNV&[G:YQ@>XJMHGBB>[2XBDB>XG269E"@*3&K  #U/-
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M-TGF1L""OL:NU0O=02QN;&!HV=KN;RE*_P )VELG\ : (6T&P,OF"-@1*LH
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M$FKC3H;-%WF<1SN#M8(H((QV)./PJ6WUB^3PU:ZA+&LTH<"Z4*057."0/44
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MVB@+'IEG<I=VL<\9RKC-3UQ_A;4?*F-C(WR/S&?0UUXIDBT444 %%%(3@9H
MR-3@$<@D7 W]1[U1J>\N//N"1]T<+4%6CAFTY.P4444$!1110 4444 %%%%
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ML)A]8@<517;?\(GI_K-_WU1_PBFG_P#37_OJCV$@^L0.)HKM_P#A%-/])?\
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M>!N QZJ:[52&4$'(/I73":DKHYJE-P=F.HHHJS,**** "BBB@ HHHH ****
M"BBB@ HHHH ***Q]=UD:9"$CPUQ)]P'M[F@#2GN8+9=T\J1CU8XJF-=TS=C[
M6F:X*>XEN9#)/(TC'G)J/\J15CTZ*>*==T,BR#U4YJ0=*\SMKJ>SE$MO(4<>
M_!^OK7<Z-JR:G;9/RS)]]?ZTQ-&I1110(**** "BBB@ HHHH **** "BBB@
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M667S=1C2.0 C"A.!CCWK<HH 11M15!R ,9I:*:S!<9(&>![T .HHHH ****
M,S7M(BU[1+S2KB62.&ZC,;M']X ^F:S+_P %:5JG_(162Z(M#:1ER!Y:<'C
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MQSV)^E9XT;4HM5LK>5FGA-O<B1\D("[90'W%;]YKUC8I.\K_ "0HK,PYSN.
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M&XB2([E&#OSZKTKI)9HK:%I)76.-!R3P *E5@RA@00>0?6@#E9+[Q$NFBY6
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: ET# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4<ID:%Q;LGFCIGD"I*H)H]I#<&>)720MN.'.#^%3*_0:MU+=N
MLMRLJK$\YBQO*)R,^U0W.CWD*I,L=U:Q[MQ+(<-]36WHNN+H<DKR60DCD(W-
M%DN!^/45WEEJ=CJL):UF25<?,O<?45Q3G)/5'=3A&2O%GF\.L7VFQF6VNIR/
M[H^<'\#74^$/%-YX@:5)[1ECC&5N N%8YP1CUK3N/"ND7+M(;;RY&_BC8K5'
M2_!HT?6?M]IJET(WSYMNV"KUG4G"2T6IK3A*+U=SJ****P-PHHHH **** "B
MBB@ HHHH **** "BBB@ IDDB1HSNP55&2Q. *?7,>-$M7TZ,75Q=1AFVQB \
M%O\ :'<4TKNPF[*YC>(]>757%K; &UC;)D(Y<CT]!6)4$#7!9EFC15'W64]?
MPJ>O5IP48V1Y-23E*["BBBM#,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ '6N:@:Z744E;S!&]VR%]Y.1V&WT]ZZ6DVKW ]:B4;ZW-:<^6ZM>Y
MB7]TT3ZG%YK+(0GDKW/^[3M8+*T!,N L9+1%RF[CJ#ZCTK1:ZLRP+30EAT)(
MXH:ZLGX::%OJ163<?YC=*:M[C,Z]<R:;9,)60-@E925WC'1B.AI3.[:);21F
M5295'S'+8W>O<5H-=V;KM:>$KZ%A2_:[3&//AP.@W"CFA?XA6G:W(S+URYN5
MN(HK19B81YTGECJ.P/MUK9AD$T22K]UP&%1?;+3/_'Q%SU^84?;;4# N(A_P
M(4U.*=^8F<)N*2@6**@^VVO_ #\1?]]"C[;:_P#/Q%_WT*T]I#NC+V53^5D]
M%0?;K7_GXB_[Z%'VZU_Y^(O^^A1[6'=![&I_*R>BH/MUK_S\1?\ ?0H^W6O_
M #\Q?]]"CVL.Z#V-3^5D]%0?;K7_ )^8O^^A1]NM?^?F+_OH4O:P[H/8U/Y7
M]Q/14'VZU_Y^(O\ OH4?;K7_ )^(O^^A1[6'=![&I_*_N)Z*@^W6G_/S%_WT
M*/MUI_S\Q?\ ?0I^UAW0>QJ?RO[B>BH/MMK_ ,_$7_?0H%Y;,P N(R3T&X4>
MTAW0>RJ?RLGHHHJS,***0$LVU59C_LJ32;2W&DWL+12.6B ,B.@)P"R$9-,:
M7;(B;'+NXC4;3]X] ?2ESQ[CY)=B2@!W=(XT+R.P55'<FI+BUN[5F6XM)H]O
M+$KP/QIMA>VL&HV=S-(/LRR;G9#G'H:F4URMQ*C!\R31HGPWK0C#_8U_W?,&
M162 9)(U5&=A( T*G!?GE?:O4[#4K34[?S[.=98\XR.U0RZ'I\NH17QMU6XC
M.0R\9/J?6N)8B6S.UX>.CB>;WFGW-C>":1;B&VFR8XI1]S_9)]:;6WXPN#<Z
MRMJ9&:&!0QC[!SW]ZQ[.SO=2N)8;00;TP</)ABO<@5TTYVA>1S5(7GRQ&4A(
M R3P*Z73_"'FWDIN;HR6B@>4T3#+GOGZ5)J?@@M&3I]RP)/,<IR".X![4GB8
M#6&F8FC:#<>(X!,&,&GL2/-!P[X_N^GUKID\%VL#1R6MW=PRH1A]^2<>M=#9
MVT=G9PV\,2QQQH%"+T6IZXIU)29VPI1BA%&% I:**S-0HHHH **** "BBB@
MHHHH **** "BBB@ HI#34E20D(ZL1U .<4 /KC/'*$36$N25RR8[ ^M=G6=K
M6EIJVGO;L<./FC.>C#I5PERR3(J1YHM'FM%7YM"U>WDV263/QG=$=P-9X.1G
M\,&O4C.,MCR90E'<6BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BFR2)
M$NZ1U1?5CBA9$?&UU.?0U/,KVN%AU%%%4 56OQNMPA)"O(JMCN">:LU7O?\
M51_]=D_G7/BG:C)KL=.$LZ\;]SK9+/3;2W+R6T"11KRQ0<"F0+I5U@0P0MD9
M'[K''Y4[6+>2[TBY@A&9)%PH!K,OM,ORD4<,\\P\G:SLP!SD<<>V:_.(MRWD
M?5MM,V&LK%%+/;6ZJ.I* "H;B+2[2(23PVZ(3@'8#D^U8]]I-U(U[;P0.\$D
M6%,C]",8"\]_>K][937ECIT<2R6YCE5GP1NC '-&JM[PN9]B]'9V$L:R):PE
M6&0?+%(]GIZ</;6X."<%!G K*;3[[^V"[2SM$-ICE&.0!R#]:ACTFXA>RN&M
MY)9O+D24^9DJQZ'Z4[/^<.9]C5!TAI!&([?=@''E^HR*L+8V+*&6U@93T(08
M-<Z-)U)GCW(WS+&LAW=<(0<_B12):WEN-+LHTD@\Y?*F4MG:$.=P^O2FXOI,
M7,^QM3G1[:=(9TMDD;& 4'>IX[33Y=VRV@.UMI_=C@UD:YI]S<WDK00S.'A1
M$V$!=P;/S9[4UK+4EO1-Y;N?.)"[OW>TXY]L=J+72]_\0YG?8U-FE?9#=>3;
M^0.K[!CKBK T^S8#%I#ST^05S0T.]CLI8X4=7FA<."^1OWY4X^E+%IFJ++ L
MWG[54*71MQWYY;D\ BGR]IASOL=!#;:=<*6AMX&"L4)"#J.HIJQZ6TBQK#;%
MV)"J$&3CK6?HMA>6>J7,ER&:&1V:(AN(QGN/?UJH^FWEI]MN-I_>;G5\\Q%3
MD#Z-4V=VN8.9VV.A_L^S_P"?2'_O@4?V?9_\^D/_ 'P*YS[->/8G4+@S!FM7
MFP&/R2'H,>PJC:O=)IOVFV:3[5YRQE"Q*$.,<'OZU2A)_;#G\CL?[/L_^?2'
M_O@4T65@6*BVMRPY(V#(K ?3;H7-X@@NUQ$L<<J29#XQDX)ZFG&ROT>6;[!N
MFEME4;7X4@\@\^E3RO\ G#G?8W_[/L_^?2#_ +X%07FF6,MC.C6D.#&W1 .U
M82Z7J,]OLF6957S610^""<;>A^M=(0ZZ61(?W@@(;/KMYI-RC)6E<J+OT.,T
M]F?3K=F.6*#)/>K-5=,_Y!EO_N5:K]*H_P ./H?(U]*LO41B%!)[5Z!X5LA:
MZ'"6C99)<R/OZY-<-96DE_J%O;0KN9G#-D9 4'))KU-<  #&!QQ7-B9?9.C"
MP^T(T4;@;D5L<C(Z4&*,]47KGI3Z*XSM(;BT@NTV7$*2+@C##-4K;P]I%FVZ
M"PA0\C.W/6M.BB[%8CB@BA7;%&B+Z*N*9>7'V6TDG\J278N[9&,L?I4]-<94
MCU&*!GEVH7YU349;WRO*$@ "'J,>OO2:?=)8Z@ET\/FJ$:-@.NTCM3M2T^;2
MK][:7)!):-_[X)_G5:O4C&,H6Z'E2E*-2_4[7PC>:<]H]G90S0F/YV68Y8Y/
M6NESFO(S+/;_ +ZUF:&=1\LB]O\ $5Z5H4E[+I43WTL,TQ'^LBZ..Q^M<-:G
MR,[J-7G1IT4UY$B0O(ZHHZLQP!2@A@"""#T(K$W%HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH R/$&G:AJ=BL%A??8VWY=L9++Z>U<N/!.JQY\J[B0YSO
M#L#FN_HJE)K8EQ3W([='CMXTD;<ZJ S>IJ2BBI*$(KSS7M"N--NY9XHWEM)6
M+[E&3&>^?:O1*YGQ7I5[>"&>R,CLN4>)7P&4UI2FXR,JL%*)Q(((!!XI:OW^
MA7^E68N;E(A$"%.QLE<U0KTXS4MCS)0<7J%%%%60%%%% !1137D6-=SL%7.,
MFDVEN ZBHEN(68JLJ$CWJ6DI1>S'8*BN9UMH&F<$JO7%2U7O9-EJ_!)8;1@9
MZTINT6P6Y,B7<R@P6V589#NX"D5833IV/[V<(,=(QW_&IM,MH;6T40L2& )'
MF;PI]!5VOCZ^9XB4G%.QV1IQ12ATNVBD$C!II!T,IW ?04MUI\4UN_DQ)'/U
M1@,<U<HK@^L5>;GYG<NRV,%DU"$YFLPT>TL6C?.,=<TR"Z%TJ_9XV>1AG:1C
M;]:Z&D  Z*!]!7IQSFLHM-79FZ43!#3P2,EV@C.?D8?=8?6EN(C/"45MK9#*
MWH1TK<9%D0I(H93U!'6LFYM6LOGC!>V[CJ8__K5W83,XUE[*MU)<'!J<.A87
MQ#JP4!K"V9AU83$9_#%177BR_LK<SS:? $'7$Q)_E40.X9!R/455U)5;3I\@
M'Y<C-:5,FPO*W%'H8?,JDJL8S6AIQ^)M2EB61-/MRK#(/GGI^5/_ .$BU7_H
M'6__ '_/^%48@!#&  !M' ^E/JHY+A6M414S.HIM)*Q:_P"$BU7_ *!UO_W_
M #_A2_\ "1:K_P! ZW_[_G_"JE%/^Q,)V(_M2KV1;_X2+5?^@=;?]_S_ (4G
M_"1:IG/]FVV?^NY_PJK2'@$D\4?V+A.P?VI5[(M_\)%JG_0.M_\ O^?\*/\
MA(M5_P"@=;_]_P _X5261C$LK0RI&_*L4.&%"R(_"NI/UJ(Y1@I;?F6\PQ"W
MB7O^$BU3_H'6_P#W_/\ A1_PD6J_] ZW_P"_Y_PJI15_V)A.Q']J5>R+?_"1
M:I_T#K?_ +_G_"D_X2+5#_S#;;_O^?\ "JM%']B83L']J5>R+7_"1:I_T#K;
M_O\ G_"D'B#4@,#3+4#T$W_UJK44_P"Q<+V#^U*O9%O_ (2+5?\ H'6__?\
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MMHH"@#0[CN&<]*K2-<7$\<DPB4H",IG+ ]JB'VJ9X)99(SL3;A5QQZ58K[#
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MJK7A35Y,4(R;]TSAJ&J6<FR[M!(O)\Q3U _K5RVUFRN5!6782,X<8Q5CR;R
M$(ZW*YZ2'##\:JM;V=Q,8YX!#<$8V^H]1V-*GB*=3X65.#7Q(FDAECF-S:;&
MWCYXR<!_<'UJA=V5EJI.PFVO-I7!&"?KZCZ58LM*DLKO>MW(\ 4@1-ZU<NH[
M=X2]R%"ISO/!7Z&NC<RO9Z$1\VPTQ0%:YEC4 Y_B]3]*PYH3/=-.ETBR2?\
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ML4A\<6XMHK@V[!'5RQW#"%>@/UK6YR<DCK:*C@E\Z".3&-ZAL?6I*9 4444
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MU0TRX@U!YKV$/C<8E9QC('I[9H TA1110 4444 %%%% !1110 4444 %%%%
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M$0("\ ,W;WXK7@EN[-0EK/B/KY<@W ?3TJ9TXS5I(2DXO1EM]+U)?N7%N_\
MO(15)=)U0:C+-]GA =57=YG0"MS3=16]C97 2X0X= ?U'M6A6$,/3A+FBM2Y
M5)25FSFVTK5-Q*FUV] I)S]<U'=:5JD*K.DT3K'R\"1Y+CV/:NHHKIN9V.42
M1)$WJ?E/KQ5.\86TBWR3[=H =-PPZ_XU>USPY-,DDEE=2+&[[Y;<=''?;Z&J
M#1:4CQQM;99VVJA0G:?<=JYZ]1)6:N:TH-NZ9J*P958=&&13J0#   X'I2UX
MS/30450OM5AL'*RHY(A>;Y1_"O7\:JCQ):26IN((Y)1MC(4#!)<X ^M.S&;-
M%9MOK5O<310[)$DD9U*L/N,O4&I=-U2#5(I)( P6.0QG<,$X[_0T68%W%(1G
M@C/UI:2A.PFCB;F:Q^W7-N/E2,X4L#O5OP[5I#Q.Z*L9MT9@!DACS5G5H!#J
M$%T(TV2 Q.P'.>Q/K6'?ZFEOJGV*>-?*$0FPK8=P#R*]J$(5J2D^AQ2DX2LC
MK-.O?[0LUN!$T>21@\YQW'M67.PDU2[?()4B/CI@?UJ"/4))M'D0L()%=#"L
M/!V'I3XH1"K*"268LS$\DGN:\/$^XW$SQ-5.*B17]PUM:-(G^LX5?J:RX81!
M$(P2<9))[D]:V+B!+F!H7SM;J1P:R[JU6PF$B!S X"GG.UJ]#*,12IRY);L\
MFK%M!11437,"9W31C!P<MT-?57.2Q+15-]1B$F$5I$'WG3D#_&IX+B*X4F)L
MX.#QC!HN4XM;DM%%%,D**H:GJ]MI:+YVXN^=BJ.I'\JSK'Q-'-,4NHA"",JR
M\_A64JL(OE;U.JE@Z]6FZD(W2W-BZNH;6+,K %N%7NY]!7>^%K"?P]X;(OI(
MPHS-L08\L'G&>]<UX<ET&&:/4]2U"%[C;^Z@9<B+/?IUK7\2^*=)N=#FBMM0
MC+L5! !Y7/-<-6M&<K)Z'71PM2"ORNYL:%X@&M23H(&A\K!!)SN!K9,L:R",
MNH<]%SR?PKBO TT+2WDZR)Y3A0C9X;'I76D6?V@7),)E VB3(R!Z5E.R=D:0
MYK>\M2:*1+B,.%('(^88-.CC2) D:JJCH ,"J&L:JFE:>UR8S(V0D:#^)CTK
M _M[Q!W@T]3W&]CBDHN6R&W&.LG8[&BN/_MW7^T-A_WTU']NZ_\ \\=/_P"^
MFJO9S[$^TI_S(["BN/\ [=U__GCI_P#WTU']NZ__ ,\=/_[Z:G[*?8/:4_YD
M=A17'_V[K_\ SQT__OIJ/[=U_P#YXZ?_ -]-2]G/L'M*?\R.PHKC_P"W=?\
M^>.G_P#?34?V[K__ #QT_P#[Z:CV<^P>TI_S(["BN/\ [=U__GCI_P#WTU']
MNZ__ ,\=/_[Z:CV<^P>TI_S(["BN/_M[7_\ GCI__?34?V[K^/\ 4Z?_ -]-
M1[*?8/:4_P"9'845Q_\ ;NO_ //'3_\ OIJ/[=U_M#8?]]-1[*?8/:4_YD=A
M17'_ -O:]_SQT_\ [Z:C^WM?_P">.G_]]-1[.?8/:4_YD=A17'_V[K__ #QT
M_P#[Z:C^W=?_ .>.G_\ ?34>RGV#VE/^9'845Q_]NZ__ ,\M/_[Z:C^W=?\
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M6=E?:V8P8UA(B7/+XZYKH<8^R3ZG,I2]K9;'8WUA;:C9R6EU&'A<8*UACP=
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M)BC%%WW"YS?_  A\7_02OO\ OL?X4?\ "'Q?]!.^_P"^Q_A728HQ1=A<YO\
MX0^+_H)WW_?8_P */^$/B_Z"=]_WV/\ "NDQ1BB[[A<YO_A#XO\ H)7W_?8_
MPH_X0^+_ *"=]_WV/\*Z3%&*+ON%SF_^$/B_Z"=]_P!]C_"C_A#XO^@G??\
M?8_PKI,48HNPN<W_ ,(?%_T$[[_OL?X4?\(?%_T$[[_OL?X5TF*,47?<+G-_
M\(?%_P!!.^_[['^%'_"'Q?\ 03OO^^Q_A728HQ1=]PN<T?!T)&&U._(/4"0#
M^E;6G:;;:79):VB%(E]3DD]R3W-6\4M+<=PHHHH$%%%% "'@4%@ 23@4IK'\
M3N\?AR]9&*MLQD'GDBIE+E394(\TE'N/?Q)HZ.4;4(,@X/S4G_"3:-_T$(?^
M^JP8X+2UL58PQ+%'&&)VC@8IL,ME/LV0K\_*[HL9KPGFTND3O^JTUI=G0?\
M"3:-_P!!"'\Z/^$FT;_H(0_G6*Z6D:,[K J*,DD#@5',]C;VXN)$B\HD ,J
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M;;&?*AQZX%-"6;2O$%@,B %EP,CZTO[7E_('U6GW9M_\)-HW_00A_P"^J/\
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MS:D.230ZBDR/449'K6IF<?JNFVVJ^.H+:\1I(19%@F\@9W>U7QX*T#_GR/\
MW];_ !J.3_DHD/\ UXG_ -"J?PW,99M6+2F1A>-] .P%0DCHG.44DGT&GP5H
M./\ CR/_ '];_&N>\6^$-+M=,6ZMH1"$<"3<[$$'IW]:]"JCJZJVEW"O&9 R
M$;0 <_G2E!-&?M9]SQF[T*UNK22*./[/.C=22=I']*CT;1)-/N&N;B5&8+A0
MIX ]:WK!4N=:L_-&^&Y<#;G.=O!''6M37O"MW;P7TT*1M9_,PCC)W!?85UT9
MTY*,VM4<_P!8Q+IRI<WNMZF$LTLH#Q0*4/W26P2/6G6E[+:/-FV/G3.,*3\N
M .N:Q+O5[ZTTR&YC6,!CL"L.0?Z55LO$-_-(T<I3*KG<J<?C45YQJ>Y(^APV
M64HQ56"^9MW4C75_<M*BH2% 4'VZUW6D^+"ND0+):32RQ@1LRC@XXS7G']HQ
MRRQS$.Y*;69(SC.:ZSP9XCAM(;Z*>"X:'S 8]D);G'.?2KGR*DDNAYM?#SC6
ME971ULOB3R)-DEE-R"591D'VJSIFN)J=PT26TT>T9+.,"J1\6Z=Q_H][_P"
MS?X5J:9J-MJEJMS:DF,DK\R[2".""*YDT8RA)*[1?HHHJC(Y#QKIJM&FHQS"
M.6)<,FW)D7V]Q6!HWBJ/1=L%V\\L,GRQ1+%E .YW>OM7:>(GT]K-;74)A#]H
M)6*0G #XXY[5P]E<Z7%;I;:DL=QY<S)&8YA\B]2P]>:OVB4;29"I2<KQ1W%G
MXCT;4)888+F-Y9LA4V\\=C6J((0<^4F?7:*\HT[5K/1O%-Q*ES'-:0*68  ;
MR>FWW'>N\TWQCH^H6QE:[B@93ADD;!!_K6;E#HS50GU1O%%.<J#GKQUII@B;
M[T2'ZJ*S_P#A(]&_Z"=K_P!_!1_PD>C?]!.U_P"_@J>>/<?)+L:*QI&,(BJ.
MN%&*?67_ ,)'HW_03M?^_@H_X2/1O^@G:_\ ?P4<\>X<DNQJ45E_\)'HW_03
MM?\ OX*/^$CT;_H)VO\ W\%'/'N')+L:E%9?_"1Z-_T$[7_OX*/^$CT;_H)V
MO_?P4<\>X<DNQJ45E_\ "1Z+_P!!.U_[^"C_ (2/1O\ H)VO_?P4<\>X<DNQ
MJ45E_P#"1Z-_T$[7_OX*/^$CT;_H)VO_ '\%'/'N')+L:E%9?_"1Z+_T$[7_
M +^"C_A(]&_Z"=K_ -_!1SQ[AR2[&I167_PD>C?]!.U_[^"C_A(]&_Z"=K_W
M\%'/'N')+L:E%9?_  D>C?\ 03M?^_@H_P"$CT;_ *"=K_W\%'/'N')+L:E%
M9?\ PD>C?]!.U_[^"GQ:]I4\JQ1:A;/(QPJAQDT<\>XN278T:*,T59(4444
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MB/\ T14$@RN^(#CUJ20:<D;2.EJ%52Q.U>@ZUE7F@RM:6T%LQQ'$ROYDA/)
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M_P" XH_X1C5O^@\W_@.M=711]2H?RA]9J=SE/^$8U;_H/'_P'6C_ (1C5O\
MH/'_ ,!Q75T4?4J'\H?6:G<Y3_A&-6_Z#Q_\!Q_C1_PC&K?]!X_^ XKJZ*7U
M*A_*'UFIW.4_X1C5O^@\?_ =:0^$KR?]W>ZQ)+;G[\:1A"P],UUE%-8.@G=1
M%]9J=R..(11+&@PJ@ #T%2445UF 4444 %%%% !1110 4444 %%%% !1110
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M4)-'G,LXB6-8Y)5D#9P>!TQ42:)=1^6V(W:,H0K'@XSFCECW#GJ=C?5T) #
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$T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U +4# 2(  A$! Q$!_\0
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MCB*E3)%FU7#U'-4LAS/+L?A\1F%2M&A4_12D#*2P# E2 P!!*D@, P'()!!
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MY?FF52JY'@,/@,OJ8G+<JI8#*8X:ABZ6*JY;0QN.K2$ "@*H 4       8
M'  '  X I:**^,/U\**** "BBB@ HHHH **** "BBB@ HHHH P/%?AZW\6^&
MM>\+W=W>6-GXATF_T:\NM/-NM[%9ZE;26EV;9[NWN[=)7MY9(U>2WE";]ZKO
M"D0>#/"]KX*\*>'_  C8WE]?V'AO2;+1;"ZU)K9[Y['3H4MK-+F2TMK2"22&
MVCBA,BV\;2",/)ND9F/345O]9K_5OJ?M)?5GB%BG1M'D^L*B\.JU^3GY_8-T
MOXG+R.W)?WCC_L_!?VBLV^KP_M%8%Y8L7>I[58!XM8]X6WM?9>R>,2Q/\#G]
MJE+VJ7N!1116!V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &* ]T# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR"B@4I&*+AI82BBBF%E:["BBB@- HHHI,- HHHH$K7"BBB@>@4444!H%%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** .,^(/_(*B_P!\5YOWKTCXA?\
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MQ14<GH.E:4:<D[LRQM>,H6B0X]\T4<=A]?K17H=#R%I$****D04444 %%%%
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MC2L.I:2EKG.X****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKN/^$*C_ +S4?\(5'_>:CZW /[)K'#_A1^%=Q_PA4?\ >:C_ (0J/^\U'UN
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M 'FH_P"$*C_O-1];@']DUCA_PH_"NX_X0J/^\U'_  A4?]YJ/K< _LFL</\
MA1^%=Q_PA4?]YJ/^$*C_ +S4?6X!_9-8X?\ "C\*[C_A"H_[S4?\(5'_ 'FH
M^MP#^R:QP_X4?A7<?\(5'_>:C_A"H_[S4?6X!_9-8X?\**[C_A"X_P"\:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4@I:3/% !12=:,CUIAHA:6F_K1^%(!:*3\*/PH"XM
M%)GVHR:!7L+2TW/%.% PHHHH **** "BBB@ HHHH ***,T %%(32 YH%<=12
M9HS0,6BDS1F@!:*3-&: %HI,T9H 6BDS1GVH%<6BDS1F@8M%)D^E+0 4444
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MXB:H/^6"T?\ "QM3_P">"UQY''#'([9I4C>0XC#N>^*YE4D>)''XF6TCK_\
MA8VI_P#/!:/^%C:G_P \%KD1'(6*[)-P[8ZTA5E)#AUQUR.E/GD'U[%=V=?_
M ,+&U/\ YX+1_P +#U/KY"XKCRI#;6W*>V:3@@X9L_6DJDEN*68XBUN8[O3/
M'VH7FJP6DD*A7.#7I2'<H->&:$<Z_:$YSN%>YQC$8KIIR<CZ/*Z]2K!N;N/H
MHHK4]<**** "BBB@ HHHH ;FBDSGH:0'/!Q1<5GNAV*6DS1F@=[BT4F:,T7
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M6XEA#,UQ)\I9JBNM*OXA*]R S#E_4>]2[,55J4;11G]AZT#J:O0:1?7, F"
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M3A?8I8"A_*<7_P *XTW_ )ZS?G1_PK?3,8\R7\Z[3-&:/9Q[%?4:'\IQ]O\
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M:3/0*,_YQ7G_ /PL&4=;:E_X6!+D#[-R>E'U6J8_VIA^YW^?\XHS_G%>?_\
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MFWUBT@>XB$LCK(."<U)'KUD=V[]WL;[P_BI^TJ+[(O8T&K<QSWV.ZVF40,$
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M3/;Y:]:MI"^ISHPX4<5?\M/[HI/'270/[$@]5(\7_LS4,8-K(6]=II/[+O\
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MY_S[R9_W:]:\J/\ N#\J/*C_ +@_*C^S5W#^UG_*>2#3KS:2;9_^^:7^S[O
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M%% !1110 4444 %%%% !1110 4444 %)@4M% "8'I1@>E+10 F!Z48'I2T4
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M&'\J^XS?[ TC_H%V?_?A?\*/[ TC_H&6?_?A?\*TJ*+(/8P_E7W&;_8&D?\
M0,L_^_"_X4?V!I'_ $#+/_OPO^%:5%%D'L8?RK[C-_L#2/\ H&6?_?A?\*5=
M"TE6#+IMF&'0B%>/TK1HHL@]C#^5?<(%     %.HHH- HHHH **** "BBB@
MHHHH **** "C%%% %2YL+2\ %U:PS =/,0-C\ZK_ -@:3_T#+3_ORO\ A6C2
MTK&3A"6K2,W^P-(_Z!EG_P!^%_PH_L#2/^@79_\ ?A?\*TJ*=D/V,/Y5]QF_
MV!I'_0+L_P#OPO\ A1_8&D?] NS_ ._"_P"%:5%%D'L8?RK[C-_L#2/^@79_
M]^%_PH_L#2/^@79_]^%_PK2HHL@]C#^5?<9O]@:1_P! NS_[\+_A1_8&D?\
M0+L_^_"_X5I4460>QA_*ON,W^P-(_P"@79_]^%_PH_L#2/\ H%V?_?A?\*TJ
M*+(/8P_E7W&;_8&D?] NS_[\+_A1_8&D?] NS_[\+_A6E119![&'\J^XS?[
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- A # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)P*
M&J,4,,UBMJ%]=3RQZ=;Q-%"VQGF<C+=P, ]*:VHZA9%6O[:$P$@%X7)VY[D$
M#BJY&<[KQ3ZV[F_12 Y&12U)T!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK9^2U<'+C:'QO' ;:<],=LUW.G7D6H6,%Y!DQ3QB1,]0#VI#+M%%% !1110
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4449H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !11FB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HS4-Q<0VT?F3.%7.,GUJ'^TK/)'GJ2%W<>E %R@]*SO[7L]H*R[B0
M#P.Q.,U,+Z*6WDEMSY^SC:G))H LDT UC:;JUQ<6=Q/=V;Q&'<<+SD#T]ZRW
M\:02A7@@F"[=QW+U^G-.,7)Z$3FH*[.OS161I.O6VL23);QS(8<;O,7 YK7I
M%A11FB@ HHHH **** "BBB@ HS0>E9$>L^9XGGT;R2/*MEN/-SUR2,8_"@#7
MHHHH **** "BBB@ HHHH *0]*6FL"?I0 @H[UP?B'Q#K>D:HT(>,PM\T9*=J
MRQXWUD_\M(O^^*Z8X:<ES(\NIF5&G-PE>Z/4LFC/M7EW_";ZS_STB_[XH_X3
M?6?^>D7_ 'Q3^IU"/[7P_G]QZCGV-&?:O+CXWUK'^LB_[XI/^$XUK_GI%_WQ
M1]3J!_:^'\_N/4LT9->6_P#";ZUS^\BX_P!BE_X3?6O^>D7_ 'Q1]3J!_:^'
M\_N/4*,UY?\ \)OK/_/2+_OBC_A.-9_YZ1?]\4?5*@?VOA_,]1S[49KRW_A-
M]:_YZ1?]\4?\)QK1_P"6D7_?%'U2H']KX?S^X]2R:,UY;_PF^M?\](O^^*/^
M$WUK./,C_P"^*/JE0/[7P_G]QZCFC->7?\)OK7_/2+_OB@>-]:_YZ1?]\4_J
ME0/[7P_F>HYHS7E__";ZS_STB_[XH_X3?6O^>D7_ 'Q1]4J!_:V'\SU')HR:
M\N_X3?6?^>D7_?%'_"<:R>DD7_?%+ZG4#^U\/Y_<>HY-'X5Y=_PG&LCK)%_W
MQ1_PG&L_\](O^^*?U.J']KX?S^X]1S[4F?:O+O\ A.-9_P">D7_?%'_"<:SC
M_61_]\4GA*@+-L.]K_<>H\>M'%><0>)?$MR 88@P/?93I_$7BFV4M+!M4=3Y
M=1]7E>UT;_7X6ORO[CT;/M29KRX>-]:_YZ1_BE'_  F^M?\ /2+_ +XJ_JE0
MP_M;#KO]QZG112$@#).!7*>N+14<<L<J!XW5T;HRG(-.9E12S, HZD]J '45
M''-'*"8W5P#@E3FI* "BBB@ HHJ&2>.)XT=PI<X7W- "3V\=PJB09"L&'U%4
MCHUISA7&01@,>,]2*OB>)L8=3D9&#VH\^+&=Z]-W![46%=%%=&M5W?ZU@RA2
M&?C Z"I8[!+:UDAMF:(ODANI4]JGCN8)45TE1E;[ISUIWGPX_P!8OIUIV871
MEZ/I]W:03)?3K+O9L(HPH!/\ZX6]M_[/U"\M&_Y9$D9_NDY%>GAE89!!![BN
M:\201&\LV,:;G<*QQR1[UK2^,Y<5_#^XF\'VGD:+]H8?/<L9,^W:NAR,XJ.-
M4BC54 50,  =*K3719S#;J)).Y_A7ZUA)VN=*T2)YKJ& +YKA=QP!ZT^.5)5
M!1@P]JSI+80%+B1O-D4Y9B<<>U2V<D4\TDD/^IP!Z M4)NX)ZFC169>ZB]I=
MQQ^4&C*Y=L\BD_MF$3+$R.)"VW'49K0HU*3(I,U3?8;F3S"W8#!H&E<NT531
M('?:H?IUR:=-!&L+L-V0/[QH"Q:[5RUK_P E.O\ _L&1?^AFNFC/[M?H*YFU
M_P"2G7__ &#(O_0S30CJJ***0!1110 4444 %%%% !2'I2TAH YSQ9HXU72W
M9%_?PC<A Y/J*\MZ9!'/>O<B,D\5Y;XPT?\ LW5/.C7$$YW# Z'N*]#!U=>1
MGSV;87158_,Y^BB@]*],^<L7=-TV?5;LVULRB0+N^;H<54E1H)7C<89&*L/<
M5T'@MQ'KDDAY"P,?RJ?4M*6[\6VWE#,%]B;VQU:N:57EJ.+VL>C'"JI0C..]
MS,?P_>Q/8HVQ6O#\F3TXSS4$&DW=SJ4MA H:6)B';/RKCN:[/59HY]7T&2/[
M@F<*!Z 8K*WM#IWB::,[9/M.S=W )'^-8QK2:_KN=$\'3C*W];&7>>')[2VE
MN/MMG*(AEUC?)%2Q^%;E[>*5[VTB,J[E1W()%<^0H4\'WKMM5T-]6@TLK=V\
M3"V5=LIP2?:KG*<+7>YC0ITZO,U';I<Y>]TN\L+Q;6:+,K8V;3G?GT-::^$K
MW:JRW-I%*PRL+R$-^72MK$2^)M(TPLTKV41#NPZG''\JX[499)M2N97<M)YC
M'=D\<\8]*4:LYZ)V"I1HTKRDF];$ITB^&J#3C PN2>%XY'KGTK2/A.Y&5%_8
MF0#)C$G(K2O=3_L^;1-3D0R,T!63U(-9]QH-M?K)=Z+=+.>6:W?[Z]Z2JS>^
MA;P].*:2YGVOT,W3M'N]4GD2!45(CB21S\JU:N_#5Y;VKW$,UO=)']_R&R5]
MZL$FW\"#9E#+=%)<<$CT-,\'L4UT1+PDL;JZCH0!5>TFTY)Z(A4:2E&G):O7
MT(-.\/3ZC8_;1=6\$!;:#,Q'(IMYX?O+*2W#M"T,S!%F0Y0'WXK9ATW[?X1:
MW6X@@"7CX:8X& >E0ZM;#1?#":=),)Y;B3S59!E5 ]*A5IN5K]36>%@H7<=E
M>]^I$O@V[D1G6^LBJ_>(D/ ]^*SK[1;BRG@A$T-Q).V%6%L\^]7?#X TC6AC
MCR16=HLD<&I1EV"!T:,/V5F& :TC*=VF]C"<:/+"RM?S+3: 5&Q[V(2YQ@JV
MS/IOZ9K*FBD@F>*9"LB-M8'UKK9C-)8R:6D$JW/V58_,.2AP>1Z#US7/ZU+'
M+JC>6P81HL;,#G<0,$U5*<I.S(Q-*$(IQ,X_I79^%?"ZW"+>78)7JJXKE+*(
M3W\$1_B<"O9;6%;>UCB4 !5 K'&57'2)Z&4X:,VZDEML><:OXYUCPOXPET-M
M!BN;>XP^GR+*(59<<J2>"V:33O'VN:]XRM] AT)+41-OOY&F$RI'CID<!LUD
M>.[C5O&/B6?0;31;B]T73)%^UFW*K(\N,@!F^Z/I47@N?5O!/B>#2YM"N+'0
M=5FV0_:65Y(YB,XW#EA]:\N[/I++9G:^*/"D4D#WUC$$E7EXQT8?XUP6<GO^
M->XN-R%2,@C!SWKQS6+<6NL7<*_=60X^E>I@ZKE>+Z'S6;86,&JD5N>T5#/$
ML]O)$XRKJ5(]<U-5+4HKJ73+E+*0QW+1D1N.S8X/->6?3F1I6AWFF>%QHT=R
MD9C@>.*>,'*,2<'![ $?E6!_PAOB"2>(R:PJ6X@,;P"1W!.,9R>N>IST[59M
M;/QHEK:Q23H7(422>8"5PQ))R.201TJE':>.5:SM6N9/.57;SRX*9W+CS..>
M-W H Z_0-*DTBVGAEE60R3&0%1T&U1C]#6N6 ZD"N @TKQNUMBYU/;*K2,/+
M889L?*.1]TGMVI4TGQD9[AFO$8J[M [N,KD< #' H [[(I:XJQTSQ6+B"6YU
M"188Y%*PM(K$IGYA(0/F./2NUS0 TD 9[5D:G+:2JAFN&A\LDAL>HQ6LP#<9
MJG+I=I<$^;%OSZDU4;)ZF=13M[ISB0Z1'C&J?PL#CJ<U;LY=&M%<+?(S.FPG
M/05I?\(_IF?^/1*/[ TS_GT3\JUYX/N<BIUUV_$Q%CT;*,VI E3Z8''M3HTT
M=1A]1#G).3ZY'^%;7]@:9_SZ)2?\(_IG_/HE/GAW8>SK^7XD>GZAIB0+;PW:
M-MZ GFJ/B21!/8R;AL$F2<^]:L6C:?"VY+2,$=\5D^)8D::QC*@QL^"O8BHB
MTY>Z554U3]^W0LG4OMQV6RR>5_?4?>^A["K,4-P$"KM@7^Z@R?SK.;3Y-)8&
M"9Q:$\;OF"?4>GO5];V:( W$3A.OFQ_,A'\Q7FVJW?,=_LE9-.Y.ME&#N='E
M?UE/3Z581F' C 4>E,AN!,H,4R2K['FI!YF2I4 'OFJ;=UN%K$%Q<QQR!3#Y
MF%+YXZ>U5%U.WW96V'EJ-R$ ?=]:L7=Q'%(L36YE)7[W' Z5475K9HT:.T;8
MA RRCI[5U*]M2&;$4BRIN4$#W&*K.Y6XEPA?D=/I266HB\<JL+IA<DM2LS"X
MFV,H/'4^U,N(\32;<B'!I7D=H9 R$?*>:$D8,NYTQCGFEGDC^SR8=?N^M,9)
M%_JE^@KFK7_DIU__ -@R+_T,UTL7^J7Z"N9M?^2GW_\ V#(O_0S0B'N=7111
M2 **** "BBB@ HHHH **** &XQ63K^EKJVERP$#S!\T9]#VK7IK#C%-2<7=&
M=2"J1<9=3PUT:*1HY 0Z$@@^M)76>-]'-M>+J$2?NYN'P.C>M<D.E>]2FJD4
MT?$8FBZ%1P9K^'KVWL+^66Y?9&T#H#[FM73_ !#:0:'B9LW\"/' 2#G!Z<UR
ME&>:B=",G<JEBZE."A$Z6+5[,1Z%NE^:U8M.2#P2*AM=8M(]0U2"Z5I+"]D)
M)3JO/!K R*..U+V$;6*^NU&[V-JXMO#\%M*T5[/<S%2(T"X /;-1ZY>V]XNG
MF!RS06ZHQQRK#TK)HIJC:S;N2\0W%J*2.BO-;BDFTS5(F!OHEV7$9&-P'?-+
M,GAN_G:\DO)X2YWO;[,\]Q7.?C1@4O81Z.P_K<FW>*?];F[=ZIIVI:I']KBE
M33X8O+B"?>'N:LV+:!I%T+V#4)[AT'R1!,9^IKF>E%'L(O1,(XMJ7,XJ_<WK
M'5K.XM;JPU176VN)3*CI_P LV)J>"[T;0EFGL+B6\O'0JA9<!,US5&:/81[B
M6+E:[2NMGU->2^MW\*)9%]UP+DRLN.QIPO[>Z\,?8;B3;<6TFZ D9ROIFL;B
MBJ]E&VG>Y+Q4GOVL:^DWUO::=JD,S[7FC"QCKDUD8X QQ1P:/QJU!1DWW,IU
M'**B^A/]LNA#Y'VJ;RL8VESBH.P]J**:5MB7-O=D]E,+>_@F/17&:]G@D66%
M)%.5900:\0-=KX6\51P1)87[E5'$<AZ8]#7%C*7/[R/:RK%QIMTY=3EOB1I+
M^'?$R^(+74KQ+;475+K3[*X\N>1^@=!_%]*B\ :4WB?Q8VIW&I7_ -ATN3]Q
MIVH7&^X$G3>R_P -=1J'P[;Q!XLN?$-SK]U$^ ED+0@>3'CGKW/K3;?X<'1O
M%-EXCM_$-W)<1MMNC=L#YT6.G'>O,L]CZ;FC:]ST.218XV=F "@DFO'-6N1=
MZI<3CH[DBNK\4>*HY8VLK!\AN'D'3Z"N'ZDFO3PE)Q3D^I\QFN*C4DJ<>A[O
M1FBJ.J7C6%F9U4$AE'/N<5Y9]27J2D!! YJEJ=\;&&-U )>54P?<TK@7Z**3
M(]:8!6?JFIPZ5;&:8GT51U8UH5R>OC=XCT\2_P"JVL4!Z%JRJR<8Z&<Y<L;A
M_P )'JH!F.EGR ,_>^;'TK<TO4X-4M1/ WLRGJI]#6=D^^?YU5\/ +X@U(1?
MZG"DXZ;N]9VE"2UNF3K&25[W.LHI!2YKI-@HHHH 8W2N:\0K&U[:;Y]G(^4C
MISUK9U/4(M+L7NI S*F!A>IK&UN3S;C3Y19M(&(8>V>U:4_B.7$J]/YG1A0T
M8!YX_.LUH9--8O"I>U/+1=2GNOM[4]M42/5X=-:)A)+&75L\<=JTB..E9M:G
M5%V2,:>&"Z*/;#;*_(E0[=N/7UJU8-.F^WN9!*\?\8&,BD?346Y-Q!(T+,,,
M%Z'\*M00+ I )+'EF/4U*6I<I)K0EV XRH/N:;Y$7/[M.>3\HYJ3(Q5/4[I[
M/3I9XU#.@X!Z51!95$3[J@?08I&AC<Y9%)]2*PH]4O9%+"[TX '!#$\&G_VA
M?_\ /WIOYFH=2*W8TGT-G[/#_P \T_*C[/"/^62_E6-_:%^/^7K3?S-0W&L7
M\"$B:QE?!(1,DG%)5(MV3'9G1@8&!P!7+VO_ "4Z_P#^P9%_Z&:Z2%B\2,>"
MR@_I7-VO_)3K_P#[!D7_ *&:U1+.JHHHI %%%% !1110 4444 %%%% !2'I2
MT4 4-4L(]1L9+>0<.,#V/K7G#^"M61RJHK <!L]17JE+6M.M.GL<=?!TJ[O-
M'E/_  ANK_\ /):/^$-U?O&M>K8HQ6OUNH<W]E4.QY3_ ,(9JW:,4O\ PAFK
M_P#/):]4HI_6Z@?V5A^S/*_^$,U;_GDM'_"&:O\ \\UKU7%%'UNH']E8?L>5
M?\(7J_\ <6@>"]7_ .>:5ZK@T<T?6ZO</[*P_8\K_P"$+U?_ )YI^='_  A>
MK_\ /-/SKU3FCFE];J=Q_P!E8?L>6?\ "%ZM_<7\Z3_A"M6_NK7JE%'UNKW#
M^RL/V/*_^$*U;^XGYTO_  A6K?W$_.O4Z*/K=7N']E8?L>6?\(5JW]Q*/^$*
MU;^Z@_&O4Z*/K=7N']EX?L>6?\(5JW]U*7_A"M6_NI7J5%'UNKW#^R\/V/+?
M^$)U;^ZE'_"$ZM_=2O4LF@T?6ZO</[+P_8\UM_"_B&VXAN'0>BN:=/X8\07
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MP6O_ !=U[7O%8T[P7>VT%F$RLER%7>>I)+=* /H:C-?/!U_XL G_ (GNC?\
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M%G_(NS_5?YBMTUB>*(S+X>NMH)*@-^1%3+8WCN<Y$!&4;.%*@%6[U%,H$]D
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MUH/_ '[>I/"_Q+T#7= M;^XU&UM+AUQ+#+*%96'7\*VO^$S\-?\ 0>T__O\
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M!<NR[ON\YXY&<\4V[T+Q=-:R1-J4DR2HRO&\BKVR,$ $'- $SZ/XK\Q NHY
M.TSEE\P*<$]L=<XINES>)HO%<%G?23RPJO[UE \K;MXYQ][--73O&?\ 9UP3
M>DSB'9;Q><HVG=R68#E@OX4K:9XW-FSIJ2B[V!=C,NS&WDC ^\3GF@!LFB>*
MM0U"!;^Z)M(KU)G"RJ ZJ3]T 9 QC(/>O0*Q/#YU6.QBMM60M<QQ@O/N!#D]
MN/3UK;H 0UD:Y.D-G&LK;5DE53],Y-:QK+UJPEO;5##M\V)MZANA]JB;:C=(
M3V*]SJ%MJ,MM:6\N\O*"PQV7FMW%8.E:7/'=B[NHTB95VHB'.,]<UO8XJ*4Y
MSA><;/L",V_D6TE@NI"%1<J[>QJO!J=G<ZM&+>=79T*L![<BKNHV*ZA82VK]
M'7 /H:YKP_X9N].U4W%PR[$!V[3]ZJE*2DDEH92E-22CL=GVHI!TI:T-@HIC
M2(A 9@"?6CS$ SN7'KF@!]%1F6, $N #TYZT-+&F-S@9Z9/6@"2BHUGB8X$B
M_G09HQP77\Z )*Y6U_Y*=?\ _8,B_P#0S74Y!P0:Y:U_Y*=?_P#8,B_]#--"
M9U5(W2EI&Z4AGSMXW /CKQ"&#E2R9"$Y^Z.F*G^$]S]C\4ZG/9V=Y=.MB/W+
M'YS\_;-1>-%<_$#7D#%&9D(('3Y>M:OP@AF3QSJ)EF:8BR +$ 8^:O0FOW"8
MDD>E?\)1K&/^12U'/^^G^-.\,>(]3UP2_P!H>'KS2]C$!IR,/@]N]=-1CN:\
M\9R^B^"M(\/>(=3URU,@N=0.9=[_ "CG/%7O%!AE\*ZJCO&RFUDX)']TUX9K
MDVI_$'XMWOAZXUR32+6V+1VZ E=Y'8#C)/6M35/@A=V.DWEX?%M[((87D*'.
M&P,XZT 2_ _PMH6M^#)[G4M)M;J<73*'ECR0,#CZ5JZFWA.T\1WFBV'P];4Y
MK,*9GMHEVJ6Z=33OV>/^1"N?^OQOY"MWPMQ\5O&7IMM^G^[0!SFW2,9_X5%=
M_P#?I/\ &C&D?]$CN_\ OTG^-=QX]\:V_@;0/[2FMVN'>0111*<;F]SV%4OA
MS\1(/'^GW,R6K6MQ;.%EC)R,'H0: .4AF\+KJEA9:C\-9=/6]F$$<TT2[0QI
M_P 7?!_AW2?AU?W=AHUG;W"NFV2./##)KI/B+_R$_"77_D++_*J_QN_Y);J/
M^_'_ .A4 :OPP14^'.AB-0JFW!( [UUYSVKDOAC_ ,DXT/\ Z]A774 8VIW.
MN07"C3=/M[F+;\S23["#]*S;'4_%TNNFWO="M(M."C]^EUN.?IBNJSGI10!A
MZG%K!U.*;3RIA5,,C, ,\\^]4F'BY;B"1!9M&=PEC/ 49^4CU.*ZJDS0!S4M
MOXA>W!\P"47!;:K  I@<?GFH[>7Q;-%"6BM(MR@L6ZKTSQ^==2>>*!UH R]+
M75E+_P!I&%A@;3&,8/?O]:U:** "BBB@ HHHH **** "BBB@ HHHH 8RAEP>
MAK&N="#RF2%PI/8UMXHQ3BW'8SG3C/<Q[31EBE#S,'(.0 .AK6QCM3L4M#DY
M;CA!0V"BBBD6%%%% !6-XAM]1N=(:/2I"EQYBDE7V,R9^8!NQ([ULUROB2P\
M0W6I6+Z/<+!!$<RDOC/J,=^* ,.^TSQ-J<U]9+<W<5M"L4D1:3;ODR-R;\<@
M =>Y-%W8>-(W(%U/(DTX4B.8=.?F!Q\B],CVJ6_\-^*)[7[,-2DFB<@L#/M8
M-@9)..5R#\M:FJZ/X@N-1,]CJ+0Q+&B1Q[\+G!#DC\L4 97]B^,(KJ)H[Q%!
ME,L\J2X#9&#\I'M3X-#\7RVD$<^JR1F-CEXY@6<%NK''/RU,-,\5SS*]S,/)
M.X"%+C;L.W&6./F'7CWJM8Z'XRL9)/\ B91R0Q+&(80V R@_=)/3C//>@#JO
M#PU)--2#55)NH?D:7<#YGO6Q7&Z'IGBFVUR&XU*\$MH8-LD9DR%?V']:[*@
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M3[?X4^B@"+RE\T2%$W@8#8Y ],U+110 4444 %%%% !1110 AKEK7_DIU_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****  ]*Y:VBD'Q*OI3&WEG38@'QQG>>,UU!Z4@X.*+@.HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )F @8# 2(  A$! Q$!_\0
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MRFL>V\(G^TX-1U/6=0U*:V;?"DC+'&C>NQ  3]:Z"X@%Q:RPN2%D0H<>A&*
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MB82260$GYC7:F:&*1(&=$=P0B9 + >@KB;/X9)IVGQV%EXI\06]K$,)'%<J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:CHH"R)//F_YZO\ ]]&CSYO^>K_]]&HZ*+A9#_.E_P">K_\ ?1H\Z7_GJ_\
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M1T%=[@>E%)UG8+#8T6.-44 *HP *?116(PHHHH **** "BBB@ HHHH ****
M$[4QG6-2S$ #J33B< ]L5@7UV;F8J#^[7H/7WJ9.Q<(<S+TNKQ*<(C/[]*8-
M9&>83CV-9-%9\S.CV43HK>\BN1\C?-W4]15GM7*JY1PRG!'0UT%E<BYMPQX8
M<,/>KC*YA.'+JBW1115F84444 %%%% !1110 4444 %%%% !1110 4444 ,9
M@@))P!6=/JF#B%<_[35'J-P7E\D'"K][ZU1KBJUW>T3HITTU=EO^T;@'.5_*
MK$.J D+,NW/<5F45BJTT]RW3BSI%(8 @\&EK*TVX*OY+'(/*^U:M=].:DKG-
M)<KL+10**T)"BBB@ HHHH **** "BBB@ HHHH **** "BBLO6]1_L^R)3_6O
M\J^WO0E=V =?ZQ:V'RNV^3LB\FLA_%<F[]W:J!_M-7/,[.Y9V+,3R?4TE=2I
M+J*YU5MXIA=@MQ$T>?XAR*W(I8YXQ)&X9#T(-><UIZ-J;V-TJ,<PR'#*>@/K
M43I=4%SN**12",@Y'K2U@,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"O=N4M)".H6N;KI;E#);R(.ZD"N:QCCTXK*>YT41K!B (R Q. 6Z#\*Y
MSP9K-[K-MJ;W[QO);7\ENA1=HVCIQ72.JNA5@"IX.>]5;+2[#3/-^PVD5OYK
M;W$:XWMZU)MU+=:.CN1<.G8KFLZM/1XB9'E/0# IQW(J?";-%%%;'(%%%% !
M1110 4444 %%%% !1110 4444 %(:6D(I/8#G93F9S_M&F'H:GO(O*NG'8_,
M*@[$5Y<M):G='5')VVHZF-5TV/\ M:UN8#)(MY(0%5\GY$C'7</_ -==8:SX
MM!T>"=)XM,M8YD;<KB/E3ZUH5,FGL")+<D7,9[[A70UAV,1DNE./E7FMRNW#
M)I'-6>HM%%%=1D%%%% !1110 4444 %%%% !1110 4444 )7(^*9"=1C0_=6
M//ZUUU<MXI@(GAN<?*R["?3O5TOC$SGJPM<74099;/4Y(E2/+0Q(C%5')9L@
MG\JW>]4Y]*LY[B6XDB(EEC\J5E8@NGH<=176Q#M,NX;_ $RVNK><SQ2H&64K
MM+^^.U63^N.*9!!%;0)##&L<2*%5%& !4H4NP51EV.U?K0!W^FRF;3K>0]2@
MJW5>SA\BTBB_N* ?K5BN%[E!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 )61J&GMO,T(R#]Y16Q24FKE1DXNZ.4HKHI;."8_/&"?4<4Q=,M5.=F
M?J:SY&;^V1BV]M)<R;4''<]A706\*V\*QJ.!UJ1$1%VJ !Z"G5:C8QG-R%HH
MHJB HHHH **** "BBB@ HHHH **** "BBB@ HHHH K75LMS'@\,.AK'EMY(&
M^=3]:Z#O2$ ]>:PJ45(TC4<3FSUJ6&VEG.$4X]3TK<\F/.=BY^E2# ''%9+#
M)/5ENL^A!;6ZV\>U>3W/K4]%+74HV,6[A1115""BBB@ HHHH **** "BBB@
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MGC_Z]5]:\,7UY/9WEBR0:E9.TUO*S'8&9OF1O4%: .H?5+!/-#WD"F%@DF7
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MV3.$-R%$DJ* 6QCG]*B_X1NU&5$DFQK@73+GK(!C.?3VJZFJ64S!8KJ-G;.
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MAOZT :0Z4444 4-6TJSUO2[C3K^+S;6X39(F<9'U%4?#/A72O"6F'3M(@:*
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MGMKM@DTT19S)$RJX"DXW'"T 3:5I<>E6TD,;LX>>2<EASEV+']36B*0=*6@
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M)W8Z],U/+J:6]E:ROM=Y@!M# <XR<5E'QC;-$TL=I*\*01SNV0,*S%>GJ"*
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MM;?>S>1'N?[Q*CFFO96LB*KV\3*IRH*C@US2Z]J,]V;2.:R6[C:8&+/WROW
M,^O.?2K;:U=S0VCP6Y5[H9"R(0(E'WV<_P AWH TH](LH]0DO5B'F/&L1&!M
M"J<@ 5.EA:1XV6T2X8MP@')ZGZUSTNL:FUQ!$8"@$RF25(R4:,DCZ@^HJ*Y\
M3ZA''));632;H#)%OB9?G#A2A'8XYH Z:2QM92[2V\3-( &+*"6 Z ^M/%M
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MNW+SJ<G>3U/Z"M&B@"@^F6DD]K+)$7DM6+0L23M)&"?RXJ(Z+8>8KB#E7=P
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MM<M[&^2W3RFMF<6\17?O0+E2#ZD^]1W@UW[/YCR7,OG:<28%B7"SG;\O'XT
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MW/'9F&9_,W;I,YR!Z&ND'2@!:*** "H_+02%PHWD8)QSBI**  4444 %%%%
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MUL8VX'S28_05S-<%9IST/1H)J&H4445B;A1110 4444 %%%% !1110 4444
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MU14225T13G:O<U,KVT*C:^NQP,LLD\SS2MEW))IE=@/"-IWFE/Y4[_A$;/\
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M8<&DT;4ZG-HRU1112-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2D)
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M;>0HX]^#]?6NXT;5DU.VR?EF3[Z_UIB:-6BBB@04444 %%%% !1110 4444
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M;;QUILW]D/+%/;0:I$)(9Y%'EAF/RHS9X8XX]:O-XG@77(M'^SRFYFBEE3)
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M0!C#P[;KXGCU[[1,;B.T^R;.-FW.<],YS[U!-X6MY]3U6^-U<*^IP);SHI&
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M\0M8:/9ROLFG>Q%RZG.9, 9Q^=+-XFE25XTM Q8!X/GXD7 )Y['GH:Z,QH<
MHIQTXZ4NQ/[J_E0!R:^)I9;V3R(O-Q:"41,VSYO,VD8(Z_C@U<TW7)K_ %KR
M JK:M;>8FY2K;P^TCGTKH/+3^XOITI=J@@A1D=* .9@\1W+:BEE/:".8N\3D
M;B%D'*#IT9><^U5+?7[J9Y$+*(?,ND:0GH8\;=I&/4\5V.U3R #GOBD\M,8V
M+CZ4 <QX9URXO#9V5WM>22Q6X$H/+<X.?TKJATI@1 054 CIQ3Z "BBB@ K
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MS-&5:^<_N9;=24&?+?L?<8K2;7]/6R^VM(_D9VE]A^4[MN#Z<FA]>LDD\O\
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M$\5Q)"+B1)I%3O(@P#[@C&1[52B\)I;ZHK1SM]E^RRP,I.7/F/N/..G)HHH
M73O"L5N+R.5@T#W8N(47^#:H50>.V,U=@\-6EO#!&CR;H8G@#DY)1CD@T44
M0-X5LA$((7DA!MS;97O%V4^N.Q]Z?%X:M87C<32Y6X6Y[<LJ[1FBB@!G_")V
MHMA";B<Q*%PF[@%7+ CT.34L?ARSCO([@,YE7S-I;!&U^64CWHHH A'AFV6Y
MD*.P26X%R2#AD<#&%QT!'&*OW6C6UW=-<'<DCP&W<J>L9[444 4AX2L!"T6Z
M3RC<+<;<]U7:!],5:CT.U@TS["A/EF'[.'P-P3TSWHHH @E\+VTJR!I9,/Y
M(''^J^[4=SX4T^YLA:,9!"$D2-0?NASEOYFBB@";^P;;[=)>"203-(DF1C@J
MI7C\":;#X<AM?(D@G?S8#*8R_(S)U)]<9HHH T=+T^+2M-ALH22D6>3U))))
M_,FKM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %: ET# 2(  A$! Q$!_\0
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MCJB^K'%"R(^-KJ<^AJ>97M<+#J***H JM?C=;A"2%>15;'<$\U9JO>_ZJ/\
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M ,)%JO\ T#K?_O\ G_"JE%/^Q,+V(_M2KV1;_P"$BU7_ *!UM_W_ #_A2?\
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M,,>,YQMK/DTATN%:TN#%#@YC8;AGMCVK5HKR*6)JTG>,C5Q3W,Q=*9D)ENI
MY/\ RSZ >U-DTNY4XM[A3&?^>HR1^/>M6@=:V6/Q"E?F%R1[&?8Z>]G-)(\B
M-N7;M1<#Z_6M"LRWUB.>*ZE\LJMOD-D\D@]O:E&J-+;6LUO$KF=MNQFP0>_Y
M5SU'.I+FEN:*#6AI450.J1?;+JW"Y-O'OS_>(ZBHH]9C>QANC$PCD8J!U;IG
MD5GRL?(S4HK.75-TEJ/*PEPH.XGH3VILFJ/!!>RSPJJV[[%"MDN:.5AR,TZ/
MKTK*N-<BMS"?++)+&'#YX!)Q@UJTFFA.+6YFOHT+S,PED5.J(IQM/J/\*IZC
MILRZ=<M)=Y54R J8)^M;W:J6K#_B477_ %SKKCC:Z5E(JC&/M(^IG,LMI'&)
MU+1D#$JCCIW]*>)$+;0ZEB,X!YQ6N@#6Z*P!!0 @]^*R-3@MMZV]O (KCA_-
MC&"JU[."S.<VJ<E=G-7I+F;$>18P"QZG  ZD^@K1@T+4+E-[2):CLK+N8_7T
MJOHLEC8RXOH@\N\LEVPSC/KZ5UL%S!<@F"9) .NULXKHQF,K0?+%6.S"X6E)
M<TG<YBYT>^M8O,(2=1]X19R/?%9TC*T;HZ2JI&TYC88_2N] H(!&" 1[US0S
M.I%6DKG1/+Z;=XZ&/X>O)+JP\J1,B#"+)CAQ5F^T>TO8F'E)'*>5E08*GUJ^
MJA0 H  ["EKA=9\_-'0[%27+RRU..ETS4H#M>T,O. T1!!]_:G?V3JOEAOLB
M9_N^8,BNO_&D]J[%F5:UCE_LZE<X9]\+[)XGB;.,..,_7I2UVD]O#=1&*>-9
M$/56%9A\-Z?N!3SH\=A(2/UKKI9HK?O$<E3+'?W&<ZS!%+,< =2:4I<+"LSV
MDZPMT?;G].M=-#H.G1#F#S6SG=(=U:0Z>U34S5W]Q%T\L5O?9P?GQA]C-L?K
MM<;2?SJ"VD5KJX5>5R#N'2M7Q-%'_;4<DX0QM;X&X=P:STE@1 J,H4#@+T%>
MG0KJK!39YU>C[.;BB:BDSD9'2EKK.8J/"]NS36X)!Y>+L?<>]3Q31S(KHP(/
M;/-25"]I Y+&)=QZD<&E89-157R9K=<V\A=!_P LY.3^!J:.9)(PZL-ON>E%
MPL2456^W0EN-Y7."X7Y0?K5F@1M:'-;75N^BWRY\PEK=R/NGTSVJM9W=[X9U
M*2%E)4'][#_"X_O+[UFEVBQ*AVO&0RGW%=EKFESZQI5K>PQ;;Q(PQ0]6!'(K
MCJ)1E9[,[:;<XW6Z-ZQOK?4+5;BV<,C?F#Z&K8KC/"^G(--6\TR9X;D,5N(I
M'+(S \Y'8UV*DX&[KCFN.6CLCMB[H?1112&9NM1N^EW&R,2X0DQ$9\SVJKX5
ML)+#0H5GC$=Q)F20#L3V_*M2\57LYD<@*R$$GWI;6(0VT40)(1 N2<YIWTL*
MVMR>BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#'\23_9]"NGVS$;,,T) 91Z\UYK;*-F\$%7 *]SCZUV7BRRUNZ5U@
M99M.;;N@C3]X".N3W%<F",E0-I7JI&"/PKMPR6YPXEO86BBBNTXAKHL@VNH8
M=<&DM+I[74X[%(9)$G'[M5Y(?T ["B0D(<#)Z"O0= T&PTRT@EBC22?R\&<G
M<3GDX/I7GXVG3J0Y9(ZL/!R=S,B\/:A)#YCO%$W:,\_F:I75I-8SB&?82R[E
M9.A%;WB#71I<?DQ;OM+ %?DR .Y^M<Y--=7ETEQ-<[_DV[=@%?-XJG1IQY5N
M=DDD% &:9*_EQ.X&=JDXIPL+B>U:22ZVATRJPK@]/6N*AAYUOA(2N0#[*9S
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MN>RUP353GNST(.GR6*-MX,NYHHY[BZ1) =X@V97/8-ZU<FM8YIS:ZA;P-+$
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M;BUBN#;L$=7+'<,(5Z _6M;G+R2.NHJ*"7SH(Y,8WJ&Q]:EID!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &=J6C6.K*@O8!*$.1SBJDFA
M%=ZVMR88GZJ1NV_2MRDK.5.,_B12DUL9$FA0+&/LA\B51]X=&^HJ./1II74W
M<R&)3DQQC&X^YK7F=HX6=4+L!PH[UEG5+_)QI,IP?[PJ'0IM\UAJ<K6N8FO:
M0(KRWBM%VB;.]G<G '4#\*HO-HR.V]CN4XW,3D$=@:NZ]J-Q-+;(T+VUS&2T
M: ABY/&#[>M TZT.YY(5WM\SDG@''-:*E%:I"YGU97M[K3&V_9W0R2Y5&?DD
MXSWJ;2HT%FDX'[V49=CU//\ *J;VUI(6^PVB';_RW;A$]QZU;M+NSBCCM5N
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M:LVW<R0 GJ"5/U'%>O@<=]9NFM4>'6IJ+]W8EHHHKU#$**** "BBB@ HHHH
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M_MW7_P#GCI__ 'TU'LY]@]I3_F1U]%<A_;NO_P#/'3_^^FH_MW7_ /GCI_\
MWTU'LY]@]I3_ )D=?17(?V[K_P#SQT__ +Z:C^W=?Q_J=/\ ^^FI^RGV#VE/
M^9'7T5R']NZ__P \=/\ ^^FH_MW7^T-A_P!]-1[*?8/:4_YD=?17(?V]KW_/
M'3_^^FH_MW7_ /GCI_\ WTU+V<^P>TI_S(Z^BN0_MW7_ /GCI_\ WTU']NZ_
M_P \=/\ ^^FI^RGV#VE/^9'7T5R']N:__P \M/\ ^^FH_MW7_P#GCI__ 'TU
M+V<^P>TI_P R.NS2UQQUS7NT&GD^FYN:V]#U?^UK)I'B\F>)S'+&3D*P]#W%
M2XN.Z*BU)7B[FO1112&%%%% !1110 4444 %%%% &)KRD2V4N/E#E2?3(JC7
M1W-M%=V[0S+N1NM<Y<6\MC=+#(YDBD_U<AZ_0U2)84444Q!1110 4A ;J ?J
M*1I$09=U7ZD"JK:E"7*0*]P_I&.!]3TH :T:1ZI;^5&$+(Q<J, CMFI1?6QO
M/L@F4S8^Z#^GUK"N]2O7O62W@/FN/+7:<A<'D'ZU?L-'BMC#]H<R3S2*KN3R
M!Z TKE\J2NS=TNV^T:E]J"D1P J&'\3'M]!71U1TO38]+M3;Q22.I<OF0Y/-
M7JD HHHH 0@&N6EL!I=V7?<\4K$I,Q)*D_PG_&NJJ-XUD0HZAE/4$<5G4@IQ
ML7"7*[G&ZHLUTJI:2-NC!D<1]>!QD^E7[9VDMXW;;N903M.16Z+6."V=+:)8
M\J<!1CFN=T]D:RC"'(7*M[$'D5YU>DJ<4=E*ISR9%>Z7#?2EY&8'R6AX]&ZU
M2_X1JU1;CR998FG,;$CG:R="!6Y17+=G29"Z#  I\Z4RC>6DSRQ<8)J73M&M
M=*D=K3>JNBJR$Y!([_6M*BB[ *BGE\F,M@L<@ #N34C,%4LQP ,DFH+*UO=5
M$4DT(MK0MN(8Y=U'3Z5I2IN;,JDU%%#4_#GB&^D7[/>6T,+?.T;@MM8=,5%I
M_P -XEO([S5M1FO94.0@4*HSU'KBN] P !TI:]F$5!6B>=*3D[L\LO+"6S\1
MRV 5HH(LR((^0\7502?0TT:P&R?LD^ <9Q7<^(]#_MBQ*PS&VO$YAG7JI]#Z
M@^E<?;W;M>7.GSE/MEFP64(#M.>C"O(Q].7-[1[&,O,J#6U,A3['<<=]O6I1
M(FJQ/"T<T*C#!NA-:&2>]9]UJ4@DFM[>+,B''F-T!^E<-"G.I-*FM3.4HI;&
M9=Q7D6ZW\HS<$[E.6*^N*ANM.2U%O/Y*"&8?.K#F-_\  U:AGFLI9999I9?-
MC(+XSM;M]!5V2SU"ZB&;N,HZ@XQD=*]Z=?$4)1]IT.W"8>E4IOE>ICQF,#$9
M&!QA>U0M<-:7(6';)).1B'^)CTR*M7JI'=1P1J5FA4)(W17'L/7WKM/!>BQ)
M;C5IE5YYAMCRO^K4'M]:]6.)YZ7/8YJM!1ERO4Q)?#WB&VM&NIH+;;C<8A)S
M&.^3WJKI=K>Z\LW]F0J1$^QY)3A0>OXUW_B#5TTJQ_U0FFERL<1Z-ZY]JYGP
M==W,&I-8QPQ^1+F5\'E#_AVI*K4Y6S!TJ:DD*GP\2\68ZQ,)VV%8?)^4#W/O
M5'1/ ESX?OS>I;K>R@%4\YAA >X'<UZ6.E+7+)\SNSOIU)4X.$'9,YZ:/40W
M[K2;-A@=0.3WJU;VHFLG-[86\<F""JH",8K8J)P61@.I!%382F[G)>%-$LY_
M#D22H6!ED< '&/FZ5K_\(QI8.?)?KG_6&L6R;7]&TW[*=.A>-6($@FP3D\5H
M"_\ $0  TB @=_M&:E/0VG"3DVFOO&^+P%T:!1T%S&!^=9]PYBAED5#(R@L$
M'5CZ5FZUJ/B"XE\C4=-C@L5GCQ*'S@Y[>M:<J%PZ99<Y&Y>H]Q7;A973L>7F
M--PY$]?0R;762UA]IN K-G!2$'*>H8'O2C7(5DEW M'E?*V#ELC)S2MX?@=2
M7GN'E9MS2L1D\8QZ4[^P;8(H5I%9-I5NI&!BNOWCSN5$UOJEO=W BA#L=H8L
M1@ &J5SK,L.M_8PL0B7#.6_N]SGV]*O+IL8NXKEI)&:(84'@=/:JMYX<M+V=
MY)9)U5VWE%; W>M#YK$J*OJ/U+5'L;NS58T>"4GS7)Y5?45'%K;/J-U"8<V\
M*@HZ')<YP:NW&FPW843;FVQF/Z@CFJQT"U\E8E,BA45 0>< YS[T>\-)6%.M
M0.@\E)'=HV< +PN.N[\:@M_$5I+9Q2D.S.N3L7@D#YL>PJW;Z1#;(RH9#N1D
M)/<$Y-0)X>M(0@A>2+9]W&#C(YX/K1[P<J$_MM6,VR,JD4B+YC#(8-_^NG)K
M]FXD.)E55R"R8W\XX_&I9-(ADDD<O(!(5+(#P2O0U7O=!2:Q\F!RKJNU2YXP
M6R:/>!119BU6WDL'O-KI&C%2&'S9Z8JI+KADE@BMH'#L[+*LBX*8&>GO4]II
M3II+6-T^X$Y4IU3G(Y[D>M.BT>&)UD+RR2AF9I'/+$C'/X47D%DBI;:Z?(2>
M[7:)$WK&B_-UP!5IM:MDE2)TF1VQN#+]S/3-(^AVS0QQYD C38K \CG(/UIX
MTE!<K<>?,TN '9\$OCIFA<PK(;>:H+.\:!P,"W,H.,Y(/2HXM=@*PB1'#.%W
MLJY2,MT!-79;*.6=YV#;VB,)]-IJJ-"MUD0AYO+&W=%GY7*]"?>AW!174:NO
M6;^:=LRA 2"R8#X.#M_&HF\0P_:;9=CK'-O7:P^<N.P%.O="2:Q,,#E9 I52
MYXP3DTVWT!3!$+MLR0D^44_Y9@^_<^]*\BN6),-=M,OD2JBJS!RG#XZ[?7%(
MVO6@@,ICF#!BIB*X;@9SCTQ2KH-L%96DF="&"*QXCSR<?6JVJ:"UVRO;N =^
MYPYQDXP,&B\A*,39@E6>&.5 =DBA@#UP:N^$ONZG_P!?C?R%4;:.2.WBBE8/
M(J@,P& 35[PCDQZF1R/MC<_@*YL3LCOP.CD=71117(=P4444 %%%% !1110
M4444 %4=3L_MMH44XE4[XV]&%7J0C((]: .0:ZC@C+7+"$JVQP_9O2HSJE@%
MW?:H]N<9[4[5='6.\L4^T/( [2N9.6;!^4?AFGS-!;P,\JHL0Y;Y>!5$V(VU
M&T$,DJSHX09(5N?:H$LI[D>9?7$@+<B&([50>A/<UG3ZII)*R"RW;'PK!<?-
MC(R/0T#6M3N$W6]DI8$[H_X@.QHNBN1FK_9-@5VM;*X_VR3_ #I=/'D(]E@
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MC@8I(9;*?9LA7Y^5W18S7AO-9=(G?]5IK2[-_P#X2;1O^@A#^='_  DVC?\
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M]I%N%C>3C.R/(&>F3CBG_:T_Y >'I]V78;CP\IW3ZFEPW_31N/R%:B^(]%4
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M (2/1_\ H)6O_?P4<\>XN278U:*RO^$CT?\ Z"5K_P!_!1_PD>C_ /02M?\
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MHMT+.UAMY97*1.KF23)#%0 ![5MIHFOQ($%S8NJC 9E8$CWI3I'B#_GM8?\
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M6O6FFS7T^MQF-8PZ*EN"3GUK EU'7TCW1WOF[5WR;81\JCJ?>O698(YH6A=
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MY^_&D80L/3-=9136#HIW40^L5.Y''$(HEC0850 !Z"I:**ZS **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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%]: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X BH# 2(  A$! Q$!_\0
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MZ#BD32?#TGF[-.TQO))63$$9V'K@\<53M]-OI-9TN]O8<NEM+YY63*)(Q3
MSST/:H;2VU*U?7HEL9@UW<2203*Z;<&, 'KD'(]* -9="T1T5TTG3V5AD$6R
M8(_*D70]#<L%TK3B5.U@+=.#Z=*YQ].\2/#D2WJR;",+.@&?LXQW_P">H_R*
MDDT_Q ]W]J57,R;_ "]\JX!,2#H#C[P<#TSZ4 ;TFBZ#" 9=,TU 6"@M;H,D
M]!TI_P#PC^B_] BP_P# 9/\ "N>FTW6K@0Q2QW,L EAGC\V5 T1$FYU?!YXQ
MC&>E=E0!G?\ "/Z+_P! BP_\!D_PJKHEO#:ZMK4%O#'#"LT96.-0JC,2YP!6
MW61IG_(=US_KM%_Z*6@#7HHHH **** "BBB@ HHHH **** "BBB@#)\31I-H
M%Q'*BO&Q0,K#((WKP13_ /A'-#_Z VG?^ J?X4GB+_D"3?[T?_H:UJ4 9$^B
M>';6$RW&EZ7%&,9=[>, 9XZD4L.A^'KB/?#I6F2)G&Y;:,C/Y4SQ397&H^'Y
M[6UC,DSO$0 P!P)%8G)XZ U5O;+6?M,BVT\NP!&AE#*/7>KCN2,8/; H T/^
M$<T/_H#:=_X"I_A3)M#\/6T+33Z5ID<2C+.]O& /J<5RMW<:UI=HEO=W%XKW
M"J$(DC9PWE .02P'#\X[^AK>UJ&[U?PAJ%I;VT_VAX_+C$I4-)T^;KC\Z +:
M:)X=DF>%-+TMI$ +H+>,E0>F1CC-.70- <L%TC324.& MDX/7!X]ZP)=*UZ+
M6+^:-II(+GR5:6,QI(5",,J,X^5B#SU]ZZ+2H;R&6^%VSLIG!A9R#E/+0'IT
M^8-0 G_".:'_ - ;3O\ P%3_  J'P];06@U.&VACAB6^?"1J%4?*G85LUE:-
M_KM5_P"OYO\ T!* $\000W-I:PSQ)+$]Y"&210RGYAU!I_\ PCFA_P#0&T[_
M ,!4_P *76O]59_]?D/_ *$*TJ ,S_A'-#_Z VG?^ J?X5%)HWAR%U273-+1
MG.%#6\8)_2MBN>U;3;V768KS3Q(DG[M)=Q5H9HPQ)#J>01DD,.<F@"]_PCFA
M_P#0&T[_ ,!4_P *:N@: SNBZ1II=,;E%M'D9Z9XK"6Q\1/*D<ANTB$JJ[)<
M*"R 2Y/7OF/WJ(Q:X&@BO);V.2Y$2#R9D#%Q =_/H' - '2?\(YH?_0&T[_P
M%3_"C_A'-#_Z VG?^ J?X51T2'6HM1<ZEO,?DA6;S%96D!'S #D \]JZ&@#,
M_P"$<T/_ * VG?\ @*G^%>0:SI]E'KNH(EI J+<R!56,  ;CP*]RKQ77/^1@
MU+_KZE_]#- 'M5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!DZO_ ,A#2/\ KZ/_ * U:U9.K_\ (0TC_KZ/_H#5K4 %%%%
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M_P#B:T-3.-+NL?\ /)OY5+:_\>D/_7-?Y4 9?_"5:/\ \_$W_@++_P#$T?\
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M]/\ _%4;=9_YZV'_ 'Z?_P"*H T:*QA/K7]HFTWV'$(DW>6_J1C[U6-NL_\
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M*HVZS_SUL/\ OT__ ,50!HT5G;=9_P">MA_WZ?\ ^*HVZS_SUL/^_3__ !5
M&C16=MUG_GK8?]^G_P#BJ-NL_P#/6P_[]/\ _%4 :-%9VW6?^>MA_P!^G_\
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MQ)+$EV\;J&5EM7(8'D$<4_\ X22R_P">-[_X"O\ X4 :]%9'_"267_/&]_\
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M($=>&5G (IG]LZ9_S_V__?P4 7J*H_VSIG_/_;_]_!1_;6F?\_\ ;_\ ?P4
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MB(/0A17*KX7ELK!($D>2=DMXXYHD&87CS\YR>F"176PQ)#"D4:A410H [ 4
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M110 4444 %%%% !61X9_Y :?]=Y__1SUKUD>&?\ D!I_UWG_ /1ST :]%%%
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M=9?\A;4_]^/_ - %:- !1110!5U/_D%W7_7)OY5+:_\ 'G#_ -<U_E46I_\
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M,*WL:0JCQQ;<@HI147'^[\Q]R:ZBB@#E3X;O0KQR7:O:-*)#%\Q. X8KSZJ
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M"&5A$Q)4$  8'H,#BJJZ1I;E@K2L5^]B\D./K\U TC2BI8/*0.I^V2<?^/4
M6I=,MI7DD(=99,;I4<JV!T&1V]J)M,M)[<V\D0,)C:/9GC!Z_B?6H!H>GL 5
M$Y!Z$74O_P 52_V#8?W;C_P*E_\ BJ +EK:Q6< AA7:@);ZDG)/YFIJR+K1+
M&.TF=1<!E1B#]JEX./\ >J_8L6T^V9B2QB4DGN<"@"Q1110 4444 %%%% !1
M110 5D>&?^0&G_7>?_T<]:]9'AG_ ) :?]=Y_P#T<] &O1110 4444 %%%%
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M9/\ WU0!/I*3QZ1:)=0Q03K$H>*+[BG'0>U7*** (+S_ (\;C_KFW\J33_\
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M;SVMK'H9MV\GRF;R7_=\>8P!8-Z @#- 'K%%8V_Q+_S[Z3_W_D_^(HW^)?\
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E4_D*** +-%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *D!+$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)'3O%?[<W[43>+?
MC-^SC\<_!GPE\/\ @7]KSQ+^SQ=? 7Q?X \,^)?"VM?!S]G#]J5_AC\>/'L_
MQ#GT*^\;V?QR^)&@^ ?'<O@-K5U^&/ACP7XBTCPA?>![OX@V_P#PNBQ\A^ O
M_!4?1?A-\(?VF-+_ &IO$WQ,^*'Q2_9I_:=^.GPW@UF?PE\(? ^H_$KX16?[
M37QD^$GP=\=_\)%:ZM\+?@'X.T6VA^%OBCP#KWB7XF:_\(;:Z\:_#_5+)+:\
MU+Q7X#;QI^C7BS]BGX"^,_C!%\:-7TSQK;ZW-K7A[Q5XF\$Z%\3?'_ASX-?$
M7QIX0%F?"/CSXH_!C0_$-A\-?B/XY\*S:/X8NO#_ (L\7^&]6UO3+KP9X*GM
M[Q9/"FB&S^>X/^"1?[&%M-/J$&C?&5/$-UI?B.RNO%Y_:-^.4GC"[U?Q3\6_
M'GQLU3QS=^)9?';ZI=_$=?'7Q3^)CZ;X^N;B7Q1I/AWX@>+O">G:E;>'=:N]
M.< YCQ9_P57^ GB;3] \)?"C2/V@/&'B7X[?"_P9XP_9]\1?";P;\-;[5?'^
ME?&OP?XAUSX4^*?ALGQ4\8:/X3&K:HG@GXOW&A67Q3L=%T+^U?@1X[3Q+9_V
M%J'@*7X@^)_L:?\ !6[P;KOPF_8N^&7[0%WXY\8?M7?'O]F_PEX\6>P\._#;
MPL_Q4^*>J>!-:\<P^ /"7A4>*?",VH>+?$F@^&M;O)?$WA#PD/V?/#.O6-[X
M1\2_%/PKXD@_L&/Z/MO^"0_[%^G>+KSQMHFE?&SPYKD?A;1/!G@I?#?[2GQX
MT+2O@WX=\+:IK6J^#K#X%:)IOC^WTKX,_P#"%?\ "5^.-*\'3_#RTT"?PUX?
M^(7C_0-)DMM)\8:Y:7F\W_!*7]C&WN;2[\/^#_'_ (*N=(MY%\*S^ _C1\6?
M!TW@75(I7M]"\4> )= \7V4O@KQ=X,\,37?P[\"^)O#CZ=J_@_X9:AJ7P_T&
MYLO#%_=:=* 5?A1_P4Y^#OQU_8^^._[6OPR\$?$>U'P&^$OBGXL>)?@_\3;'
M1?!?CX:?IGPNOOBYX-L[Z]\/:OX^\*V$/Q%\&PZ;K&B7^G:UKT^EV&L6S:[I
M=CJD%SH\?F^B>./VR?A+I_P[_:X^,O[0GA[XC?LHW_P:\;?&'XY_"SP[\&=)
MTWQSX2\7>,]!\$WOPF\&_!B\\/Z7>:EJ'PJ\+M=:S%JE[\2_$R^(]*OKN[\7
M^//BE<>!HI;+P?\ 6'[-/[#'[.W[)$NOGX'Z!XM\/V/BCP+\-/A[KVA:Y\2/
M'OC/PYJ.B?"7PM%X*\'W\^@>+O$&LZ5_PE*^%[>UT?7?%JVJ^(?$]K:6J^(-
M0U%K>)EY#3?^";W[*6G?\)A:R^%/&>M^'?%'A_6_"VC>!O$WQ6^)/B/X>?"7
M0/$5_9ZKK.F? 7P)K'B>[\+? ^WO-4TO1-0*_#+2_#9@NM T&2U,(TFR6( ^
M:E_X+3_LUZEHOPC\4>#OA;^T#\1_"7Q3TOXT:GJ7C'X>Z9\%_$WA+X5+^S>]
MI+\?[;Q_XAMOC='IFK'X4Z-?6_B/6=1^$MQ\4-!\0Z0S)X#U?Q;JZ/I2^,P_
M\%@;71OB-\&3H?PW_: \>_ OXF^.?VSF^*GC#QG\/?AM!XP^$=I\!-$\+:SX
M=\->#=%^'GCC3WU/P5!#XBT[6F\0>(-%\7>(1X&\1:5K'BG7-.N],\3G0O0/
MB/\ \$>?"&N_&3]G#4OAWXYF\&_LY?"R_P#B9KGQA^%>I^)?CIJWC_XWZ]\6
M/#&D>$?'<VK?$W3/C/H446C>/M,\/:;<_%OP[K_ACQ-I?QFU2]UR]^),.OO>
M0?9OHO0/^"4?[%?A[PWJ_A.+P+XVUC0]6^)'BCXIBV\4?&'XJ>)YM&\2^-M*
MM-'\76/AB^UOQ;>WWAGPAXDL]+T%M:\$:)<67A34KKPSX7O+O29;CP_I4EJ
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M>OQTA\;^)[CQM\?-.L1!XU^(7BGX-R7D$6B>.OAKH'@SX4W\^BP)K/Q"L?\
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MH^GM  > ?MD_M>_$G]D7]LZ#QIXA\:?&CQO^R[X)_8C^(WQY\>_LV_"7X>_
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M1?$[P[\3;#5(/'FC?%=?%]W=^,W^)-AK\'C";Q=>7GB"XU:74;RYFE\9O_\
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M^)M/@US0?%/BF&\\;>,]!U"*?2_%_CK7?$OC#Q#;:AX@\1:O?W?;?"#]AO\
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M6T-G965I;HL4%K:6END<%M;P1*L<,$,:11(JHBJH J1ENBBB@ HHHH ****
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M&GD4?U."E_R,\=Y8/+5YZRS%_H%%%%>,=X4444 %%%% !1110 4444 %%%%
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MQ6_:ZD_YY_&_PO9^A_<_ #X-W(&.XQ>Y#YR=Q7 "#/M9;IEO$;_ZE^6Q_P#
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MB@#^2;P1/X)M_BYJ/CKP[\%OB3\+M>^"TO\ P4$^)/PZ^*WQ!^#'CK7/C_\
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M%'EED1%9@ ?RO?';_@I]^V%X"N?CI:6OQ0^)G@/1?B+\ /CI^TS^Q%K'B?\
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M:;?6>N:E+)"][%IXU?6GT+2M5@\)^&EO)3!)XJ\62Z)X:B:WOC+JR)IU^UL
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M\.O&&L_$+7/&&EKX&O\ QAX,\$>"?$%[ID7BB_UVR\.ZC_95IOCN$NXDEB^
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M7OKV[N&MH+KPGX<M_"TOB+QYH+.ID?Q3X'TKQ%X9AM2E]-J\=E)'<, ? /\
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M$?Q4^+?A[2_'7CJ7]E7X(>*O!W@?Q3HGQ:^)FKZG9^)O"7Q$^,W@S3_^$_\
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MRMM.FU<7,MM;V<TUK CB&"62)%=O;P00"""",@CD$'H0>X-% !1110 4444
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MW620^_-,3+_VP\_$?[_EG_=1?W8.DO\ VX^EJ***\8] **** "BBB@ HHHH
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MIBTGXF>.-;T"?1/!_P (_A]I5KX6L8=5U"75K@?U*T4 ?R*?$3_@FU\2= ^
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M.-@MC(YZ"-'SQS7TM7LX[3*.'UWIYW+[\XI1_P#;#@PW^_9IY2R]?^6$Y?\
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M^*HQC_FK7CWMWYUOK1_PR7\,.VM?%89Y/_%VO'G]=:-?3M%+_6//O^AMC?\
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M. Z?\U0UCC'UB/X_A1_PRQX5'3XD_'(=\?\ "T-6_K :^G:*/]8\\_Z&5?\
M\%X/_P"=P?V5EW_0)3_\"Q'_ ,UGS'_PRQX7[?$OXYCMQ\4-5Z?^ _;'%'_#
M+/ACG_BYOQTYQ_S4_4^,>G^B_GZU].44?ZQYY_T,J_\ X+P7_P [0_LK+O\
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M/\_ AI/^&:M0[?M*?M/#_N?_  P?Y^ S_P#6[5]/44?ZQ9S_ -!D/_#?D_\
M\XP_LK ?\^)?^%6/_P#GB?,/_#-6H_\ 1RO[3W_A?^%_Z^ J3_AFG4N?^,EO
MVG^N?^1^\*_E_P B!T]O_KU]/T4_]8LY_P"@R'_AOR;_ .<0?V5@/^?$O_"K
M'_\ SQ/E_P#X9IU+_HYC]J#_ ,+WPG_\[ZC_ (9HU/\ Z.9_:A_\+SPC_P#.
M]S_G/6OJ"BC_ %CSG_H,A_X;\E_^<0?V5@/^?$O_  JQ_P#\\3Y>/[-.J?\
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M,J0>FC4HR36DDUH%%%%>0=P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\P_&C_DN?['?_94/B?\ ^L\?%:OIZOF#XTD?
M\+S_ &/.1Q\4/B?GD<?\8\?%;K_GT]:]OA__ )&4O^Q9G_\ ZSV='GYG_NB_
M[#,M_P#5IEY]/T445XAZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Y?\;_\ DBWQ>_[)?X__ /44U:K'P<_Y
M)-\-/^Q%\+?^F6RJO\;_ /DBWQ>_[)?X_P#_ %%-6JQ\'/\ DDWPT_[$7PM_
MZ9;*O9_YIS_NX'_ZHXG!_P S7_NF?^]%GI%%%%>,=X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1W%PL(4SM;P/\$A-<+ KHTYA1Q"KHTI4.I,O_#RWX.?]$(_X*!_^*Y/VVO\
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MKSXD6?@VR\,>!_'OQBT7PWIMQXJU_P"'^E^"](\9^(_C[8/XAU?QWIEI\.?
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M\7_%@_%'Q#\*OB;XA\+ZII(\-M\&-/\ !_PWL;/4M6'QZ\?_ -AZE:M^@O\
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M?"WX%?'6_E\12:%X-UJ#Q/X? /V$C_X*>_ J:XDM(/@W^WA<7<,D\,]G;?\
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MWA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?G?\:?^4FW[ W_9LO\
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MK:!(_P"?[]N/XD_&?7?VV_$O[1'@GPE^TM;^$_\ @GAK?P#T#0OAEX<_9?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \O^-__ "1;XO?]DO\
M'_\ ZBFK58^#G_))OAI_V(OA;_TRV55_C?\ \D6^+W_9+_'_ /ZBFK58^#G_
M "2;X:?]B+X6_P#3+95[/_-.?]W _P#U1Q.#_F:_]TS_ -Z+/2****\8[PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>&+;PEXO_'KP9\%?^"I/AW3?A)X=3P-^V1:^'O$,?QQ^(_QLL?"/B_\ 98^
MFCZ+X9NOVL]0U70/ACX7\'?L\?$GP!X3\.?'_P"*G[(6H?M!:QKOBKPEI,.E
MW7[5/QS^%?C/5?BEHU[\.?"GBCX2@']7%-=Q&CR-NVHK.VU6=L*"QVH@9W;
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M_@D7_P HR?V'O^S=OA]_Z:UK]%Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \O^-__)%OB]_V2_Q__P"HIJU6/@Y_R2;X:?\ 8B^%O_3+
M957^-_\ R1;XO?\ 9+_'_P#ZBFK58^#G_))OAI_V(OA;_P!,ME7L_P#-.?\
M=P/_ -4<3@_YFO\ W3/_ 'HL](HHHKQCO"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_A&P?_'J_1JBO(.X_.7_ (=$?\$R_P#HR;X!_P#A&P?_ !ZC_AT1_P $R_\
MHR;X!_\ A&P?_'J_1JB@#\Y?^'1'_!,O_HR;X!_^$;!_\>H_X=$?\$R_^C)O
M@'_X1L'_ ,>K]&J* /SE_P"'1'_!,O\ Z,F^ ?\ X1L'_P >H_X=$?\ !,O_
M *,F^ ?_ (1L'_QZOT:HH XWX>?#SP-\)? OA+X9?#+PGH/@3X>^ ] TWPMX
M,\&>%]-MM'\.^&/#FC6T=GI6BZ+I=FD=K8:=I]K%';VMK!&D<42*J@ 5V5%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3_'K_DAGQH_
M[)/\1?\ U#]8K8^$_P#R2[X<_P#8C^%?_3)8UC_'K_DAGQH_[)/\1?\ U#]8
MK8^$_P#R2[X<_P#8C^%?_3)8U[7_ #3:_P"RBE_ZH8'G_P#,U?\ V*U_ZLI'
MH%%%%>*>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"TS_\ .<H _2FBOS6_X>\?\$_?^BS^*_\ Q'?]IG_YSE'_  ]X_P""?O\
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M\V\,4$/QD\51PP1I#%&O[._[36U(XU"1HN?@Z3A54*,DG J3_A[Q_P $_?\
MHL_BO_Q'?]IG_P"<Y7S+M=VVN[7T=KNUUK9VM?5ZWU9ZY^E-%?FM_P />/\
M@G[_ -%G\5_^([_M,_\ SG*/^'O'_!/W_HL_BO\ \1W_ &F?_G.4 ?I317YK
M?\/>/^"?O_19_%?_ (CO^TS_ /.<H_X>\?\ !/W_ *+/XK_\1W_:9_\ G.4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY7HG_1DO_!2?_P 0R^('_P E4 :'_!(O_E&3^P]_V;M\/O\ TUK7Z+U\)?\
M!,+P+XV^&7_!/7]COP#\2/">N^!/'?A7X"> =)\5^#/$]HMAXC\,:S!I,37>
MBZY8I+.MEJM@[^1?6HFE^SW"21%V*$G[MH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'DWQ\94^!7QI9B%5?A-\1F8GH%'@_622?8 9-;7PI5E^&'PZ5@5(\#^
M%<@C!'_$CL>HKG_VA/\ D@?QP_[)!\2__4+UJNG^&/\ R3;X??\ 8D^%?_3%
M85[3_P"2;CY\0U/PR&E_F>>O^1J_+*X_CF4_\CN****\4] **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA7M/_DG(?]E#4_\ 5#1//7_(VE_V*X?^K*H=Q1117BGH!1110 4444 %%%%
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MH_MC]LW_ *)Y^S%_X>3XJ_\ SB:^G:*XO[9I_P#0BX=_\-^+_P#GZ='U"?\
MT,LU_P#"JA_\[3YB_MC]LW_HGG[,7_AY/BK_ /.)H_MC]LW_ *)Y^S%_X>3X
MJ_\ SB:^G:*/[9I_]"+AW_PWXO\ ^?H?4)_]#+-?_"JA_P#.T^8O[8_;-_Z)
MY^S%_P"'D^*O_P XFC^V/VS?^B>?LQ?^'D^*O_SB:^G:*/[9I_\ 0BX=_P##
M?B__ )^A]0G_ -#+-?\ PJH?_.T^8O[8_;-_Z)Y^S%_X>3XJ_P#SB:/[8_;-
M_P"B>?LQ?^'D^*O_ ,XFOIVBC^V:?_0BX=_\-^+_ /GZ'U"?_0RS7_PJH?\
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M/VS?^B>?LQ?^'D^*O_SB:^G:*/[9I_\ 0BX=_P##?B__ )^A]0G_ -#+-?\
MPJH?_.T^8O[8_;-_Z)Y^S%_X>3XJ_P#SB:/[8_;-_P"B>?LQ?^'D^*O_ ,XF
MOIVBC^V:?_0BX=_\-^+_ /GZ'U"?_0RS7_PJH?\ SM/F+^V/VS?^B>?LQ?\
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MFO\ X54/_G:?,7]L?MF_]$\_9B_\/)\5?_G$T?VQ^V;_ -$\_9B_\/)\5?\
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M *&6:_\ A50_^=IXE_;'[9O_ $3S]F+_ ,/)\5?_ )Q-']L?MF_]$\_9B_\
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M_9P\>:U?>'/!/QT^%/BSQ!IGQ3UOX'ZCH?AWQUX=U?5K#XP>&O#U_P"+-?\
MAK>:?8ZA/=6_C/2/#&EZCX@O]!EB2_M](L[B_>$6T9DKW>O$/1"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \@_:$_Y('\<
M/^R0?$O_ -0O6JZ?X8_\DV^'W_8D^%?_ $Q6%<Q^T)_R0/XX?]D@^)?_ *A>
MM5T_PQ_Y)M\/O^Q)\*_^F*PKVG_R3D/^RAJ?^J&B>>O^1M+_ +%</_5E4.XH
MHHKQ3T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _*;_ (*@Z=;RZU_P3\\26GPC^(GQ*\0_#_\ ;X^#'CC^
MW?AK\%O&OQ9UGX;^!=,M/$-C\0?$>I:EX)\->(+WP1X?N;'5-+LM8OKN;3K;
M5K4-;M]KBLYU@_&C6O@Y\<K33O\ @E#X1D_9X^/T^L_\$ROVOOBI\=?VMI+'
MX*_$;4-(TWX:^)?$'Q(ET;4_A#X@M?#DNC_M)ZI=P>+-#G_X1?X!7OQ(\30P
M3W,UQI,,>GW[6W]>%% '\F7QP_80UK]H?P1\8/BS<_ OXX^(/%?[2/[4GQXU
M3X4_#GQ1X#DTGP=#^SSJ=S\.?BO9_%_XV?"KQ_\ #^;7O#WCCPMXG^&^J6_P
MT^&OCO4_A_K/BC6M7L;8^%?$UXVCV,G[B?\ !,?Q3\=_%?[+6@W'QQ^$EM\$
M;31]7C\.? _X>'PEXR\":_X>^ >B^#_!UMX%T'QIX4^(GB+Q%XZT_P 7>#M1
M/B7P#JFI^*GT;4_%\/A*R\<+X>TFQ\2V<+?H310!\L_&7_DX;]CS_L<OC%_Z
MI'Q?7U-7RS\90?\ AH;]CPXX'C+XQ9/_ '1'Q?7U-7N9K_R+N&O^Q3C/_6@S
M4\[!?[UF_P#V'4/_ %5X(****\,]$**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _DR_:U^&GB.
M\^-_[4_C+P#\ ?BGX7^'GPJ_X+!_L%_M=>.M;?X'>-O OASQQX \"? G2OA;
M\8_B+\+I-0\,Z1:?'CQ3J/QA@O+&ZTKX:KXM\8>.-1U*Q\0:?9:U9:U9:E=9
M/PU^#WQWL-'_ ."D?@!_V>?CQ:>+/^"B'_!2;X8?M?\ [++ZC\&OB'9>&KWX
M':%\8_@CXVO];^+GC"?P_%X<_9V\16OA[X;^*[R?X<_'35?AWX\5[6PL4\.M
M=ZYH\-[_ $?_ +99(_9_UX@X(\>? P@CJ#_PO?X:\U]25[>)_P"2>RCSS;B!
M_P#E'($>=2_Y&N/_ .P+*_\ TO,S^32R_97^,?['?[9WASQS^QM^S!X^^(FJ
MV.M7/[-?PT^-_P =?AWKGBS5=4\,>&-6\!:M\5;OQ)XH\):7\(+7X=_#BY\"
MZSKGP=^"OBOX@/<?#BX_X47!X_T:\^(WBKXHW-_/_67117B'HA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XJ_\
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M%#39O">K:/\ L#:-XF^&VE_$;Q1^UKKFMZI_5_117C'>%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y!^T)_P D#^.'_9(/
MB7_ZA>M5T_PQ_P"2;?#[_L2?"O\ Z8K"N8_:$_Y('\</^R0?$O\ ]0O6JZ?X
M8_\ )-OA]_V)/A7_ -,5A7M/_DG(?]E#4_\ 5#1//7_(VE_V*X?^K*H=Q111
M7BGH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17YK_\
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M"X^)O"&LS_\ !3:/2_'VG:W\0]+O/"/@YO!%UK\OCC6!;0>$(]:%]9/<>H>
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M-?VN/!OQ M-/\.^(-7\&77C-1X.FU&PTGQWX?N=%L->N;/Q39^'??;;]D?\
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M\/\ Q3X>T[4;;]JFX\5P>+M U?Q[X1N[NSU7PAIVC76EZS'/I>NW]S:WUI;
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MS_1.BOQZ_::_9&_9M_9?_9^^+/[1?B#Q-_P4G^(?A;X->"=7^(OBOPS\,_\
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M_P#16?V[O_%C?[=7_P!$#0!^AU%?GC_P[+^ O_16?V[O_%C?[=7_ -$#7/\
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M82X^%O@NS\3?%S]GC2_!E_\ %3X8?#WXQ_LQVUM\=;'4_"_Q \"?%?QUX/\
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M!\)_!OQ.^(O@N3P#XB\ 65OHWP5^#ENOPW^.&K0ZAJ^L^(_!6M:Q\4/WNHH
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M:U\3K+7?"L&CWOAC4?UB^ O_  5(^#WQ2U_]J35_B)XQ_9<^%/[/'[/WQ?\
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MY\8/%7C?XQ?!1/#GA6\N?[1U/X'_  [L?A/X.\3>![+6;@S6.E>.?$-MK_\
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MM^VW\//CK\)_"GCJSMO@3;:W\(-%_9O^$G@7P]:_#KPGX8\4>-- U3QA\/\
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M@#Q)K_PWTKXA66@OXBOO VC:]^V7\,&F^'OP^\4>.I_!GA.?Q!K_ ,-/B?\
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MTY?#-[#<_P#!.SXU?%_]H;XI^+?CY\)?V=+GX0>,_P!M[X@_&R[TR3XAZ_\
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MY$7QI_V*?B/_ -,]Y765R?CW_D1?&G_8I^(__3/>4 ?)7_!,C_E&_P#L!?\
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M5@LO#TL_B?PQ:^)X[[4_#/@?Q!XVUFPT3P_XNU;PM%XNU"]:0Z1JOTQ^SO\
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M_P"S+_V6_P#U1W@6OM"OB_\ X)O?\H[_ -@K_LR_]EO_ -4=X%K[0H ****
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M?X%:MXH\)ZE+91_#?X9_!K0_#OPSTV+P[JMY>?T>H"J*IZA5!^H %?*O@?\
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M<.D60!]ET5\T_M+:[^TAHGAW3)_V>[W]G[PBEI#X@\0?$3XI_M&R>*]2\"^
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MV,EKX<T.VT3Q%K.GP5_0I0!^:W_!7_\ Y1R?M*_]@KX>?^K>^'U?I37YK?\
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M#J/Q,;3+GQ]<1>(?-O\ 4[R'2+"W3P/]C/\ X))?'+PMX!^$GQ<^,WQM\4?
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M[5^'W_!,;P5\+OC%X&^+7@GXO^.]"M_A]XZD^*'A[X?6/AOX>0>#+3X@^+?
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MO_P45_\ 6\OVBJ /T/HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P *XU/Q!<?#:2>[_LB3PXV@00:8G!/^UE^V5\+?VBO!W[,VN_%WPC\4]%\
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MX2M;C2=.T>QT^+0?$\E]+J7B[3]6OH+:6+["^.7[&&M?';XH?LO_ !+\0?M
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M%CPSX5\+Z(FF^&/#%KXJ\.7^E:;%J'PU\$RZ;\9W'[>G[8$O[.'P'^('Q?\
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M)J/]F3W#6KR-9-?73P!@CRLX;'5K\3OVJBRAOV5O"JJ2 S?\-&:,=H)Y./\
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M>> 8/$MO+XE'@U5&GZC?)I:ZR=0BTBUC'QX?^"+G@_7/A]IGP@^)7[5?Q_\
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MY_ZM[X?5^E- !1110 4444 %%%% !1110 4444 %%%% 'C'[1_\ R;Q\>?\
MLC'Q1_\ 4'UVNT^''_)// ?_ &)GA?\ ],=C7%_M'_\ )O'QY_[(Q\4?_4'U
MVNT^''_)// ?_8F>%_\ TQV->T_^2;I_]E%6_P#5!ASSU_R-I?\ 8KI_^K*J
M=G7YN_\ !-#_ )$O]KS_ +21?MX_^K^\35^D5?F[_P $T/\ D2_VO/\ M)%^
MWC_ZO[Q-7BGH'QA^U'\(/VFO&'[7_P 6G\!_LC6&M_#SQI\0?V;K>WU_6_\
MA7GBO]G_ /:83P7X6\(:]K_B[]IWPCXJN+KQA\,O$7P&:QNM+^#_ ,;?A-;Q
M^-/$>O\ ACPA\/==TB7PMH$&IW7R?\;OAM_P5$\-?$7XS_L_:&O_  4(\;>
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M6UO9V\%I:00VMI:PQ6UK:VT206]M;P(L4,$$,2K'###&JQQ11JJ1HJHBA0
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M"_[,N_9?_P#5*>":^X:^'O\ @F1_RC?_ & O^S+OV7__ %2G@FON&@ HHHH
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M-M\-_ OC;7KN_P!=\6>&M(M&M-6U;4+N\9HG:(1?+"_\%S?#VJ^ +OQMX/\
MV8O%_BJY\)?'?P?\'/BIH2?$CP_X?/@'2_B-X(U[XE^!/&5MJGB3P[IEOXQF
MO_!'AK5KO7?#?A^%UT;6X[?1]/U_Q!;W<&K/<\._MR>)OVCO^"D7['I^#?\
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M7[SQU\1OA7;>'OV:OB\NN-X#^(/QB\$Z#IOQQ\'^'/"/CSPMXJ_9K^(GQU^
MEI\0K-],EAFN?BI\*O 7C/Q"FCZ@'7X,>/-*\/VNNW&L2ZE:W<>QX%_X*K6O
MQL?]E;X@:=^SC^T!9-XJU?XT:3KW@7X>?$/PYXAOK+XH>&_V3+3]I+P[\,M4
M\&:9!:1?&ZU\6?![QEI?B#PWJ>B7^GZ=X4^(]K%IMY%<:AI!=P#[7^'O_!.W
MX"?"KXM_#CXR^ =;^,OAOQ%\+OA)XY^#?A_0+'XL^*%\!W_A[XH>);SQU\2_
M$'B7P<TS:3X@\>^/_B-=0?$GQ9XSOXWUG5O'>E:1XAFF%S9*K>__  (_9_\
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MC5*]'KSCXQ_\DB^*G_9./''_ *C&J4 ?.W_!-[_E'?\ L%?]F7_LM_\ JCO
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M#XB\,>&_$OQ:TZ;X9ZE_;6D3:)H_AZ[OM:MI/#2V*W$D-ZX!]O>!_P#@F_\
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M?X*\-Z;ID6GRVVM?#KXLL;O4#\/_ !#;68!^HU%?EWK/_!3'3])T3XW^.$^
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M=1^*.L74?[MT44 %%%% !7)^/?\ D1?&G_8I^(__ $SWE=97)^/?^1%\:?\
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MFN1:)=/=-/I4>LVMMJJ6,D"ZC;PW@FC7LZ /AWQI_P $U_V%_B)\)_#GP/\
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M %;WP^K]*:_-;_@K_P#\HY/VE?\ L%?#S_U;WP^K]*: "BBB@ HHHH ****
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MX=6MKNQU+3]/GA+@2*?%/^&<O^"E/_22_P  _P#B!G@?_P"??0!^E%%?FO\
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M^^C_ (9R_P""E/\ TDO\ _\ B!G@?_Y]] 'Z445^:_\ PSE_P4I_Z27^ ?\
MQ SP/_\ /OH_X9R_X*4_])+_  #_ .(&>!__ )]] 'Z45^>'_!,/_DW#QY_V
M>O\ \%%?_6\OVBJQO^&<O^"E/_22_P  _P#B!G@?_P"??7T7^R#^SQJO[+_P
M3MOA;X@^(\WQ;\3W?Q&^-?Q4\6?$"7PCI?@*/7_%OQS^,GCKXS^)WL?!VC7^
MJ:;X>TJPUSQW?:9I.G6VHW@ATVRM?,G>5G- 'T[1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?G5_P %<O\ E&1^W+_V;A\2/_3++7Z*U\]_M9?
M&T_:H_9H^./[.-]XJOO UK\:OAKXI^'DGC+3-,L]:U#PP?$>FS6,>N6FCZA+
M!8ZI-ILLB72Z?=SPV]WY9@EEC1RP^6_^&<O^"E/_ $DO\ _^(&>!_P#Y]] '
MZ445^:__  SE_P %*?\ I)?X!_\ $#/ _P#\^^C_ (9R_P""E/\ TDO\ _\
MB!G@?_Y]] 'Z445^:_\ PSE_P4I_Z27^ ?\ Q SP/_\ /OH_X9R_X*4_])+_
M  #_ .(&>!__ )]] 'Z445^:_P#PSE_P4I_Z27^ ?_$#/ __ ,^^C_AG+_@I
M3_TDO\ _^(&>!_\ Y]] 'Z445^:__#.7_!2G_I)?X!_\0,\#_P#S[Z/^&<O^
M"E/_ $DO\ _^(&>!_P#Y]] 'Z445^:__  SE_P %*?\ I)?X!_\ $#/ _P#\
M^^C_ (9R_P""E/\ TDO\ _\ B!G@?_Y]] 'Z445^:_\ PSE_P4I_Z27^ ?\
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M ,E)Q#_V/,V_]6&*/-R?_D495_V+<#_ZBT#\T_\ @C]_RCG_ &<O^O?XI?\
MJ[/B17Z65^17P>_8)_;;_9Z^'NC_  @^#/\ P49\/:!\+_"=]XFD\&Z'XF_8
MM\#>+-=TC2_$GBK6_%C:;J/B7_A;>C'6YK*[UVYMTU%]+LI;B&.-YH1*79O3
M?^&<O^"E/_22_P  _P#B!G@?_P"??7AGI'Z445^:_P#PSE_P4I_Z27^ ?_$#
M/ __ ,^^C_AG+_@I3_TDO\ _^(&>!_\ Y]] 'Z445^:__#.7_!2G_I)?X!_\
M0,\#_P#S[Z/^&<O^"E/_ $DO\ _^(&>!_P#Y]] 'Z445^:__  SE_P %*?\
MI)?X!_\ $#/ _P#\^^C_ (9R_P""E/\ TDO\ _\ B!G@?_Y]] 'Z445^:_\
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M/_L54_\ U9UO\CK:_-W_ ()H?\B7^UY_VDB_;Q_]7]XFK](J_*S0/V'/VO\
MX6>)?C%+\ OV^M#^'/P]^+'QU^+?QYC\#^)_V1?!?Q'U'PQX@^,7B^_\:^(]
M)A\8W'Q0\-7>L:;::KJ,\6F27FDPW45FL4$CR>6K5XIZ!^J=%?FO_P ,Y?\
M!2G_ *27^ ?_ ! SP/\ _/OH_P"&<O\ @I3_ -)+_ /_ (@9X'_^??0!^E%?
M,'[66'^'GA: _P#+S\7?A;!M'WGW>*;5]J=]QV9X[ _4?.W_  SE_P %*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K
M?L1_\FK_  <_[ &H_P#J2:W7U37RM^Q'_P FK_!S_L :C_ZDFMU]4U[G$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^5OV(_^35_@Y_V -1_]236Z^J:^5OV(_P#DU?X.?]@#4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^(GB_X17>E?%[PGX6UOX:ZSI/BB]^;M/_X(]_#'PWX=\6>"/ W[0OQ_\$^
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MQM^ G@31]6\8_L]>)/%U_9?#[XBW<VK)K/B'Q%K'B3Q)8^7HGBG6-8TF)+0
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M9)_;_P"UVO7X:_ :7/I\5/&T&WZY^&EQNSZ?)C'5L\?3%%/^V*7_ $(L@_\
M"+&+\LY0_J,_^ACF?_A10_7 ,^.?']I^U=X_\">-? &I?"_X)0:=XX\)>(_"
M%_?V/QF\7V]Y9V7B71[W1;JXM%G^#UW$;JW@O7F@:4-'YJH'B90<[6C:M^UK
MH6D:3HUO\'?@?=V^DZ;8Z9#))\=?%\$K16%K%:QR2D?!"9'DD2(,P18U5LXR
M" /JRBM?[>3H+"O),A>'5>6)5+ZKCU'V\J,</*K[N=J2DZ$(T])<O+%>[>\G
MG_9K]JZRS#,O:NFJ3G[;#-^R51U5#7+K6523GM>[WM9+YE_X2_\ :Z4X_P"%
M%_ Z;/.X?M$>+;?'^SL/[/MQN]=V]?3;QD@\9_M;*?G^ ?P68'IY'[1OB9R#
MWW>=^S[;@#'3:7)/4 #)^FJ*R_M?#_\ 1/Y!\J&:+\L__0OZC5_Z&F9_^#<&
M_P \L_4^9_\ A-OVKU^_^S_\)F)Z>1^T-K#@#T8S?!&W(/?Y588QSG(I1XY_
M:I'W_P!GSX9L#T\G]H"\<@]]PF^$$  ]"K,<]5 YKZ7HI?VMAO\ HG\B^5/-
ME^6>.P?4JW_0TS+_ ,"P+_\ >:?-/_"??M0)Q)^SQX$8GD&#X\^8H'<,9/AC
M"0W< *PQ_$#Q7C'CWQ3\8]<^,'[,UEX]^$V@>"M,'Q,U6YBU72OB3%XND>:#
MPIJ7^CO8#PKH+QB178B432 ;.5&:^_:^8/C=\_Q?_9;A');X@>+9MG8BW\%7
M[ER#\N8\[ES\P)^7G->MDF8X:KCI0CDN4X>3R_.6JU!9FJM-K),U?-3]KFU>
MES+;WZ52-F[QVMQYAA:L,,I/,,;52Q6 O3J?4W":>88+27)@J<[/^[.+[,^G
MZ***^0/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?PSM_&^G^!_VJ_VS]4_9U^)OPB\':5\+O#GPY\!VFG)X>\/:9?\ AKQ5XO\
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MXTU_6-$^%>D^+FTC0%\4:?X)L='M]<B\.>'H;])HM(LTC^EZ "BBB@ HHHH
M_-;_ (*__P#*.3]I7_L%?#S_ -6]\/J_2FOS6_X*_P#_ "CD_:5_[!7P\_\
M5O?#ZOTIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M8?C,=WQP_97AZ;O%WQ$FW>GD> KIMN/]K=C.>,=#FOIZOF'XN_/^T%^RE#UW
M:S\7I\'[O^C?#J5\G_:7=E..N>17M\/Z9A-_RY7GTONR+,_\SS\S_P!UBN^,
MRU??F.#1]/4445XAZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_;)\.6UKHWACQR_BB3Q5H]I:1?LP+;"VU9_&GB<LTD4DUH-5D6PEM5M[,6Z
M^8/@?^V;^TM\2O#?_!([3O!TWQ-\9Z]\./$/PX^$W[0GQ"\5?M%:UX2@^/\
M\9/BI_P3C^(O[26D?"[XB^ $\+>(+7XB^']=T^U^%WBY_CIXEU"?4O GB]?$
M<>E^"=35]2OM2^Q/V<?^"LEQ<:I^S/\ "S6OV8OBDG@_XS_LN? [XL_#/Q>W
MQWLOCA\7_$7BOXO^"/C/XH\-_##Q%I7BO0_"=[K>O&?]G/XP:)<_$?6?'_V+
M4K^S\#7MY;6<'C.\;PQRUA^R5XPTKPS:^#-+_P""%'[%6F^%;+P3?_#FRT*P
M_;)\.6>GV?@G4_&2?$&]\/6D5O\ LP1_9K.7QA&FLK)"R74,B_9(+B+3R;0\
M!?\ _!/YKKX:^./A/I__  0=_8X\*^#OB#:Z-!KL7@O]M[3?"6LVMSX8TWQ=
MI?@_6/#?B+0_V:K/6_"FN^"K?QYXOE\':OX=OM.O/#=YX@U*]TJ2VN+F61@#
M]./^"?\ ^VE\5/VV_#GC'XDZY^S=9_"#X,07&EP?![XJ6/Q=G^(.E_'&&:*=
MO$6J>&]!U7X6?#+Q#HNA^%;Y%\.7.MZE93Z;KWB2SUV+PK<:UX<T_3_$^M?H
M?7\\?["W[.?[<G[ VB^+= ^&'[#7@37]%\4R:8D/AMOVUOA=\-/ GAZQT6V6
MUTY].^'OPO\ V1_#_A2]\6R6X%GK?Q#U.QG\6^(-*L]$T?4+PV&@Z?&OWW_P
MT!_P4Q_Z1Q_!S_Q/[3/_ *&*@#](:*_-[_AH#_@IC_TCC^#G_B?VF?\ T,5'
M_#0'_!3'_I''\'/_ !/[3/\ Z&*@#](:*_-[_AH#_@IC_P!(X_@Y_P")_:9_
M]#%1_P - ?\ !3'_ *1Q_!S_ ,3^TS_Z&*@"O_P5_P#^4<G[2O\ V"OAY_ZM
M[X?5^E-?BE^UG9?\%+/VMOV?_'G[.UQ^P[\%?AG:?$R7PAIU[X]N?VW;;Q;%
MX6L-'\=>&?$U_JA\-67[.>D76N21V>B3QPZ=#JFGM<S21H;N!29%_:V@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY>^++'_AI#]DV/
MC#7GQO<GOF/X;H !VP=YSQV&,5]0U\L?%E2W[37[))'1#\>6;GL?A]IZ<#N=
MSC\,_C[G#Z3Q]>_3)N(G]V0YDU^)YV:?[M3_ .P_*_\ U984^IZ***\,]$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /E;]B/_DU?X.?]@#4?_4DUNOJ
MFOE;]B/_ )-7^#G_ & -1_\ 4DUNOJFO<XG_ .2DXA_['F;?^K#%'FY/_P B
MC*O^Q;@?_46@%%%%>&>D%%%% !1110 4444 %%%% %#5.-,U+'_/A>?^D\E>
M"_LAL[_LJ_LX.[O([_ _X7L[R.TCNS>#='+,[N69V8DEF8EB22237O6J_P#(
M+U+_ *\+S_TGDKP/]D'_ )-3_9N_[(=\+O\ U#-&KVJ?_).8K_LH,O\ _5)F
MAY\O^1M1_P"Q7BO_ %8X,^BZ***\4] **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?^*2AOVE_P!E
M7N8[;X[R<?PY\%:)&&;'0$.R@G@D^N*^H*^8?B1\_P"T[^S2O3R=#^-4Q)YW
M"3PYH<6T>A!&XD\$<#FO;R#3&XE]LEX@?WY)C8_^W?UJ>?F?^[TEWS#*_P ,
MPP[_ /;3Z>HHHKQ#T HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M19L?\\S)J.C0[_;>,IU_"OI^OE_Q#E_VO/ARI8!8O@MXWE P,L[^(](BY;J
M%R<#J>3TKV\B_C9D^V09X_OP-./_ +?_ $KGGYE_#PB[YGER_P#+B;_3^G8^
MH****\0] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E;]B/_DU?X.?]
M@#4?_4DUNOJFOA;X-7/Q\^"7PK\#_"I/V==9\:WWA+2YK*^\0Z9\2?AOH^A7
M,MUJNI:@&M!K.M0:I(D<5U"LF=/#+(67'RY/B/Q(^,O_  4;M?VG?A;X7^&W
MP&\+?\*S\2^%VO/'5AXGUJVU'P]X=6U\0?99]7N_B'H>X:1JHTV61X-!@L-5
MEU7R$^S0;QEOO\5PSBN(.(<^K83,^',/AZV(SW-J&)S#B+*<)0KX6C6Q&,2C
M)XFM4IU:]"<7AX5Z%)U)RA3<8SG&)\Q0S>CE>5993KX/-:M6G2RW U:.%RK&
MUZE.M4ITL.VU[*G"4*=2+565.I-1BG--QBV=7_P1^_Y1S_LY?]>_Q2_]79\2
M*_2ROS/_ ."/!E/_  3A_9K-P(EN38?$LW2V[.]NET?C-\13=);/*J2O;).9
M%MY)4CE>$(\J)(64?IA7P+5FU=.S:NG=.S:NGI=.UT[*Z:=E>R^GWL^Z3UT>
MJ3U71ZZKH[KH<!X]^%'PM^*D.C6_Q/\ AKX ^(\'AS4QK7AZ#Q[X.\.^,(=!
MUA4\I=6T:/Q#IVHII>IK'^[%_8K!=!/D$NWBN/\ '_[,O[-WQ7\0#Q9\4OV?
M/@A\2O%0M;6Q'B;Q_P#"CP'XQ\0"RL1,+*S&L^(M U'41:V8N;@6MO\ :?*M
MQ/,(D3S7W>WT4@/&?"/[.7[/7P_\.>)_!W@+X#_!GP1X1\;+$GC/PKX1^%_@
MCPUX<\7)!%)!"GB?0]&T.RTS7UA@FFAB75;6[$<4LD: ([ ]//\ "CX6W7Q!
MLOBU=?#7P!<_%73=,;1=.^)L_@[P[-\0;#1F@O;9M)LO&<FG-XCM=,:VU+4;
M=K"#4H[4P7][$8O+NIUD[^B@#Q3Q!^S5^SGXMUCQAXA\5? 'X*>)M?\ B%!I
M5MX^USQ!\*_ NM:QXXMM"N-+N]$M_&&IZEH-S>^)H-&NM#T2YTJ+6I[V/3KC
M1]+FM%ADT^T:'D?B?^SQ^QQ?:=8>*/C/\#/V9KS2/!WAG0_!>E^(OB?\,OA9
M<:=X6\':-.T7AOPG8:OXKT1[;0_#.E75X\>AZ#;W%KI=C/=,EA:Q23D-],U^
M:'_!5/PYX9\7_ ?X(>%_&GA_1/%?@_7?V^/^"?>G>*/#7B71['Q!X>US0)_V
MN_A+_:NFZWH>IVUYI^K:9<6:RK=V%Y:7-O<0AD>&0':0#VGP5\/?V O#:7L'
MPR\'?L?^&)/BMIVL_#FZ;P#X:^".E2_$'3]9?1O[<\%2IHVGI%XPM-0N+_PZ
M^J>&+J'5;.^GN]$^WZ=<&XLEDZ[X#_!;X4_LR:7>?#G3O'6N>+O'OQ<\3ZY\
M0?%OBWXO>,=(\0?&#XU^+++P[X<\+W_B?Q!-%9Z##XBNO#7@#PQX)\&J="\.
M6-CI7A+PQX>MKNW,T<U[=_QW> /%?@7X0Z5^QQ\=OA+<?L[?'?3_  O^WE_P
M5-\:_LM_LA^&/V0=)\%^++7XAC2OVK[GX0_9/C'H]E?^(KVR\8:QXI_9KC\%
M0+X'\*0O/XM^"3Z;>F3P/X9FM?KKXV?MZ^((OC5^RQXZL_%WPP_;W\?_  1^
M)OQ/\7?LN?&_P#\$-8^$LGQ@^('CG]B_]KWP)XO_ &4]#M=(7X@W6COH?Q&F
M_9DA\1:M8^*+>+Q/KOQ[^&VD:GH<<^@Z;?2@']1?PMT+]GSX;Z5<>%O@IHWP
M;\!:'?>--6TB[\.?"W3_  3X6TJ\^(FFZ4G]NZ7<:1X2AL;.X\:6&AZ%'_:U
ME+;OKEKI6CI]LBCM-/7R<OP[^RQ^S%X0T[6='\)_LY? ?POI/B,7(\0Z7X=^
M$'P^T33M=%[H>N^%[P:S9:;X>MK;5!=^&O%'B;P[<B^BG\_0_$6NZ3+OL-7U
M"WN/Y;/AC^U?X;_9M^*NKW%U^U_^S9:Z)^T7^W?\;OBT_P 9KG]C./0_#>O>
M%?%O_!-[0O!_A+]LOX:^&]$\0RV/@R'PS^U+\)?%G[.WCR_75+S4/C7XOUOQ
MU::]XAT6^UFYN+W3D_X+8?M23_!#X(?#;Q%\9O@%\)_VN/&_B+X=C7?$GBOX
M0ZY9PV_@WXN_LI_#']I/P_\ %OQI\(_$'B+3K/PE^SK\/O$OQ)\0?!7XA>,?
M"OC7Q?\ $F[\8>"O .E>'/!$_B7XE:GI'A\ _J\O]9^&'P8\(:%9ZIJO@+X4
M> M"MM)\(^&;2_OO#W@7PAH]GI^GFVT+PQH4%Q+I>C:?;6.DZ:;?2=%T](8K
M;3[ Q6=LEM:E8_/- ^"?[+,/P_N_A;X7^$?P B^%GQ1:7QG?_#G0/ 7PZ3X?
M_$5XO^$?GG\5W?A#3M)'ASQ<T7V7PK-+KLVGZ@4^S>'Y'NAY.FE?CO\ ;;\)
M^%;S]C[PSX_^(7@WX2_M:_&O3?#GP\^#WPG\;>,/A9IWCOX+/\8_VE_&OPQ^
M#>@?'75/@K-K'BCPO+X"T+QWK_AOX@^)6TRYUSQ5X>^%]AXQT/P;XF6/7=5&
MK_C]X3_8^_:)\,_MT?"G]G'5OA+\8_@W\.;K_@F_^W1_P3S^ ?QK\&_'/P#X
ML\$?"3]F?P0?@%X<^$WQY\->&K+6])\767QSU74M1M?%?C&YO]*\$^*]1OO%
MO@WP=X?T_4/"'P*U/Q30!_15IOPP_8V&F:9KFC_#S]F4:,;70_$NC:OIOA+X
M6#3#9? 2$:/X:\0:9J%KI_V4VOP6MYAI>AZK:S>3\.89196$^C(_E'<L_@[^
MRU\3Y],^)6G_  L^ /Q#N3#XPMM&\?V?@?X=^+9S;^-;S7G\?P:9XJ@TO4)#
M#XMO_$7B=O&$5K?[->O-=UXZTMW-J>H&?^9O_@GCX=\._ ;]M!?@OX _9YMO
MBOX,_:K7Q5JVO^*?&F@:SX9\,1?LM^*+_P".FF?$#]H+X1_!*UTCQ7\'_!GP
MW^/'[1G@74O$'B?PQH&L>#M%NOV=/C=^QUX<UG2_%_B_PQXEU%OVR_X)7>&/
M#?@KX(_'WPCX.\/:'X2\*>&O^"@?_!0;1O#OA?PSI%AH'A[0-'L?VM?BI#8Z
M5HNB:5;VFFZ5IMI JQVMC8VL%K!& L42KQ0!]Y^&_A5\+_!O@FX^&OA#X;^
MO"OPYN[?6+2Z\ >&_!_A[0_!-S:>(6N6U^UN/"NF:=:Z%-;ZXUY=MK$,E@T>
MIM=7)O5G,\N[D[C]FW]G6[^'-C\';KX!_!6Y^$>F:F^M:;\++CX6>!IOASI^
ML27-Y>R:M8^")-";PS::F]YJ%_=O?P:9'=-<WUY.TIEN9G?VFB@#RWXA_ WX
M*?%W3M&TCXL?!_X6_$_2?#@G'A[2_B'\/_"?C73M!%U#;V]R-&LO$FD:G;:6
M+BWM+2"<6,4'FPVMO%)N2&-5R[?]G']GJT\(6_P^M?@/\&;;P%:66O:;:^"+
M?X7^"(?"%MIWBJ6SF\3V%OX:CT-=&ALO$<VG:?+KUK'9+!K$MC9R:A'<-;0%
M/9J* ,/0?#'AKPM;WEIX8\/:'X<M=0U&XU>_MM!TFPTBWOM6O$ACN]4O(=/M
M[>.YU&Z2W@2XO9E>YG2"%996$:!=RBB@#\UO^"O_ /RCD_:5_P"P5\//_5O?
M#ZOTIK\UO^"O_P#RCD_:5_[!7P\_]6]\/J_2F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KY@U;Y_VPO!ZCDP_ /Q3*P/\ ")/&VDQ!
MESQN)RIQ@[>O'%?3]?,%[\_[9.A*>D/[..N2KCJ&D^(VEQ$M_L[1@=.>_:O;
MR/X\V?;A[.G]]#!1_P#;OZZ^?F'PX)=\TP"_\J8A_P#MO]=/I^BBBO$/0"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX=>._P!K[PIX>_9_\0:Q\3M)T7P9X(^+W@WQ7J?@C]F_5EO]1^(MY9?%;5?
M/BGX82VVC^,],\/:Q9^%?CUI7AWQ%I_@&VM' /V\\!^._!_Q/\&>%_B)\/\
MQ#IWBSP1XUT33_$GA3Q-I$QN-+UW0M5MTN].U33YBJ&6TO+:1)H7*J61@<"O
MFBY_X*"?L36C_%>.X_:?^#L4GP.E@@^*Z'QAIY;P9+<ZE-H\,>HA68W#'5+>
M:Q<:;]M\JX39+L++N\4_X)[_ +2_BWX@1^.OV>?C2_Q3_P"%W?"@3>.=%N/B
MU\-=8\$>-O$_[+_CSQEXLT[]FWQM\0[[_A'_  ]X8E^,?B#P+X<MYOB[X6L-
M)\,:[X4\;+J=AK_@CPM.T=C7Y&_&7QCXX^.?[9_[&?Q2\,?L&_MC_#7X.?\
M!/+XY_$37O /A_1_V2?'G@C0]&^"?_"!ZW\._B%X[BT<:):'XAZ_\7?$.L^
M+7X&?!+X.Z)JOB7PMX%\,^+O'_C[[!=:A<^%?#P!_1AX-_:6_9^^(<_PPM?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX(_%WQ)K7C;Q=\/+[Q+;?#'XJ>5J.J:I\4O$>@_$H _>OX>?"CX0_ +P=?\
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MZBOSQ_X59_P5'_Z//_8U_P#$!OBG_P#1YT?\*L_X*C_]'G_L:_\ B WQ3_\
MH\Z /T.HK\\?^%6?\%1_^CS_ -C7_P 0&^*?_P!'G1_PJS_@J/\ ]'G_ +&O
M_B WQ3_^CSH _0ZBOSQ_X59_P5'_ .CS_P!C7_Q ;XI__1YT?\*L_P""H_\
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M_P"%6?\ !4?_ *//_8U_\0&^*?\ ]'G1_P *L_X*C_\ 1Y_[&O\ X@-\4_\
MZ/.@#$_X*_\ _*.3]I7_ +!7P\_]6]\/J_2FOR5^.W[&_P#P4"_:6^%OB3X(
M_%K]M+]F%?AOXXG\-Q>+U\"_L/>/_#WBZ?2-!\5:)XIDM-!UW6OVU/%6E:1?
MWDNB16B:A>^'-9BM4FDE%A,ZHM?K50 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex23-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ /@# 2(  A$! Q$!_\0
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M?155[ZPM-3LI;.^MX[BWE&UXY!D$5T4<1.D]'H8SHTYZRBG\CYZ\%>-_#-E
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M[G)JE\.[B6Z^'^CR3.7<0F/)]%8J/T HHH D\;QS+X:GOK:]NK2YL0;B)X'
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LX!X=^*?BF*XTG2EN8/LJO#;A?(7.S(7K]***!'TE1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? 0,# 2(  A$! Q$!_\0
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3548"@8 %.I:+W&E8****FPS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>nivf-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:23 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.newgenivf.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nivf="http://www.newgenivf.com/20240630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20240630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20240630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20240630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nivf-20240630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" id="nivf_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Unaudited Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nivf_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" id="nivf_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3" id="nivf_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow" id="nivf_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" id="nivf_r_OrganizationandPrincipalActivities">
        <link:definition>006 - Disclosure - Organization and Principal Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" id="nivf_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountsReceivableNet" id="nivf_r_AccountsReceivableNet">
        <link:definition>008 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Inventories" id="nivf_r_Inventories">
        <link:definition>009 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" id="nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet">
        <link:definition>010 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PlantandEquipmentNet" id="nivf_r_PlantandEquipmentNet">
        <link:definition>011 - Disclosure - Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" id="nivf_r_AccruedLiabiltiesandOtherPayables">
        <link:definition>012 - Disclosure - Accrued Liabilties and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ContractLiabilities" id="nivf_r_ContractLiabilities">
        <link:definition>013 - Disclosure - Contract Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Leases" id="nivf_r_Leases">
        <link:definition>014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Equity" id="nivf_r_Equity">
        <link:definition>015 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans" id="nivf_r_EmployeeBenefitPlans">
        <link:definition>016 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" id="nivf_r_ProvisionforIncomeTaxes">
        <link:definition>017 - Disclosure - Provision for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues" id="nivf_r_DisaggregatedRevenues">
        <link:definition>018 - Disclosure - Disaggregated Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Risks" id="nivf_r_Risks">
        <link:definition>019 - Disclosure - Risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" id="nivf_r_RelatedPartyBalancesandTransactions">
        <link:definition>020 - Disclosure - Related Party Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LoantoaSPACI" id="nivf_r_LoantoaSPACI">
        <link:definition>021 - Disclosure - Loan to a SPAC I</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ImpactofCovid19" id="nivf_r_ImpactofCovid19">
        <link:definition>022 - Disclosure - Impact of Covid-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/Contingencies" id="nivf_r_Contingencies">
        <link:definition>023 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SegmentInformation" id="nivf_r_SegmentInformation">
        <link:definition>024 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SubsequentEvents" id="nivf_r_SubsequentEvents">
        <link:definition>025 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" id="nivf_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" id="nivf_r_OrganizationandPrincipalActivitiesTables">
        <link:definition>996001 - Disclosure - Organization and Principal Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" id="nivf_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables" id="nivf_r_AccountsReceivableNetTables">
        <link:definition>996003 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/InventoriesTables" id="nivf_r_InventoriesTables">
        <link:definition>996004 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" id="nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables">
        <link:definition>996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetTables" id="nivf_r_PlantandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" id="nivf_r_AccruedLiabiltiesandOtherPayablesTables">
        <link:definition>996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables" id="nivf_r_ContractLiabilitiesTables">
        <link:definition>996008 - Disclosure - Contract Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LeasesTables" id="nivf_r_LeasesTables">
        <link:definition>996009 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EquityTables" id="nivf_r_EquityTables">
        <link:definition>996010 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" id="nivf_r_ProvisionforIncomeTaxesTables">
        <link:definition>996011 - Disclosure - Provision for Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" id="nivf_r_DisaggregatedRevenuesTables">
        <link:definition>996012 - Disclosure - Disaggregated Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" id="nivf_r_RelatedPartyBalancesandTransactionsTables">
        <link:definition>996013 - Disclosure - Related Party Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" id="nivf_r_OrganizationandPrincipalActivitiesDetails">
        <link:definition>996014 - Disclosure - Organization and Principal Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable" id="nivf_r_ScheduleofCompanyssubsidiariesTable">
        <link:definition>996015 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company&#8217;s subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" id="nivf_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" id="nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" id="nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" id="nivf_r_ScheduleofAccountsReceivableNetTable">
        <link:definition>996019 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" id="nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable">
        <link:definition>996020 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" id="nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable">
        <link:definition>996021 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable" id="nivf_r_ScheduleofInventoriesTable">
        <link:definition>996022 - Disclosure - Inventories (Details) - Schedule of Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" id="nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable">
        <link:definition>996023 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable">
        <link:definition>996024 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetDetails" id="nivf_r_PlantandEquipmentNetDetails">
        <link:definition>996025 - Disclosure - Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" id="nivf_r_ScheduleofPlantandEquipmentNetTable">
        <link:definition>996026 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" id="nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable">
        <link:definition>996027 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" id="nivf_r_ScheduleofContractLiabilitiesTable">
        <link:definition>996028 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LeasesDetails" id="nivf_r_LeasesDetails">
        <link:definition>996029 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" id="nivf_r_ScheduleofLeaseLiabilitiesTable">
        <link:definition>996030 - Disclosure - Leases (Details) - Schedule of Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable" id="nivf_r_ScheduleofOtherLeaseInformationTable">
        <link:definition>996031 - Disclosure - Leases (Details) - Schedule of Other Lease Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" id="nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable">
        <link:definition>996032 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EquityDetails" id="nivf_r_EquityDetails">
        <link:definition>996033 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable" id="nivf_r_ScheduleofSubscriptionReceivablesTable">
        <link:definition>996034 - Disclosure - Equity (Details) - Schedule of Subscription Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" id="nivf_r_ScheduleofAdditionalPaidinCapitalTable">
        <link:definition>996035 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" id="nivf_r_EmployeeBenefitPlansDetails">
        <link:definition>996036 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" id="nivf_r_ProvisionforIncomeTaxesDetails">
        <link:definition>996037 - Disclosure - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" id="nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable">
        <link:definition>996038 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" id="nivf_r_ScheduleofIncomeTaxesTable">
        <link:definition>996039 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFibXubgjR+e+3QKK77oumrV5YgN9cRIZEI=] CSR-->
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" id="nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable">
        <link:definition>996040 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" id="nivf_r_ScheduleofBusinessOperationsTable">
        <link:definition>996041 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" id="nivf_r_ScheduleofGeographicalInformationTable">
        <link:definition>996042 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable" id="nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable">
        <link:definition>996043 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RisksDetails" id="nivf_r_RisksDetails">
        <link:definition>996044 - Disclosure - Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" id="nivf_r_RelatedPartyBalancesandTransactionsDetails">
        <link:definition>996045 - Disclosure - Related Party Balances and Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" id="nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable">
        <link:definition>996046 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" id="nivf_r_ScheduleofBalanceDuefromShareholdersTable">
        <link:definition>996047 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0">
        <link:definition>996048 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" id="nivf_r_ScheduleofConsolidatedFinancialStatementsTable">
        <link:definition>996049 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails" id="nivf_r_LoantoaSPACIDetails">
        <link:definition>996050 - Disclosure - Loan to a SPAC I (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ContingenciesDetails" id="nivf_r_ContingenciesDetails">
        <link:definition>996051 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SegmentInformationDetails" id="nivf_r_SegmentInformationDetails">
        <link:definition>996052 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails" id="nivf_r_SubsequentEventsDetails">
        <link:definition>996053 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" id="nivf_r_ScheduleofCompanysSubsidiariesTable">
        <link:definition>996054 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company&#8217;s Subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0" id="nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0">
        <link:definition>996055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0" id="nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0">
        <link:definition>996056 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0" id="nivf_r_ScheduleofAccountsReceivableNetTable0">
        <link:definition>996057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0" id="nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0">
        <link:definition>996058 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0" id="nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable0">
        <link:definition>996059 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable0" id="nivf_r_ScheduleofInventoriesTable0">
        <link:definition>996060 - Disclosure - Inventories (Details) - Schedule of Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" id="nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0">
        <link:definition>996061 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable1">
        <link:definition>996062 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0" id="nivf_r_ScheduleofPlantandEquipmentNetTable0">
        <link:definition>996063 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0" id="nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable0">
        <link:definition>996064 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0" id="nivf_r_ScheduleofContractLiabilitiesTable0">
        <link:definition>996065 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0" id="nivf_r_ScheduleofLeaseLiabilitiesTable0">
        <link:definition>996066 - Disclosure - Leases (Details) - Schedule of Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0" id="nivf_r_ScheduleofOtherLeaseInformationTable0">
        <link:definition>996067 - Disclosure - Leases (Details) - Schedule of Other Lease Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" id="nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0">
        <link:definition>996068 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0" id="nivf_r_ScheduleofSubscriptionReceivablesTable0">
        <link:definition>996069 - Disclosure - Equity (Details) - Schedule of Subscription Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0" id="nivf_r_ScheduleofAdditionalPaidinCapitalTable0">
        <link:definition>996070 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0" id="nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable0">
        <link:definition>996071 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0" id="nivf_r_ScheduleofIncomeTaxesTable0">
        <link:definition>996072 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0" id="nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable0">
        <link:definition>996073 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0" id="nivf_r_ScheduleofBusinessOperationsTable0">
        <link:definition>996074 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0" id="nivf_r_ScheduleofGeographicalInformationTable0">
        <link:definition>996075 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0" id="nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable0">
        <link:definition>996076 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0" id="nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable0">
        <link:definition>996077 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0" id="nivf_r_ScheduleofBalanceDuefromShareholdersTable0">
        <link:definition>996078 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2" id="nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable2">
        <link:definition>996079 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0" id="nivf_r_ScheduleofConsolidatedFinancialStatementsTable0">
        <link:definition>996080 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ScheduleOfCompanySSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAccountsReceivableNetAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
  <xs:element name="ScheduleOfPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfSubscriptionReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfSubscriptionReceivablesAbstract"/>
  <xs:element name="ScheduleOfAdditionalPaidInCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
  <xs:element name="ScheduleOfTheProvisionsForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfBusinessOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfBusinessOperationsAbstract"/>
  <xs:element name="ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract"/>
  <xs:element name="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfBalanceDueFromShareholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
  <xs:element name="ScheduleOfConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ImpactOfCovid19Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ImpactOfCovid19Abstract"/>
  <xs:element name="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonCurrentAssetsAbstract"/>
  <xs:element name="NonCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonCurrentLiabilitiesAbstract"/>
  <xs:element name="OperatingExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OperatingExpensesAbstract0"/>
  <xs:element name="OtherIncomeExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OtherIncomeExpensesNetAbstract"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DeferredTaxAssetsAbstract"/>
  <xs:element name="DueFromShareholdersConsistOfTheFollowingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
  <xs:element name="DueToARelatedPartyConsistOfTheFollowingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract"/>
  <xs:element name="DueFromShareholdersConsistOfTheFollowingAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0"/>
  <xs:element name="DueToARelatedPartyConsistOfTheFollowingAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0"/>
  <xs:element name="LoanToASPAC" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_LoanToASPAC"/>
  <xs:element name="DueToShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToShareholders"/>
  <xs:element name="StockIssuedDuringPeriodValueDirectorsRemuneration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
  <xs:element name="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
  <xs:element name="WaiverOfRelatedPartyBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_WaiverOfRelatedPartyBalance"/>
  <xs:element name="ProceedsFromAmountDueFromASPACI" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProceedsFromAmountDueFromASPACI"/>
  <xs:element name="PaymentofInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_PaymentofInterest"/>
  <xs:element name="SubscriptionReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubscriptionReceivables"/>
  <xs:element name="DissagregattedRevenuesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DissagregattedRevenuesTextBlock"/>
  <xs:element name="ImpactOfCovid19TextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ImpactOfCovid19TextBlock"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
  <xs:element name="RelatedPartiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_RelatedPartiesPolicyTextBlock"/>
  <xs:element name="NonControllingInterestsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NonControllingInterestsPolicyTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment"/>
  <xs:element name="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
  <xs:element name="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
  <xs:element name="ScheduleOfLeaseLiabilitiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock"/>
  <xs:element name="ScheduleOfAdditionalPaidinCapitalTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
  <xs:element name="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
  <xs:element name="SubsidiariesBackground" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubsidiariesBackground"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems"/>
  <xs:element name="ForeignCurrencyExchangeRateTranslation" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_ForeignCurrencyExchangeRateTranslation"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentEstimatedUsefulLive" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
  <xs:element name="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
  <xs:element name="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
  <xs:element name="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
  <xs:element name="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
  <xs:element name="AllowancesForExpectedCreditLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowancesForExpectedCreditLoss"/>
  <xs:element name="AllowancesForExpectedCreditLossReversalOfProvisionProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
  <xs:element name="AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
  <xs:element name="EquityDetailsScheduleofSubscriptionReceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
  <xs:element name="EquityDetailsScheduleofSubscriptionReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
  <xs:element name="EquityDetailsScheduleofAdditionalPaidinCapitalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
  <xs:element name="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
  <xs:element name="IssuanceOfSharesAdditionalpaidincapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_IssuanceOfSharesAdditionalpaidincapital"/>
  <xs:element name="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
  <xs:element name="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
  <xs:element name="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
  <xs:element name="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
  <xs:element name="DueToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueToRelatedParties"/>
  <xs:element name="DueFromShareholder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholder"/>
  <xs:element name="TransactionsWithRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_TransactionsWithRelatedParties"/>
  <xs:element name="OtherReceivablesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_OtherReceivablesNet"/>
  <xs:element name="AllowanceForExpectedCreditLossRevised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nivf_AllowanceForExpectedCreditLossRevised"/>
  <xs:element name="OrganizationandPrincipalActivitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
  <xs:element name="OrganizationandPrincipalActivitiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OrganizationandPrincipalActivitiesDetailsLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="RevenueRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_RevenueRate"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_LeasesDetailsLineItems"/>
  <xs:element name="OperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_OperatingLeaseRightOfUseAssets"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EquityDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_EmployeeBenefitPlansDetailsLineItems"/>
  <xs:element name="ContributableWageRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_ContributableWageRate"/>
  <xs:element name="ContributableWageTotalRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nivf_ContributableWageTotalRate"/>
  <xs:element name="ProvisionforIncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_ProvisionforIncomeTaxesDetailsTable"/>
  <xs:element name="ProvisionforIncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProvisionforIncomeTaxesDetailsLineItems"/>
  <xs:element name="ProfitTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ProfitTaxDescription"/>
  <xs:element name="PercentageOfAllowanceOnDeferredTaxAssets" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
  <xs:element name="RisksDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_RisksDetailsTable"/>
  <xs:element name="InterestRateOtherVariablesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_InterestRateOtherVariablesPercentage"/>
  <xs:element name="DueFromShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nivf_DueFromShareholders"/>
  <xs:element name="NumberOfOperatingSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NumberOfOperatingSegment"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nivf_SubsequentEventsDetailsTable"/>
  <xs:element name="ASPACIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ASPACIMember"/>
  <xs:element name="CurrentTaxProvisionCambodiaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CurrentTaxProvisionCambodiaMember"/>
  <xs:element name="CurrentTaxProvisionKyrgyzstanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CurrentTaxProvisionKyrgyzstanMember"/>
  <xs:element name="CustomerTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_CustomerTwoMember"/>
  <xs:element name="DepositsAndOtherReceivableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsAndOtherReceivableMember"/>
  <xs:element name="DirectorsRemunerationToMrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
  <xs:element name="DirectorsRemunerationToMsFongHeiYueTinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
  <xs:element name="FFPGSHKLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FFPGSHKLimitedMember"/>
  <xs:element name="FirstFertilityBishkekLLCFFBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityBishkekLLCFFBMember"/>
  <xs:element name="FirstFertilityPGSCenterLimitedFFCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
  <xs:element name="FirstFertilityPhnomPenhLimitedFFPPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
  <xs:element name="HKSARMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HKSARMember"/>
  <xs:element name="HarcourtLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HarcourtLimitedMember"/>
  <xs:element name="HealthCareSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_HealthCareSchemeMember"/>
  <xs:element name="IVFTreatmentServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_IVFTreatmentServiceMember"/>
  <xs:element name="LatePenaltyProvisionKyrgyzstanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_LatePenaltyProvisionKyrgyzstanMember"/>
  <xs:element name="MedHoldingsLimitedMedHoldingsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MedHoldingsLimitedMedHoldingsMember"/>
  <xs:element name="MedicalInstrumentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MedicalInstrumentsMember"/>
  <xs:element name="MotorVehiclesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MotorVehiclesMember"/>
  <xs:element name="MovementOfAllowancesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MovementOfAllowancesMember"/>
  <xs:element name="MrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MrSiuWingFungAlfredMember"/>
  <xs:element name="MsFongHeiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_MsFongHeiMember"/>
  <xs:element name="NewGenIvfLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NewGenIvfLimitedMember"/>
  <xs:element name="NoVendorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_NoVendorsMember"/>
  <xs:element name="OccupationalRiskSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OccupationalRiskSchemeMember"/>
  <xs:element name="OneCustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OneCustomerMember"/>
  <xs:element name="OneVendorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OneVendorsMember"/>
  <xs:element name="PensionSchemeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_PensionSchemeMember"/>
  <xs:element name="RevenueBenchmarkOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_RevenueBenchmarkOneMember"/>
  <xs:element name="RevenueBenchmarkTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_RevenueBenchmarkTwoMember"/>
  <xs:element name="RevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_RevenueMember"/>
  <xs:element name="SeazenResourcesInvestmentLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SeazenResourcesInvestmentLimitedMember"/>
  <xs:element name="SubscriptionReceivableIncludingCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubscriptionReceivableIncludingCommonStockMember"/>
  <xs:element name="SubsidiarieMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SubsidiarieMember"/>
  <xs:element name="SupplierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SupplierMember"/>
  <xs:element name="SuppliersFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SuppliersFourMember"/>
  <xs:element name="SuppliersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SuppliersOneMember"/>
  <xs:element name="SurrogacyAncillaryCaringAndOtherServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
  <xs:element name="TranchesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_TranchesMember"/>
  <xs:element name="VendorTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_VendorTwoMember"/>
  <xs:element name="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
  <xs:element name="WellImageLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_WellImageLimitedMember"/>
  <xs:element name="Within90DaysMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_Within90DaysMember"/>
  <xs:element name="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
  <xs:element name="DisaggregatedRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DisaggregatedRevenuesAbstract"/>
  <xs:element name="OrganizationAndPrincipalActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_OrganizationAndPrincipalActivitiesLineItems"/>
  <xs:element name="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems"/>
  <xs:element name="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
  <xs:element name="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
  <xs:element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_SummaryOfSignificantAccountingPoliciesLineItems"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nivf_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>nivf-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:23 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"/>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20240630.xsd#nivf_LoanToASPAC"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="nivf_LoanToASPAC" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToShareholders" xlink:href="nivf-20240630.xsd#nivf_DueToShareholders"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nivf_DueToShareholders" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProfessionalFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestExpenseDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LegalFees" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="14" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nivf_WaiverOfRelatedPartyBalance" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFgA7JGyFnL3NCGt40HvClwoUAP7wD14Ip8=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivables" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_SubscriptionReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20240630.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_ProceedsFromAmountDueFromASPACI" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20240630.xsd#nivf_PaymentofInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nivf_PaymentofInterest" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>nivf-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:23 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ShareholdersEquityType2or3" roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivities" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountsReceivableNet" roleURI="http://www.newgenivf.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Inventories" roleURI="http://www.newgenivf.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNet" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccruedLiabiltiesandOtherPayables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContractLiabilities" roleURI="http://www.newgenivf.com/role/ContractLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Leases" roleURI="http://www.newgenivf.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Equity" roleURI="http://www.newgenivf.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EmployeeBenefitPlans" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxes" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DisaggregatedRevenues" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Risks" roleURI="http://www.newgenivf.com/role/Risks"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactions" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LoantoaSPACI" roleURI="http://www.newgenivf.com/role/LoantoaSPACI"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ImpactofCovid19" roleURI="http://www.newgenivf.com/role/ImpactofCovid19"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Contingencies" roleURI="http://www.newgenivf.com/role/Contingencies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SegmentInformation" roleURI="http://www.newgenivf.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SubsequentEvents" roleURI="http://www.newgenivf.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountingPoliciesByPolicy" roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountsReceivableNetTables" roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_InventoriesTables" roleURI="http://www.newgenivf.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNetTables" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccruedLiabiltiesandOtherPayablesTables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContractLiabilitiesTables" roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LeasesTables" roleURI="http://www.newgenivf.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EquityTables" roleURI="http://www.newgenivf.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxesTables" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DisaggregatedRevenuesTables" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCompanyssubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofContractLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofOtherLeaseInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofSubscriptionReceivablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBusinessOperationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofGeographicalInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCompanysSubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0" roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable1" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofContractLiabilitiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofOtherLeaseInformationTable0" roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofSubscriptionReceivablesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable0" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofIncomeTaxesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBusinessOperationsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofGeographicalInformationTable0" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable0" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable2" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNetDetails" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LeasesDetails" roleURI="http://www.newgenivf.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EquityDetails" roleURI="http://www.newgenivf.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EmployeeBenefitPlansDetails" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxesDetails" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RisksDetails" roleURI="http://www.newgenivf.com/role/RisksDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LoantoaSPACIDetails" roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContingenciesDetails" roleURI="http://www.newgenivf.com/role/ContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SegmentInformationDetails" roleURI="http://www.newgenivf.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SubsequentEventsDetails" roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#DocumentAndEntityInformation" roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MajorityShareholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_MajorityShareholderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20240630.xsd#nivf_LoanToASPAC"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="nivf_LoanToASPAC" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToShareholders" xlink:href="nivf-20240630.xsd#nivf_DueToShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nivf_DueToShareholders" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_CostOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_GrossProfit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nivf_WaiverOfRelatedPartyBalance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LegalFees" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20240630.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nivf_ProceedsFromAmountDueFromASPACI" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20240630.xsd#nivf_PaymentofInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nivf_PaymentofInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivables" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nivf_SubscriptionReceivables" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossAdditionalImprovementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Inventories" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ContractLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesAbstract" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DissagregattedRevenuesTextBlock" xlink:href="nivf-20240630.xsd#nivf_DissagregattedRevenuesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesAbstract" xlink:to="nivf_DissagregattedRevenuesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Risks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACI" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ImpactofCovid19" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ImpactOfCovid19Abstract" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19Abstract"/>
    <loc xlink:type="locator" xlink:label="nivf_ImpactOfCovid19TextBlock" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19TextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ImpactOfCovid19Abstract" xlink:to="nivf_ImpactOfCovid19TextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/Contingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartiesPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_RelatedPartiesPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_NonControllingInterestsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossAdditionalImprovementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/InventoriesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ContractLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfLeaseLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesAbstract" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FFPGSHKLimitedMember" xlink:href="nivf-20240630.xsd#nivf_FFPGSHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FFPGSHKLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WellImageLimitedMember" xlink:href="nivf-20240630.xsd#nivf_WellImageLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_WellImageLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20240630.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiariesBackground" xlink:href="nivf-20240630.xsd#nivf_SubsidiariesBackground"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_SubsidiariesBackground" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_HKD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_THB" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_KHR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_KHR"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_KHR" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CNY" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation" xlink:href="nivf-20240630.xsd#nivf_ForeignCurrencyExchangeRateTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_ForeignCurrencyExchangeRateTranslation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MotorVehiclesMember" xlink:href="nivf-20240630.xsd#nivf_MotorVehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MotorVehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:href="nivf-20240630.xsd#nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_Within90DaysMember" xlink:href="nivf-20240630.xsd#nivf_Within90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="nivf_Within90DaysMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MovementOfAllowancesMember" xlink:href="nivf-20240630.xsd#nivf_MovementOfAllowancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="nivf_MovementOfAllowancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLoss" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivableIncludingCommonStockMember" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivableIncludingCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nivf_SubscriptionReceivableIncludingCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:href="nivf-20240630.xsd#nivf_IssuanceOfSharesAdditionalpaidincapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_IssuanceOfSharesAdditionalpaidincapital" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionCambodiaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_LatePenaltyProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_LatePenaltyProvisionKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_LatePenaltyProvisionKyrgyzstanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IVFTreatmentServiceMember" xlink:href="nivf-20240630.xsd#nivf_IVFTreatmentServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_IVFTreatmentServiceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20240630.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFjsOxBIqpnVvSKuJxi9GsWZEAlli90dCfo=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HarcourtLimitedMember" xlink:href="nivf-20240630.xsd#nivf_HarcourtLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_HarcourtLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToRelatedParties" xlink:href="nivf-20240630.xsd#nivf_DueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="nivf_DueToRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholder" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholder"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_DueFromShareholder" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_TransactionsWithRelatedParties" xlink:href="nivf-20240630.xsd#nivf_TransactionsWithRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="nivf_TransactionsWithRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20240630.xsd#nivf_NewGenIvfLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_NewGenIvfLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FFPGSHKLimitedMember" xlink:href="nivf-20240630.xsd#nivf_FFPGSHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FFPGSHKLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_WellImageLimitedMember" xlink:href="nivf-20240630.xsd#nivf_WellImageLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_WellImageLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20240630.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiariesBackground" xlink:href="nivf-20240630.xsd#nivf_SubsidiariesBackground"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="nivf_SubsidiariesBackground" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="srt_CurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_HKD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_THB" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_KHR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_KHR"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_KHR" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CNY" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation" xlink:href="nivf-20240630.xsd#nivf_ForeignCurrencyExchangeRateTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_ForeignCurrencyExchangeRateTranslation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MotorVehiclesMember" xlink:href="nivf-20240630.xsd#nivf_MotorVehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MotorVehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:href="nivf-20240630.xsd#nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_Within90DaysMember" xlink:href="nivf-20240630.xsd#nivf_Within90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="nivf_Within90DaysMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MovementOfAllowancesMember" xlink:href="nivf-20240630.xsd#nivf_MovementOfAllowancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="nivf_MovementOfAllowancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLoss" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nivf_MedicalInstrumentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivableIncludingCommonStockMember" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivableIncludingCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nivf_SubscriptionReceivableIncludingCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:href="nivf-20240630.xsd#nivf_IssuanceOfSharesAdditionalpaidincapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_IssuanceOfSharesAdditionalpaidincapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_CurrentTaxProvisionCambodiaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_LatePenaltyProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_LatePenaltyProvisionKyrgyzstanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="nivf_LatePenaltyProvisionKyrgyzstanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_IVFTreatmentServiceMember" xlink:href="nivf-20240630.xsd#nivf_IVFTreatmentServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_IVFTreatmentServiceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20240630.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholder" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholder"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_DueFromShareholder" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherReceivablesNet" xlink:href="nivf-20240630.xsd#nivf_OtherReceivablesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_OtherReceivablesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowanceForExpectedCreditLossRevised" xlink:href="nivf-20240630.xsd#nivf_AllowanceForExpectedCreditLossRevised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_AllowanceForExpectedCreditLossRevised" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_TransactionsWithRelatedParties" xlink:href="nivf-20240630.xsd#nivf_TransactionsWithRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="nivf_TransactionsWithRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="nivf_OrganizationandPrincipalActivitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiarieMember" xlink:href="nivf-20240630.xsd#nivf_SubsidiarieMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="nivf_SubsidiarieMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSecuredFinancings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSecuredFinancings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_OtherSecuredFinancings" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RestatementAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SupplierMember" xlink:href="nivf-20240630.xsd#nivf_SupplierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_SupplierMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersOneMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_SuppliersOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersFourMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_SuppliersFourMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NoVendorsMember" xlink:href="nivf-20240630.xsd#nivf_NoVendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_NoVendorsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_VendorTwoMember" xlink:href="nivf-20240630.xsd#nivf_VendorTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_VendorTwoMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OneVendorsMember" xlink:href="nivf-20240630.xsd#nivf_OneVendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="nivf_OneVendorsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="us-gaap_OtherCustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerTwoMember" xlink:href="nivf-20240630.xsd#nivf_CustomerTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_CustomerTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueMember" xlink:href="nivf-20240630.xsd#nivf_RevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_RevenueMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueBenchmarkOneMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_RevenueBenchmarkOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueBenchmarkTwoMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_RevenueBenchmarkTwoMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OneCustomerMember" xlink:href="nivf-20240630.xsd#nivf_OneCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="nivf_OneCustomerMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueRate" xlink:href="nivf-20240630.xsd#nivf_RevenueRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nivf_RevenueRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_LeasesDetailsLineItems" xlink:to="nivf_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_LeasesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OperatingLeaseRightOfUseAssets" xlink:href="nivf-20240630.xsd#nivf_OperatingLeaseRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_LeasesDetailsLineItems" xlink:to="nivf_OperatingLeaseRightOfUseAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="nivf_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MrSiuWingFungAlfredMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_MsFongHeiMember" xlink:href="nivf-20240630.xsd#nivf_MsFongHeiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nivf_MsFongHeiMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_SeazenResourcesInvestmentLimitedMember" xlink:href="nivf-20240630.xsd#nivf_SeazenResourcesInvestmentLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="nivf_SeazenResourcesInvestmentLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20240630.xsd#nivf_NewGenIvfLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nivf_NewGenIvfLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_OtherBorrowings" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockRedemptionAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="nivf_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_OccupationalRiskSchemeMember" xlink:href="nivf-20240630.xsd#nivf_OccupationalRiskSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nivf_OccupationalRiskSchemeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HealthCareSchemeMember" xlink:href="nivf-20240630.xsd#nivf_HealthCareSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nivf_HealthCareSchemeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PensionSchemeMember" xlink:href="nivf-20240630.xsd#nivf_PensionSchemeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nivf_PensionSchemeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TH" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KH" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KG" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SpecialAssessmentBond" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ContributableWageRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="nivf_ContributableWageRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ContributableWageTotalRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageTotalRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="nivf_ContributableWageTotalRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="nivf_HKSARMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfitTaxDescription" xlink:href="nivf-20240630.xsd#nivf_ProfitTaxDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="nivf_ProfitTaxDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20240630.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_RisksDetailsTable" xlink:href="nivf-20240630.xsd#nivf_RisksDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="nivf_RisksDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RisksDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RisksDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_RisksDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsAndOtherReceivableMember" xlink:href="nivf-20240630.xsd#nivf_DepositsAndOtherReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="nivf_DepositsAndOtherReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_ASPACIMember" xlink:href="nivf-20240630.xsd#nivf_ASPACIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nivf_ASPACIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_InterestRateOtherVariablesPercentage" xlink:href="nivf-20240630.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="nivf_InterestRateOtherVariablesPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholders" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="nivf_DueFromShareholders" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACIDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/ContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="nivf_NumberOfOperatingSegment" xlink:href="nivf-20240630.xsd#nivf_NumberOfOperatingSegment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="nivf_NumberOfOperatingSegment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportingUnits" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsequentEventsDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nivf_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nivf_TranchesMember" xlink:href="nivf-20240630.xsd#nivf_TranchesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nivf_TranchesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.newgenivf.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="17" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>nivf-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:23 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Total Long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (loss) before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income/(loss) before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Total comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive income attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares ,shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by/(used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Principal Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossAdditionalImprovementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract_lbl" xml:lang="en-US">Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_CreditLossAdditionalImprovementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Total accounts receivable net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts receivable , net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis_lbl" xml:lang="en-US">Financial Asset, Aging [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Schedule of Movement Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Schedule of Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract_lbl" xml:lang="en-US">Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Deposits, prepayment, other receivables and deferred IPO cost, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Deposits, prepayment and other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLoss" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl" xml:lang="en-US">Balance at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl0" xml:lang="en-US">At cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfPlantAndEquipmentNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule of Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfPlantAndEquipmentNetAbstract" xlink:to="nivf_ScheduleOfPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Plant and equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accrued Liabilties and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Liabilities and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilties and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract_lbl" xml:lang="en-US">Contract Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_DepositContractsLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Schedule of Contract Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Total operating lease liabilities, net of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Other Lease Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Payments under Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfSubscriptionReceivablesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfSubscriptionReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfSubscriptionReceivablesAbstract_lbl" xml:lang="en-US">Schedule of Subscription Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfSubscriptionReceivablesAbstract" xlink:to="nivf_ScheduleOfSubscriptionReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Balance at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl1" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidInCapitalAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAdditionalPaidInCapitalAbstract_lbl" xml:lang="en-US">Schedule of Additional Paid-in Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidInCapitalAbstract" xlink:to="nivf_ScheduleOfAdditionalPaidInCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Balance at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Provision for Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfIncomeTaxesAbstract" xlink:to="nivf_ScheduleOfIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesAbstract" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisaggregatedRevenuesAbstract_lbl" xml:lang="en-US">Disaggregated Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisaggregatedRevenuesAbstract" xlink:to="nivf_DisaggregatedRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentsGeographicalAreasAbstract_lbl" xml:lang="en-US">Schedule of Geographical Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="us-gaap_SegmentsGeographicalAreasAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract_lbl" xml:lang="en-US">Related Party Balances and Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_RelatedPartyTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfBalanceDueFromShareholdersAbstract_lbl" xml:lang="en-US">Schedule of the Balance Due from Shareholders [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="nivf_ScheduleOfBalanceDueFromShareholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule of the Movement of Allowances for Expected Credit Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Loan to a SPAC I [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ImpactOfCovid19Abstract" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ImpactOfCovid19Abstract_lbl" xml:lang="en-US">Impact of Covid-19 [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ImpactOfCovid19Abstract" xlink:to="nivf_ImpactOfCovid19Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAccountsReceivableNetAbstract_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAccountsReceivableNetAbstract" xlink:to="nivf_ScheduleOfAccountsReceivableNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued Liabilties and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Bank balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_LoanToASPAC" xlink:href="nivf-20240630.xsd#nivf_LoanToASPAC"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_LoanToASPAC_lbl" xml:lang="en-US">Loan to A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Right-of-use assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Due to a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Lease liabilities &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Lease liabilities &#8211; non-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Ordinary shares, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary share, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCurrentAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentAssetsAbstract" xlink:to="nivf_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits, prepayment and other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToShareholders" xlink:href="nivf-20240630.xsd#nivf_DueToShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueToShareholders_lbl" xml:lang="en-US">Due to shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToShareholders" xlink:to="nivf_DueToShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonCurrentLiabilitiesAbstract" xlink:href="nivf-20240630.xsd#nivf_NonCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentLiabilitiesAbstract" xlink:to="nivf_NonCurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: net loss attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: total comprehensive loss attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earning per share &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earning per share &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OperatingExpensesAbstract0" xlink:href="nivf-20240630.xsd#nivf_OperatingExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OperatingExpensesAbstract0_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OperatingExpensesAbstract0" xlink:to="nivf_OperatingExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherIncomeExpensesNetAbstract" xlink:href="nivf-20240630.xsd#nivf_OtherIncomeExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OtherIncomeExpensesNetAbstract_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherIncomeExpensesNetAbstract" xlink:to="nivf_OtherIncomeExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherComprehensiveIncomeLossAbstract" xlink:href="nivf-20240630.xsd#nivf_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherComprehensiveIncomeLossAbstract" xlink:to="nivf_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl" xml:lang="en-US">Directors&#8217; remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:to="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl" xml:lang="en-US">Subscription receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl0" xml:lang="en-US">Settlement of subscription receivable (Note 2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl1" xml:lang="en-US">Settlement of subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Business combination (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Provision of expected credit loss allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Directors&#8217; remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Other borrowings, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Amount with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in)/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of foreign currency translation on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplementary cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Loan to A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivables" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SubscriptionReceivables_lbl" xml:lang="en-US">Subscription receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivables" xlink:to="nivf_SubscriptionReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Listing fee paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Audit fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Total provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalance" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl" xml:lang="en-US">Waiver of related party balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Deposit and other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl" xml:lang="en-US">Finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20240630.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl" xml:lang="en-US">Amount due from A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PaymentofInterest" xlink:href="nivf-20240630.xsd#nivf_PaymentofInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_PaymentofInterest_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Deposit, prepayment and other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MajorityShareholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorityShareholderMember_lbl" xml:lang="en-US">Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Total attributable to the shareholders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non- controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND PRINCIPAL ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Company&#8217;s Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiariesBackground" xlink:href="nivf-20240630.xsd#nivf_SubsidiariesBackground"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SubsidiariesBackground_lbl" xml:lang="en-US">Background</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiariesBackground" xlink:to="nivf_SubsidiariesBackground_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Ownership %</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl" xml:lang="en-US">Principal activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Currency exchange rates, period-end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation" xlink:href="nivf-20240630.xsd#nivf_ForeignCurrencyExchangeRateTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Currency exchange rates, period average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ForeignCurrencyExchangeRateTranslation" xlink:to="nivf_ForeignCurrencyExchangeRateTranslation_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of the Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:href="nivf-20240630.xsd#nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:to="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of movement Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Reversal of expected credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl1" xml:lang="en-US">Reversal (provision) of provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Medicines, consumables and reagents for clinical and laboratory analyses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred initial public offering &#8220;IPO&#8221; cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl" xml:lang="en-US">Reversal of provision (Provision)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Effect of currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:to="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Plant and equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILTIES AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Other tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Withholding tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Compensation payable (Note 1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">CONTRACT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Recognized to revenue during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0" xml:lang="en-US">Recognized to revenue during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfLeaseLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:to="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Lease Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short term lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments under Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Not later than 1 year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Between 1 to 2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Between 2 to 3 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Subscription Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of shares (Note 1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:href="nivf-20240630.xsd#nivf_IssuanceOfSharesAdditionalpaidincapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:to="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">PROVISION FOR INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of the Provisions for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax expenses (credit) at the effective tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Tax expenses/(credit) at the effective tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Tax effect on non-taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Tax effect on non-deductible expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Tax effect on late penalty provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Tax effect on utilization of tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeferredTaxAssetsAbstract" xlink:to="nivf_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">&#8211; Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DissagregattedRevenuesTextBlock" xlink:href="nivf-20240630.xsd#nivf_DissagregattedRevenuesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DissagregattedRevenuesTextBlock_lbl" xml:lang="en-US">DISAGGREGATED REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DissagregattedRevenuesTextBlock" xlink:to="nivf_DissagregattedRevenuesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Business Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Geographical Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue Information above is Based on the Locations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">RISKS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Amount Due from and Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl" xml:lang="en-US">Due from shareholders consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Relationship</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Due from shareholders, Relationship</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl1" xml:lang="en-US">Due to a related party, Relationship</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:href="nivf-20240630.xsd#nivf_DueToARelatedPartyConsistOfTheFollowingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl" xml:lang="en-US">Due to a related party consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Due from Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholder" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholder"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholder_lbl" xml:lang="en-US">Due from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholder" xlink:to="nivf_DueFromShareholder_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl" xml:lang="en-US">Total shareholders amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Movement of Allowances for Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_TransactionsWithRelatedParties" xlink:href="nivf-20240630.xsd#nivf_TransactionsWithRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_TransactionsWithRelatedParties_lbl" xml:lang="en-US">Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TransactionsWithRelatedParties" xlink:to="nivf_TransactionsWithRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LOAN TO A SPAC I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ImpactOfCovid19TextBlock" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19TextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ImpactOfCovid19TextBlock_lbl" xml:lang="en-US">IMPACT OF COVID-19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ImpactOfCovid19TextBlock" xlink:to="nivf_ImpactOfCovid19TextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Effect of currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0_lbl" xml:lang="en-US">Due from shareholders consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0_lbl" xml:lang="en-US">Due to a related party consist of the following:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OtherReceivablesNet" xlink:href="nivf-20240630.xsd#nivf_OtherReceivablesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OtherReceivablesNet_lbl" xml:lang="en-US">Total shareholders amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherReceivablesNet" xlink:to="nivf_OtherReceivablesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AllowanceForExpectedCreditLossRevised" xlink:href="nivf-20240630.xsd#nivf_AllowanceForExpectedCreditLossRevised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AllowanceForExpectedCreditLossRevised_lbl" xml:lang="en-US">Revised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowanceForExpectedCreditLossRevised" xlink:to="nivf_AllowanceForExpectedCreditLossRevised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xml:lang="en-US">Refund to customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueToRelatedParties" xlink:href="nivf-20240630.xsd#nivf_DueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nivf_DueToRelatedParties_lbl" xml:lang="en-US">Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToRelatedParties" xlink:to="nivf_DueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl" xml:lang="en-US">Less: allowance for expected credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FFPGSHKLimitedMember" xlink:href="nivf-20240630.xsd#nivf_FFPGSHKLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FFPGSHKLimitedMember_lbl" xml:lang="en-US">FFPGS (HK) Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FFPGSHKLimitedMember" xlink:to="nivf_FFPGSHKLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WellImageLimitedMember" xlink:href="nivf-20240630.xsd#nivf_WellImageLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WellImageLimitedMember_lbl" xml:lang="en-US">Well Image Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WellImageLimitedMember" xlink:to="nivf_WellImageLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20240630.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember_lbl" xml:lang="en-US">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl" xml:lang="en-US">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl" xml:lang="en-US">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember_lbl" xml:lang="en-US">First Fertility Bishkek LLC (&#8220;FFB&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityBishkekLLCFFBMember" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_HKD_lbl" xml:lang="en-US">HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_THB_lbl" xml:lang="en-US">THB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_THB" xlink:to="currency_THB_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_KHR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_KHR"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_KHR_lbl" xml:lang="en-US">KHR [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_KHR" xlink:to="currency_KHR_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_CNY_lbl" xml:lang="en-US">RMB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MedicalInstrumentsMember_lbl" xml:lang="en-US">Medical Instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nivf_MedicalInstrumentsMember_lbl0" xml:lang="en-US">Medical instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_MotorVehiclesMember" xlink:href="nivf-20240630.xsd#nivf_MotorVehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MotorVehiclesMember_lbl" xml:lang="en-US">Motor Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MotorVehiclesMember" xlink:to="nivf_MotorVehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_Within90DaysMember" xlink:href="nivf-20240630.xsd#nivf_Within90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_Within90DaysMember_lbl" xml:lang="en-US">Within 90 days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Within90DaysMember" xlink:to="nivf_Within90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MovementOfAllowancesMember" xlink:href="nivf-20240630.xsd#nivf_MovementOfAllowancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MovementOfAllowancesMember_lbl" xml:lang="en-US">Movement of Allowances [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MovementOfAllowancesMember" xlink:to="nivf_MovementOfAllowancesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Building improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubscriptionReceivableIncludingCommonStockMember" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivableIncludingCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SubscriptionReceivableIncludingCommonStockMember_lbl" xml:lang="en-US">Subscription Receivable including Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivableIncludingCommonStockMember" xlink:to="nivf_SubscriptionReceivableIncludingCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl" xml:lang="en-US">Current tax provision Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CurrentTaxProvisionCambodiaMember_lbl" xml:lang="en-US">Current tax provision Cambodia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionCambodiaMember" xlink:to="nivf_CurrentTaxProvisionCambodiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_LatePenaltyProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_LatePenaltyProvisionKyrgyzstanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_LatePenaltyProvisionKyrgyzstanMember_lbl" xml:lang="en-US">Late penalty provision Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LatePenaltyProvisionKyrgyzstanMember" xlink:to="nivf_LatePenaltyProvisionKyrgyzstanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_IVFTreatmentServiceMember" xlink:href="nivf-20240630.xsd#nivf_IVFTreatmentServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_IVFTreatmentServiceMember_lbl" xml:lang="en-US">IVF treatment service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IVFTreatmentServiceMember" xlink:to="nivf_IVFTreatmentServiceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20240630.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl" xml:lang="en-US">Surrogacy, ancillary caring and other services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HKSARMember_lbl" xml:lang="en-US">HK SAR [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HKSARMember" xlink:to="nivf_HKSARMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KG_lbl" xml:lang="en-US">Kyrgyzstan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KG" xlink:to="country_KG_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_KG_lbl0" xml:lang="en-US">KYRGYZSTAN [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KG" xlink:to="country_KG_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KH_lbl" xml:lang="en-US">Cambodia [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KH" xlink:to="country_KH_lbl"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_TH_lbl" xml:lang="en-US">Thailand [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TH" xlink:to="country_TH_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Mr. Siu Wing Fung, Alfred (&#8220;Mr. Siu&#8221;) and Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MrSiuWingFungAlfredMember" xlink:to="nivf_MrSiuWingFungAlfredMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nivf_MrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Mr. Siu Wing Fung, Alfred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MrSiuWingFungAlfredMember" xlink:to="nivf_MrSiuWingFungAlfredMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_HarcourtLimitedMember" xlink:href="nivf-20240630.xsd#nivf_HarcourtLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HarcourtLimitedMember_lbl" xml:lang="en-US">Harcourt Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HarcourtLimitedMember" xlink:to="nivf_HarcourtLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Directors&#8217; remuneration to Mr. Siu Wing Fung, Alfred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl" xml:lang="en-US">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl" xml:lang="en-US">Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NewGenIvfLimitedMember" xlink:href="nivf-20240630.xsd#nivf_NewGenIvfLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NewGenIvfLimitedMember_lbl" xml:lang="en-US">NewGenivf Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenIvfLimitedMember" xlink:to="nivf_NewGenIvfLimitedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nivf_NewGenIvfLimitedMember_lbl0" xml:lang="en-US">NewGenIvf Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenIvfLimitedMember" xlink:to="nivf_NewGenIvfLimitedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Equity investment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl" xml:lang="en-US">Dividends percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:to="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Settlement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSecuredFinancings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSecuredFinancings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSecuredFinancings_lbl" xml:lang="en-US">Secured funding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSecuredFinancings" xlink:to="us-gaap_OtherSecuredFinancings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US">Received from secured funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Salvage value percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueRate" xlink:href="nivf-20240630.xsd#nivf_RevenueRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RevenueRate_lbl" xml:lang="en-US">Contract revenue rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Lease liabilities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xml:lang="en-US">Borrowing cost rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Lease payments rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Threshold rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">progressive rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OperatingLeaseRightOfUseAssets" xlink:href="nivf-20240630.xsd#nivf_OperatingLeaseRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OperatingLeaseRightOfUseAssets" xlink:to="nivf_OperatingLeaseRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Additional ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherBorrowings_lbl" xml:lang="en-US">Other borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherBorrowings" xlink:to="us-gaap_OtherBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl" xml:lang="en-US">Amount received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionAmount_lbl" xml:lang="en-US">Remuneration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionAmount" xlink:to="us-gaap_PreferredStockRedemptionAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAdditionalCapital_lbl" xml:lang="en-US">Increase in paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Consulting service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl" xml:lang="en-US">Scheme calculated rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SpecialAssessmentBond_lbl" xml:lang="en-US">Special concession amount (in Baht)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpecialAssessmentBond" xlink:to="us-gaap_SpecialAssessmentBond_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ContributableWageRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ContributableWageRate_lbl" xml:lang="en-US">Contribution equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageRate" xlink:to="nivf_ContributableWageRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Average wages per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ContributableWageTotalRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageTotalRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ContributableWageTotalRate_lbl" xml:lang="en-US">Contribution equivalent total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageTotalRate" xlink:to="nivf_ContributableWageTotalRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Contributable wage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProfitTaxDescription" xlink:href="nivf-20240630.xsd#nivf_ProfitTaxDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ProfitTaxDescription_lbl" xml:lang="en-US">Profit tax rate description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Profit tax percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Estimated assessable profits (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_lbl" xml:lang="en-US">Estimated assessable profit rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl" xml:lang="en-US">Corporate income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl" xml:lang="en-US">Rate of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Provisions rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US">Corporate income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Annual turnover ranges (in Riels)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xml:lang="en-US">Profit tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forward (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20240630.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl" xml:lang="en-US">Percentage of allowance on deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Allowance for account receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFiA6rPMtHOym3ErEh4njwhY] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl" xml:lang="en-US">Allowance for deposits and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) interest risk rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_InterestRateOtherVariablesPercentage" xlink:href="nivf-20240630.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl" xml:lang="en-US">Interest rate other variables, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl" xml:lang="en-US">Increased (decreased) amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DueFromShareholders" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DueFromShareholders_lbl" xml:lang="en-US">Due from shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl" xml:lang="en-US">Loan outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xml:lang="en-US">Contingent tax penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NumberOfOperatingSegment" xlink:href="nivf-20240630.xsd#nivf_NumberOfOperatingSegment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NumberOfOperatingSegment_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NumberOfOperatingSegment" xlink:to="nivf_NumberOfOperatingSegment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xml:lang="en-US">Reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xml:lang="en-US">Original issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation and basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl" xml:lang="en-US">Deposits, prepayment, other receivables and deferred IPO cost, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Other borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xml:lang="en-US">Retirement benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RelatedPartiesPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsidiarieMember" xlink:href="nivf-20240630.xsd#nivf_SubsidiarieMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SubsidiarieMember_lbl" xml:lang="en-US">Subsidiaries [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiarieMember" xlink:to="nivf_SubsidiarieMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCustomerMember_lbl" xml:lang="en-US">Other Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCustomerMember" xlink:to="us-gaap_OtherCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Trade Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_CustomerTwoMember" xlink:href="nivf-20240630.xsd#nivf_CustomerTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerTwoMember" xlink:to="nivf_CustomerTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueMember" xlink:href="nivf-20240630.xsd#nivf_RevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RevenueMember_lbl" xml:lang="en-US">Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueMember" xlink:to="nivf_RevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueBenchmarkOneMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RevenueBenchmarkOneMember_lbl" xml:lang="en-US">Revenue Benchmark One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueBenchmarkOneMember" xlink:to="nivf_RevenueBenchmarkOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RevenueBenchmarkTwoMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_RevenueBenchmarkTwoMember_lbl" xml:lang="en-US">Revenue Benchmark Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueBenchmarkTwoMember" xlink:to="nivf_RevenueBenchmarkTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SupplierMember" xlink:href="nivf-20240630.xsd#nivf_SupplierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SupplierMember_lbl" xml:lang="en-US">Supplier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SupplierMember" xlink:to="nivf_SupplierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersOneMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SuppliersOneMember_lbl" xml:lang="en-US">Suppliers One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersOneMember" xlink:to="nivf_SuppliersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SuppliersFourMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SuppliersFourMember_lbl" xml:lang="en-US">Suppliers Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersFourMember" xlink:to="nivf_SuppliersFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_NoVendorsMember" xlink:href="nivf-20240630.xsd#nivf_NoVendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_NoVendorsMember_lbl" xml:lang="en-US">No Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NoVendorsMember" xlink:to="nivf_NoVendorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_VendorTwoMember" xlink:href="nivf-20240630.xsd#nivf_VendorTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_VendorTwoMember" xlink:to="nivf_VendorTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OneCustomerMember" xlink:href="nivf-20240630.xsd#nivf_OneCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OneCustomerMember" xlink:to="nivf_OneCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OneVendorsMember" xlink:href="nivf-20240630.xsd#nivf_OneVendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OneVendorsMember_lbl" xml:lang="en-US">One Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OneVendorsMember" xlink:to="nivf_OneVendorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SeazenResourcesInvestmentLimitedMember" xlink:href="nivf-20240630.xsd#nivf_SeazenResourcesInvestmentLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_SeazenResourcesInvestmentLimitedMember_lbl" xml:lang="en-US">Seazen Resources Investment Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeazenResourcesInvestmentLimitedMember" xlink:to="nivf_SeazenResourcesInvestmentLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_MsFongHeiMember" xlink:href="nivf-20240630.xsd#nivf_MsFongHeiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_MsFongHeiMember_lbl" xml:lang="en-US">Ms. Fong, Hei [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MsFongHeiMember" xlink:to="nivf_MsFongHeiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">HK SAR [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_HK_lbl0" xml:lang="en-US">HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_OccupationalRiskSchemeMember" xlink:href="nivf-20240630.xsd#nivf_OccupationalRiskSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_OccupationalRiskSchemeMember_lbl" xml:lang="en-US">Occupational Risk Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OccupationalRiskSchemeMember" xlink:to="nivf_OccupationalRiskSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_HealthCareSchemeMember" xlink:href="nivf-20240630.xsd#nivf_HealthCareSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_HealthCareSchemeMember_lbl" xml:lang="en-US">Health Care Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HealthCareSchemeMember" xlink:to="nivf_HealthCareSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_PensionSchemeMember" xlink:href="nivf-20240630.xsd#nivf_PensionSchemeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_PensionSchemeMember_lbl" xml:lang="en-US">Pension Scheme [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PensionSchemeMember" xlink:to="nivf_PensionSchemeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DepositsAndOtherReceivableMember" xlink:href="nivf-20240630.xsd#nivf_DepositsAndOtherReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_DepositsAndOtherReceivableMember_lbl" xml:lang="en-US">Deposits and Other Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsAndOtherReceivableMember" xlink:to="nivf_DepositsAndOtherReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ASPACIMember" xlink:href="nivf-20240630.xsd#nivf_ASPACIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ASPACIMember_lbl" xml:lang="en-US">A SPAC I [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ASPACIMember" xlink:to="nivf_ASPACIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_TranchesMember" xlink:href="nivf-20240630.xsd#nivf_TranchesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_TranchesMember_lbl" xml:lang="en-US">Tranches [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TranchesMember" xlink:to="nivf_TranchesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Schedule of Accounts Receivable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain_lbl" xml:lang="en-US">Financial Asset, Aging [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable_lbl" xml:lang="en-US">Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems_lbl" xml:lang="en-US">Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable_lbl" xml:lang="en-US">Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems_lbl" xml:lang="en-US">Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of Subscription Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="nivf_EquityDetailsScheduleofSubscriptionReceivablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of Subscription Receivables [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of Additional Paid-in Capital [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of Additional Paid-in Capital [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable_lbl" xml:lang="en-US">Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems_lbl" xml:lang="en-US">Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Schedule of Business Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable_lbl" xml:lang="en-US">Disaggregated Revenues (Details) - Schedule of Geographical Information [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems_lbl" xml:lang="en-US">Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Schedule of Revenue Information above is Based on the Locations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Amount Due from and Due to Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems_lbl0" xml:lang="en-US">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems_lbl0" xml:lang="en-US">Schedule of Movement Allowances for Expected Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems_lbl0" xml:lang="en-US">Schedule of the Provisions for Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsTable_lbl" xml:lang="en-US">Organization and Principal Activities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="nivf_OrganizationandPrincipalActivitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OrganizationandPrincipalActivitiesDetailsLineItems_lbl" xml:lang="en-US">Organization and Principal Activities (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="nivf_OrganizationandPrincipalActivitiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LeasesDetailsTable" xlink:to="nivf_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_LeasesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LeasesDetailsLineItems" xlink:to="nivf_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EquityDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EquityDetailsTable" xlink:to="nivf_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EmployeeBenefitPlansDetailsTable" xlink:to="nivf_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_EmployeeBenefitPlansDetailsLineItems_lbl" xml:lang="en-US">Employee Benefit Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_EmployeeBenefitPlansDetailsLineItems" xlink:to="nivf_EmployeeBenefitPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesDetailsTable_lbl" xml:lang="en-US">Provision for Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsTable" xlink:to="nivf_ProvisionforIncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProvisionforIncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Provision for IncomeTaxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProvisionforIncomeTaxesDetailsLineItems" xlink:to="nivf_ProvisionforIncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_RisksDetailsTable" xlink:href="nivf-20240630.xsd#nivf_RisksDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RisksDetailsTable_lbl" xml:lang="en-US">Risks (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RisksDetailsTable" xlink:to="nivf_RisksDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Risks [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nivf_SubsequentEventsDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsequentEventsDetailsTable" xlink:to="nivf_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowanceForExpectedCreditLossRevised_lbl0" xml:lang="en-US">Allowance for expected credit loss/revised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowanceForExpectedCreditLossRevised" xlink:to="nivf_AllowanceForExpectedCreditLossRevised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl1" xml:lang="en-US">Represent the amount of allowances for expected credit loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl0" xml:lang="en-US">Represent the amount of effect of currency translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:to="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl0" xml:lang="en-US">Repressent the amount of reversal of provision (Provision).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ContributableWageRate_lbl0" xml:lang="en-US">Contributable wage rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageRate" xlink:to="nivf_ContributableWageRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ContributableWageTotalRate_lbl0" xml:lang="en-US">Contributable wage total rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageTotalRate" xlink:to="nivf_ContributableWageTotalRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DissagregattedRevenuesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for dissagregatted revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DissagregattedRevenuesTextBlock" xlink:to="nivf_DissagregattedRevenuesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueFromShareholder_lbl0" xml:lang="en-US">Due from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholder" xlink:to="nivf_DueFromShareholder_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueFromShareholders_lbl0" xml:lang="en-US">Due from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueToRelatedParties_lbl0" xml:lang="en-US">Due to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToRelatedParties" xlink:to="nivf_DueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_DueToShareholders_lbl0" xml:lang="en-US">The amount of due to shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToShareholders" xlink:to="nivf_DueToShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation_lbl0" xml:lang="en-US">Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ForeignCurrencyExchangeRateTranslation" xlink:to="nivf_ForeignCurrencyExchangeRateTranslation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ImpactOfCovid19TextBlock_lbl0" xml:lang="en-US">The entire disclosure impact of covid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ImpactOfCovid19TextBlock" xlink:to="nivf_ImpactOfCovid19TextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl0" xml:lang="en-US">Interest rate other variables, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl0" xml:lang="en-US">Represent the amount of issuance of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:to="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_LoanToASPAC_lbl0" xml:lang="en-US">Represents amount of loans to ASPAC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_NumberOfOperatingSegment_lbl0" xml:lang="en-US">Number of segments operated by the entity. A operating segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity&apos;s financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NumberOfOperatingSegment" xlink:to="nivf_NumberOfOperatingSegment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_OperatingLeaseRightOfUseAssets_lbl0" xml:lang="en-US">The amount of operating lease right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OperatingLeaseRightOfUseAssets" xlink:to="nivf_OperatingLeaseRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_OtherReceivablesNet_lbl0" xml:lang="en-US">The amount of other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherReceivablesNet" xlink:to="nivf_OtherReceivablesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PaymentofInterest_lbl0" xml:lang="en-US">Cash outflow during the period as interest paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl0" xml:lang="en-US">Percentage of allowance on deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl0" xml:lang="en-US">The cash outflow paid to A SPAC I.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ProfitTaxDescription_lbl0" xml:lang="en-US">Profit tax Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl0" xml:lang="en-US">Description of property plant and equipment estimated useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:to="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for policy related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_RevenueRate_lbl0" xml:lang="en-US">The percentage of revenue rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of schedule of additional paid-in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl0" xml:lang="en-US">Tabular disclosure of estimated useful lives of plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of schedule of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:to="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of movement allowances for expected credit loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of balance due from shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl0" xml:lang="en-US">Value of shares of stock issued during the period to directors&#8217; remuneration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:to="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl2" xml:lang="en-US">Value of shares issued during the period to settlement of subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_SubscriptionReceivables_lbl0" xml:lang="en-US">Subscription receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivables" xlink:to="nivf_SubscriptionReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_SubsidiariesBackground_lbl0" xml:lang="en-US">Background.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiariesBackground" xlink:to="nivf_SubsidiariesBackground_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_TransactionsWithRelatedParties_lbl0" xml:lang="en-US">Transactions with related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TransactionsWithRelatedParties" xlink:to="nivf_TransactionsWithRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl0" xml:lang="en-US">Waiver of related party balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule Of Movement Allowances For Expected Credit Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl1" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl1" xml:lang="en-US">Schedule Of Estimated Useful Lives Of The Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_HKD_lbl0" xml:lang="en-US">Hong Kong, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RelatedPartiesPolicyTextBlock_lbl1" xml:lang="en-US">Related Parties Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RelatedPartiesPolicyTextBlock" xlink:to="nivf_RelatedPartiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl0" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_InterestRateOtherVariablesPercentage_lbl1" xml:lang="en-US">Interest Rate Other Variables Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_InterestRateOtherVariablesPercentage" xlink:to="nivf_InterestRateOtherVariablesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl0" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonCurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentLiabilitiesAbstract" xlink:to="nivf_NonCurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract_lbl" xml:lang="en-US">Schedule Of Revenue Information Above Is Based On The Locations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:to="nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl1" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OtherReceivablesNet_lbl1" xml:lang="en-US">Other Receivables Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherReceivablesNet" xlink:to="nivf_OtherReceivablesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ContributableWageRate_lbl1" xml:lang="en-US">Contributable Wage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageRate" xlink:to="nivf_ContributableWageRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0" xml:lang="en-US">Accounts and Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ContributableWageTotalRate_lbl1" xml:lang="en-US">Contributable Wage Total Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ContributableWageTotalRate" xlink:to="nivf_ContributableWageTotalRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MotorVehiclesMember_lbl0" xml:lang="en-US">Motor Vehicles Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MotorVehiclesMember" xlink:to="nivf_MotorVehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl0" xml:lang="en-US">Management and Service Fees, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_TH_lbl0" xml:lang="en-US">THAILAND</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TH" xlink:to="country_TH_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SeazenResourcesInvestmentLimitedMember_lbl0" xml:lang="en-US">Seazen Resources Investment Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SeazenResourcesInvestmentLimitedMember" xlink:to="nivf_SeazenResourcesInvestmentLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsAndOtherReceivableMember_lbl0" xml:lang="en-US">Deposits And Other Receivable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsAndOtherReceivableMember" xlink:to="nivf_DepositsAndOtherReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl1" xml:lang="en-US">Deposits Prepayment Other Receivables And Deferred IPOCost Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:to="nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl0" xml:lang="en-US">Workers&apos; Compensation Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl0" xml:lang="en-US">Subordinated Borrowing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl0" xml:lang="en-US">Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OneCustomerMember_lbl0" xml:lang="en-US">One Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OneCustomerMember" xlink:to="nivf_OneCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSecuredFinancings_lbl0" xml:lang="en-US">Other Secured Financings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSecuredFinancings" xlink:to="us-gaap_OtherSecuredFinancings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MovementOfAllowancesMember_lbl0" xml:lang="en-US">Movement Of Allowances Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MovementOfAllowancesMember" xlink:to="nivf_MovementOfAllowancesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="nivf_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ForeignCurrencyExchangeRateTranslation_lbl1" xml:lang="en-US">Foreign Currency Exchange Rate Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ForeignCurrencyExchangeRateTranslation" xlink:to="nivf_ForeignCurrencyExchangeRateTranslation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl0" xml:lang="en-US">Contract with Customer, Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ASPACIMember_lbl0" xml:lang="en-US">ASPACIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ASPACIMember" xlink:to="nivf_ASPACIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl0" xml:lang="en-US">Allowance for Credit Loss, Receivable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HarcourtLimitedMember_lbl0" xml:lang="en-US">Harcourt Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HarcourtLimitedMember" xlink:to="nivf_HarcourtLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProfitTaxDescription_lbl1" xml:lang="en-US">Profit Tax Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProfitTaxDescription" xlink:to="nivf_ProfitTaxDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorityShareholderMember_lbl0" xml:lang="en-US">Majority Shareholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NewGenIvfLimitedMember_lbl1" xml:lang="en-US">New Gen Ivf Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NewGenIvfLimitedMember" xlink:to="nivf_NewGenIvfLimitedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl2" xml:lang="en-US">Stockholders&apos; Equity Note, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OperatingLeaseRightOfUseAssets_lbl1" xml:lang="en-US">Operating Lease Right Of Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OperatingLeaseRightOfUseAssets" xlink:to="nivf_OperatingLeaseRightOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MrSiuWingFungAlfredMember_lbl1" xml:lang="en-US">Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MrSiuWingFungAlfredMember" xlink:to="nivf_MrSiuWingFungAlfredMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowancesForExpectedCreditLoss_lbl2" xml:lang="en-US">Allowances For Expected Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLoss" xlink:to="nivf_AllowancesForExpectedCreditLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HKSARMember_lbl0" xml:lang="en-US">HKSARMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HKSARMember" xlink:to="nivf_HKSARMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RevenueBenchmarkOneMember_lbl0" xml:lang="en-US">Revenue Benchmark One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueBenchmarkOneMember" xlink:to="nivf_RevenueBenchmarkOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RevenueMember_lbl0" xml:lang="en-US">Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueMember" xlink:to="nivf_RevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SuppliersOneMember_lbl0" xml:lang="en-US">Suppliers One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersOneMember" xlink:to="nivf_SuppliersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl0" xml:lang="en-US">Amount of Regulatory Assistance Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_VendorTwoMember_lbl0" xml:lang="en-US">Vendor Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_VendorTwoMember" xlink:to="nivf_VendorTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl1" xml:lang="en-US">Stock Issued During Period Value Directors Remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:to="nivf_StockIssuedDuringPeriodValueDirectorsRemuneration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RevenueBenchmarkTwoMember_lbl0" xml:lang="en-US">Revenue Benchmark Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueBenchmarkTwoMember" xlink:to="nivf_RevenueBenchmarkTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SpecialAssessmentBond_lbl0" xml:lang="en-US">Special Assessment Bond</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpecialAssessmentBond" xlink:to="us-gaap_SpecialAssessmentBond_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToRelatedParties_lbl1" xml:lang="en-US">Due To Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToRelatedParties" xlink:to="nivf_DueToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OtherIncomeExpensesNetAbstract_lbl0" xml:lang="en-US">Other Income Expenses Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherIncomeExpensesNetAbstract" xlink:to="nivf_OtherIncomeExpensesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_KHR_lbl0" xml:lang="en-US">Cambodia, Riels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_KHR" xlink:to="currency_KHR_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DissagregattedRevenuesTextBlock_lbl1" xml:lang="en-US">Dissagregatted Revenues Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DissagregattedRevenuesTextBlock" xlink:to="nivf_DissagregattedRevenuesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Additional Paidin Capital Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:to="nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OtherComprehensiveIncomeLossAbstract" xlink:to="nivf_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DeferredTaxAssetsAbstract" xlink:to="nivf_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_TransactionsWithRelatedParties_lbl1" xml:lang="en-US">Transactions With Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TransactionsWithRelatedParties" xlink:to="nivf_TransactionsWithRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl0" xml:lang="en-US">Directors Remuneration To Ms Fong Hei Yue Tina Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:to="nivf_DirectorsRemunerationToMsFongHeiYueTinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl1" xml:lang="en-US">Percentage Of Allowance On Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PercentageOfAllowanceOnDeferredTaxAssets" xlink:to="nivf_PercentageOfAllowanceOnDeferredTaxAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl1" xml:lang="en-US">Allowances For Expected Credit Loss Reversal Of Provision Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:to="nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Of The Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:to="nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholder_lbl1" xml:lang="en-US">Due From Shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholder" xlink:to="nivf_DueFromShareholder_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl3" xml:lang="en-US">Stock Issued During Period Value Settlement Of Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:to="nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Finance Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl0" xml:lang="en-US">Increase (Decrease) in Obligation, Pension Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl0" xml:lang="en-US">Policyholder Dividends, Rate on Policy Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:to="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl0" xml:lang="en-US">Settlement Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0" xml:lang="en-US">Repayments of Other Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl0" xml:lang="en-US">First Fertility Phnom Penh Limited FFPPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPhnomPenhLimitedFFPPMember" xlink:to="nivf_FirstFertilityPhnomPenhLimitedFFPPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NoVendorsMember_lbl0" xml:lang="en-US">No Vendors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NoVendorsMember" xlink:to="nivf_NoVendorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl1" xml:lang="en-US">Allowances For Expected Credit Loss Effect Of Currency Translation Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:to="nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Waiver Of Related Party Balance Of Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:to="nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_TranchesMember_lbl0" xml:lang="en-US">Tranches Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_TranchesMember" xlink:to="nivf_TranchesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CustomerTwoMember_lbl0" xml:lang="en-US">Customer Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CustomerTwoMember" xlink:to="nivf_CustomerTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl0" xml:lang="en-US">Investment Income, Investment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl0" xml:lang="en-US">Other Noncash Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Currency Exchange Rates That Were Used In Preparing The Accompanying Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:to="nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_AllowanceForExpectedCreditLossRevised_lbl1" xml:lang="en-US">Allowance For Expected Credit Loss Revised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_AllowanceForExpectedCreditLossRevised" xlink:to="nivf_AllowanceForExpectedCreditLossRevised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl0" xml:lang="en-US">Due From Shareholders Consist Of The Following Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubscriptionReceivableIncludingCommonStockMember_lbl0" xml:lang="en-US">Subscription Receivable Including Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivableIncludingCommonStockMember" xlink:to="nivf_SubscriptionReceivableIncludingCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl1" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of The Provisions For Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:to="nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl0" xml:lang="en-US">Postemployment Benefit Plans, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToShareholders_lbl1" xml:lang="en-US">Due To Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToShareholders" xlink:to="nivf_DueToShareholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityBishkekLLCFFBMember_lbl0" xml:lang="en-US">First Fertility Bishkek LLCFFBMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityBishkekLLCFFBMember" xlink:to="nivf_FirstFertilityBishkekLLCFFBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl1" xml:lang="en-US">Schedule Of The Balance Due From Shareholders Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:to="nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ProceedsFromAmountDueFromASPACI_lbl1" xml:lang="en-US">Proceeds From Amount Due From ASPACI</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ProceedsFromAmountDueFromASPACI" xlink:to="nivf_ProceedsFromAmountDueFromASPACI_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl2" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl0" xml:lang="en-US">Contract with Customer, Refund Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CNY_lbl0" xml:lang="en-US">China, Yuan Renminbi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CurrentTaxProvisionCambodiaMember_lbl0" xml:lang="en-US">Current Tax Provision Cambodia Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionCambodiaMember" xlink:to="nivf_CurrentTaxProvisionCambodiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionAmount_lbl0" xml:lang="en-US">Preferred Stock, Redemption Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionAmount" xlink:to="us-gaap_PreferredStockRedemptionAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl1" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LatePenaltyProvisionKyrgyzstanMember_lbl0" xml:lang="en-US">Late Penalty Provision Kyrgyzstan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LatePenaltyProvisionKyrgyzstanMember" xlink:to="nivf_LatePenaltyProvisionKyrgyzstanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PensionSchemeMember_lbl0" xml:lang="en-US">Pension Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PensionSchemeMember" xlink:to="nivf_PensionSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl1" xml:lang="en-US">Issuance Of Shares Additionalpaidincapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IssuanceOfSharesAdditionalpaidincapital" xlink:to="nivf_IssuanceOfSharesAdditionalpaidincapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholders_lbl1" xml:lang="en-US">Due From Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholders" xlink:to="nivf_DueFromShareholders_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfCompanySSubsidiariesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfCompanySSubsidiariesAbstract_lbl" xml:lang="en-US">Schedule Of Company SSubsidiaries Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfCompanySSubsidiariesAbstract" xlink:to="nivf_ScheduleOfCompanySSubsidiariesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MedHoldingsLimitedMedHoldingsMember_lbl0" xml:lang="en-US">Med Holdings Limited Med Holdings Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedHoldingsLimitedMedHoldingsMember" xlink:to="nivf_MedHoldingsLimitedMedHoldingsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfBusinessOperationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBusinessOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfBusinessOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Business Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfBusinessOperationsAbstract" xlink:to="nivf_ScheduleOfBusinessOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAdditionalCapital_lbl0" xml:lang="en-US">Other Additional Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SupplierMember_lbl0" xml:lang="en-US">Supplier Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SupplierMember" xlink:to="nivf_SupplierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl2" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl1" xml:lang="en-US">Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PaymentofInterest_lbl1" xml:lang="en-US">Paymentof Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PaymentofInterest" xlink:to="nivf_PaymentofInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_RevenueRate_lbl1" xml:lang="en-US">Revenue Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_RevenueRate" xlink:to="nivf_RevenueRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NumberOfOperatingSegment_lbl1" xml:lang="en-US">Number Of Operating Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NumberOfOperatingSegment" xlink:to="nivf_NumberOfOperatingSegment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl0" xml:lang="en-US">First Fertility PGSCenter Limited FFCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FirstFertilityPGSCenterLimitedFFCMember" xlink:to="nivf_FirstFertilityPGSCenterLimitedFFCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonCurrentAssetsAbstract" xlink:to="nivf_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_HealthCareSchemeMember_lbl0" xml:lang="en-US">Health Care Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_HealthCareSchemeMember" xlink:to="nivf_HealthCareSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl1" xml:lang="en-US">Investment Owned, Balance, Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_IVFTreatmentServiceMember_lbl0" xml:lang="en-US">IVFTreatment Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_IVFTreatmentServiceMember" xlink:to="nivf_IVFTreatmentServiceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl0" xml:lang="en-US">Surrogacy Ancillary Caring And Other Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SurrogacyAncillaryCaringAndOtherServicesMember" xlink:to="nivf_SurrogacyAncillaryCaringAndOtherServicesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WaiverOfRelatedPartyBalance_lbl1" xml:lang="en-US">Waiver Of Related Party Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WaiverOfRelatedPartyBalance" xlink:to="nivf_WaiverOfRelatedPartyBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OperatingExpensesAbstract0_lbl0" xml:lang="en-US">Operating Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OperatingExpensesAbstract0" xlink:to="nivf_OperatingExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_WellImageLimitedMember_lbl0" xml:lang="en-US">Well Image Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_WellImageLimitedMember" xlink:to="nivf_WellImageLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Movement Allowances For Expected Credit Loss Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Receivable Net Of Allowance For Expected Credit Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:to="nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_Within90DaysMember_lbl0" xml:lang="en-US">Within90 Days Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_Within90DaysMember" xlink:to="nivf_Within90DaysMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl0" xml:lang="en-US">Current Tax Provision Kyrgyzstan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_CurrentTaxProvisionKyrgyzstanMember" xlink:to="nivf_CurrentTaxProvisionKyrgyzstanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportingUnits_lbl0" xml:lang="en-US">Number of Reporting Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl0" xml:lang="en-US">Directors Remuneration To Mr Siu Wing Fung Alfred Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:to="nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl0" xml:lang="en-US">Accounts and Nontrade Receivable [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MedicalInstrumentsMember_lbl1" xml:lang="en-US">Medical Instruments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MedicalInstrumentsMember" xlink:to="nivf_MedicalInstrumentsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ImpactOfCovid19TextBlock_lbl1" xml:lang="en-US">Impact Of Covid19 Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ImpactOfCovid19TextBlock" xlink:to="nivf_ImpactOfCovid19TextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_MsFongHeiMember_lbl0" xml:lang="en-US">Ms Fong Hei Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_MsFongHeiMember" xlink:to="nivf_MsFongHeiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherBorrowings_lbl0" xml:lang="en-US">Other Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherBorrowings" xlink:to="us-gaap_OtherBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl0" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Premium Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Movement Of Allowances For Expected Credit Loss Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:to="nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCustomerMember_lbl0" xml:lang="en-US">Other Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCustomerMember" xlink:to="us-gaap_OtherCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OneVendorsMember_lbl0" xml:lang="en-US">One Vendors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OneVendorsMember" xlink:to="nivf_OneVendorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_FFPGSHKLimitedMember_lbl0" xml:lang="en-US">FFPGSHKLimited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_FFPGSHKLimitedMember" xlink:to="nivf_FFPGSHKLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_NonControllingInterestsPolicyTextBlock_lbl1" xml:lang="en-US">Non Controlling Interests Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_NonControllingInterestsPolicyTextBlock" xlink:to="nivf_NonControllingInterestsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_LoanToASPAC_lbl1" xml:lang="en-US">Loan To ASPAC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_LoanToASPAC" xlink:to="nivf_LoanToASPAC_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SuppliersFourMember_lbl0" xml:lang="en-US">Suppliers Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SuppliersFourMember" xlink:to="nivf_SuppliersFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Amount Due From And Due To Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:to="nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Lease Liabilities Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:to="nivf_ScheduleOfLeaseLiabilitiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl0" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubsidiariesBackground_lbl1" xml:lang="en-US">Subsidiaries Background</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiariesBackground" xlink:to="nivf_SubsidiariesBackground_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_THB_lbl0" xml:lang="en-US">Thailand, Baht</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_THB" xlink:to="currency_THB_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl2" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl2" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0_lbl0" xml:lang="en-US">Due From Shareholders Consist Of The Following Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="nivf_DueFromShareholdersConsistOfTheFollowingAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_OccupationalRiskSchemeMember_lbl0" xml:lang="en-US">Occupational Risk Scheme Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_OccupationalRiskSchemeMember" xlink:to="nivf_OccupationalRiskSchemeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubscriptionReceivables_lbl1" xml:lang="en-US">Subscription Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubscriptionReceivables" xlink:to="nivf_SubscriptionReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Secured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl0" xml:lang="en-US">Due To ARelated Party Consist Of The Following Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl0" xml:lang="en-US">Receivables from Stockholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl0" xml:lang="en-US">Provision for Other Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl2" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0_lbl0" xml:lang="en-US">Due To ARelated Party Consist Of The Following Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:to="nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl0" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_SubsidiarieMember_lbl0" xml:lang="en-US">Subsidiarie Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_SubsidiarieMember" xlink:to="nivf_SubsidiarieMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl1" xml:lang="en-US">Property Plant And Equipment Estimated Useful Live</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:to="nivf_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KH_lbl0" xml:lang="en-US">CAMBODIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KH" xlink:to="country_KH_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KG_lbl1" xml:lang="en-US">KYRGYZSTAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KG" xlink:to="country_KG_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl0" xml:lang="en-US">Investment Income, Amortization of Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>nivf-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 31 18:07:23 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedBalanceSheet" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedIncomeStatement" roleURI="http://www.newgenivf.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ShareholdersEquityType2or3" roleURI="http://www.newgenivf.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ConsolidatedCashFlow" roleURI="http://www.newgenivf.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivities" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountsReceivableNet" roleURI="http://www.newgenivf.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Inventories" roleURI="http://www.newgenivf.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNet" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccruedLiabiltiesandOtherPayables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContractLiabilities" roleURI="http://www.newgenivf.com/role/ContractLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Leases" roleURI="http://www.newgenivf.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Equity" roleURI="http://www.newgenivf.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EmployeeBenefitPlans" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxes" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DisaggregatedRevenues" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenues"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Risks" roleURI="http://www.newgenivf.com/role/Risks"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactions" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LoantoaSPACI" roleURI="http://www.newgenivf.com/role/LoantoaSPACI"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ImpactofCovid19" roleURI="http://www.newgenivf.com/role/ImpactofCovid19"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_Contingencies" roleURI="http://www.newgenivf.com/role/Contingencies"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SegmentInformation" roleURI="http://www.newgenivf.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SubsequentEvents" roleURI="http://www.newgenivf.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountingPoliciesByPolicy" roleURI="http://www.newgenivf.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccountsReceivableNetTables" roleURI="http://www.newgenivf.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_InventoriesTables" roleURI="http://www.newgenivf.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" roleURI="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNetTables" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_AccruedLiabiltiesandOtherPayablesTables" roleURI="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContractLiabilitiesTables" roleURI="http://www.newgenivf.com/role/ContractLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LeasesTables" roleURI="http://www.newgenivf.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EquityTables" roleURI="http://www.newgenivf.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxesTables" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_DisaggregatedRevenuesTables" roleURI="http://www.newgenivf.com/role/DisaggregatedRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactionsTables" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCompanyssubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofContractLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofOtherLeaseInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofSubscriptionReceivablesTable" roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofIncomeTaxesTable" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBusinessOperationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofGeographicalInformationTable" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCompanysSubsidiariesTable" roleURI="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0" roleURI="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementAllowancesforExpectedCreditLossTable0" roleURI="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofInventoriesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofInventoriesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable1" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofPlantandEquipmentNetTable0" roleURI="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofContractLiabilitiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofLeaseLiabilitiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofOtherLeaseInformationTable0" roleURI="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofSubscriptionReceivablesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAdditionalPaidinCapitalTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleoftheProvisionsforIncomeTaxesTable0" roleURI="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofIncomeTaxesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofComponentsofDeferredTaxAssetsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBusinessOperationsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofGeographicalInformationTable0" roleURI="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofRevenueInformationaboveisBasedontheLocationsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofAmountDuefromandDuetoRelatedPartiesTable0" roleURI="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofBalanceDuefromShareholdersTable0" roleURI="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofMovementofAllowancesforExpectedCreditLossTable2" roleURI="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ScheduleofConsolidatedFinancialStatementsTable0" roleURI="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_PlantandEquipmentNetDetails" roleURI="http://www.newgenivf.com/role/PlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LeasesDetails" roleURI="http://www.newgenivf.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EquityDetails" roleURI="http://www.newgenivf.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_EmployeeBenefitPlansDetails" roleURI="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ProvisionforIncomeTaxesDetails" roleURI="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RisksDetails" roleURI="http://www.newgenivf.com/role/RisksDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_RelatedPartyBalancesandTransactionsDetails" roleURI="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_LoantoaSPACIDetails" roleURI="http://www.newgenivf.com/role/LoantoaSPACIDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_ContingenciesDetails" roleURI="http://www.newgenivf.com/role/ContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SegmentInformationDetails" roleURI="http://www.newgenivf.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#nivf_r_SubsequentEventsDetails" roleURI="http://www.newgenivf.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nivf-20240630.xsd#DocumentAndEntityInformation" roleURI="http://www.newgenivf.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MajorityShareholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_MajorityShareholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanToASPAC" xlink:href="nivf-20240630.xsd#nivf_LoanToASPAC"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="LoanToASPAC" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToShareholders" xlink:href="nivf-20240630.xsd#nivf_DueToShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="DueToShareholders" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="7.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueDirectorsRemuneration" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverOfRelatedPartyBalance" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WaiverOfRelatedPartyBalance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LegalFees" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInFinanceReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInFinanceReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInFinanceReceivables" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromAmountDueFromASPACI" xlink:href="nivf-20240630.xsd#nivf_ProceedsFromAmountDueFromASPACI"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromAmountDueFromASPACI" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentofInterest" xlink:href="nivf-20240630.xsd#nivf_PaymentofInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentofInterest" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivables" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SubscriptionReceivables" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossAdditionalImprovementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Inventories" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ContractLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesAbstract" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="DissagregattedRevenuesTextBlock" xlink:href="nivf-20240630.xsd#nivf_DissagregattedRevenuesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesAbstract" xlink:to="DissagregattedRevenuesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Risks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACI" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ImpactofCovid19" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ImpactOfCovid19Abstract" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19Abstract"/>
    <loc xlink:type="locator" xlink:label="ImpactOfCovid19TextBlock" xlink:href="nivf-20240630.xsd#nivf_ImpactOfCovid19TextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpactOfCovid19Abstract" xlink:to="ImpactOfCovid19TextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/Contingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_RelatedPartiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RelatedPartiesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonControllingInterestsPolicyTextBlock" xlink:href="nivf-20240630.xsd#nivf_NonControllingInterestsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NonControllingInterestsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossAdditionalImprovementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditLossAdditionalImprovementsAbstract" xlink:to="ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/InventoriesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInInventoriesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:href="nivf-20240630.xsd#nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract" xlink:to="ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ContractLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositContractsLiabilitiesAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilitiesTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfLeaseLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfLeaseLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalPaidinCapitalTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ScheduleOfAdditionalPaidinCapitalTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DisaggregatedRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesAbstract" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="ScheduleOfTheBalanceDueFromShareholdersTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySSubsidiariesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySSubsidiariesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FFPGSHKLimitedMember" xlink:href="nivf-20240630.xsd#nivf_FFPGSHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FFPGSHKLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellImageLimitedMember" xlink:href="nivf-20240630.xsd#nivf_WellImageLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="WellImageLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20240630.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MedHoldingsLimitedMedHoldingsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPGSCenterLimitedFFCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPhnomPenhLimitedFFPPMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityBishkekLLCFFBMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubsidiariesBackground" xlink:href="nivf-20240630.xsd#nivf_SubsidiariesBackground"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="SubsidiariesBackground" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_HKD" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_THB" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_KHR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_KHR"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_KHR" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CNY" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyExchangeRateTranslation" xlink:href="nivf-20240630.xsd#nivf_ForeignCurrencyExchangeRateTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="ForeignCurrencyExchangeRateTranslation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehiclesMember" xlink:href="nivf-20240630.xsd#nivf_MotorVehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MotorVehiclesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:href="nivf-20240630.xsd#nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentEstimatedUsefulLive" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:to="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Within90DaysMember" xlink:href="nivf-20240630.xsd#nivf_Within90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="Within90DaysMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MovementOfAllowancesMember" xlink:href="nivf-20240630.xsd#nivf_MovementOfAllowancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="MovementOfAllowancesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss_0" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLoss_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPlantAndEquipmentNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubscriptionReceivablesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfSubscriptionReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubscriptionReceivablesAbstract" xlink:to="EquityDetailsScheduleofSubscriptionReceivablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivableIncludingCommonStockMember" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivableIncludingCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SubscriptionReceivableIncludingCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="EquityDetailsScheduleofSubscriptionReceivablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:to="EquityDetailsScheduleofAdditionalPaidinCapitalTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueDirectorsRemuneration" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueDirectorsRemuneration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="StockIssuedDuringPeriodValueDirectorsRemuneration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesAdditionalpaidincapital" xlink:href="nivf-20240630.xsd#nivf_IssuanceOfSharesAdditionalpaidincapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="IssuanceOfSharesAdditionalpaidincapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:to="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionKyrgyzstanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionCambodiaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LatePenaltyProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_LatePenaltyProvisionKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="LatePenaltyProvisionKyrgyzstanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBusinessOperationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBusinessOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessOperationsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrY63RHmrBxIANqO9LUCucCp8oXRqjHcmjV5+uiuyKjdP8byxstI7JlwlfIwgjDo/uwL9G9cte91JTdkupwQAiBJ37fSwlfjBcXI0MONuSEUDJRrLJyqiLnouSkimx7VEmkLknc2fEsQmJB1JQLlrCret2XEtR9QjU6UbtFaUqMrBZ4ipUTcqVXCZ/tGQC0SGhWnl94gojkbv9FPx2hPSFUiSkw5KQBRWFhrwXojTSENgT229DayHJAD] CSR-->
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IVFTreatmentServiceMember" xlink:href="nivf-20240630.xsd#nivf_IVFTreatmentServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="IVFTreatmentServiceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20240630.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SurrogacyAncillaryCaringAndOtherServicesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HarcourtLimitedMember" xlink:href="nivf-20240630.xsd#nivf_HarcourtLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HarcourtLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholdersConsistOfTheFollowingAbstract" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DueFromShareholdersConsistOfTheFollowingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToRelatedParties" xlink:href="nivf-20240630.xsd#nivf_DueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueFromShareholdersConsistOfTheFollowingAbstract" xlink:to="DueToRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholder" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholder"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="DueFromShareholder" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMsFongHeiYueTinaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithRelatedParties" xlink:href="nivf-20240630.xsd#nivf_TransactionsWithRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="TransactionsWithRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySSubsidiariesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCompanySSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySSubsidiariesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NewGenIvfLimitedMember" xlink:href="nivf-20240630.xsd#nivf_NewGenIvfLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="NewGenIvfLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FFPGSHKLimitedMember" xlink:href="nivf-20240630.xsd#nivf_FFPGSHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FFPGSHKLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellImageLimitedMember" xlink:href="nivf-20240630.xsd#nivf_WellImageLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="WellImageLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedHoldingsLimitedMedHoldingsMember" xlink:href="nivf-20240630.xsd#nivf_MedHoldingsLimitedMedHoldingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="MedHoldingsLimitedMedHoldingsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPGSCenterLimitedFFCMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPGSCenterLimitedFFCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPGSCenterLimitedFFCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityPhnomPenhLimitedFFPPMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityPhnomPenhLimitedFFPPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityPhnomPenhLimitedFFPPMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFertilityBishkekLLCFFBMember" xlink:href="nivf-20240630.xsd#nivf_FirstFertilityBishkekLLCFFBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FirstFertilityBishkekLLCFFBMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubsidiariesBackground" xlink:href="nivf-20240630.xsd#nivf_SubsidiariesBackground"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="SubsidiariesBackground" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_HKD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_HKD" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_THB" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_THB"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_THB" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_KHR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_KHR"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_KHR" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CNY" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable" xlink:to="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyExchangeRateTranslation" xlink:href="nivf-20240630.xsd#nivf_ForeignCurrencyExchangeRateTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems" xlink:to="ForeignCurrencyExchangeRateTranslation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehiclesMember" xlink:href="nivf-20240630.xsd#nivf_MotorVehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MotorVehiclesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:href="nivf-20240630.xsd#nivf_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentEstimatedUsefulLive" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract" xlink:to="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="us-gaap_FinancingReceivablesPeriodPastDueDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Within90DaysMember" xlink:href="nivf-20240630.xsd#nivf_Within90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="Within90DaysMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable" xlink:to="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:href="nivf-20240630.xsd#nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementAllowancesForExpectedCreditLossAbstract" xlink:to="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MovementOfAllowancesMember" xlink:href="nivf-20240630.xsd#nivf_MovementOfAllowancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="MovementOfAllowancesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable" xlink:to="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofInventoriesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLossReversalOfProvisionProvision" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLossReversalOfProvisionProvision" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowancesForExpectedCreditLoss_0" xlink:href="nivf-20240630.xsd#nivf_AllowancesForExpectedCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowancesForExpectedCreditLoss_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPlantAndEquipmentNetAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalInstrumentsMember" xlink:href="nivf-20240630.xsd#nivf_MedicalInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MedicalInstrumentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubscriptionReceivablesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfSubscriptionReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubscriptionReceivablesAbstract" xlink:to="EquityDetailsScheduleofSubscriptionReceivablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivableIncludingCommonStockMember" xlink:href="nivf-20240630.xsd#nivf_SubscriptionReceivableIncludingCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SubscriptionReceivableIncludingCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesTable" xlink:to="EquityDetailsScheduleofSubscriptionReceivablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" xlink:href="nivf-20240630.xsd#nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofSubscriptionReceivablesLineItems" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAdditionalPaidInCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalPaidInCapitalAbstract" xlink:to="EquityDetailsScheduleofAdditionalPaidinCapitalTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalTable" xlink:to="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesAdditionalpaidincapital" xlink:href="nivf-20240630.xsd#nivf_IssuanceOfSharesAdditionalpaidincapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="IssuanceOfSharesAdditionalpaidincapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofAdditionalPaidinCapitalLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheProvisionsForIncomeTaxesAbstract" xlink:to="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionKyrgyzstanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTaxProvisionCambodiaMember" xlink:href="nivf-20240630.xsd#nivf_CurrentTaxProvisionCambodiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="CurrentTaxProvisionCambodiaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LatePenaltyProvisionKyrgyzstanMember" xlink:href="nivf-20240630.xsd#nivf_LatePenaltyProvisionKyrgyzstanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="LatePenaltyProvisionKyrgyzstanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable" xlink:to="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBusinessOperationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBusinessOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessOperationsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IVFTreatmentServiceMember" xlink:href="nivf-20240630.xsd#nivf_IVFTreatmentServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="IVFTreatmentServiceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SurrogacyAncillaryCaringAndOtherServicesMember" xlink:href="nivf-20240630.xsd#nivf_SurrogacyAncillaryCaringAndOtherServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SurrogacyAncillaryCaringAndOtherServicesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable"/>
    <loc xlink:type="locator" xlink:label="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:href="nivf-20240630.xsd#nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable" xlink:to="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholdersConsistOfTheFollowingAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DueFromShareholdersConsistOfTheFollowingAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueFromShareholdersConsistOfTheFollowingAbstract0" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:href="nivf-20240630.xsd#nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DueToARelatedPartyConsistOfTheFollowingAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_0" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueToARelatedPartyConsistOfTheFollowingAbstract0" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfBalanceDueFromShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholder" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholder"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="DueFromShareholder" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesNet" xlink:href="nivf-20240630.xsd#nivf_OtherReceivablesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceDueFromShareholdersAbstract" xlink:to="OtherReceivablesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForExpectedCreditLossRevised" xlink:href="nivf-20240630.xsd#nivf_AllowanceForExpectedCreditLossRevised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="AllowanceForExpectedCreditLossRevised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="nivf-20240630.xsd#nivf_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMrSiuWingFungAlfredMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsRemunerationToMsFongHeiYueTinaMember" xlink:href="nivf-20240630.xsd#nivf_DirectorsRemunerationToMsFongHeiYueTinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorsRemunerationToMsFongHeiYueTinaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithRelatedParties" xlink:href="nivf-20240630.xsd#nivf_TransactionsWithRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="TransactionsWithRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandPrincipalActivitiesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_OrganizationandPrincipalActivitiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandPrincipalActivitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsidiarieMember" xlink:href="nivf-20240630.xsd#nivf_SubsidiarieMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="SubsidiarieMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="OrganizationandPrincipalActivitiesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSecuredFinancings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSecuredFinancings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_OtherSecuredFinancings" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="us-gaap_OtherCustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerTwoMember" xlink:href="nivf-20240630.xsd#nivf_CustomerTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueMember" xlink:href="nivf-20240630.xsd#nivf_RevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="RevenueMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueBenchmarkOneMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="RevenueBenchmarkOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueBenchmarkTwoMember" xlink:href="nivf-20240630.xsd#nivf_RevenueBenchmarkTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="RevenueBenchmarkTwoMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneCustomerMember" xlink:href="nivf-20240630.xsd#nivf_OneCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="OneCustomerMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SupplierMember" xlink:href="nivf-20240630.xsd#nivf_SupplierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SupplierMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersOneMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersFourMember" xlink:href="nivf-20240630.xsd#nivf_SuppliersFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoVendorsMember" xlink:href="nivf-20240630.xsd#nivf_NoVendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="NoVendorsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VendorTwoMember" xlink:href="nivf-20240630.xsd#nivf_VendorTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="VendorTwoMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneVendorsMember" xlink:href="nivf-20240630.xsd#nivf_OneVendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="OneVendorsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RestatementAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueRate" xlink:href="nivf-20240630.xsd#nivf_RevenueRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RevenueRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/PlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightOfUseAssets" xlink:href="nivf-20240630.xsd#nivf_OperatingLeaseRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="OperatingLeaseRightOfUseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NewGenIvfLimitedMember" xlink:href="nivf-20240630.xsd#nivf_NewGenIvfLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="NewGenIvfLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeazenResourcesInvestmentLimitedMember" xlink:href="nivf-20240630.xsd#nivf_SeazenResourcesInvestmentLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SeazenResourcesInvestmentLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrSiuWingFungAlfredMember" xlink:href="nivf-20240630.xsd#nivf_MrSiuWingFungAlfredMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrSiuWingFungAlfredMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MsFongHeiMember" xlink:href="nivf-20240630.xsd#nivf_MsFongHeiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MsFongHeiMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_OtherBorrowings" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmountOfRegulatoryAssistanceReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountOfRegulatoryAssistanceReceived1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AmountOfRegulatoryAssistanceReceived1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockRedemptionAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAdditionalCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_EmployeeBenefitPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OccupationalRiskSchemeMember" xlink:href="nivf-20240630.xsd#nivf_OccupationalRiskSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="OccupationalRiskSchemeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HealthCareSchemeMember" xlink:href="nivf-20240630.xsd#nivf_HealthCareSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="HealthCareSchemeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PensionSchemeMember" xlink:href="nivf-20240630.xsd#nivf_PensionSchemeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="PensionSchemeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_TH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TH" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KH"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KH" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_KG"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KG" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="EmployeeBenefitPlansDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementAndServiceFeesRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManagementAndServiceFeesRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_ManagementAndServiceFeesRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SpecialAssessmentBond"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SpecialAssessmentBond" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContributableWageRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="ContributableWageRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContributableWageTotalRate" xlink:href="nivf-20240630.xsd#nivf_ContributableWageTotalRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="ContributableWageTotalRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsTable" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ProvisionforIncomeTaxesDetailsLineItems" xlink:href="nivf-20240630.xsd#nivf_ProvisionforIncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ProvisionforIncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HKSARMember" xlink:href="nivf-20240630.xsd#nivf_HKSARMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="HKSARMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsTable" xlink:to="ProvisionforIncomeTaxesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProfitTaxDescription" xlink:href="nivf-20240630.xsd#nivf_ProfitTaxDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="ProfitTaxDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAllowanceOnDeferredTaxAssets" xlink:href="nivf-20240630.xsd#nivf_PercentageOfAllowanceOnDeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionforIncomeTaxesDetailsLineItems" xlink:to="PercentageOfAllowanceOnDeferredTaxAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RisksDetailsTable" xlink:href="nivf-20240630.xsd#nivf_RisksDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="RisksDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DepositsAndOtherReceivableMember" xlink:href="nivf-20240630.xsd#nivf_DepositsAndOtherReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="DepositsAndOtherReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ASPACIMember" xlink:href="nivf-20240630.xsd#nivf_ASPACIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ASPACIMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksDetailsTable" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOtherVariablesPercentage" xlink:href="nivf-20240630.xsd#nivf_InterestRateOtherVariablesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="InterestRateOtherVariablesPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPensionPlanObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPensionPlanObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_IncreaseDecreaseInPensionPlanObligations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DueFromShareholders" xlink:href="nivf-20240630.xsd#nivf_DueFromShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTaxExpenseAbstract" xlink:to="DueFromShareholders" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/LoantoaSPACIDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/ContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfOperatingSegment" xlink:href="nivf-20240630.xsd#nivf_NumberOfOperatingSegment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="NumberOfOperatingSegment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportingUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nivf-20240630.xsd#nivf_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TranchesMember" xlink:href="nivf-20240630.xsd#nivf_TranchesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="TranchesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.newgenivf.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nivf-20240630.xsd#nivf_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>130
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %1785D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !45V%95B@K2.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NLD&0E'7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0:@\8^TG/L T5VE*Y&WW9)8]B( W/0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!5U0UX8F,-&YB 15B(HJDM:HQDN(\GO,4%'SYC.\,L K7DJ>,$LI0@FFEB
M.(YM#1? !&.*/GT7R"[$N?HG=NZ ."7'Y);4, SEL)IS>0<);T^/+_.ZA>L2
MFPXI_TI.\S'01IPGOZ[N[K</HE&56A=2%I7<RK6^OM5*O4^N/_PNPKZW;N?^
ML?%9L*GAUUTT7U!+ P04    " !45V%9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M %1785GLB^,3;@0  )<2   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MK9A=<^(V%(;O^14:=Z;33I/8$H2/%)@A"20T"<LDV=W9WBFV ,_:DE<2(?GW
M/;;!IEMS\.[T!ORA\_J19+WG6/V-TE_-2@A+WN)(FH&SLC:Y<%WCKT3,S9E*
MA(0["Z5C;N%4+UV3:,&#+"B.7.9Y;3?FH72&_>S:7 _[:FVC4(JY)F8=QUR_
M7XI(;08.=787'L/ERJ87W&$_X4OQ).S'9*[AS"U4@C 6TH1*$BT6 V=$+RY9
M)PW(6GP*Q<;L'9.T*R]*?4U/IL' \5(B$0G?IA(<_E[%E8BB5 DXOFU%G>*9
M:>#^\4Y]DG4>.O/"C;A2T><PL*N!TW5((!9\'=E'M;D5VPZ=IWJ^BDSV2S9Y
MVU;+(?[:6!5O@X$@#F7^S]^V [$7P X%L&T R[CS!V64U]SR85^K#=%I:U!+
M#[*N9M$ %\IT5IZLAKLAQ-GAM?+7,,B6C&1 QM*&]IU,93[;,&I]U\)#TJ:N
MOQ6\S 79 <$V>5#2K@R(!2+X=[P+< 4AVQ%>,E3PK[4\(TWOA#"/M1"]9M'C
M9J;7/-;CO6Z2>VA$IE;$IJK'N6"K6C!=-Q<FX;X8.+ PC-"OPAG^^@MM>W\B
MN*T"MX6I#[=S\BB6H;&: _>,QZ**$M>9C3_?C&?33Y/&S>.'CW-R/WV8/H^O
M$<+S@O <52X&]/D]J03#PR>GU!TA&.T"HXWJC( AR#@F$5]6<>#Q5J\%@M$I
M,#HU,:Z%\768'%I&-64:,W5&L/>^6X!UZ[Q(5Z"I>01O?R#>R)UXKV+#E3S/
MH[TN;;<9@M4KL'IUL,:QT,M0+LD-Q-L5N5)QPF4E'*YW9!JI5QJC5POLC3S#
MLC-AYA-SH4,55+HBKK;@D4&Y]@R;UN&:2E_I1.G,OT[(D^56$*5AX-8PP3#/
M*JA<C$?4K[L8)"LA61W(41" (YJ3W4'NLQ]D-1DN2=W)26,>"DW8R>XMQEC+
M?$!1__X/ZW8$*Q%QI=L[#*AT?%K+\DN@] RF]EEMJA,R+G>KY+)Q!S\87&GV
M%+?K[^'FREBPD[_#Y/ KAROV>CVOT\'@RA1 <0_/1FH$U>EA%ES@#TI^8Y3]
MCM&4F8#B'GZO?!B9^4K!.S];QR]"5Q+A(N?-SFFKY;4QHC(%4-RY+]<&KL Z
MO((:#0KB2AY4XB>K'5JF ]K[O\LSBF:$GR1F9:)@M1+%#WG=$4G*6&/,C24M
M!F4YW('R'F,MDP>KE3QJ6\L1N9G8-+[ 5Q?&5N8,]F,YHX:S'%&D'FUC^8R5
M.8+ASG[<6(X('',55F8'AMMY/5<Y(M)K=4X[\.6.$94I@>$&OC63M#@R2DH1
M'?Q$.2JT%-)_;]Q$ZB4K4?TS#+!,"PQW=72%/F]4)2HN2;M0I$XBI31&6*8*
MAKO\]X1%.3?7ZC64?O5HXIJS+U5H[MY>05IS9SLBAOAIT9-O&Q17BUV74;[7
M4#;/MVP>>%JR&Q*)!81Z9QV879WO@N0G5B79SL.+LE;%V>%*\$#HM '<7RAE
M=R?I XJ]J.$_4$L#!!0    ( %1785D.:!<9#PD  ,8Q   8    >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&ULK9M=<Z,X%H;_"N79FIJI:K?1!P)Z$E>E3:;:
M6]GI;)S>K;U4;#FF!H,'Y*3[WZ\ QX!TD.T,-XGMO#KX/1Q)CX1R]9KE?Q8;
M(:3S?9NDQ?5H(^7NTV12+#=BRXN/V4ZDZB_K+-]RJ=[FSY-BEPN^JAIMDPEV
M73;9\C@=3:^JS^[SZ56VETF<BOO<*?;;+<]_?!9)]GH]0J.W#Q[BYXTL/YA,
MKW;\62R$_+:[S]6[R3'**MZ*M(BSU,G%^GIT@SY%-"@;5(K_Q.*U:+UV2BM/
M6?9G^6:^NAZYY3<2B5C*,@17OU[$3"1)&4E]C[\.04?':Y8-VZ_?HO]>F5=F
MGG@A9EGRWW@E-]>C8.2LQ)KO$_F0O7X1!T->&6^9)47UTWFMM9X2+_>%S+:'
MQNH;;..T_LV_'Q+1:H!H3P-\:(#/;4 .#<BY#>BA :TR4UNI\A!QR:=7>?;J
MY*5:12M?5,FL6BO[<5K>]X7,U5]CU4Y.OZ5\OXJE6#FS+%VI^UF_*K(D7O'R
MX\\\X>E2.(OR$H4S=KXM(N>7?_QZ-9'J\F60R?)PJ<_UI7#/I?ZY3S\ZQ/W@
M8!=3H/G,WCP22]4<5<T)T#PZOSGN-I^HG!T3AX^)PU4\TA-OML]SD4J'%X7*
M"Y2-NCV%VY?]^5.QXTMQ/5(=MA#YBQA-?_X),?<W*#=#!HL&"M;)&SGFC=BB
M3V>\V#@\73G+\H7X:Q^_\$0E$DQA'<JK0I4CV,L4!12YX=7DI9T<4^8I%>VJ
M(E.%?<]C1U7'#CW:H58[-\MEME??7HV!2Z&L/"7B@Y,*";FI([&V&Q]3W]/<
MF+*0^+H9(!9Q71<VXQW->%8S\_1%W8DLCP5X-SSSFBX.L/[] 1EFF.D.3!EE
M(>IQP(X.F-5!)'99$<OB@Z-*=\=_;*LNJJHMDQN1MVY2T7N7F/&]?)<$H:^Y
M-&4>\BG62C."HN' @UWZ1Y>^U>5=QE-'9LZ-L[B_F3ESR(8U MS''6C@\<V[
M2=UVI=4^__[E.ID(CID([/=[+YQUGFV=8L-SL<F2E<C!VK6&N2 =@9$.XM'V
M#:W3\8[+G1QAPV-.0FM.'C/)$\4.I^:GT+RSB!'B,JW2 1UV$?4T763J, D#
M5D[64+$CMT$4USK5_I&EX]-V#D$&FF\'C18-%:V;P!;C(6M%W"N$JX?!<K[=
ME8-B[_!W"-6YW5X8$J15!:1C&'G:.!E!.HR9WU<5#7\A*Z9,JR7*.%N/]X4X
ME$6_*6S69CGU4MT4H M(0 U3IHX$A/D]LQ=JX C9Z6B>2IX^QVJ"LE4Z 29B
MO3O.[%<Z?\B+WA/H=/$V@(7LA#7 E(X I$*NGB_KU[@D7^\(=#I?#<,A.\35
MPW]ZWI@)0!BAQ#<Z.Z"CS#40&]!Y+E,1>_I%@W7(SG6/7Q]O[IR;Q>+V<0$:
M,3E+C5H^\W5L@X1,#01,!QI B$.7AJQGP8 :>$/^62O').9/<1++'MI&[T J
MRWPV9+1HJ&C=##;0A^S4=UQTJ>&@[/E@^DQ20R%U&=67*Y#0+Q<L>D$ .I<R
M#_740X-KR,YKRDV^%ZMV/;3&MX-%N$1,Y"**S,(@T#T";$810T3W".C4TJ?5
MB[I[)0W"82OA3&=9*G.^/%GTAS =1[X78LT/(//5(EES Z@082YB08^=!JBP
M':B^[D3.99P^.XG@"C]:KCZ\D3=H#X"A,,3&XA+08=='.- = O&"_IK$K<TM
M.US]'J?5KM^%]MZQL02NLK#)5TQ-.+I[4X4"W^N[NPV$83N$/?+OPCJV8!/
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M8[K;-+^5;W%V/""WY:W*3;W_WWH[VMHS:[6KFW)[;"Q[L,V+P]_TS^.).&M
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M+(_16(\Q9.C9OM &*JX_WF:>+_\-)$>GYA*SG/L]DVLDY7:!!5IB@0(L4$@
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M$Y=^9G1**C4KJ=\Q!3:3I^0+UI):+%" !0HIM,:5^ZZZ9G*D70S9N;ZC_2
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MG[-TG56M@?S^L2R;;V_:36!/6R/?_A]02P,$%     @ 5%=A6?'K)+T4#
M(4L  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM7&MSVS86_2L<=:>3
MSD01\>#+M3VCB.16.XGCB?/X3$N0Q2U%JB1EQ_OK%Z 8400N8<E!VZEE^>"
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M5C7_MYY:K#VR%KNJ+C9M87X%FS3?_TQ^M$(<%> \< '<%L!R 3I0@+0%B%S
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MG])ZW3M!.#2+5?=/7=NA\DKX#, AAS=T3UXWA8"^2["\!Q(!0#Y^4[%L+0]
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M;5>6+%\\6W69Y%76/D5UKI[ UJQ/E2WI&8 C/&LJ<D*^TP^4O7X AUPDT\4
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M)2L%@/]]57#/VOXB*CB\%>OZ_U!+ P04    " !45V%90K"G+!4-   _-
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M"0R;.?'MVTM9P0I^F4<Q2-QY:=_[\MLK\QXN* PXAC5?FPV,%58HSD&BOU5
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M4L$BQ^PED/Q,( P!@_%K Y4T2&=Z<0L*N*O420O:74"/!32G%1\W;^P4CU3
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M>.UB%0_;1^X.VT>T8_LTW,N_/6P?T6HA/0#;YT'82(^/[</'<MRXY'ZQ?>Y
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MB]WO6/*Y,GB1R)1]PJZ8&[9=B#9*B[P,I@SRE!<MNR]U. KH^B<"@C(@>&Y
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MI9E WY="Z,/ +%"5V*-_ %!+ P04    " !45V%9TPZXB+@"  !M!P  &0
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MWT.MY\3RI9)K]TNV52R-/))NM)%E#<8,RD)4_^RYKD,+, Q> = :0/\4$-6
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M15,VO#)=O->2OG+"Z=$XR^0:%W#-V9P7FJ,"5BW@5J]0PHP]L7F!:N!K<F4
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MU3[0I4*6.E"1!]%H- T*QH6_G+NQ.[6<R\KD7."= ET5!5//5YC+P\(/_>/
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M>ZO$[FTB=F@D=N]_1NR/L_>;$?M#9GXG]DW$_IT7UHG=:R+V3?\&/I+8BZN
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M=CCVQO_%401.@^.W@#F563XQLQ.^E(XKF.,4M9!B,>-OJ3$B<;L2%5^UL!*
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M<MLV$'WG5^PHF4P[@U@D -Y\T8QC*XZ;)LU83OK0Z0-$01(G)*$ D&7WZ[L
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M"(RMN.<@;_GX@7Q'=?9DA]ZZ2X4LVXP15OQ\=T"U6",>F]'JZ%N7I@W EVO
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MI$%WMU%0^4EXL5I8LP7+UL3&+\'5@"9Q4G-2[KVE54DXO[HR0H,W(.#^+KN
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M@9X6L5G0H43'"V@^MY3,58<W:)Z3HW\!4$L#!!0    ( %1785F^S-4NZ ,
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M@-)+55RI)R__^8_AZ>!%# 8/-%@ D6,+D>.NT5]^*-+U--UDL&, RC1?EP"
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MTE7+I)+)?&YH I:5%WB"R8IH0\#BX'FEL25+DTF:I56JAYJEY33+R[JP=(N
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M='1,O0*)#\"$41U5@<@J*A*I.,H+PF"GM@#95]=8*L=^[)QEZ-/V53SSBBX
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M^A,-9,E"FP+M8=Y9<%(ZR3H$*QZ4V1S:B/D:]A!G2_"BL"7,'%2ZSF69UP6
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M"5QM:F1*2C\GW'-&(?_EPR>KD+MZ% \,IP-KF>].IU_MRY^3$AZ&P8A6;=I
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MZ4;OARE2>K43H.=#183,)\Y!^16G_0=02P,$%     @ 5%=A6>Q5?5Z4!
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M1XPZZ<B+:."DPBR)[)AF2?K"[H>K&Q*]]?T 3?J)G8:!EZ%9G-*,>C2DT0A
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M3*J]$[0+(VMWK+Z3!@_I;KK!:Q0H*X#O5U*:?F$!AHO9XB]02P,$%     @
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M4>MSKN#5 ;P@J1-)%Y&F <K!+!'F,J,+C8O%R".WH',+[3OF,U1V[SUK'6<
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MYHKI%9>&""@1&AV_.0F(;GMW:UBU]NTO4Q:;J1]6^-R!=@MPOE3*[@RW0?^
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M(SJKXKU1^%8@SJSN&MX9PKN*O/W<BQWJ8P+R"W;/ZX]\W8"^6(0&M[&+P_)
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MQ;ML,= BLT^;4^C)1&(_%XQ",9@-L#X3D)7EP!Q0/XZ/_@%02P,$%     @
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MQ5:G-R>SS8-52W^XF2J+/<D/%WB8E=HMP/FY4K9[<!OTQ^/)?U!+ P04
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M\A ['4YC8@[3>X"[Q&30F!Q%TX503\Z6^='Y<S)-EW)R%#ZV/#=;#4^R#7I
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M='4QL ;D-BWD/'_SXT*$,Y&5!\C?S].T>'I1!GA(L^^;TQG_'U!+ P04
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M"MU_(_0 Q0N52G)1))!8^--N?L_O$' QCTTR_5TRS_U.Q1_KXICTO4/B>_[
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MBM\F(#0 GR\Y5[N%?D'SM1/^!5!+ P04    " !45V%9<>(@U7D"  #J!@
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M+])*@+3*P2_?:[*13U2\ [_+^?8FP2(E!7\+KL"#G&UY76! 5^ DX I\?4C
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M,K#]GO7^1-!-LXO[2(6@97.XQFF.F2J0]U>4BI<3M3'<_7.P_ ]02P,$%
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M:%RMU6.*=VJ0Q@#?KX70^X%QT-[29_\ 4$L#!!0    ( %1785E:#3L,X0(
M )0-   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;*V77V^;,!3%OXK%
MIJF3UO WD'0)TEHTK5,K5:VZ/51[<,A-8A5P9IND^_:S#66AHXQV?@D8[OG%
MY\27F-F>LGN^ 1#H(<\*/K<V0FQ/;)NG&\@Q']$M%/+.BK(<"SED:YMO&>"E
M%N69[3E.:.>8%%8\T]>N6#RCI<A( 5<,\3+/,?MU"AG=SRW7>KQP3=8;H2[8
M\6R+UW #XG9[Q>3(;BA+DD/!"2T0@]7<^N2>)*ZC!+KB&X$]/SA'RLJ"TGLU
M.%_.+4?-"#)(A4)@>=C!&629(LEY_*RA5O.=2GAX_DC_K,U+,PO,X8QFW\E2
M;.;6Q$)+6.$R$]=T_P5J0V/%2VG&]2?:5[6^8Z&TY(+FM5C.("=%=<0/=1 '
M C=X1N#5 F^HP*\%_E!!4 L"G4QE1>>08('C&:-[Q%2UI*D3':962_ND4+_[
MC6#R+I$Z$5^ #(VCHP0$)AE_CX[1[4V"CMZ^G]E"\E65G=:LTXKE/</Z6A8C
MY#L?D.=X08?\K%^>0"KEKI;['?)DN-QKRVT92I.,UR3C:9X_-)F["UF!S@7D
M_$=7.!4NZ,:I_CWA6YS"W)(-RH'MP(K?O7%#YV-75"9AB2%8*T:_B='OH\?Z
M27),5\<E!X0Y!\&[PJL@8PU1SZI=[$5>$,EEM#N,I:-LXD^"J%V6_%WF3_PP
M<IJREI6@L1*8L!(,L])1-@VCP'MBI7=*K_SMQHWA<:_A2_Q \C)'=Y>0+X!U
MKOI>PDM7O4E88@C62BYLD@O-/CQ"DS&:A"6&8*T8HR;&J'<!GA<")%4@A@5T
MQ5;)7?>@BYR1$X9/>FU86=([F5=:G316)_V]1HI_]EHOX:6+Q"0L,01K)3=M
MDIN:[;6IR1A-PA)#L%:,KO-G*^C\7[?5^FF[C<9/FFU05=(_EY=ZM0]VP.I]
MY1*S-2DXRF E\<XHDG\&K'H%J :";O6F>$&%W&+KTXU\;0*F"N3]%:7B<:#V
MV<V+6/P;4$L#!!0    ( %1785E\#*IWG (  *P'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4W+GAM;*U5W6Z;,!A]%8M.52NM!0PDT!*DMFC:IDZJFG6[
MF';A)%\2JP8SVTFZMY]M*"()C:*I-^"?<XZ_<\!VNN'B62X!%'HI6"E'SE*I
MZLIUY70)!9&7O()2S\RY*(C27;%P926 S"RI8"[VO(%;$%HZ66K''D26\I5B
MM(0'@>2J*(CX>PN,;T:.[[P./-+%4ID!-TLKLH QJ*?J0>B>VZK,: &EI+Q$
M N8CY\:_RB.#MX ?%#:RTT;&R83S9]/Y,ALYGBD(&$R542#ZM88[8,P(Z3+^
M-)I.NZ0A=MNOZI^L=^UE0B3<<?:3SM1RY,0.FL&<K)AZY)O/T/BQ!4XYD_:)
M-C4V2APT74G%BX:L*RAH6;_)2Y-#A^"';Q!P0\#'$H*&$!Q+"!M":).IK=@<
M<J)(E@J^0<*@M9IIV# M6]NGI?GL8R7T+-4\E=V##DVBLQP4H4R>HPLTUK_6
M;,4 \3FRT^B>D@EE5%&-O$!/XQR=?3A/7:77-RKNM%GKMEX+O['6UU5YB0+O
M(\(>#GOH=X?I.4PUW;?TH(>>'T_'VW17A]8FA]ODL-4+WM ['-.OFXE40O_5
MO_MRJI7#?F6STZ]D1:8P<O16EB#6X&2G)_[ N^Y+[3W%\G<2VTHT:!,-#JG7
M_R)BG11/3V+L^]=Z(P@!I4(5%^:TZ(NTEHZLM#GKUIF?)#@9INZZ&]8^#'M#
M'\?;L+Q'+0X'D=_"M@R&K<'P/PV6O+PXPF0M/^B6Y8=>,M@QV0>+DV&R8W(?
MAD/LQ\-^DU%K,CIH\CM7A/45'^UE&OA!D 0[Q?? \,#W=CYDO@\+\2 .XIWB
MW<[1:.ZQ;T0L:"D1@[DF>I=#K2#JNZ'N*%[9TW+"E3Y[;7.IKU,0!J#GYYRK
MUXXY@-L+.OL'4$L#!!0    ( %1785FZ3LJ&] (  !L)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;*U674_;,!3]*U:8$$BC^6I#"VTD:(;&-#1$
MQ7B8]N FMTU$$G>VV\*_W[6=9J5+ TCTH;6=>\[U.7;OS7#-^*-( 21Y*O)2
MC*Q4RL69;8LXA8**#EM B4]FC!=4XI3/;;'@0!,-*G+;<YS +FA66N%0K]WR
M<,B6,L]*N.5$+(N"\N=+R-EZ9+G69N$NFZ=2+=CA<$'G, %YO[CE.+-KEB0K
MH!09*PF'V<BZ<,^B0,7K@)\9K,76F"@E4\8>U>0Z&5F.VA#D$$O%0/%G!6/(
M<T6$V_A3<5IU2@7<'F_8K[1VU#*E L8L?\@2F8ZLOD42F-%E+N_8^BM4>GJ*
M+V:YT-]D;6*#GD7BI9"LJ,"X@R(KS2]]JGS8 KC[ %X%\'8!P1Z 7P'\'8"W
M+T.W G2U,T:*]B&BDH9#SM:$JVAD4P-MID:C_*Q4QSZ1')]FB)/A=T#3!#F*
M0-(L%\?DA$SP:B7+' B;D1\R!4YT$+DNS2U3QW5"[B<1.?IT/+0E[D)QV7&5
M\=)D]/9D#,@-*V4JR)<R@:0!/V['NUX+@8WR:P^\C0>77BOCMV79(;[SF7B.
MUVW:4#L\@ACAKH;[#?#H[7"O18U?GZBO^?P]?&\YOE\74R$Y_N=^-YV?X>\V
M\ZLZ="86-(:1A85& %^!%1X>N(%SWN3=1Y)%'T3VPM=N[6NWC3U\T"4$DA.Z
M HX5$8N>*JM9.2>Y-E@"+\CA0=]SW7."=9FCUYN'HLGG]GQ]4IAK[I*$/C=9
MVXYWW=<(HE<(R#-03EQGP^/U%9%H\;)7>]E[GY=))F*V+"5!T^!=)II$ YU(
M];A5Z'2<WM!>;3OUEJ#HE: 70H-::- J=)(R+LW-,)<D9D(VR3 TO:WDKH.?
MP8Z0AC"W._!/=Z3\']8?^'UG1XN]U38*X'/=?@71!V&J9[U:=_@+W=AVUL?8
M^4VC_D=C7AMN*)]GI4#Q,Z1T.J>X)VY:L9E(MM#-:<HDMCH]3/'M!;@*P.<S
MQN1FHA+4[T/A7U!+ P04    " !45V%9,>S@FS(#   %"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U.2YX;6RMEEUOTS 4AO^*%1!B$EOB?+>TD=@B!(B/
M:F5P@;APV]/6PHF#[:SLWV,G6>C2+*K*;EH[.>_Q>5XGSIGLN/@EMP *_<E8
M+J?65JEB;-MRN86,R M>0*[OK+G(B-)3L;%E(8"L*E'&;-=Q0CLC-+>2275M
M)I()+Q6C.<P$DF66$7%W"8SOIA:V[B]<T\U6F0MV,BG(!N:@;HJ9T#.[S;*B
M&>22\AP)6$^M-WB<QB:^"OA&82?WQLB0+#C_92;O5U/+,04!@Z4R&8C^NX4K
M8,PDTF7\;G):[9)&N#^^S_ZV8M<L"R+ABK/O=*6V4RNVT K6I&3JFN_>0<,3
MF'Q+SF3UBW9-K&.A92D5SQJQKB"C>?U/_C0^[ FP_XC ;03NL0*O$7C'"OQ&
MX%?.U"B5#RE1))D(OD/"1.ML9E"96:DU/LW-ML^5T'>IUJGD(VC3)'J9@B*4
MR3-TCN;ZT5J5#!!?H[>E*@6@3S2G69FA&;G36ZXD*O,5"/2E $$4S3>H27..
M;N8I>OG\;&(K79Q9PEXVA5S6A;B/%/*AS"^0Y[Q"KN/Z/?*K87D*2RW'E=SK
MD:?'R]V'<EL[VMKJMK:Z53[OD7S_X>&/-PNIA'X??O:96"_K]R]KSHBQ+,@2
MII8^!"2(6["2%\]PZ+SNL_0IDZ5/E.R!W5YKMS>4/?G,%6)$:3O5EN0(HSL@
MHL^^.DU0I3$GXFV"1Z,PT _<[;XQAV&N[\1>\# L'2SJ1&2_1?8'D2]![0 ,
MJ^+(K8!E'W&=)=Q#B49.-.H 'T9AC$/L=8 '2SH1.&B!@Z. 70/L/0X<'*!X
M@8/C#O!A%':\J,L[6-&)O&'+&P[R?N6*,,3,H8"*YLSHXPT/>;$7!;@#W!,6
MNK';"4L':SJ1.&J)HT'BCR#E&-&L*!6L$,WU^PQ2]3%'!S#G7M#=XKZ@,,*=
M=ST=K.E$XK@ECH_88]Y^ NK=9I0L**.*@GR%<MWZZ8_(D!OQP6FEGP!OU'F8
MKWK"W! [4<>/PS#?#6/OG[LUJ;W7<Y@&\1,1&YI+C;#60N<BTAE$W735$\6+
MJ@U9<*6;FFJXU7TJ"!.@[Z\Y5_<3T]FTG6_R%U!+ P04    " !45V%9_H=1
M-;8'  !O3@  &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6RMG%USVC@4
MAO^*AMW9:6?:@&5CH)LPD^"O[#2[G3)M+SI[X8 "GOJ#VC)I^^O7-@Z.C! X
M^_:B@*/S'!F]'-GGR+I\3-)OV9HQ3GY$89Q=]=:<;][U^]EBS2(_NT@V+"[^
M\I"DD<^+C^FJGVU2YB\KHRCLT\' [$=^$/>FE]6Q#^GT,LEY&,3L0TJR/(K\
M].<-"Y/'JY[6>SKP,5BM>7F@/[W<^"LV9_S3YD-:?.KO*<L@8G$6)#%)V<-5
M[UI[Y^EZ:5"U^!RPQ^S9>U*>RGV2?"L_W"ZO>H.R1RQD"UXB_.)ERV8L#$M2
MT8_O-;2W]UD:/G__1'>JDR].YM[/V"P)OP1+OK[JC7MDR1[\/.0?DT>/U2<T
M+'F+),RJ_\GCKJTQZI%%GO$DJHV+'D1!O'OU?]1?Q#,#S3AB0&L#>JZ!7AOH
MYQH8M8%QKL&P-ABV#89'#,S:P&P;F$<,1K7!Z-PNC6N#<36ZN^&HQM+RN3^]
M3)-'DI:M"UKYIA)$95T,81"7VIWSM/AK4-CQJ?T]#_A/\LIBW _"[#5Y2S[-
M+?+J]]>7?5[PRU;]1<UR=BQZA&62NR3FZXS8\9(M)?:NVEZC"D"_.+']V=&G
ML[NA2J+%%A=D8+PA=$!U28=F:O.__/B":..CYM8YYH.CYK;:_#I?%>;#RIS*
M1N.$][SPKN^\&[+!...KT[6CG??.-Z>*D=3W.M4KGJ[6Z=?WQ7%RRUF4_2OI
MU,T.8L@AY3SP+MOX"W;5*P)]QM(MZTW_^$TS!W_*Q(&$64B8C80Y2)B+A'D@
MF" X8R\X0T6?_I,N@[B8S4FV]@OZF_J5^#E?)VGPBRW)JR F\^JH+%C>*/E=
MM8B$64B8C80Y.YA9P<K+KNU4&]3_+OO;YT([;#F4M?-.MQ/D,=S+8ZB4Q^>$
M!_&*I.6E428;?:5YU]%'PBPDS$;"'/57GL1,%G%>8N2!NBU(Q]Q+QWQ19 FR
M+#\=593LKKI"PBPDS$;"'%,2531CHH_-5E Y;&A.QEIY_2/$%$FS@3;6CX24
MT5X7HVZZV/IA+E/OC9+350-(F(6$V4B8LX,-VQHP6@HX;%8JH#7^DD;%^,M'
M?[P?_;%R]*^7RZ"\F_=#DHA".!41Q@=JI(.A0<<MU<Z4_KL.M,3IB$Y:+NW#
M5H;P.]D-#;)C+A+F@6""("9[04S4X8"O64KND[2P*RXUI!<92D+70("$64B8
M/3G\O1G:@ Y;.D+Z=)$P#P03=*0-FA3/0*FD>7Z?+=)@PW?YQ@4+MOY]*)U9
M:M)0#";ZL/W+GDD::A.J#\9B.TO2KIA0AZ-VI)"TT[7)>$1;8ZP^U:Z#7-/$
M,*;3]CT$RJDX?L]2=)IZ:HB2/.;UR$D3:S=J0M=(4--.#R[2JPVE.5":"Z5Y
M*)JH)]KHB:KC09?[C9HE7A,?W&;/U"Z[SAY0FBTY!=EE"-2I"Z5Y*)JHF";Y
MJBE3;=/;>)$R/V.DT,K&#Y9OB]>%OPFX'THU TW#0FD6E&;7M.>1<F)J6GL&
M<:!>78E7:DAR7RBOHFJ:#*JF3J%VBS/0="F49FF'2439W0[4J0.EN5":AZ*)
MPFIRKYHZJ7>77I!YD),O90K6R>/5&W(=/J2%R+[>L>B>I=+:D!K:66'0G"R4
M9D-I#I3F0FD>BB8*L<GD:B:B*JE!D[90F@6EV5": Z6Y4)J'HHG*:W+%FCI9
M_)%%><Q2?[< J+I!E"H/FBJ&TBPHS8;2'"C-A=*\FB:4,^CQBJ;69* U=0KZ
M+KL@3E+.IAX+U%,I,LLZ@](L*,V&TAPHS872/!1-%%^3[=8FD*D4FO*&TBPH
MS8;2'"C-A=(\%$U<(MBDQZDZ/7[F5*JF=%4>E&9!:3:4YD!I+I3F44D50S&5
MTB9E3]4I^SGS?[&8?&19DJ<+EI';>,LR'K&8D_=!%/ 3]ZIJ?&>Q(6D6E&9#
M:0Z4YD)I'HHF2K+)^E.*F& I,F\]@](L*,V&TAPHS872/!1-5%Y3/:#JZL'+
ME[;4X%/%)[7_SBJ#5@B@- =*<Z$T#T435=94&ZBZVG#.>ADUHG-P@Q89H#2;
M'I8L3*.UCLV!NG2A- ]%$]74E!BHNL308<V,FM195-"Z0DUK+;_1VQ'4AGIU
MH#072O-0-%%73<6 JA=_SY(XR\/JV8$2'BSDDE)#M 'YR?Q4%N)F:M/.^GEQ
M1VQH1QPHS872/!1-E%13"J#J4L LB:(B2,UYLOBFOJF$%@.@- M*LZ$T!TIS
MH30/11.UUY0,Z!AR4PFM%T!I%I1F0VD.E.9":1Z*)BJOJ1?0$\OC__?SF6H'
MG44)+25 :3:4YM2TDX]>NE"W'HHF/G[>5 GT$XOHNRQF4[.Z2@M*LZ T&TIS
M],/U^!-CJ%&SM=3.A;KU4#116DVQ0%<7"_YFCRZ+;[</9Y4&U+#.VH*6!J T
M&TISH#072O-0-%& 36E AY0&=&AI $JSH#0;2G.@-!=*\U T47G/=G51EP;*
M=$BP/%U\5V,Z2P^[LPMV:Q?I$P5#O?7LE0/UZD)I'HJV$U7_V>Y6$4M7U4YG
M&5F46MEM=+4_NM]-[;K:0ZS?--]MQ7;GIZL@SDC('@K3P<6H^)K3W>YFNP\\
MV51[9=TGG"=1]7;-_$*@98/B[P])PI\^E [V>\Q-_P-02P,$%     @ 5%=A
M64J-"[G= P  X0H  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULK59M
M;]LX#/XK@C<,+9#5;XGCI$F -MGA"JQ;T=SN/A3[H-A,+%2V,DE.UOOU1\FN
MFZ:.[P[8A\0613[B0](4)WLA'U4&H,G/G!=JZF1:;\>NJY(,<JHNQ!8*W%D+
MF5.-2[EQU58"3:U1SMW \R(WIZQP9A,KNY.SB2@U9P7<2:+*/*?RZ1JXV$\=
MWWD6W+--IHW G4VV= -+T-^V=Q)7;H.2LAP*Q41!)*RGSI4_7HR,OE7XD\%>
M';P3PV0EQ*-9W*13QS,. 8=$&P2*CQW,@7,#A&[\J#&=YDAC>/C^C/Z;Y8Y<
M5E3!7/"_6*JSJ1,[)(4U+;F^%_O?H>8S,'B)X,K^DWVMZSDD*946>6V,'N2L
MJ)[T9QV' P,_/&$0U ;!L4%TPB"L#<)C@_X)@WYMT+>1J:C8."RHIK.)%'LB
MC3:BF1<;3&N-]%EATK[4$G<9VNG9IQ\ETT_D; &:,J[.R4>RQ-)*2PY$K,FR
M7*E$LJW-T3TDP'9TQ4$9M?8MPHJ$ERDK-F0N\ASWEEHDC^3A%O(5R.]H^6VY
M(&?OSR>N1@+&#3>IG9U7S@8GG/4#<BL*G2GRJ4@A?0W@(O.&?O!,?QYT(BX@
MN2"AWR.!%X0M#BW^NWG0X4[89".T>.$OSL;#9P0B-QIR];TMK-6I_?9336<9
MJRU-8.I@ZU @=^#,/KSS(^^R+22_".Q5@/I-@/I=Z+-KRFF1 *&:K&##BL+4
M&4;F":AL(UZA#2R:Z8"[6>B/XB'F:G=(J?/0=DJD@\V@83/H9'.C5&GI( .5
M4<0F9U^$!N*W?1S7W6 /?FOJ*Z/H( )!'$7Q(#H*P5N]HTB]8A@U#*-.I_#:
MT!SPFM"6XV']RI>649$.6DEWXS\$K:2C-V0^!OXH"N(CTIW@_S_OPR8JPTZO
M_Q":\C:_AV_*-1A%0]_SCOQ^J]>5K-@Y$HP:/T?_5E+D:T&NR@U>1,0?5'VN
M1W0&IKEO:?%$&-8PI(06^.-<:&T6:<I,CBDG?;\7AQX1$F\$'"N>RUP+L@3Z
M-Y@VID0I$Y3=%#M0VM;*9Y8S W3VX5T<!-YEI6L7_N6Y^?J-"XG Z2,%26T]
M87V]'T5^;Q#&/;/89RS)B$!%G R$1.K8*Y15B] K+QA8I\V"J)<RW5.CLT8)
MWL0Z.SH$-[=4:H;,#FPL#F:@ARFP *<*/2V!K*7(:_(7;;7D'ESF.<B-'8H4
M^E$6NFJ4C;29NZ[MN'$DG^,\YK?(K^+Q/&Z3C\9S.[^Y+\=6P]\ME=AK%>&P
M1A>\BR%6GJP&JFJAQ=:.&"O,O\CM:X8S*$BC@/MK@1]XO3 '-%/M[!]02P,$
M%     @ 5%=A6>W)FI8I!0   10  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL[5A9;]LX$/XK S<H6L"U=?EL8B"Q$]=!@PWJ=HM%T =&HFUN)=(E
MJ;CNK]\A)2L^%-7MYFTW#[$TXO?-R>%QNA+RJUI0JN%[$G-U5EMHO>PWFRI<
MT(2HAEA2CE]F0B9$XZN<-]524A)94!(W/<=I-Q/">&UP:F6W<G J4ATS3F\E
MJ#1)B%Q?T%BLSFIN;2/XP.8+;03-P>F2S.F4ZD_+6XEOS8(E8@GEB@D.DL[.
M:N=N_[IGQML!?S*Z4EO/8#RY%^*K>9E$9S7'&$1C&FK#0/#G@0YI'!LB-.-;
MSEDK5!K@]O.&_<KZCK[<$T6'(O[,(KTXJW5K$-$926/]0:S>T=R?EN$+1:SL
M?UCE8YT:A*G2(LG!:$'">/9+ON=QV *X_A, +P=X^X#6$P _!_C':@AR0+ /
M")X M') ZU@-[1S0W@>TGP!T<D#G6 W='- ]UH=>#N@=J\%U-IES; 5E*;?U
M,B*:#$ZE6($TXY'//-BBLW@L$\;-])AJB5\9XO3@\EO*]!I>C:@F+%:OX0U,
M<0I&:4Q!S. \BIBI8Q+#+6'1&\9A2)9,X_L;&(HDP1*?:A%^A0D/XS1B?+Z/
M@2W,W0U-[JG\@N!/TQ&\.GE]VM3HA;&E&>86#S.+O2<L;L.-X'JAX))'-"K!
MCZOQKE=!T,3P%3'T-C$<>I6,UREO@._4P7.\H,2@RVKXB(8(=RW<+_/GW\$G
MQ\.]BF#X14'YEL]_]H*Z>X]4,-$T45_*RB+3&Y3K-<M(7RU)2,]JN$XH*A]H
M;?#RA=MVWI:EY#G)QL])-GDFLIWD!47R@BKVP06)"0\I$ WW=,XX-_,9L[:F
M1):E)&-K63:S$#\, M\+NC[.@H?M:!^.<X-6MQ>XN^/&1XZ;'([S6IVN]SAL
MQ_M6X7VKTOL1D[AJ"ZE>OD"NSEM<_I.44TE,P9:X?U%-=^>6EG$EZ%?+^#G)
MQK]!!F45G/&TM[,3./A7GIUVD9UV93@G2J6V.+$>U8*@"671K>0XWH=1M2UW
M7EEJ+]N'CG?;6+_^;OE>_0[Y^$CR=S\A]\O()X?DO;;K>LXN]_4O<N_DN5/D
MN5/)\E'@8E"6VL[!I-^=\UD.#D>5MJ3QD>,FA^/V6]*.E]W:GJ!7N-W[6;>
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M%FJE1;IHW=Q:A]Q:;Z(K-F[H*@^=M$ K+=1*BW31NN5QV)I!HV_XI[1&6[$
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M%<C["TK%TTFU"=W^K1']!U!+ P04    " !45V%9I() >YP$  #U'@  &0
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M&ELH@9345-ZQS2VT>DR",:/"/-&FC74L%-="LJ(%JPR*O&S>Y*GUH0=P_1<
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M-7 N'9+!@FX*=<-WGZ".IZOY4EY(\R2[VM9S2+J1BI<U&#TH<U:]Z7VMPP$
M>>R H 8$3P'A$4"G!G2> J(C@+ &A*?NT*T!)G2WBMT(EU!%X[[@.R*T-;+I
M@5'?H%&OG.DZF2F!7W/$J?@&"JH@(U,JU ,9T8*R%"2A+"/?!&62FGQ*<I:
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M@= &^'W!N=I/] 9-)QG_ 5!+ P04    " !45V%9^X#_BNX#   !%@  &0
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M<&.$RJ:[-1,M:M<@UD*;=N.&I?D@@+0!9G\CA#Y,;(+N$Y/^ E!+ P04
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M970X,BYX;6S56>]OHS88_E<L)DV;= >8W^F22-<"ZNU6J6IVVX?3/KC@).@
M9\9)VO]^-J$D4(>C5]^D?DDP/,^#_?C-^\;V=$_HUVJ-,0,/15Y6,VW-V.;"
M,*IDC0M4Z62#2_YD26B!&&_2E5%M*$9I32IRPS)-SRA05FKS:7WOELZG9,OR
MK,2W%%3;HD#T\1+G9#_3H/9TXRY;K9FX8<RG&[3""\P^;VXI;QFM2IH5N*PR
M4@**ES/M [R(H2\(->*O#.^KDVL@AG)/R%?1^)C.-%/T".<X84("\:\=OL)Y
M+I1X/_YM1+7VG8)X>OVD'M>#YX.Y1Q6^(OG?6<K6,RW00(J7:)NS.[*_QLV
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MD$JQ4*58I%(L5B36":&@#:'@1Q25@RBT3[*3[>F!XSJ]K"D#.KIE>6XO<\J
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MEMQ^.+!=T6)=O7M_%%J+O%I<09*!M >8_0LA],N*;:#^?&/R'U!+ P04
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MEX$P#GI]P;EZ-<Q-WK[TXC]02P,$%     @ 5%=A67G+##LR P  ' H  !D
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M6'^#6L^AX4L%4_:7K.O8P"/I4FE1U&#,H,AY]4_O:Q\V ,CC!H0U(-P&1*\
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MC&35BU0#+4I[.T^%QKO>/BZP?0-I O#]3 C].# +- UA_!=02P,$%     @
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MQFF.F2J0]U>4BI<3M3'<_7.P_ ]02P,$%     @ 5%=A6;Q!;-TV!   &0\
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M7-G_9%?[>@Y)2J5%48.10<%X]4M_U(G8 _CA&X"@!@3'@,$;@+ &A,> _AN
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MSP'K&\&VU;G5/1."9=7EAI*8\M) ?K]B3#S=E!.TI['S?P%02P,$%     @
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M3E-)'</7.<"W7Q5J"<^NC)^7,ZD$UMLO6VE4OKMVW_HRO9 KFL+ P=M2@MB
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M'F1I@/?70NBG0;E \U?![#]02P,$%     @ 5%=A6;JB\2F) P  YQ<   T
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M.9X'JXIYPW8PC@0!AD MFFO4]Y'9\>%K7A]LEWA>$)@1P,P./ ]#8#?B".8
M/&"(YQ7WP:W[D;.^3SGUO_9'?P%02P,$%     @ 5%=A69>*NQS     $P(
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M56\/T-NKWAZ@MU>]/4#OH'H'@-Y!]0X O8/J'0!Z!]4[ /0.S<-N@-Y!]0X
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MB^4?R#<_ 5!+ 0(4 Q0    ( %1785D'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 5%=A658H*TCN
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 5%=A69E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !45V%9[(OC$VX$  "7$@
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 5%=A60YH%QD/"0  QC$  !@              ("!L0P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %1785F?FF44S@(
M +4(   8              " @?85  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !45V%9L?#=*X$(  "7*P  &               @('Z
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 5%=A6;)J
M1W'6"@  )ED  !@              ("!L2$  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( %1785GQZR2]% P  "%+   8
M  " @;TL  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !4
M5V%90K"G+!4-   _-   &               @($'.0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 5%=A6<'_M-2G+   U=0  !@
M         ("!4D8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( %1785G07X0WV0,  &X+   8              " @2]S  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !45V%9TPZXB+@"  !M!P
M&0              @($^=P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( %1785D#:H7"- 0  ,4+   9              " @2UZ  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 5%=A6;R$%;L9
M!   @@H  !D              ("!F'X  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !45V%97O&CSOH#  #T"@  &0
M@('H@@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %17
M85G1X1=D$@0  +H+   9              " @1F'  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 5%=A6=2VKF,[!0  !!   !D
M         ("!8HL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !45V%9AR'Z710'  #6&@  &0              @('4D   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %1785GTHOYH> 4  !D5
M   9              " @1^8  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 5%=A66T,3E?-"0  IB,  !D              ("!SIT
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !45V%9?BL>
M$B<%   G#@  &0              @('2IP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( %1785D[2'L; 0L  ,<M   9
M  " @3"M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M5%=A67/R8TFH!0  -1(  !D              ("!:+@  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !45V%9(1 SQ^L#  !F"   &0
M            @(%'O@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( %1785F_*W&-.P,  " '   9              " @6G"  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 5%=A65;]IJ"S!
M6@X  !D              ("!V\4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !45V%9OLS5+N@#   :#   &0              @('%
MR@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %1785G&
MQ.T?I 8  ,H1   9              " @>3.  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 5%=A69\\)?K?+0  K^8  !D
M     ("!O]4  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1785GN/1R+&P0  $(,   9              "
M@=X4 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 5%=A
M6>\I/JYZ P  [P@  !D              ("!,!D! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !45V%9L68KU]4#  "@"@  &0
M        @('A' $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( %1785DC-2(\  0  (<+   9              " @>T@ 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 5%=A6>^;4XZ)!   ;PX
M !D              ("!)"4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !45V%9LZ2.E/4%   H%P  &0              @('D*0$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %1785F1]$!7
MW00  /0/   9              " @1 P 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 5%=A66\.1%L6!0  *@\  !D
M ("!)#4! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !4
M5V%92J61V> %  ":%   &0              @(%Q.@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %1785E  >2Z @0  &P8   9
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M970T-2YX;6Q02P$"% ,4    " !45V%9ZL+_RYT"  "Z!P  &0
M    @('W80$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M %1785G@&G5,K0(  #\*   9              " @<MD 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 5%=A66I_\,C] @  ^0@  !D
M             ("!KV<! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !45V%9<>(@U7D"  #J!@  &0              @('C:@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %1785G?.OA/5@,
M # +   9              " @9-M 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 5%=A6;.=SSQC P  L0L  !D              ("!
M('$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !45V%9
MA_/0$^@"  "9"@  &0              @(&Z= $ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( %1785E025/.300  $48   9
M      " @=EW 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 5%=A6:%B++XC!   WPX  !D              ("!77P! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !45V%9K,-V6%@$  "Q#P
M&0              @(&W@ $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( %1785E:#3L,X0(  )0-   9              " @4:% 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 5%=A67P,JG><
M @  K <  !D              ("!7H@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !45V%9ND[*AO0"   ;"0  &0
M@($QBP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %17
M85DQ[.";,@,   4+   9              " @5R. 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 5%=A6?Z'436V!P  ;TX  !D
M         ("!Q9$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " !45V%92HT+N=T#  #A"@  &0              @(&RF0$ >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %1785GMR9J6*04   $4
M   9              " @<:= 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ 5%=A60)$'S?R!P  VED  !D              ("!)J,!
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !45V%9O4;(
MXWD'   */P  &0              @(%/JP$ >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( %1785DS%3?J!@0  &\:   9
M  " @?^R 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M5%=A66I?56Y;!   XA(  !D              ("!/+<! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " !45V%9ZQ2+)ZH"  "!"   &0
M            @('.NP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( %1785FX[ >7V@,  ,,2   9              " @:^^ 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ 5%=A6:9F]QZ.!
MF1T  !D              ("!P,(! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " !45V%93U19RO\#  #B&   &0              @(&%
MQP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( %1785FD
M@D![G 0  /4>   9              " @;O+ 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ 5%=A61#A_DDD @  '@4  !D
M     ("!CM ! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1785F\MH@,9P(  &X&   9              "
M@?OA 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 5%=A
M6=8Y"0T. @  Z@0  !D              ("!F>0! 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " !45V%9>!@V2TH"  !#!@  &0
M        @('>Y@$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( %1785D2N<\?5@,  +T1   9              " @5_I 0!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ 5%=A6:A<'YM.!P  ?2X
M !D              ("![.P! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    " !45V%9O?3BWN($   T'P  &0              @(%Q] $
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( %1785F,F2)
M@@0  ,HA   9              " @8KY 0!X;"]W;W)K<VAE971S+W-H965T
M.#,N>&UL4$L! A0#%     @ 5%=A6>K"_\N= @  N@<  !D
M ("!0_X! 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " !4
M5V%9(UDI[*X"  #U"0  &0              @($7 0( >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( %1785EYRPP[,@,  !P*   9
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M970Y,"YX;6Q02P$"% ,4    " !45V%9O$%LW38$   9#P  &0
M    @(' %0( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (
M %1785D L1_;600  +,/   9              " @2T: @!X;"]W;W)K<VAE
M971S+W-H965T.3(N>&UL4$L! A0#%     @ 5%=A67P,JG>< @  K <  !D
M             ("!O1X" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"
M% ,4    " !45V%9ND[*AO0"   ;"0  &0              @(&0(0( >&PO
M=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( %1785DQ[.";,@,
M  4+   9              " @;LD @!X;"]W;W)K<VAE971S+W-H965T.34N
M>&UL4$L! A0#%     @ 5%=A68'8T>T+!   G L  !D              ("!
M)"@" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " !45V%9
M>>^<N7H$  #\$0  &0              @(%F+ ( >&PO=V]R:W-H965T<R]S
M:&5E=#DW+GAM;%!+ 0(4 Q0    ( %1785GY=.JY\ ,  /<9   9
M      " @1<Q @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%
M  @ 5%=A66MD4P?T P  <@\  !D              ("!/C4" 'AL+W=O<FMS
M:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " !45V%9-1WSU9\"  !="
M&@              @(%I.0( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q0
M2P$"% ,4    " !45V%9N.P'E]H#  ##$@  &@              @(% / (
M>&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " !45V%9IF;W
M'HX$  "9'0  &@              @(%20 ( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,BYX;6Q02P$"% ,4    " !45V%9)L:JCZ0#  !(%   &@
M    @($810( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M" !45V%9Y;:4.P $   4#P  &@              @('T2 ( >&PO=V]R:W-H
M965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " !45V%9_D^[?\,"   N"
M&@              @($L30( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q0
M2P$"% ,4    " !45V%99&&JRCD#  "G"P  &@              @($G4 (
M>&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " !45V%9J%D<
M-WX#   V$   &@              @(&84P( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-RYX;6Q02P$"% ,4    " !45V%9NJ+Q*8D#  #G%P  #0
M    @ %.5P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %1785F7BKL<P
M !,"   +              "  0); @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M %1785DWSGCHM 8  !Q&   /              "  >M; @!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !45V%9F-"7[@4#  #:/@  &@
M@ ',8@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !4
M5V%9\GX#[W$"  ")/   $P              @ $)9@( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     <P!S *0?  "K: (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>138
<FILENAME>0001213900-24-093266-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-093266-xbrl.zip
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M$=(+*5=8A\ ;13%1AJ]6408+$6LAH;Y-"W$>)JD5Y26=0/!66I'2'9KJ3)R
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MBOI(L3P:T^!4-X):SH)C@539!+:RH\CA1QO=V=ZYY=%L!QLTVR(TV_8&S?;
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M55/7#F03R*U6K*G=V#-!-&=D4IEZ%FDR+&T%CK;)#<B3H:Q/9,2&WC$ 7<6
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M8F,UQ+HBB70<*U>9KM9@.,$MP*2"88JU+%$[-HP*:SM[S2KGNKQYQWG<5-9
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MXCL29\K7X3UZ S(\)_H>G4?7)G''V1UJER^[9IW4*0P5L4;IDB0H&.(6(ED
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M&EU:=%2A')7/2F@5PD_,S.D>"Q.PF>2X'Y6;0&[J/U*5\T7T*$R*14+XY<Q
M<CFE(GR@ W2CI:3,C=;B<Y02OPXV(/Y)'X<S=\[CQ#EC\5;1!/ 8@JYP4K&E
MMWBN8J)S;X/\:T(CI&3@+LJ""L;<NVF(4']Q'=&!],<-B8BB4=N MX#,(Z(T
M0L.(SU%)P(TJEUQ/M?E2R<+=P]Z_7WG^("3I;T"%*$"O*49_^]>O'[:1H"03
MU\G"P)6%43@@14XOE2)"5Y<)B[^?'J!/C/QB#$W)YB@R2127L-P/]B*[DM5;
M\1_V%W:M947^OZQHL9!09"^P"%FR*X4&!'0=D(2>/'UR]/3)64=(=[X9F0H7
M1'H:X.U%6>Q=SE [7PCL.5KY_[8@V*<JM0/)Y%FK>'%X\"1Y^N3XZ9-73WWZ
M00DZ4<!S1 JDKCP=%J)!1XC^#NR:JIZ.#IA"O5UY91?X&GB%GG-TF;3M;"9*
MDDC$:$!<ERUHLQCG&Y$=05-IA_(\Z>D0V]9B-+!$S9>F*TG#JTO2P45S%2ZA
M(_8$:;"-(/6N!_!KW!!6L,!ZRRHS'])*NOI3A#KOD'@-KB]>OS[V_JX(US+P
M8$L&_O[GFW/P\!(.'FS!P6]J!_S]\'20M5,GCW8">F.^"GY6>:I'\K; +-@E
MZINR]-!AZ:^Z+!T^&MPQ3_>/=@U3#S8Q]=<#3)UY\P!WO)3QXGQNR'EQB&U8
MKT,,5[1@@EMGO?UE;^*]CA$3W#/O'39M@JU,F[,<V$81,[2C3S1HZ<2$Q(IS
MK.*BGJIJG6M0?PD>_6C5^%?Q,D,H2;[8^P^7N?_M%@>:?"_;(@6YQ#K>@H28
M@!Z+!,W9  ]WJWY0>7F!]WJ(5I+^VC-G[6%,A?-G[0RA2J1L_N3;A[P=%(BY
M-0*\HR+=M76Y';RE;3I5]^MTU[0;U_O=;-.;W'G8# ^3Q+/ZG[\=F25?K2<X
M1P?_]OV?'_Y^]6ELD>+6W9#.DB];U(;'M_[XU5+L]%ARZ"]>_&,(^>I57,_I
MZM(?4*:=HRW8U-U-=*J)AY;:?6KH6\-$HH.-G5>D8>'AZ?/HV8N#M;.Y[#MW
MT).]_\$?__?/MQ__+SS[_77XZ]NS'][^^O;CVQ\_;"2-M6,-;]+ SES^X.WN
MQN64IN\9?A<MI,,CLI%(.]32XHXWY?#@,#IY>7)_N[*&1@:W8HA6SZS#>1EG
MZ1ZJ[O>R4T^>1R>@H[]\WKM;_4&??C'JZ6_9=^$:=GZ6).VBS2DVP^9V<P-Y
M="T9M.D(KC:2.20XHN<GIULM9&@NMW!R6W+!_KD0(.5'0K<GDA9%\;*UG%SG
M2#8WV;W"B5S2/Q=NS8OG1]'IR>$6R[CL0$R:=C"0_N,F_]Q$>;TL3^INA_^
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M-?.R]FHQ81<N0"?%3ML\G=H6;G[X\=5^>(8 E<,?H%=Q4E@ VEEG#=:4]YW
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M<JP%J1NBRF4)^0%EX:C<4"3"T*.:.2D2?!V2/,[07L*?]"I)R8V#5#V+L9,
MCNZW*1_I<Q>6>U?T.9C=>-5\1)H+:?F:1YJ<C'/I.Z%9M\9K9ZM<M;270)OZ
MBZCCD4O(_@@-A7:!O-HE:JP1R7%B;<V]0C*Q9-R"$7Q<HD"S-J[ I%&*31T&
MC;=U )CLJ:M<V6>/^P!&$@7'53556;/OW![I%4.>4&^Q".2- DZ7Q\!-W:,'
M8MN 96!*RB:'XO)4.1WOW2XL]\XKK_*R)@0=23\6_9O5[[(@$J0V!%A8Y=\:
MF@GHJ2W<4E1:JJ$*J4L*_<=JZ=U<[MTZZY%OJ6(6SYASNMV<F/!T)OR2+3]F
MI.C785^1^[RT!@Z79:,H PK9X33/$B8Z'=S4W<(V)XA<P]^_.V<VDN@MDJB@
M.3BI;:S%<GS;47.9:W)\"8DM1["H5KBCB;$[RG",6$ C">W"<J])0E_$[?1*
M6C2&6_R3QDTLG7\V]D#":@IL4%A@'9"E_0O@F)*UI$P'O:Q*]Y =KVCTK:9!
MAF:9YZ;'T4(U59;4_ $V_HRR"BK .>Y5QE5)CJ;K(+*AQB#H5UX3HJ_<EVK3
MT9U6@O?9>NPQY'8]?E^HJ#!L3,?DTB1\0Z(84L6X\11?.2PZ=\)XG'OE94D6
M+>(R4)8D/J<^,Y((]F[KQDL8.YV*<DO)NJRSAMH95N4Y6>"@LJFB%M &;D[9
M[> Z7$!A%#83ZUM3ZB,A[L%$X"TR+D==\+$)\LT"ET+.:QQ/I@8G;.+/C+J(
MV2#P9]M45N?E;C8W1JKZJJAJJ, 0,Q50T3*,QP6K'722,-];,1Z8\/.$/(7<
MWIB:4:*_<J8*H"G*RZ5$<S:X31/*?[=55F._I9'H=F6Y(]'MPBF,1'?C]0YB
M?%JL9!"7_V[3&6?3>$X4S+7$#N[:Q>P269EGU'$;M48EW<"![LH*^\MOZ$HX
M>IP?*0E^$5^,W\ODLG^RVG4C8IGN'A(LY^A&_(-)E8$IM9*_+<I"H;5$</-
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M7FG3/(.8RN4*7%]*/)">4P]%Q7KC9%RB8NLG6JY3M(MTJ[-:WQ'%0V)8 6T
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MP8S_PHV"1AI]_#3JM*ENXL]$ER/!C01W+P1GBP2L'YM-<@(^)+@M7>Z*?V2
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M'70QBEQDEAU716\1$QTMB/FXL!L[$?Q\XQ,0)P#KA9<;ZR1C_0*+$TD$ZBC
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MNBRD!$ +Z]OX09U]? C*2\U*U'B6T.+GOF+7WK/#Y/#P$'?G6>D$D]X<"[@
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MS\CAR"1XH7KQBLYS5A7 W$_-*K)>0.4-#\*7&/755 :31&=$(&BV508EGOG
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M7:Y[ (_7X0269)&2V-IO97U);(2QLT42QW;JH?J9GA4E2FL2@@5X3C@13=A
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M2PT; T[@.>;(.?%#X; =Y!I2O/;OD-+AM;BCZCE([*4J;OMU!8SUTD># >S
M//^8-FG\KK*[R=PMVA<<=$.X>\!=5;>VC^^1B9"3Y!8#[SU&T3/E?NSZ>]^+
M?X]-I^^L?YS!A'[>1_@BDDX[6&@H)JX'(F&/55$U^+V"(X64(Y[@.1ZO$EIV
M(L\,(/SNI+41>$DN0,"(TVN^<9TKUZU#N0N"AS!Q4MU)(LK./AZ"OIO+96E\
MZ@@YIC.FY23NJ2&K3)%=D@Y7^Y4K&:AU.5PK&B4!B@Q!4JXQJ['>8<(V_,%L
M8V//MG)KD(M%47.;VJ05^D"+("<?D'S2F('!$X!B=@&416%R<!J+;81]#M:M
MA!4"#2;9'%P,=#:PZG"@VF_T$A.':0D>%@)<*/V4B,@4S )*2VS7DN\ SH(N
MC8%C-(V\=\,_E1(M]Y%@Y3IM\"ZJM.&P!2JQXAYDBVPXY B(T #1EQ,U*,U/
MX"1$K_&E+K?PJSU>I3(#870OS%F).3/[;YF7VJ%0U^RAV @>OY) DS%4D^3G
M8F)0]U=[7Q([:C7M "&J(>!2.XA/N$(%#Y=IPO0YI5;)O<*9PX=;9M:"G8G%
M&<4_!708=<JLALY)PB7R>\)Z6%'["(%>\<P49IF):,.".IWY_?& <2&!>3NK
M[#)+Z3R_8/VBOO<4# '+:77(,E4WY=R&]:SBX[\\E+L=7/=4]!/4E+6_' AG
MW=G5OXKZK3PTE,G\+&.$5<HLX(NW5G,^S'AK/EIC@P=QO^^?8A!PA05P94EC
M*<FFW(P9-E&<#9^PE!.4Q5\9K !"EC7J&'S&8%@/A5?E4T?\*Y.*ME+,RK02
MCF%-W[_'R4_\RP#+2T71E"& [H>\G$1B@8>@2,[L["R]>$'O/J@ZQA$_J,48
MX0/VW^1J)A(' X^+[(>7#%XA&-=4+U@S5#"#3>J1WE=PUM<$Y=4>DC6+T(WB
M8P$C"'=X$3-=.L?]<, J]O&QH(F;)\\.+*4UP3$.I9)9DC"E)F"&%@,GO_U[
MY*R#@OA:[]!.[ALO!H_KG#>6\O0Z'-+4NV7ZQE598U7=&K #3%&W,"VY08\P
M"H)TH< JJ[.TR/[M@4,>@>6'[3!?ZO3V>.\'M('A_>W;.#/4!.$&)K_&.GN4
M+M9VL5)/X[DOF<RW#Q.<:IH74FG"BJFHE0P\$[BRSLOFR582*;2;48NV1-:9
M4-%'.SH7KNGO:@0N'BX+7*QG52IP^:YT"_TI*C<>,\74G-L-(>XAN[0(\#O>
MAY##8D$,CP-;OSLGIDK%+;K<IS#[\>L",O]@T\?PS@A*G>; 91Y@O751<^
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M>NAH*<2OF&WW),IQTB^YD$V+,\2/%JD5%'H9;1%&$GY1.T^1WZ?]]K]:0O-
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MPVB/&U(&MA:Z?MJ5:*/S-'$_V%<1/-2FRL[3.6V!3B^[JWG-%%GNU8"H0;7
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M*^X.&LI&1:?88=F+J:@EW5]F-(90D8^JW='O??7N-=6^?%HS>.YHG^>F<?#
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ME.Z<.8+>01K.Z/5 N[P/5<)KX0-H'057@A]'NVH7 )OZZD8!I"'-@[WX]((
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M,.*O'%W6RD1G57D!'0"7K+7/\UZ_9D_HO9W\ :H].'M7-MS,G50J$PGI*'"
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M-T!%KZ00!31!Q"Q4"-8]PBRC!AER+(EK5'%7O5'H7.U:ND@S O4;U#MKJ3L
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MV,V#]DA'I5Q._4Y3D'NC06Y?X(%89HB=!7<.U/<Q+HV9?O1?9TH"'$<HBSX
M;* =2'J"<>,BQ0>LWUI7O,5P1-;+E(*<;/_N;!\.5DRDPW\U0 2=>9:"0$FE
MKP]#Z (,2M:3T4Y&>R=&RYF'%$*+FN@R9F7;=/G/K27G]M?X,5")5J#K J,
M.X<?:_YQ8/E:@.\(-#)KW*LYJN>(A_W)A"6VVP6V.Z'^D?5I,M]!Z(5][&TV
MN0VE:).7P#QQM2?4X)Z71;G.Y@Z$C._5AB_G6546E)@:.%"0S?[/ =WY(CH%
MOY\Z!4<[!9],G8+W8B%-)]AG/\$44RO*>-'1@N>1C7N1?/=CNLX*Q2:3+NR_
M,SP^,#C9;.RQ5O\@C2M?]=8_6>QGMUC,O_@(0')M0$N%Q,K$1"QLL\K[6I2>
M;HW@/O;@LF8?Q,I3[?=6JPZ.8EMEU>O+:D\[LZ?W+Y5\_Y/=@X3C984BTJZV
M(Q,^SM\UVVJ^PG2.;%&P\#959J^QR8W(4Z-"(E8OB$K*45MUU]Z4"[_A->=>
M2G3I2WF_ OY&4)8Z2=?0'))B"/C+MCK;_AO@!1B6JMZ.CLCL;!O2EM7M!HI;
M-6D\$S,W%?CALD*@RETHJ"Y Y-55N6[S,R1O8UH"O$F'UFW V)#5' V24Z(@
M:.6?F@G6E)1MI#<>3=Z]4^+(K95Q,2,F'*2+T*3 ;["/9MDA=<UM,+'81H[8
M-8"H%D4)*LE2?$SY^8@,/5V4&UW>=$IQBY'%2&RQNB,!M6-]%@.K_(XI"YN2
ML5I*SX20FR&\P,C4L6C8R,:2,'9%(;O<=R(_7\N\!1@NNY_VU55EZB 3=*L-
M/#51_/??337XQ"3RTDG?Z#*W>W8T5C6=/#ND98ZR&""_)@1D^I60 7J)M_MX
M$MS_L^KU@$QII%)BE;W<XHS\""J8D%0/JI=4G+S2RT':ZG7Y'*HJ565M*1GW
M-3QQJCL*(SD*IY/KQL?Y'HDRS29EKGO2F.8M! I4QJ4B0:W:'A_@YB,\[Q\'
MIP?TF#\='[^3]5]K-F/9"+PAX3)W#6&2A\7WBV+M4H-S.TPV=#8 B!&286FX
MY:GQRG:"7-1@D$6)MX<H&HMO)J_-!:@"TB&6U4X3KZT/E%8IY(=KX@+UJZ&(
M[0^:LJ*4K>M/IF:#PAVZU'?0>US-WDX+ ZKC)<'54 &$@%E9-6_7-2)1X#2O
M1>9D(:7(FH6'[)F?VT]A>HZLT65_>]-G=ODQJ^=M70LD[]CNOMLZP\7WRDW@
M20#;^]VOS[>>:#84-(;7C_<X^H'^<2*;@?>)XG=.+?SO;A.!&[R4&85U?8##
M?_P#GKEJ:Z#]W4\^V"":BGTS&4F46AN#V_@=BLH".(EI5>'[1P0F,8-C!2#I
M=8D0)[$74?=B'<SC1]\2)GK4M!4%4W N@ 3'VE>*:#I2T:%6+B+2.8A/]?$=
MK @_\K:FUTMK<EB 9]CZHV"U IX"G)NRY@(W>7TH#F\ JLBY)ESP:58YA"J:
M^DEN)\FZ>6]%+>MTE58\UC_LC*;R!F5F[*9>GA7$_ZN/!X?4JH#4FUJ$&GQG
MY-X4)0OD 'IX:V!AF,(M_@3> 3AS(D6%&E%#KN+5&)&SI=21W,)DAQ:<5Y2\
M@8ZD8 %RW9Y>+,UK5G0O$WIMZ'A%XR<=M/NE"!.UK@T5A11 %[ZL^+%37+"B
M7(XH/(3.>'@P:I0NS#S/"B=WQI VZYP2!'K?ESMY49\6\8/4K KA #/^"'P?
MZOE)Z(-9E<U,M>5_64LWH*/,$E!GM!$1$V_%A7KXI AP[704(T@;,?+SM' W
MSE!YP7IGL-@14CK/SK-<H>G@>I.VXKT;YY@9P8H^!EMY@[;RJ[,5>]@V\8N#
MEP?QT;.G1_&#Q\^?/W](3VO?E<\XX 7L5T^!'PC/"HFH[,GO4@?VX/<[.#"I
MO\-MWID!_!HP]'Q\G#B[EB%\^SA^<'3X^/NA(<CI^@[DLNUO%WCH^+\O0'?,
M>A QKPYO^1&[4Z"!YF^)CM[0^J'UX!B][%%>=?M6P+H)(NQ:6@]H@H=NP .*
M\+H8D>-A9< K!L!Q>G:&LX(Q,V;?YNB P11LK=?)3FD5*DO/;*"]R#%S[O-%
MUM%;93,<H5-BH587Q_44\41FK-'X")09J'$#4CQ9BD^+IQ7K0?X;-Y62T6<.
MVYP1[G*106"6;RE_(_]* %6.C;E>4*_T5,41HBWFV2:3( %!$JC61M<'ZDMR
M5,NJTZ)!(D5UL/?0GI?F?!RQS?,%Z2I.2L 49U"BQ:8S]WO1_6([&YT8C$SP
M;,1<C+@I?%/1%*!&%!B"8FL!YXG\1Z29X&T9C3/2TI7"W#**ML>KU[M&Z=#.
M]#[TNZ&O2GH+3X%R2>089!N>%<RNKS/HX"H(,F/-;,Z,-.@R/@()'&RZL0Z2
M/1?05X3E3NLAZ X AVIE<NH 9 D:6E^X7CR9=88JG7G4:Q8'T9#1!Z:\@-(A
MM9X@*"T5#19!A<M/8,/!RX;GPD(J"%>@AT=@&2 /L::&^H&Y$T?]MQ'Y*K_R
M?[0+<M[T9:4$$@=JD<C)P^PE%6F1VMD*N],[I[T[F"-)D869O("3$P@XDZYF
MD!<%HLXO4V08]4B0U[$PZR%T'82N Q*%#DA9[=I#R9OU7@6LD L(@',SLYZK
M?=M:AE5-'0D$V+ :.JE(994V2S+$N4CXV7'RETE#D37\EK"D$Y%83-BRR(<!
M9T8<FPT<)2(BDQ7_:OWEVAJB-98069A92DH].(UB2L+@%,U-A<N>Z'C)^KB3
MCQO^$E<U0Y,E85$[.+4%4!FY07P[!&J,>J'^-)0?:F>;THZX]JHFC@3''@X1
MS/Y\!<&/_;M?MV1P'%'*A-%ILL8&N82#EPY6C.11#8A&B0"2 ZH-3*63HZ5^
MN.OV]KDD'LR:670,U/YF4Q)U%CK'HO/+#4+9!Y.+WEJ$48T([N;;\96SO\0M
M.];J.J W7HLRK'^5T.Y#?H[=R9;&=.*[ZZDTWHL2ZQ?K/3_=8Z"ORBI",=\,
M$Y:4YZ"4D#6 ^/3E20SG7'$&NU..C2FU,2I]]@?F!?]9MO&)O<TK>_?X#5SO
MM;\>!#V2L(*7ZG_\&I+<FY+>:S3;6F_:>ERP!^@LUZU-XV=^BU?%3SZ?\).C
M^,FG$W[RILT;_R>-L\5__R7]?X>'S\!<T[_=R@Y&]K%'WNCD^!_O7[_][?CW
M?T:_O7W_,O[]Y4_'O__X^K>?XE=O?__#_N>C7]^^_07^??K^^/W+-R]_>W]Z
MJ_F6+^(@V.,<."W7AJ%0NC2T3A=29O&[]CM7_(E/@1ZCVL)NG<@6[[_X.] #
MOJ((9.0K_>I+=%/5EY$[OF"GHWLJ]8I<D2]RH7=*.NX0QEVD-B;+R_*#=*;1
M;*'GAOB]>8JQ+C2%0R#H9"G'?XM0%2PU4/LW!5RUC-L&M_(H$7\$_E_W\>H5
M.%O=3[D-OOLQM%WT/L2,4;:!:DOW3U*'ZP[$E6=Z-Z@,X*CZGPNU4^=SDC.M
MY=/2V1Q$'QF(0ZD_4:*!-.\]AH]5$2L77ZRA6HN-)GYR;\]__%IV Q0LC798
M*VEY8^&,VI"EN.=;D1/]?5WG K^RQ/B8TA1HAQ1GJ/X?_^,HH#NUB_)?9N[R
M!\,A%1C <BBH2+STV#S=9! I%C:&JX-RY>#(A88!4BQI-5\E&B^:B(ZN;$@M
M2H+CHPJW J<G\J#T_D#*=?@RW,?VIZIH#JW?]4,NHC(EB\_%4!:'<HT!A)5$
MD2F#"MEB>O)$9C"1PKID-&C94US)XL/E'(3% ]'V:?'L$5+I9:-KS;)*SMH4
M2H><<.0.!VN^&#().*(#;?2,8@"_P^P+I>+^,)QAQ^X\V@?'EVY4%D$QET$F
MW"3()[X]C,!T%3HE _9'Y,9>2G8]A'+0A_8C0&]RFD'9< -%;<A)$H-.Y%9D
MK98D3T1@Q3[#P P(I(@NMDN8$(7#G.SSLG&^7@-BP)I?Y&?4B7 3 )*SM@X6
MV7LCKH:P,'.$TV*5@,O^*@.E$ !^BQ%,3M].!W 90[B&VV.YN)^].'N$S4'#
MCGV*G2TY(U7[:*Q'YYN_C?7;A%?*S;*Y1@?.IS7?V(T*P^I]_Q]V&XOTJ$(L
M,:28O0+T!>P.!?I'8;L0=N#<2OO-UV)\4TL86J5N]!*Z+*37 O]*.88!Z=;=
MM:E/UO9U61N%40!BXFB9^F&@9D8("XI;T-HT@1R<V_1/XEOP%'10L+;S[N5:
M"%-E7YV8[F2MD[7>P-Y(BH2X*0ZHMSF!M@0"DA:<5GLJ5UZ6D N0#'"8;'*R
MR1NT23RG&VF:.[=773"'3=E6@2H#R1.+,@,8)C#P/EJ5%Y-)3B;YR29)"I>@
M@\UTR\!TL3;KV;3G309V$P:&\,(BU2)*R+?%VQ_X?>!.%CYO.+K[3?8XV>,G
MVR.1V5-EQD8;4)L@;L6%O1R AEWCFJ^VD**&1BA/H<IDDI]FDD&CF:?R@3\!
M*=4<6L00'7G'RN>3G7T]=M9A 4'Q3]::<'(NV-UA;0T WJIL"'^_6[VKR?"^
M'L/#$Y7$,!C]-2^KLDC/LZJMXP<G;__OZQ\?/7[^,(;^(R,<K+Z1UH/N*1TC
MR(S"'LJ)%)%]SB;QV1RBA;4OG#5IOA3SO3=U7 +I=- %*"\E6P<#L'R=/T04
M.)''4"PH"0$&@Q7XM%%23^!W >(&\R'DG/FV@DXE&:MNU/E#")9M$@ ?4"4%
M)488Q(+U?551IAJS:TSIU98CYGS:!=/[ YK$$&0(UKGUW5:$L>B37*",.9!^
M&\#8-- ?XKDG5L!G8.\0XAXCA7O<"3/47!J(HR<0'U,EV"=&6I\=6"PDN_ O
MVI\,A N: !&7,I+EUHK:LU5T83RNA,77NM[?,F=:A.(2*\/%YKE*$D!BL620
M0__T:+-I=43[KHZ#^.5'@-N "7"_'%+@69< [P=#(#LMRGC14EC5;A:L%D/,
M7+%? 3O@&-#-8YBB)5#:HK2 Z_5(0N-S4,P+>Z<D3I<-+QH:P[*W KY68[UB
MK\>SPZG78[37X]G4ZW&+O1[U_SL\?/Q9>CV6Z3K+MW_=?6UL WES_-OQ3]C=
M,=S<<4]F]=Z<<,!<IE@!,0!#:0>[!)I5T/L7)CA\I0$;YL5MI[9Z< 53)VP^
MMJ/?_L9Z#X/1D#W;;K5G56E/8F#0+JN_0F=L8SZ!5IMVI7YX>MDF[P;VY)D=
M%S_QHPJ O?:SS2!X;Z]5^4,\U*T%.W>P0 =B5AF$VVAAM#_0##V"=V#@)+JH
MTHV?U?_TKW7@BGM/PO?_>:,[T_ <')_=YREX]NPNYN ]<.YU9\'%^)= 5?NK
MISJ;/3@Z?)H</?D^.7KV[*%?!S<X[#]@"WS5 E]0O@2_^C1K=^9R^F]KYRNZ
MW4G_]ON;&.L-#NADE680Q,AI\:*TIPS\XT<Y2I+XQ$8V2QO2\)&#HWA+Q\[-
M&,X?\-RW8BT_FRS^9VOLUXHT?E469U^.J3P]NF>F(A8A!O$&L;.P'&_4&.YD
M%_FY_&#'7\1_!PIJ8$J)C[^@7>3IDWMF&J^MTPNX?$C_B9G<]ZWAG]DF?FF-
M]^^F,NNMW1S*+\< OKMO>\/M&< =;0?QJS2S^UK[)9T0WSZ^9U9 YX(G ]AU
M+OS)*TA(M0J^;-3S99F)%'EVA"QVB$#YT;+$)'(2OZD.XB&_.$%*8H#= +5C
M32290PZ?$#%V73UY@[$FS(X?*-F)D[RLD5[N5W.6SK?^6P]C^_G<Q$>'CY\?
MQ.\J8'L#\% -[SVKH5^P]QL@RH+OXQ/1P]NG4 ^0N@P'L4Y4=1._@GT$L4GO
M?CJ-3W"5Q2?E@1U2LSCPHWAZ$%X5J"TSN"[D1=9I;7_FJ"X6YJPR6 FJY[Z5
MUFY.*V,W)?<.^E_#VM=IDT+B9A'_HR!RKP:H#3Z/M5$SX$BF8XR4^+,O#.NV
M1X';?A .\4U]@!]W[#MU9T\<&G3/5=W;H*,K&;2_I+=D&>JG6'$46+%<T5NP
M_>X.XUR[IT?SM&=UEMIYG:SS)H=Z#Q9-&2DGAF8+]SSZJ+-6^B?*R.G-9O_6
MVNO,_NOQ86+M\.AI]\J -XF?',;($@R5THNRPM*KXB.PMGA<9^E!_+/];U@'
M &?(EID=$=/CLOI*2LP&L!Y!H>.>OG-57OI<;]Z^@XC>@7^S 1D3Z##EM-_]
M F_C!+:87XD,)K%OX&?82'Z!_YF9%"K1=9ICM1AVBK^G10MTP?"^8:][DV[Y
MW;]FC(2]NL'3FD=A0((!J000A[YFAF[BOV F: ]"(9)DDDGZ 0H?<;MAYEQL
M@11V4U+(L!OM<NDZ*^3K3(QE_P)D$VE6@XH$7I%^E.;P!%!2-Q=AT9['RESV
M"[X*XY*QR/\#MP#CC5(LJ2OJ#;;5F&HTBD88'S+"+DW3P#[N[R3B%(ZG86V:
M*IO7ZD )YY57V 5[;TJ0A!BZ[$G7Q"_HU?T*H_VYS$G<TIX;0)%+"*&=KQE>
MJQV7/5V^@P'\9I<RS#%]=O3DP"[:@1OKX<W:+*>7AR2BV 'C)BIJRC(GMNJR
MR.1P9HTP)-X1E(,SW(Z0UE+8<#T6#N=8]\P:17[A^8JH4Q'XWW\B8G(W;=A#
MAE"A4K ;@S;J!W56 A'VM!?ML1<U*>H>@27/4^N%5$3;Z[=WZ_4O,^ B?@>J
M'O$?@.!:E0!:>\!PK7<7)PS/>@A\S-Z"K3DB6F4)5K9LK?D0,;T_<B+L4&@)
MRF6OHRWU7V4&)!-V,;=BXXZ?'E<?2#U90ZZL^0!E;L!5109KC0JH E(GCJ@W
MA7^5,T2EB2V:.B+"%+3CU+J)L.RH:*LHJ!J3&SN.=5L(7OT;:OMA<@*DZ6TR
M\$SQ]%RE"WQ:WFB)8LC>UI[A19J\3[,+>*^G]NOI!CQ;D!YX8[?"K3U^1360
MA#. 7JL!?NESXQXZ[CUUSB>YFU8\QZ>U,+867I15$6FKU3:XLELT>#\OV&4'
M(_PUO1"/'?=D[YSC7\MB(3(.=@?3L:KR\]4>#=\D/\!$>#U[-LSQ=_K*#_[Q
MRT/MQ]G]K72C&[W-:^I'8TIQN-,[<MZ.EZ#"Q((-_L11<49T;<=OLJ]!C_]#
MU*]B:,__N+W4[<]4ZM;%I>3S'V^J+(^?:(>_=T'T2NHZJY&Y:M#W=+$XG]JG
M9@X=%= JUM@/RWQC-^7&VE5A_8-Z+2Z,N*D\&'(^K8M"JT"'T'__X\U/\<F[
M8^?81B?.OL0VG7W5\G#MF9UACJE_-EH:5'96>CI4MW<2M25Z7"?DU\8G!W_
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M+O%V;U[_]N/+5XDCS:*+G+Q\B[_'/V()K#(L=^D>,N!KQ0$_?OZ<)_3P67_
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M%FR-VIIT*ASUHA-@I3](4J9FV4%JO^:>:&(1\(?GIJWJ-BV<4'35BHINY9[
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M]HL.FUD,+SUT?SLR8I<&F%?;!L)@=%I&TS+Z8HXP!TS!90()#C-'Q8$JJS^
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M3M''K(M'EMQ'FSR]_]'SO_)QOSR3"EN=)9?;24"<ALXSG@?-<[UD2'["\U0
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M8(YD9P8Y4I0%<Y2C+QJ/)\]H9!W(YN-8I0%2U*>R,/C0E/&V84KQ!5 [ /[
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ME[!],JU(/9]=LIBT._'/W^LV6'ZV]>K=!Q00?S ?-Z#_(GE=5*:C)  S,=W
M-RGTK99R5CFVO^;'_:U[E"2W0;\PX^L6F&$".+TUEXA^4= %@N:WWV[/)8?-
MZ/5'6 .R<RK;Z;?0:W2WR\1[<[0KWE?O;O3[/VYNB=.HG<//L,R26ALU#GR1
MUN_UB@YVTXJ'@J;1[6T&90\GL_U]'N8MA]A3Y=]8U9$<U6^\(\F!$3/H-<_H
MF :-3H74KV,RT*]VJ/^;,?W^'W;@O?>Z?6/4KD"E1SF)WK%.8J>4B[QI(03M
M!!UQBG!\+UQLVV5%0CAM9* A/-'?QRZ,-#J^/\-L@[,"YB@\F)U]AX/G#IU#
M8PP&(Z-W-H*Q-6CT.F?"C_G/YD80'A@;;:/3[I^1VFJW&Z,*>;?'U%M%HQ\/
MC(7K,SF-+>$X-K/\VU[J[T&6_2_SV6(%[.*=%S[.!8ZCL,GM',>H_FV"_()C
M^6RN%MZ&ZK;Z/([$)S>.DPD%Y>TSO.\AE_; J.H:K6;OC,R!;G,7?S:3U';V
M.6WE*Z]K=]&KVUV4M;OH->MV%UM0&?W'U.W)_[P*_E^SV<;&*^:[[&>+3G!;
M4#:=]?C=Y_>_W7QY_Y/VQ\WG+__6OWR^^7A_<_OE[M/'^\/D\9TJ/?*S:%CT
MA^F'JUS#N-/ =";YDC=:$"T6U$1W&C=V6@*>E/M:V1S9)M7(\R>?X>3NXL-:
MFS2VV[56R36:3" ;K;]L*'L;@;U&=##4%8^^N8R7;*]?<?/-80):\97A_M+(
M)+>*_'#.'TH^VV:#D;+U\H?Y?VYOW[__\"$YC3T"?<_,?YBK?V:!%_G8$/HN
M23>*(^Y*8EGV^BA_=(7GM4^(D[2([=%[$!S^[C<P! =^4S8PAU;Z[T&#8D"&
MKH:%SA>IHG5X/(0BB);OKEIO >!H>0$$_8OI6T#*YTJ]-[&F$K,>.'[;Z_"[
M/C_Y4C16!<LNI=;VE]<L6Y =,H&9<\@)DI=!O&R5-HRB",TA2F!<>M2<>ZH+
M$;9Q7E)-?>=)?>T341^F46]#?>D2C6R&8U9V4P8VDF;1C5>L7(5:W0J.^&;F
M#"C^D,Z:_4YQ&7FZ^!J+3XMUIEUWBRSU.W^*<)0)I6*OF.GK?%1/MJEANZ1[
MI,P+YZ5Z/.<<R2W@ Q8JV.-&DE(MX8C<@(6AP[++8_O@+!3I*2MDG/(<>=Q,
M4+8;XC;>%)-/X/)GV)3<7, 9A:D:ED=PM/^\?]UIC8SAH-W0;V)G/%5-N/0]
M*EN(Q*RNL>E08V?XN^-ATG:"FLJ80;T&G]8_VL[QZFDOCG[O1;-\9V5H.1(%
MA]JG"4P+SV6K+3#O4K$+4$@3ZZ( -M G1'_4=)1AFVPGKJ.V1 JFF& &)LP7
MRKW_9B^BA8 !GT-:^N77GRAS#O^?)]XG?[=,W[=Q-!9-5HE;Y9NAWAHVFF^P
MI('*5A<XTTK\433SQIJ>,+48?$P#ZNGVC-%P2/0./P$IZ1-B>'T3PRLL(DIR
M[ = ,G$ 0%307I:&?1=SD'L0$CZCYL1YS:15U?1J7D6MJ,H9_1<[ %.+EY$;
MF@5&++4T$ 2',^^">3)Q@LJ&2'%@^1H2+R_Z>:01-T'HV^,HY-5,VQ\4L43D
MA+Q41\(PB81L!T985-84YFSF@]@*4SHCNZ)P:%(1&%VJIE[7: ][FF#QMH&-
M]T%79?EV#XHQ"T\^1J25QX@DO J FT#.;)L3(7?Y0/ZY='I8-F6[$>,U;TM3
MSJ/"IA=4,J>6,=(V MH'".L@PLX5<K()32+C(]E=/DXI/D!:EU=1R=(S.M2)
M?A/-<&YBJ\N%8*VG2]GWSM7DF"I#T=!48,@++-DD-8*"FGVK4QV-0C;@2C3[
M8CF!"BIL<15LT+_%@ M!CBTQY**:HMRD+@NA Q.AG$&."9J6 BVS;)F4R*Y+
M@&.QKJ@Z=DW*>!?,,S5M7\?![2RI-/4?:%RCE-8:2.M"$4<=:,P@(1"T)3R7
M1'TBWJ4-1.-,!(VA.6;:$Z!":9XEXB2A":(^,?=%H[DO"8/##X^FK*!59+,J
MYN,;.3B;X=!H]5J(@UH2[&8QY8/=M3U4U1Y:[_/D0E%RGF'L9*!O(Q);$L:*
M^)3B%+.O-R2TK3WL6.JUFL9@T)%VTR;+)'9T0(J8*_*K@6'E/K5XGSCT,%E=
MRE'TJ3/2\/AI3D]?>;O4J7Z=.E6:.M6J4Z=V2YTR_U^SV2].G=J+""Q/;,@D
M*_QV=__E[N//VD_OO]S<_7:?RE<X .>M!4?B[4"?WT))K(?S4^1KV;8O5N1C
M(P=GA5/E)A18$H,C^8Q),N!6B['GR,85'^_^^M"033\J>+W4I,V%#S@VS0VU
ML,)=2W<+P:L2?"X#'6@''/HX+?I;>E"W%S#1J<2CUA3Q$/9[1BTV]%2.@'0&
M-7(&,_#&<^ #;*@@.EM0.PW??K =-I-A9^H@HK2N,W!@O,02&#P_L<#R[:5L
MV\)[!8KZ;8ICM_\E]Z3)7@?V.XG:<Z7FC# 8G(,P^//^O?;I@_['YT^W[]__
M=&["X&SX_^_MKAD?;3'T6?86HL9)OH<3H(/$)PI,)W;ULM)E#1,:6\$R!N.5
MX)&PY.%@WYAOV4$,R]^F#QY'2$.B4S_3J'3Q\&0K*-!J1F=4-NB)@2#0QC@0
M%./Y.$ \<U>03.:4MPG@X2X]&ON;W"-L PM*1I>%6QX( 3KS9!2LZ& :.=8Y
M@1[;!]_L5] -ST'0_73WU]U/[S_^I/WQZ;>[VW^?F: [3ZM'SOM%239A8'V@
M=0 LBO$B$FD47@*8[0G&F#VWR-H0+?'6&#H-_6^F6%-)Q%K,/X0O:5/>&P(<
M:9=<6<I5].)FR[P-'L:T^:QL#E'<W<_%T!]? @PC%R<3^GP>-L-H-H K XZX
M1/*ZV)%LN:B)QG6/7N1,4&B)1FTX>AM@%=8*OO&C9V(?O&E2N96>79X>/\[C
M^WQ5/B98?GD*WW6I(54<:S<T?J5"6!41",^%-:3 5&>A&['0C$<A)T%[0Y&M
M4Y.GYU#SN>(=X 1V (\M,)61/8!"R,N[9\)!VP8,!G7 H#1@T*X#!OLB[P+U
MBOJU=;J"K$U:]_>;CS<_O__]_<<O(OWH7OOI[O[VS_O[NT\?]9N//\'_W_SV
M[_N[>QV\D ]W'V\^WM[=_*;??OKXT]T7^<SG]_=__O:%'OGTQ_O/-TJ]UXGD
M3Z8:ZMP5.=XAS)F6])%'C171R"<QVMYT5H$=2/55J&'HR0*%A"UGA3X$5D7%
M/6.D4\2@!,I-0Z%%]\#Q EH0PB](2]'*I*>]D/>%!6WJJ=HI_FHJ:,!="9-B
M"=3+=*(S)V"/^#Y7_3;>B,W$D!<$57ZSH7]2U:L*#)D\8\9<,%$P98IG.9D6
M7JS1U1;MZ\_&?4,J5S!:X,]L2:FK\%SD\EZ]O$\TYOA=B=@&O?7SS<T?(E3Q
M%A.4XJLX0TOK_ (,%6(BV?[Z36,G7X>ZH9)1,S-=^Q]3W &&2HDAY284H,$D
MCQ!?%M::XHK!UR*+;#3,=J3W )@E*"XFV[OB-0I/$N#F Z9IV=X$W*8T-]DG
MY6O@%0D, G(Q[&T'6L#X'2%F>H#A3#,B'L&,NW8\CWSJA*!D7^7R)XBO%)OU
MP83#B@)I*1JZ;P=?.6%&KD@RPHBD1B:D12+!,O%B#%[@ R2X4*'&NQAJ!&R
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MQO@MBEZ1OQ /[L* #1U0DNV2Q,:$=_?]RPA"5 ,&W!><F.6!.\/<!]OW7+1
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MS]]MJ ;AA\1 T.@V+PB#,W%SSC5,L9\ /6%:">**+'69ETE_-N);UIF'0B<
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M18"H8 [V*";JD.F*Y;%8#(9U9C^:[NRK!W+CJ\U34K#B>LF\I>A 8[O_X4F
M4S(+X!,N,6FR@[@':H"%TMCRQY>HP+8HH9@C%@]72,2;AGCF)=-*M:F-1 AR
M@TI9%=>CL-83&8SS4:'XSG9W+FP+I&4#Q;O6P)5.A1&%4G5@:'\FPL]X7:"E
M2FC#N" NIW.5PNE$" B5(4/G(JMSR1OD^/%H KO87@ NY+.$N=C% .R8K;S"
M>FNJ9?"<HGN"PK:LPLK80('"_$C:]Z$?5 1MQF!] 4V)MPD^ CAU\+$L^-BK
M@X_G2^556F_?2J^(1,S)FFR_(,U4V@,2F_U1JSBETR-:6^$*K\UH@#VW0[[?
MO;HC*<:H$W+41MUT '6D9B= 3\EJ7U)-Z'FF-Z;3XNR-<+[&9Y?=.V2?"!QG
M0_,\&J?%IJ*_=D]B+\U&SV2M5]W/IB1VKIF3//9X%Y@BF^2#$Q4_4A@>WW$F
M_]+%9A+=CE;0*_7].*D<]H#4_C^O6MU7:U8LLG\V&UP?!#G<V]_TWV'1N:SF
M^-\(_-E.T\CNI1!PD:2N I3:2YPN?"ZH[.\?D^UFN[L?9%W(;CO/DS3:^T?6
MG_>O]TT9N^ULY\5J-!\'S569 = !VY]1TV94=Y[_O>[/QE?M9M=H=X9&N]=[
M6UI>U6N_R5:;M<@[E@ Z;!I*@TN8B$%V,U*?OBG&1O:I])GB!\JP)%X995ZA
MDB*0.T9_V#=&S78I/%M_Z<A;^.XBH0;$MX"N^NV7AOC"0J?:+WK*#7:1WZ)S
MO\74*3!&G?[6W5;+]G6Y$ %="IEC&BO(,#$G4OIL)JE)E$W/\Y+$BL9:S^@<
MW,TS+ 6NYF]M[45M6_F[DW6R<WEQD3^VR3@I,#F*K)Q-4(&W1F @F?X;;]U+
M6GZ4(*>Z-;3U">Q@Q5_(*?>/?<C<M3KV ;X<Y+9K[MC? ;:/?8#DY+T,YC@Z
M;M_4F*VI]N)P>P*J/7*81G%.JP=N]M=OYNZO#]SJS%V\_A!$RW=7K;> G&CY
MKN0<%&]_3RU]BKWV)_#'^M#'^H6[!HX)ZX_ZF[9_&)B?*UH'PT:9%;P.W.(@
MS_-$4=L8MD9&J[\+GFK**V?H0:-[%(P^18O\/;=#EE<=>751H@5WUR+JINYE
MS@W!L3;O9ALE_72ZVFQZ[)7<MOM<)2IL&:U6U^CV!MM9-WO=5GTX99*WU7CJ
MN7Q7([H"HCM&J]T# ZOF@C,\G%Z[46;T'NY<#NMZ;7!(BU5J=W\*]0M>21%0
M?GSOOJM'OWT#V:I4"BOK$R\:.VRC"W\8NMT"@&J4;+0Z?:/5JQIW[Q8&$O:\
M\_J(]WG$K6:ST:R/][D>;\\8=;M&:U0?\;,]XC/AX.*$H/T.'FL7F!0ON2%\
M>0[,KC%M'K0NY:@#=W"_$[/T3*Q+59L741B%DI8PJ4DF.Z4JH[ 1._:EH8)8
MV5*(]Y"B*;CYG"G7<Z_3A5.\@#TU7S5I3QI9O!.X&>C6G%E?KZ.EVKYT[-!H
M4IPOG:J_XJUV%K;K^07%5G7/\'UGTF$N$)]PBU,N>!..DA[RHA\)3OIU5[E4
M.FS:\3JV@/FTZVT6UC8L+!1SXRP0^YPH(.F,RKO^A\F <"XJE+:H6/DO.LX\
MX"#@"$<%8(O0Y9P&LL_B3A2%9645TS/CYD38'&Z"77QEUP$Q89@Z[ZECK#Q0
M_=@(@TVJ9F[J&S,WM3ISL\[<K#,W]QQ0N[Q3KC,WGQERZ\S-2\[3JG/@GE4.
MW O!;$VUSXIJ+S-S4]W4+[_J]S>?7V9J5J=K-#O#.MUMGSAMEJ:RU C=":$4
M#&EOW'R-U'-%ZJ'R,I\L^I.&K1D\//G(]WK..V5Y=8S>J,QYW@MT%XZC?K-1
MIOAJ].#]?[/?-$:#FH3*5QOV&JW#H>>PEO5^!*AL?_V\SK6/]4>M44WYI:NU
MVGNC_*S/>N&8Z0P&1K]9:Y8UW%5:#72>IN9!"W[D)($Z57[;:IY.#]N6;7D]
M5-<Q'*6:IYS%]W0N6P4ZZR,!<[[9 [549M+4W'+"HQDV>G713UWT<_GYY'71
MS[,_XC,I&:B/MR[ZJ8_XDCFXI.CGD,G$%Y&E?MI)*&5?7S?4K%4/-2L=:M:O
MAYJ=(-'_?.M*<F4=<B@C#G549BT:6*[ASG@)&$ GQBYB04=@.O"/I8_C<^6$
MR:D366'$"]AP-C10"X"L6Y'OTW1CK&0)^/36/^]!FV _H:"AW>B]-V+I[,J/
M-)B43TQ-/;1FW/6/:HE*JJQ%K4^A"97V.")@;5<##EQ0"8J %FMKJ.QNO%**
M\; @14ZD3<%3;:^I_9C+I>]]LW'FI;,"P=)YHU7:7_Y/IICBRS&7JA0JF:NV
M9+[.3&M.?[\5V].O3!Q0/;5=-M'&S/$>WU*I5PI03NQ_WK_66UUCU&LAL#0M
MF0IZR@%)3W'SF4-52Z5=I6((M;@550)G#BA \>M6TQBU^Q*<9U @=#9B0Q8D
MKB\83 8:XQG",YW>0.&<B":2/WW,GZ%Q^K%0.R<4)VD-R08+7=5IY3$4-"H^
M1S==HS/L'YE>-J$\,T_PS$!+G:*6-(([-JC/CNMV+3O?6#!:I@9\[\$F-@K5
MFM)P;BK3OL68YO0<=V+2DNGM"32F$WC$J\"+_R0P!05 H5%!M?/TF408J H!
ME.R"_SU)F"O2A]FM:[FMBS)46"ST4 C$'3=I7_"+N/FK :LMP3R"EU$,I<4'
M]C)]0Z]@;\DW*%]LV$FJBC60*HD$%Q8[X9+!$FPL^P$6X;6Y;D3B%!8H/"I%
MD%ZA*,:MMIO_4K4WC?5NM_[U5@YU%_@,TI)5*Y.LF98#='1HIA23CE&@A-O]
MD=RK$=N$A2:!MKUM4JSS4R9(+,//G_\O75"E>EZD&,QV'SSG@80(DSQKHK.)
MNA</V>:5WL#(>,V3Z5T!YVNQ2>1+(83^B.LA<2Q-GQ_[Q 9(78L_[[GPFS&2
M<:"/0?1-@?TT8&G+L7')QSES=3!4_)6GV\@(%A!8,(UPP+R]6((@H_IT9E.+
M"YN[#.)=L/1-R3HATQ?D Q&S^N0'&^LDK(VN52SV<"/ZTK,)/7H(9\(AL_%!
M\$0 $B;D*WS<M2TN$\0?A#<5SN%9]0LZ0]D-J"4?Q=0??3L,856$!&26YX=R
MTA&@1TOV'B.$(X#<M1,.3SZ*I5,!BOMJ]F=MY1RHU04IG!+S96OG<6N[1C$H
MM T&145')6MBQ'U_I8D1MT!=9V)HV)&6FQC8E7.#B:&O,S$FS +I$5!X(;4A
M? &!I!50SRY]^+H/EBC@CP=)V 2E:DBK@"0.04*30 >S;\:EOKZP)]=<]7/S
M@_]A;D[(G #9YWN3"(55%&0"*E4]/_A^%&A@1I"M".^#>K#)K=SJ7'"',9UE
MK:]JE*:M-\OR(8O8."NP8UK-=NK\2JVFS#:U[0(I>AU(.;6PNW.URK0NE#0=
M.3 /<_%&3 ?>X[Y2D-@OTF[)VBKPB_$UA3E-$<Y-9%]#^RFB#Y*5YK.9:V+0
MDO?9D:'2[()JC$=(V& -X7'_ W^%M.6[=IA[1J-0C8D4/HM@$1W<R15O3B;-
MP0?@<&X /=@AN,<N=3);@F'$O49\C&Q)VT4)[^6@AN<GGA7ATSPR+3[.792Y
M!V2OF1:(DX4W23T0-/3/N\A].] KV'Y%"-9F-EK.8]L/YR>TR,8Q0XU/:)&-
MW]UZ@=HM[Z#@/#-A=-KK6_IX6<<QC7<<RQM95OJXUXYM/256E;O+W1MZ56O3
MQ4-]5?:S=4,ON8M=NU(H[Z]MP[4A;:/Z$'C9O?#>_J;_#HO. _T]W47\;^0R
MO=,T=F\VH>)BA[Y !T5E?_^8!+.NNQ]D7<AN.\^3--K[1Q8UQ=DO9>RVLYT7
MJ]%\'#0?K]]. 0HREF&PIF=&$0*R3Q5E$A8C9GVGBZNVT>P.C-&@N54?B[?G
M 7[QA+VM%S\ZTEM&NXD)PR\(Z<59J[4KM&-<!EP5[0G-D7.>RWA%EJIKRC@I
M72O!0U5;(6MQ*^3,TD&N)[)>]T0^TAR#)_<#??*+5?H<C]=7 I;W[]LU]^2'
M\18]D)4(SE,0LHLI?L+3*FVI>XK#XO[0G@[B&2.I_5*IM;1;Z"D.@CRE\R/6
ML\+1FQI#-16=$17M1]X]82OY\,">SSX50CDZ =5@UV ?IJ7&_[F]??_^PX?U
M\;A\'XRB?AG[E$[(SP01\/3,0Z<7A.*D$.?Y8,Y3R['WOU3E/KF[XJLWZAJC
M8?=B$71)N&X-&NUJ6_JNQERF%53;&/5'%TM:EX3K5JMQ*''P)(7SN+[5X1%5
M#.7=$QP8<@WV:PE4M/+WWCMD@Q^Q=S)K&\/>R.@4JYX36& O!>_#=KJ'N 3O
MNQJ'E7'8P2Z>1K=7J,UKVCT<[0X;_3/V?(ZOBGX8*XT#L_=_^P]EK*."+E$!
M;_MT($)3/W%@2@/$(H-WC4Y_>$;AP!=U *+M5XW\4R"_:W2;?:/;;M4'\!RH
MOS@-Z(6V+=DE[P? I=!B*JS8T!%X>860_%ZIBK0\-[ #K*F")Y:1;\VQK!+3
M>":VSZR0:VU,U-F^WXV6*2<JZF]AI8##(KX%_ 8 4^J.)FI]EU)%50S1)>0.
MG1-Q[=*@L%TW*"QM4#BH&Q2^$,ZI*)9Y.(Y"<4(@TV]X<*Y,%*L%KRC\0"[[
M,P37FTZQ6IOJ1FTI?T-S.L4":].7OQI[;A3PBG"'W@QU;*,!DA-5A*5"@$*W
M]'.I<OXIPR)LTZ8^ %04SQOL@*SV(QLASU6LBHQ0L3%1WILJ8C4TW'CD\(8!
ML@0VW4[%][&9(/T[G(.S.YM[4:@\$/=:*50QZF835<-\EM<U6IFNR7=Q.FE5
M:X8-3EO<"L#\['L!]:J8VKR;S8Q^P5<Z.(S/+,W[$BM>9RH!%&6&UR6P=0EL
M70);E\#6); ;,RCWAJQG4)M9H_F9E<#FIU95'5"EVICG4?'XK@];'G7:I="<
M>\7IA=;) LJ-_O"EH;VNE#UFI>P.+@[ZO=C04/5],]6P>EP-&U?!:G45[-:;
MJ>9O';P*=B?KY) 5LP6S,RM9.57&)B 8FZMB"Y%3W1HZQWK$$YUR:1'IH0Z9
MNU;'/L"7@]QVS1W[.\#2>L-#'2 Y>2^#.8Z.VZU&C]>8K:GV+'![ JJ]A##-
M^DVE@SB%^#M$>5.1;_T$NMZVUBE5OV3TARUC,"R;4']@F)\K6COMQF#_&"WC
M\6>.S);1ZPR,0;JBL:;1IZ*UW6L<!Z-/T1-_%]<QEJG,)VN$SW$Y2#43XNFD
ML4'['V*Z^M:DTC-:G;[1ZI5YY$??P\M .P5[VSM^H4;ZKK0^ZG:-UJA9H_VY
MTWKQ'=;%76N<S256,G.,?<,966(PV&Q=.J;^:#L.#0VWL<-KZ.GCU*1T_<'T
M;2\*<-Q8Z/GJ]!N,_\^8-_/-Y=RV=,>S*(47LX QG3:9@*KAM,-XS*F!MV"/
M#+YJBF&*/@ZYF?&9XGAEQ@<5 K;XJ*T@&A=D(\<CI>)47CYY1F1"QY/28 L+
M\S^>KRWAO85IL8A,'QI":+HV'HH)L,#[8KP73F9D,R^T:?Y4,J"Q3O%5@/E$
M(^;P.)#4W$#.#ZSS>@_!S_+66?-R:)>% DKI ":H WO%&?2F_Y6EWR$A0)/B
M')Z2/UG8+BR":S^P^+FB_'FQLE:VLL\42 +/LN$3F,-OKEVU C#P-1N'HHKI
MOSBOSV>P/%4Q@!Q+4./0,,#/G_[$4@.&<L1!>>>Y.&)UZ04F<3L-&:,/LO]&
M]C*>U)HNGZB97F5Z,4T61Q36['X,=E<0+AD]2'/ZHPE,XO-."GQB(HZQ7($K
M[^!TXII^%6#N,)"/Q4]"IM0T? 0:MC-(IQ&/KA7Y/B\!([+%NBHP/='XD\]?
MCQDO&!Y[OD]I634M*\!\,;\1VDX/SKG,N;XU5["*?A> X)O4XZP/Y5IR]O7\
MI1?/F$;'*XU]GOT8\!'WT?@_V#L YRR;W] ,$PK-\W7+7-J8_S@#VR[0(X (
M?H>B 8RQS(J.^=C0[UP=0\J\4C1:PEI+>(JFVD_!NJ.Y\1,^+16\/3;WG D-
M2G6]['+H;.*?>;KG-^X&@^MK+\!"/&2VY<7PTR^>.^.0_ K_JOEIK_ST)Y*Z
MAHP3/GK7H<U0&_(034#TB,Q%XX,!&$-/GP5_@ 5([2'WN10FRSRK+DKJEL:G
MDP?$_Z+)8>/H1/G@5_E@44[X:.#,6F:H#^$8WL3UFU/;!\W^RZ^OV_RI!7"1
MJ)&6WQ6!F?]&@+3I"K^#-TQ+':O(PY4AQR%S2,8>>'SYY21SPA[XY.%6O]%[
MPPO:E>\H"V,("(6/\ED)<P6$:T5!L?CCICX%DX5>P*]R6&K>V!MOW%B@7E P
M.RN#6&0=10>@0QPK$L/B)7UZ[B;RQ#^#E4GCX:DG 0L"2D^7JU,H0E":)M;S
M&08A*."QYM4CT\)^%,JZ!B^=NL%+:8.78=W@93]D>@KI5(%UOLQ-&RW&VO[9
M>[U5? .3<R@DTLFTX7H7K0#/=R:/8/0(!Z*AWXA;G%5Z!2\*T39",1^O9 ?)
M0G88Y(P?,G<\#+91H$WRL= 4XP@> C$/RL;W;;%* B>W1.)OQ:!(3T?:%PA%
MN_D& 4=^!R3*#6AHK.#B9*K ZO$75738@6KH@1UBNR 4LZX,O&TQ/S31,P/A
M1::1HJ4$3%>L,6L8<;C%2-PG0_.]E>F$-F_YXX*#%G [372[H=8_;WGO'P5O
M:6Q(\TAH:1'A=U9ZJ_?&T-DWBRUY*[GDN^(&#IYN-=\8&OP$X/(8*+?.%N9*
M-Y=+6(2[BJG&/'R?HN4A?99N($]Y;W<NKMRMN1A[$]NLA=C>A5@0 L6;_B2F
M]T+F1SI/Q!VY/ P,&A<C%\!\P)=V,*>[<F0D>5S43@M%H.5@TZRI3>8F7:=%
M"UJ%NGGA%Y;FBOF!)N7+A^K?*_Y&L,!+\7AA0]RTE\@U>>_GS4"4!. ^:ORW
M)!R:;U!8$5AWKOY@PQD)J6JZ;H2MO2+?]<0E!O\,B40I#JC;EUCKUU\^M_2Q
ML.)A5?BY'_^,2)82BHOAQ8+Y> .I!8R2%PQU??(=\$YE0KZ@*?!*)SR1#UVD
M+7\JT'Y=^;/5/\@1M: Y7/0U90$4LJ0P<<P9L".UWQ.,)AYAIN\"A<?F5$/_
MZ+G7,IZD._".DT11$J,D"F.K1,-<G ?^@.C!!\"4R!@4:0EI9,-5(B])P(W\
M*< TP]"WQQ$:=!@Z1GF1?)1$A1EJ96*MH?^1K)L+$IA)\ :D$YH-):ART (S
ML2T =IYED\BB#*>3WD1)HCWM%=1GAET:Z2!$+A#@Y=1 '0<UAUB3[O2P_=D"
MEIB+[@]86(^<)[N@Z=C=2[]%S80:B_+EXG>T\G<ZV9O+PPJZN& N?2!U3[UC
MMJ%26NG],/;%O!S>5"_Y.2:2Y%=GW$#NO+!TY,9S3RKB'/3?% *25-OLO1%2
MK@G:^E(I;.'4-T;-,VGCM#7T+3B"?GMWZ ]0HU7"8OD9PCLWFTO+YC45UE5/
M;KN5!/*OVD:S.S!&@V9%CLQ#\_;RD= RVDTLG7DR$@XKD"H5DA3U]EN'^ZJ8
MK=ZS;].*!X*FI)7=T43'<7:Y^<$CHGP78,Z 18KJ+\X.3V<%S $T;/Z#]VOK
M+@Z,E:M>WQA4D65O#PU(VQ@.!Y7A."P[Y7N7E"CWGS?7H%R^F3#LC^!L^B_<
M4FIWC/:PJIM[$+JM%>]%*MY2X4&#3?5\>=[EL\NHW3?ZK>$+EQC]OM$:M&J)
M44N,?4F,Q(*7"3E8I?H,N*4]'& P[R4+C/:H8W2'HUI<U.)B>\]>K?F]DG;$
M6T-WV:&#82_Z^"KZ^-FF9J-EYLR.<5 #H]7-"=@3G=/0Z+5SUN$IN:S2B<6E
MX+*;P4%QU&H;HW;.>CS1@77Z.<_WC+@JHQO7'5U<Q7_IYD*KW31:_5S@[B59
M3*VFT>U7O5(_W[NK3?&!"KK]DL^P:31'O1=-QD:OCA*\++MQ3V;_G1H$T'D]
M(%4L'?S6J /^^F!8P3HY_+71J&<T^[D,AF,PRM:W17_$\\"GGJ\D7S^#D&_<
M"G1',58,RL6AX6K8,0;MW#7FQ=DD6#X0%@<9G[](Z0R& ,EQ[J*?*E)^8T'P
M/9J"O%^AK'^@-.G0TUW/O:8^J![/,9"5FY<O<*[@C%ZT^S-H&L/1[IE[9V7*
MY,F[NRR203GZIO:]2M<F60YXRROQ-F&GN\L1PTNB8+A2%O!6:\0B:-0W>MV-
MOFUW1^(^P+ZWH.R-FV\.@+0W*M'UFZ\=HA?H$/&8.I;A@D1@+E85']6(>=%G
M>("P[0?9\(+:^UDK/?1--Q"]/\T)5L=BY>;%Z_(V*/-V9_?K[V?B/750[N^>
M8G>ZZR(9JSV=Y+EJM09@,>0"J:=PG[IHF>9LES-VG\*"PWMA[A2XO-T\];PT
M 735;QGMUDF#\8?TI]8(J4V.%0'Q3)RKUJAGC#:[SL_2N6H/1D758A7W?B!3
M\7SMX;,"YM@VS7O3I[ZE2_"I2!9P8"C4W_H7_V%L!K9%Y2\3V\&^*[OA+<?8
M17S;;#0K9*$<W+YI-GK5H]3[Y)(?L[C6N1; _C2P*K;EI&,*J)DA]ABSL0?W
M0;'1:AJM[LCHY'-W3\18_6;+&'8JW <6<59ZJ-P^.[7(KQVBDTI1>YEUK7F[
M=6O>TM:\H[HU[TD(F'H9_9N9ONBD\A.SV&+,?/[93HOW),KT,5KWO ;/MR70
MV1Y&Q^XNI2*OI,?45IV-JL-;K0?2MIV-BJ1JW,%IKS-)2US(G:>KQHV!^MDV
M46L\Q4JM@S8!]<'S"0KTH(AP&1)NTAXH1\$E2*K>,NA@0[^?%2&TCTT(O _4
ML<_VY2"W73..BD.^ /[Y>QWG)MG6?L5GI4_N<I1_WK\^[BX/[&!OZ*NV'MJD
MZUHA1I2>87N@YQ+("U<O"A,]@8"5GFD;/E5Q,'RKTS=:O3*!>_R=U4>4.Z)1
MMVNT,!Y[FB/:9XAF_<?S;?12.WXR$>SUF+<^R*N.T>UUC4Y_6&'%*N"]?6;X
MZ1K=9M_H8E'? ?!S\DNG3>"F._154^Q/%XR'EH;[$($MHS]L&8-A;[=O['\/
M+P7MO<[ &/1'1T7[\=1-(0(O7(A67FUGT&H$G=!'V@/+%76YK ^XYH"SX(#*
M34'70[6I9>AS.LZKUM!H=LJ\PY?N4V!T U-F+\ZAV-I[J-)I]5D=;0LP-S*H
M\TI-^H7X:8ZZQJA?%N\_'?7O2<K?1!,;)]#1Z,QG=GB=?AL3AVK2+L3.P!@U
M#Q-%.R^A+M"6>V9J+FQG]?VF<4P_C'E*,T].+K#[E7R+.O"1$IW]SH@7F!XJ
M\I%ER1KE+4!YLU2;[QWE=9SIG)W(&D'/)\XDVT'6\B[Y0+=MM+MEEGE]GW$0
MG'=&0V/0/.XE4JUESEF(U@BZ>"VSMOMG?=0U+YP%+^PIXJ52^_,ZO%8+R](&
M-7F7KM;N&,W6O@*"1Q?UVP*8ZR7_G(ZRU]I7\/)9$OJ^\O_.4X;G6^T_I\.[
MZN)0K_K>HA@Y@X$QZ.U+R5U8>FN5;OUUM"+Y $W'Z]<1HJ/>0O2ZQJ!5QJ#U
M%<192=/:(;Y@A_@H*D?,?T@/?JCEG>)U-X=&M]09J97,8:XANAUC-#PNTL_
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M]H G*;$U/_@BO7G)ZHS7C('@*PU-O/WG&Z^,1U +R[*8Q>K#8-10C*M@'#/
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MCLJS40XYI%[I\ZNFE)ZA9(8*@)5F['UN0SOZS>-U8 L"S5.2E3P!PD\R%EJ
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MM 9/D;*%G$,V@5,60%ZH.;SL=L?TW8S9<@"MK])-<"H<,1[W3C-L[]<<H><
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MX':6/>)&%0?6 E[!E;"=+K79PU3]ZKV[?E\/@K>HQ9FH:V:D*.P7SP@W\K\
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M>\; WH!TJ[F=IWZM][LWOC5$WR8;?,1P^>5ZLA#BZBQU!E!UTN6[&M9PESZ
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MS(UA\D;FI6JX# F#_YBCT(A#0ARKD5GQEB62-['$UV8.*!I8H8?77FGL D@
M2U]N]CZF/UAZJH?3J ^%K'';.M;371WKQCK6PUT=ZR/,]?T.3?S:*T_YKH1B
MXOL&A/6L&]_;2I7/U^]VT-VSSY6Z^\!P1]+-TDJ)!XER?O4#%U5>[<C!_G (
M"QU4!H4ZVFM-+ZAQZ4(B=)J^7#.%1-G-N%J5#(*%IUWQTJ&G477 /JRSEN@
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M:_M$QBT; Q3*=+;4_E2B]C\%)!1K.R[3D6'@<H 43-L>^J$,!V#]U'TQOJS
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M9>;@9KDR=MF]RU7?WGZZ7/U^SXAR-V#XR)X>[I\=[(=&!M[!&>!X)7VDN_\
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M=^A,P<WL7GPU+X(BSU8T@H1[Q3U*YC3W!NOW@H.D#D^9)^./>\VR\BF2LZ(
MGV75&:TTF2_2'+S-YH-GN$GH=711!.AHG15"@C%N-867R30I2VFII;=B;0[V
MO^'>[$PY@.T/^,/A-\\?CD'S027LML#*ISM@Y8W RH<[8.7'*N.C;P6- 8KC
MY[C\F( ":H>D\F>05-PEL*0KO@#-ZJCDB^.*="S=], O*(MF)K!!E:!A)+'
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M68&BJ9SOPG4Q&H?M>Q?/-?,^R/[$BH]^P/ED561%7"<K%71"%WVBFL5J%GN
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M@= A?+76]JH9YVZ=<:[,.!_4&>=ULW<.,[2U'LS0!16H#T(2/3J^/+PX.4<
M4004O7S?NSAV#WOG)U>]T^\.472)_;(^0(\8"K "2/K_PF/$@U#\\-OAV$_
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M<3,0\Q:]LL(>V!]SMP*Z<-NY, C!VMJ?I-TQNL6HVB,AMU<=-F6LP-8$ZX9
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M.:>GYQYMP)]1_"7[5\.55+IE5+[]XX0HFO_BL^L \:CGOM^%]],H\QA-07H
M?:U@&R@"KK'.63JLDHR--19SU[6["=?U^%_GQQ=7]45=-CN5A4(T,"@924#*
M[R(\N1VYIYA1E!WF(_=(# 1%'CLM#]%#.[HP&4TLV0R!([M"[M<U,1T#&ME
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M0GH)!C ^A3[ &'6)IT!:+\Q':O1)Q!^PFHD]Z=GA+XU@5/FWO1*PM7&6^S0
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M'%O"ZOBQ+/.28'TJN:\FN3/R5>%\(_-0A]EARU&B,@$I*2)D*(*\4MEN53]
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M65(I(GC*>I9 LT.3)?Z]'-DDY8IG&%.9>(D%\"$)#=V,Z9@JPBOC1EM'&87
MFDTI3,>13[:BC%Y/2P-)!K;C"_ ;K%]7H4KPX&<3FE> I>?^>" !VE&WX3S+
M)*N7-2.@YW.M9U^7JLC "<O=6$PDFG[V)$<-\+&;L?"[$YQ)B1,M\5CJR[&^
M#$'JE,2V<G$Q;$0S^ZYD@*Q8+&16X5O9XNKR?SQJ?I#S=ID'Y6K[Y6-JCE@;
MG7\+?I/GD1WLT\[)>G5;_*O;]P=?KD&6A4.<"![%OV T(!5+C6(KW*K'U'MD
MV6VR@<K*."KOIE/2,*/)DI_)W/_5"@^*63.4-$:EI:DLG+D^=4F4;MO=HGI8
MH\@U(^DH<P6WO5QA:;'Z4LDI5I665ZB3I#IPF-LBL.FHC@"T9F@%?8^!A0(Y
MHODCO[(L\%[8([0CG=Q2EE[!BL13NL^?I1'.O^$Y?3H5J#*Z\]:#9@6> 0(D
M>7KF&$\%5!E+ D3SY81)@Z9LUDYJX.L7GN%0=IIRC>JKB8Z^YQ>TK?H'\M=K
MR?(AZZ:9[.Y4A/.7J/\I$O/(FAZGNJ:G\IV/J-,A[T5C15A5.T]9B9.OKOGV
M$G\3-=/*E;K[=5%N65%NNR[*?;DU%X\*&)!(=XK*+1=ZTH$#)7)S(424DIE:
MKC"DR,!P,U]\JU3H.R5"?YOF-\O.W0J%'4EE7&%@>1@<R^65J@T)"D^HP87&
M$^G/U84$M9A>-X=F>^^8>Y\+;.5395F(JX0;5K:TO1S?. OX!BEH-;/$[%^S
M"![- 2Y,AYC)VI/M)?J^\MU9.G! J1:SD! ,(_JQ9-F4^SLYR2<P%3.7IF"K
M7^S:+W:J7^QQ+HB_HO(]QA3%PNVBY$9]N;[%Y2KFE>BTJ B3V%5B1N1,_9Q<
MU_ 2BMGU]\M2?5*Y2+^O5';S$R7K_/&Y=ZZ>55+\)?]R%?M#_OJ]Y62R*Z5+
M#,K8T#%?7==T/C+"]M:*L+T(RM4FOP1RK\KZ5I\\G%8>H?:<%0)D1J#B[9*!
M"LXU\4HT+IJL<]TI@PURCI6<,@U<.SBVN&818WFY6J/*YWIE8LEA^;A,;.JM
M%28AC!HS469:$C^V)*J=H5[-%-3;8%A4I8XRJ%>3H#R0LE2.+K4M.5@=Y R@
M17D'EL>Q[2V]V:4+>,!>.R5Q0&9?5WL 3+)KD[Q"_,LX6((F16!,@=EPU8W@
MT$6#(V>(]>+#?FPVFLW6PV)F3R;'^+^<$/C.;*A\ 6[!Z4716O*!M]D'8E%:
MIOMVN3+=*KS%?*5NAK>8;TWC\DT;[.5Y6],V'9L1S1@"E9+0IB_#*'@I5RCK
M5FGOEW6K9,BPY#+S2>1P84M@,5<&<';TI9)35$K>9U/&I0)XR^9CGJV&IM9P
MKI9Y9+(ZQ BL:QJ%F>VG,%DK7R4+BNVXWB/3;>6!.\J4M;W67ML[V#E@E9JC
MRRG=@C*$V\72K].4K0HOY9*\%#I1']KX@P/!S9-DH$S!* '3FJW'']L'7G<?
MP17VJ$@Q.]Y0I&J\3))5&)9=\H##$1@1YD(K_&6.@9?%53K0V,LV/ESQL3DD
M2'T#\B)G?B\<:GX2(1829PDR$5L(\IZ 2F[M>;L'^][!WFY6R48%:]CU@5M1
M3;-CO_1M'G[1#+X%1B03[,Z=YH&B5.YXOD\:OYHY;;+ T\.<9B:_N2T/:^"(
M= 68LW6WG>>.?:^SQ\>!:%$F1^![)&,9H/X*8;!Z\5YNNV -3O6G]?EX%,+*
M4=?:]UK=CM>$,UB.O,7I:<>FKIH9"GO,#G*YNX I=M7PN:00=Q;2RHR1N*T#
M;W^OY1UT=CP*S14VJ?6HW7%,%*[*W7G[B-W).5/$W__-K</Y$9322JR87TT)
M9$AQ->5X%7HUSG)GK1$XY#PEN,25'F(!7%9&_E%@:Y0$BV;'Z-ZO@Z*K5QX<
MU)4'994'G;KRX$5?@D7SO:2]AO:%*J]R+L&=&L[&(OFE'KNZ3/TZV"HCO8U9
ME5JBMI$'+])\O$B.Z.L+GKHH@I0A2.5(2Q[.1;"<8-RHWQAIL$AU_:,GR75Q
MZO,J=HR*)6L)+FB2/$!#">F)'.K)Z#8,@$H/3Z-7&VIZU("\_88&K2+(UI);
MY>I;M<F7*N6)H&(\GJ+3%U[__8?F#_0S?&&@?EZ9Q+M@F-[\0D476C'BK Q_
MF@!EZE\_H!S_6QI+<9X.U8L(963@C]7I@.;0SSSXJ:!J^R6J=M$QJA#%1^1P
MXWS2X4K4M'Y:\0!*GK]H-;^Z>0KXH]F6X"X_C)N/1#*( W+]\ML _XGE <W=
MB6+?07S=WVHWNUZ[L^^U=W:V?]!+7D!0I]$JVZA'[_!#]L9W;V(Q^OL/-VDZ
M37[Y^>>[N[M&(@:-Z^CVYUX\N '+//E9#*_]^.>AG_H_MP[V6[N[[9_!-6DU
M6YV]W7:[TVSN=7;V?AZ-NNUFN_-O'^]4"R<@^X._&C?IY'^N]IIM4"@3RN<Y
M"CKO0I!D'BXY-QI_/)_U#R,L@*\"B0>/HQ>&XBLG,^CC6B-8B/U(1*;3%#S]
MNS===^M=,$9OI.%V.ITW[;V==G-_VY,!O3(T\ZIIK_#_S@9IA/YOF^?Z=+;_
M]K._)N[[S%TO2[-<^W__]W^?D>M,OEJ1K=JMSD&SV>XV]SO=UL[/PF^V6SN[
M^YUF2WR% _EW*.ZN18B,M="$88Y[*+>9D7?&G;D44^ 8.M%.'GK&_V;RI+NA
M\N2AY]YI[7:[=.[-3A=D"IQ[^TW+.O?+J1B *N9[?#CV$XP5V2$F]Q"WG<8L
MB_QISI<@2FFVL_$6N3$6[>:;=X9$("J6EPH\@$[.R_QF(J';:+]^KFE7<XU*
M#ZV!3=K+L4D^0J\4X3.SR2/D3.?%<LS^[O[>W@YQ3*O9W=TY:&/U5K.Y^W,Z
M:<,_=KK#5O??XFOW39MY117I(*T&=C#K@:P,C,=(MKW""-[+PQ[]XA!(#T*L
MZ4*O*0*;E\"-@(_<_^=/X("N8LP/+F8Y%C*1-5<3S1UXD39Q#N74G8OBU)T'
MV2_9.CE1WOZ&TJJ[D;RWJLTLQ56GN0\V<4?9S'X+.6]/FL[,@'AR1"T;)K.)
MQI15DLL8^KB4H.HV]E2>,!\MJ>A(E Q$9+P@V_C!$FZGT7I>,_GIU>+^?FM?
M&M%[W?TFJL6=G#%U-@5?3?I$F*F[#D3\K>YYJ_F"C5E#R>A[WFIW#W#_6WN=
MO9T.6[)\S:5W_,-O'T1\+>)R3<.%L9D<9L3+CM8W//$)E8!GC)(_Q>YO#+4J
M2&_*-AKSC4H^RF/8B8JJP?&<KK3GM5_.^L4/KF!@5Z@PHF/]:FQW<V0-CJA[
M59S>W=]MM9'3]\$$;Y9R.A58,:/K*0VJ IXN0?$"_&,6"E5MOS3;9[A)EP;C
M>S;K,AT%UGTV%I?LS6+WL2S.V]3YQF$FX.E7X2)HGC[H@)E&/'W0W=\KY6FN
MU%V-J8_$@,-(N^OE:Z*B7':_4-&=WZD-D=R;Z8P\C,N[(*Z[N[L<.FF!46^R
M.?/XU4T0K\CB'WQXN]M2]=6UW"[G;]ZFW6\<"P2.WGD-'#TWM--JOMF1(AOC
M,$3J<3*(H[LE CQ/%=\A*DHY$,_DV0(\1,83!'D>(V-W7P-'5OJ!P(T%4^*/
M".?-ZKCPY6Q*I_Q0IU )PQ(_SA:4)1_0PIFHT0(:G[ZT3[FDJ$67_UED[5.Z
M@2O+V[W7SMWM@O-G!C3+,K,79A#R@B?7KQKC1*]ZL=3D@.;&,M-CI.;^1O+5
M \/DI5F][IM]*WQI\M4I*. WGZ9+LXW0H?']7/+/"(TOSND='^J$'5'RK7.[
MP <'&\D':_-0#/6IW7 SKUKL?BJ8=NV#.<[)5<8)GGLJKOW!?:;@/!.K&;\I
MG2!T."Q^(U(>H??6Y%\0&>OW,1XCIEK-5\^?[<IT'C63*D_"X+3\G+QUJCQ[
MN.S+]E5;KRE%5,X\'8MY>H,O870'1W;-K0REJ:+%$9>\'&,'%LSX(2QQ:6;K
MY)F-B[">0G M9K:?J;3[&2 9^IJ!GK#,O:P1:M66KU:S;ODJ:_GJUBU?R_+;
M*G)T(ULMUF;(J ?IKHQ%NX/:J32MFWO2.CHJ'ML7L?[:?[;+#RS==8XHC$0Z
M*!T1([(&*"(TS3%TBE-F=:K7#]FC9JP,T&3*1GI[)(.I[]VKX\/W\,T&:+.K
M(X[Z,VS'.SQK NDZOPDCA%(+;]S3%"</AM?C(+GAP"S/W=DF@I:/3QT\K'!J
M8=$4D;$YA5.K6V*;F>Y=(S>WFS8WQ]$4]I(#YA5LC*GX-E<L-#,>OCS[I_O^
MN/?Q]P?S[&K)@W;SB7CV(;7,FUCLA^R[F7G<=;*O'27Y$ SBZ%)%U)E_Y9RH
MVV @DBJO@F,EK8.,G1<P,$5%U,MX%"R#MOOCU4(D[=;WP<:KB][-S-BNDW?M
M",H'/_0-_Y?R_4-L,V0FN!5SN/AC=,ME)"U=KU_%Q[]?NH=D"&=\# ]X'XW1
MF$U8.J_$P.WO@X$?)8<W,]>[3E[N/%(.4W+!<_<7RF&+?QMK%,2=[X./5Q?$
MFYG*72?S=FWF%4/<1P[[16$R&V/9@N+=DA)>Y=?EW;HE9.\B.WDE#NY^'QS\
M*$G\.O+'\YAYQV+F"\)2PZ#5HL2A*D7U%&SLBE9$W' O@YGG?L;+\FZ&4?GQ
M*,Z7R2QDXIWO@XE7%\.;F?%>)^?NYNQA'!9(]%:;#;I^NOT0RW>MTG?W^V#<
M1S4$;696?)T\/*?)5=?LX$R"RQ38ZII:\H\G_?@^2CSW^/HZX1K$RREA:RN3
M8P66OA#3.!K.&'/R^"L&\X W\,^KA83;#^REW9B0\$*1.X?OE\B"M#<S1[_>
M0K1VJ[(2+4NR_PZ;/-4UL80IS0 E)R%FW) /S\<+$_!9I5J[M;!4+:MO7%2N
MMDJIVD,29P]DGM?4&;F6ZK6L\6!^Y39)B7_T_NF>4>WX+&39\<>)>WIZ6%4!
MMT)BH=NHY+Z!K ")%U> F S8?0P#KE=D;68RZQO4I#T+DUD,QMTX!K3)!C'9
MDTFYS<P^/51#[A[L[^\QTD1KI[7/&C('V[6TF$MS59&JZ:3/E9$R)LJS-?:6
M8; E)!C1M#J#V>.--D&.[;P*K#^.U2R/]O=.#KVR)%F>CQ9(+9NCEL#V>T9I
ML9DYDH<>^%YWM\7V=*M]L+=7)BTJU=/##E4->_JV<D(- B(Y43P>9C'GT?&R
MI0K71OXD&-__LJCVKLB-N^4@/4]0XU8*9IX5OJUS5>MAZ^;^3D<JP7;[@.38
M;HZO3T6J G<TP./SYT///6\<-C!TX,<T_I+PMUN[[ZC14SMR2T8G=JN-=#\,
M<<#.BIZBO$#-;]M"\M"#;;?6C"GU IAN/\]S@03> ;ZXG/638!CX-,MF.9;:
M7YZC%G$3-R\\&4<MSAL\F(TZZT>'>S*,MW8GQP +5/K#=NF'WS#_BVJ095I.
MGND5+S2C-DI<(%CV$YTRG=%!M[LGSV@5-.NUGM%9*!+89$*6C&DV(SC\:S^O
M)[V,G?5?QJ<W>Y> 8WSL.2LQ3SB.)-]Y8B5XSTJ<[S1:V]8IOQQ=WMU4(;RW
MV^DTE4/3WGLS,D_U?Y+@^M_-YNZ3W7'JLJ L6II&<2CN7]!=/MC[MIB?FV:[
M'>SE),+AV+_# ^&@630.!O<Y:VQ96"O<ZD<;<EQR\"I<@U:SU3CY>/GD>N2A
M])V$XR 4[K_>7IRZ)R%.7H;S/(H&,YH:O>D6,^[NY>'[%[&[5_[7*(PF]W!5
M4A%28AU'6TW\=6_WL_'U8>_TI>[\H3\>S+CKR3T-PB\XT)>H>%&L?W3\[J4>
MP)$8!6'PY/O_;'?AM/?VI1[%J=\78WT*+^L&G%\<O]1M/X\%.E-/+X.>Z0YT
M-_8@#B/8*0)JX/84GVOSCL!D=JE.;HN'@DKD0SXWHH/.CK+#\$P??FLYN<"
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M?LZ1N$@D]A!QO].+XK7#H''(>/2E1?0NXUC=C\%*M.ZR-QCU+O..VRU(95L
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M%^]N)14;3E1L "XPA(R^P [, .-_M\^#-):W&!,F!K.LD)V^.^=T08'@KRS
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MHWIRMPCB27&VGT:51%79>_,7G^QT5'+)1OW'(Q>ZDJ:%VK*UM]KGXYVX3N,
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M:O6\VC4YBY4CE5)HUCNIYDFEULBO>;*XI6=<F16)HTZ@G5&I-?-L9^2*JUA
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MK';UM?$B;3+@MS\DO X !5_]9U6N;C5R7Q51KYPK.7%L*5;=4N&\]%@.W"W
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MQ9\6SE&9HRN?!I4*)DL/C<KB&J[7Y$$S:*)L;EM3XF" !%Z8DA.S67-SXBD
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M3$I^+E.LX2L1OPI/LMV&6>OZ5Z*\S+X-QRA_Z*QY_7R_+3E+]8H;AH\N0A&
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M/"A@YJ5Q>\!-8=6GCFP)8L@F$SP',(P%8@\XYX6^!T0DTC=(T[<Z12\-BO\
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MYMYV4T^[FQJ9#\)T&X;'0IZZV/%8Q%TN=21)J@O-Z;6BJS)'I4;@OK![H![
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M.< PI)XXU@G9$5>/U]%.]V"G:V+CS!4<8%Y>)#S%]15/X7>FA9DR;!(I;QP
MM:2\"SO,DS9C!+'.("O&6P9*)JZ*AD.M)-"IE)38KA2#DV,312X62A*?"8N=
MKWW.#-<+?"(850""BL2CP5RA?G+"JC>&2&;^_@J\M3?PEEZ!MY+ 6YT*O%6!
MMRKP5@7>JL!;F4%8W9S@K4Y6\-:-X6(99.^>N8]CT*OR&BP;QHG9*>T]56Q)
MR=-R*9A1HGJXF).T4C)0_E"-$U2P9^C?8TLD"Z+5-_>/09"05R!&DV#1WFC7
M MC6,OG%\Q?J)\.#$P4CJJ:GA-GH7M3IB-Y<J@D09$\AK,N93+".*8XV=BR"
M.('4(*>A"+#)Q'AXD+FH>T2?\;#O+IDQ.'D9X./UQR^4SZ8UPR=Q8H&]QMV:
M%D_B$?Y.@MC 4^=B62&\AC?TPC$=']$ZF';BV.CX%-%#_IMOXH(\!M8(=\**
MF4AD%Z].'I8JA3^_&BYBAT1<,9@1%B08<#,I>"5'@"6]AK)>)30NZNDUO'-S
M)# +Y+G^R(%SD2&7-B&<8CB]X"6<HZ*OP'8N0.@Y<"0<"^$@OU#O(Z_  <[E
M>_ALPLDK004";+[-77<8)!?8*.29D&MY:AS_([%1\*?WPC%-V"I11&@8(7PD
MVBNK19"I:3O1#5:"W8CL+O>.4^564*W'[!SXCLWY.L*_13EPR/LV+-BLS,:9
MI4I/.D$G(/8O^/<#=XK>\^;262]3T0)AS1"Q>[1SZ,4*^&D5G;9/\1+-1O-#
MO4:-(0A$(!1<B@*?W(+K4)(/US57/X>U7K3@ I(IR(, 9.+&::[&R\0L?@-N
M/O1F<9##2=8?@"V>F-Q#=V4/K^EOS\P>Y! .D=! RB%CPJ)[\,$!N2ID&F40
M7=<IBHZ<K'%(,N36IHJ#-H*D4%^<N1X=\3XJ3\SSXFV<J(T@E87G&G%DO5JD
MO+[%GA&>B T-V9#T<*IY;QGF!%4TD_0RK&<@T&OR93Q0P*4+%0M07Q'%#O*%
M%^6?&+X/ZJS&FPF SAZ67\'FBUB)2A93)-^[\5,^$D\.B$9($44OP9TD%''L
M".O.,5AJ^M$0\4*]+X$((%4/TPZ<@:C>0NB&:-)%4"!?HO;P$9&&C@7XX[.<
M&'-%9E-@S8-YI)&!++' DS3"M@<KFAS(2$30;6!$BCM1Q70'LPEJA1*38L#>
M\FT[06E.M_UWQZ9"@6!*1B"@^52]=&/%Q'BO_+J#98IQ6-'Y(%P2WW&))#A)
M.9Z3*0Y)CJ\GFA(O&L&[VLDJ,D' DT[_7S,4A$Y".8Q8VR@N/##^^0ZEV'MI
M!I/'@.I9Q2.G^"6:!0@6*H<E<N7"*?,!UR[CY!&TP( 8J>%G\L'T?O "BOA3
M!MURY1A1*:1OH85TN<ID9!G F0JH#3_V)7TV+BI>IC@]AC85P26,-B5W[(6J
MYC+!1"U0I-O"MAP[WC$'#1M9:'A80,F@,K!BAI6!N=8;]=&RGU-TCLX\(=?#
M97(@3<@-/$?8PS154(==$Q[&+V#U5=)(\0>\AUX,2]J2$@H4:<7%>XH'&"?+
M0/UU]2 $;(K628,-\6<RN1G^-C:?Q\$L*3G/B_3AVL=U<TC\V\S"OX?57#.A
MQ5V$\TA-,;G1*^OL1[X8!%5$:]ZPDM=B@UU[.$.;2G!06&J/<[]\2J.<Q6C"
M-I.P<<+"4>]:4+>PHQP8HUR5$G[^.9\-FJPK9@%*$LS:! TMH3/?T)GU?<RB
MEWWME' 7%OKJ24.3>N+.>+R ],'((<8T?&E.AM,Y90@;_F^[Z)QLF+5ZA5E+
MPJQU*\Q:66BPG:.;*IQ:A5.K<&K'V\,MV6I7#[>-VPK#?9NXP%Y.7&#W;--,
M4BGGK2R:_)YZDR=Y$Z2*N7M?PK:;&.4@8CL+$0^LXWC*$D*O#OWVW8Q43Q8%
MT+&FQ@N5M>)PL\"C3#F:E$6YH;Y%.UHDHIZI2,32EM\S%S\ O4U/6R*B=W:I
M)U6(P+B@BYVXH]W8A;F&B>!@Q6U86"=_]8L2%M:MG5WVVA>-574[TM= @QT"
MRHMSLZIHRN)>[3,^<(!"HI-%2)2/YRX8SB(@*N_7)4]_KJ/>V^M1[^H!FG]5
M1:/:?B=8WSA!?;\3;"0*R\T?_!)IC(-S/@Z8:UI#8:L1IVX6R;&UAJY9U404
M&-YL.L56@)6:&#4U4A+]D&Z E&HBW!/TV\B9N2'QR](3]?I^15]SDYXX->8+
M2B).4=FPJ@(ETLI8%=@CC5J^XFZZWMSOW$%-:O<NELLZ_K)>1Q5T.F4%-;V@
M.:RVNU\<WG0;%8,L>H&&IFEHI^)_0=48.H'T218X>HVSBD,5/&?N8"QJ9"D1
M[EDXSQD,)T3UA(:3MNDTM?=[FD!U:+56FXOKY[YG4Q>NRT8K48JMD@0+)-^_
M+-@ZGNV+8;H4HKP;!2B22'OIC%U@4XT6Q;C5]:TA$<IRF'^)(5+$2O: <BO&
M$6OTU(PL(+%NF3GGD*Z42&)6</I'282.)DVLA"X%ET$4F *?VLS'&H]4J@U^
MY5"1R#<H!R>H 7E[?T>EA<5S5+D9.U^HC_=7U^IMY"5"5^'OA6.X7+)1M"\/
MOX<98K+GW3O?>1_+DM9X\XF!X;ISPOD*E W/F\"VZS]Y5@2,:KKJ""C/JU][
M:MC+VW1Y"P?,3! YKTL5I[KU, ,<^8>C(]1O/,F;-T['J4;RX&1GCZ#;NTAT
MDX"7<#(HU1-IJ(Z9M5AB.6%JK7!J 9XNPM!R(K(#9.3%..48L ?>Y#)V;C&X
M.?CP =@(E 'F&G##\%R62'=WFG\XZ"3<%)YUP^PQ3P&)I/J)7>'+Q/&6!Y!%
MLQ:)NU!\:RV2'$=&IE<V<'_(>K%SD/#WS2PLYQEG6Y'8J,C41\J%(0#@:(ZH
M^60&D%5,U^7Z+#!VGPV,F1<D G'6YK4 9%][T@<=UWS&BN4B-9/RGA9?S4</
MRIV*^J.\N%CP9UY[#(^/^X.%O>@EM)Y3D?A*);XB?@G;Q89LQ2O%\M[6N"-4
MCL'[L&W]A?YM=J=^&BD-5__2';S[JZR1[RI#?ZPO>O18UM08XNU _0;P=YCM
M0/Z><T?7HJX^8LJ=/\;Q:K_@3%SY&JKI )JQW'H8984*H?R//XRI/HO$$J\0
ME^G?+R/?C_TIIXK2:W=Z(6']X>7Z^6P:\"N>!X)KI?V?SGDKAE0Q[>F,-SC"
M<QT*;%Z+PK&<YSDOUO_7S*'<:E#S1"5IGJ(-6Y]I$LF5J:G:(Q6/X)(@@MB$
MC5+@7Q=_1/ZK#O("]CGS^:\.\I$?Y'K.@RP;@BV?9=&Y+,])7BR>OG241?7U
ML,-U4&C5Z2-\/>@#SZONP*"9IA&1)'--929I6D/0#P<^9G"XY&[GOVDBD[J/
M><4B/R1>,CY48H+&-%GF,II9%C40JZ37)C'4RB>]FI7T.G;IU<@IO5!BS.R(
MS$"YXH5HQ4R3$&]*-CUWK7SL(2*2^;0>J",+F,"PYE@R PMY)QO"/,>.H8>&
M.QS@1(^73&^18LY+? ?UBIK=T'GSV?00"SLSO3'Z%+Z& RADJ]_0"-)E@F.&
M98_T5I6#M,,<I$:5@Y24@]2K<I"J'*0J!ZG*03K9'*1$92=[*DS&4M>P[,C
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M"S6X_2G4%NN\PD^^(MJTT,F+/DOY=B/,X5K/XIO@:8?*__N:93887;."T27
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M3P!45RH*6G UOP"1LQN;O<H5,O60S\[892S=Z6G!Z:EIC4[NCM>' 53=\3U
M0-2%>@_5%5 F&Z?CWO;99:-=U[KUU!DPE>Q?S(#QO ^J.9G.?,9+L<L*-I7@
MWUOU]0Q'Y@];AC;9\.;G +YZ-<'?TIV?#IX?K:,W]UJ,?2]Y9&6G)80>-YK+
M4K4+3;49E;K(>+XJ./KAY3%TNP>3Q[ 1CKZR3NHA5HG<_K2R%4OM5<52DXJE
MMJIBJ3LLM5G53-UCS=24Y4*W6S'UT7<&/\:.!:+#N_EK1@FI/D%F+,>;N<D1
MQI[>S2=-=EP\5:_%JZ?>_-\_;I_^%6QC;$>W%6W>K(0$%#8/9#YW+N@36%+>
M&QLN A:W.['C10RLG=V5IQC^BJBX%BN;C_'WF3]V7%/T730];\;6UT<MU(9F
M,G%L.OB/1."KX.6)*BKG@KB6BA!)K5:KX?\OZ:FJ$V>@"_7&&(P7/L55PVZ:
MOL77O$F(K5S#/QU4M:GB9'R2O=K9I6.S12U5?0$!=Z%@]5XA]]!T6IBRBC.$
MO75B<Q3-'500NB:PPA";,S";O6"#!VIE@$]9[-FPK+EJO!BF1=%^+%2(7T2*
MP243=C?XY!CND"H<FC"T[_"I1%ACJY4NBS#W81^].UNYFKJFI?*;OQD_;@/X
MK\7PZL=/98L*_%@VEN7M)*[4Q_NK:_56I2:T'G5^AD'<:465W'6W&:D8"UR^
M%D 4E/F$TR=*(WN[$XVW*(E3B\6>?G;9[G4UO;X<\]A<\KI0<ZAB\Z[#O&NZ
MUFUL%N:J04Y Z@?L;*\8<E3 HYF<RGG2:\ ZM%YWV66_W>+'^2;;Q,G6].6R
M YJRLVK'AZND9D)CAC5PE^V9G"#,]$/&+*-F*\5>/L[ZWL UITAMA2L5.&)<
MT]X!7K(X]1=!DL7)4N?;F9.D%<!RMP#+JK#QFR!S5=CXQ#:W*FQ<J+&RVF=P
MI]HR(KN^O?(;!27KG0(:=;);.JHW>0^!WI1.W<8"<7I/ZW;J^\$BGR!#K&_L
MWDLH=R#<\17X.W_%"#3M40Q)R2/,<E#2W_&NN.]C:OKI0P;U3BN+H!&M?YO_
M1C9=E#MR<X75<64/_S1<U[!][XOC/HK6NG?NM668D]4Y$)=UK=MN:]W6<NNS
M@TK3/2HBMW,0N;5-(F>\32IX:'Z9]\A\WZ*^B('4BZ@":NA""<5@/4D,5DC3
M0DC3?)*V'3N$O%T8GCONH_Y,_<_O@?#.D)RG(:WA?$:HG$+?NZS#D6RG[UFQ
M%<AIQ669U,1Z+;.:>.1Y(E45\\-'_^J=SD$9K]C84^NU.YJ>@+?8,2ZX8JD3
M\(>T:[7,&NPQUSW7.Q=MO++R1\'2U @I'OYJ% A_U;<7_DH!^5X(A*VY0V&4
M%110EIU!,-;?$WQ$M8N6:6?G/NXA^9#"1(M%HD>.X]OXJ%!I&_^6GYRI/R?6
M!\O C06=YH_'S=@D]6KV#(-S?M);6J3Y=(@(1-680 N&9<$>XR] 3F0RP]K4
M.;V;7\[P/*^\0))V33^[;*;$D?@.,)?Q7V:K#\QS9BZ\6+VU7YCGH^ZO?C4G
M)B[['>J"H"3R[](O^L?WZ(.G_NG8YW?(W*"#^GJ,A][JY=\;:F4=P8)=1]_]
MY!JV-V*NNV*SEL0O'-9>6]=:"6TG-%S(Z]A$S"1V#0B;QWMIEEB _-2DX%/P
MMG0K0= -$+U67R[RD0)V X=@Q_-MTGR7Y^H%AJ?Z2HBT$7S"H8!Q-H,_3@T0
M:7 2(\^D6&H1TBQ"O,3=WV?#3S/_#YM+C$(*P9H "6W(*I?+<,;4D>M,Q'$.
M\4H1P2E4/;KJU]WSQW'-Y[ZA&R=U0R<"0S-?VRGIPIUZV6[N31?Q_S& HNY<
MW,3=)&R^@'QOEF(%JH'RM.J[T0-[GEF&[[ASN&I,ST<?]8-XOY[N#+?/+O5>
M76O4EF^5Z!G58%W#V8! G+#852>[/]^X[!+!MN5+M,[JW;A00_H#0R2G9110
MPMH%C+VB2ECW[++>T>J]!!!R@A+V- ,N^(Q+&JI?X+S@>G]S?JA?9Z"I@F*K
M?C5F>=6M(KNP??;HG5UV];K62JA00^PAL69JLWSV:!;T!2P[ST4N3ZB?)JM#
M"0RCUQ"VGIS*$_+)9_**7%OFX(<J@V2!E@[\L8D5,H4.2CT0.G:SUFJMIE;O
M)I$:Y.\&03BD?::O(-!'VPGN?3M<K]=).C3J"<0F+8\TVB!%:>HZ(]A[SM-X
M_&<68?\]S@&P29AS"=]?V"(5/Q^&1TBF<US$7'];UP=/$NZ.(;2(^GD5")U[
MPP3Q?FU,3=^P,N+>>5PNVZ 1Y#O<.K44VQH."R:4.3PW;67 1SXQ['LQ&@D0
M?%%"5VCX"@U_*+#>$R)SA88_L<VMT/ 5&G[K:/@"OM_XQ7\K+_Z(K9!.]6^<
M7>I:L]75>@G^[S<)@M]/IRN]4R0,51(S-$'TM3I9"IQ6\/P44-6@E =AV#H?
M:8XNF\QLZ38[):3^>FB?GAG:5^'@-XF.;J9 @\ K=+)!< ,>?HCP[1K4;3.Y
M#E %A-]Y\D^%>B^]L+[>S010$">NNWSB(FDGW%4?7.13<N<(1]CZK**6UDV(
MZ^P<*%TQU3[$>&\+3(4@)#TA&%!A[ROL_9Z TMT"\;.RK*/NV653:]2;6K>1
MNX+]6P7<9Y>TVT3='X#?I9?#[W+,8/L<I7TSH^N+Q<8:9038*KS]KO#VK?QX
M^Z<XF ^ESS#NC\&"N[ZG#J71JZG?W O.CX_F3%/_1%S#%T1)75DC5T!^OGD7
MZA?'?M;4WYBI_FO&@("V<:'BZQ9'SST< 3(VX6HRY<7'Y=N]RSADG639 QNR
M"6%*TO=Y:==K(-OJ*^H IT%_%\BS*V/Z^IKIPU16X5EB-4KK"*>,%&PD)@C8
M*0#-+?*=@6V7A7ZNFO9_&-\?^.M8-COE$"3JT>QCH?J!X8WI90*%8R)<;WM@
M)(+7AT+Q>H,M$=O8^FJ_$$Q[X%(3&YB_@('(C=@K>GR[B/&B-U9UV6P!(IYP
MV;1+2.Y2U^9U;1")!336TK&A]4:.C"Y-GG")"(S@8A?.>PJ,>>&$IIP2K+G:
M.9(>/;X]?'0>)&R]E0D:'@-_8LK3G.[$!!BH,UI?P+_=BZT-PT8?AC,7;];%
M=7UF??_6]GQWAFE53\R=Q)> *0ZU18@@W=%>N7S7*9"8MG48;[W#P>N-A/LU
M W@]+5Z]4R"]I2!ZN]XMC$[/R;2=>FE,V]L5TQ:!V6^=:1LU#L1O:*T$"51
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MD9KUV:YYXG:B.VCJ*-^>=F-7Z7-YRTN7-(NXA9?+=D:S+\@?E0IVLA$E,MK
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M9)9>LPDV3N[R2Q6S'&WADFS,TD9'EP[7K5[?.[,L(@</-:"<@ A:C(AS-$Z
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MK[Y?WUY]51^?X(-O-]^?'ODS7^X>Z.O_NKEZ>%1OOG^&;W^^N;[Y]NGF097
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M^#J^!+[6GT=WE&_OT(1E$0O+Y8AT#R";@2QL8#\(&$ UN.110L'CX6QA@Y;
M\M0,@#: ^@$ P?^V-;>$G.,7Q_T,IHP_FEE21MZ[;&+.)MZ5/;Q#UGL(9Y[.
MIJB?7294TZ&%K5]0$:MYFPMJG%W6ESL\:\"VWA38 /C4FL>TWD.]25:TH(DU
MH-F:9KYJ"=DZTC2KCC0)'6D:M:HCS>Y.4=6DIFI2<R 6M++#GC3;-JH/>K9Q
M^WJI%= !L-,*DWM]_Y\BGJPZUY(R^[_VM#O7AC<F)72 /Z";\P54/] /*T]
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MA'J%):RPA&\/2YC61MT#G##]U(HC"OF/.X05GAH5/EVHMX'FCH""W6(%2]W
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M]]R] N)*5,=CO97GGC9 LEAB')]2V$46N\(Z:\H;XC\PY_\*_JL50G?NR3C
M.0DN\Y]*\N;^MN'8Y56N?&=[1QZOC&UW\)^;\+Z7WA7X C, #YFUZ1QYG*_=
M::BU:M+ZK TF*R<+RH*!?(=4TAY!WCCK-1'BC?U!/-?UNA'>DSO;1) >#1E5
ML9BW4@ M><$R&LJ1KQ97T-TS3XCL=+C%-&E;4QOMYEKDKKO_(6"WRU[(G6'7
M.NMUU7I[/5MDQPOKU5,"$V!8U?)LQV"K%7IQZ5[>8 8H2X<K&I.LJ1WMW='Y
MYK"B+'%+U5J'I.Q=I/PUHT9.<"VGCAP*%YF4%\I^]YB%_R/>S1C>\$8*T/4T
M].Z2#/6-Y%CWK->NUM5.-VD#]$GSQKY V*Z"B51KJPUMO55Z2&60BGN^S$T0
MS!JWD5#LJF',C<CD90I#G29I4EL1HN#9OD3XIZ._VO*YE046V7,!GB1)[C->
M;Q I'ECPDS<(9:4.7Z6EB,V>M"')-]>0_!(XICW[\<$M(S5 4C_T ]P-'8&V
M=M:K@X>L==8;EUNA+%NEL"92NX)ESWK/-F9E!XE!PM,DLUV\]<WM"HQVJ;56
M7:TGS+XHQ4%&D8'-\=1 /&G5FMIH9H2G/2KF? RC]1_,T4K;YC 'E[IGO7O;
M.D\6K@6"4Z$.<ZB0PZ.IBQ@#)G2FO*WIF&,+.(+ F]&UP"^^D9=*&T1J8V"Y
MV56[]:35384@K^R""KO"#EMW6II::^X:D"E -.$; OO<'IW[V(M(,NR8&2,8
M]/$%ITC3Y1Y&WUU&-D,Z[+;/>AJE7'8-KQX=9^P!>!T 7J>N=AJ'9(U=%,6=
MY>G6"Y_%EX=&SRX%(^_!S640;C<_1?/<[[8]Q&KB="CMHNU<36$W'XH;4D9K
M6CL%* \EJE/$X+;+IIRF6YE1O@8,_<$&_B9.WNG6UL=ZWUU$("6KMK,(K&:@
M478/S5E+/<CC17*FX;E-.1%GT]8;:KV]WL]Y=]R8:7QN4T1I@*A&2ZVF*&,K
M4)"^N)&60AVF*+*W09+WX?GRBQ(O(5]&6HUM6!B^I QM'TRN5 6H&STC%R&;
MCF,I^='LMM56>[VWEP#8[47K46)E9XF:#BN4ZF@UVFJCM;D!F@(KI1Q]=W+T
MK/?E[O+SW9>[Y[N;)VJ/>_KC\MO-'P]?KF^^/8F9O\K-__Y^]_Q_"PBT0AVF
M %DKV3,D-R5D7V?\KK&VEWX(L>-Y.] LZ+8\#0IQ@T=^@4VR]AV:$==M5$&=
MY5T6OC/(]M#YL W(6KQ?I*7M&JXM0&H*X.#@Q)>(G(KN4^?0.=;X_!R2@W C
MO_.7\,H;H;^-PRZKM8;:[70*&Z_/AVWV!%%,:#7 H*[5CS2AA3N>\,0YJOO,
MVE3%5?YM>.,KL?E7XG6V$5:[P"=M\%VU]\8D>P-AMWK6:ZO=^@F40& 1.XUG
M=IA)DSUHQ>,A$=S=L59Z2V'7I45N:K? C48I$TB=@^5Z=^J+XX28U$MQ""JL
M;3' F]ICX![/]E/D%NFH3P.)TM)4+44I=<')KWN4I0812@PJ@7!'J,NBMH,J
MVPF.U(B(%SEMI_LP\MWMJEJ!!64N)6+;0:^!8X7::DW;U44YE)R^I?TN[("\
MD5(.U:KOHRE34J= S ZTV3SKM=1&XUBC)^NKQ9[UGVPAG'B:)0P[* F"TA;Q
MMVY+KD+.J-7P5'&U ]-OC:OV\K75>\%548H>$GM!$Z)!ITE9.TB!;=WH#BF1
M;E5MU,L:T+S$P+;(HO)VW+I2R-;0LF*B>)G;C5M#RT1[X0WGM+&/2+WV:<4_
M-BO7[51QC4VMH5:[Q0W6Y1L"V12 .!*HUE&[[4..I,I@)%!TK^O4L2>&Z]K.
M3*QX/67;9;?$IH39->M[FY(2SK=1Z]AVV2J['+:.E=6*UG24QV@@:[69<KQ8
MS]XEW)1+Z\BEC6Y;[::8&_#NN#1[KW!3?#72*^A#AX>*:\\7ZC %%,:-4!1O
M('Z/LO]E/U(W'>\V<?1WM],!JZAL3<I+P*9#38M&L35J:J.^>8XDX_ZD4JP>
MI5@]ZT6+C60_$@[ZRKR,[UTC;U7T0"[:/.\NQ@GD\LV'^&)B=<VNVI@"T39T
ML"<3VZ*ES8^Z\^#P%6ZT8^61.40]RZ07_'UQC7.GVMY$I![ZL)VS7O6BFA0;
MF-^T.]4=Y17?I*Y>H1W#Q=W][;87%'O$?6]L.\9?J==H=ZK=8(UV\LI@;!1)
MCZ #W !K<YK+SR\WL@;/Y7N@E7_X%@M7%>(MK]F 3?K,4>HU^FW]4YZHVVC[
M>0>#+#D>[L'W7 ]@!*(G]0DU)"RUUNB"[9@4VSXPH6T([_HF8NH@\ 8WN]7M
MJ#4MJ<%F"5=$5H';X2O7<@C7>Y)-XGN&MU/-A^RLC$ _];*P3@U[*G$.<C?O
MZ8:'[*C<#E0M+./H=G8=D%J E.:3WW<'CC$EH(8#X3(V1S]D1?F$2&'MWY"5
M?V][+'K)R-:P=+AN8S=3HUU7V]UM\/WQH*#<@3,R "5V3*K=5ENM;;7MY.,!
MLIK1IF/X#9Y4-Q6<!@A^C#+@R^V/--\?7N@1[G-G7?';1$1B.K2"P=ULJ^!:
MO[=\_YX J(&]WU#K6D/MU(N]DC =GPP&_L3G_9)#-C(&1M8%,9FIDV_,TPV+
M#6]TQX);NI&K7?.;11'LPIG^U]GY*DR#D]-!7MG*QCI:5;)W,.)$P%9-K3=W
MT,@%*XZ)<@T?8S&P)U.'C9GE@ANB?#!MU_VH&!;\NBR763'I04*1VIVOHC"\
M(]A] 3C>,^]A]*S_3">>J:>OKFJMLG,C-Y&Q R)3R(\&VO1:BD$HJ?&Y!Z&R
MIX0'M]45W?,<H^][:)UCZS@ ,=8^CO$0_!T"5K>R3H;DZ/!M2 I-&E;1[H)/
MLLTDJ:QU<G[>73I9V (#IMM2J^U#]D%FH'ZI*!\GH-BFB0%# \#L,/<$AFYG
MQGI?#<MV@'#N!*@V9#SLL:O5U-8^^R$_GCBV=F#X';'5 6QUJVHUA<5]=#IS
M9>V5N[9^(,=ZGPT(;4W13XX*&:PUOESFT7;P59<1R^39QMK+4.YN29U=T$IJ
M'>BSO<5JC2650VME2:'QFY_=L"MZEV*UCF&Q*M@:6ED-]NX+BC(5]#3U?_-!
MUB=5Z+F?&MQ+:[BE9U&OE3L#<I+A^\&7EM,V@5])DU"S5J]2$0U8TRC7@XE9
M!4@^&Q/F*O?L3?EF3W1+Y;]0E2?F&*-/RD1W7@QX$WZT&G_Y@*%>"E\_S>5M
MSV.FZ(,!C[^@SXF-D*X"YJ:B6^2 OCB4:W0\Q1Y5O#%S&=( .0\4)Q[14",#
MK50L!,3U;NY%7L?/%UB+[_D?Y^?*K<',X6_*H_X"'/0$9CFS!@S>V82G4#D'
M_%LY/Q??)+;F7XYT_O&7GWOV%#ZL(5V*WTA:;>'OUCES9UM=?/&FP=OI/-6$
MXU1ISMAY]/[RYI^4Y]D4[GSI (,//BGWP/8<.O<V@J'>BG[K5_DU@A#"-X#-
M,ECU':;_..\S$#;PX"F!/7K>5L)Y$:91Z$20'2.BY)='SXL7";%Y&.JF_]%)
M$ +W_5FM:CH2I][+EOK[O?N;?_]^<W_WKUOE]V\/WQ_!7/EZ]WQS_?>^\VNO
M\OW^\OLU_JA</=Q?W]P_\7\]/7RYN[[$7S\]PW^^WMP_/RD/M\K#X\VWR^<[
M^ !:.G__M9_ 7IE=Y.KAZR,85G#(NW_=*'?W\/.-\N'+P]/31WZ9VX=ORO,?
M-\K3W?]1OC[</__QI-S I:Z5?WR_OPG+]]!&PV(]_J4/O!0:Q*;R_4FY!G=#
M=]R/.5]-$DW22WD@?L!,4^A"4J_XLSO5!_+GC0\FY-( +SQU@2GEOSXI;\;0
M&^-3JK^<I;*[ESHT*TSL#0)L<#*XJD4U[ZE#9&NL>@E\I(B4<:B%)RXS$PM]
MV_I^;INM2R8HL-WZ)?$@W]@KL_S%GD9)N+^LM,J#3Z6RO\6GN[]L;FEO,>LX
M+'S@-TQG4=>Q/*[5::G=ZOKI\RNOGTS0!8-KK9$78!L(V!J0:4O;(V SR& M
MD2]7MHLN@.(L89@3RW+LP' (J8>1H(YTQ-%$XJ@V, F\QY%\IYZ)VH5YMT 2
M;PVN-G'GT^DEH,YZOSNVZ^)0I%'FQ9)9L1Y=X9%ND ZG[;->"Z#6K1_GJI5=
M.&!C6'7.>@ G, YVA569]7AW68_HW$+V<\HLMQPV68#JI+/>$^.U1MB(.-&=
M'RQ/%&5F@HE;75K#K_).-_Q*Z40==I.TU/966N&P%?*[:(0=H=:HHA7;23'2
MYD!64,K:/+"$F,4P[8%,H0\GAF6X'@JO5[; &2=J6N]B@W'@ 15=QD"W$2EA
MCTJK"\2TQZ'7I3N4,=(H&ZMI=57KK&\MRM-!*HW&HS0:UPP'M9=:E"?*X#L(
MY<#Z%@R=+FC9J(/+I[745FW_72HGBZ5=Q/"6:&J0X&VUU%J[6*71I> ]+<$;
M.O&\!U1TA)XX1^]#[H;M@IN5E3<P-=!I8TJN%,&YBN"M,=8"C'7K:J.SQ\G,
MI2Q^K[(8A"YUXDN!*VW=CZIBL:SS-.\:?;O,Z8GB+ ]$9::_\!Y<$J8S16E2
M56WG#:7'ET[;&%(=[!=K'G3+\)Z&[<B.JKG!($=&ZG?6*]P!Z]<Y%C?J$VO@
MP%=-[1[I_*E="'\GN#6K9[UZZY #IS+HXP_X0>CJ$[>V]\IS\N=- L]-;-O2
MJFJMM3Y?5_I(F;#\5FCCLXP;K:31NH?SDW()7:<PZ4^4[G:0%O>V9<>]\P1R
M6^^@-^MB.'NWG/J1B[C8%]XHS-TL0]SOW"_?4UCE+AK!5G@_H>+I/X^WZBF,
M6-XZ]N0*GFI8/O"!"&G:EON9;LD_]XQ7O?GI.;HM%IW<>6SB[F,62K,)5GVG
MK;:WFDY^O 54Q4$ Q:";:C5%6WP>4G'C"JQ'QWXU7$0.P$L:2C'F/%H]&VQQ
MW5)G)1_EZ,"0-1<"=PDKXS.S6-HB]V;[K->IJVUMCSM0B^*3G/7NF9><N#TV
M3<?;%C;/S34[[U,Q;0VO+L"KW0%X':BH=U<]\H6Y[F_H52M([PL#::UW.G%S
M%R><>:&9L_\Q>JTJID7:920OE]C]3LA<CL/:6:]=53O=/;9)%LIY7#+#;4&]
M;CL >QETBCHD+!]ALZ$@T4!U=5MJL[%Y>/DDIW%F&-_; 4MUP%(5EY'L;=Y>
M&=-[OS&]AX2E)7DZ/.\:AQEDTF]M!S .HLIW'&8-9HKGZ)9K4BQ-T8?_\7G6
M\;0-O%W+MY:L+1&PO1*@?4;(\M=?6L/G$,Z7 9@WVEC3:ISU-+ "M?H>"Y=/
M)/:5;1':@?"-,?]T6\4*:/0OOILGZ@^G2K)K25A"(]O31^+0]4?P<JQ-G7\<
ML5-K@\U>Q#4X&?8<%!@E;6#K!CKSZ]VH D< O01N?F<1P4/8&#S=N8P>=PDQ
M=<YZ[8[:2"$HWIMQD;^8V@>F4TBB[EFO55.U6K'J?[+?_I-H@ZR++-(ARNCB
MFAF "Z2\W2['=A6W<S;5[A81[Y.,-68XMC$5RI9CJH9>:3?5$+MRG\^)!ZRV
M<0O%^FAERAPN;_EAJ*BG]HG_T-==8T##HX:&Z7MLN!W<%H3G;K)1VXC1Y)KL
M1^8\X36O^4W6RD7X/('%C;.=MHG]N=M)/R/TMSUG_:Q7O:@FA3".VAT]*.X;
M&^F# R*_B<A/7"Y9 ,>W]WE>JBC<IH1_Z/!4W$O"+Z78ON=Z\$$ 3,8TF)ZG
M[^YO-T+LO\7=+OG5[OU)GSD/(T&*A&OW(;QGHO)/PG'K (=>..T"E:X\<IO:
MI&J-KEI/' )R]/VF1:&-SB%.O2-QH%-<K:F=>I+GL9>FVG+W6;G[;./=9[5R
M]UG2[K-VN?MLW[O/ZD>X^^SJC\O[WV^>E+O[I VO.2\,X_MDE0_7-[=W5W?/
MFRU  Y7%,55N0<MH"]K?<8-7+)0\TB>&.?MMW7GHLZ[Q%YRD$V5U?-Z"*9!^
MSUB&YPFLSRSWENWM_-R $W%V(GWA?RT!<?KE:"7*"XKR!]&GR04='KW$^&EC
M_,GONP/'F*+_%&+=80-FO*(:*3%_JIB_!/ @UG63GYL$_%0WAN=@V/"?!OK4
M\'2SI(&3I8'!P)_X)IJS(?,/V<@8X(:T$NOO".LTL4FP?30'S7_%BS)^E86A
M)66<)F50/4Y($]$:'$X'O! GX@R(:AS^&UZ.P_\=U.24M'*:M')O6^=TXDCA
MFQ0604EIB?S31#X7%$5&;RY+U[5ZTM)U 7O#&C*,K9W7JHO=7[7J7NGILV[J
MUH"I=,YK\-XP=*/4:Q3%U)8@2ERB>M'\)1_27GQO4KU9/DPO#M%>LE-]7V=8
MF6]M-'?)MX*&G=C6DV</?FR=$NY45Z57UU'-P;%WLJ3[MZ.AV@TW<"*U"IOQ
MYK^^X<WNK('I(\GNNX.B4P/25JN)F[U*PGZGA+VZIK#1*A)EKR_+[^ (D%I7
M[;23BKT/2N3+@@0E?1]0<+>+1-[+J1K'5ZN-9D?M-I)J54OA_4Z)>XWP[A2)
MNE,([\99K]FMJ<U&4C5^*;S?'WVO)N]ND<A[.54WSWI=M=DNW<F2L-,1=G.'
M!M<\";L%XKI55VNUI#D1)6F_4])>;9,T:T6B[10V2?NLUVAI:J-XX<#2)BF>
MZ*X7B;J7$W6'KT-J=3:5W+7<Y78N@X1RST[=,X].A=4C<Q#/DV4/I8*SY,]@
MV<;:-^=QXQ*;H%]=-C@W?IZ/C2%PV&\*_R\<9>"=MQKB926VWP.VFR6VWQ&V
M6R6V3PO;V?F%K1V">=NNNNET5TVBSYOHYMVYDM[62)=V*5U."]O929?V#E&G
M;:5+MUI*EW=+;]H!Z&W5"J:2W$Z9W ZQ)["KK=H3>%AZRW="Y '"AV)*/&\V
M25B4PNDTNBVEY,8RQ'C"V%SI*'1*1^$=8;M;8OO]8+M=+;']CK!=*[%]6MC.
MK!"C?9PK]+KULYX&CD<M:<E-2;4G3[4[Q"D/2;6-DFK?,]7N$.T\)-5287ZK
MW2V)]AT2[9'N7.VV5NQ<+0#5'G*;=.YAV.BHR+DID1M-^LFU3'N;787YR(+M
M=ESF$]1-O5\P'U"59)0E&:V,06A9QB!*,GM'9):9;=/:8JR!9;R.> _*G>OZ
M;'CM.]AY F^WA[37XXEYGDD+3QY&4<7W+=!YZ0P8W&W4U=1Z-?48FI(IWA%3
MK)2]]5+VEF26/9EEVI-2DEE)9IS,,FV&*<GL'9%9H1(2N5F2G=*2+)EB2]F;
M:6M:26;OB,P*E:'(3?9VCU/V9EL93@=(,3;_T./0_^%;C -';'6LEY+CE"1'
MNW[@*>K=ZN93U LA'TK27S-DZ6BHOJC#E[K53:>PEXQ1,L:.[:@[U+H<8.A>
MMZJ!=:FUU68K=95+_DRRT=*WDC^*K#B.8GU'M[K-%/A2>93,L:/R.*X5(-UJ
MXZS7Z7;51I&9I%0>1\0?J]GC*%:(=*M-JAMN=U*W:)2:H^2,'37'<>T?Z59;
M9[U&NZFVZZE;0DK-4?+']OQ1J 4F*?BC?=9K:G6U55I6)7_DP!^=0NU!2<$?
M'=0?:K>:>O?@H=DCJVZM/#.;9>MD)LU0*5]<]L&6R"R162*S1&:)S!*9)3)+
M9);(+)%9(K-$9HG,XT)F[J7AAZT!OV8#-NDS1ZG7$DO 2\K.,&G<[!Z\0+M[
MUFMU.VI-2[T"M)2M>XV\%X3X#AU67QI-KV$+@=KMI,XUE?1Y-/2Y9A?<D>5]
M:K6SGJ9V6VVU5BV7[YP4H:ZFTT+MLE].GMI9KZ'6M8;:J1=T:F1)H]D)TQV&
M\QY$F-:!6ELUM=XL@N(O16E>9%JHYKT49-HXZ[55K9.ZBZ\DTF,@TM4T6J@V
MNN6DV<0&B)9:;;<*0)REML]5C!:JE2V%&,62ZVY5K9;:_K3(="65%LHD74Z;
M;:#-*LA1K0AK3?(IW(R-V<\]07'//#J5:;OS\_-/A!7+E:4E-L7?5XZG:V<Y
MGJ[$=L&P72ZH?4_8+A?4GABVLW/G.CM$'!X=>V1XN))J0Y>L<]:K=UMJLU&$
MRH 3=<DRDRZ=<B'RB6$[0^FRPV27K:5+MY0NITMOJ\EMATDIR>2VE,JTZEFO
MH[9;J1MQ2\%V7(2V6K#M4#^TK5S3:B#7.CA@IWB![&PKFPL0-Q0[5^ED [%X
M5?'"7:N<3/5@XVK)C&5L\:2QN=)#J)4>PCO"=J;K2DML%PS;F2Y(++%=,&QG
MNJ>PQ/9Q66&K?>\=ZH(>O#%SKNS)U&%C9KG&*[NS!O:$H9,D+.\K870_H\W-
MWW]I#9]#"_PRL+WOF?<P>M9_IO/C<1!\MZ:VNT7PJDJRS9UL=XA0'I)LZR79
MOFNRW2'2>4BR;9SUVAVUT2A"O5M)M7E3[0Y1TT,2;?.LI[6KJE8O:+5[+J6:
M64^W_>R[AL5<EX=8[4G?L AI2R#\SH?M'NO>P$YME[$42]:.\A$5EX/_^H9K
MX#N34W@),RJTUEFOJS::-55KI<X6EVL+2D[8-R=LT:*P9/WN,C9(D6!L S,T
MU&:MY(22$W*M$MJU6V=#5EC. 3A>76U66VHKO5]]Z GK)?T?/?WOVIF^-_KO
M(OUKK;9:+;(2*.G_$/2_,D_4S#)/5)H9[XC,"IF@RL;@KF]:0UHR0LD(!Z[*
MWZN]4:\A [3:5;6AE0OQ2OK/B_YW7:BZ-_K7N (H?<V2]HO?N+!?TJ]ST=]5
M:]W4$TT/3?ZY#W"?OW!C>HCFA]A4]W_X%N/47Z_26/=&2F0UBB ?X!#*T/;[
M)BN8>%AVL(T]\=9NGGBMJM: .SNM]%@MC@/RGDALHW6KFU!7=@YXH99U+]=,
M#>2"FMKHIAYE7#)%R11;.R.%VI60(FC5Q+&TC79]D]K3>9K4"N.WE-Q19)71
M+=2>AN4\T3KK-=MJ1RLP0Y0ZXYBX8K7.Z!9J+40*G=$&9Q\99'N3JM08)6^D
MTAC',?FWWL'^G;JJM5)W0I0JHV2+'53&D6V_J'?1S>AB?+A:8!8IE<9I<$>A
M]FZLYXY&]:S7J-745LD;)6]D': Z,M:@FI)ZMZJV:ULG%O-F#IE8_)4 T?O[
MT'CM52I__Q7_^_=I]'T\N;?N;1/=>3'@T/C1:OP> X9@#?EDFLO;GL=,T0<#
M>P)WG@&D%<OVX)&Z [^V% ,^].+HIC+5'4^Q1Q5OS%R&9$CY<MUC0V5D6+HU
M,.!#K@>_P"Y.]R*OX^<+K,7W_(_S<^768.;P-^51?P%Q\,3^ZS-K -14:VJ?
M%,K!P[^5\W/Q39)Y_,OP/_*8_.7GGCV%#VM(XN(WDO!;^+MU]0MG6UU\\:;!
MV^D\U83C4![[]CQZ?WGS3\KS; IWOG3TOC'XI-R#Y.'0N;<1#/5.]%N_RJ\1
MA!"^ 6R6P:KO,/W'>9^!O(,'3PGLT?.V$LZ+,(U")X+L&!$EOSQZ7KQ(B,V,
MZ:T?G*V?0'ST/SK)6&#"/ZO5AHXTJO>R/M3]S;]_O[F_^]>M\ONWA^^/RI>[
MKW?/-]=_[SN_]BK?[R^_7^./RM7#_?7-_1/_U]/#E[OK2_SUTS/\Y^O-_?.3
M\G"K7%T^_:'<?GGX]Q/_^NW#-^7YCQOEZ>[_*%\?[I__>%)NX#'7RC^^W]\H
MLK1!N;R_YJOKZ4L?GCR218:E?']2KD%-Z8[[,1EJ!T$5J0_XL&D*C49*$W\&
M93.0/V]\,"$0!GCAJ0O<(/_U27DSAMX8GU+]Y2Q5;4Q8]Q+<)*Z+4Y3!B&*S
MR/<#&P].AGKU?YVUSE;:5K%RK(17)@'_UG84T$S\M4_&3^4K?&_L\I]OK"$;
M\F,@K<3K9%(6,BV<(W;'U.5'>8%8VS^(>3W1/H"UME1Q;U=+Y-,]V(FUJ-;H
M]T@,$==O4I"Y&_TL)9BS7BA0E=MO#U^5A\>;;Y?/=_>_*Y=7SW?_NGN^NWD*
MAJJDA'6"DQ-'Z8H?]_?<;*O\A,!LMWY)\B_NF0?:!0>;*!]P1]G'>31+>?M+
M,@'/?RKI'7];\LSN+XEN9N$&83>T58.PEX K"1"%!V[M ,M9&G6 ;KL#T&WO
M!;H9#*=9HTOXZ\-A/Z[BV8K# +(# ZPC"UB,\Y;D-/@S_G*@NV-EZMBO!FAR
MI3]3["ES= ^]5;S_J^$9S/UMI>Q)D#?\-,F:::U<2OO  ATF[U'P\<KG+NJ\
M:S8%=!LZ,90]4J:F;GF*;@T5< *-*9_/GBG@LA*9T9O!OTTFAEQ=3C"<]A?]
M/E7^L8%%CIK:JB6U716"]C(3C/N#81-SN&HCL7TG+Y;9>'Y7A$^B-T8^(<B?
MVZ-SWV6*[KK,<X^43QZDY/["=)=]PY<]C+Z[[!(O%;WVS<\ILUR6#M^X25IM
M-)+:=4^;9;(!)Q8%-=1V_9#LLR>-\XA6@RO8B $0!A@F&CAL:'BT:UC13=-^
MPRZ:S%6VF*1PVA09 /S6=OAH2((UFKLL70-:HW/6:]5VY>7#6+?S-%@U+'#(
MQ[KUPEP,3D8,5Y+B9/N8AMXWS-*(/1*1<CD8P%,!=V"L,.,5 [L9 RHS1__.
M DD(BN.:\?_>6?)RWX*[I>/9+EA<K:;:;'6VX-N/!X7?+M)N;P!LXL21FMJL
M)96-I(1?!B(O@?SOK%=PTVP'I-61VJ"+2(O<:;.83+-VUM,TM:9M0_:Y"-D\
M:7\)&)=#3R/H-9K;&)I[(/H]*80OMFYAJ.I2>7J\O%+N3H8MKGWV;']C)J96
M'W7'2XU7W('0J*K5:E*=S[MCBS5@3"%E&KO ,SOMD#;F9[N&IRI3ATWU&<;X
MR.JUT3F(V%"NBK'>D^$=:0=<6D-R@T)[8%/DXY#[IEJKKX_ZGYHOF2546\!2
M:J.:M#C@6/T1X*X<G)'\6>B1WRN=ZFDC7MOM?>#VE!AF(QAVSGK-FEIM)O4$
M'D7X?#!P?!8+K$14CF"3T_%>2!+.(1K3)AP*7T(@I,,^N/(:<%!5K;=W#0"?
M @?M%[JM*J6F6BDJ) JO>*ZP(P .'^6SDV$J>;E_&][XRG<!DLR1R)ZE0S7&
M!@#5S6U".B?G!*6&YWK;K86;(8%PJVKW&!VB(&<''P'0Y,@].<:1XXG);1%=
MIUJ(=FT;0^24@LK[@6;CK-?IJNWJ-JFU T?;YBJ,$[CJ6?_)%ER@+0J-MRHN
M7D4Z6\T<79(L3CUF<^=ZZV* (5]'">TYOKN0B&D3EZG5!-ZJJ\T4%4=;X?!P
MBP3GIYI6+ZH)+,A_RZNDYZLU?_W@N]2:\S%,?]-APMK-TR;4'10KP/,*P/DH
MH/EY]MU%&@WTP64 PG1D2H526A6LTNYZJ_2]29OL-/IV:$RATGFTJZJIG<;Z
M>M'4^,Q%V2?H\,)6G13J,(>JVY_O*[J[_]?-TR9]127NBF$_G_4>?6<P1M]S
M=0W^B4KR73JC> +3?;9IKK[#0*2#$/=FCPC%2VMX(V&83A]W:*YWO9NTTVTW
MX7W$V-NG\W/(#=Q1+C,L3[=>#&P"C]?O'RV6\N.QNP!V5-:>TM3%BD2UVER?
M!"PY*W?.VJ,J"SQ.X63"_W]E[EQOX-$C+C-F6^*9W$D@;NN9M#'/55,;&;@E
M1XS&HO#?G&8KKKU<J,/DOF1HO0]V>W=_>7]5^F %JTHYZ]W24#3&4WS'FM83
MEZ"DTZ-C6 -CJIO2/$MEA;5K9[T6:(%M2K&.-X&W![AI9[VN6J]M4_-YD%3=
M68_J9' @E6._@3([ZG)>,(<&C W=6\>>X%X]Q.;#B&[XQ;9>GIDSN6;]=#Y^
MNW[6:[8*70R_56MJ+F+T<H)E5\J;X8T5AU?0TRC*XZTTBI+6-UD0[SZ,(OT!
ML_2TU0#Q6FVJC<[[FQ:Q7T#BQ BU6:^JG?8A.X^W$;Q/?M\=.,:4P!OIIS@V
MJ\,R7D>_12^S=7%_NX63ACM=3>VFB/_D;WGLG2?2@FXYQ#"1"/"J5W=M9#QD
MP/7*MNAE&&6=@E@P7-=V9C31^.A#!WGHHPC\TDO.SEFOKM8[5;6;N"[X?9<4
M%"7@DT7 -2CK^34ZFDU, R_#K[N$7V\E$+<.OW:QT*?>! VHE;G%/,S1[3"Y
M%(&=*E7VU.IJI[5'!)8!Y&.-/&[C&:"H_C 4):X??S5$T2MFR4B"8]$'_0,K
M/UZ!)JW,Y\IE)DF1^?#_;L*K?&.NYQ@X\ O_<&D-X[^(?/*1.88]G"\*OODI
M5J+ /VB$TS=P+&]&(S;8</-)IP;,W&RHK?8.\;SC\48.CY+EF- H+5G=JJ,D
M]^@7OQB6C^"J"_B#,O =AUF#F>(YNN6:8D#DX=@Y*V[F-W\81='\8.U$4.GH
MHW[6TSJ-/?1G'A^['@SF#9P:KK:U0_+D'AVDJV6\J"I]]F)8%CI'6'A)$NZT
M+>H==K[F0'C-LQYHY5IU/>&]M[C%2J3NL+ T!Z2V0(*WU>8^"_\.'M]LK)$K
M#(=;I)4HC6U(;_46QH7="EMM3<QHUV$.-(?1\PY*DLVKW1J[R)'C1.6AO+QT
MN.R<]=IM5>MNKA12H#(;$Z6X$8]"'2:KQBGZ]V^*X<%3!DD4\.1/IR8MQM2=
M&1??(]-^4PR+DSX05SGXN5#&?3A/P!AN!XP%.;JONIO#5P'E-S\%IPWS5<,9
M8R+#R2C\_(]P_'N6,DB%K2M:5:VU=IC4<: ([FY#&3:'51?G9F\U&O- 99)?
M#-Z<,F+L74F7[.K >.77PRA,M5E#VF\N*S>O;#>E\=?%<N5V4^UH^YH+6NX-
M+_>&;[PWO%[N#4_:&]XM]X;O2-T+"\.;15@8?O_P?/.D/#_0VN^UV\-%R]/E
ME\@><?Z<HBP(7[L,G&N6>W\"7QXLF)KXLV'Y;'@)"O#/!^=%M\02KZM ?/+%
M>(]@+:%3B3\&^D\WGP)Q>FVX ]-V?8<]PQL^FZ 4SP?5/_$-?];.% 8J<8JJ
MS/'9PF:Q/;\WHF>KK5IS.XFS".;8.F<B/C 3;(?[U&"J,<<T+/ TD,9 F@J;
MB"/GX=OOE_=W_^_R^>[AGLCE\=L=4-8CD%:TFTXL=>:(!!SNB4GD1*WJA=;$
M+5$AS^[O'8(1<=^J,9HM>3$\\7=FW;V.E"_&Q$ F^0#:FD"E53]=<0U//]4^
M5?BB=?G'W\$<GHH_?53>=)<6MSI31  \A^!/GS?U-Q<CU/CO*S#8 &=WKJE;
M0Q>SU__0+5]W9AP"M18R<*VKZ"ZW)+ 3F;8&C&T3XVV*,#HNC@\?\^] (VID
MXP(ZO)=!%[8CC*<,QMQ^0L!5!"HH!V!XKN+Z?=<8&KK#%X=E0#B+^B3K5QB3
M%T4W0?"!O>X,I)K2+OXS?0F6AHOEQJUF=?KSDS(6+;/U9G/Z\^S7/7-I#H"8
M)XJ-U,/38,R&OLD>1D^2&F8/(\'(P:!003D/CO@#-L=8S'''QO2:!4T#&^N(
M3%X>=\BTL]XE28Y_^!;CT)<:7N72))1/M?8GMQ)E"O)&ALS3#9.K?OP".60H
M7#CC(>?$ )ZGF(<7"W3J@5.<%VXU#NC,*0A\9H+X@)FFR)B0$XX_@VH=R)\W
MAK;<<5ZM_A)X. ,T[*8NF/?R7V>]];$=^LRRA%=_,6$NWJQIOX2I6D=((7(7
MHD8)I0A&^L0P9[^MNQ)/)QA_,0X!;CH#RW'K0Q@BWC!VW#<,I9XC).%;EOWF
MZ-,0-K_$HA);W;+>_66)6;_/6WX.@FN'O&NMEL==']X$YRB_'/*R6C./RP;]
M[[(?9#9_9XJ5K6)2<,[315^7CY>L51<GV8HC[NVRW(XV0CMZ \0NQ>9\CED#
M-3+U5AL)6K.[T!@H56+(9S&'##?Q[:SQZ']Y$&H.TAJ/EG1;[:[PO:+_>SGO
M$@@#'Y6D<K!3W44]&=#-M9;T4[A_PL,^\Z;##JC.F!57ENDAQ80!>&VC /R6
M9D,@!67:)XC0GVN1$/W4=UC<),2E  FS%'[9![LEXB =J^T(CL^^:UC,=1]]
M(#J7Q;@3E\;LCQ+N%CSJ '()U+RM=!89WL.*Y-O;Q]^?E ]__//CP64RX'!#
MF8S#G0\HD_^PK1?^[W_:8="E6#+YF@W8I,\<$3GJGJ!D;E6/1S(WBB290X;+
M4#+CW)#]4<)7W?G!^.A*:ZCHPXEA&:Z'P>Q7IKC,>34&V$R]?V%=-%/ZW\PT
ME;L)9LP.+K=KF\KM3A:V],I(?K&$^4Y'G9?P__!-F1>HH73'^22G)-UKQR/=
MFX62[K4<I'NWM+NW5&3 O'_P.[IA5E$D#:-_#'*''^YMCWT\G)37-I7RW<-:
MY\]CW3"I&:B(=GDLH:N1X*XU3TMP:YL(;DXW?]:T/T<Z=JKG+LA["7.X?_G_
M#B.YM>PE=[NZ5[L\'\E=-"/\UG!<3[G%PR,F% RE7!&&%T3Z[>U5821Y?4-)
MWJX=-O9=;$D.+NE@S/_$ZW(:IR7&Z\=C?X/!T5YL2CR0^5W/08AK>S6_:3*7
M2_-21@I6HGH.TSV^[NI$S? %"3ZV[(GRR*QQ@@1_?)0B?!>*6D,VC4V%L];>
M)T!6IB G?1O.$HAA+!M64LO)2__%=ST1J:A*@W<Y71VEL&P<C[#L%"I8T<A!
M6M;W:O+N)"UETU,F5<SQMHNY"KK%8U'A?;0]XQWW%37*OJ*$OJ)&M>PK2M_)
MLZJOI6P?VC\4 JF7*^RC;\VFQ:82MMCPCWY .7[Q<:[?I@B@75VEG5F#EBS0
MSK #;-W=LJT-K^=2@:Z=<@5Z_9=3JS9OE]7FIUEMWBJKS;.,[7PVW/$/]D/Y
M\N4J$M3YG$-,I[EI3*>[5T]U14SGGS/G9?:7Z^G6EE&=AX%GA^6%-5E>>&)A
MG>;QA'6ZA0KK-+,/ZW2J]6S".F 2.O:+/N#MQ&@VHD^#T^D<+$#<H-I01GL6
M8C&[]U#2_VJ-16FJ->)^<D(O90ZF93T[TS)%O"-F?^))5JNT1,^G$N45_K2J
M86$7]>+OJ8$U:;SA_L@S5I&PA#5#KPTP/K)M#P</R0J+[I_R-V?*SXGYFZDC
M IAU_OUIK_6I8Y!:<'O75;PQ/'--<TUG>P'[U;!L!TA4"LI <CXR!X64_L(^
MSX!>X9^I9&BS6JV>]9H)(E2.9\#!PF!/P$_!] 7&<#;!F)G#6,\USHD [?XR
M7IA&\)'J)%Q:C6&,@!0MSYPI$QN ]FI3@3.URPKHX:-LVA[[BJC$K\*_;4>.
M0F!!;AQ/%?F,>Z%<PM==%Q#!JS-T5^DS9@&W#!F<5?]!<Q4LSZ995;A*5#=-
MN@,6XMB.BUM%V2N<#YB$?D];1@$@9#'3WE'\K82#BA_3W0$PF&YP/#NV&;X7
M/@3R $PQ-B2Y&OVNXHYMWQS"!^-SL'#.10B]63 F(YAR$4I@2=R<02HD@+.4
MOWL>>'#6P]J0/8^J*,P<E4N@,(<&E A2NN5+.RI2O2N7 R\V6^7V\Z6TSSEC
M3?3_$+<#J0!+CV4%)5"$*?*UDA%B<U: $H,J$@-)&EC8@=_#.8#8;! 9PTI_
M1I\!\8*T 9+H",>GI$+#O_FNX!%S*(HO<#'0ISB?M^)ZCC_P?)I2-YP31N'?
M ."$2F1'0H5+'Y^&CQ6_C6+S"7^E/,F'! 51\+!8/2P\J7)[>Z4&HFC^L?*P
MB$M"'N[5T^/HNU!P=DRZ0X[U5T8O<D&UR,OB*7#NGH\S>^@H\-$I&\"?V,\!
M ZB/Q*R?(?:@&'W?$]G J6./4.##H=YT$E=# W>>8><N"4P^<<,-9VSLB^/I
M?QN=5.9@]B&_U7$]L+GB(0(9!VE,?RYU06*?V9^Y\D%?ZO\G6U9[>_-U0!DC
MQYX$I)/ $@JP!!(L$"+(+/B//2#9)OA7*'Q.?_,$KH-:5U 4*B/C)TZ6Q'=Y
M<#+Z-OX7:!6?TK=U9\@IUF%<_T\= ^G<EJ^,R._(.^<8[4*YXV8+>P4"5$%[
M#\81+N!R=[,[\*N#<B?V@R^EGTB\F47Y"(;'8,;/$J"'[_KA?[K1'5Q1XZ:U
M)VFYV7)[TK-1E.E\D7M,6, !P>5,PM>GA(B=,'-.3XJLGCY,<F1^#N\R6;+R
M<WN4)_V8/%DU)3@#F7(YPA)DR:Y<)P5$16<!Q3.%CX#8X[#1^_8K4X5Y[\IY
M:A%*#.1.H.N *L&*@M_.D'2!&[PU(H$<#&G^T2G@\X83L^042IHN$G=D4'!)
MW@4@[\$AR?LY25. E*1CQ)0%T"M@UO!,KF)"<K8M$ST$:=$)>N> G#'=<<FV
M>QL;@W',GT<W-A#*>O! 9<I';*MD- K2=EAX"LM6!O[$1\?Y-<)6G_#S);$7
MG-B'AR3VT#Z,6DN2QA+Y0/( T#?3@8"1H$-2E'ZRSN4U&84ZNG;240Z4 C+)
MA7(/AA\0 W>JYC4"G://Y_0O->+"(UUD2^M%<[0_Z[C_W9_:EHA=6/H+%9T$
MLQC_XP_Y;Q3QF2>.NL!'5A$W40F$(U"12P'8["=S!H8;"8H(;WUJOX%R-[@!
MSBWZ":.Q"?'HI(CXN144=HGNAAZ/6LI3\I0EQB:]98>3@;_$QX*S(0Y/T4?P
M=^05*FNO(";@9TXK"96S"Y/"]UUVM3#H=+/JU699O9I4O5HKJU>W(/^R;K4@
MQ95EW6IN=:O95I/NHXN6KD1#Y<%WB0Y"/^'Q^X^^@VN** &ID^TQ?_E*-,N0
M]($@U0"/<$2" (QL'O./)C5BYM'\%/F92"ZA)?0!'3Q*<)HFPTHZ9LXJ@;E+
M.=#E>P#@>V :3W5^E""/8(K-5W .>B_9@G&3K0\,BE"6AG9DVK\<@L^I QY[
MR_I.9,@$B;_ZA7+)O\T_]H9N*M]"0+D/:;8)4 2Q&33H1;K6<,BI=H)$N"$R
M[RY_FFZZ=L4W/6,"3 %N-F;%97@Y]CQC,F$ 5OI0$&26YN4\!CD88FGA<"D2
M0<Q"R"BR3QQ>PRP7T%+A?U!7?9>O<R>/*7I"8:;+>_)'+W^(W%K)IZIS!//L
MM4'KG92![V 9@KA?2'=C?<B3X^BQ_00BX'DY7CI@^]S&AA\9.T=?CN.3KS+&
MQ<;PCOB8OWJ-XUK%$@$PL0=,1O:FG%0K>/X :CQ+"C#^-4C.<Y=D)//]//]/
MH929JKQ1;,,;@[5O4&9^;#L8<.0GVG/6-)6$.)AHPE"4;^G^4*2>\<_@\U5B
M9-+739WG,<"#H:1?XK1^HB]$&Y(.:AF"/M9N\&0DB =>C66P8%.(CC8I(@NP
M%^2^\>^6_58A-N N5H3A*:85H;@P2_YKK#;#7<!_[![*4 0.#/ZI);1=2:9M
M\AMM<%TY(?;)41;.94P.Q2_(<[I2%C(,95CT (QM1$IIN$B2<E&<VZV0 '-T
MR^49&.)W%+3IEJZ=H&9%:$[L5QZ!$-L?YM=%Z#Y@RJ$:HWCN75;O6#Y*GJ2
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MC#',E;A$7%.LX#)XO 8XACD3X=\+KJY05/=:I*PV*PD)YFP)4KD1 N$*LZ]
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MS&F+VU"1X'E4U,E8)D<O;VO#<*80?#&9IU:DR NA)F2=W,R.M10>;SW#9C1
M$"<G$5,_'LGT#3,?/KMU[(G<'?QOPQM?P8/! '2V%%.;/34NL]J'EUGB^%*[
MX9^/1&[M!;DR%;@U;1PN":@/[2E*O,NGJ\JS/34&'%JM:DM5)%8IRR8O)#KV
MY9UD:0,X<J%Y!4_[+LH')C;(%X._('@T^G:7X.F9_#<UC 36VMR"(1]UY,/S
M'.8YMCL5I@RW8$2&Q,'R*$=X<T'OCQWDT>@9P3R"B%&%/A^>E5M1+A5%C)3X
MQ96Q/@2K#^0@[R$BCY>^!-]QY%>Y\)3O!DZ@3A5'@ P^"N^>DOU*X O=8A">
M=V 0&G Y980E:NBN$RT&K<#_NI6MP!4/_'F/M[H F%TP;^T7?3 3]20# ^.C
M,\S@H/'G,N<57?F+..H&<=0-).KF[-'0@ QWRH\0]*['IMA;DY&$IO]M="ZT
MQ0([K7%1BP?HLV+A^FXLG$\G3(IVEZ4]+5IC^C-5,PA];G]5@1]J'U>5,*Y7
M.SN]W4!"@F>*N(S@ SI$G!<^;5:%=R)4W]B-ZNLEU2^C>JTP5 _ZBAP22U06
MVWUX+X\J\*D!(/)MEX7<\3Y9H;D;*S1*5EC&"O5#LD*0$B##QL/1IMPAIG.(
MS <%TTH>^+.U&P\T2QY8Q@.-0_( >"&V*,1<R@+@XLPIBYBBH%AUG$/0!7F7
M7-+>C4M:)9<LXY+F(;DD\(0#)QZ+G7DSECX8+V&-9!,*/6L7_NYBZ"/TQN/^
M-CX>XP(3PZ5D//?=*0Q-3"K&/?$A2W2.@6E0E;!%5:>\6).B+ X;F6P@QGC%
M([=!>;"!_^;%VA0&X4<.0@9YLW*Q(GB=W7@ZLQ!LFC)^S/&AA/;LBL"FHK\X
M3$2\R,TE[S<(^Q#)V+YG2K.(1LW#L1SF3I%X^H9),SC%Q+>('@!+B3.#[G@S
M'@*+O$LW75 CPOF@0)X[L*>409%TILI_X00Z\0(QC4U!2\V]4"XC#\3Q+@,<
MYFFR(0X/HR 8 (A7>/1MCQ_%P)C7I6E*^A=<.-9?665@3^#6/!#H]WES G^O
M(6KO[3Z)XZ!-04*6RE-PU A."8UQE<L#:W&P(E/)RV&!C&W!'<IBZ;3%TMVR
M6#JI6+I9%DN78^N7UDSG>].R./N]%V?G5WZ<D%)6YN&2$4R6FY\95JHWMZM4
M;ZP=![>E2=O=S2+N'- BELE8,,\JPI<3!IOW9H/N]QTP1']3/M0^<LPZT60I
MRO$@Z<KMQ ]:T@?3YF+SKFQ!664$-&L$XB,KUZE6W8U2NAF6KQ HOBU%;Q0\
MQ6Z-W0^F:CO6J616';FTGV*+.@DJ^L=66,-%6\5AHG$ *QFH\=OX+X_MX'",
MEQ?>G.!.<9@;S;'@_I[P->6+N=%CZGW45%C!3ST1U(S.)GUG9E\HM\%'*_Q7
M>!(/8SS&!">71@9F2Y\1.VUU*4@\IDQHLLA%G$BQR< V7T6Q2RP*-<)O,T=L
MRYCPB6WA-ZDJCTJ6ASXOEA&#O"T;7" &CC.\U,1B9T""-> E)K8%O^D[5%+<
M9Q;#=G5J^9!GIK!5>$/7'V +!5;LS,*;TN1YAYR.RG+Q.A<0P],I4]O@(2X/
M:(B_S!#-U=1SPC$Q "/!&,@Q*/%)X0CVZ!L8CAL&> TK?9#5LJ6#3L*;H>6D
M A+;P76"._([Z7R:<53/"%)Q@P &K[:1@**JQU?"%(8&8C?G4XO#]GXG;NW\
M)8?(R%B&8AJZC,I(*IJO9^638N)UXZ"-+.RP&>'$*SS1O>V)\<D=^+UIOYV^
M?MJU.B_+@>F+"FJU62$C?.Y[4UT[UF?5\IX,$9438N*Y&^*VLM)DQ/ 4HY4?
MRC]GSLOL+PQ:7B@W7!X1E?1-V\; J4-A4L.-ZYAYC1*($=D8%YSMHG+M.[P'
MD+U@O>1,U#>JL4AH<(/E9^9SK/!7\"0?/J+T[2'VT['!#T4HHK "$M2Z/C%P
M/12M+^'A7H(*:3'P -VDBXBJRQ]LMBP=@Z#@ 6B#S[P"#0F',MFR+W!#0%?Z
M.D &^P1MQU(K@?92MK'Y4^JU!32]D-O2-QQO3!>M+&@:?0I@_$G=F4 @^^Y*
MH&'N@L-P$VS*"?5U</8:"2/J>:^K4&"N/U'\*4!1>E4.P[%E-%<G^AG2]-($
M,V@OEZ>;IL@'#!R<I1(0:R7LAEJTHO+3L)7#:M@#B.,="P=K>8_\DX<+Q_W1
MC!R2.%'$DP=@HO,@Y0=U%&+YM1AUA[ORQ*\B7XQ/U(LOT9%# .?7YDB*',P&
M)JLL;#+(B&8.8(#M6%I7V]."2;JVB*E%E[>)U3/YV%,'X-4=J[IJF8TA7 *2
MRY!?)(X(195X@QZR4+ W4LAY,<( NS7LM\#S"DH@!@X8%QZ?QV6C_J56DH 0
MA,I8^]T*.I7!C 0^MR#86S6O,U!NN*Z8H*B\@J%@^\#F 'S;B5I-X+;BY AT
MX/&=X-13GIK&>KV$$[X685,1T@8@+P43GSL'#P($VA/>TB;F":AR3!R_F-!A
M7*H)OQ5;;E"2*?_U09@9^)E7/A$!?F'*G^4->)>/#B8M=1TGPB#(D<ME7UQN
M\I8=?7:A7$919HA" IH*088266/X>YLV=N+KI5,O2EG"V7WP2'"R7=L"V(2C
M+*)SUO@L"9[S1W3N-46_(G=0B!S]_/DV2]+#5<HD?4*2OE4FZ7=-IIUD>KX<
M:59FS4\^:[[<H\@P7=[:+EW>S"I=7MNQ*KRVI^%NA(G VXUXJ"?LX.Q8O%O+
MNWHW"3V4IZ3F]<I<I:D<O1'/+KG1]!*&OZC:?"8[N.<M\&5]';)Z/:R:)2?(
M96+T=+A#8" B%WWX47>P !<KB^$0-4VLXX0'C+DKL3R*$@V9G'SB:<<2FEIF
M-302%C<)SNWQ))9V@FUF52?+@AI/WY5[^X)?2*O66N>UN@H6N)A14;D+5ZQ%
M5M=(4^B*X^>+C<$$Y4-D7D5=:WW\3?D*'B\X]3+*$/\X@"IXCQ)Y3SA% _,E
MR)+H//LN9D-"?ATQ2E@DQE#X3 X<I$^N_(2?(K(O@.H2!LSQ<.M).)"#QU(O
ME.]BXH01>U2%ZNY%K!V[5G0']]O';!I<N\=O1W/P(V),'#R85LD7K6#:1!^,
MU?GY(6\Z;4Q7*&H@^W_XQ/8*VA+F?), O'BLO^)7:$)(.''NF>>1X/]X+B=(
M=[E24/(UQB ?=4?L11<AD[']-@\S_HP 8I7(F@2Q(H$&*_&\&JD-&C4O%ZX#
MML1<S@%<!8L_+I0D9A<1;WX["LF<OS%L!I&[#&3\! ]5B7WQ0E)9Y#F" (+P
MG!S'$LS1PBDJM)+ '=N.-X(?@9J-"W;! UW+1E$%2PR4H<\J(GQ.1$M)4@R*
M.4/2;=3M$E5GP3"^R$,6&CTX<;N""E#;?@1X77T14UC#=0KB>\& O4HP8(_6
M/(@@W1RA'\]LJT?;]=AD:MI4SO*95__@&B>Q<"'U8OHUSXG.KVKL9:CG)AX2
MKFPB22G+FPHZWG@#;.2KRQ) *(99XDS="=](!6*."N5><'*E12NLJ;G,=J1L
M&<(W+9JZ":QJ]'VZ.58QB#0<3>(EFY,9) [%*JOH)BN%SW.B]F;ZZ)O^ GI,
M=ZDM+!BV'.9_,S0[=QEWR5X00M^H'$TZL%N/O$SSL!@+[F7L97H6% <$)/*:
MA+RFQ6TQT')#O.0\0I<7(5#AR4O8,!G6OR ?!)V(KE@C1)'1J8/KZ_2^[7O"
M))+UH*3N'%JN%*BQ"*(H._.J&R990Y0AXVND\&^BMF@P-EA0(F&]5+#*A I_
M)OH/8.,/^!E1PGOU</U5UO#2)J;H9_%FN*MSBEN<Y"_D!\BN1<N)#V?C PY
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M!)LW7/6Y-$8*7N!\I$\,<_;;NBO09UWC+\9OC,?HMMK=3X'ADG"<C$_P!3E
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M.PQ(*TF"#B? UG\H=2YTT]JMI'G#SU>IV?-:9SE@E*(Y;.3V'9!-%X,RRX9
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M2NH4);OT%5 7^GY#+&\7)WV",5]O--)VZR]TH]*4XNZZ4RZ&NUOE<MA>.Q
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MVR-92G@D9WG _E,&VAH+]X3M!48Z^2>L/W(V2CNE #&<.K/[R2-YP6E;NK&
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M8F'24J.!)Z#4Z=8;8O(&55$-TCBF9&SUA\WERI5,M^$XJS+H-@AE=]\VD=3
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M(;H"QEPLN]$[]BXX'S5=(X*.1 </X$TW?N*8@1EB^ 9Y44P<LXN>@O]#.B+
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MO!DZ;3([F)L,QFJ&#HC,'M=BP"1-IHV=S>-88$+(N,YN,UFT"QG3Y3RQF(S
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MSR)"1N7-#%C$<-!+/*%NP:P?.TMXTL^)LS*D8RYFM1@N=2QN0<SUA-0HM:_
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M@ 3M'@%!E[4RV/#X1KMP:F4*BUL41,K>$9#RD5BRHI'QE6QHBO9B'J!$]H^
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M!^CR; =U##A5.5RZ@@AZ%,E3Y0G0Y4G*8\#92A*@RY.,QX":E<M;*H:P[6.
MP?8:H,N3>,> 8)7 ?RF(FL> 2)4A)%6VEDSM8X">RN&_E)L/C@&.VK?;4VX.
M. 8LJC0AJ=)1_QAPK'(Y6>7FAV. P?8<DBH=S8\!+RN!2U=N)C@&M&W_(:D<
M&^5WC@%6*X=+5Q!!CP%JV[=O5A ICP%G*TE(*D\R'@-J5BYOJ2#"'@,,MM>0
M5)[$.P8$JP3^2T'4/ 9$BN.05&YC!3K' #V5PW\I-Q\< QRU;[>GW!QP#%@4
M[R&IW*C?/08<JUQ.5KGYX1A@,#Y#4OG1_!CPLA*X=.5F@F- V\H0DLIM>F;W
M&&"U<KAT!1'T&*"V??MF!9'R&'"VTH2D\B/C,:!FY?*6"B+L,<!@>PY)Y4>\
M8T"P2N"_%$/-WGX0J;+NQC'@,64(T+5V\<=;^?GCO6, 9<KAS96;#XX!E]FW
M$UAN#C@.7*<D ;K24?\H0*!2N9SEYH=C0)+V'* K'<V/ 78J@8-;;B8X!HAJ
M_P&Z5HZ^_#'@5.5PZ8HA:/\HDJ?*$Z#+DY3'@+.5)$"7)QF/ 34KE[=4$&&/
M 0;;:X N3^(= X)5 O^E(&IRB4B9AO7I_DTCACE5Y@[E-.5U\FEH/YO*6)$-
M)4IIYD*G'&O[^OM!BM)YW6O[L?=.+7TNH1=D=E]M#4=$ _;6'::G7[F?7.L&
M&<DQE%1>*@K_+Q?6YQ(KV:2BKJ\?/@^_?+U59@J8?+R5+>0GFES"*9N(_(.H
MZLU,?B'QR'PD-!8;"+$<!(&_D?$7'7X*?K=/8O^32JA]@HN'0O!KQ3"M:V)8
MB@JO "K\@J!3X!+_^OJ"LYK#'&DN'2C-IYH^>R#:U*?YPT,EZ3[5FX=)]7/%
MG/XD/V]O+ZZOSZ/(?33$;O%(["?%4LG]Y$8;*Z_*V);5I0]U,57(Y.J=C&Q+
M>85K)LHH1HCK:,C=YI'<C\3TG.:PL_Q@D%=%MTUU\4CFNA'#$^,-,!(;'1ZI
M]DW^0S<N;-/29Z"95T%9)S[B?A?'I4H"#%_H&O"&9<@8'GU4S)_GBW.BC:8S
MV?@9BMCHMF:9R^!X3#,@Y7*>%G.REF#A[D7HXLK?=$2@>R@B0"T3[[.G-STK
M[L]+45:2=^22USL4R:L.'SY$H&R#JL5&_U!$@!X^C^25:'8DMU6L7VE_4>02
MYX]B?9\M[[6".*\2!,[/ )'+^$=L08AV1"I!V(L@B+L(@IBG(' 7%-J=&Q_D
M10Q6+"$?)EG-<"H;Y%PVR?BSKH_-@3:^TS4RFZOZ@I A,5Z5$3&?#%DSY1&N
MX7PQM.=P4V*LI.LY'U5FDR,DW,70*B$I3DC,6&;G\0@+=S'(2E@*%)9KW=[3
ML5(^)X2[\&TE*?E+RIW^&W"9;D1F*Q[-@<)=O+P2D_S%Q!&2&$#'T9PFW,74
M*S$Y?#$I'^#%90#\PC8,$(F%0]F1^Z]/7[Y>%N1S%I0;)W(9FRT3=:0<J2-Q
M&3XL$W7$/*G#94QK W6>OIP?EF:3N NTE(TZN6HV[A#^LE$G5\W&':2\A3I?
MOSP>F&;C#L8L&W5RU6S<H6=EHTZNFHT[T&8+=2[N?C\PS79(6,%>J).K9CLD
MK& OU,E3LS6YQ H>9>V%+(NMOBF:,K-GF>?6/Q@Z;*RU>%!AOP?:&'O>S7')
M+,#YVC8TQ;(- A=>*^_XU_Z&_N7(,%S"%^L,([]7#%,4PW"'J.Q$S5LBFP1[
M>]_,YH;^2LM!8Y S0WJ6.SV@R25T4Z:#QFN<I8QD]08DU+!C\AA_*H-+(*E,
M9\P1\0J7L%;Y](INZ<9O9*J,U,.T0KC$U\JG4@Z=3;@$^LJD3?Q^#[0)F'_)
M(?(*E[!CF53*$?$*=R"HCU(HFJR-%.TE,,OJ@6[#@VQ:EW;P=/BA6%-%ZS<N
MY46QKF]!5&QQ!Y;R2L4\ Q(M[A#,];SJ.]TBYJTN:R:%#D.D/5\L_PX9< XT
M=3\9J*K^!K^,M./X(S"WB.,!$3C/H%6+.RSQ4 A<;HRYQ1UN>)!\4;J:JQ9W
M&.&A\$51ACEWZ-Y.?O*YK:@X(259B)$_:G('PO%.S5RM<>Y@LBJ;8PLUN06R
M>*5FGK+9YA;0JJ+@JX3D%M/BD)"Y2B2WV%4B_1HWA,R?('(+3?%#OUSECUL(
MJ8JXKA*26\R'0T+F*I'<83LITRRXDC+NH)J4^5)<$:=XY"6=$FGT3L5V/EO!
M+6PQ,$UB#4:@X$T%VX<%6U"2M\]$NWF=Q)N2GB$#KX=[@G2+&^Y9^5&FX9X.
MMZC&)7FVEOYML"\OD?\BVB,Q==L8$?-&>R6FA=?$(WU.AWY^\MHI'L_((!8N
M]I+&PE=^E*T0% \DI#L'5[8B6V8JWB=/OQ6-?+:B>/<VK5R!?=1H)96KE1]E
M*U?%^Y6I[<OE5F3+3-QY9MXY^TA48(CQ S#3(M":U<0TBN4W0>S9&"KV#T5[
MN;:UEX$Z,?8T\#I/1[O#G2^W.SG-:UU[^4*4PR,B!SY?R;T';EW%\GL/#).Y
MD8SR:S_*E/+=RF\L)A$P/_NVRVT<G#,2YF=5=KF-@)>?A.5VK;K<QLZ'%FP"
M_AX#<=;B0I_-=0W^&1S^.K2?S9&AS.D<"C]9^T8;J39F@<)O9KHVM/11U(0*
M_HS2+K=!]0,@;)Z%6%UN@^R\$K;<!5A=;A&A\O+#__X?IZ?"__WQ[;?.__N_
M_Q[-[???M79__%?W]>7WA?;]TG[[W#7ZW:_2']^?%J;:?1W]U5#_:?UJ#<D_
M_^HV?[Z+HUNK\=_7U]+PZZ^O[^<7OS=>QT/C]T[S\<O,.'^_&=S]>=^__7YA
MCR[F/?W?CW_^\64T^^.W]G_9BKWX^L?XH?>\>#>MF^X_U3=U<O/V\L>E_JO]
M=MO_W!]9I"_^\VG\TYZ__6N@G/^SV9T,X:(_SD?_OFE\N[^SAU??+__Y:-S^
M<_&G<JOI]O"G,GOO_G8U^WG[4QM)DROS7[-_GHO__->M:EP8Q)+^?64]]O_U
MQ_?.]V?K6O[^YS?C_+];ROS[T^C/W_Y]\=^_6I__==$8?I[^T-1^ZT7_X^?S
M:__ZX5V:/@ROORO#GV_MK_\Z?_QQK2B3Q9_:7Z-^X_VO[Y^)^5]_]::]Q>?_
MNNM;5Y?GP\?&__E_PL7P\?1T![RB7,5M76YAN_+*7#)'**_#E=O"F0C"+N>X
M^<3S"3H8CVF:@ZP^R,KX1KN0YXHEJX?6HJ#++<AX&+3-TRCN<0LC<DS;<MO%
M/6YAR4-AB=*9;3UN84Z.6:(@RZW''9"):= ^73\3_<60YU.LMG/G7V 3"@.'
M,5:JG#LL,R9MG[X<D !RATO&)-+7""(ET>-87W0GSX(EMO>CD3V7'0V-L[*'
M=&,.L95CCSNDLH!&OQ43%LR$W$%W!700KIBP8";D#F8L!X=\(;)J32]D@\3E
M#?Y8@SN4\F@.R2/@OCYW..K1G(['P'W<0;;E8(T'YYI8?,$?4W 'VA[-@;@?
MOBLW5MGG$H<^BA.T8E<&NQXJM/[U<T7;0T7DHT)B2?3$C3;29^1)?A_8UE0W
ME)6:U2]?AX/'2$/[:/CIV/#[8Z#IL<'AQT!3[M#ES<IXS82[L T#;@]7/!CZ
MJX*__KHP7A9_H<-9F70.^;E#D'DF?]F2W*0&=Q!N&O)?R+-G?:S(1:*AI19_
MJ<$=B,HU_<LG_]SAI;'I?PN;]$ T6;46R?7_\2@ [A!(OAF@?!J 2TP/"#JV
M1]:],23&JS(*DOWFM^LG@\BT?8?[;67K.Z3F$N+C@=3EDVHNT3<>2"WN0FHQ
M3U)S"<IM(?40#'?]11XM!MI(45796%S(!M8F:>-[:TJ\7Q0XVJ;D:IT[!(]O
M!BB?LN<.P^.; 4IW!(C<H7@1L=OX\=1C4?(B=T!=V4E<.C4N<H?%E9W$Y5/4
MW*%MI4V@*I_X<@FDE9*VY9-;+I&S#))HC\&RXA(J*R5MRZ>3N<3&2DG;\NED
M+F&OLO1Y*;E.YA+1*B5M2Z>3I4,#J_9'V]+I9*E"J=*3N)A264FJX*9,:95C
M-V))JG C#@2J H XD*2#17(*)E*.#;HEJ8)D.%!W%;;"@;H[5)"D:"+EJNXJ
MM*/\DM2L8(OR2U*3._S!JV89C"@]S#O=(N:M+FOF0!M?*YJLC13M93E8"2>F
M>W\_+>;!K+E+,M=-Q3*]++GEA0>'732YPRY\.K_)QGB-<(/AP^#B)KHHD4,Z
M<8=;E)=.N1YNW$$7AZLW<ST?N4,_RBN/N=*).P#$H],C4<'B'#_(AK5X,D <
MY1'V:#=1_I;?!(CXS1@J]@^0U6M;>QFH$R-RVGJ&Y"QWI+3)'<)R %Q0NER(
M)G<0SLY<\$4VX#0WK%MEIEC1'' \BH [@(AW%BB=%FAQ!S]%L$#0 %<,,K)T
MPWPD,ULC!IWJ\J3O<"8<$T-P"W4=!D.4[I!H<8N)'09#E"X9K\4M^+8[0YC7
MNO;RA2B_V^1)T2(;O1W-8<$MOL<[*Y3OF. 6 N2=%<IW0!P:RAA@A1^R\DJ,
M^TGPRG-9E;41N9\DMQN.YJ X-,B1.Y8HWX%Q:/@C=RQ1OH.C>#PR3:0.M&P'
M=B.72%V;6UQN:#^;Y$\;;G#U"O]9QE8W7!#+:DJZ &6LR,9B**L@;T-+'_U<
M7<*#H;P"USZH\HAFL>TKUMLZ;4BG4C\?#N(6R,N%@[@B';>06WE)MW+RK1$O
MWLFW]J-,3[XVMY@:*X$&C2)88;P^BH?!7D5I!FX!MXI/>%!#W()X_% <_J^9
MF.+!'V5+<6ZQNO)2?/4L")(NV[. 6TR-(]*U\B$==]@7%GW=OVG$,*?*?*6E
MMNML*\7-35@E4N>TV<B'2-QEQVTBTAUY^TRTF]=)O.RW_,Z^Y'#C&H$S/?LZ
MW&%LFPA\??WP>?CE:]SDQN.A,'<8V"8*_R"J>C.37T@EPBL$Y@XIVT3@;V3\
M18>?:B^F3V+_DTJB?8)S!Y1MU-F*85K7Q+ 4%5X!]/<%W)L8+O&OKR_VE:->
M/IIS!WK%I/E4TV</1)OZ-']XJ"3=ISIW6%0\JI\KYO0G^7E[>W%]?;X_&*ID
MQ.8.AD)B/RD6!IAOM+'RJHQMKP,*?G4Q5<CDZIV,;$MYA6LFRH@8E4;WR,T=
M=(4T_2;_H1L7MFGI,Y#Q@(#?:\3[.(Y=G@0JN]"U$:S623E]5,R?YXMSHHVF
M,]E8RVGP.A;$;S.P W+'6$X8O?/V(G1QY;0XW,\E^K>1^[W/GM[TBOM+Q_VE
M2P7N< FK%JG[\7F/LO9"EN;$-T539O8L\T!Y)6"'=[QTN82UBSQ>6 (FOU<"
M5DX!*]T)UN4RJK!1P![)*]'L>$W)*M8_\K.%RWA+%.O[;!E]QF3$>94@%'(&
MY"@(W,6A=N?&!WD1@Q5+R(=)5C.<R@8YETTR_JSK8VS:>:=K9#97]04A0V*\
M*B-B!JK]SA=#>PXW)<9*-I3SD0E>8:$U124_-;@+X%7"4J"P7.MV+.RD-,=*
MCJX%ET'/TH)5E3!6)U<Z>>0R+EU:;*N2Q^IP3"&,W&4-'"T"4+B\P+'U&S";
M;D3GRA[-V<5=FD%UL!R#H)0/R^,N(Z$2E/P%Y4Z/*2?'<I[TN,LKJ,3D\,6D
M=*=)C\OL@ O;,$ DW)$9(_=?G[Y\O2P(!RJHJ+O'90"[3-1IYDD=[J*J6ZCS
M].7\P&2'NS!>V:B3J^QP&3K:0)VO7QX/3':X#"24B3JYR@YWR/(6ZES<_7Y@
MLL,=D%DVZN0J.]RA9P6F+#P8.FRLM7A08;_!P;[ZTU;FN&26XW]M&YIBV0:A
MHZ;?\:]".W\4),Y][G"D F/J%<,P&(8[1&4G:MX2V21371W?S.:&_DH;T\<@
MY]'@SWTNH9LR'31>HREE)*LW(*&&'9/'^%,97 ))93ICCHA7N(2URJ=7=$LW
M?B-39:0>IA7");Y6/I5RZ&S")=!7)FWB7>PTS?(O.41>X1)V+)-*.2)>X0X$
M]5$*19.UD:*]+'.:S0>Z#0^R:5W:P=/AAV)-%:W?N)07Q;J^15&1.[!T/3/J
M3K>(>:O+FDE!IQ!ISQ?+OT-'OP-JW$\&JJJ_X33,*"(?";;1;'"'B1X*7Q0C
M^,U&\1AF.A%IGC:Z9:K^:3:X@_]VLF3.;47%GN_)0&#^Y($[@*Z*T&RA)G<0
M6H6%L@G)'<BUDUC&Q9_XHQ]WZ%/E[K,)>6S0$%?$X0Z+28GQ<D4<;B$6?Y;B
M8BCC7(FAI8]^KLU:'!G*G-:#^<[TC392;?08+O393-?HCPHL[5W),ESQ_C*E
MJL@M0,(_5?.359';S"XNJ5IN#%3D%N#AGQE*A_:)W.)#7#)#0;:9R"U.-+2
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M1!Y3(!@N!0X\\_[[K(\79_#9U)JI9_\_4$L#!!0    ( %)785F4'%:H[0,
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M-ZG,MWSC2*\/6)1WKBHR1P.>:TYV;'A*+#;L+,^PZ<S_H<WRMO)[Y9F$A7S
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M#KT^&FOC=S/!OI:J3='EBNR1V$%1>5O\O?Q(2@H+C'$XX^7AB%<*,K0:>KP
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M")+^YMAO($"3L'2-@":N.8)QIZ[? ^4_@&DZXSCJG3#Y,>FUP<MRHL<_1-$
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MM[Y3SL'.DW.B!WNJATN^UJ.%PYT"R=1E.!0Z_-]P_6?F*7KKMOI79%9=H3/
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M;GTAFF9A?'V^)PYC3MM=DH'O)F->H!T36LQ-J6""B4K!7RK%,HR:/0%_1TH
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MJ@%]BW472,7LE3,43P5=X(94JMM/T$DI@21D0>LP^^:A90U/%+4-_3C=%+9
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MG'&;=;4R3C6M**SZP%I+WG6SL"/.C>7FB-::"[#56$=V2M,I%<\HLP/.IQX
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MK%(XL4,<FJ"Z6Z=?@,\&2:P;]A,AR+8ZO;,LVP"R%W637082FA(0[L7Z24?
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M6VJB2[R&W#!%<<;-D49SP^TA066XU?LC#$<*GZ<17V ?- ;AQI=0.,E6@?M
M%<+V'9'6-6@CJ!Z;96-]NOW%N4$<YS$7,!PKB&F.6_H8U9Z;"-:+"5K&1E5H
M18.:D?/94-+G6@-]?DT9R>[X@DHSNX^9@&W6-KXIP'A<C-HJ]4TF0L#MZ<F)
M65CE@1XHZ3B2P=[>S4Q ^P]U34+\]<5L)8>6..2%>A:89%G^R5)G*.8VO@X<
M/EP-3O\Y2+K0[)Z=% 0VW) N8B<RLH9"R?L7C;'MH$U8;52W<!G1I=.J.PKH
M-@I;X&<^@[$+B,\%.P;-(M" E06D6"-,>/I:J3$OJ##&.*>ZICKC)O0E>F0
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MO 923/ICIJA>:+N,%_=)+_/L[636\MY4-CTVCO<87P\>/>#!/@IJ346P1N1
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M2\7G<4>+7)'4X=LND"]>DB*?T'2B"$?SXJ-C-V=Z-C2UIMV*;14ZU-JB][]
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M--F2>J*ASO:6U15UWAI>"%K8)5E"S1@![\>]>0.$X-@5,N-96$?MC#(/#D1
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MQ.^?$/YH?@J3"ZDGP+F&K(11*PV,.N1Q[/C@='Z[LDFEK7I;3P?.$(?]X#"
MUZ+/M80> N'R9Z!(($J.PM1\+@>M\T%Z',X80*)<90-Z)5T$G)*L=K.74,MX
MS:Y>9X#5R553-C<X7/48(Q?;A^<2C(GS]LW,>LQT%J@C%9!64K7 H6;\'H@1
M7JIUDN_2<Z6?7.OJC>\B1RS>3)0EU7X7^X4+?O+]&%WOK]\#N\1(?8^Q^[E]
M18*(W-/>XY12.:1D4+5!HS;,6IP?.-6<9P)VW:[-F2&UWKI99IT3ACWE9V<?
MC;4*@CT7O>!M/EFI4MM]AW :15-98U;9LYW5B8<>?!NC;$.IHGA7EE#0'J^9
M=(>%9BU:A^< )PJ08^,P*ZAHD"FY3*@V8' Q$]Q5R@+\KBF2(7SP^M,/-LEB
MEA;E16AB/]X$MAOX!+C=V0H\2F]OM6_T<R+U6!"J(S6(_4QH9]?,?;!=1K]'
M"(K5D;<!TW6_4?$&_CL!9LH\9OFD?CF(EI#E81\Q&[@CA1,JM>Z(U<1$_X/L
M(951:;SE7(5(_^/P1/Z\,\?;LI<2Y[$X281V+:&F[4.!FA-07[FJ1[6\FV8X
MY7^@#J*'2K$Z2ZAK%!]?HMZ8O^\'?NF4$)U4&XL5Y&VL^TZV",SQ!G<RBB9N
M-MS,+PU9L/O=SC,_()K0A]'"6U /0F^?^%,J)%&I<XS-E%\[2(.X_:JMW3LR
M9X\U#%IIW E]ZE@<DG?&.]3SM%OSUD&KZ-G:F)ZLY[Q7:?HHS)NH:3_ 0\IH
M)@XSQ($SK6*T43!("6D3>4)&*WC3EXJ@0*GM] H)RQ#V!$?'VWCIV5X)0Z^%
MV#3N@09H3]=KVOH(D!</$^G1@66.,;I1/A&V&ICN3!YPEC#B(HEJC9.1DDC:
M7SE>"DL*Y@3P/D=*TJ.TR]U TCTJMI)J"[($#N1FU1IE%>PK1:^!W$2M-$S=
M .= "=.$PGAM8O*\MH]C6^KMQZTNH5QKDXY=5)X_:V S.%0WI!^5"?@)_9HM
MV0-5?[EWA86'X<)TY0OK3[)TNUUU:F^T;JN]<?ROC,JBN\N@> 2*HI25-#O:
M4#7U-%0()LIS>G'7"T,];]KRM B!H;R[PL 6WF8*AD\?,1C\!GLPSV?Q_74'
MX0!@H9WF]ZB+;UM7,_BD%X<IFYB2+J%T)U7[N;F6A.OFX[-W12_JI^<5]B$F
M>P:X&K Y(+K-)AJ.&C$WA-@%RN-'YR<?"_^.4(16^2O<<YR["UY><N E1D3U
MS1D%WWU++A%,Q-/N/%G.]5'6T3_UTP[2/]R/7$(59YZ;MZ2R%5>74&_+8 1I
MJK=-+:%<+"H^2IC_[/XY1M7^BJ"J!,QR$=!^4VJ%O'^3L(1RWZ?67^ON2 DL
MH(AF=)Y"3D<@=;#P/#A?A0ATK2A^S*X1=,P=3V1Q?$,C"XY*FAQ9,U]Q^XJ_
M^'PN9+5:+9/%[FP_/K"7]2B=HV]PQ@[QL^V)TS(I'4-[?P"1=P>.GX21=*M+
M@,4X(R/ZX@444SR9)7I.I:WO7T+]BEU%296AIQOSX6O@9@.N(40L=?Z/PR:Z
MT'4Q1N@BU4J\1S,=\YL<VY$E<4K1B_"["I]Z60.2Y...*,1)VR@K5?@NQ6G8
M!GJ4#\T*OJ%7P5N@1T"]!U+8$WU5[3[3JNW]A !Z"JFV=%HCLH!Z=H"[RA&0
M=KB!>DI$"+1L9:+I[X40\63*X)3D<ZJ8M%[58]=UCT6UOU2.T:$]I0W2,?0K
M7<-+*,0"*7Z"3T+O,4Y9+<QJ@QG'0A'TM4-L*V E&0CQY: &,LO3;3_Z8C\"
MZ;=5AI3JZ4C+F!. 69MMS]Q+-N79]%RG?6NU*SE +4G&N*"LK!R]Y-V+LR^:
M]%E(LO:S/=(]%VI413P_R$Z=\CO@W%L[LM'_\X)[/]MH^)>:ZNJ:^@SGK\^^
MEJ2,C>E&!]S7]KZM]JT)'%&MC55<I*P=EQ47LUK1R7DK>FC;8!3T17%*)?!I
M3T;(5K0^-,]FH KG!"CD.(BAV 5O 0D)U /B)=2&B4&?NFJ9993\!61<-DR1
MRHZ"?]VGX,.B!$"P'?>^1*'TG?>2,&86JB"B7!V1H"!,AH]:*B<0M)<[@:3V
MKGO<GX&N>-4F:(AO8@6Q9>BX,>M!JC'0AO# G_XZ3?7$#;3N;%O87*0K]*,8
M\OVAT/Q)WGK!3<-'W#N%_L]RY*1FUL@*>0BD%,]N1.R,A-3*6Q=*0T1UQQOP
M?55E<R7%2*5M[NM*4'CZ72(]![\^EJ033P&2Y[ZI23CWR !,XK4V9H53Z%/7
MO?>?.@63CBMK" &=X6*#%'J(.3&=IE$#J8MCM&+.()6#O/["&,7+!8BO3RA^
M8'F6PB2"#GGW64&VERY[!#?0RHN$DX9_E^07BH)N-J3GO2KLHBZ#*X7PY3[:
M:EJ7B;7R]Q^;')*\>";4@#)5-P%PI8_$2-I;,2M4G;Q:ZICF*\2L-\J3("-0
M1\9E!9=,B=91G5A?2(:S<[/+X2-*%B](ZY;YC%G7("](&7BBUTK+U*-VJ/8$
M-V>0+B[XT38G+*1+2N9W,'4A!C(_&=3#"A?:>^Y:2$_6B!Y.D;77"TM*9;/I
M<MXZ0M 2ZO9^:+GBM9,3L#<'0$L,DCG:X+,1$I0E=0@77!^;<BV9Y.G YXJ&
M0^2&7K-, 7:D7HZ'W,%UY'O(W!."2 DJ+>B^ 3]T-M4=LK\P:-CGRP/<LJW&
M&U[VS*0W:H4+CFA=<FJJ!W:F+:CLF_K8Z69G7@ #;<SR#Q\_QGH%1ZY"RL1,
MQ3^90YG J.\;=]G^P]<-.W3^^/OL?=NVR9'MQR+?#YW[Y1!*1:>'S@J]6D2U
MI;"V2()!5(&[[">(V4[:Q+M4#E\$8-@ ^=%#0*F L(PV0-!DBU(7+]!6]'/4
M*REMPHX6DPV D^"5M:O/[*%8F_'#??,_7YVW/-EQ[H6JMT693Q!7\G38C-0E
ME":+?G$)I4$9:><M@S%2'IH2*-T-HE]CDKAK$.X3_%%DMXX'WIQJL9M-HRY7
MF8%N#,!4G%$3#>J/.P'K<L4._AA=2LCL<:8/.% U7Q^_394\\03=BO[@@@!8
M,7Q.<9GJK7Q$",;J3'*W(Y-]% '.#(ZO6(NV(#Y>#LSCP@H=%<=AUUHH6OJ*
MZI4?9 X %Z;H-?%=S;SUA(2JR,985WK=*J6<<>F9\[/@;/),[/]&\'_I/%M"
MC1!._G;Y'TP-.LGTYQ6HC_ Y@'_;^=,&RQLH\>V15QHDXM!?UU4+\K;'2ZCQ
M(?F-!^@C^#X00\RY Q_ZQ]0,^I<:Z-7W:":0]'TGJ8/_ZJ1B+)2@Y'S_MH3Z
MAQ'[_4*X(G,M01'D[J@GS;O];RL!RR!WQ +>!WE)JITAI%7T7PD)/&TI1) Q
M-R)V9 ,ON#-&&I7*-:"2H'B@XE"W:A6%(-"AXONL19"GX;X(*+V(ZL1)E3^&
M?GI!R>R\"M,5.X-[)NT\2_'UDB:L-R0=D=^!ID!;>1QDJ[A,^^LF21NO!Y7*
MZY7I],M+J+A]L -H.SV/26+/IM!U8#/%(6H4P)M1"P4U6DW,@(2XIY!]&[,Z
M"U$98U;;F_&AG)8Q72@SPL^4KY_%-0,FLEPP_?.ZRV#ZE @XBQTIHMR<DH@8
M]. JDCP2*3"YX:^1\APYI:^\@PN4C=J[0W<JJ<LA>[,TG*^,O%X(Z0AH:L!X
M"S9>9%3%/7@!4DV]#I/&!@H69B7T1#HZ4L/>-P>]H8J^ I$V5\+5T%F](WEH
M99T*2Z68'@=1?=155?3FW3A7H-0#O/)*ZJ?F :(3I V!0.>?7!0P_EJT/#B[
M/0EO#;L/<%PJH5ND% T)3YU">JW: L@?2UWHZ^D7];XSVD3"<?EUY9_LV=64
M2S*O5C^-U]D+C*\;T%K!]8.W/A=;_-8T[4,9F"_MKJWR1*M#P>0=/SE+6?HN
M!920G?7<_9-OLB,5OBC:.MI?='9IBLJ>)N0!KE6^\C2 5BZ9%:+Y*C7E*YQZ
M!25%)'%*]\'H(EQ52U)G\0*Q1E"<=%TRT'<8BBVAMTP"6?<0 V$BG) _H/@>
MZ6,)57TJ[2YTB)9^9C@O#+$Y3($G8M/:V HGB'0>C.?QB=#.A525.KP+I//?
MX-'4JX/42-"3E.;SK(RG-X^][6_:S<$0X@N!9Z4FC0@NRAY>.$_A*YQ<E;FU
M\MZ]<^>X?2PR/0:_G_:!64.85E92#/@($G"Q%'*+8;N 4>,LT3!(/#_X"?G<
MWH(7=>#J I51GW42YZ#DX+7B]:PTG,O.^Y)?ND<S!_6ND@W7D?B\^J'I2&D3
M2>J6_(0:"[C.S[;X;9LE@95_"9OR'JY+_?6S>:<'WT>IR@K-IZC:QBYI<>I-
MEO5370T_CGVI&_X^[VIG_P3]FJ<&*>0B91YM*ZU_3$.9Y>7'!C)J%&?A,&69
M]1(JH5!^HZ>HAV9 51_"[Z5@!'D_MBIQG&VRBEFI5PG!HL3L<8'ES=F3;,X@
MY[H8#1T>=,#PL]VJKSL\DHA%T!["3#YXR16*J4*RX',C"\HA0F$R+=]6D0;.
M5+&3\L(AA*CS)6_;4)5;(4A&AF0#;H7$P=<9B,Q**.F);#)K):E3(W4FJGU]
M",D<+=EN\M[ISZID_&K:$+/&:6:_I:\8W49>!7N[L-2]*>*WXH[A^?.5. =Z
M^<<@>5?5R<P.3.(\<\;<)=67H3'%**44O,U'7%4HY=!O2N-#F'<TI+ZN.H1P
M5=887W'PBP<5#[0E&XO2R+4,;?@8%)\_94B(I_WD&XH_V%O+B\_,V]$/'P0\
MW%V.@4NHEHK.**G5!G@OT,4?ZF,W&1#[(AMG5K?$=.ZE7X#0R#=K0DTR!K2K
MM(5W;^QGJ/0IQ&^VP9C\V(D[+!_G9V=-ATEG-0N"\M! W$>J*20+ #-("7)W
MRJ\*:6+J7A;-9-+&YV8361SFX09PO'Z*MJ1?=^B:*_^_' G\;OMZ7Z-4;89$
M@.4(<(0<^*#,$I>V:)C&]8M']*[.10:0?K.,/4"RHG7=YJ7P@BOB!F7R._U-
M+RRYQK#]BTW^*?0>4#5HNX32BSE(>^REC8>N%A!HT>KTF41FRA(J]AVGXA)S
M-,N9/M/>.X>P=?M_62'7^V8[LQ M2<5^2)779+49GAZ*V,0+9*4:QK8A([QF
MK%2F-L!B$U=-+EY)+3TJJ3(Z.63MY_/YNV]C7]5,V'1$SDC\JP>[>[?^O4EG
M*GO7"J@*LI4RDPDUK%;F\$(K5P\J9%'&6[-%L Y1'@5$,#=N5\9;PCMB%!CJ
MIG[NM@]^5(_^B"H,'[.V5FG>CM\*D22Y-GY'5=K$C<I&099^9^1FKDG_JH]U
MWY2I1?1F9QZY2D/*NAUFS9OIVJAZ_QPJ]>T-A(8(TXHRB.@./5+L.QKX"]51
M$>A'V=;W>C&!O;<>D,N_2;9 T1)[TO+A$2T''3_ +.W7@:IG580R(?*39S@_
MNEZJA#0M""LAQJL($#NR6-7-U*<ZBK7H"/<(D)$8Q@H6T1DX,B!JQ^^&:@I"
M#<>2 2DVT60;H,>+QVM^,5D.T 6$U+#R"0,\(552GQ+Y-F+4U&4P,9&<-5\H
M!<";C8"72GT&9,@(@A&L< DECX;"I);D=E(=/8-F BW?!6\%-^V$8J0.!$08
MUG_%KX0\1\Z^ZJ=J SFRS4*;QBK(S3S6UQ](9R1<X0Y%6))]>]GV^Q:SP HQ
MIADI?N8MIJ]YACB-8LHL7WM27UC%SLBW*;P8>;'<Q^9B4Y]UNO["J<&Y5\,:
M(Q_QN67"G(Z#@=6-WZ?'L]5M*J_2#. 54*#>H]_]]2$24"JI3V2&9-5TX[ 2
M,OI+=6T-$?<=YRD'=^^_X#?Z\<2005:X2WBX9>O??STXL0S.@S<JR[C;J.N@
M].AR6B<)C5LFP=S[\3"KJ]@1TFGH(J"0+$Q7*9RAWBXI*YDQW2GI$&G -S.6
M4-)KJ0%2T3WS9[ 3.7$)I3;#T998.KWFH@;G#U)C=OPY(REEIYZ<9-'%Y1C@
M= 5F.77OT)-^C@N! :\HH_4LH;1QYP A>IBK:-<7U2Y,=P =XI)2T%Y2+QAU
M:5<9(@$5:_[:@(:%6!*,'G5M&$:B2L^'\KX.&)SN@[?:-"ISRT(PO4XMO!&T
M/!#J \9;1?I<$RH)>%\,*%Y;_@L7+C6^X>#[>DH,556Y3OE3<DZ!@SF2IL!C
M?:5L[RO5_?/&=B*W_@<:S&E%Q</0?VT#[R,%Q%$9A[Z'V-K-&"'FD!_: S2G
MN G'B&OA8XS6?2$5(4-5X660/E&-E6'%T$HZ&R>S].77^:]7'+= ](OVH6,9
M"I8K[Q#(I!1"'7FF%3SB1Y"_!(J[ICLDL22I02)W([R]%M(CQ$?PA&NGCO59
MU<8)"&MHVZ'Q9JX)F!-$UU@IE#\"B4=X0["35'E)IA:'HV;OS94P$_#KFMBO
MX%XH4:R!6"VV\BE,!PHE;L4@1I(E($,6K.ES^:IN_*8!KA;E!68U]6<V1&31
M.A99MY'R%&I$,* X$;M_@:+"6!13>0'THXT6 6UQ+1)C/&6ROQOG(17I$N*I
MYF2;*L4H5K"$@G;8-J.%B6TF^\C&U%4 8X; HMJ]@O(K_ ZS1D53V4-Q\Q<1
M4V W="<B-337B9_-2+'^P*H-CO0SD[0Q;1GS(P0=[Y!;";DQH;)=7^?I_>JF
M&4%CN]UWI)P-^I3AZ)5Q8O1D@]U/>R8F3[YXON?=B2UQB#XPFC$CXW(I))-@
MDIBU"W'TJ\8$@<DJ* H,E<PF?5;FS-&'O8Z%,O55[Z[#-_"&T(C"$;+U':1N
M0A@ZQ6YV&L9KN_$VX#4Z)+NHL>!Q?G.J)-=%:E/ZC,*0KKM3>%08)*IS@O5L
MV_UU(#7$:-)^_H'T=!UJ@#*=8ZWX]0MI]?SLG6RSVYQS51!/_@OD+&6L5'U8
M0M7@#$G)E50':>PF[E;:$&$]/0"-AF+.]Q?6@3O3)4P#V(<+7"LW88AG#,-(
M"U,2@^E2!8ZZ"B2F<\* 1 DQ@:HE929%';A J?#JS50%?STC<W\U4-)76\8V
M&ADA:0;="#&PO#%F#' ,;>[ZBXBDZ5FL2]^9O@I@Z#7O'A<-E8(&,G(B%5V$
MR)F>RF($NM$E5<M(]1\+;5!FW9NK"-,Y_/P[Z^O7@MY*B]H.<Z-@BX@3$2,N
MWR]=PA=JC78^JNQ!T:WL1+!NEEQ1I\SC:L(G@"[!>9PK:'H(:E9XN%3!=@A>
M6GI)SRVAVD5QF.6$RZ,D^?T$3(K=5P80*AE[",0)XJ3ODPNH*U\0$WP<V%U)
ML YH=GP@XB#U,&CW3G*54$9.Y%KWT+93T,WT]1S;B(4Q#-@>7XO6G\AZ$-S0
MEK'@XY44T>CGV2*I9:X_'WSKZQ^](W['/_.]^ZR49[KK[],#PB(>M.3&_]O.
MHE1:-U*2J"L ';$HG;8']NB!79_!]L H]WZP5'F@!:\VR-T^M3^(NQM<=U^B
M4?%0S$2?#VEXWU3XA>_OYR3H_A"<?2^3:U@[,*]6\RJA]P1)&/0$_4DDCX'8
MBC.J'X]QPJ^A+GO9O5>E2V_A0;' ?5A'8>JDL&Z7-JG)7P"!C*\7AWA!79LH
M'4@,25S/<8W'J#NZV3S#,?R=X(H)0V:2*6#9$&+H61_^S#IW-I&Z4EE#OTI
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M2J#1_.1J#<&.IKH-];OEG?_?>^K$_Q\.9JEJ'?X1FDP)INEC3C"=,]B?VK4
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M7E6[7(S&;GR>@JMVPE]2[X1.;XB\DUKHN-MZ#S<>FL@R98Z'-].(N F#M==
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M!,Q72NG(%Y ,[,U)RN//T&38HE-:D#:44 7+(RQLT* '$8Y=2SXX<(DT1J7
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M$7>TX.F>RD*A=2+SN/1<SI0RNC%C5;WSU%=Z=66M,6WL*B\I=WJ8-#]')RE
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M-?; G E, LP7%K?;R1[P[S%]+5Q0110LK@VP:AV$V/R*@L1N)(A33[-@#/C
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M.,M7-2.DO1$T8AJ.Z:GV@PN::!A=#YO? T0VA#%NM/C>1W96"6K@LW)]FFX
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M3M")F35Y<JM-OE:%CQKML^BZ]1)W5JO$$ @A#H0&5(,WQ8B[CY22.2VXC*Z
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M>?@H]SX0A'8G,**;Q*[S7O'-T>0/]/&0NC&JJIN5Q:Z('1@A,;MXDM"TJP;
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M11#PMMI]$?:T*LT<@#/:<$\#F_HG;YLZM!W?C$4GNGEL;QVQ3.Y4$)/T0K!
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MS:ST#A7;19:9RN[S\NM[9L;Y'WB<;>?+61;XW+2#['?E(,EP2QH!SY,MYM/
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MQ*AU2+0>:Z92CW0 4=!OR- -(@842FEVL7<>:\6HODQU>R3N$KX8<&'O;%H
M:G?[?EDZ5,3\.N.?8\W%&[KXOE#14M?]S4[6Z-&;)5,V!(KZ"<_\3M./4W1R
M27R=_=(Q]<E.NA7J'8Q4_)RZ^BS7/ K?\0JS381VV\!W_2BO/S LQ^Q[Q"V%
MT<<Y?DZZI@M1=;67+EY)A [R76.)I5UG$F_HHG,O0Y+,/,'V1L1'-;&&?Z!
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M];09S!;B5S",J0ZU>#22.A09 R#4*T*9.8NP%I@-[]D -%XVKDKZR.K09BF
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M]P-8Y!*=0=F"A^V\A7+N)7<X#E6"@_EBY*MG0*&$90*OAJKONHC86(@!F01
M!<J"%#7E,N%TW /Z#6'S:<&5,P+ /XM';4T6,G&9LGT#FJ;N:0-+9#O[<ZPT
M02AH<LD51*/JQ6[R(M-\'M/>"T@F>Q^$(3TLLY:0"P_IBH.]A U@F&3$"EJE
MDN:?>R_GOACS>)DTY7("6!VQ"=!55,!^SV26(Y_C:=-?]G[]^,W7)F-1;9S7
MHZJJ%XH"EBU_-YTL9JWT9#DPJ(!,.(]9"FG((%<TQ1(3E\7M4C&O.64K7S;@
M311?=S-VWX\)C6E-G[IXK/4YV<"M\7C0,=/X68OJ4V4I9RG#3D6YBE@"4A2-
M\@_4&\J)6[%729:>812YE20(NM82=6[#$^IY_DI9S]LDW%)ZI&CN=%;Q'3I;
MV+R^L3'T:GK%F)SUX7C_>NX_$!1LVR*92QAFT"Q(4Q:*L-DC/O7DK-+E(/]9
M);WP>VKJCZR5$PJ+Q!+ODV $VX(=274OOO-^K(IZT5^W[WDU5#$3UOF2>ZH/
M=BD+"]V3DOJ1-2E9J),"S0#!?E";4GIE'F/*W, @0]EUS$$*CYP%XU1X:Y@)
MT*[P<)E%)FW:;(X%<SM]0E4@$54!NMN1==$1)E#P??J0VB0=?Z?7UG50W<NT
M<Q56=QH_NH.K%=1+)U^J\6D1:R'D">,@^"4ZELC:<:?E/<2E\*KN)+/7!#O]
M;@C;-H)EF>>S4-*(MXSUL16H)R:>)7&M_2//S]F/7SQ^X\'8K4>Q3453 W<_
MTC($RGS.$UF:]J'G%$[-F;J!OP)[E6YC9;.6>U+D3>JK-1IVID^52+IBB,Y6
M5^4@#A.RYHPG]!0QR=K)-!'O"%W?3^,54-N#92.V=N?E6U[&V.6AK+68T@+*
M1+3,\R-.AB(^WOWIB!&4#N:W^5@4@Y(V9#7 9A/<4(G/5;M(*)=N<98_5'Q_
M:U4=\RO&5X#=%7AO$?&.(W,9_=-W@*'N^;F' =6APY+'2@KT%8_;(3'<Y*^)
M4=2SIQ;]-/)5/^(1XS-[F>G$\ 5&<V@/^9OH--WW#89[+;N SJ/ F=N+[U$<
M:ADA0$I'*"6'X%W]OG".6:(BY^@>QS1=0QWJGF2,GJ+2PE9-2I=V;C[+@K@-
M,@F#.E6"%0QWZ("&D\[$O=K"W +=99BP5-H\IPT+KR983B]LZ]H>0UP#:MF(
M<_@>T$5<NEU0,%,2)KEX_)IZ5:6=UW>UVH4*WE'S&".FM-2^+Q&_E )UBGVD
M.4D;!EIB0)PZ.=^3DD.RAEDU0JI%<=6XDQ<XTKI>WM'J7E F?_W>?K45X7SH
MOOQ3U,A3U"^VU.)5?Y" $++<D>@5S71%_=EI[3(Y\GLS;O(QV*D)%N.@O:1H
MW)<+.RYR-VZ[()>SF$&JA3ZXK=.T.5F!J775R@)7R9&88,J2F7 7?QGC((-R
M#TKK2:&&K\-/.=WX9[*J/R"U4(6;:E61,CA&=00K_1'D3TY]80&R':+L UD%
M#,]:Z/R 3,7.:7$!])J-S[E4YV_G,1E.[QENH/3*%H5PQ+&'X:MV8.>5.C50
M+Y/2>,6YB0[+L>^_RX/7]+&4U1Q+OO%[CATA$+33;8.$[L\KX(N0!I!)F,NS
M=>D 131!^Q(.AY+UC@PO0QG?#O:&DI(B5?I=9U#(*S">)0.%&6Z)T#KD-ZB7
MVU41&/E@G._96[M^+EVW4"FL&&5K,?02M%*V9K?C'.A6H1"K FJMFWEYL%;-
M68KJU^70N%2%E>"^G."[-P"E-Y3##F% H?@9S]SHQ>8J>J&(!D:V^SCQ-,/N
MBKU/>FF)SW_&]L[!J&I..S6/>?F4_@F14I"EKO.8VK=ZO^#WJ4SZ/^7;7V\(
M%^8Q4=R%%/FH6OMH*+MO-$W\CSII_^Z'_9,+N1;"Y<XZ5!77_PQ=0U5F"'7Z
MN.!?7+[H#OV/[=MV*;1)FT6*H5DQA]"GO#.(BZ@"'C['@[N:^8>B@9+;$@=4
M*9NF4BN1WT=LTF956#%N\/D!0" *X<5%MC&W-/4GA:UD>D%LX1R2_>/C-U":
M[ C0.M63SUHBL1E-19?:)I>I#150G4SGVVHH+M2E&9X@=M'!]GAQ'(IOQ4I!
MNF 9LH9*60;C@101R9:Y'MK[Z60/;P=,*HMU<C#<8YTAKX9H;3+;A(A[G 6O
M4<4/0\/$'BE_>(GY>S?ESWD,*IB5/'NMB)N!L_6D9+(><SI*DH5>I"]1F930
M I[)!Z5M%%,XZ)1^$Q2FI+61\_DK(;W*C:GWZYO'/()C- HS1E(*&0-]LSTV
M-$J$S619-OPTH.6VF->EI@\B7JRV W!P%?3I*+2'JO>"#SX!R&F(&_('TQ(,
M9M^%/M^%-T/#%C=!!TU5.R5;CK_:0,FREV;<ZT/6,+;W$2AJPQ>=XEZ()&ZN
MG^!8,+ZI5J]DX),U;MOW_VJD>X=VYC9*]#.0.<C2X,6D H34SW>?8#I#SU"K
M2C$E^*D*H6IU--,QQMY$B+<)72@$<ZL))7 C\;;W(W9@DY"3 YQ$93@EO^%U
M;_ K^-R#<?E,2X=ZYB;3"93 MKO$R$H@6RAP?,]ZG)P+!ZNX<B>I,&*;X:9[
MMH2<+5\L%6LS0K4B3@;*!1^8:Z GO<>ZZX$L?0#H/V4*K"IN*YIN_K,ZJ9(N
M$WFG?30&O,J-[^K8^20::1EV4*H[!TT -U2*7+X+E<,;S6$X*[6#&E5IS?VQ
M>8P%#3ZFEMK1'3I85G'34AMZ<5CVX1X8&Q6E)&<S/?K?]=/BDI9L?-Y[-O%Y
M]%^<8-[-;[8BILPV&0XSCXD>(N>7FD*C8/9A(%PA+*#Z0R4J10YI.1P .HAQ
M#79B<\KAWLD&?(YBE:?6JG,WOZ(:7@^EJCCF=!-55D79T)A<Y&1_:U8X-ST[
MMZ] ];KVJ2 7!^Q'+91:VX%W8$1!U]3S&'F8N(C+AEEW&8= ;)HG7NZL7@F=
M&/$&#MY,K8"W]D\R%L?=WW,O9 ]P/:!O %D5#1J5T<-$<\S;ZOT>8[Q\S^>T
M$D$42>ZORS0\82G+ZE_'SFD8&Z'%^EVPM6 @B9.&AHIWWA;XD*"AL@ L5TLF
MI\"$=I8U(Z"R@V$*<E\05X&L=JZU2T85K[Z[X>59%2#-\RBF\T)@WVC.$E8<
M(Q8R\7JF/TJ7Z*H,SYE;&"Z ]U0-BA"VAK\3PH%4H@]E=^G=<LBG5_T/7#V?
M%W,AZ8[[[;(]JAW$U1-,L_KK[XX)0))H'N/(\'QZ=6[B2*];8LFW1CI48BIO
M<>K%(H[%PO;S:F9/**> Z 3' =HI$Y*HUE>C*(@G.C/\H4+EL!VR@O+E.,ZV
M)7BT8E1D[MI6:I;"_9(>Y3M@/=8<E3%C[GM@OZ/[V[\9S(!@70!T#@B0E'I#
M59%J4A[+DKF1/B[5+YV5*%8AZZ@<2_C('6BM9S%W12CL#5RMJ//26C"(C\#%
M,Q]XD:IBZ[ 3G@[/ZLR>;;+ZG YRVN8QT&:3#,9I8$(Y*]3*G9&E1OK]C&]
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M\J$'A .HYU58> 9D %/\V^[91.[#F-G-22[9HT43D_@AK*X'C)KL5$NS(DP
MUHLP09Z/1-1TRQ5G2:]7[[L&D%7'*LOB-]3WPIL4UH0]Z*A#3-+JV(2.]?6
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MCWD9\5_W..1[T F8R2>=G3-@N5+L$ ?Y;G:A>FP/EC:/>1BBCY*]3\4P?A8
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M.\Y?]XK7^5R:ZU-ZXX)Q-I#FMME#>M7>H@ EKJSZU.3JL BZV9'F1EY+[AJ
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M@XD(.U@N(JV:%$2QC!D^@B90>WG2@[N"<6@@'EV?E=!VR8AC*WCV>)-BF8?
M.@#,%_,] )O:?S!7@W"$?>^DJNE9RXV.BP?92:H2W/'&2T;3*>I@V)*-F"I
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M.PDM5G/D)FTDWD$!(//OF\=$X[.=K/M:L$IV[J<(ZH$Z>D*[S^_CG371ME[
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MX_AA&(O4+&@#&[;ZU,&T[V<XJFF#K!<^39F\!N /G\I,3UG>J=ZZJ18758W
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M$S01D:4+;<%5R)'WA4I@]L%!ZW:^YN*YA\=B_;C@XCSV!8%M,?NSX@3_@7_
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M>/+%0/=,-"\HV1>-+,#K(>,Q%B6(G:?YOHFV]N$:=F%]WS2$,/T+-+,'5H+
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MS#D?.D1E^S/C"50'X%M+X-XVW$38 ?H4!V('6L8@R]?*SXK>L,X::VI_03V
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M0^\KJ)0!:[G61K-&=TMP1+N=4#\.Z?A"S(, $0J%;:&"&GCG@M; !8FTD_?
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MSAG]5[WH?TF._H)%5;UQT),N7TF!AL_<@ ;%\\\\ ["T-7RMN1P:,S_WI8!
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M?4S8/0AELMG[UVQSJ5=K%&\>YZVHS"N3>R$W%+>3#<7&#,L*WJ'&0WZZNP)
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M,P=#9? >:I=A'97?C;HK@_)4-CJ;&KHS4I5!MT-9B.^>QPA(G]$<S9H_R+&
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MR12SHV24D&7#U[6>X'+41]4;4-^$?8U8U%'.NS'JR?/9X4J[JRK B!VL>(W
MV]%QR63AAK2^U7!, F9P1@7-1K<[;6IXS#Y29N0N$=JC[N$1B,@+%O ,7;S)
MIHW489:6-42QQ5RTI]B?&[YY#Y.'.[4;V86U05/;2BE=(RJ1&*(,4F8.X]-
M>[3K+C^-;H!.V#*5[Y\AAI[,E,J"Y(Q<6[C\,F_>[1;G(E8-W:@L.>AQV8T:
MC-"(TY;K+H(>*N(=YUZG;>"S@YGH2264B*^ 8U)!1SCA0'N9]*MPP*",TM4C
MKC3G(;?[%14854^:VL.VD<]#-RF"4C@4; \LJ"SGR@OCPR4M[&1)T$HTH9C-
M5W,3>$^6\.&8+>C'%:)02D;N"O2<=F- 3YAP'5JHC+"1=Z.W6Y6<'/D+CM4
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MY:SY;%]/.%G<&^F/=(K)UFAEBZI&. ^MDA<!3#1 "5AN!AWOL(6?@WY\Q')
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M>4N>G@KN&A>109]H6%6#F[:XR$S1=?U;.EVT4J-CE1U%\3&%;S>P;U)FX2\
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M'/4BQ0+S5(K2\9FH5,DUPE8AYE>55>3:F,H^08CN-WS5L2S 9(Q'T:7O$97
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M%;!(F=-"M/X+';!?JJV:)-\ C!"?BJ!1-C:CA/$I/&L9: P[ROZN3B R-^Q
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MF$],(9B1YM)#824D4GXJTSCTHW^A6^ -D'^SU'B"'J^@VB%KX'@Y-4%:6?%
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M$XV.O!\),05%S/**B3\[WEZ)16)I>@+&;-BKB"$BV'%-_V*\D]I-8D$2':2
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M )DW%H-WWMTKWO8$+N1GE/O(WYZ)U/?JKHY?,:WAURT7,#_P)F*4E'ZJ+SP
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M3ES[ZZ!1%<1!EM;P\ W!,="F(X/AYT;?/*KESW6YYQG%79=LW=NI:A)MQX)
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MZ,87<H(ULD=[<QE3!C ]J1!1&*('EQ;2T$&J%=PO++#O648P/H73:!2Q$ZO
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M<_9!\/HO;Y C<"TF+E]W,U;1:M5+M-E<1_H&N VR59^'8S1FC&[>;-0#[<:
M<--I@IYK:UL&N6HGO.7\,QCCFP4VH%@03U106HC&,&\_O$])-:7O\(O%U#5B
MHN MHON#PEJEH8<P02RH#?3OPSR)_+Z7(C'C\UZRTJK(,^@_P:^(XR50=0/P
M!'&&J9!2@%4"$+Y1(F[2X5( @Q@[VZ:"-1W<%?0E8'Q)AHO*%&8W#JY%)5#
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M3T.P=9%T%)M4;QVNL$V; 4 SN*N^M]VAP\VO1.>S=#AOML8&BS=Z] /?VWV
M;Q]U^B)"+<(0"P+*(JM==;B6.7#)]\:]D=5M\&JRUAX8C\" U1#RQQI]=Y7L
M]8331H /L<&#P+2G#O=>K,,9VRHPB>N=3_COP?R7#6:!_[]RGF(YPX,AU.'
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M>#::7<U?=YF5Q7X+J['"6)7N<.VE?0M :"8D/6MV(IZ"Q2Q5W4+46AO%O;K
MSKT\5P$.M[_!@T)<%"QJSS9JV_*UVJM$H@\>KC+I9:R'5X:[N]J,0+(G,]>/
MW(F$?%6ARBG_XVW)C^W/+Q^. !B&191KFA".3Q?NE)$]PQ<+?Q*)?-U/Q8N2
M1V:1LJ%+IJ)O]45:/N4C"9:-_]3.M^DI6^7 6?@EU0.IW_E8>O8&-P8FWU-4
MC$!SNQR:?S,O&!9<\=7=C+C!:(%6=1L5_9C=RJ.F6SKWU32Y2/)'53$R"#RX
M:P8^"EF6=3,=,\L+D5+=Y4<9(HNA1J9K>>D;H%:?VL9A'1JM$,(COIUP[KW
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M9SL6)Z'R+XY07S%\PULNF&1I=O=ZZ<>/LV5%I*I3/J)U':'GT(X7K6A=?_-
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MRU6!+/ MA&APF NTKH9(?91/*D$MR#DMD-?,@ +O;$=684.&Z U^GA1J];1
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M[03#7>O]-8!N0_6DQ3/7N\' V57\&V-=26SV.DM:N?B[O_:ME6J%>;04FVN
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M&#R\=PU(4$,Q<W -.-517PPM<13N1\7BQJAK0!>"1C-78NN%A%,=BMD;5.$
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M*(=@1;F+E>$Y-@,V;DJW3X7(M:C6,X"@\W3=Q'5>[.=JM#)8$0[3Q9]<!IQ
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M<$FIFHGM6UQ?;MJQ;[K<P$WJT*BOZ[T0M_G=ZJ<9DCBGMZZGDJC>".SPI!"
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M^Q-R5^V=Q*=:K@WFQ?QW2[;5^7;B1F3+^=6^7UTMC-ZS6'64O;C<@YL<_)+
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M/0PT"":?TQKK8'..\&H2FT0^K[RGU-(RG>\9<:TH+29Y?[<K8,NYZ_G+N&T
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MU)1O,"PO*LUC<;Z8L>U;_MM]![SJBLT>S+I208P <.Z6XZK+Y(;+69'O/A$
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M"HRE,C0R^)63OJQ?M:C<A%L+CL[7%GSC0N$]+^CU,2&,4;$KC#X+]O]_913
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M,=*)9\HOYG-37N2RTG@CM%3>\Q*^_3-7/QQP4>1J_2''PY!K@19[V)$NI2R
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M&8$4]62 %PY*JYT4N_H$N+@9=[4C-F*->;0W[H+!W5#]7SG0YO)+*0W5*!R
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MY_>RTE=F%RJJAP6ZR7"ZNZ-]3#&+X)E:YSJ?#AMZ ?4BXT3!"59LIHFTH P
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M_7GL\%17J9YOWL:VLT74ST>"J.$VSC6X\O+M )Q>!_%L14S[+&=,4%"^>_.
MPARQ5 9=&+*BNML2XRP=[ZT)273/H99G1K%Q[N&5_M%[&CL;C-T=IT[B;1VJ
M?B\GNTUM7S0P,9/"M&UN"GSB&2"'^_6[ !U=KYM$/S$&/WFV?$S!<[1E7->R
M>+\*L:$PH;<@2UM[PZ->ZJ:/TM9H>%Z%TH=HSY*J<<'&,9WI)WW#XH/$Y13M
M->%Z_+Y>MF[%R:(AG+,^9V%#81S N<_$/1WB3EV#-I?!C-'G1528X":SM]1'
M1C;R9:!'Z[FOK#1I)W).TO#D2NWD%0CYS5Z)^J&F"+X\V[[%,$;(4^-:MF/M
M3P7Y9F;X$T^!-^]4.1-'F+DM^8]2<BZ24PZWK>8UJ2P+O+54ZX4JBX6I-2E,
M[\1PE!P_#J.+UK!BC>4C/:+9W^0=/@FW&"75I^0DS$K2!"@WN97N!0LBC?4U
MEU2ML[97.YK@\!;_V;1KR-DY7Z2[]9YV-G]MN=90J84]*PN8)6.AT\P]NIB+
M@HH7I+OTPKN,/],6M1;6LFDUO?GAR"T\[*#%@PQZWH(:ASP]B_?-7YY80ESE
M0!*?MVDW-JYTR:[+VM[K3/-+F#<\R.Z\=XB)N$B+_R,P,%T'*PUH_<<D]]_0
M1V&H-"2G,0:6X%V22U08/]8Z 7*)"[7DG74M\+K6()S2,#Z8UHM@ ?I\1#X#
MW)-!-V40OS]S4FE:7V7&LVU'?DZA]ES9<_9[-@,L>X%=;E'X^?>)>63@A^U!
M<7+'2"^\P]H(LA'1&;*9Z[M/G!>H\1(4&3L9.P^3L%CG:H<F=TXV7S+7%R<8
M6@]7<7CX7URR+UA%J(+)9M#V]A5:@N$4/>-:,7P!^&(F?I#E\NQ#>TRQWL%"
MHM#%Q1]Q(IV!N>@ MC-UYPZXKB_%!<4^/AXEEG#Y1ADGWT_]CZN$0>:0\7=K
M6>Z,79)0R-* " &1#VUAB WQ9D>8X5MP0F'7OOQU-']1"2>_^A-E[15X]CQ]
M4MRT8L(^K-)8;QTB4,X[WB4@')DI.M3B#<ZT*;&H6=3MI:QO%"7XT7,&P2),
MD-A'L]E\)UNF(T(VA%0_?+!Q/JR!9A4_Y\P7 2MV?A95B^A[/8*/HZY0'^&[
MO;=NON*[1NC[K+K<LT'(BPHYL?FAM2U1[B<6,H5?JU7:!H$SUM32X;FFA8+%
M("*X#Z&;ZU)3>$ H"#"P[%\?T$=A\JW>U32>+0,/&3[_MD=MY%=E"N)-T_K>
M\\P+QF>LO7XD')4X$S_LAWLPF*\,\B8VWK@[(YDQ:^1,9,,-:JW ):4JDN/&
M(MS_QD Q_V6>?:0EG4XIR4C31A+,R?M>'(KE-@O9QDJ];K)6NTWN4BP2T7PT
M7.-F0.2&*O2*&,I=Z>%JDZB1D9Q%[WC-9;A?'&Y%4$[@7(CW]][Y9ZWR7C:K
MA_BU4@)Z(CX+USS2[Q\5A9&^-E6442-@"0-( )\"+.3Y=[4PA7/H^&0^._:5
M99W>K]?6A1VS*J\ ]IEM[2L0W%P^EMX;+>?/.82/1;Y/>+27N\&'F&YQ4\Y[
M>B8UN[-E4;8"XGH\$%%[V,KN."<_3N@P67!Y%G\9C=9;WPDAAB5WG8H3QO*6
M]6)?0YFZ=L\S=BN_5VN"W5M4P<47.MV_RIO]BGW(I478GY:84BP>.$!@Y_G;
MS__R*6^[@B[;%UE3L*70LLQDO5"[KJU6N_T3<GB]4)M_^(/:&O>),)'8IH5M
MJ_ZYMMKY[^^\^>&.BY+EL]67'4D0S4*!S:U:E3TG@D@Q+H652XS&QE?DV0,<
M-;EW'WM$+[!+RS1'>(>*?WELTO.W]33B;)6LW6&/W31QE-/^.9.<-1U(I\S&
M__ *^,"19'H"1V&@(1*$W++>./.40"7::HY6OV("XI_S8I6!DG,DLRX"9@JS
M!?4VYWGA5?T1QU4 U+-55J.?SO((8BSV)VJ' W%JR, [!CR)\QY9A&S'RW?^
MLZ<<!Z+YQN[&/0E?L28-INGU) (P^K24$W9V]NHEI('+*,*WL":$ZXUOY0$A
M#]DE>+>#JQR9IIYGL2R>GM=K//.;X43E!JW_O5"\V9$>5M5LJW*!>X#%A_>>
MCLT?2WH,5Q?(L=IY%6 3W*=Q*KZRWK'BYDJ1N=MBQ2S0BNA+?Q=S.A_H'^A9
M@*H,K@M!2G$N<V](N@G/%-6=S]_4)I3O?3#M8(\+:V-G[2[I)$5>(,<\PW37
MEKMP#5\VS2LC7R&D"/>[^'4P[(4'; O2@MN"RS?UL=B_G-26KNC:$+MRD=@*
M=D;-M['"*[F3)U"AXA=]L7<W\,0KQDZ$FTK\W&S:ZB>ZT]0("@\+]UZ-,-1T
MY[0A8JHY:+YYCL\\UV:6BF4R68.'!+.#)KQ-FJR>\0:Z$X2EBJW>4X?@[)19
M.H[[ #=EKP!&)S_Q!5\WWNR*1;G5<R+]0)X9CDZFYQF[+[S%@UPN9\&9P&DQ
MZV\O<,'JA_732AS%WW02ZE._.599;824ZF7"-(-Q\1^(LAXGH<\=03=EF9C,
MKT"@LD87+K;C_LL=1YC51NF)(/BWJR#=7'8UI&7OBTYXV")==2QWN0P3DJ:F
MN9N6DI03A9OATWU^=&NDAD%:"M!Y)V]AQ]3]C)S7$!(2&*L)HMKC6*Z=[",3
M'O]Q"O=I QMR4OV=V7D?^XD@'R(3YEW VC1I8"1=/$BB8>1,R[,RH+Q.ETNV
M/E%IEKQY1N[8ZF#W^;*>68J[:_ &$S3@+7?>GUF@=]!.-F6@+6#U*(WCWX#_
M>3.*Q']V^V&AB*>N%6-I9/=SET0ZHF%5S(JG&F%B( :#W+KR' ==F]8I6,C,
M*CW;<+#KBRI@>\O#/J;<Y;!N]0J ZWG+7Y*+:HUH])9^EI7PPJA!*<!2FFT>
M"R%ZV]9\%]:O >LORC#LYGF3;6QP\IDLE(+\-;28@AF<M5/#9OAOFR/FH182
MZ7$744+YH(D"&M1/)R&FQ# !Q?^?_K] %2 Q3$7[MY(ES._M20<BE+K@C:/P
M?T.0A&[9.C$QL^I"_(D*GZ?XITV<^9I##TJ"\RWV>]I@QSN*BF.;V0LI,@HD
MEDU?@8QIWW7QJ-JQ5T @[Q5HCQ 3,W8J&8Q>D?/=K<V\G<H]>><[82%TEJLX
M)=83C^&38W=_0O5\;7ZU]\^NN3EA03%4RQ_^I4GP'P*6O-2(9/)O#T>OP)N6
MB=07SXZ_N8V:J%?Y;\*5;]D C__0=[_T%5@73Q8#F0B-)_XM9/[O]U\PH:/?
M#G/Z]P=_:_E+0.CYVN*G K9X>[SS.!(K"SV/DM=\H>5N3O0 [6 AM#S1S707
MZP3"8!M<N=%II%9,#65.*.UH;]G;*+RX;O015<U.D_/E8OQT_)^_=\B7FRDQ
M*LXXYOR^87Z9XGJZ\1V/JI5]\X3^RT-!,[LCIFUN&V?K/@T#HTM>"/]]U%.=
M[^/!U/ZPT.[?1N?F)/*="JI([8_\HPN[Q^4K,*'^EQ<EQ!C-5NC?^OP37Y2@
M_C\\4720<_8O%T3]RP6Y_W !P2C]]_OI-Q42?ZD@<LZ\FGH%SG(_YT2:8HL^
M'0K]0RZ*4_X?[BA0E&!#)'VQ_J>81"K5T_6;?3/4N<E!,;;CN[EIL*:T*XZ>
M:I,55E4#6'6&#ONBM6G5YU850?+5H[0]Q?:*8EB+!D[M9#(MC@UJ5X-5SPL*
MO8"/5>;+9-N9"]?SM55;"F8&5:@P G<75I?^DD#$=F?G=LD#NO:TQ<$'XN7W
MF5<W;U(6R,_[3\]O;O-)J12S&PZ4_W/<<?^0^O+([M-\]O*UX W,F(@8MK#\
M'_"_^/7_-3_X\OCEZY>_^*)O?-D_(Y7W]XE_R5>_\4W_S6]YX_^MIV+_?^%+
MVU;X[F_I/_Z>^E,:=7_WUI$#"U,3Q+1<(?0W>RY=2#EE_H;20S>.VWZLGS:"
ML)B[%'3(4MUJ.+NK88+GXK2&-\N_J#6N?%5(<TJ7C=4_EQ[ZMA6CH4D/)2RS
MBU?NF:V5KSJ(1:1:D.E:<-]3(H\&LP2-B8EA^:\$A%)G0?PGJF?W91OQ?@5*
M)T9NRI*F\J+%OU%&$<U-BR!T(?2W05M S_;73/?.*HJ9.T%38F%>EC'75&TH
MV0[_QJ[HMRU2'M?-W7]ARE?,=V/E<3V2LZ ;26U-Y3,J*\-4%!,1^4^10,WY
M^16PTDT7"CM4]2366OK5<&FX(C&Z\@QM(\ZH=,U:3$?W7D):2V0ZH8W\)UWJ
MA;+(;G>>J?>NY!&LYP%EC&%$GE.08JR5?T>+U?% >C/1^T6UG[EN#JP-TZ'4
M%570F(K"_X%FJ&;R :T9[[,3:OZHF]1@P?0K/;\VG@JO'BW?Q'=ZDH)FFP()
MS>@Z\81+'Z?$L)*031'RDS9 L5:IS8U<7,BDAY.H(KJDH&"XP6OV"3+2)\1[
ME2&=1BD)Y:2<YBA:H5.F79G=@>>^IQ(/9)^&F!%%7?F$S!7]X8B0Y[FGHAU4
MFQW'68,'=>4JH68A6MV0YZE[Q4$B\.#N+Q_JKNN*0J-7P/FKBHV^B 2)EQUY
M0M<UN\$#WI%KE(CXU 'USOOZ2QZ;PLD7%1N[T\SAYO3<2<5:3P0>2+ '0?W\
MR^%3T>+ZJE"\"S=10"+DY#_TUG/=:E_FCOB><NWJRL%FY4(N1PK_61/7B[-4
M9VN.'@B"J>-3H+&<K@IS<WM;2TF!9>GBV][M2IGQGO-US+V!.R7[AYJS8;'5
M7\2*6M).L*8\%%\!!U]:?0:A1B':O8>:4YN3UDC'T(.GVI>#M_$S5XGCB56O
MWF Z_527JO)] \E9>2NQ*W^T9O@F: <['4XL?<A9F95K^8 @6+[W9N+>N0\R
MCN#WRXHX\VO,%HFLW*,UHS]K$ES?#LR7?5!W=8G>D'=>8_IHCPHTQ(S_C3RB
M_'GF7EW*_T0<MHY8[>_1O/ ?"R_S%U^!5;OA9GY4$7&!(&(UW1ZP!TZ"ZQC]
M1G5TV-"$)Q@RE#N__'!&00M7VGN4.B=T-B[U0C"["GL(E6'T.WBZ*?3:K"%H
ML>93^$ Q+7S>(SOQ5;_0XXY:55%.N:'&50G=5"!:U+U1YNU@_J7A6X24>@6\
M0RMM=K#YMXEFC9?;B(?#7CP*GZ^DR:(>P^Z5_ZR)&(^]H:-&_LO<W'N'OUW'
M7_NR]:+B94=2M8_S;S"YO^5/*W=EWI9%1_R;4^@]VOO_GM!78,5NN(W<\E_K
MXE[I+ZWC_ TOVU]5/.R>^Y\B/ 7GKHGC\=4G%4]: P;2/)1\)[C>@HXL=:C\
M_5L:O!VJE.A^0& 6@/Y;[T \H^_<7X:GU!D6RKIY$(ASJ5 Q2A[0M75>Y_=1
M:2[2L[)K;*LH0!1U0F2*8?WH_B]"!M2)K)G&; T:<"1+PPU;3P?Q\'ME5(5X
MM5+D^$R9RF@3Q50_43U$#AWW^4'%6!-W[UV4L2:[FO?HP1]%7CZOP0J)P74N
M%P$QC1.=DB8)I$(H9XY)39VP5/N!8 +FV]+P"D-NQZ,P9T4QS:3_KAZ9-_"+
MM8<VG2@QV,*:>)15/%*'WKT4Z:Y<>YC#VRK579OBI9F1U4UX!6IM0>/JEZ5H
M1W[1-8PKMUC)8D:EL@(CSEOC,9(&</QX+B:'#=#Z0\;1'OJ6<Q4/3DKJ/'E-
MND$Y_F+FDO_9 %,KSZ@_/C$T+W4OJG]NL^E:@.-GH_F>7==U*A,]6>..T)W5
MQQ95R.>""H_T]!$^;",/P8+8YGC*677>4CO,[M_86Q^BA'IYL%HPJR9P8KF0
MOF?#M&[57MO(_K:-Q]G#1<&5%_:QI)(I04SOPPP5P84EGT_XA?-_J,] T."?
MM=&1V58I%2F[2 F7)*=Y"'L.D0+<985-4Y^L8$C@!I'D0+;?SBN<NE+&3FML
MBML>^R^U]8=L@]Z;+_,ZZ)*7-&,9(&2@>,UI,S#V?+[ZVF.!U9$"7A%O7%NK
M^[ JXY*;V_0>)3UTKZ947N)',I'R)!*"PTIH)GR-&*;: ,E_,DT)3^LCC8#?
M_A>>Y(E'\21/O(Q+)MK# >,KA&]56+LC4I9N$BJ.KLN1!1RZG$(G5MI)2+$,
M.X'0ZD/W&"P+]J_ S8*&E2 #K$2 <P8#ZSQ/3 /=CWOE8RTL5HO?<+$K,4ZX
M9XWJHAJN++B,/[=W]:P<6^R'\IS4/,/$,-45H_^34?&#=P4?77 FG^>BA,I=
MYD;<2U;*SE>V=[\LRA=Z-NOC)$^H83<V_V =,2L>PLCS,#?Z9%3"0[\$]:+:
MLE8\D:\YX<#0&X-.7W6O5%T%/3.Y75113[K\987KX4O=7.N>>[[P"(UN_O/%
M<EGF H$R20"=.0:.L<:6&$)1+H#PD\85(9=QP/+9''*2?>GSLDWK]V(1M1)$
M;N\P[IR7+;^O=0(. L-_9_?_G,J$X37Q@C/ HY/AWVY_JO51?JA0,=DZC50*
M/=BM"3"^ZH>_(5!^_[E..3WY(64B)O71Q$@;+.7T89; 32#(F?.\O)4.+Q)6
MRY.,[$0!N,8\JL/'&;?]*^=]^N_&Q*HH3]CC)\)QYHAB:(WF&B\\UH7U_ @Z
M'C-4"HW)L^1.6SI6ZK&AWX<K)"K,M_5@V>=[+R0=;8#"79: 2U7*,.\#9U,^
MOR90.G3J8_EU]F?=;*XQ]NE;J:#PGVH4R#:UMMK(/W,;T?:>Q*)JYKECH/W;
M99?^3!K-^-#]77MN#J4VRBD3I8KLGW_(B@1#"OEL.4,RK4-7U4Z#C(. A.Z
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MRVP]JW?KN'SY8C_),3JXQL5M"WS9V-;(9J1_BMLVO>X,-5W(:?R^5A8WM"0
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MVI@ICZXR/<@XW- $)MX.F?W@?Q]4*XA&^ U]6ZC.7&:%EP*LU5@<%L8FMHB
M$:ZEV@903UX*X5]HKJQ(LD7WEEP+/,*_4=T6=^(<T,6 CGM'KUIR:2(/,4:N
M^OER<IV@-^#("B-W]-YF5>.9:W_]#L0UQI4A*(LX@!_,0LF,LF)BGC1JC'Y:
MK&NL89*I&FQPCQ:_9C7Y.5$@SEVX++MMX>P!X[IE7J_ZL8]L?TPH[?<?@)?
M#=2B1.AG%J[W&A\[[V%3;6R0\\&N%R02N?BJXD)T\1(NN*;S>^YGN.95X:()
MRS*I*$(#WV=(4GNQ73^^=Z7#RI,;(0/T"_VP&"@F;P.X)F.F>:FSE_84R]OD
MMS7YL%>BB[^70X/G1H(B^%!8/%!ZV%";SOC)T2CD#%X#F^7[IOEKAG<1=$WG
M35[G#=; 4<2V2$-;74.L91@LDXXX7K$2_&:XISF,ZI@2_G.$L@C0S(<>5V#R
MK-"6X[+Q'2\$_3CHNB_OFM"73^LB;EP/=]EKN1I"*EX//GT6OJ5>SVG#.U]Z
M&8C=T^>5H^BL9L1V:MC=N<Q"F2"?!VT9-<P9S^U&:\O72R=KF$I"?2]CONLJ
M;?[^M,IT>*DC3S$MB09R<=:]E%R:*#JB@2[/2<4A!5#$PE'<%_YSMJJ<.S][
M_0%03R#)L'@4J8;T&(1?WK([@@#] O@S82TU,B?/B*PRO>EEFEYWU&S76Z?<
MR<R1,J%ZAL_]S^/PQ@OMLD!%(5S$K5/ZKR0<2^$B59O5@I_3*K=9NXZ5="P2
M.;_@C^#7YMG@V/Q&CYB3/../L)P2^JBUW&<.) 33U=/,DH7O YR+#_[?I'$J
MX E64YX*0@;0\EV"BF'SS9U,[ S3]5;-&;D/[('8/3T-B6Y3M;IYB=7%82/<
M0^&$@S[K<.%/:LY$:+,VUN0-H+WWQLBC3L;V*"8&"G\ G1XO!]!5C2W^\V-G
MA=$4:!5W3HN>L]6#L;TUY._"H6#<8)N\*E'6=0Y3(L -:$/L@P(R9:-\K47X
M<CQ^RDON/]P%-NSHA^G/;'8BE/AV"1AQ.S "A/"OI:)[KWC?J^)23ZJREAUV
M[Y_L'<*LS/,'5^SA*CZ >N51K8RF+ZE:@L0SD%#;_&CPOWDS^WL??7D0/1\O
MQ5J1A5)M;$@(IHQ*3)775X;,ASH3,3.%(ZD,(;ZH<I$O#,NW)[VE=S^%3M*[
M,X*J]B?/(O-='."6PMU80BDVTCO?=P[LC)FON!NK^]\A)K6#Q$!+)-$<$JE(
M<O)$/XT/A0BS^FD=^8'I55.5-C8XDJXS>O3R>,,GKDU&$O3\HG^7!^Q4O%;<
M@,EJ2^8@33(U6U >%_&Y"9$%=-5@'M?AP(Y.63M>6^RJ-K)026B>$S6WQ6!W
MOS?@+7[AXJR0ET[2 3VB?KB3U6F70_OMB<"'!W!$&<OK3B1&JHA9+>"K\O5N
M*@OTC>^'RB A(A-^_!7\2Y]3YD7D$9GD[*K(W97',0&]W&+/CN4+D_O]=E[+
M9"6^='5-)"*NB&NI'>O@:)XO',!7#@$3JL/%"VCD+]V2G"7&A4P7B/MB96$6
MZ:ZDH:O'B:NF'"UJHG<XO:;=@UDE[AANOU7%%P..BHOTV,F8\Y+TWUZ1:O _
MZ#<3[?$P1ER(%$C.0@3_ZR0LEI:EC6'C&D5T7K93H@'*QD4I^\A#P+?FV3KU
M#'8B9<LK;?,? F;<Q($ 9X<1C)8<B;(AWTZ"F Q1#KJ0PHU=B?+=^H6N<?@3
MX*\PR06RA@1LDT@%8^;DE=^\1A^$"5T3[R<\;1*C2E?6$<M*V)+Z-6,H>65$
M[=WY/;)02I:W\8NP+2@TR6W#"P,D& V 20WHM+\P6:D\ /<5G))3?-\,#2W-
M3,/%"?Q6R3<?O4*9GXBR]LJ0,=3K+^GT.]],6T1B!FLD@^/V*")Z"@3UXJ'F
M/*9PB9C)/LEI?G/,NB>O@S=HCJ#\&ENH:CA8)EBEOP)\JGM1H ]UP53LY?3]
MH2!,/5VS,_7RM3ZR_7LH22 V4^TF'&JLSWD*X,0DA2L=[;>J)<I'C/NH.HG6
M2+K$5&F(UJ&ZWD4LUL!.HC0RZ21.IVR/*<N3Q]!M50QSGWX7^[O_"$5R0D$.
M&>#<OTUJ3W+]:8RND?J[YZQ_TQB=S*SQ' /CN9@>+RO2Q)[M&I53-#^RLW$^
M@.'O@7O6$6%2^UP/'&J"[4Q1P'^;5N%_5U(D +$.(!=Q,@1R]Y6S*I))6&-@
M?5B)N'F3A#N>:3SGB*]#U'@%Y6M>++VE SZO^0<<\\BZG^T?-:8IHQ0;O]DA
M- 3&(Y68H-T>/JH4;V43]HN4"3<^JZ? (U7\N/*+:K: MD)< 48C85#\&N?(
ME*LS<2ZS8&.V_'&O=H^*YG1-!D!KFJ";$7@%FCC_?WN _U/^3_G_0ZD]L\MK
MB,\.09LEN"W_4.IAL]\M]-R3D!6ZOHSY!U"7^>:!.AYUJOX'D&%\7?;RT=YS
M2M4X:5F^*?>U[ _@>O"'LP]0\.6*.-U<431@6;HI^[64^N5*'T*B*;@?^^:2
M*8J-:LFX%WP'SKP>\N$1K,N#M"3]..^-J<&?]YQ"O#SM,T'Y<BA89PJI!SZF
M9/_C_MT_@+_T*6]FD'9\(+\N7T'T1-.Z(W\ RS4^$^PO!V]S<6\>E?LJ-#G=
M=[%G^F]S27\OQ>_*.J['K (Q-7Y,ZXYIZXJ,,8DK-!V(6KA66*/#D^S D378
M4'_Z2.=&0%Q.%5$L]\32AXD2K\2)7G,;(67#0I'"!5,=%T2Q8V.%!]J&/S-P
MS]?)14*34@<*]^7=+NYV;#&EOGE_>GO*?<- Z-B?$CPOZ>FHB9-O]7+[C:+R
M!"K78<R;J9L05BJ8.W'NN$B6_P,0*/X#\(;89H2?$+2.,N_GG%24[F;.!(WE
MJZ=]N@T%7YX*7V\L(+:[V^?Q5O[Y8(%3E&C>>^#$\H[GVPYBN .0^/7&4G"+
MJ>D/(%/C;Z8@G5U,+\W[3]6%BP=_ /^I7OR%ZI/^]?&GUQM@6DX44&#K;Q."
M#S*,'?O+7YX/_G;F F%GRF=#K&F9YJ[V'RQ,^73KN_VM_6$6]2!]]@< N7=T
M@?<O"WTGAHL''5M?6B =N'>PBK]0WOM<GW_: Z;G)-5EVM\QG3C'/+3OC.ES
MK#/C<ADA;*IK8X;16QTXEK'0C51WW?"7EE_4Y^^)6/^V;G;\>4^44/>YO(45
M;U9)/71F2H)':4&S7W&.<;\&;+GU4[;AG-%AH-SI#^ B61K"3A@$,W6-84*I
MF&@Q^$K!>?!,P4:"XO,O!!.V=^R"_Q "QMLS&^21./_B=P=,R8E1XY%_D*&"
M,*OR-Z40\;_!Q]L[R*)WSOQ/%:CAU*=_<06FYOC6\##O($8]WD2]/;%!)*;C
M,U'F<S]580MZ-R#VW1#"D4#UW\18$!Q]]N<A."YPBT(9Y_Z5U_&;M]'?5$_4
M_P+^+S*^_T#T+\[5_T2TXU^ 0AGG0&C:S]^\MU\@S"6MF:=:A-Q1022!2/3+
MW#')M7H"=[AQ3%[')[".^+.Q,?GWJ%'SR04]VMA_&%5,)0R_%,#@[";:((4.
M\JMXFV+Q.2/?L[_X&@&#L%HD+OCW"<0'@OEO,Q-H5:7UV$,]5W9AJ8'95KS'
MS0P[MRQ9-C,Y@JH.13%5TKL@T00L:BCXIJD*Z/MU!'[0SG:[,:-U07Z[[9M3
M>;A-YV/>P %=<L6',>X#3S8,A5F:'%#OZG]>A?R_K4AJ W\Q,!HWAE_C3BS,
MJJCZ2%3Q1.;$&-\#K[EOB#(C5)1M-'ZQY9QYOB\[=@(2#,.C9&W.@A?GE-A5
M<128X/)YVB@\2#6;Q_SU%WF8/PQRYGKB35=X]>%%+9V*YEGS#;7?U\S .#0.
M$*4?Y.+L3(-$_^>T!/^YH(B[K^FBX$J0/*'IA>;K17R3!^W H#-U/BU F5O<
M+SBL#,Q-"/3,M^$MP]0W1.+TH\&^9]%DAQ#^+.&)&$A"Z1-D_>%?J<H-OLE0
M)N<U>8LGHW8M"[>BTW[^_.6\CGC)P<>[I,+)"Q>73:WC3D=PW6X\ZJ316_LZ
M9^O$Q$11ZP]@R?ZI :*8=(C*'Z?L[UA8:,HA-_!K7^<^LZ"JO1PTOH:'>](9
M__/B;;3A#P#X#UKC*6WBI6B?NK\YQ<RZWA;V17L6!_MSZGUJ#6[^]C'B\^T?
M[3$7E6>>K/B<98XG/7-L/!?^LV.Q($UL]B-YK0T0.XA=E !*L<\2";7I$[+R
MM/5R&K<;IG,.B!8O-*6X:'W T)3B?-&>7SY?N\_<*D7*"A1*41%2R*O>5)QP
MFJU8=[NX29DHN>>1;]T2*\O2@K:%*'<MY?-9_T'$&J(NRCK2'7A8;?<=>X4M
M',#JYG\ \!%)+[>I;T_$6])_+Z)>;OYQ(;\H(5 -'9;3(@\A]-G/V[B?_ /X
M(+B%444\P/EZ^P<PG[LHH:_AUS>E6_A"YNES_S?#6+'/%L;,'T ;Y ;QJF1O
M(S@L4=>-B]##MUJ?#16?;MK"/X 9_>>C*$.2IUX4*M I1"%BSKQ20BB+(+--
M7>XF[NTY]V_'&"$Y+5$/HL[G9T,0!:# QU 0M14'4>.0_VJA@W-:,A]$;S;.
M!%]O__+<_NL/@&\#H@^\]81ODPF^\,-1U[G]()YI[S$JV_2H^3[JW?+!^0?!
MC&&,B4;H9T>6WOFJ0VVE_)&F"*W5X:E_),K(VB-K_,6PY9''I8)+U;KW='E>
M2='HLRWX^0EE;L-*#5JQX8I(782:VLYSB.@C&&+YKF(>%!#2O+$6_P"ZR4TS
M;VO>C-+_ \MK3%!3O^)?6-0$KZ=]1GT"B2]"-7PF)/\ F-\PWX\S@DY]MM"K
MWE[^B2D$X!N(0?B;TLWGM@@Q31=K&=(H=>'3!*3F#^#V+S3*<A 1/?\!'"M\
MXBJAJR?"G.DX;'B]_RN%-S19WK>4/X -Y_?C_X04:Z;M+Z0'?R&5?3O)O%^#
M<OH7GAO_P!,R0KN_0.0UP2UXWOQN'UE<#MA,A#,CN!_WMYG<'AX#[BOM2V,A
MG>(M&\[!>D['J'4IIO81W8^'$B'56:(XJCCOTF6B<_X?+U?20-&6#8,T0P!N
M;#O35>>,*1Y2 <]U?*CZGI:XX]^+6JB*\=+($N\/%2.T,XQV%N=M,$^<GC7Q
MJW3[!#\LVGV;+U/G*%,,H.U!":H_.1.80I%'XF)+X2A43A73@@Q__/]E[A@)
M"4#<S'HJ>9G%^,"'7(HG==0R8*W^X%3G'J]A/U3_N2.0>TQD&G-U/5B;L;IP
MI5J3,1=NACL_6*VZT:!:IU][,@WO.DUQH%"^N^FMZIE04$T7]\C@>7H!+1=X
MM3Q<I=/DCN\[4))RJA*D(#PHD#"#4$R7FY+/"6?& Z(I9?WOUU'*O-TT\4Q(
MR7MT).^A3L\LH*6\DAF2G*_RC.<B/R<O.(\M/FN9-=*>439%#_%%D!,Y6@D.
MQZCQ\]!NI[M](QOD5]G+(Z0;/:THK(V7MB,5)WHAKBQWX^$H2TFOEQ]A\;Y]
M _=.%4.L <E_(8[_7-[A)]+:D*-D S,K@IQ9OA[PQ/0Y+0X0I:F2IW0(XR9@
MUE:I0E.&;JJA1%7H' F0SC*8H(D"T>FTJ06 E1[X4_)6Z\Z:'W.S3/E#!LM6
MO#^,;^BF:H0W-B=2!E[]T"V=A)+ITNI/UYM>#%WBQ1I3+'U2,1_SX#5^%_<Y
MLS?"DX:0IIC7_W_AU2(18ZV"\0PBY)#*,#-M;WL7]'?@AVK]A;C4]R^Q!M61
M[<)OF/X H+3N[GCA16+%6<]X58W"6S!N,(^E8]S@TJK&\.)\*67+?%#F4+*Q
M1B.L#()H8TQ'ATA)3@8N8C:.%2SJ.5UI71G-5F/EIH6Q3QXE%\UJIOL7W-A1
MO\T0S:V[.QZL'AQH[$;'4S7RG+;2XHOG8_/9.8K:?-MFZGVANH7XG.J6G?_Q
M#N__7$BY*GGF*K3.51M=^6"7!?S;,".=]"P]<$%/VQPX=.2H\]%3</;OC0>V
M:1BAV_+05W-TO-.2+QMC9@//Z$P(\':#?\*X$AOZ;XH3K[3/4ZGVICN!%11G
MW=@+LW12;8P(".B#C5&U1H\AD[TT1<:&L=*J=&$4[@(3(2-*%#H?<^A_MY:'
M7G->EMR42#GNZ:<%CL>@*:9C3<EIR*L+4DX2SE3L8[*\V]PW^U&GSOT:QD+J
M+QV\'#;@Z*7V^V,9VN<O5IYD6=V^<'4"<695!3F0AR57^%^-L8)LLZ1YI94.
M,4)O9(^UL;)Z-P:8PV"]IC-^44]OI8X9ACJ<NPDBB8.>HA?@!_!CW9&-5&G
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M:>NI,JG>*.LIZ<F&_?]- %!+ P04    " !25V%9?R-@&HEM  #I=   #0
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M'6\36#XBE^%%GYW?7'N;63FS4T!+4MG5^.YT.>OTG8FJ$#G1Z,\KH=&%7F.
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M[>1]]BA<5/CY1R+CIYFZ9<J=A/ONZ@-,U2G^":B.\XD;YGW\]>PN[@0:^IT
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M>U402GEKI79LQ5P@%1.G9G1NHWJ"W#[@XXOF46H@RYHQD#3[<=&0$HG">E5
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MRYW2AT]W<BR<8CHFGSAZX;,^? E'+KD!<3D6\ SI&E:IF+SN^U10$S->:U6
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M*9FL*"2<O"<Q=M2G;(VV'$R2!_AKUFZU2$/4^ER[_E1HCV6[JT]W]5UH,5K
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M$;#*Z_)+RUYW2$%6SR(BHM&+%,_YG48X GS&7>PO;-3^!IENUX9CF=2RV(Z
M:?8!!L_TF7]I.B(1US%'.#K<#T-P\UU;*O^/%RSCBF;X< N)<HYZT:NI1X"9
M9PC<!^R_RB)[+1OJOPL-^7T^[0?">\CV-OJAT09-W"%^C8W,H1C+N7OR:;9(
M)7>)MYCE2"Y'NV&)I%YS(9R\[U]"71/Y$KL)=UOI=VYJS<05M]\D_3OSB 5)
MISX/T\N"_EP;:Y["@0 )\:4R09=H?\']O\%3HM%;OFA \-8';V@;'-SM/:.
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M.GA_Z6^O$HQ!C1<\Y7>F#&JFM3>>?8L3/**)6T29K#VY&KX7$Y6=H/.D'+S
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MOD/M9#O#+ /Z?WPFN)*E92>S^ +T/NJ%J,P!XXS)C6!<4\-3"H?^[WPH)X%
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M*%4EY[#%VK>Z*U0<X]_+L4KY>==I0[?K^FEX,A3UN3?6939_2#L'>*,E+O;
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MN* \J_\QN9B<Y^\53/4>1WE<^%]02P,$%     @ 4E=A6?<F88L1%@  1!<
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MN/R1Y7P;A1NV-]W>$/3PYARJU(6V,U2+91^8N:WD%1&$Y.CTF]Z)7"C-;O^
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M%.+!:4^5$E-?@4P"9<D.1_OD=)54'*FEEDY/D&/VC QL4"&D-+\'OJ81J+E
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M "5S<MJ+"^B/0*$\RH4!K_4::[VLURY>B]R[+;JTX6J+ YR6;X-- B:!L=L
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M+Q0L-+I3YZ=J!78):XC4Z#JM2U8QHY?_GGX<@+SW(5S6'KR($ST.'_9D:!@
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MTN\:^5&[=3/4VFL)Q2QQ[P8L-20HT3*"SI*=&<I03]C(PFO T)UL))E@_C5
MG*R!D#H4LAWOMA-5'6J@A$\#FF3(E?3#G*PP_C9Y#6CK&K\&K/^23:"]M<+%
M$<W^Q-FY+\ F_A4^9=5Q3I&2"YN-\#O##[M'0W0.Y- 2LCC9CT;?)W,?SF9.
MAMDIB%Y]%!E<-%FGZ+!HM._MN1 O;5$N=W%9_I$%&3]N^[OV &,-HKK^,0=3
MG%H39+ ;;I%X8_'Y)13!?')??EFP_A>YY+\,F;4T_OM:.TFFMM):3"I^^_R[
MMX)SX8<JJD/JYWL:F>;_U,"@*8TF0NT _.%[Q-.)83_L+*;72$\AU7.".SNE
M3#/TQZ2F2.*T^\C@.VZTHH"S/!>IUV#V=<%H&:.JHJ7M0#@#?[%R\6OGC]NF
M^VEV"X>S6N VKVSP$,A$NH+,-$&(^A@]5^ANPFWW +1T^P ]L\- !:L <@0+
M4 AQ2O*WI5+E[LJ1V:5L'_4?^O;N34<[M%]:$GZC[;P&8,,CKP$2G2R_;R!=
M/I-5_$*2Q9!*THHN?IH]W4,&,MZ.W;H&_+$WRBR_)4K4N&='I,_]F/[T*JG6
M[!"ZY1EM\:[+7ZVCD,3#^L-WG!_Q=YZP?8^8?+6A+%4#\[T&)+YJF5^XD@4W
M&9.L>P90>O,^?S_[5D$9*,WF*.__SMPN"X+Q[^: AR5W]\CL_;UF9H:XB5A[
M29L7/"<C?(?1E^Q_8LZ1IBFY9P]U+]G*8G<<$9RI'P5+!8M0YJ*JL2UYE*<N
M-;]X^4.88D.I)NB.V19?JT&G*\.4U*((RMW6OZ-*/.S!Z&N %.GR(AHF#L%A
MKA66M"?;1BP\J38&[*2W[7\-0+"(2B$0?ZZ\U?Q2VWOXWJMN@$7*RQ\IX;@-
MV3.*X!G2IE\D#_XBF>XWB?K1SFKK,0 :MENO&KII,[5/2C1$2AL9ICXOBHY\
M7J_/04%<_PT1;-<S>VMYLH5Y)%T:P7I2@I*W\#2  &4KU-8X4JCU*+3U9;33
M?,-:.]3[K"?]IC.D>\,G,+%.4>]\;TY8+MY#RNX:%S1X<\ 7,W";8CCUML"V
M1+&_^YJ^Q#8^O>[&80\0J P</OH?6^CX%DX6?T!^T36@AW?YJMV$X/'%AM2"
MP!Y5&2*$2VHKN0PSZ<HS8P^Z5AH(]SF1)YZD<<P=T=/.4CLAB2SMSXR<3QBX
MN!S+2E14MXB-N:1:%\?A.W%9]R,V?.+'T=]7B14,HN7&9R])$KQ )C_2T\Q,
MI/]@2\$9,@#J84X[R1:+[VW=>NJNYOR0=>?^^FU\]E+O*Q"3+;%^1Q.Q5J3.
M8QRTF:WG5Q?>N38V[MLJ/+OJ]F+0MTYNNH64$GAXF,@GM1E[D%-%Y/>RN\/@
M%3%[Y%F9IT8C1VE4]YA5THG[,9T<B=[Z\-]7OM2G;\6E^?&D=FY)K(\VH!V(
MRI*&OFW=J]?77IK#<?;1^,F9IG,YB2M)O9FB&SA5#_N>->2#1GTW_W)GX/&9
MP4]+I+C&NA(J<XEJG!]*I3U#Y3[78O"0':JM" 7=G!2K2!^1BI<U@)%D3AF'
M*V!1J46;WFN I,)A$=U^J8#I^0[IWXX<TB*\GU:O 6<&E>"A6,0/E(@4%L0Y
MW6 !N*U^ KQ>K?.W(Q"M-^'T,2I$!^*1@='K"HA'WZ36>Y!>3Y"D7<4H!\S*
M_MM)UC"^ZK^T.=D+=^N@KZCPK[*Z!F3PG8_2O46A2 GV4D"2?OIGF51A^K/#
M*'@9S%++'4@OX.&2^"E9I0)-H0&%&?4XW3[LV E<!OG8L$^6Z^CRLXKAS7@M
MIC\G(!^W=%WI^QXEYR8L=-FY?HARS_AL11_JR]<ZB.N?<&$A[?YNP^0]QLCS
M\=4?OA1GP[I@4/DF:U:5\#\X:(IZU@NBV$8JH/S'-P>?J5%^.B9TF7VN+QHP
MJ; <2$#2IY&)U(UWS9TS-KSZ2*I,'.48EM\Q]+H3W*PTM6!?LM/,X]R2':6$
MP4O../9]V.DU=^^KR,@EV6^W)Q\S:J]T].T6_WS1@E9H[2Q_FVQ@[8UV:L!P
M,@BZ15Q2/U:R:\[S.A*+7<D([_C6F8=&PZ-<X+?>MK# ==*^O28]Q2HV[_-7
MXZ<,FGU&JC_7*72RUDI+J,[PI CM3H#6<;VW7T9$ %J15!.&%"OI<- MB;IO
M@X8,JP(]YSX>G0R?UI\'*$V7?.LNF)TYOZ<Z;^B.[ID'Y0U5] AD7NT*M>%<
M"?K,=^LK%UAY9<OA\%)]T:+:7I ^ C1?E5_>4'V[)Y6U]T*G9[ F0V9:'Q$*
M V]EEGF%2#X%[T+V8:SQ1=.UOKRXD%,[J7&68;UQ08GF>,4>:!R$(^?BH=V_
M^Y4O:CAZ"BS3\ET#8J'@4[D D0WH00:5)9+(\26RI\31R3>Y71EB0^!/0')4
ME_@\)X%OM8NW0RO%_CD;88/^NG IWTJ"X+'\T&LX<1"?>H'NO=3Z0?8EH($#
MIX='1G74B\=?ZZ!KQ#LX!MD&F/LQ=T08FZK.1ZRCH^J/8<258H4ZSR#OWDZU
MYAM,MZZ:<1_Z,JX4=.HY8W3>VU/'LA?_,I_P-;P9/>E]X@9R0J3TL<(%@]+C
M0@UE'_E/\U)]7D_:&L'?GL[[Q]?U=^W..7*HU!D62V@^E'O\<G5]RX#>,!.[
M/P63E"O9U4^\]%&ZG)D0#Y K8DZQ;C]-YT(@9_'V/N) X=!98BL9[LQ0^<G.
M@D(:#5UDD]U9\E#3\*TY[@"(I<^@B /&CGS(,?NB7P2LN:>UW:E;*#\B#S;?
MDMYT.**2.^Z_9?:"9;]7U^5A@$&$UL\)01$F=<TY&H(7UX 5*XU3O !,F!_F
MBT/4\X0>7.\X>>58&=T6Y**-(/A07?V^IG#[?VSI6?R!ZD=H&KK7@!A4..]2
M[?N!)WN1YV4^$^ 52JG+L&9ZC>.?X$^.T-KU_O7HQ?MRN(I:"@YC(]4U$UQ,
M+R1Q.A1+@UP"CQZL'=W/WK14;3S$87PC+P(L#O Z^=K \O >SZ(T3&Q'2+7&
M@#/1_LZHY=[5]"?QQW8G(\W:BKM]N4/[D%(][[X$A?O4-72+>L=BFK8%*LZ4
M/32;&;0-PFM9QE%LW0G;=C^D?M)4W7ROT\@R2[KH3X (ATDMD.Z^/;WC-3)U
MD9IT]D?";O[[6H#/GD8X$Y?6WFZHYM;GI^CQ*C*4>TJC[P#56IJH2IB)Y,\3
M--Q);WCG[4,%2H]0W*G9H"(7/%]PUYSL)@&QKP.KM=V$S>T[PG,]9?:5WG%]
MY.#F'NR+87*63H%E^=O</1+V1R!I^&N'\-7OK"8 4LX'N7_YM+R=PU\=%L;0
M+>YQ#6 01WZ@ZXM7;Y+)O$HSN/WQK5@*M=;90C2)QA@%75_#H,A1*=MGWS,G
M-1/5I]6;7MY"M2,&C8H_**A7/ ;(@3E$#S39ZY+9XQ2I<58!% !J''Q,S/U<
M=Q/F2X:*=&1GA!BC#/LM(3.MWL)I7D;W_D\NPF:8&/6C)-]/2=R,!/D@Z1;I
M;">BAE]GP-L-WVWTZCV[5G?MIYW'0=//$]E)V'#%U@7Z09_=Q,=>1V&,SM*&
MC&;P0#OX=T>&:>JHPKZY$+&V/L*I]5!ZM#IZO!(+I'MLMIY>,T0XE9%2:O^D
MW#CED]Z6\E(Z_98%/.$:\-"0;^N!N'Y3*_*CU!SI(I4^%2RS6^E.0#/=)O'5
MB#&_1@!S$C]CKUVF9R[L(D.V[5]_??]?S$IP=(G;UR&) B+2!2$G'L.H@J__
M&M"I)@F*S*J 52S9<HWC-*HAO 7)'5J-TX*?!< _3)C5ET?J6RCG6%E&Z'.^
MC(^P'(U2*"_5F1A*"6-(</*JW(2#^M/5!T*Q/**7"KI@S@Q+WMJTPZ+X-5_-
MU2A(9N2"'#0^3G0&V;T98,C#O"C!?[\5I-XYWMRD>B5DYLX1]V77-WMUV]X(
M;)!0*[JQM\U8E4QNMQR!?ZS2[N-FT,EJ_\*'D4<B:;IAK^F+.)6D9K?,#(F1
M!J$/N:7L%6P9CCZCJ&HPN/U]8FW<0O20)Q8*?]Y6+Z7<>MDB+7ET"WM3.+-3
M/V$N=HSY(U:C'6SU%O>M(IXO7_8,1)MCOA;P=<U\JDD5C&^B$^"25W=3NS->
MNE(RF/+%5I)%-=V;-F%KO065,MS%%5\L[U*=H,\W;@2RC%OCC$M:C(YJP?/+
M_\<R.QS&^3 3!_BKRIL56"2Z!I3&7QV:[!6!>WC!IWB^_-VG/ST0-@W%NX%P
MST_WJ(G3P\KL_5/L77YV\3%P36>G'G4O*TA.#'D';ENS;D86MWAS?'AWE\DP
ML6O#?^*#N!9GYEV:\H47%/'PAI;Y(UL6F*2-ZW%1T_.J(._)25<W:3V7MN)]
M?UR0@F16Y-3%I4[+H)^REC^4"I45G/_("KYZKQ1.CM,U#B"G.I>O&G]L!^DI
MP]1-LE&-WNSIJ^)N/^='923:#+UT\W).L1H?$E[)BH9*]34_7M0]1G689('R
M<8.[J8B<?4D'P"GTCW^*I&+-S8KLFK* X#'[9LJ.*,5NR2O R/#DLN+I7W@H
MZI-%C,#C =KE[5+*_?":*ZGV$R(3!R%L7#M>-/&ZT3+EP3?;F40D";1YS3*?
MJ'WSNQM7)N=96P("2),(9PJ1=+D<..L9@?)G49\X#TC3)DK0.+=-/9\>NSC.
M!-,B]$8#->UI<MMA,(09FX(PWE$9[UGN(AY#V\5DN-/1EN[SG)A'J5=(!>"V
MU\(K/2'X_B;5[8'\!2?<6W646>T-VR_64R.\,]U%2AD6RQ",PS^JOIU]L%F;
M-XY5!$<&.=:AHT-N<Y)X* W!T,D@ZG9KD=) -I%LJ "JN5V+LAN_,T#Y^Y@5
M#Q7)?D86 [F91/\P$4AL7KR)Y\<?%VX>@=ZI>5/1YJU+.BVD>:>.(@6XV%JB
ME,Q^#,QU+%T#%HWLZ[N3A=9ESCSRT)"5IH--&ET1!RJQWBR;)%+OE\+;8<(>
M:RK1,,LY7Q7U<+THN-#[CH6@)LC18,.0?V]#V,-BV4_/S\.9B[C#+6A-GYRK
MWC[SR1,-(U*IOAQ%5;?U8P2(ZJ3#T@$=^8\*,J-IT"1U\JG<%Q\1^>37 )QE
M-53K5!7L"6ZK&^.)YD5MKCH"E4@-(#VFHNL#G5P#"#RW'#^L*]G,4?:LP[SZ
M4IX1R$"T50:TC)H8'#S-5;[K_:(E/:]M1&F >J3@KAP+OX=\)I?=P*\C)TGJ
MR #5BVHM#P5^AUMK$:._CW_%Y!\,_N42Q\1Q!*%YD6FO#W\<9C 6)F3C0)Y-
M(&@D ?BLJ,&F-(H/554G9QS'W^A1/R:U7H+B.2.2+E*#?MO\ER+@_5+^H?,-
MH9LN V?A1N?X8*_I$07& .SOK&"VSAOUI=9S%M(T49;+LX>[LHO#'E "CLID
MAP04]*+X\E6WF]YH0QSN;3\N>(;4CAX+O)L[_RWGD]7';S+FZ6&P7_2%,.8?
ME.:KOR7J(M.LKL2=J/C2B7]O^R[:DW/UQZCZ/QE5]ML@-C3:(Q\MG\8AO:9M
M(BY'>FG?E!4,([4A4OC\_0>/V@]N&H24"%>4P28ECVRB=*>2DA87OHG &%H3
M1>7.FD)7N#"X-4A'E^(/,M&W=!(::?@WY.-67PU[_6(:^@[*]]L.T+\B]S>I
M1B,##VE^Y.$:C4#56;]D\I,S1T!5-2$ (!N/BO+W)Z!;L]('0CCM& W$^UOJ
MC[H'4^+3:[Y!10I!6K/KQ;)III%&-UYKN)&\IJ2Q?$/HLBJ*T$J41J///M)V
MF6JB?"MC,QASC/^2):4_(0=]Q>@XS]X$9\SKOEQLNE4\I5?I@O9;QO*T9!FK
MB 26#<T?/XKS6Q_2B67VD@;&U+9=1!*LB@R=Z5W8(HZ2#G-NFL!\_#B5\TE'
M.86J:#-?7+%+%@;[[_?OJO3L:AFH=+FCB>L#L^UN)4;H,L:VL)-L<,@\QP=-
M1X[?XQEPEY1*ZN!87"8/?W9_P]!F$?'@-,_UHT)W!G%U-)9!LXG%[ (W>_G'
M08(67\P027HZ/-_I/4/HE+A/SGF1:":+N'Z1K\?W5.E/^4OOPCXU6\T_2T>W
M:" (GR<:%=A[0_M@S!5&"LMZ1,AW*K(CO=V4?K[XF<0^G75L]%"U7NE>=#+?
M(=LI+*[[ :[59*@)@O. _-6Q3.&9Y'DZX)LOQ3'MAS*GL7E[)\Z5!N,J?@<C
M?T&13#VY/E1"I6Q"SQB-20^ 8T+$I>=IQM2FPOM%NCC"45S4\;%*670YBDQ$
M"(GMGWLS$-/:R?\X!AWGZ\?3O>-CWQ6T= %!3<\,M>.C*W#AX.=OQZ["(S;H
M.HXC-"$_00<.EJD&GC><U@DASB&F!N&@:X#Y,CCI0,(L58LZ/:PY&TDV/K<=
M^AC!F=QD\%+-PNPN8Y?KU[/TLK@[#RS\(8>&IF_'9H$#CZ<F3ZUP;!&<V#UT
M/QR-WV_T%35K,! J^_JG)O#;YL>(G13D)_74Q6G===)R$YM,066BX13A2ZJ;
M%Y2R3HLEX2V.Q\I=DG"6C+,4N8/N#F/G8U;/H:IVZX>7W.X8;OZ'1V5Z9QYE
M6U1="4QY3?DML..DW:G8]N4(2 \="7//->")D6WJ,TE65:.E7H]T]D^%AN4M
M)1IJ77;=+7X9"$[*S^L#]E*+=H/NDAW5GXH-RZ\J)?AM6SC]5L,[E,J$0ARR
M[0;$ V7>I]YUL0_2*[-,+Q5,$++G&V8=.N_TNP8@'E$J&#J8GCTG6B&H<O?7
M/ ;F24U_"%X'9QQ"^) @$S!*"PQU\$BC%XHNW&RD<<$%[!ERK/U4 EUJG<06
ML=1\#4"2D60<[K)*W;.F#DI)'T<6ZI>#[1<OTY"\6 -<?J5DD]U:LP-5VV</
MK,:E]LNM<=NWY_ T)AS"3]+I&GY07@.$LZ762;^ VUJ3A"^Y!UA0D#RBJU!(
MLI#C[3[_O,^.R@TB5=OM61RP;A'=] >7=3"4SR18\F&/O%P=R6?4!M> # ?)
M8AVIZOUK0+_/MSUY=XZ0D.[*KVX,@G/V3 >(BOZO)TX%V9LU"E>YX?/K 4A_
M/>O6P2K D*OR2G0');=2;>=3I)!/(^2)"R^&G%;;A#&V7QK^>M8Q?<1D1O0;
M7DND1,,0?_[2;10=H70Z11<$E]H$LWN'\HY#J'1A]O4:(-F6A"2[C7*^[AJ-
M"?9WEQJHZ8O12_V,L@Y*%=9+(6UMH[-=0Q_-$Z<5F^BB"0[4 L?9W2IY\"#'
M;Q&QR,C)7+K?NIAO*$PXO+O4QFU,?_GW5C&*/7%1 &)V4!(@FE!L9:/8^B^K
M( )EXC..7-+L4 $0\ICNQYS_/Q!J176X?( AS7?B4..U[.>\")%QC5F.ACTN
MUJ'JW]\Q67?]$TH/>'4Z^NPY[R$R<BQ$8[/F:94JWZ8_!GCPOQQ(AF%[%H+9
MP4:@\HOV&NZY(6G4)&69%-T])JF?.S<OO'#4.H(^6'FA2 _XQ=81;7@94*)J
MP.\4\8C-._[$)0 G TE<*-E11V>+?$2XH;(Y@6;CZU,E5L2W=Z&?0?=&Z_A2
MB+8:95ZF;D2 9_XQ\.-58?CN/P(!951IWC!C>GZ2?ZS<$GI5&/;'BL\;1IBH
M!>#UZ7B4%WT^W%&88#^A.\F[<<#,=.E2=)2Y&M"W)RSHJ)4X<PZ#,CYL!L.>
MH3SH:G"!_P\^WT>?G5S<1#6&QOD)2A&YJ^*P/P&XH8S%),%Y\R+O)1?VI="M
MC+]ML+"&\AI44FB-^?[.I9KN#6_TN?<-#9@GZ33'$NC\R7LWT-B$I6Q(!>JB
M<C](.I]KI@:@K-42<JE",+MK]Z=Z/H0GYCO*P0_ZL*\!\ALW&A#LB$MY?%XY
MO6)/+.Y*D+H,KP&U+]W.#;\0PLA*Z78?NMOA'$9A46C.?D+<O[]5./<<W!U:
M,82HHNLK.2H3"^\NPY5]Z"28":!Z'RB3]/+$!:2TR'Y"CHK+8K%KP.%H!$IO
MA$P,[M4'G5C?$X5X\]KNW,=%\&W3DP3\]0 Y-R)?I(Z[9+_PEM*O+"$UTCAZ
M =.\B?WTE] ;/T5%I:*TE T%_^_@%J#3*WB\8R3E,8R:O/&P%W_2]?+@EO8U
M@&L\")AY#:CAOAJ\!J#<E+C[&@#\%?FW49$O<Q;*VGTA0*=;Q 1=S- >9D6
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MIJT++-NL,3V((9#@^(QR+1C;EE5#ETPGYE)UQ^,+G)7CI>A"_6TZ8(Z_>G+
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M(VLB(F:YN[PYBC:QYIAW9BB+?:C49OFJ[2F]=J6+8M/B%%BLW)1*$Q!*@(3
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MLV%S%$1S*T2,BX#R&,(&NJ$DL_2Z%E628+.!LFOJ=H!6"'9O83D2,,:8U&#
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MI4PBP>)N[.,U-2^ASX@030ESX%\.U+S3O"!W& _VAI?W0N[13^B^['O&HL%
M>[K*:7H:Y4T>?H+C*;Q P2T@F?(RF_R "7U[@%*%3]GT,^7[/1.F@(!+!_GJ
MAXKH*H7/C/9-=OJM>)!G6?(6O,AC*-IYAGD40C\5<T@-C!N=34ZXS6?ZT ]X
MT))%%2!5169\L%AV* Z;5QQ\GA$@+_S\OSHX4))E_UW#X&TQ;#T1I_=C\W#N
M;-'\X$L[:ER3\4K%+9+UD)WJWXV5P$3D<S67Z("1V"@\M9]'(S,DY-YBG-*3
M/6N_L(]0XZ15G8:ZQ^7]1C<C H$)X#?^PBT\""ZLC ==JJJ$'^U+'+199@Q<
M>UQ"7Y/5VR2I0QV] N8)7Z$YK*N-NOTA2U;;G7Z_2/!(OA)QO"^"^!WJ9$BR
M\:FY.0-%^K&()9I[VO%5_-U"'=,X_5^D^LRVW,=^3I:O+8QU(NV];;+!OT/6
MI1Z(O;>1/D$M1V1_+.)?Z'4;A<[2;GTE)'_8>D+)+3SHO8GQV026BRG0J\02
MQ?[:H^[UM%4LB+TZ(\D[;4M+P6,Z)1)&*.1EO";[_M_^H@NP[<*"I)TBW\T(
MF?8G>SQSZ<V5_DQ"BSI]!,&^ #\I5H2XFKNC:WA]%5L779G5$BN<BY59ZLO4
M6"('%G@VB]D?H'\71#1;)97NIC._E-E3H@*U9/?VOPQ*FF!2+HYD+^V:G(*C
M<F39 J8VR1->0B738@>6KFRR,5*A?(BFO8=Z.PZ2 L]*@G #/ARSYMMWW=)&
M\* CI0@S.\OFXE=L2X3'U\,EEFR'>ENL'3F=3'X%7\SF[U1S(0,;NU3F/<RC
M$>H(IO%=19?OM=_CD0,M65Z_Z_=SQ;8;.?W,_.L(9:^GM4C+F[>4QE_1F77U
MX19<UNGM9.Z&$ZSU&(GT"+<!]MCO!<J,7\,_,V,*7.D[!^;R]1_B..E.SR9N
M'H_Z4@;(-?=IVBIB/C1!=X=@J>2'EY2['5?KIV =Y7ZD:KQ,KD<8S?2\#]X4
M-MMYIWR#A+)K]O^ARCT/)?\M$:)5Q'4\:-085N\TP#>(N[U#F8MMK]^&C!C0
MF@V$]L7N$$=&^,<^1;6KSK29,#WGS9,-(S6J:A#K[$YG^<Z\BJI=67;U^/'V
MT]E"J_V>P(M.@\P;DPE)CPKG()\I#F&3>1 TPWWB]$ )B,C/@\],RS;T8 ^[
M[!?^."Q+2HU'-=O7,KHY.V)S._%(/UZ?3_3!$,/;WSRY&@R^-IGD!$\\L.6(
M3JN\MWZ!MS"(F:=[+TPGJFB(V*-8XX2=?3Y@[W*[C"-24J>"U(Z$1,I1IT0)
M%6Q(_&,)K&(Y&NWF?O7>M;=3^0;59N2(4A]*29EFTOB P1MZ6\]L*R]QO.QQ
M,^ 88U1Z9'N%9%W+_%?&TB-R[@E4ZGVS^Q[J2O-+2-:DVZU?>->K&0:R(0XW
M*2Y%WXJ_@-.SP5WGNHJT%B6*=^&]@#;C?\0D1Z34[^=@<G7I>B!CFX\JC\!X
M4#)5@]RV=IMED:M(H XFJ/]2?IF9,C&"5[U8XY5.9OUKE-I5\X=1H_6+6G,Z
M]))NZ/:8K\\0EC<I1-(L&4!Z/JI*Q0O\?-UV/U]Y9CL_05]G)[*5,9$XXU8W
M9+*.4LC1AJ*I^.)$?F7FN&>=1!7#F<.<%V*.O]R/VY!_,/FH196!9C5"4P68
M$;>_@)C&3FIXC\ FBR'7?ERE4A2U:-*TC&IMS/C$:/F^HF.,Q3$L4N1ZPO1;
MQ6S3:'TO:A!WIWB?;I*52/O#@+318=5)BUD)/E[/PXN,BMA,0DT22"32??;K
M]9%5Y37WJ5,A/(C]H 1;6<H';@7O"AKC074FQ V7-OP#/N)H_*[.RQ.'/)W_
M7\M3_CN;<H"J/(B3+)N>-0;YF-C26RM@[<\))KE?I/PTY)TN@U+DIMI##PII
MM.1)_RLUIVE<1.HHJJG=[5R%PP.56L'H#%P+"OJ3P0X/\C<XY5.)"H7<5Z'6
MCY^V@UDZ@/<I*O"@)@H<S7GCRI\&;;8\G=R&U6G!EC"L5 1^0CJ!!\U]()3Q
M)K0N&OW=0F6$LF'NXO0.&9K&&17/B#?PH.UOA#K@_U/+04L^PH<>QHL-F]N@
MA. "/&&'\[!O\//CN/-CY)>,3IDP:*Q?NROF8B0>]* 'BOW=-*_XSX:QKI8M
M:SNXNW'Q/I9$"0]*?X(X.[+XG6U&H:Q_Y:MS@M5@D $<A;3_NZ=OI(3/^.I\
MR7CWX#\;U3(!G&@%GO$+@F[JE_:2:0J1V.SEXT'CC)IG)/S0[6Y ;7L4JBSZ
M_>T"I3Y<\[_@NWG*?=ZX^:?!IQ+B^?#_#P#/_QR NG\"4/>? V!V#D#F/QM%
MO-SEU#;4RQ9NR6<!6;!!@0'<J>"1UC^.]6-IC,C*/NZ6U/3]TQ+N?]H(F'7G
MW7CKL<'T4SSH/U"$XO^%(O^]]5^C2-S_'J%6]D!QR+4VQ@RJD$R0SII]^O_U
M0R?XB?\&4$L#!!0    ( %)785EHECR9QCP  *=!   -    :6UA9V5?,# X
M+FIP9\6[!51<S;8NNO#@P1V".\&U"1 < @1W2(+3P1T2F@1WAP1WEQ :=P_N
M$MS=W;F=_>^[S_GWN_>->\Y[8]S58X[N7K-JUOQJK9KUS56UGF:>EH'G"C+R
M,@ <'!SP#O8!GN8 2> 9,C(*,M(S%!045-1G:!CXF!CHZ!@DN'C8^!2D5)04
MI.3D+^@X&%_0L-&2DS,),+-Q<O'R\E(Q"HD*<H,X>'BY_QB!>X:*BH&.08R)
M2<Q-34[-_5\^GEH!G&=PF/#/$>!H '@<. 0<N*=.@ H X)#@_G$ _SS@X!$0
MD9!1GJ&BH<,*5#T'X.$0$. 1$9"0$!%AVL\P/8"(@X1+S26!C*?Z'H7& 9_[
M2W3F,]K7%6T$:J/'=#P?'+^BHA$2$9.0TC,P,C&S\/+Q"P@*"4M*2<O(RLDK
MJ&MH:FGKZ.J9F)J96UA:63LYN[BZN7MX^OKY!P0&!8?$Q,;%)R1^^YZ4E9V3
MFY=?4%CTLQ):55U36U??WM'9U=WSJ[=O;'QB<FIZYO?LRNK:^L;FUO;.[LGI
MV?G%Y=7US>T?7'   MS_//Z7N'!@N. 1$1$04?[@@H-W^U, !Q&)F@L95T(5
MY;T#'@WWEV?XKZ,S*]I0:7G4C@D^.(ZB$=+QKM"?_('V#V3_9\"^_K>0_0O8
M?^":!3 0X& 7#P$'$ .N;IER&.%]2+/Q.0<_5&=^=@%5[$R=\+ZM[O9(":NQ
MY\16 %L+^T=KM53[M<HAK3BZ;M4A8K'4D0SM=;VJ/K0;E<.2D6:7'\%7E0;^
M;XB,#ES*LJ:5"YF<9NA\)["70""I.S VJ^L1%CU,C4L@2 >7XLUG+DJD%,9*
M'R=$T0=O/2;/,.2A[&C+6>UO@W@P/FO%^54W3:(A,BY-3,&U@4W-L@:.POC+
ME;[H+I0_>K?>?VX!_D2",9;<-*H1D'^PG.*]TQ=EV%1TQZ5I926@^,DR9K#S
M3>"EZ9@>Z>8J\2C!9K@^PM?V?+4<,[D75P0*2AQ]VVRQ<])TR>+S_;$AN1;/
MQB^JH7[IE;U$2<]C7G,*KLUL9N8<F9@)R4SKB9"=:X*SA?7Z;**-[/VZR^Q)
M&N#!0QP@L[4]N^>_MQVO[62(:J+E><6-^1<*KWZZWDU0,!:H&M"GAUP$W9OE
M6^HUY<9G*^7+NSELR.G0LKX#>L@_-&BF$04.Z:IF=7]J;2U[!87C(\#@D72@
M^HY12$,I0 LOQJ4<8YD)]-*\$!7@),E 92K W5V4>],+4B$6Y"A#B^R.,M2/
M6E?!P7DX:_S48JP 5$A+(G42<=U$*9$7IMB&^V(/J*N=SNKJ$1_2>&@?T=2R
MB:'!RH@G<BJR=I"/@H*OH@T(J525B*KS("\,VLV'0!4O%FY<,M!Y-=][6=N"
MOCB@?G/8"$8^ZBO>\TRRG*6_S*4YTM>A5*OKWL=8]>&UY.N[YC&<Y(O$+BLL
M9??_.4"HX]\X][6[@]9#%-/9R@7QAT<O2(GH:K+->,B'(>=(E>[DC:%)/$5L
M %KKVI[!8_YJY/X2@56]9'NSTFKZ8D*;UCZ7$L,E^8?U_8A$WOR0S4^ZJPXK
M,Q\''.C&#88J6"I-$$#I[4EIK#J'?%_<<'N04_ /U6-N2+J93T4,JA24G'1V
M*KN K2;'*>'I8(Y%U'3) !$A.3'>ZWC\*]:0$I!\F:&1<5YRSNR@G9G(:[?A
MJOE(B3#UC??[N5[>^19#ED<&86E\P=!0D6)]>8N&QJ@N@A^@(RIWO&TFW\[9
MU+Q<,+AL)WI.UOF.)HW$K<"[;_'<D?-2702--32Y<W;ALAQBD6'%/XTS([\^
MR#[8DYC8;0_<7A1>4!$8[NA))R]8A;EX]6*\U9%^(9(^[98G5+AAKBVK+V]@
M^HIEBHV/5<3X^?:HGJ3'BQ"R9(_[+FU1@E-DU +UKE?TS8T3,HE9>BI@$_MC
M+J^8LHW/R,RG7$ZT=5FUZR<<5<56KO4)OOEZ_7C%GS,Y-IE.A%,(EITTH50$
MUX$:%9&:#6/[+\9<&_II# BC-9U2.(1V%*-S'<X8W)RU4_(C^.1=3.#UI4K3
M8R;;^L,S3QKMR:R&W[@.N@F[K.OYAQ%%F7:!/D@-O\6VEN08E<8'5/_K A=9
MK*_<OKC[VZW7]JZQY>@KI^QTDOYG#17NKDL1J$G;2TI\;[XB875W\LDE11X4
MI4(A1O#A>]OZL2-;N>H8+W#@&8)T/^L[>*Z='KW0MXWI;VOX5\<L:>AX?P[P
M^ZOVEF(R[,IW3:?\9K;?Y?DMJV#H$&=9HRMV.C#)6)HTT=8S;Z.HW(G027CH
MVUO=$(]]PL:(GX#NX%+8='\,Q0FZKQU]/"'I98"6C)OE2!*W8XFAI42(=>="
MRV+XPH44AE36Y0V0JYX ^LKVI4NLAL?XI<N2WU OLG#S.>T88'JJHO%M_X)F
M?9@&!6.J>[;DCQ.4[E*6'K7PW*K'WNC9%QN2*[?D+I23G4N*?(%^%J.E)JYC
M@<'KU5XNW[I!F;^"ZNZ*E+SFMJ=PP=%@=ENL3'P&Q.3:UX[2FD^ G[KD'>9!
MK%64:-5^'C@HU8TMPK/B*@.+:J4[L6"GF7F2E)T%DU$V8>%91<B%+8$Y"ED
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M"7%6S5=32PMWU:2,M&*HXX<E)M3H&\>K1_R\5F,[3N>5P!;TK7,\G1C9B_5
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M\4I;CGDA,&6T^]6CWY[=/2;5BCBI\3_+;@0^W&4_$K3X0K8-?CP!+2[)L(2
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M21S!NUUW^'DO]Y[9X8MND:K*M\G)Y$A6.$5I <]#UNCH62@W"9LBKQFY*>E
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M$.%%&<HC/F+ZN8 U5?GUV!/0(=8/:\SUGXT)U092[6630SYIIUYC62:N;/[
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M65&?%)KCNA=UQS_ G72[I?$82NS("0IF+0O_+^CC?U>PGW[_#U!+ P04
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MOH?)/,31L5BG!Y*Z37(-3L /<C8I$ZR>>_2I/;9$S^P^2>#R\DZ,2'M@+B:
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M946$T:.TR+UJ20R4):N$"D/+%MS)<TZ+[X!ZH(T^LT1CW"=,O<\[$@,Z/>^
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M.8C$B);)X"DUP!9!TM6965L&MR9V]8[6VIC>08+K. 9N<*]Q[+4CX:.F:1G
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M9;P33? E$B"\AC63.G2*DK;+BKH<V_& VOCER/VV)+[G#L[#5M#1<8_5?^A
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M@)^; V"(Y0"TZR" W5/2^HC[8\HU3P]X*N1^]GV19O)P=\D[J,MW ,\ X#Y
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M;1UV45D+E\!KAY7>Z2^G@]02,AE^.&@R\8IG8H=I9',G' ^5M1Y"3D;XXMN
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M>#T]#<=;[E>G=5]M*>L>:,:Y;,:=9G@GVD6Y@T'[LU=:VR[VE:6=21=YL?Y
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M%F.ZC=*=Z3)GV9JX;:L\?;O30"7G[,]\%8:27'DJF*ZBIZPW/$ V-K158G&
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M_B$0,!'=H] #'_MNI#^S#;P[OF="]B1TQHD=_0-D'?M]A[TT0#_6!!^EK"^
M)#1>3:U7T^H#CE_;5# 5$?$+P/D)#?05TIXF3R0W'LWX0VQ8Q%00X6_8GQ?
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M?%69Y/GGY.HMI._(D_]_$P!02P,$%     @ 4E=A6> =D"YK;0  O70   T
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M.Z\9HIK!8,R 7?HXDI7LJLLBAYC_CA?;.1H)1)46OK8@_")"L5ZLF$V\4M_
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MU\QB+T,4;'A;-F[4K.CO(BHD#+0FA_=H2=ZFU^):5:Q\A$IQ?YC_.!47K@A
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M>=P/-*+?#5K?;ZE)=$"G1F4!DR2=578!TF/^O:[;AMPF*,&V+Q,Z+9\] %X
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M;Y1!U#QJ1L*IR\/TO* [S]J*N[ G4%QLOI3?)3: ?R?@GP24J'>6Z2T0T?H
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M6"RLN]T#<3,K9&I,%VRET2Z^E^EMF;DH:4#2$P#9'9;3Q;O'*E.928P B'Y
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MZFQ1O: ;]&.^Q9+5@)>/S2N3RLZZS%*Q+:)"4B,U>A^?_"]U8,69WX[3O[M
MESEEL+@1K.+ZGYB<XY,V5ASPDR31<HHKXV_7@6BG17;GT+JLA5Y)+6(,#7H:
M1HKF :L^BDW!L=FN/,,.A,D\=4T@DGN9>,BN]0<N/HNSEX#E#' >:\KH+MY\
M*C&OY N>2K*S<2U?;_RV>>J@[]X$?>M\:%D,-79U+HI"44G?:Y_6UL5"[8PS
MEF_&J,</:*3\;I!C\>NZE+^6_N:*[*^.2.*.EM,2G6E==NV43&,9]]<SX;7L
MQ2WUY!NTW(AQW"J>W@8.+Z.B"8'V-*G'EY.6VXGBCAWU&6>R8>ICMAN*\CO?
MAA(H^[!]/B:HTB7[Q[<%39A\2CG2IO;.ZE#;B+I"4W-7I+8=0E_OS72Z"C>2
M=XISB5HKXY\2HHODE\#+E=SJ8UB)>1(YN+)K+3WVEN##&;-D&0U+W2&?OBF^
ML]0%)3SMAFY6/BHS&A9=!^I45[3H50"5A8;W?@)_)PL6*@G[_(&?8U[V,UZ*
MNQW*1K1W&I@%:456_;77.Z+>+-C@TI:B-&^U64,BB2*U.W.1A:2KVZLIYV"O
M3D'%%VAXQ<AEI/DN ]\6BS\AZ*9CG0NS"%%\)IP*#5B"9>U&%-"G^M3\_9T5
MU"^=#I41:2,=.P/]TI*B+O4*J.3L%_F<'2\#TM+Y[7LZ7;HEFLQ\N:R:]5&P
M'%.I@QY3R9>Z725Q,2SS&0P]E R4F9@9>O"N/47FTTR3V%YB6:HK\IT+M0Z[
MRD_N1,<AZ_:Y,/=2PRTU#VV"QWSO__1O.?_P7;CHK<3 X'MR-.6T\7<ZD;IZ
M[O;OO.XI\QU&*1(YP/'5R$/@!MF3WD8S"7CR\#BG#'&T-L,SCN4,9YO2[Z,/
M@)J5LW[IV0-G_'6R:^1=YO@O Y'4/G)3IK9QM;XE_BV)JQIM2IG*'J:$I)RY
M5<?]5@6]D1[\Z45C[C@+5)H]9OR2#>[)";S93<1$IVR<H^5Z!K-<3E+D_4IS
MT@!'N<Z7TYU"!_"QERU+[OT4(")0N06CGH2Y:=AD9T$Z;$&7L%[%+JK#H<GV
MC$-IR7;U6T-52XAL[3A*'#&=Y<2K>[+OQ679:L<;T:7V4:/U-^]>$[9V 4 H
MWB1^78D.?@5T6;2)! NQ:$9-F.>E^6&%].[@&BZ^1NV6CTVU6>.D?=*OI2(V
MG" A"0=Z%+CCA_&C;9.7/ZEXG9HB=F?>B&TY7I2!V^5#E(-UQIM@ @1)<MCO
M?ZZEP3ZLS/D\J\E0%&Q1^Q)$8QOQY0(ID8S+BF>5)K?,F8)Q<B [TCXO'LD4
M3-0&LL<0:H'KJ67N<RT([\^Q]I5VC0K@8M!#M:56OV-W!N#G&Z=IU<>1&&0D
M3@OK>ZMOC(SI'$?5O*B._""08!,43F;*_66;4>D=R[.PJ%6@,#$'*J'VY0B!
M)S7(Y,G:,8R<7B-=NS+U4I0,BUKZ9CR>GV*-O+7,IKV%<OR-D?K]B!P!2!8B
M&_\A^ '@2;+'!:-@82F,,X^WLD>WHO$U6S9V9"XCW!BWG@0U"ZB?8.?G+BJ0
M=".7U$7U1A,K82\9)NJUG^TU''Q+\"MMYU(,(16A<;?GVVS8/E?PK$EUG5Z4
M>K1;QOX.*>MG[\::1$SS#5+WUTY=<"/CE+'0Q/UV? 0.VQ>JB0N4O;BAL[O@
MD4$Y*?M/7?P0;<KBG;'V(J$O+YK;NUH1<DFFE.J0"^X=&N0+8+(#5'=AWO )
M*=/[S'+.,M3#98N"?"#?3!5)_<_I)87GH9<\$--/&8?SZ*Y#J@-4*H%,=R/#
MVNK VM1R/9:MF7K?P.X->^'$N.+M>*O)(1>4*$$&CNWV3>1QBHM-$S:X;H.'
M[*"JA=7.T&N$+P/;U5<L*O,?Y/Q:>!7F6(7!',PYQQ5W$S,/@(+OHU4_EF:G
M5>:WBW+!5P/_L0+U3Z4ILOO-,"'^+L.3'/;%9 <8"SX@Y9PKW6O0:OS/K1$$
MC!\,L%_D'ZG-E +P.C2SSNHR/&F4(O7<4\H-)*XFWW&_&2OZBGK0NIKY/VO\
M_(\KK)H[2GA+!?%";\$O4_FZM5J@.]]J9#9!#OID*W[FI_4A*XLACW1W2I$H
ME2L5&&Z^^@PJ>S]$=MP/O?*=/[R]F;)=)II^$7>DN05'L+&Q24KSXP-_' \^
MKY/+9;&+?F=#$IM90(C)2V'"_ 5Y6&-RD6ZB,',$5OI!TJ]Q/9TTO(C<)I=@
M\M9_5>1F6<6.Y3-DKL._B(FA-]>[,9*'GY%UBTTV]P4&6O\3Q,MMC8E9\ *0
M9415O&@;T*EH&,^%"YE0(,*;I0OF0V'/R_Q*%I+EHLU0@"P?S.9%$9:7M4JJ
M ZGNJ>SBKR;#3(,:2N ?HZ31Q'E@DXM1PJC0W]H=BJ?0O =V:2;'6NVQ(D6Z
MYU52L1[6Z.7*H%B#2_*J()C19C)9J.9JO5LHT5( U00#B=*R9 >4^'Y08@/Z
MU%06_*/&6++JZ*$M N5ECI:QD'6;!&YCO!@)!CJQ<1[]2?'V/-8"CNQGB='5
MBC Y&MFSL-CUM'25>@2\QJ/!F)K:BFC090[H7&(@'>^E-Z+W_%:"FW.4'_VL
MF=\C"X0(1''AH"?J#>F2<A<F1+[AD1A/3:>?A.7#&K9P)87M>Y@F2F@<5X :
M]MMYP*T/Q?FJ5:_A]19_RB>'_UV%(F-^A1/8C>OB*\[#S/\"4$L#!!0    (
M %)785EI94BV11H  &1A 0 1    ;FEV9BTR,#(T,#8S,"YX<V3M7>U3V[K2
M_W[^"C\\,\_TSCDT(4 I?=K>@4#:M+10$OIR[MPYXSA*HN+8J64#Z5]_)=E.
M;.O52:#B7'V#6%KMZK>25JO5ZN4_[Z:^<P,B!,/@U=;.T^:6 P(O',)@_&KK
MJK=]U&MWNUO_?.TXO[W\G^UMYPT(0.3&8.@,YDX[G,YZ'G3ZD1N@41A-G2?Q
M]!_.MC.)X]F+1N/V]O:IA\L@#T8 A4GD 41^<+:W,<&<9#L"A. +IS])G',O
M=G9WG)WG+YH'+UJ[SE6_[;2:K;VTRF\O[] +Y$W U'6 #Z8@B#NXV1,P<A,_
M?K7U(W%].()@N.5@N0)<-HJWX_D,H%=;&4\C%PV>AM&XL?C4(/2WG-B-QB#^
MZ$X!FKD>6%0@0@3@=@P">#,BW-/RS6>[S;P1'P;7I>)W@\BG;;2:S=T&^3QP
M$<B+$SHUJ-\QY&]W*?&=P\/#!OV:%TV02-C\2R9K1AGQR&*>=QI?/YSU:#<O
MRF*1AO&B?%'"_4;Z,2\ZC"-^;^ /#<(%8:*UW=S=WMTIDH>2/H0!BMW  UM4
M;YS?'(=H@AL$8>S&6'5?IS]F/\]F,!B%K[.?\(^DDU[D.%R"D4.[[05AYM46
M@M.93]"AOTTB@-$A:&SG2/SENX.GF,^\B!MY4>@#.2:-613.0!1#W.D%#: $
MF-IE8<GG!FX3^&=+EK<:KS<ESBP"#RX.;A/AT4K!JDBU,9B&8/3@<N$V80 Y
M4FU()L_U'UPFW*:7^%RH2E*1PGTLAT/^N+KL2B8U2K<=!BCTX9#,]L>N3\9S
M;P( GCC@,)7[K^@O8:'7SE)3<@Z6O?\:SUIXX>EA#:/+ O[[*G"3(21+%:8Y
M! %*_UI0=S+R#J6/7C:J)#D-)IC(>?":_EU5Z8Q 5D1:M:PUU8KR9BOH5"KG
M #5*"#&#;%/0_77A1K@/)B"&F"^DA62UCA+8UGK .D_*#?Z#@[2%F8&YB\W
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M$*JM;2S1[HZ8'U5-^C]:,**A'<4.WJ?_#6-M1/(*!(K]9:O:** H7@$&7*L
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M$^1>B>^-NLYI^+Q1NK"N"!I*DA,NQ/X\WMZI*X3Z6)F;CLW07E#P6C>XIYS
MQE"9]5C6FR;P#",^=36Y$^HP+IX2"L'(QZYW/<9-!T-=5]I]RLEG3+H%H4_#
MA*/"PS#+=V'R9V&R>TR%VU7W^\32@WLEA_&+":X9><D =*M]:F0//29,SV!
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MTK -+6+?C-T;\LR",I  9<JV ^292U8* B:9OAGDF1C+J,^K3)8TV=:<H'B
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M@3!C<,LR9"_TRZU:VAK2KJSI@;;@/96$C- @#)$:*/=L=R*MW$-$,<GC")E
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MYRV&H(7>71,I2@9#>U)3\>D:'HUJ0Z-H/0(WKY&Z(AP+@W.NM]>$;<% "%M
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M/88?IJ_I)Z_+WWG=_;S<-,B\4M/&#XU9+;[>"Q^#V34=(G:S._*J)JS'+V^
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M/'EX]H:$@^E;[$9H= P:4?,24'YR.I@(8:6X<=Q@9V Q:Q ^W1M7!UV5VJ:
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MB%E=V7QAM>O#RZ&R=<8S#7)?C0MDY19#(JW<@\$'=3->1P$%/2F&_!RE!-]
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M70JUK$#+J)0BZNI049C2K70>Y*<!/3B*NN60A_O\H>1A\N@K[9F>4[L]'IZ
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M($6J;"ME9.8GN3OMQDG)-8E=["M(@?RIRY8+*9)-NUA'<<J63\TVL/0X!$Y
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M>AP")R ?'BP*[V[8-\]%QD+=R_[HUT6YM(1:S21N+Z@1K1YJ8E6,L+X^8YI
M M*F"MH521)"!'I'@]!G"N3M PGNR2=J"Z^AWV*,V;#GWC-9&<W=9HX\THVG
MRM OQ(EO'R)+*Z"B;O.I=2S1UTAC!;5H,4(%#9V)KD_?HO]P5*D78/?>OIA"
MMR3K8_2+P0L9*W%)2O]+Z)5:-O'.'UWZJY,-^]N8DA;R<(S.&B"YBW%7R9)Z
M=KR-+,L^+YS=V)A%=I>XL;]E@S3*]2)T9F?)!NFNTP] P,"55ML_T[$-4YGU
MR*GW[C,9%\EDX;?F&RC#.@W:"$!KO<@96[[G._%NX;#2,HLT<K\AU-@1T['=
M&6_ @F^YA,1 XH06-<A\=C;TCXV6("A%=10(HMD<2A5U>M=R2UX*\*F\TR+)
M#KR2CJ+TK/8%!Q:@8@$=_>JRW*/A,G2#S,O+9F\V49@SIE$%1'M0NYJC^NE3
M7XSZL"$=G(S$.@KHV$EQ^+-VBTWN\)KHZ=&V8M]#*4.&<(-7;*WXN$R2C)4/
MK8Z5T/OJQ'31IJR>Z(+$]SXU-^?Q-'!\\,J8>K2?A-@UX5;)6C,XJ1EIQ@GQ
MFHW0?G:"C"Q(F@9E35K^!-7.[6$D;#CG0<V=H1!CI;EQ@ORG]*CQO=QC$87Y
M?57TNX".-M$B;:M$-^!6UX-:L=P1;B4&S\L'<()KARJ<X=39^JD3C.<9$C
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MH40LP1:G'J@&'_;$^U0EBY7Z+6 A7TCUC^CUT'7E8TF53]K6RQ.43 6 *D2
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MNPGS4P9.O*.&(DM1"HMH^(I7K6H^6D..K^;KB4,7(9P6.>5E!JTFU\/:=76
M:G-[J-2"&5'MKO<D6L7.=NV[3J#1$L? F3OS$V>UBLG*28E78= )X!'P(S##
M!#L<B)1AWML@ZNI)&P!D1JW4 "O_^OB#0'OT.@[LA*\3KIN\ 1E$XK'M647
M>Z/2^R0P(NC?BV(A-&F!F4#BL2V:0+VKM):#&)DQY0!B!_5(PIH=-%P8.,;0
MAX^+R8V&!M[\?3OJ=>\^KN^7UMQ@BU[FM?3CW:\?WTO6;$+<OZRB^]?E+Q?+
MMOS+?M4VAK(0F**,:'/&H,NP'O@#')0?3@/*#\#% *J!;^&@O#T-*&\_* 2U
M/1O'R%K]49K))3,-WIV[Z)[XR9E#.6$=S<@56P)J#Y=FC]][I%GX7L62P#(>
M_OK=1\X\,(H_,L9SHI04XJX1/@NJ"K'U>B_%Z]EV'?%%3V7I/ANFSX;ILV'Z
M;)@^!</TSVQ-P1JF?VIK"K9*71GR&(5N414!6&?L#&\QSM- 6^RBH[*><2NZ
MYVTB9QEALW-"C_XIC6Y(P$S&:R=F4:@]-I.9T5T3V#4:X&#92[WD .(V!322
MLUWK7U#C,G5XL&%AJ8J='U^IA;"U\N]J7"*4>M,@;-]8&[1OVIXH=;BQ\E::
ME%!*OG$(6"_TIK_.16)#+1O?)01>X$T@'8MEW:!E@U$Y/K>3/L4+/_OJAZN+
M+%Q-@F5,/ V+4/RUU9PM\7%0VX>2>6-4;9L5D7!YV>JRHUQ>QCA)Y\O;-;F(
M6&X8"TLL\Y3>*,&O/ZK%FOLZJH<I9BAY=0+&9Z1N-]7J(3F.4B&D;JTMF_$2
M5U FQ%BC7%E5]8>JA]AGDDY1K&D)(4O%K4"D*,,/O$MFQ?9M-&FN'ICC56]0
MNV'8)@>L)FC@O2Y;*Z:1=XNXW3A4;$8(&"[<SG;C@:=R..+F+3L!2W@OG5O-
M0P6Q5..>Z.%)9E@*16% W3<$P5EKJ/4=1Q43==PE*AZ>CZ NOW 1Q;,HNTN7
M67!X4>$<.SJ43U"21@##YEGE_'.T#J7]Q/O.?OTR@]W$!4#URD:]!SY%][G3
M-UK6BX35'V9%O%B]RRFUOOV4U;G)KX7O4*X%>IU6;,P;;%SPV#"\*(Q(F'>$
MX^RWB9L_,":B5N H9QF'Z%$<8T,DWG>P\8!&J[=5%^WF,  L7RFI)R55.:@X
M9FIS)76YO2&4(7K.J1PZ:B-9<P;!B4L'-Y6 "N0:D&$2!;['C+D+/Z0<^TY0
MAW^!&CTLXF3**L^&"9?6U,G=9:+.;D8!=GKTS"($&T41Q<24'_'[(@8UJ(U8
M)LE8MG4@H0Z*Q_90/][+O.6G>,/UKN O1RISU.>EQWYY[](:X9E7_P5>Y5F7
M QMLE*H24=27>+ZTCO%9WDA@JD_R)B4R8JKA1#%5;#996#6ZC88]U6L/>I2/
M&8+7?'W$8#>;E FJZX:K#\3_)2.W]&@'D!E_Q*,)N3"7EP JE,B79EC.5S]=
MMT-NE>33,X2U:F7&NJ,2,)8BIN?QR@G]/XKTTM"[CGTZLZU#;?;4O\_?O<K$
M6J%]I>]15B4I,+)$#F?]80W7N#(E]<)*FD..6D3)7%Y['[HF8G833!<N"9W8
MCZ"32UOC(BH":F61S%9Q)].T#1;T,V-AS!44OH3)EKC^TB<>7)JI<.QC2#/E
M+<2],T*(RJA"@,DQE8O!?HZID234;!E=2<P?J&J7K/TMT/'4'@]/NQKC5#K
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M3_. 6#=6$T&.;>DHWDQ&#U=1R)Y BQC[&S_Y=K:[I9\AW#HR2D_B2I%"V?]
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M"A=IY'Z[=N)YG%>N]2K:N:<#^C5*@:*5@Q)8ODK(8EH.K!R;C@Z;_[ZEJG1
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M#TQ$UC[XFMB !GA7)-Y3WJ^B))F'5$/:1DD.RWR96YH)M,[20\QJY*:IC/H
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M16 7.4&\#Z,C^#PY?@%>@H<D.7WWZM73T].7+FX3NRB"<9A&+HS)+\#+EWC
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M')?LJ_'%N?Z7'C#MG?B>+D(^:H8HZ"=Q\9L*6AJ$7[5$- G6U/GB8"]O!IS
M [=A$.7_)-T0C+O8,PD^?:D3,&HN4;8!*2-S@<&>Q,LTBF"0C R^YMC9US,J
MPI*:W=$_.PZ2J D"W*P-<&@/.TI+*),Z-+K3JG^\&O+'7Y [(01JPU<P-8F
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M)YX'=++\CD13X!+;OW!-1CXX2(3<:W#)"KIGZIT7@"?1?QV1OA[/[?9M)M0
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M\]?W??*M;N^%*VAN0^QGAAF*SI7G')Q@(TE!?6_-+%/,)I90HI[WBMW3[/&
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M[*D-\$-=.RCZZ/@I7._W%XY/7K%O'R!,,D(H=OTP3B/8GRM\L'8<PHE))3B
M3R$.K;^;&A$2=84V=+T&@)M4VH:_I%A!7CWB_YLL@IM/QW#I*!X?W'BBHCV@
M'?C!VU9VW#[I-;9-X=2U D-:0^I$4 H&,'F7)V)$$AH]KED+ 67]PJF%C?7,
M7_?6KS7P5%LCEXQ1XY_#A#2 9G".E96;0+.(-J=19."%+HT^H%LAZVLNTPU=
ML[(-T9AXZ/'2J#3SC,$BU9.;I7K"6W'\*LI&^-*:UTIJ@IV/7&%91K[<D)=8
MS.2-,/6&91?"$V:'?$$DX8V3Y?0.]\!IYNMB"?%+>X>8GLGRY29:G/'MJ*%"
MN]KO\6^JI(GT$6+V%GOA_9S&"1F<]Q7R) OIH.0GM\B F53C J<<^$NKF^\8
M2Z.* X7U'MW3,!0KI-!'%#O^>E_Z0LL?Q!!A8"3*!R,_GTJG\>?E@%]\:=-)
M/& E5!'1OZHV=N=E&"01ND\38ES^X&195'E";C0&3[@UB'!S>ULOD_N.8 1S
MM*"H.]SLPL3Q%9<](7U:BV]_]<N9](N@-6D+<KB$)Y)M):8Y@JE;>HTU5U3E
MT"3/]R_A'F(%[JTVZV48)[<PH:]VSCOXG%S@P]8GGLPJ3Q$U@:HG3R?:GUI"
M7L[!"ZP8"QY>@)!P@=5FR0;-#./EC !T"H&+67D! IA8U9WC+& '*F/*9>P#
M9S^H4!P[6<VL6N7 7K3L\):)AT48+5X%'(J1QH!T-R4C6OSJ>Z;8E:?,DMCX
M_K/"S_1RZB'T/1AQO^6B+E%<M8WM;7I=QKMKSIF;>5.SRPDW96K/,L]@G1F%
M0GG3LV'+869V8:T4$(+"M4Y"K$ZR0DBGK/67%@,0&<RS5IL]06NK+8/K7>,\
MY&4K/Q^,-R?!7G,FOHVN-CY2070(6#4?:D=KG@CRW@ 6]3F(Y0Q24I0#RZ+P
M611BBK&U%81'%-!O P5@GP8TMA*;W)6C@WP]IS"B1EWQ6ZOVF-P2=02LLK+F
M]X_5\>10/PH^*7MOOM6TI! =A3JJR#@V]1QO0AVYB&=N0^.M@@3B@1,"#6J3
M?W0B1"WR#8Q(GB!\KN/)I>B;?7G9&>>QZ(X/0.4 5C\AF1EV!26]+!:LW%4<
MI\0GM=Y3'1XO/ ]EJNSD( \%KG-"^"2NZOE%^;#D9[J56;4=)"?9E9S*XMCX
MXFY")]B%B^UFL>R54%P3CQ^2IR5XBZ)=;8JF-H/.\G=F9^'[N T#ZIL*??RG
M0_$IQR-Z>8(P>.E6)+ ]D=.P=X*4FW1'7BIK9=Y2N$V/]S!:[]=X+W&($+;P
M(+K4RMI3!98UC$%(NV*;[_Y,]1VD^8F_!(O\+T1\>6-2]=T!I*)8&,#\GC/(
M.U"Q/ST@]X&,$M$*\?B/-7A$\)<4FRATH-*0Q$/C<QC9'O=E]3=4JS9/R\L[
M28TH"FIL_J=S"N,_Q;7.9<XVFR<,GEBZZ!+*SX;V+3FAN5SNT.$!FV,?8DB3
M=4@>]RK@^&00$)%1R!_PX0,X="![>D \P8Z$9-;#N,>U[1R^A=POOB69MI_=
MXD?"F$1W]7D3M?%IY('\X;[8!;AW5T[\ ,(TV?OA$_#2LO3E*<M\Z<3E?@B(
MS67O6^C,J", SIQ->T*J0\6Z*A2X#HH;$?*04JB?JOZ-X!RRO9273(GSW%%.
M%EYP2<ZT*RFE)3*NLC91Z$+HQ<1SO*#Z*'<C4U-X)5)?;OUS(A\,-?(!Z0=6
M%C\>\8RZ I)9 0NG <S7'B48'Y<P=B-T$OD4L[;T4ZFUMNJ^8+'/6GO.'&U\
M"'@?2,[D^5>R"#R2M.9$>ES%"3H22QQ;%_O4OT&/7,=2;19YB!$=$IS(F/3J
M'!:C E@,2ZPO/"[P\< V]WV5!6 )4G'U;%@*S>N:$<_5^8^"*RSS#^)$<^W(
M3V)E[ B,WM"+ I)VF0%7,R/RN(1V1)(%"93,,]:[-3$+&TQ5O;SR-6ZHKW&9
M^1KI(X_^6P[G/O6=J'[%0?P8M9JC3CG\_^ONVYKCQI%T_PHB-F*C.Z)Z9Z;W
MQ#EG8Y]*DF4KVK84EKH=O?/0056A)&Y7D5J295OSZP\2%Q(D$A>6Y 3G/,RT
M+!%)9(( \OJE5!-^*BNFO9E9=\A,_ITU/$E^U!KZ,$GD)&ZO=V+[.&?VO)7&
M+S)Y_[G77CZU\!1!!)9\KC3SK;MTD+POB_MR+SOOO=:N5CZD_4 XYUF;RFY@
M15/D1*Z5#M-S.Z:CF=TO6=V#Z6H_JTHFWU*?))+ %_ "$=.'&(9IBT-'%X<C
M&6 O^1[N%569)K2@G,.3. \L^VSY95ALZ%L/$6*^O9!^2]6L1V(#7)2-^$#K
MIOW$#\>*-\'D(SEB")3+GX"V#**+'>YZ1;M:?!7Z#?_Z+__WY[_]G_\4&O;P
MIJRG_ERQN%_!:8+-80N%IGK+NVXOSZ[K'13=&B_$X**'>?^<\$&$OH.V?XL<
M8+W'"EWD+:][F9!F?1ZI,B?7_-"Y>%WPM_@RYG5>>'APUR?$:X9C6DQ'V']%
M(]3'LV+SYT-3'RMO/?GP1'99NY-&1>WCC?H3M[J6MGTGYVB>N3V*?17#@OXZ
M\G4(,^6L1XH,R,V5SX6P@YOKG3699ZU;^59%#5%^NV$UGHWRF7=- OPX"Q+E
M?2;JYY:7?ZRW6ZAD3D)?:OGFWQ[J+W\1XQ0PBOAAP$/!J1% 5:,O]B$7JN<6
MT0@W*'Y8=#]CI,V)9"J&;N36WA3/< &NJZWX32.T%LN?X=N DH!IA-<R34*Z
M[3019E')BR29S*R]4"=*B@AE:C0[P*T4IB>O6G&6*,!7\#B<\5W= /3K#=1X
MU-6Z&PJ8[^J/0FYN*F1XN4<O,A#,/\"[?ERQ>_DZ0&1>,?U&9K\2;('Q2YEY
M:V[@L]>6HO<[>O65(CTTG.P3Z^L/)*V981+H70U<,?%\3GCW""O8 B9Q3[S]
MU436]VW7"*7."T$EGV)_-\_E1;L<SQF3-,85@<[1XX\-$;J$8S_-57IKA4!2
M+TT-^\> .)/4\R[<2^2"+?/+Y4QZ^KTIFDJ<OU 2)5V]%^7^V/EQW\SCT"&=
MR0$KIH?D//@\7&#K$V28%F?5/FH%C[+0LXL=>]:@%1N&H>=@E@T5Y I;D00Q
M$)Z30S*]4&'.BZ9Y%EH,0*+[C8:^E "&L-&8[#J@EQM4FXOP3JP'? )\U8IO
MS9;]P*$2Q5]PIYYF_1GU=S4@]X; V<#D'V*8M/N>E0;\R:#]M&-W#O0X#:3@
MRO$J4OK#0$(H"C\R385),@SH9%Z@5':Q)9LG*MI6S1/]PU$^A$8B[3?K5T."
MI\(=Z*(ZX%3O6V%*WTIJ@\K<MG7!X74K=FXNLJ5HAJ\K/]0D^ XK1*O"?.90
M;<:WZR_BYGC@IE90E6U?'[NV$PLOCK*SHBTW7K>W)L(T%3:4@"I"S**T8I)6
M7M_;++:QE3]!;K-[]9V6T3/5U,+0]"=3IVOC<O(<?8CDQNB]WC%#D0TDF:#)
M#%&FJ"K%T-!=1I[OB9_#Z:EB([%2>Y34R0HE-KQM97;R)>>M/D$#5YN\R.QA
M#,;UEU5N]3[,E^?*B4J"5$NYE&7Q?)1Q^AQ9&#V&R4&K7J-X1M8E1^.; $?8
MDL0E0'.G2UVD>?[CW2\^)/EWUQ_?LE_$_V61[S _6XK369/U:3PU_QT3K'VG
M]-28(L<D/?@+E/=(DDS09#W1!22?9B@C^!N%4\C@QXFOZ\)W&+VKJP?V2PV:
MZ46]WQ=-IKBP/=?1!G%XH&K*'2VDP[M5#-X!,!'5,"M<D#4)YI4K"?]&K0B=
MUY6P.+I26)O@E1C\K0&,<S- NFILGW-FMXV7%^R2C3!.HO) ELQ[8:KM;Q[K
M2MM\7C<_/,?D@]H<SG',8S.>YOW@'%&Z*T-)"!#7CD14$K) (,:_F !+(KMS
MTS4<25$&I_'<<HW^MQ'W?BN+2EM?ZKXDP!0%ID@P16.E?4C@EQSHY#;<DAE&
M0\SSI$79(C 5<Q.[^7LH4ABLG<7]<#:,__\6B/1[]*<Z>==]Y%_EG_S%$@E;
M3A!13RQ[P_6\SMYM$RG1KI]X^;J'X+AIZDK\N%' @L):.I=PT>U593]35IOR
M:9_0^6(8Q&[!%PU!8/;KTU:B<0OK4U$'I$/KR9Z^)XB39>5?0TK8=_%ZTJ?]
M:B14J+CDH5#B_-AVXOKOXTO/0AUHP ]UP=5_+^O&/"\O%FCM4IT=V[+B;2L4
MB7L 8P_46)K!JL;$O&[DLC.OA,ZPZJ<?9:5U/]2\&#XV\VIFO3MGXM%W$:;'
M?OE>JT87B@&@6F5UV3'.B'HN!O6Q83MVO(1P2I A1P](8)_8'7 EC&+5\E#9
M ;&$^>%Y;2&MD&SW#-O0QP>VD\(\SRQ,FK@P-921U81^?5\+(ZL]$[MR>UW=
M/7(PEZ5R?F*@]:17Y(BVGC+1A)"K)LLLNDP2%HHFDZ39=25=Y3UU]ZC(YRE_
MR1>"^,Q/%G*6E/ZQUPVS ?M""M3)F"^Q/^Q<Q+FC+IHRR9L0>J_:^,4ZY*V:
M$1X?5];$U2DWJ%LKS#K=Z>?!@L:^=.7?L)X=%0_]4T%=DW_J;F6%J6><Y,^=
M1TX;K&:EKP%UDQB1K(\%Y"7&N/>D@9P@06KW1@<HY;(9\Y9OSYY_;<&.Z3?[
M>M.57]),"-XQ"7AN:$$CB1^ G+ I?V3#03B0Q(_"+.Z+N5+ G16GR9(T%4AZ
MVC36%,3ZN^?8PJJG5DY%[DWAKXG)Y7Q$&?,Z' -BH/3G>UMT8\?IN!\V/"U=
M^0MJA#VO#3GU@6<.97$:JYPPL3&'V[9/KP3O3I]5&4W+ARNMIV;I&ZLA9U6Y
MVX9,U;R;Y10IA*ZX^=(D2R$+=U]/W&)RS&2CY=]II[:<I]YS[[FPW?BX@T[O
M5_U0=,=&_#>M&EJ16EGJA)N?*NZF>\X &7G%#/6E542?(!)L_YTL6<K[[4/=
MU<UO_+'<"',F7%\H'V7F6:8>SKCED*D[>\W+'I&,VZ;[XW;#JZ(I:^AGNRG:
M+BQE\Y1;O$DH7_^T;0G'F*,]R#X4E3A+91U&M;WES9=2W&V<MZ%^ <,8J2;H
M4;K$(9OJEL(1=N#$)4"[(I!G.%3KQ7MKB,>M@LCEU$%Z^,"6(,@RC?1A5WXH
MJ_)P/$3.<_50]H-F--GI^8)P0IB6=UX?#G4E[5&G,M&7B:?&,#EH2 2R!F;]
MED,<X6'WF 1HSY0I0H P<HZ'H\PRO^"[<E-Z724N/,(/UF"F1_^X,*P$ES]L
ME5*E0IG1*K\6E3;FS:#3FT,]E1<%R9HNZI-RV*%,\ Z:$KK]8WMQY+_SHKE[
M;+A7X9EKH@%!)BGF]8G,%L!L@\PO1<)-<P$]TS=E,*/,?B9WD-*>"ZX.3?FA
MW#4>G[_*?QGY_$^,F_24K+A)]F3/5)YG1$F\$J-8365EFGR/\[K:0H3;N#2+
M_6W?3#S-2]538#T)-M (^J+H3?#Y;+L&^JFBHRVZOGOGA6I_M[YZO_YXD<,^
M&69GRW4Z9[J2:U[\@U>?-,EVR.1[7QY*H>R%#3XUFO7#F97-J GD]^JEL>@X
M^N9(AAZ2&ZDX X=9^:#S83?/%H+_NMK*?^WEM?E6*/82/:0I6W$"VQ48XK2^
MWMT5WUY0UZ=GP<PTF#4/Z1*S9L)@*GHDT].9UKW A5GOH%PPMVI"('?L!B5;
M;D*MU*C&=[5.IO<V^/7BX1GX.V@*KF@P0V2E(!T40IJ+Z9 '$"^98^P;F"LO
M2IW8S:U(['QL#_S7XJEN_Y.9Y!.-4/!W!ZD@,[!QC-6TW)- _V.2.U_84'5;
M=CT4WA#"#]_V9IS$2IDF6T[O>>I;/L:4<[^G28$*V,/,YJ8QB)?3S% Q3X,L
M?W5S?5ZWG3B^$Q% ^I4;R#L+J):UQ^#7[Y#W;P@P)-<ZOTQ0WJ_A->1/>?J:
M4AMPK@5:*_2%X,H)]^;;9G\$ASO3O:3+?\"2ZX=6:/IFWOMSPB=VT**B(-7,
M/]?-G^*4!V5-:&I2^TK%7]-#]3UH4PAAL>7 Z8SSB"U.LFAHTV./]W6SA=)-
MOCVKFZ;^:C5."87Y[8&L'SF4[HU#_3E4E1AGJ*J2)@[:^!P8WE57-\\S O_]
MF$5&_T,<X0=;3 +D2;50TJ#,4&$^)J-^:E>!'+(TP$^7&VPI(JS3]AG9[3C<
MSKR?#6Q1H;$(GL6Y*L]8\<NAD6PKO;-"CY'X4MX" $/66BZ%'S,FK2"<!NHK
MY?.61K=\P<H S&1M8_(R(6'?P*O(G7;'2JVVW.I:OKXT2=981@JZ]%!3T&C7
M<^G"TB4 Q"8PB/I54N5"NK&]SIU [>/$]S5V?:WR%4*F\(2O3$P&A+EOQ;>$
MW#?U4/[<-WNRT] =P@FAU[<_+Q,=A,/]D^81S*/+X3SA>ER(?]JD$'!VJ',N
MXNW3QWQ>*8\F[$D+F7)$<SX 7.>;JH.*0M6L5__G?5GQOWE5+#F Z4=7Y@<&
M@]AUE0N.+\B++?4$ILE!>"=)I>MC]U@WX-;RUWVY6;5L&)8=B=?+$/;]1_DG
M2R@0GZ\!TPI?F.+!'KW,31*@!VN8SMMQ$7LX(VIRKO8;7"'-4]U((T.:%><J
M<^2\WGJ=5?JX&8TUUII$A9,4&)#(98PG<H@?0@E"(3J.0@?CSR?=!G=?ZP7>
M!C^GW@8_9[D-I!5WRS?'A@^%RI$.]?KQH;"[S6K0XBQX\T,\S))"AN-9T'&
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MV"7\?J^$GE(]@+&A:J@^\N[-M\W^" ?7V[K>?BWW>W\JFQFKR\QD]A/[H2?
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M.GZT"L+MB_\9;__7BY<O-G&\^_NK5P\/#]^[['<BEX8D"I+0)1'_P8N7+QG
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M6='X]R18A\YNPVLO 4Z&1G!6%I GPDK(G#OF:-+HC)GK9< +2XNZ8&.)Z..
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M^A!K(ZIQV<9FKN4R_2N.'Y,^$+8:CX@PH%Z$Z E/R*!<9C\BV5?K/LFPW1&
MG !<84!7 5HO#VC&-8(:@19F81;>2,YK:W<9[?@&M$U-KIJ%+,0L'F!1ZCT)
M8WY=.B5WL37)RO$,QX%5$V@#QW!3-D(WS)I V[ -)%&C)M-6UB&7"P@7U,<Y
M.H+K2PEO.H0=L+>9]L0T+N%TBBH 1-+;E7+S)?+ !:9P9_PWK!N)[3;P4_JL
MO!T\!8\K*YWPK\X93(^R3OOG(";E5MFEUV_6MUX3;O22#ATA:[+5P!5]EVF
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MDHL-S,(VBL1G"_$8:9/EEOJ4+R*F]\2.,-NPC4:BK6Q#KKO@AIY$45HZ<$G
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MZ%.[@E0#A74/.0Z]494'<&+>;HY4-#8M6,7YV+1R3^Z6G*=IUE-];IMA%M,
M06\),4/NVTANZ9)B<+ELF:Y><H FY*#XE  ;K(/GIZW8,*D7[;3;+;?@0#FW
M(ZP1!1&F]C^H\:_W<NL#?E$MEKD$!U"35=/*"KL%9==&O/M$?;I-MF#<J\)#
MK#B4LN]DQ3B# U-"G$=8UE?@#9+UU16#5A' S4TYVR_8YZKG@4;8KH(126S]
M'QQ:8NB]"/*0'DA"G\:\OQ>?5?O(_R1\XM ]I2-'A/G46V.35+(J#6S#[I28
MMH?FS0;*0TBMR+0)$VY1HZ%8&UF'<;/TB2R9J?*N?!:S)%)!RM\?B3\>YO0J
ML6CD',!Z@?0I8#_[F6RHZXEMI4P<@N]&)0G1N@'?%QD9N]F*G>7D0+D5,R?&
M,<)32\(L^(='3]JQZS/%9[Z]C&JT6O6KH'T%7=*N@O&IA@Z-]W=*HD!YGB.E
M3+!RI0-2"^"8KGX[JH(>HT'S/7:OY8H!A\=YP<5(W(8;.,/)&R)4AG=MS;"Z
M=UPNX'\.8A)=!XX?I5%F>G_KKX]8[;83TJ/"O']0!0]O%\Y1'<%+[KLZ+U09
M+=:IHZ>ZS1-$%34)Z7KJ4)$P=XGOA#0 NJH2P\5N*-EQGQ\:SXF95A*A4<Z^
M@/;%CW;$94<<64Z#K4-]"'E(8>,573;JWK')GY0II]=3H]8K?9,,.V3.^.PX
MTO8^#*)BY+*E$T."#'_PM-8Q*I*WC(W(DP .K50O@W :)'<Q\W7K)%L2NA;N
M,>N 'I,-7(5WF4KX66=ZHW2X7&&92]37KB^APO8E8#=]F8<=#'L0.UZ/'6J%
MZV _+O1Y%82\AZ_+=.Z<K8'&U\RTM99Y0H:9LU5Y<]6)@0Q#E7%I[CPALEJB
MH[LL&M=NG8CA,$42]O;/F*$'PKJ;BYM ^\J,$$D?2A/JCGYT0UCTLKQQHGB:
MV"C\4<.)$^7U9;DJY2%J,NC_);8R@>I!/Z2:E-(!:#Z5UO[1$KHD9Z#5#)C&
M&^J_>SUU]CJE!X+/L%U7;3:+E@Y;DO-$C5(_7@I(!>-S,#@L7>H>0!KDC.Y)
M>!?8'^YZ9,VGO-+OP(O((&8$TUQ+D^-@+RW5=,Z$L0!QCA9:[5L24!ILA'G:
MJ#$KV90O-VUH'(3_W?G*N^&"YFQ?NJRQ\V2C$RE(&0%[QD=Z":8MI-[?"1;+
M+>5#](J3I9\/P3QTV2E9[;*<.\#%<T]F(]@ZZ  B!7NWB"C7AP,/'4Q]&?WK
M1:/-6+U7S'((\]@)X^[O)^]IQ(0@(!F^^EF.ZNDK1S.GL5O JZGNKZ_Q3,<3
M5@UUYAL<*R++<>$OJW;#;N[ARK]G, *%L:I&NEN W]M++ A1F&?S#N#2$B1;
MM&; 4>\9FD13W@&G#($KQNJJ4!85"?GYL+9L4FYT.*@J-3/6C<Z4[(*(QE':
M-VZ?QD7QAH2EFQC'7T[S!5S=S,Z#*&Y_F6'F8S$*Z+(8LNTO4T(F443BHOS0
MDMG2P=SE?>H)8X%740./^RI56YB5UZDU5N&:NGR79/0#RZT*&_LNMJ/@3AB%
M[:^GQ%>79.<VL '1V+>AA'VX#8V*$VFV8O]/VYM&%C:F",>(Q2EA&ES?!L-C
M?TN3;2F":XKSX$]^'>0CEKTNFPT:04B*^DUMM\*"^_<#L9]U=->"=IYV&'+;
M<[U_D54JU:Z8U&N85OB+;I(@J_KUX6O7;C3#5:M$:(&!VPS86$;IM5<;>\RC
MDIWP;@)2>+?DGAW/CC=;'7+JAS] "+81/O)4-YM2;^8K1F>X%H(OF+OGQL=1
M=Z7>_9/E;TD4;VM'J9E&J"%"ZP[5BW8H,ANK85T+]:<W5^8F_\D*N'2_9! Q
M[0072_;]I%IO(=@,[I'QM;9$YIUU&D%UF>)]Q"#KI62WF4X+6O/K,BG@VJVJ
M[49MUT.9[JJBC^)V.6W*@?=>Z[F7MR NUMW5IEVYAR1O3IR5MWDJ&-'S($9=
M3Y5X67V39R*RLX013OVU]:[;#8A&V).VB6W8-TG/S?%M-<<WB(%.GX4]]U&'
M[:-N$-AT$DFQCJ9.ZITWUHC;K<OX ]>M^[G?.FJ_=8.[%LF&>RJ^]S7P<W)0
MS]M>!:T2RD&J?RW)H"3F"B>1>PM*B;11?MR";*CA54O^I(V%V/.0)JZ;;!./
MUR=,"2/ I2E7V9\]DK+77TZV01C3/]*?2Y<#K Q@9 UTTE*C;8"3"5PC2O#C
MHL=C8@ EI-!'!%P/RCY:4(8)(XTZ=]2C,4WKY[,Z2F>?UC+;ZQV28^ ;ID:%
MW0IZ$PH,<VM9Q9(,NHVR7CFR@?3X-9![K<JW@:,#.+3#Q/$N@W#A/)(H)7>Q
M<?PKG^T_DO[,6HLG5<2X!R^0(N@P&BP?:ZP19-F/ @CQ/(V=W\!'K *5@K2O
M0?B- 3H/MKQ4-3^3L[7M[0A;!>/3$+L2;[&G.9ZL-35&=COYB3 ]%;LN9R58
M#AG&<^W5O=-&CQU:V5$(!;:#O0FP'X&=!WZZ\-(RX$,N7@3L)^222:? QYO2
MGB=1S([2T%*8I8K5=#N*@!Y.!N8EA'PF]I1D_V=N8O'[$Y<%Z_Q]N'^61"S(
MC_C9<D?]5)# /+!#(_+!KJE.Y;UL26:X[ZT;%Y4SZY:XP=JG?Y!EGQI61XYY
M&V-+;P0L!BS @=*(6[)*_,-QM>]!#4XQ/BVS4>-GYSY*G:. 1BWM<]_C7K';
MVN?=GS) =-=K)!&\F5J[F)^@H$NO5@PB/=&K%>M^_#5W6)2=>,,2)K8RA\_K
MKB#;6W+?V["9WHB(P5JZ$6E&AKQ]%.59N?UHX1[<\ )(X7X.?+=/^9;P8>=
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M4CH"?9H0S@;'7[(_Q<$M\7BJX\8)^;N$EHH!P\E*!5Y>C#%)\2Y.\)I.6=*
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M;#F>IR'G!CYBYU>_!N$W!H@_(B9^E-O@;&U[.\)6P?@TQ*[$6ZR:E!/=9&[
MBD2\FLKQ+HGEC2Y#]C3$WL91[!EK)\O,F@A8[5,IPH0;,L&)6LY*L"QQ%V>M
M=966_+9VO$-HV07DORDP&:K WWH@=1[XZ7I+U-N(G'@]KY^02R:6 B-OKWR>
M1#'SD4)+T9(J5M-=)P)Z./*9^Q?R@;13DOW_,@B+WY^X+.KFS[W]LR1BT7K$
MG88[ZJ>B!.:!'1J1CVY-=2IO8DLRPWT\W;BHG%FWQ W6/OV#+/O4L#IRS(/
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M4F9!A<"==M$BB!W/?"L=/Q_E?BJM'G!4LNFF<D)*(DX6KR28K59,6\*H7$<
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MC.M\&-EA/ ,?H%C\><'@6JBJZ40*DBV7;MO*6(1./.Z])/^@SA5B+(W,%:!
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MN ]N2 5R" R0"ZRX]Z:R@.M49J)":<,:9AJ^TGASGD1QL"V35UY45L7);U.
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M+FAT;5!+ 0(4 Q0    ( %)785F4'%:H[0,  'P1   <              "
M 99N! !E83 R,3DT-#<P,65X,C,M,E]N97=G96XN:'1M4$L! A0#%     @
M4E=A682#T MS-0  ]#\   L              ( !O7($ &9I;E\P,#$N:G!G
M4$L! A0#%     @ 4E=A63FY,"1T.P( U)8"  L              ( !6:@$
M &9I;E\P,#(N:G!G4$L! A0#%     @ 4E=A67X )G4U'   "QT   T
M         ( !]N,& &EM86=E7S P,2YJ<&=02P$"% ,4    " !25V%9\?2K
MB4MG  !Z>P  #0              @ %6  < :6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( %)785F:V@USTSP  ,E!   -              "  <QG!P!I;6%G
M95\P,#,N:G!G4$L! A0#%     @ 4E=A6>;R$K7XA   *(\   T
M     ( !RJ0' &EM86=E7S P-"YJ<&=02P$"% ,4    " !25V%9?R-@&HEM
M  #I=   #0              @ 'M*0@ :6UA9V5?,# U+FIP9U!+ 0(4 Q0
M   ( %)785GW)F&+$18  $07   -              "  :&7" !I;6%G95\P
M,#8N:G!G4$L! A0#%     @ 4E=A68",F=3N9P  ;7L   T
M ( !W:T( &EM86=E7S P-RYJ<&=02P$"% ,4    " !25V%9:)8\F<8\  "G
M00  #0              @ 'V%0D :6UA9V5?,# X+FIP9U!+ 0(4 Q0    (
M %)785EDDBVATH0  /6.   -              "  >=2"0!I;6%G95\P,#DN
M:G!G4$L! A0#%     @ 4E=A6> =D"YK;0  O70   T              ( !
MY-<) &EM86=E7S Q,"YJ<&=02P$"% ,4    " !25V%9:65(MD4:  !D80$
M$0              @ %Z10H ;FEV9BTR,#(T,#8S,"YX<V102P$"% ,4
M" !25V%9Y;L8G302  #'#0$ %0              @ 'N7PH ;FEV9BTR,#(T
M,#8S,%]C86PN>&UL4$L! A0#%     @ 4E=A62+$BGE<90  E%\& !4
M         ( !57(* &YI=F8M,C R-# V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M %)785D$=K,)2;<  -@#"0 5              "  >37"@!N:79F+3(P,C0P
M-C,P7VQA8BYX;6Q02P$"% ,4    " !25V%9[*M)M))E  !BJ@8 %0
M        @ %@CPL ;FEV9BTR,#(T,#8S,%]P<F4N>&UL4$L%!@     3 !,
*G 0  "7U"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>ea0219447-f1a4_newgen_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nivf="http://www.newgenivf.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nivf-20240630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-01-18</startDate>
            <endDate>2023-01-18</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-12-04</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MsFongHeiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nivf:SeazenResourcesInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-04</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:HarcourtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <instant>2023-06-12</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:TranchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:TranchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:SubsidiarieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:NewGenIvfLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FFPGSHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:WellImageLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:MedHoldingsLimitedMedHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPGSCenterLimitedFFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityPhnomPenhLimitedFFPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">nivf:FirstFertilityBishkekLLCFFBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nivf:RevenueBenchmarkTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:SuppliersFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:OneVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:OneVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">nivf:NoVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:THB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KHR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">nivf:Within90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:MovementOfAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nivf:MedicalInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nivf:SubscriptionReceivableIncludingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:OccupationalRiskSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:HealthCareSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nivf:PensionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:CurrentTaxProvisionCambodiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">nivf:LatePenaltyProvisionKyrgyzstanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:IVFTreatmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nivf:SurrogacyAncillaryCaringAndOtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nivf:HKSARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">nivf:DepositsAndOtherReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nivf:ASPACIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nivf:MrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMrSiuWingFungAlfredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001981662</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nivf:DirectorsRemunerationToMsFongHeiYueTinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="thb">
        <measure>iso4217:THB</measure>
    </unit>
    <unit id="kzt">
        <measure>iso4217:KZT</measure>
    </unit>
    <unit id="hkd">
        <measure>iso4217:HKD</measure>
    </unit>
    <unit id="khr">
        <measure>iso4217:KHR</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-42">Amendment
No. 4</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-62">NEWGENIVF GROUP LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-76">D8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-119">1/F, Pier 2, Central</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-34089">Hong Kong</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-34090">HK</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-34091">999077</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-34092">+1 (212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-34093">537-4406</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-143">Cogency Global Inc.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-34094">122 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-34095">18th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-34096">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c1" id="ixv-34097">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-34098">10168</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1" id="ixv-34099">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-34100">947-7200</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-246">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-254">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-34101" unitRef="usd">54104</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-34102" unitRef="usd">27556</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-34103" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-34104" unitRef="usd">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-34105" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-34106" unitRef="usd">46910</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-34107" unitRef="usd">517429</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-34108" unitRef="usd">70285</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <nivf:LoanToASPAC contextRef="c2" decimals="0" id="ixv-34109" unitRef="usd">140000</nivf:LoanToASPAC>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-34110" unitRef="usd">354285</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c5" decimals="0" id="ixv-34111" unitRef="usd">2240872</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-34112" unitRef="usd">1201456</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-34113" unitRef="usd">2398623</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-34114" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-34115" unitRef="usd">122673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-34116" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-34117" unitRef="usd">383670</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-34118" unitRef="usd">446004</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-34119" unitRef="usd">506343</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-34120" unitRef="usd">1647460</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-34121" unitRef="usd">2904966</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-34122" unitRef="usd">172626</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-34123" unitRef="usd">104651</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34124" unitRef="usd">241613</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-34125" unitRef="usd">289777</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34126" unitRef="usd">7937</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" id="ixv-34127" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c7" decimals="0" id="ixv-34128" unitRef="usd">110773</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34129" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-34130" unitRef="usd">184651</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34131" unitRef="usd">6446</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-34132" unitRef="usd">18758</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-34133" unitRef="usd">486706</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ixv-34134" unitRef="usd">486872</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34135" unitRef="usd">1122456</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-34136" unitRef="usd">2555650</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-34137" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-34138" unitRef="usd">242187</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-34139" unitRef="usd">6446</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-34140" unitRef="usd">118979</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-34141" unitRef="usd">248633</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-34142" unitRef="usd">1241435</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-34143" unitRef="usd">2804283</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-34144"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ixv-34145"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-34146"
      unitRef="shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-34147"
      unitRef="shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-34148"
      unitRef="shares">698123</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-34149"
      unitRef="shares">698123</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-34150"
      unitRef="shares">601830</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-34151"
      unitRef="shares">601830</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-34152" unitRef="usd">6981</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-34153" unitRef="usd">6018</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c2" decimals="0" id="ixv-34154" unitRef="usd">2967100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c3" decimals="0" id="ixv-34155" unitRef="usd">319872</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" id="ixv-34156" unitRef="usd">4324834</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-34157" unitRef="usd">1458941</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-34158" unitRef="usd">-461351</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-34159" unitRef="usd">-591544</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-34160" unitRef="usd">-7288</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-34161" unitRef="usd">9570</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-34162" unitRef="usd">896076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-34163" unitRef="usd">563113</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-34164" unitRef="usd">-490051</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c3" decimals="0" id="ixv-34165" unitRef="usd">-462430</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-34166" unitRef="usd">406025</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-34167" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-34168" unitRef="usd">1647460</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-34169" unitRef="usd">2904966</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c11" decimals="0" id="ixv-34170" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="0" id="ixv-34171" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c13" decimals="0" id="ixv-34172" unitRef="usd">4118120</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c11" decimals="0" id="ixv-34173" unitRef="usd">3454368</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c12" decimals="0" id="ixv-34174" unitRef="usd">4406421</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c13" decimals="0" id="ixv-34175" unitRef="usd">3093340</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c11" decimals="0" id="ixv-34176" unitRef="usd">1681785</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c12" decimals="0" id="ixv-34177" unitRef="usd">1537769</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c13" decimals="0" id="ixv-34178" unitRef="usd">1024780</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="c11" decimals="0" id="ixv-34179" unitRef="usd">18030</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c12" decimals="0" id="ixv-34180" unitRef="usd">36194</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c13" decimals="0" id="ixv-34181" unitRef="usd">24693</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c11" decimals="0" id="ixv-34182" unitRef="usd">1259364</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c12" decimals="0" id="ixv-34183" unitRef="usd">1094962</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c13" decimals="0" id="ixv-34184" unitRef="usd">801329</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ProfessionalFees contextRef="c11" decimals="0" id="ixv-34185" unitRef="usd">362149</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c12" decimals="0" id="ixv-34186" unitRef="usd">7908</us-gaap:ProfessionalFees>
    <us-gaap:OperatingExpenses contextRef="c11" decimals="0" id="ixv-34187" unitRef="usd">1639543</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c12" decimals="0" id="ixv-34188" unitRef="usd">1139064</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="0" id="ixv-34189" unitRef="usd">826022</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c11" decimals="0" id="ixv-34190" unitRef="usd">42242</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="0" id="ixv-34191" unitRef="usd">398705</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="0" id="ixv-34192" unitRef="usd">198758</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c11" decimals="0" id="ixv-34193" unitRef="usd">111837</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c12" decimals="0" id="ixv-34194" unitRef="usd">23019</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c13" decimals="0" id="ixv-34195" unitRef="usd">45652</us-gaap:OtherIncome>
    <us-gaap:InvestmentIncomeInterest contextRef="c11" decimals="0" id="ixv-34196" unitRef="usd">518</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c12" decimals="0" id="ixv-34197" unitRef="usd">21</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c13" decimals="0" id="ixv-34198" unitRef="usd">63</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c11" decimals="0" id="ixv-34199" unitRef="usd">46179</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c12" decimals="0" id="ixv-34200" unitRef="usd">77757</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c13" decimals="0" id="ixv-34201" unitRef="usd">88289</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c11" decimals="0" id="ixv-34202" unitRef="usd">66176</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c12" decimals="0" id="ixv-34203" unitRef="usd">-54717</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c13" decimals="0" id="ixv-34204" unitRef="usd">-42574</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-34205" unitRef="usd">108418</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-34206" unitRef="usd">343988</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-34207" unitRef="usd">156184</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c12" decimals="0" id="ixv-34208" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c13" decimals="0" id="ixv-34209" unitRef="usd">294716</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-34210" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c12" decimals="0" id="ixv-34211" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c13" decimals="0" id="ixv-34212" unitRef="usd">-138532</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-34213" unitRef="usd">-21775</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-34214" unitRef="usd">-322820</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-34215" unitRef="usd">-137999</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="0" id="ixv-34216" unitRef="usd">130193</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="0" id="ixv-34217" unitRef="usd">458667</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" id="ixv-34218" unitRef="usd">-533</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c11" decimals="0" id="ixv-34219" unitRef="usd">-22704</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c12" decimals="0" id="ixv-34220" unitRef="usd">-1920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c13" decimals="0" id="ixv-34221" unitRef="usd">7751</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c11" decimals="0" id="ixv-34222" unitRef="usd">85714</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c12" decimals="0" id="ixv-34223" unitRef="usd">133927</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c13" decimals="0" id="ixv-34224" unitRef="usd">-130781</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-34225" unitRef="usd">-27621</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-34226" unitRef="usd">-323458</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-34227" unitRef="usd">-136396</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c11" decimals="0" id="ixv-34228" unitRef="usd">113335</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c12" decimals="0" id="ixv-34229" unitRef="usd">457385</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c13" decimals="0" id="ixv-34230" unitRef="usd">5615</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c11"
      decimals="2"
      id="ixv-34231"
      unitRef="usdPershares">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c11"
      decimals="2"
      id="ixv-34232"
      unitRef="usdPershares">0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c12"
      decimals="2"
      id="ixv-34233"
      unitRef="usdPershares">0.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c12"
      decimals="2"
      id="ixv-34234"
      unitRef="usdPershares">0.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="ixv-34235"
      unitRef="usdPershares">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ixv-34236"
      unitRef="usdPershares">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c11"
      decimals="INF"
      id="ixv-34237"
      unitRef="shares">615135</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c11"
      decimals="INF"
      id="ixv-34238"
      unitRef="shares">615135</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c12"
      decimals="INF"
      id="ixv-34239"
      unitRef="shares">575930</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c12"
      decimals="INF"
      id="ixv-34240"
      unitRef="shares">575930</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c13"
      decimals="INF"
      id="ixv-34241"
      unitRef="shares">560000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="INF"
      id="ixv-34242"
      unitRef="shares">560000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-34243"
      unitRef="shares">560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" id="ixv-34244" unitRef="usd">5600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c17" decimals="0" id="ixv-34245" unitRef="usd">57821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-34246" unitRef="usd">-1049678</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c19" decimals="0" id="ixv-34247" unitRef="usd">4704</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20" decimals="0" id="ixv-34248" unitRef="usd">-981553</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="0" id="ixv-34249" unitRef="usd">-2576</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="0" id="ixv-34250" unitRef="usd">-984129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c26" decimals="0" id="ixv-34251" unitRef="usd">-533</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c28" decimals="0" id="ixv-34252" unitRef="usd">-533</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c29" decimals="0" id="ixv-34253" unitRef="usd">-137999</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c13" decimals="0" id="ixv-34254" unitRef="usd">-138532</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c27" decimals="0" id="ixv-34255" unitRef="usd">6148</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c28" decimals="0" id="ixv-34256" unitRef="usd">6148</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c29" decimals="0" id="ixv-34257" unitRef="usd">1603</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c13" decimals="0" id="ixv-34258" unitRef="usd">7751</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c25" decimals="0" id="ixv-34259" unitRef="usd">200000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c28" decimals="0" id="ixv-34260" unitRef="usd">200000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c13" decimals="0" id="ixv-34261" unitRef="usd">200000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c30"
      decimals="INF"
      id="ixv-34262"
      unitRef="shares">560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ixv-34263" unitRef="usd">5600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" id="ixv-34264" unitRef="usd">257821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="0" id="ixv-34265" unitRef="usd">-1050211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" id="ixv-34266" unitRef="usd">10852</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" id="ixv-34267" unitRef="usd">-775938</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c36" decimals="0" id="ixv-34268" unitRef="usd">-138972</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-34269" unitRef="usd">-914910</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c30"
      decimals="INF"
      id="ixv-34270"
      unitRef="shares">560000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ixv-34271" unitRef="usd">5600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" id="ixv-34272" unitRef="usd">257821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="0" id="ixv-34273" unitRef="usd">-1050211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" id="ixv-34274" unitRef="usd">10852</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" id="ixv-34275" unitRef="usd">-775938</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c36" decimals="0" id="ixv-34276" unitRef="usd">-138972</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-34277" unitRef="usd">-914910</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c41" decimals="0" id="ixv-34278" unitRef="usd">458667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c43" decimals="0" id="ixv-34279" unitRef="usd">458667</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c44" decimals="0" id="ixv-34280" unitRef="usd">-322820</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c12" decimals="0" id="ixv-34281" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c42" decimals="0" id="ixv-34282" unitRef="usd">-1282</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c43" decimals="0" id="ixv-34283" unitRef="usd">-1282</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c44" decimals="0" id="ixv-34284" unitRef="usd">-638</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c12" decimals="0" id="ixv-34285" unitRef="usd">-1920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c40" decimals="0" id="ixv-34286" unitRef="usd">240000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c43" decimals="0" id="ixv-34287" unitRef="usd">240000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c12" decimals="0" id="ixv-34288" unitRef="usd">240000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c38"
      decimals="INF"
      id="ixv-34289"
      unitRef="shares">41830</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c38" decimals="0" id="ixv-34290" unitRef="usd">418</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c39" decimals="0" id="ixv-34291" unitRef="usd">-319872</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c40" decimals="0" id="ixv-34292" unitRef="usd">961120</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c43" decimals="0" id="ixv-34293" unitRef="usd">641666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="0" id="ixv-34294" unitRef="usd">641666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-34295"
      unitRef="shares">601830</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" id="ixv-34296" unitRef="usd">6018</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-34297" unitRef="usd">-319872</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-34298" unitRef="usd">1458941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-34299" unitRef="usd">-591544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-34300" unitRef="usd">9570</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-34301" unitRef="usd">563113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-34302" unitRef="usd">-462430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-34303" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-34304"
      unitRef="shares">601830</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" id="ixv-34305" unitRef="usd">6018</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-34306" unitRef="usd">-319872</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-34307" unitRef="usd">1458941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-34308" unitRef="usd">-591544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-34309" unitRef="usd">9570</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-34310" unitRef="usd">563113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-34311" unitRef="usd">-462430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-34312" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c55" decimals="0" id="ixv-34313" unitRef="usd">130193</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c57" decimals="0" id="ixv-34314" unitRef="usd">130193</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c58" decimals="0" id="ixv-34315" unitRef="usd">-21775</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-34316" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c56" decimals="0" id="ixv-34317" unitRef="usd">-16858</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c57" decimals="0" id="ixv-34318" unitRef="usd">-16858</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c58" decimals="0" id="ixv-34319" unitRef="usd">-5846</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c11" decimals="0" id="ixv-34320" unitRef="usd">-22704</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c53" decimals="0" id="ixv-34321" unitRef="usd">219628</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c57" decimals="0" id="ixv-34322" unitRef="usd">219628</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c11" decimals="0" id="ixv-34323" unitRef="usd">219628</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c52"
      decimals="INF"
      id="ixv-34324"
      unitRef="shares">96293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c52" decimals="0" id="ixv-34325" unitRef="usd">963</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c53" decimals="0" id="ixv-34326" unitRef="usd">-2866856</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c54" decimals="0" id="ixv-34327" unitRef="usd">2865893</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="INF"
      id="ixv-34328"
      unitRef="shares">698123</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c59" decimals="0" id="ixv-34329" unitRef="usd">6981</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c60" decimals="0" id="ixv-34330" unitRef="usd">-2967100</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c61" decimals="0" id="ixv-34331" unitRef="usd">4324834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c62" decimals="0" id="ixv-34332" unitRef="usd">-461351</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c63" decimals="0" id="ixv-34333" unitRef="usd">-7288</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c64" decimals="0" id="ixv-34334" unitRef="usd">896076</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c65" decimals="0" id="ixv-34335" unitRef="usd">-490051</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-34336" unitRef="usd">406025</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c11" decimals="0" id="ixv-34337" unitRef="usd">108418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c12" decimals="0" id="ixv-34338" unitRef="usd">135847</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c13" decimals="0" id="ixv-34339" unitRef="usd">-138532</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c11" decimals="0" id="ixv-34340" unitRef="usd">31173</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c12" decimals="0" id="ixv-34341" unitRef="usd">100533</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c13" decimals="0" id="ixv-34342" unitRef="usd">166709</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c11" decimals="0" id="ixv-34343" unitRef="usd">198535</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c12" decimals="0" id="ixv-34344" unitRef="usd">203411</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c13" decimals="0" id="ixv-34345" unitRef="usd">175830</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c12" decimals="0" id="ixv-34346" unitRef="usd">-114013</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c11" decimals="0" id="ixv-34347" unitRef="usd">625</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c12" decimals="0" id="ixv-34348" unitRef="usd">10777</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c13" decimals="0" id="ixv-34349" unitRef="usd">6717</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:InterestExpenseDebt contextRef="c11" decimals="0" id="ixv-34350" unitRef="usd">46179</us-gaap:InterestExpenseDebt>
    <nivf:WaiverOfRelatedPartyBalance contextRef="c11" decimals="0" id="ixv-34351" unitRef="usd">88151</nivf:WaiverOfRelatedPartyBalance>
    <us-gaap:ShareBasedCompensation contextRef="c12" decimals="0" id="ixv-34352" unitRef="usd">240000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c13" decimals="0" id="ixv-34353" unitRef="usd">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:LegalFees contextRef="c11" decimals="0" id="ixv-34354" unitRef="usd">27320</us-gaap:LegalFees>
    <us-gaap:OtherNoncashIncomeTaxExpense contextRef="c12" decimals="0" id="ixv-34355" unitRef="usd">208141</us-gaap:OtherNoncashIncomeTaxExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c11" decimals="0" id="ixv-34356" unitRef="usd">-1166</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c12" decimals="0" id="ixv-34357" unitRef="usd">-129922</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c13" decimals="0" id="ixv-34358" unitRef="usd">-56183</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c11" decimals="0" id="ixv-34359" unitRef="usd">80665</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c12" decimals="0" id="ixv-34360" unitRef="usd">7219</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c13" decimals="0" id="ixv-34361" unitRef="usd">-1352</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c11" decimals="0" id="ixv-34362" unitRef="usd">448266</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c12" decimals="0" id="ixv-34363" unitRef="usd">15197</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c13" decimals="0" id="ixv-34364" unitRef="usd">-10987</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c11" decimals="0" id="ixv-34365" unitRef="usd">71362</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c12" decimals="0" id="ixv-34366" unitRef="usd">58752</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c13" decimals="0" id="ixv-34367" unitRef="usd">-60989</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c11" decimals="0" id="ixv-34368" unitRef="usd">-51167</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c12" decimals="0" id="ixv-34369" unitRef="usd">190689</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c13" decimals="0" id="ixv-34370" unitRef="usd">79853</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c11" decimals="0" id="ixv-34371" unitRef="usd">-1352231</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c12" decimals="0" id="ixv-34372" unitRef="usd">548010</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c13" decimals="0" id="ixv-34373" unitRef="usd">812158</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c11" decimals="0" id="ixv-34374" unitRef="usd">-230433</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c12" decimals="0" id="ixv-34375" unitRef="usd">-175132</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c13" decimals="0" id="ixv-34376" unitRef="usd">-148677</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInFinanceReceivables contextRef="c12" decimals="0" id="ixv-34377" unitRef="usd">19476</us-gaap:IncreaseDecreaseInFinanceReceivables>
    <us-gaap:IncreaseDecreaseInFinanceReceivables contextRef="c13" decimals="0" id="ixv-34378" unitRef="usd">19476</us-gaap:IncreaseDecreaseInFinanceReceivables>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c12" decimals="0" id="ixv-34379" unitRef="usd">-12170</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c13" decimals="0" id="ixv-34380" unitRef="usd">290887</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c11" decimals="0" id="ixv-34381" unitRef="usd">-1766135</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c12" decimals="0" id="ixv-34382" unitRef="usd">1710901</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c13" decimals="0" id="ixv-34383" unitRef="usd">1433002</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c11" decimals="0" id="ixv-34384" unitRef="usd">69848</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c12" decimals="0" id="ixv-34385" unitRef="usd">94452</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c13" decimals="0" id="ixv-34386" unitRef="usd">16575</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c11" decimals="0" id="ixv-34387" unitRef="usd">-69848</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c12" decimals="0" id="ixv-34388" unitRef="usd">-94452</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c13" decimals="0" id="ixv-34389" unitRef="usd">-16575</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nivf:ProceedsFromAmountDueFromASPACI contextRef="c11" decimals="0" id="ixv-34390" unitRef="usd">140000</nivf:ProceedsFromAmountDueFromASPACI>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c11" decimals="0" id="ixv-34391" unitRef="usd">9317</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c12" decimals="0" id="ixv-34392" unitRef="usd">19476</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c13" decimals="0" id="ixv-34393" unitRef="usd">17221</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c12" decimals="0" id="ixv-34394" unitRef="usd">128204</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c13" decimals="0" id="ixv-34395" unitRef="usd">512821</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c11" decimals="0" id="ixv-34396" unitRef="usd">192308</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nivf:PaymentofInterest contextRef="c11" decimals="0" id="ixv-34397" unitRef="usd">24704</nivf:PaymentofInterest>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c11" decimals="0" id="ixv-34398" unitRef="usd">1863206</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c12" decimals="0" id="ixv-34399" unitRef="usd">-1742509</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c13" decimals="0" id="ixv-34400" unitRef="usd">-2039969</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c11" decimals="0" id="ixv-34401" unitRef="usd">1881493</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c12" decimals="0" id="ixv-34402" unitRef="usd">-1633781</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c13" decimals="0" id="ixv-34403" unitRef="usd">-1544369</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c11" decimals="0" id="ixv-34404" unitRef="usd">45510</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c12" decimals="0" id="ixv-34405" unitRef="usd">-17332</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c13" decimals="0" id="ixv-34406" unitRef="usd">-127942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="0" id="ixv-34407" unitRef="usd">-18962</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c12" decimals="0" id="ixv-34408" unitRef="usd">16124</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="0" id="ixv-34409" unitRef="usd">50514</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-34410" unitRef="usd">27556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c37" decimals="0" id="ixv-34411" unitRef="usd">28764</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c22" decimals="0" id="ixv-34412" unitRef="usd">106192</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-34413" unitRef="usd">54104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-34414" unitRef="usd">27556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c37" decimals="0" id="ixv-34415" unitRef="usd">28764</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c12" decimals="0" id="ixv-34416" unitRef="usd">12170</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c13" decimals="0" id="ixv-34417" unitRef="usd">3829</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c11" decimals="0" id="ixv-34418" unitRef="usd">24704</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c12" decimals="0" id="ixv-34419" unitRef="usd">55469</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c13" decimals="0" id="ixv-34420" unitRef="usd">65582</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c11" id="ixv-22749">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 1 &#x2014;&#160;ORGANIZATION
AND PRINCIPAL ACTIVITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;NewGenIvf
Limited (the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;) was incorporated under the laws of the Cayman Islands on January&#160;16,
2019 as an investment holding company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
following is an organization chart of the Company and its subsidiaries:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;img alt="" src="fin_001.jpg"/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023, the Company&#x2019;s subsidiaries are detailed in the table as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 22%; padding-right: 3pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 23%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Bishkek LLC (&#x201c;FFB&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;According
to the Foreign Business Act (the &#x201c;FBA&#x201d;), the majority shareholdings of limited company incorporated in Thailand is required
to be owned by Thai nationals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;With
reference to the capital structure and voting rights structure of ordinary shares and preference shares (the &#x201c;Share Structure&#x201d;)
of Med Holdings and FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have
the same rights and status in all respects except for the distribution of profits by way of dividends with details as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;After
                                            allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed
                                            equally amongst the holders of ordinary shares according to their shareholding ratio;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
                                            holders of preferred shares shall be entitled to dividends only in respect of the&#160;years
                                            for which the Company has declared a dividend payment, and there shall be no cumulative dividends;
                                            and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Dividends
                                            allocated to the holders of preferred shares in each year shall be limited at the rate as
                                            stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred
                                            shares.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Based
upon the management&#x2019;s judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board
meeting, the Company accounts for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings
and FFC by exercising its majority voting power in any board meetings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Group reorganization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Pursuant
to a group reorganization (the &#x201c;group reorganization&#x201d;) to rationalize the structure of the Company and its subsidiary companies
(herein collectively referred to as the &#x201c;Group&#x201d;) in preparation for the listing of its shares, the Company becomes the holding
company of the Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests
were also ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and
comprehensive income, consolidated statements of changes in shareholders&#x2019; equity and consolidated statements of cash flows are
prepared as if the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023,
or since the respective dates of incorporation/establishment of the relevant entity, where this is a shorter period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
consolidated balance sheets as of December&#160;31, 2023 and 2022 present the assets and liabilities of the aforementioned companies
now comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
movement in the Company&#x2019;s authorized share capital and the number of ordinary shares outstanding and issued in the Company are
also detailed in Note&#160;10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December&#160;31,
2023, the Company had bank balance of $54,104 and may have challenge to settle its obligations when payment become due. The Company is
always closely monitoring the market opportunities and is currently in the process of exercising various fundraising projects with various
potential investors to improve the Company&#x2019;s cash flow position for its operation and short-term payables. One fundraising project
was completed on April 3, 2024. As of April 4, 2024, the Company settled $2 million to any payment with respect to accounts payable,
but not, directly or indirectly, for (i) except for expenses relating to the Business Combination, the satisfaction of any indebtedness
of the Company or any of its Subsidiaries, (ii) the redemption or repurchase of any securities of the Company or any of its Subsidiaries,
or (iii) the settlement of any outstanding litigation as at December 31, 2023. The Company secured funding subsequent to year-end with
total of $2 million, and that the Company received $2 million funding to date. Please refer to &lt;i&gt;Note 20 &#x2013; Subsequent Events&lt;/i&gt;
for further information. The Company can make no assurance that required financings will be available for the amounts needed, or on terms
commercially acceptable to the Company, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient
to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Company and its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c11" id="ixv-22770">&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023, the Company&#x2019;s subsidiaries are detailed in the table as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 22%; padding-right: 3pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; width: 23%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Bishkek LLC (&#x201c;FFB&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;/span&gt;&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <nivf:SubsidiariesBackground contextRef="c98" id="ixv-22801">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c98" decimals="2" id="ixv-34421" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c98" id="ixv-22813">Marketing and administrative services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c99" id="ixv-22821">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c99" decimals="2" id="ixv-34422" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c99" id="ixv-22833">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c100" id="ixv-22841">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c100"
      decimals="2"
      id="ix_0_fact"
      unitRef="pure">0.49</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c100" id="ixv-22853">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c101" id="ixv-22861">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c101"
      decimals="2"
      id="ixv-34424"
      unitRef="pure">0.74</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c101" id="ixv-22873">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c102" id="ixv-22881">&#x25cf;&#160;&#160;&#160;A Cambodia company &#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c102"
      decimals="2"
      id="ixv-34425"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c102" id="ixv-22893">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c103" id="ixv-22964">&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company &#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c103"
      decimals="2"
      id="ixv-34426"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c103" id="ixv-22976">Provision surrogacy and ancillary caring services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c95" decimals="2" id="ixv-34427" unitRef="pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PolicyholderDividendsRateOnPolicyEarnings contextRef="c96" decimals="2" id="ixv-34428" unitRef="pure">0.15</us-gaap:PolicyholderDividendsRateOnPolicyEarnings>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-34429" unitRef="usd">54104</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c97" decimals="-6" id="ixv-34430" unitRef="usd">2000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:OtherSecuredFinancings contextRef="c2" decimals="-6" id="ixv-34431" unitRef="usd">2000000</us-gaap:OtherSecuredFinancings>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c11" decimals="-6" id="ixv-34432" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c11" id="ixv-23112">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 2 &#x2014;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation
and basis of preparation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Management
has prepared the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted
in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual
method accounting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates
required to be made by management include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ
from those estimates, and as such, differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency
translation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
accompanying consolidated financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency
of the Company. The functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong
dollar (&#x201c;HK$&#x201d;). Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom
Penh Limited uses Cambodian riel (&#x201c;KHR&#x201d;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States
dollar (&#x201c;USD&#x201d;) as its functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial
condition in terms of reporting in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.2265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.6153&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33.1964&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.7867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;35.1428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;32.1003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,080.0304&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,114.3335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,068.9577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,105.4181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,083.7043&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,065.8164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0971&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.9091&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.3551&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4569&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4368&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original
maturities of three&#160;months or less that are readily convertible to known amounts of cash and which are subject to an insignificant
risk of changes in value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, prepayment,
other receivables and deferred IPO cost, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Deposits,
prepayment, other receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;) cost, net primarily include deposits paid to suppliers,
prepaid expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Deferred
IPO costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the Initial Public Offering and that were charged to shareholders&#x2019; equity upon the completion of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Plant and equipment,
net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Plant
and equipment are stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the
straight-line&#160;method. The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment
are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss
are included in the Company&#x2019;s results of operations. The costs of maintenance and repairs are expensed as incurred. Significant
renewals and betterments that extend the useful life of an assets are capitalized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company evaluates the long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of assets may not be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies,
or if the Company has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present
if the carrying amount of an asset is less than its expected future undiscounted cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;If
an asset is considered impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value
of the asset. Assets to be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value
is based on the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and
obsolete inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes
the basis for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory
would not be reversed if market conditions improve.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Other
borrowings are recognized initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized
cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements
of operations over the period of the borrowings using the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s ordinary shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received,
net of issuance cost, and the par value is recorded in additional paid-in&#160;capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606
had been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify
                                            its contracts with customers;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify
                                            its performance obligations under those contracts;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;determine
                                            the transaction prices of those contracts;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;allocate
                                            the transaction prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognize
                                            revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
                                            when promised services are transferred to the client in an amount that reflects the consideration
                                            expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The
agreements also identify the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties.
All the contracts have commercial substance, and it is probable that the Company will collect considerations from its customers for service
component.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company derives its revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary
caring services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue from
IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
vitro fertilization (&#x201c;IVF&#x201d;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized
in laboratory to become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the
performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to customer when
embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation. The Company collects
payment from customer in advance for IVF treatment. The amount of revenue recognized from contract liabilities to the Company&#x2019;s
result of operations can be found in Note&#160;8 below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue from
surrogacy and ancillary caring services&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother
contracted by the Company. During pregnancy period, the Company provides ancillary caring services including regular body check and provision
of vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result
of operations can be found in Note&#160;8 below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Contract
related assets and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to
the revenue cycle are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Account receivables,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accounts
receivable, net are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected
credit loss is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the
accounts receivable balances, current general economic conditions, future expectations and customer specific quantitative and qualitative
factors that may affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence
for the Company to reasonably estimate the amount of probable loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Contract
liabilities represent considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under
the contract. These amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Expected
credit loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;ASU
No.&#160;2016-13, Financial Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments
requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using
this methodology will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to
recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments
of other financial assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates
of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows
due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the
effective interest rate of the financial asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Retirement
benefits in the form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated
to wages as part of cost of revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (the &#x201c;CODM&#x201d;), or decision making group, in making decisions on how to allocate resources
and assess performance. The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing
Fund Alfred, the Company&#x2019;s Chief Executive Officer. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers
as of December&#160;31, 2023, 2022 and 2021 by geographical area are presented in Note&#160;13.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company measured the lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the
present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not
have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life
of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease
exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;twelve&lt;/span&gt;&#160;months or less.
Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense
is recognized on a straight-line&#160;basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, there were $283,847 and $383,670&#160;million right of use (&#x201c;ROU&#x201d;) assets and $326,107
and $426,838 lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#x2019;s
management believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate
(&#x201c;BLR&#x201d;) minus 0.125%&#160;was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the present
value of the lease payments; the rate used by the Company was 6.6% and 5.0% respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company recognizes deferred income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated
financial statements or tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences
between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will
be in effect when the differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred
tax asset is not realizable or recoverable in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company determines that the tax position is more likely than not to be sustained and records the largest amount of benefit that is more
likely than not to be realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain
tax positions in income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company presents comprehensive income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states
that all items that are required to be recognized under accounting standards as components of comprehensive income be reported in the
consolidated financial statements. The components of comprehensive income were the net income for the&#160;years and the foreign currency
translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is
measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period.
Diluted EPS presents the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise
of options and or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the
potentially dilutive effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities
(i.e., those that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially
dilutive securities that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company adopted ASC&#160;850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and
contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such
contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments including historical and the specific facts and circumstances of each matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of
risks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration of
credit risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable.
The Company places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accounts
receivable primarily comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers,
and generally does not require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts
primarily based upon the factors surrounding the credit risk of specific customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration of
customers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, two and Nil customers which individually contributed more than 10% of trade receivable, accounted
for 96.3% and &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;Nil&lt;/span&gt; of the Company&#x2019;s trade receivable respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;None
of the customers contributed more than 10% of revenue for&#160;years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration
of suppliers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, one and four suppliers which individually contributed more than 10% of trade payable, accounted for
30.6% and 69.8% of the Company&#x2019;s trade payable respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;For
the year ended December&#160;31, 2023, 2022 and 2021, Nil, two and two vendors which contributed more than 10% of total purchases of
the Company, accounted for &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;Nil&lt;/span&gt;, 55.3% and 35.6% of the Company&#x2019;s total purchases respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and
deferred IPO cost, net, loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders,
have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements
and Disclosures&#x201d; requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial
Instruments&#x201d; defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash
and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related
parties each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation
hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            1&#160;&#x2014;&#160;inputs to the valuation methodology used quoted prices for identical
                                            assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            2&#160;&#x2014;&#160;inputs to the valuation methodology include quoted prices for similar
                                            assets and liabilities in active markets and information that are observable for the asset
                                            or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s
                                            full term&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            3&#160;&#x2014;&#160;inputs to the valuation methodology are unobservable and significant
                                            to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities
from Equity&#x201d; and ASC&#160;815.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting
pronouncements adopted &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#x201c;CECL&#x201d;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting
pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments in
ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for
all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report
a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions
about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and
depletion expense, to be disclosed under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure
requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective
for years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively.
Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
December 2023, FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740)&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements
to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU
2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit)
from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable
statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling
items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires
disclosure of, on an annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state,
and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual
jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective
for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact
of the update on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Save
for elsewhere disclosed, the Company does not believe other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income
(loss) and statement of cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c11" id="ixv-23119">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation
and basis of preparation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Management
has prepared the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted
in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual
method accounting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c11" id="ixv-23172">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates
required to be made by management include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ
from those estimates, and as such, differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c11" id="ixv-23183">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency
translation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
accompanying consolidated financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency
of the Company. The functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong
dollar (&#x201c;HK$&#x201d;). Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom
Penh Limited uses Cambodian riel (&#x201c;KHR&#x201d;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States
dollar (&#x201c;USD&#x201d;) as its functional currency.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial
condition in terms of reporting in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.2265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.6153&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33.1964&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.7867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;35.1428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;32.1003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,080.0304&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,114.3335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,068.9577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,105.4181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,083.7043&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,065.8164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0971&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.9091&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.3551&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4569&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4368&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c11" id="ixv-34433">The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: HK$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.8000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.2265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.6153&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;33.1964&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: THB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34.7867&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;35.1428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;32.1003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,080.0304&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,114.3335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,068.9577&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: KHR&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,105.4181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,083.7043&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,065.8164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period-end&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0971&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.9091&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.3551&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;$: RMB&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.0835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4569&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.4368&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c118"
      decimals="4"
      id="ixv-34434"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c119"
      decimals="4"
      id="ixv-34435"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c120"
      decimals="4"
      id="ixv-34436"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c118"
      decimals="4"
      id="ixv-34437"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c119"
      decimals="4"
      id="ixv-34438"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c120"
      decimals="4"
      id="ixv-34439"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c121"
      decimals="4"
      id="ixv-34440"
      unitRef="pure">34.2265</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c122"
      decimals="4"
      id="ixv-34441"
      unitRef="pure">34.6153</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c123"
      decimals="4"
      id="ixv-34442"
      unitRef="pure">33.1964</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c121"
      decimals="4"
      id="ixv-34443"
      unitRef="pure">34.7867</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c122"
      decimals="4"
      id="ixv-34444"
      unitRef="pure">35.1428</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c123"
      decimals="4"
      id="ixv-34445"
      unitRef="pure">32.1003</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c124"
      decimals="4"
      id="ixv-34446"
      unitRef="pure">4080.0304</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c125"
      decimals="4"
      id="ixv-34447"
      unitRef="pure">4114.3335</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c126"
      decimals="4"
      id="ixv-34448"
      unitRef="pure">4068.9577</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c124"
      decimals="4"
      id="ixv-34449"
      unitRef="pure">4105.4181</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c125"
      decimals="4"
      id="ixv-34450"
      unitRef="pure">4083.7043</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c126"
      decimals="4"
      id="ixv-34451"
      unitRef="pure">4065.8164</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c127"
      decimals="4"
      id="ixv-34452"
      unitRef="pure">7.0971</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c128"
      decimals="4"
      id="ixv-34453"
      unitRef="pure">6.9091</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c129"
      decimals="4"
      id="ixv-34454"
      unitRef="pure">6.3551</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c127"
      decimals="4"
      id="ixv-34455"
      unitRef="pure">7.0835</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c128"
      decimals="4"
      id="ixv-34456"
      unitRef="pure">6.4569</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c129"
      decimals="4"
      id="ixv-34457"
      unitRef="pure">6.4368</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c11" id="ixv-23524">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original
maturities of three&#160;months or less that are readily convertible to known amounts of cash and which are subject to an insignificant
risk of changes in value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock contextRef="c11" id="ixv-23535">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, prepayment,
other receivables and deferred IPO cost, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Deposits,
prepayment, other receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;) cost, net primarily include deposits paid to suppliers,
prepaid expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Deferred
IPO costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the Initial Public Offering and that were charged to shareholders&#x2019; equity upon the completion of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;</nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c11" id="ixv-23551">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Plant and equipment,
net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Plant
and equipment are stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the
straight-line&#160;method. The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment
are as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss
are included in the Company&#x2019;s results of operations. The costs of maintenance and repairs are expensed as incurred. Significant
renewals and betterments that extend the useful life of an assets are capitalized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c2" decimals="2" id="ixv-34458" unitRef="pure">0</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment contextRef="c11" id="ixv-34459">The estimated useful lives of the plan and equipment
are as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.25pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c130" id="ixv-34460">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c131" id="ixv-34461">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c133" id="ixv-34462">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c134" id="ixv-34463">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c135" id="ixv-34464">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c136" id="ixv-34465">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c137" id="ixv-34466">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c138" id="ixv-34467">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c11" id="ixv-23609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company evaluates the long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of assets may not be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies,
or if the Company has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present
if the carrying amount of an asset is less than its expected future undiscounted cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;If
an asset is considered impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value
of the asset. Assets to be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c11" id="ixv-23661">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value
is based on the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and
obsolete inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes
the basis for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory
would not be reversed if market conditions improve.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c11" id="ixv-23672">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Other
borrowings are recognized initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized
cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements
of operations over the period of the borrowings using the effective interest method.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c11" id="ixv-23683">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s ordinary shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received,
net of issuance cost, and the par value is recorded in additional paid-in&#160;capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-34468"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c11" id="ixv-23694">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606
had been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify
                                            its contracts with customers;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify
                                            its performance obligations under those contracts;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;determine
                                            the transaction prices of those contracts;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;allocate
                                            the transaction prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognize
                                            revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
                                            when promised services are transferred to the client in an amount that reflects the consideration
                                            expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The
agreements also identify the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties.
All the contracts have commercial substance, and it is probable that the Company will collect considerations from its customers for service
component.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company derives its revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary
caring services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue from
IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
vitro fertilization (&#x201c;IVF&#x201d;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized
in laboratory to become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the
performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to customer when
embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation. The Company collects
payment from customer in advance for IVF treatment. The amount of revenue recognized from contract liabilities to the Company&#x2019;s
result of operations can be found in Note&#160;8 below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue from
surrogacy and ancillary caring services&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother
contracted by the Company. During pregnancy period, the Company provides ancillary caring services including regular body check and provision
of vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result
of operations can be found in Note&#160;8 below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Contract
related assets and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to
the revenue cycle are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Account receivables,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accounts
receivable, net are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected
credit loss is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the
accounts receivable balances, current general economic conditions, future expectations and customer specific quantitative and qualitative
factors that may affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence
for the Company to reasonably estimate the amount of probable loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Contract
liabilities represent considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under
the contract. These amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Expected
credit loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;ASU
No.&#160;2016-13, Financial Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments
requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using
this methodology will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to
recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments
of other financial assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates
of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows
due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the
effective interest rate of the financial asset.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <nivf:RevenueRate contextRef="c2" decimals="2" id="ixv-34469" unitRef="pure">0.40</nivf:RevenueRate>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="c11" id="ixv-23927">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Retirement
benefits in the form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated
to wages as part of cost of revenues.&lt;/span&gt;&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c11" id="ixv-23938">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (the &#x201c;CODM&#x201d;), or decision making group, in making decisions on how to allocate resources
and assess performance. The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing
Fund Alfred, the Company&#x2019;s Chief Executive Officer. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers
as of December&#160;31, 2023, 2022 and 2021 by geographical area are presented in Note&#160;13.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c11" decimals="0" id="ixv-34470" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c104"
      decimals="0"
      id="ixv-34471"
      unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c11" id="ixv-23985">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company measured the lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the
present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not
have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life
of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease
exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;twelve&lt;/span&gt;&#160;months or less.
Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense
is recognized on a straight-line&#160;basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, there were $283,847 and $383,670&#160;million right of use (&#x201c;ROU&#x201d;) assets and $326,107
and $426,838 lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#x2019;s
management believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate
(&#x201c;BLR&#x201d;) minus 0.125%&#160;was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the present
value of the lease payments; the rate used by the Company was 6.6% and 5.0% respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-34472" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-34473" unitRef="usd">383670</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability contextRef="c2" decimals="0" id="ixv-34474" unitRef="usd">326107</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c3" decimals="0" id="ixv-34475" unitRef="usd">426838</us-gaap:FinanceLeaseLiability>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c11" decimals="5" id="ixv-34476" unitRef="pure">0.00125</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="c105"
      decimals="3"
      id="ixv-34477"
      unitRef="pure">0.066</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="c3" decimals="3" id="ixv-34478" unitRef="pure">0.05</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c11" id="ixv-24002">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company recognizes deferred income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated
financial statements or tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences
between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will
be in effect when the differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred
tax asset is not realizable or recoverable in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company determines that the tax position is more likely than not to be sustained and records the largest amount of benefit that is more
likely than not to be realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain
tax positions in income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c11" id="ixv-24018">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company presents comprehensive income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states
that all items that are required to be recognized under accounting standards as components of comprehensive income be reported in the
consolidated financial statements. The components of comprehensive income were the net income for the&#160;years and the foreign currency
translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c11" id="ixv-24066">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is
measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period.
Diluted EPS presents the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise
of options and or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the
potentially dilutive effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities
(i.e., those that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially
dilutive securities that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <nivf:RelatedPartiesPolicyTextBlock contextRef="c11" id="ixv-24077">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company adopted ASC&#160;850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/span&gt;&lt;/p&gt;</nivf:RelatedPartiesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c11" id="ixv-24088">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and
contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such
contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments including historical and the specific facts and circumstances of each matter.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <nivf:NonControllingInterestsPolicyTextBlock contextRef="c11" id="ixv-24099">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/span&gt;&lt;/p&gt;</nivf:NonControllingInterestsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c11" id="ixv-24110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of
risks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration of
credit risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable.
The Company places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accounts
receivable primarily comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers,
and generally does not require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts
primarily based upon the factors surrounding the credit risk of specific customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration of
customers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, two and Nil customers which individually contributed more than 10% of trade receivable, accounted
for 96.3% and &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;Nil&lt;/span&gt; of the Company&#x2019;s trade receivable respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;None
of the customers contributed more than 10% of revenue for&#160;years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Concentration
of suppliers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, one and four suppliers which individually contributed more than 10% of trade payable, accounted for
30.6% and 69.8% of the Company&#x2019;s trade payable respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;For
the year ended December&#160;31, 2023, 2022 and 2021, Nil, two and two vendors which contributed more than 10% of total purchases of
the Company, accounted for &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;Nil&lt;/span&gt;, 55.3% and 35.6% of the Company&#x2019;s total purchases respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c106"
      decimals="2"
      id="ixv-34479"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c107"
      decimals="3"
      id="ixv-34480"
      unitRef="pure">0.963</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c109"
      decimals="2"
      id="ixv-34481"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c110"
      decimals="2"
      id="ixv-34482"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c111"
      decimals="2"
      id="ixv-34483"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c112"
      decimals="2"
      id="ixv-34484"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c113"
      decimals="3"
      id="ixv-34485"
      unitRef="pure">0.306</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c114"
      decimals="3"
      id="ixv-34486"
      unitRef="pure">0.698</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c116"
      decimals="3"
      id="ixv-34487"
      unitRef="pure">0.553</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c117"
      decimals="3"
      id="ixv-34488"
      unitRef="pure">0.356</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c11" id="ixv-24213">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and
deferred IPO cost, net, loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders,
have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements
and Disclosures&#x201d; requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial
Instruments&#x201d; defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash
and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related
parties each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation
hierarchy are defined as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            1&#160;&#x2014;&#160;inputs to the valuation methodology used quoted prices for identical
                                            assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            2&#160;&#x2014;&#160;inputs to the valuation methodology include quoted prices for similar
                                            assets and liabilities in active markets and information that are observable for the asset
                                            or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s
                                            full term&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                            3&#160;&#x2014;&#160;inputs to the valuation methodology are unobservable and significant
                                            to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities
from Equity&#x201d; and ASC&#160;815.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c11" id="ixv-24296">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting
pronouncements adopted &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#x201c;CECL&#x201d;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c11" id="ixv-24307">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting
pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments in
ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for
all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report
a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions
about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and
depletion expense, to be disclosed under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure
requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective
for years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively.
Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
December 2023, FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740)&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements
to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU
2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit)
from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable
statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling
items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires
disclosure of, on an annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state,
and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual
jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective
for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact
of the update on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Save
for elsewhere disclosed, the Company does not believe other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income
(loss) and statement of cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c11" decimals="2" id="ixv-34489" unitRef="pure">0.05</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c11" decimals="2" id="ixv-34490" unitRef="pure">0.05</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:AccountsAndNontradeReceivableTextBlock contextRef="c11" id="ixv-24354">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 3 &#x2014;&#160;ACCOUNTS
RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accounts
receivable, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,393&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of the end of each of the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based
on the invoice date is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Within 90&#160;days&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reversal of expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c11" id="ixv-24362">&lt;span style="font-size: 10pt"&gt;Accounts
receivable, net consists of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,393&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" id="ixv-34491" unitRef="usd">9393</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c3" decimals="0" id="ixv-34492" unitRef="usd">13026</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-34493" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" id="ixv-34494" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-34495" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-34496" unitRef="usd">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c11" id="ixv-24452">&lt;span style="font-size: 10pt"&gt;As
of the end of each of the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based
on the invoice date is as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Within 90&#160;days&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9,374&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;13,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c139" decimals="0" id="ixv-34497" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c140" decimals="0" id="ixv-34498" unitRef="usd">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-34499" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-34500" unitRef="usd">13000</us-gaap:AccountsReceivableNetCurrent>
    <nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock contextRef="c11" id="ixv-24523">&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reversal of expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c141" decimals="0" id="ixv-34501" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c142" decimals="0" id="ixv-34502" unitRef="usd">286</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c143" decimals="0" id="ixv-34503" unitRef="usd">7</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c144" decimals="0" id="ixv-34504" unitRef="usd">260</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c145" decimals="0" id="ixv-34505" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c141" decimals="0" id="ixv-34506" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c11" id="ixv-24615">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 4 &#x2014;&#160;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Inventories
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Medicines, consumables and reagents for clinical and laboratory
    analyses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;126,264&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,910&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;126,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,910&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c11" id="ixv-24623">&lt;span style="font-size: 10pt"&gt;Inventories
consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Medicines, consumables and reagents for clinical and laboratory
    analyses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;126,264&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,910&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;126,264&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,910&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryGross contextRef="c2" decimals="0" id="ixv-34507" unitRef="usd">126264</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c3" decimals="0" id="ixv-34508" unitRef="usd">46910</us-gaap:InventoryGross>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-34509" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-34510" unitRef="usd">46910</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c11" id="ixv-24720">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 5 &#x2014;&#160;DEPOSITS,
PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Deposits,
prepayment, other receivables and deferred IPO cost, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15,910&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,295&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;123,008&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,131&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Prepayment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,848&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-111; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d;
    cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;373,677&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance for expected
    credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;517,429&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;70,285&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reversal of provision (Provision)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Effect of currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c11" id="ixv-24728">&lt;span style="font-size: 10pt"&gt;Deposits,
prepayment, other receivables and deferred IPO cost, net consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15,910&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,295&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;123,008&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,131&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Prepayment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,848&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-111; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d;
    cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;373,677&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance for expected
    credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;517,429&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;70,285&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherReceivables contextRef="c2" decimals="0" id="ixv-34511" unitRef="usd">15910</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c3" decimals="0" id="ixv-34512" unitRef="usd">30295</us-gaap:OtherReceivables>
    <us-gaap:DepositAssets contextRef="c2" decimals="0" id="ixv-34513" unitRef="usd">123008</us-gaap:DepositAssets>
    <us-gaap:DepositAssets contextRef="c3" decimals="0" id="ixv-34514" unitRef="usd">40131</us-gaap:DepositAssets>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-34515" unitRef="usd">4848</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-34516" unitRef="usd">373677</us-gaap:DeferredOfferingCosts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c2" decimals="0" id="ixv-34517" unitRef="usd">14</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" id="ixv-34518" unitRef="usd">141</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-34519" unitRef="usd">517429</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-34520" unitRef="usd">70285</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock contextRef="c11" id="ixv-24890">&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Reversal of provision (Provision)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Effect of currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c3" decimals="0" id="ixv-34521" unitRef="usd">-141</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c37" decimals="0" id="ixv-34522" unitRef="usd">-115</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision contextRef="c11" decimals="0" id="ixv-34523" unitRef="usd">127</nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision contextRef="c12" decimals="0" id="ixv-34524" unitRef="usd">-30</nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision>
    <nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment contextRef="c12" decimals="0" id="ixv-34525" unitRef="usd">4</nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c2" decimals="0" id="ixv-34526" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c3" decimals="0" id="ixv-34527" unitRef="usd">-141</nivf:AllowancesForExpectedCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c11" id="ixv-25024">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 6 &#x2014;&#160;PLANT
AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Plant
and equipment, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;At cost:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Building improvement&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,438&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;72,519&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;250,493&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;246,682&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Medical instruments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;844,809&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;791,514&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;142,936&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;142,936&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;150,688&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;146,432&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,481,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,400,083&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,319,207&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,277,410&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;162,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;122,673&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Depreciation
expenses for the&#160;years ended December&#160;31, 2023 and 2022 were $31,173 and $100,533, respectively. Loss on disposal of assets
for the year ended December&#160;31, 2023 and 2022 was $&lt;span style="-sec-ix-hidden: hidden-fact-114"&gt;Nil&lt;/span&gt; and $114,013, respectively, due to moving of clinic to new location in First
Fertility PGS Center Limited in 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116"&gt;No&lt;/span&gt;&lt;/span&gt;
impairment loss was recorded for the&#160;years ended December&#160;31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c11" id="ixv-25032">&lt;span style="font-size: 10pt"&gt;Plant
and equipment, net consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;At cost:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Building improvement&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,438&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;72,519&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;250,493&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;246,682&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Medical instruments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;844,809&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;791,514&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Motor vehicle&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;142,936&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;142,936&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;150,688&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;146,432&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: -0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,481,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,400,083&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,319,207&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,277,410&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;162,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;122,673&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c146" decimals="0" id="ixv-34528" unitRef="usd">92438</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c147" decimals="0" id="ixv-34529" unitRef="usd">72519</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c148" decimals="0" id="ixv-34530" unitRef="usd">250493</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c149" decimals="0" id="ixv-34531" unitRef="usd">246682</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c150" decimals="0" id="ixv-34532" unitRef="usd">844809</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c151" decimals="0" id="ixv-34533" unitRef="usd">791514</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c152" decimals="0" id="ixv-34534" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c153" decimals="0" id="ixv-34535" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c154" decimals="0" id="ixv-34536" unitRef="usd">150688</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c155" decimals="0" id="ixv-34537" unitRef="usd">146432</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-34538" unitRef="usd">1481364</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-34539" unitRef="usd">1400083</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-34540" unitRef="usd">1319207</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-34541" unitRef="usd">1277410</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-34542" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-34543" unitRef="usd">122673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c11" decimals="0" id="ixv-34544" unitRef="usd">31173</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c12" decimals="0" id="ixv-34545" unitRef="usd">100533</us-gaap:Depreciation>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c12" decimals="0" id="ixv-34546" unitRef="usd">114013</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c11" id="ixv-25272">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 7 &#x2014;&#160;ACCRUED
LIABILTIES AND OTHER PAYABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accrued
liabilities and other payables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;43,633&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;22,345&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Other tax payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,180&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Withholding tax payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;82,240&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable (Note&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;144,015&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;117,935&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;64,077&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;241,613&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;289,777&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c11" id="ixv-25280">&lt;span style="font-size: 10pt"&gt;Accrued
liabilities and other payables consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;43,633&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;22,345&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Other tax payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,180&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Withholding tax payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;82,240&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable (Note&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;144,015&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;117,935&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;46,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;64,077&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;241,613&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;289,777&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34547" unitRef="usd">43633</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-34548" unitRef="usd">22345</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-34549" unitRef="usd">3180</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="0" id="ixv-34550" unitRef="usd">7349</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-34551" unitRef="usd">82240</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c2" decimals="0" id="ix_1_fact" unitRef="usd">144015</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c3" decimals="0" id="ix_2_fact" unitRef="usd">117935</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="0" id="ixv-34554" unitRef="usd">46616</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-34555" unitRef="usd">64077</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34556" unitRef="usd">241613</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-34557" unitRef="usd">289777</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c11" id="ixv-25439">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 8 &#x2014;&#160;CONTRACT
LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Contract
liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;812,158&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;112,006&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Recognized to revenue during the
    year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(122,662&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(812,158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Refund
    to customers (Note 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,341,575&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at
    end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,937&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c11" id="ixv-25447">&lt;span style="font-size: 10pt"&gt;Contract
liabilities consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;812,158&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;112,006&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Recognized to revenue during the
    year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(122,662&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(812,158&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Refund
    to customers (Note 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,341,575&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at
    end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,937&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,360,168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="0" id="ixv-34558" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c37" decimals="0" id="ixv-34559" unitRef="usd">812158</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c11" decimals="0" id="ixv-34560" unitRef="usd">112006</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c12" decimals="0" id="ixv-34561" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c11" decimals="0" id="ixv-34562" unitRef="usd">-122662</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c12" decimals="0" id="ixv-34563" unitRef="usd">-812158</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c2" decimals="0" id="ix_3_fact" unitRef="usd">1341575</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c2" decimals="0" id="ixv-34565" unitRef="usd">7937</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="0" id="ixv-34566" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c11" id="ixv-25611">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 9 &#x2014;&#160;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company has various operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The
Company&#x2019;s management believes that the interest rate of 6.6% and 5% was the most indicative rate of the Company&#x2019;s borrowing
cost for the calculation of the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, the right-of-use&#160;assets totaled $283,847, and $383,670, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, lease liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;207,128&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;184,651&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;118,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;242,187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;426,838&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Other
lease information is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Weighted-average remaining lease term&#160;&#x2013;&#160;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.91&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;114,937&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;89,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
following is a schedule of future minimum payments under operating leases as of December&#160;31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Not later than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240,835&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Between 1 to 2&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;111,613&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Between
    2 to 3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;362,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: imputed
    interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(36,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total operating
    lease liabilities, net of interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c156"
      decimals="3"
      id="ixv-34567"
      unitRef="pure">0.066</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c157"
      decimals="2"
      id="ixv-34568"
      unitRef="pure">0.05</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-34569" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-34570" unitRef="usd">383670</us-gaap:OperatingLeaseRightOfUseAsset>
    <nivf:ScheduleOfLeaseLiabilitiesTableTextBlock contextRef="c11" id="ixv-25627">&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, lease liabilities consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;207,128&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;184,651&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;118,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;242,187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;426,838&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34571" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-34572" unitRef="usd">184651</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-34573" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-34574" unitRef="usd">242187</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-34575" unitRef="usd">326107</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-34576" unitRef="usd">426838</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c11" id="ixv-25717">&lt;span style="font-size: 10pt"&gt;Other
lease information is as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Weighted-average remaining lease term&#160;&#x2013;&#160;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.91&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;114,937&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;89,380&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-34577">P0Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-34578">P1Y10M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" id="ixv-34579" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="2" id="ixv-34580" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ShortTermLeaseCost contextRef="c11" decimals="0" id="ixv-34581" unitRef="usd">114937</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c12" decimals="0" id="ixv-34582" unitRef="usd">89380</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c11" id="ixv-25807">&lt;span style="font-size: 10pt"&gt;The
following is a schedule of future minimum payments under operating leases as of December&#160;31, 2023:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Not later than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240,835&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Between 1 to 2&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;111,613&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Between
    2 to 3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;362,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: imputed
    interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(36,714&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total operating
    lease liabilities, net of interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,107&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="0" id="ixv-34583" unitRef="usd">240835</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="0" id="ixv-34584" unitRef="usd">111613</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="0" id="ixv-34585" unitRef="usd">10373</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="0" id="ixv-34586" unitRef="usd">362821</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="0" id="ixv-34587" unitRef="usd">36714</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-34588" unitRef="usd">326107</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c11" id="ixv-25918">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 10 &#x2014;&#160;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Ordinary shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
at December&#160;31, 2023, the Company is authorized to issue 5,000,000 ordinary shares. Each ordinary share is entitled to one vote.
The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
equity of the Company as of December&#160;31, 2023 and 2022 represents 698,123 and 601,830 ordinary shares amounting to $6,981 and $6,018,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Subscription
receivables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,866,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement
    of subscription receivable &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(219,628&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,967,100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Additional paid-in
capital&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,458,941&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;257,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;
    remuneration &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,865,893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;961,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,324,834&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,458,941&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-34589"
      unitRef="shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="c11" id="ixv-34590">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-34591"
      unitRef="shares">698123</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-34592"
      unitRef="shares">601830</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-34593" unitRef="usd">6981</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-34594" unitRef="usd">6018</us-gaap:CommonStockValue>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c11" id="ixv-25945">&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Subscription
receivables&lt;/i&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,866,856&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement
    of subscription receivable &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(219,628&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,967,100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;319,872&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c173" decimals="0" id="ixv-34595" unitRef="usd">319872</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c175" decimals="0" id="ix_4_fact" unitRef="usd">2866856</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c176" decimals="0" id="ix_5_fact" unitRef="usd">319872</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c175" decimals="0" id="ix_6_fact" unitRef="usd">219628</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c177" decimals="0" id="ixv-34599" unitRef="usd">2967100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c173" decimals="0" id="ixv-34600" unitRef="usd">319872</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c158"
      decimals="0"
      id="ixv-34601"
      unitRef="shares">41830</us-gaap:ExcessStockSharesIssued>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c159" decimals="0" id="ixv-34602" unitRef="usd">961538</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OtherBorrowings contextRef="c158" decimals="0" id="ixv-34603" unitRef="usd">641025</us-gaap:OtherBorrowings>
    <us-gaap:OtherBorrowings contextRef="c160" decimals="0" id="ixv-34604" unitRef="usd">641</us-gaap:OtherBorrowings>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c158" decimals="0" id="ixv-34605" unitRef="usd">319872</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c161" decimals="0" id="ixv-34606" unitRef="usd">192308</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c162" decimals="0" id="ixv-34607" unitRef="usd">192308</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c163"
      decimals="0"
      id="ixv-34608"
      unitRef="shares">27293</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c163" decimals="0" id="ixv-34609" unitRef="usd">812573</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c164"
      decimals="0"
      id="ixv-34610"
      unitRef="shares">69000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c165"
      decimals="0"
      id="ixv-34611"
      unitRef="shares">2054283</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c2" decimals="0" id="ixv-34612" unitRef="usd">27320</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock contextRef="c11" id="ixv-26080">&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Additional paid-in
capital&lt;/i&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,458,941&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;257,821&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;
    remuneration &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;240,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,865,893&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;961,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,324,834&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,458,941&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c178" decimals="0" id="ixv-34613" unitRef="usd">1458941</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c179" decimals="0" id="ixv-34614" unitRef="usd">257821</us-gaap:AdditionalPaidInCapitalCommonStock>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration contextRef="c181" decimals="0" id="ix_7_fact" unitRef="usd">240000</nivf:StockIssuedDuringPeriodValueDirectorsRemuneration>
    <nivf:IssuanceOfSharesAdditionalpaidincapital contextRef="c180" decimals="0" id="ix_8_fact" unitRef="usd">2865893</nivf:IssuanceOfSharesAdditionalpaidincapital>
    <nivf:IssuanceOfSharesAdditionalpaidincapital contextRef="c181" decimals="0" id="ix_9_fact" unitRef="usd">961120</nivf:IssuanceOfSharesAdditionalpaidincapital>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c182" decimals="0" id="ixv-34618" unitRef="usd">4324834</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c178" decimals="0" id="ixv-34619" unitRef="usd">1458941</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:PreferredStockRedemptionAmount contextRef="c166" decimals="0" id="ixv-34620" unitRef="usd">120000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionAmount contextRef="c167" decimals="0" id="ixv-34621" unitRef="usd">120000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:OtherAdditionalCapital contextRef="c2" decimals="0" id="ixv-34622" unitRef="usd">240000</us-gaap:OtherAdditionalCapital>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c168"
      decimals="0"
      id="ixv-34623"
      unitRef="shares">41830</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:OtherAdditionalCapital contextRef="c158" decimals="0" id="ixv-34624" unitRef="usd">961120</us-gaap:OtherAdditionalCapital>
    <us-gaap:SharesIssued
      contextRef="c163"
      decimals="0"
      id="ixv-34625"
      unitRef="shares">27293</us-gaap:SharesIssued>
    <us-gaap:DebtInstrumentTerm contextRef="c169" id="ixv-34626">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c170" decimals="0" id="ixv-34627" unitRef="usd">812300</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c171"
      decimals="0"
      id="ixv-34628"
      unitRef="shares">69000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:DebtInstrumentTerm contextRef="c172" id="ixv-34629">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c165" decimals="0" id="ixv-34630" unitRef="usd">2053593</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c11" id="ixv-26217">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 11 &#x2014;&#160;EMPLOYEE
BENEFIT PLANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5%
of the employees&#x2019; basic salaries on monthly basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company is obliged to make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession
had been determined by the Government which saw the standard amount &lt;span style="-sec-ix-hidden: hidden-fact-124"&gt;THB750&lt;/span&gt; per month per person reduced to &lt;span style="-sec-ix-hidden: hidden-fact-125"&gt;THB450&lt;/span&gt; per month per person.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Every
business employing one or more workers must register its business and workers with the National Social Security Fund (the &#x201c;NSSF&#x201d;)
for the Occupational Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension
Scheme.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Once
registered, the business must pay to the NSSF:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A monthly contribution equivalent to 0.8% of each worker&#x2019;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A monthly contribution equivalent to 2.6% of a worker&#x2019;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between &lt;span style="-sec-ix-hidden: hidden-fact-123"&gt;KHR400,000&lt;/span&gt; (approximately $100) up to &lt;span style="-sec-ix-hidden: hidden-fact-122"&gt;KHR1,200,000&lt;/span&gt; (approximately $300).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15%
and 8%, respectively of the employees&#x2019; basic salaries on monthly basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c183"
      decimals="2"
      id="ixv-34631"
      unitRef="pure">0.05</us-gaap:ManagementAndServiceFeesRate>
    <nivf:ContributableWageRate
      contextRef="c185"
      decimals="3"
      id="ixv-34632"
      unitRef="pure">0.008</nivf:ContributableWageRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c186"
      decimals="2"
      id="ixv-34633"
      unitRef="usdPershares">0.4</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c187"
      decimals="2"
      id="ixv-34634"
      unitRef="usdPershares">2.4</us-gaap:SaleOfStockPricePerShare>
    <nivf:ContributableWageRate
      contextRef="c188"
      decimals="3"
      id="ixv-34635"
      unitRef="pure">0.026</nivf:ContributableWageRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c189"
      decimals="2"
      id="ixv-34636"
      unitRef="usdPershares">1.3</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c190"
      decimals="2"
      id="ixv-34637"
      unitRef="usdPershares">7.8</us-gaap:SaleOfStockPricePerShare>
    <nivf:ContributableWageRate
      contextRef="c191"
      decimals="2"
      id="ixv-34638"
      unitRef="pure">0.02</nivf:ContributableWageRate>
    <nivf:ContributableWageTotalRate
      contextRef="c191"
      decimals="2"
      id="ixv-34639"
      unitRef="pure">0.04</nivf:ContributableWageTotalRate>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c192" decimals="0" id="ixv-34640" unitRef="usd">100</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c193" decimals="0" id="ixv-34641" unitRef="usd">300</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c194"
      decimals="2"
      id="ixv-34642"
      unitRef="pure">0.15</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:ManagementAndServiceFeesRate contextRef="c11" decimals="2" id="ixv-34643" unitRef="pure">0.08</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c11" id="ixv-26336">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 12 &#x2014;&#160;PROVISION
FOR INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Cayman Islands&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;NewGenIvf
Limited was incorporated in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law.
In addition, upon payment of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Under
the two-tiered&#160;profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates
regime will continue to be taxed at a flat rate of 16.5%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Accordingly,
the HK SAR profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the
remaining estimated assessable profits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
companies incorporated in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from
or in consequence of the business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying
on business in Thailand is subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends,
royalties, rentals, and service fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%,
while other rates may apply under the provisions of a double tax treaty (DTT).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
standard rate of corporate income tax (&#x201c;CIT&#x201d;) for companies and permanent establishments who are classified as medium and
large taxpayers is 20%. For companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive
rates from 0% to 20%. In view of the annual turnover of the company, the annual turnover ranges from &lt;span style="-sec-ix-hidden: hidden-fact-143"&gt;KHR1&lt;/span&gt;&#160;billion to &lt;span style="-sec-ix-hidden: hidden-fact-144"&gt;KHR6&lt;/span&gt;&#160;billion
for service and commercial sectors, the company shall consider as the medium-sized&#160;company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
company is subject to a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying
out business activities through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities
of that permanent establishments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Profit
tax is calculated at a rate of 10% of aggregate annual income less allowed deductions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the provisions for income taxes for the year ended December&#160;31, 2023, and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Late penalty provision Kyrgyzstan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;208,141&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;108,418&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;343,988&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;156,184&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expenses (credit) at the effective
    tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(124,591&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;36,755&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-taxable income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(39,173&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;369,101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;114,656&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on late penalty provision&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-133; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-134; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;145,295&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-135; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-136; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect
    on utilization of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(36,369&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,990&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;208,141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;294,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax asset,
net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Significant
components of deferred tax assets, net were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; Net operating
    loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-140; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Deferred
    tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-141; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As
of December&#160;31, 2023 and 2022, the Company had net operating loss carry forward of $164,721 and $297,207. The Company believes it
is less likely than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry
forward. As a result, the Company provided 100% allowance on deferred tax assets on net operating loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <nivf:ProfitTaxDescription contextRef="c11" id="ixv-26360">Under
the two-tiered&#160;profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates
regime will continue to be taxed at a flat rate of 16.5%.</nivf:ProfitTaxDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c11" decimals="4" id="ixv-34644" unitRef="pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c195"
      decimals="-6"
      id="ixv-34645"
      unitRef="hkd">2000000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment contextRef="c11" decimals="3" id="ixv-34646" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther contextRef="c11" decimals="2" id="ixv-34647" unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c11" decimals="2" id="ixv-34648" unitRef="pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c11" decimals="2" id="ixv-34649" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal contextRef="c11" decimals="2" id="ixv-34650" unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c196"
      decimals="2"
      id="ixv-34651"
      unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c197"
      decimals="2"
      id="ixv-34652"
      unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="c11" decimals="2" id="ixv-34653" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c11" id="ixv-26440">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
components of the provisions for income taxes for the year ended December&#160;31, 2023, and 2022 were as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;196,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Late penalty provision Kyrgyzstan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;208,141&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c199" decimals="0" id="ixv-34654" unitRef="usd">196116</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c201" decimals="0" id="ixv-34655" unitRef="usd">11323</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c203" decimals="0" id="ixv-34656" unitRef="usd">702</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c12" decimals="0" id="ixv-34657" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c11" id="ixv-26537">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Income before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;108,418&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;343,988&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;156,184&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expenses (credit) at the effective
    tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(124,591&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;36,755&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-taxable income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(39,173&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;369,101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;114,656&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect on late penalty provision&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-133; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-134; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;145,295&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-135; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-136; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax effect
    on utilization of tax losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(36,369&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1,990&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;208,141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;294,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-34658" unitRef="usd">108418</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-34659" unitRef="usd">343988</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-34660" unitRef="usd">156184</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c11" decimals="0" id="ixv-34661" unitRef="usd">10732</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c12" decimals="0" id="ixv-34662" unitRef="usd">-124591</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c13" decimals="0" id="ixv-34663" unitRef="usd">36755</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c11" decimals="0" id="ixv-34664" unitRef="usd">-39173</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c12" decimals="0" id="ixv-34665" unitRef="usd">369101</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c13" decimals="0" id="ixv-34666" unitRef="usd">114656</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c13" decimals="0" id="ixv-34667" unitRef="usd">145295</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c11" decimals="0" id="ixv-34668" unitRef="usd">28441</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c12" decimals="0" id="ixv-34669" unitRef="usd">-36369</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c13" decimals="0" id="ixv-34670" unitRef="usd">-1990</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c12" decimals="0" id="ixv-34671" unitRef="usd">208141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c13" decimals="0" id="ixv-34672" unitRef="usd">294716</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c11" id="ixv-26792">&lt;span style="font-size: 10pt"&gt;Significant
components of deferred tax assets, net were as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,
    &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013; Net operating
    loss carry forward&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(28,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-140; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Deferred
    tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-141; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-34673" unitRef="usd">28441</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-34674" unitRef="usd">28441</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-34675" unitRef="usd">164721</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-34676" unitRef="usd">297207</us-gaap:OperatingLossCarryforwards>
    <nivf:PercentageOfAllowanceOnDeferredTaxAssets contextRef="c11" decimals="2" id="ixv-34677" unitRef="pure">1</nivf:PercentageOfAllowanceOnDeferredTaxAssets>
    <nivf:DissagregattedRevenuesTextBlock contextRef="c11" id="ixv-26914">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 13 &#x2014;&#160;DISAGGREGATED
REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s main business operations are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring
services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;For
    the year ended&lt;br/&gt; December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Revenue from external
    customers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;IVF treatment service&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,021,696&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,819,163&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,199,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Surrogacy,
    ancillary caring and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,114,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,125,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;918,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,136,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,118,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Geographical information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Revenue from external
    customers originated from&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;HK SAR&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34,038&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-145; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-146; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Kyrgyzstan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,123,593&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,060,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,110,483&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cambodia&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;621,619&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;377,608&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;313,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,356,903&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;505,609&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;693,900&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,136,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,118,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
revenue information above is based on the locations where the revenue originated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;Long-lived assets located at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;HK SAR&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;584&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-147; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Kyrgyzstan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-148; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;22,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cambodia&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;137,472&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;229,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;332,799&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;307,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;254,745&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;238,744&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;446,004&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;506,343&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;592,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s long-lived&#160;assets consist of plant and equipment, net and operating leases right-of-use&#160;assets, net.&lt;/span&gt;&lt;/p&gt;</nivf:DissagregattedRevenuesTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c11" id="ixv-26922">&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s main business operations are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring
services.&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;For
    the year ended&lt;br/&gt; December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Revenue from external
    customers&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;IVF treatment service&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,021,696&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,819,163&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,199,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Surrogacy,
    ancillary caring and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,114,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,125,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;918,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,136,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,118,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues contextRef="c204" decimals="0" id="ixv-34678" unitRef="usd">4021696</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c205" decimals="0" id="ixv-34679" unitRef="usd">2819163</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c206" decimals="0" id="ixv-34680" unitRef="usd">3199683</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c207" decimals="0" id="ixv-34681" unitRef="usd">1114457</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c208" decimals="0" id="ixv-34682" unitRef="usd">3125027</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c209" decimals="0" id="ixv-34683" unitRef="usd">918437</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c11" decimals="0" id="ixv-34684" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="0" id="ixv-34685" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c13" decimals="0" id="ixv-34686" unitRef="usd">4118120</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c11" id="ixv-27079">&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Geographical information&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Revenue from external
    customers originated from&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;HK SAR&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;34,038&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-145; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-146; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Kyrgyzstan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,123,593&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,060,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,110,483&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cambodia&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;621,619&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;377,608&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;313,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,356,903&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;505,609&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;693,900&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,136,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,944,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,118,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c210" decimals="0" id="ixv-34687" unitRef="usd">34038</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c194" decimals="0" id="ixv-34688" unitRef="usd">3123593</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c213" decimals="0" id="ixv-34689" unitRef="usd">5060973</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c214" decimals="0" id="ixv-34690" unitRef="usd">3110483</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c215" decimals="0" id="ixv-34691" unitRef="usd">621619</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c216" decimals="0" id="ixv-34692" unitRef="usd">377608</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c217" decimals="0" id="ixv-34693" unitRef="usd">313737</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c218" decimals="0" id="ixv-34694" unitRef="usd">1356903</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c219" decimals="0" id="ixv-34695" unitRef="usd">505609</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c220" decimals="0" id="ixv-34696" unitRef="usd">693900</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c11" decimals="0" id="ixv-34697" unitRef="usd">5136153</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="0" id="ixv-34698" unitRef="usd">5944190</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c13" decimals="0" id="ixv-34699" unitRef="usd">4118120</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c11" id="ixv-27255">&lt;span style="font-size: 10pt"&gt;The
revenue information above is based on the locations where the revenue originated.&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;Long-lived assets located at&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;HK SAR&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;584&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-147; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Kyrgyzstan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-148; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;22,513&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Cambodia&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;137,472&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;229,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;332,799&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;307,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;254,745&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;238,744&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;446,004&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;506,343&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;592,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:AssetsNoncurrent contextRef="c221" decimals="0" id="ixv-34700" unitRef="usd">584</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c224" decimals="0" id="ixv-34701" unitRef="usd">22513</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c225" decimals="0" id="ixv-34702" unitRef="usd">20835</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c226" decimals="0" id="ixv-34703" unitRef="usd">137472</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c227" decimals="0" id="ixv-34704" unitRef="usd">229085</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c228" decimals="0" id="ixv-34705" unitRef="usd">332799</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c184" decimals="0" id="ixv-34706" unitRef="usd">307948</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c229" decimals="0" id="ixv-34707" unitRef="usd">254745</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c230" decimals="0" id="ixv-34708" unitRef="usd">238744</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-34709" unitRef="usd">446004</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-34710" unitRef="usd">506343</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c37" decimals="0" id="ixv-34711" unitRef="usd">592378</us-gaap:AssetsNoncurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c11" id="ixv-27435">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 14 &#x2014;&#160;RISKS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;A.
Credit risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
order to minimize the credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover
overdue debts. The Company considers the probability of default upon initial recognition of asset and whether there has been a significant
increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit
risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date
of initial recognition. It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and
nominal GDP per capita. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account
receivables as of December&#160;31, 2023 and 2022 is $19 and $26, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Deposits and
other receivables, amount due from shareholders and loan to A SPAC I&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company assessed the impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on
internal credit rating and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk
since initial recognition. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for
deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and &lt;span style="-sec-ix-hidden: hidden-fact-149"&gt;Nil&lt;/span&gt;, respectively.
The loss allowance for deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2022 is $141,
$17,059 and &lt;span style="-sec-ix-hidden: hidden-fact-150"&gt;Nil&lt;/span&gt;, respectively. The loss allowance for deposits and other receivables and amount due from shareholders as of December&#160;31,
2021 was $115 and $6,312 and &lt;span style="-sec-ix-hidden: hidden-fact-151"&gt;Nil&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;B.&#160;Interest
risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Cash flow interest
rate risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company is exposed to cash flow interest rate risk through the changes in interest rates related mainly to the Company&#x2019;s variable-rates&#160;bank
balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company currently does not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest
rate risk. The directors monitor the Company&#x2019;s exposures on an ongoing basis and will consider hedging the interest rate should
the need arises.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Sensitivity
analysis&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
sensitivity analysis below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period
and had been applied to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is
used when reporting interest rate risk internally to key management personnel and represents management&#x2019;s assessment of the reasonably
possible change in interest rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;If
interest rates had been 1% higher or lower and all other variables were held constant, the Company&#x2019;s net (loss) income for the&#160;years
ended December&#160;31, 2023, 2022 and 2021 would have increased or decreased by approximately $541, $275 and $287, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Foreign currency
risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Foreign
currency risk is the risk that the holding of foreign currency assets will affect the Company&#x2019;s financial position as a result
of a change in foreign currency exchange rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s monetary assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional
currencies of the relevant group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered
insignificant. The Company currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors
monitor the related foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need
arise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;C.
Economic and political risks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s operations are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#x2019;s business, financial
condition, and results of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia
and Kyrgyzstan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s operations in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#x2019;s
results may be adversely affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes
in governmental policies with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad,
and rates and methods of taxation, among other things.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;D.
Inflation risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Management
monitors changes in prices levels. Historically inflation has not materially impacted the Company&#x2019;s consolidated financial statements;
however, significant increases in the price of labor that cannot be passed to the Company&#x2019;s customers could adversely impact the
Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="c2" decimals="0" id="ixv-34712" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="c3" decimals="0" id="ixv-34713" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c231" decimals="0" id="ixv-34714" unitRef="usd">14</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c232" decimals="0" id="ixv-34715" unitRef="usd">17818</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c7" decimals="0" id="ixv-34716" unitRef="usd">141</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c233" decimals="0" id="ixv-34717" unitRef="usd">17059</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c234" decimals="0" id="ixv-34718" unitRef="usd">115</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c235" decimals="0" id="ixv-34719" unitRef="usd">6312</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c11" decimals="2" id="ixv-34720" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <nivf:InterestRateOtherVariablesPercentage contextRef="c11" decimals="2" id="ixv-34721" unitRef="pure">0.01</nivf:InterestRateOtherVariablesPercentage>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c11" decimals="0" id="ixv-34722" unitRef="usd">541</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c12" decimals="0" id="ixv-34723" unitRef="usd">275</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c13" decimals="0" id="ixv-34724" unitRef="usd">287</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c11" id="ixv-27655">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 15 &#x2014;&#160;RELATED
PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
summary of amount due from and due to related parties as the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Relationship&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Due from shareholders consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Shareholders and directors (note 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;354,285&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,240,872&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Due to a related party consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Harcourt Limited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;A related company (note&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-152; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(110,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 24pt"&gt;&lt;span style="font-size: 10pt"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
balance due from shareholders consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Due from shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;372,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,257,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance
    for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;354,285&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,240,872&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(6,312&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;In
addition to the transactions and balances detailed elsewhere in these consolidated financial statements, the Company had the following
transactions with related parties:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Directors&#x2019; remuneration
    to Mr.&#160;Siu Wing Fung, Alfred&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Directors&#x2019; remuneration
    to Ms. Fong Hei Yue, Tina&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Waiver of related party balance
    of Mr. Siu Wing Fung, Alfred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(88,151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-153; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-154; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c11" id="ixv-27663">&lt;span style="font-size: 10pt"&gt;The
summary of amount due from and due to related parties as the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Relationship&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Due from shareholders consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Shareholders and directors (note 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;354,285&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,240,872&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Due to a related party consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Harcourt Limited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;A related company (note&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-152; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(110,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c236" id="ix_10_fact">Shareholders and directors (note 1)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <nivf:DueToRelatedParties contextRef="c237" decimals="0" id="ixv-34725" unitRef="usd">-354285</nivf:DueToRelatedParties>
    <nivf:DueToRelatedParties contextRef="c236" decimals="0" id="ixv-34726" unitRef="usd">-2240872</nivf:DueToRelatedParties>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c238" id="ix_11_fact">A related company (note&#160;2)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <nivf:DueToRelatedParties contextRef="c238" decimals="0" id="ixv-34727" unitRef="usd">110773</nivf:DueToRelatedParties>
    <nivf:DueFromShareholders contextRef="c2" decimals="0" id="ixv-34728" unitRef="usd">354285</nivf:DueFromShareholders>
    <nivf:DueFromShareholders contextRef="c3" decimals="0" id="ixv-34729" unitRef="usd">2240872</nivf:DueFromShareholders>
    <nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock contextRef="c11" id="ixv-27847">&lt;span style="font-size: 10pt"&gt;The
balance due from shareholders consist of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Due from shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;372,103&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,257,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: allowance
    for expected credit loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;354,285&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,240,872&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock>
    <nivf:DueFromShareholder contextRef="c2" decimals="0" id="ixv-34730" unitRef="usd">372103</nivf:DueFromShareholder>
    <nivf:DueFromShareholder contextRef="c3" decimals="0" id="ixv-34731" unitRef="usd">2257931</nivf:DueFromShareholder>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent contextRef="c2" decimals="0" id="ixv-34732" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent contextRef="c3" decimals="0" id="ixv-34733" unitRef="usd">17059</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss contextRef="c2" decimals="0" id="ixv-34734" unitRef="usd">354285</us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss>
    <us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss contextRef="c3" decimals="0" id="ixv-34735" unitRef="usd">2240872</us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c11" id="ixv-27973">&lt;span style="font-size: 10pt"&gt;The
movement of allowances for expected credit loss is as follow:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance at beginning
    of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(6,312&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17,059&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-34736" unitRef="usd">17059</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c37" decimals="0" id="ixv-34737" unitRef="usd">6312</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c11" decimals="0" id="ixv-34738" unitRef="usd">-759</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c12" decimals="0" id="ixv-34739" unitRef="usd">-10747</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-34740" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-34741" unitRef="usd">17059</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c11" id="ixv-28063">&lt;span style="font-size: 10pt"&gt;In
addition to the transactions and balances detailed elsewhere in these consolidated financial statements, the Company had the following
transactions with related parties:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Directors&#x2019; remuneration
    to Mr.&#160;Siu Wing Fung, Alfred&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Directors&#x2019; remuneration
    to Ms. Fong Hei Yue, Tina&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Waiver of related party balance
    of Mr. Siu Wing Fung, Alfred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(88,151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-153; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-154; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <nivf:TransactionsWithRelatedParties contextRef="c240" decimals="0" id="ixv-34742" unitRef="usd">125000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c241" decimals="0" id="ixv-34743" unitRef="usd">120000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c242" decimals="0" id="ixv-34744" unitRef="usd">100000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c243" decimals="0" id="ixv-34745" unitRef="usd">125000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c244" decimals="0" id="ixv-34746" unitRef="usd">120000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c245" decimals="0" id="ixv-34747" unitRef="usd">100000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c246" decimals="0" id="ixv-34748" unitRef="usd">-88151</nivf:TransactionsWithRelatedParties>
    <us-gaap:DebtDisclosureTextBlock contextRef="c11" id="ixv-28185">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 16 &#x2014;&#160;LOAN
TO A SPAC&#160;I&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On
June&#160;12, 2023, NewGenIvf Limited (the &#x201c;Company&#x201d;) and A SPAC&#160;I Acquisition Corp (&#x201c;A SPAC&#160;I&#x201d;) entered
into a First Amendment to Merger Agreement, pursuant to which the Company agreed to provide non-interest&#160;bearing loans in an aggregate
principal amount of up to $560,000 (the &#x201c;Loan&#x201d;) to A SPAC&#160;I to fund amounts required to further extend the period of
time available for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative
and operational expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Company. The Loan will only become repayable
upon the closing of the Acquisition Merger. As of December 31, 2023, $140,000 was outstanding under the loan. The Company completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to A SPAC I was eliminated
in the subsequent period.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c249" decimals="0" id="ixv-34749" unitRef="usd">560000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="c11" decimals="0" id="ixv-34750" unitRef="usd">140000</us-gaap:RepaymentsOfOtherShortTermDebt>
    <nivf:ImpactOfCovid19TextBlock contextRef="c11" id="ixv-28198">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 17 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;IMPACT
OF&#160;&lt;/span&gt;COVID-19&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
COVID-19&#160;has negatively impacted the global economy, disrupted consumer spending and global supply chains, and created significant
volatility and disruption of financial markets. The Company experienced some resulting disruptions to the Company&#x2019;s business operations,
and the Company expected the COVID-19&#160;pandemic could have a material adverse impact on the Company&#x2019;s business and financial
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;Due
to the ongoing recession caused by the COVID-19, the Company&#x2019;s business is likely to be adversely impacted. The effects of recession
can also increase economic instability with vendors and customers.&lt;/span&gt;&lt;/p&gt;</nivf:ImpactOfCovid19TextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c11" id="ixv-28240">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 18 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the Company was not a party to any legal or administrative proceedings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First
Fertility Bishkek LLC (&#x201c;FFB&#x201d;), the Company incorporated in Kyrgyzstan, did not report the current year tax &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;to
the tax authority till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of December 31, 2023.
Since FFB had no profit for the year ended December 31, 2023, the tax department may not issue tax return at current tax position. The
tax return is not yet filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible
amount of tax penalty. The contingent tax penalty is reasonably possible and estimated at $486,706. Thus, no provision was made. Except
the potential tax issue, the Company concludes that there was no contingent liability, either individually or in the aggregate, that
could have resulted in an unfavorable outcome with a material adverse effect on the Company&#x2019;s results of operations, consolidated
financial condition, or cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c2" decimals="0" id="ixv-34751" unitRef="usd">486706</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c11" id="ixv-28261">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 19 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;segment
information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company uses the management approach to determine reportable operating segments. The management approach considers the internal organization
and reporting used by the Company&#x2019;s CODM, specifically the Group&#x2019;s CEO and CFO, for making decisions, allocating resources
and assessing performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company does not distinguish revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses
by nature as a whole. Based on the management&#x2019;s assessment, the Group determines that it has only one operating segment and therefore
one reportable segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be
found in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <nivf:NumberOfOperatingSegment contextRef="c11" decimals="0" id="ixv-34752" unitRef="pure">1</nivf:NumberOfOperatingSegment>
    <us-gaap:NumberOfReportingUnits contextRef="c11" decimals="0" id="ixv-34753" unitRef="pure">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:SubsequentEventsTextBlock contextRef="c11" id="ixv-28280">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE
20 &#x2014;&#160;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;The
Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements
were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have
required adjustment or disclosure in the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Convertible note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;On
February 29, 2024, A SPAC I Acquisition Corp. (&#x201c;ASCA&#x201d;), A SPAC I Mini Acquisition Corp. (the then name of NewGenIvf Group
Limited), NewGenIvf Limited (&#x201c;NewGenIvf&#x201d;, the &#x201c;Company&#x201d;), A SPAC I Mini Sub Acquisition Corp. (the &#x201c;Merger
Sub&#x201d;), and certain buyers named therein led by JAK Opportunities VI LLC (collectively, the &#x201c;Buyers&#x201d; or &#x201c;JAK&#x201d;)
entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;), pursuant to which the NewGenIvf Group
Limited agreed to issue and sell to JAK, in a private placement, an aggregate of up to $3,500,000 principal amount of convertible notes
(the &#x201c;Notes&#x201d;), consisting of one or more tranches: (i) an initial tranche (the &#x201c;Initial Tranche&#x201d;) of an aggregate
principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500, and (ii) subsequent
tranches of an aggregate principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;On
April 3, 2024, JAK received a certain amount of ordinary shares of the NewGenIvf Group Limited (the &#x201c;Commitment Shares&#x201d;),
which were converted from the Company ordinary shares issued to JAK in February 2024 and equaled 295,000 ordinary shares of the NewGenIvf
Group Limited, as well as an additional 100,000 ordinary shares of the NewGenIvf Group Limited, which were converted from the Company
ordinary shares transferred by another shareholder of the Company to JAK in March 2024. In addition, a subsequent tranche of the Notes
in the principal amount of $250,000 was issued and sold to JAK shortly after the closing of the Business Combination. As such, as of
April 4, 2024, an aggregate principal amount of Notes of $2,000,000 were issued and sold to JAK.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Business combination
&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp. After the combination, the combined company
will be named &#x201c;NewGenIvf Group Limited&#x201d; (&#x201c;NewGenIvf Group&#x201d;) and its shares and warrants are expected to begin
trading on the Nasdaq Capital Market under the tickers &#x201c;NIVF&#x201d;, and &#x201c;NIVFW&#x201d;, respectively, on April 4, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c250" decimals="0" id="ixv-34754" unitRef="usd">3500000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c251" decimals="0" id="ixv-34755" unitRef="usd">1750000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="c252" decimals="0" id="ixv-34756" unitRef="usd">122500</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c253" decimals="0" id="ixv-34757" unitRef="usd">1750000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="c254" decimals="0" id="ixv-34758" unitRef="usd">122500</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c255"
      decimals="0"
      id="ixv-34759"
      unitRef="shares">295000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c256"
      decimals="0"
      id="ixv-34760"
      unitRef="shares">100000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c256" decimals="0" id="ixv-34761" unitRef="usd">250000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c257" decimals="0" id="ixv-34762" unitRef="usd">2000000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c8" decimals="0" id="ixv-34763" unitRef="usd">184109</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-34764" unitRef="usd">54104</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c8" decimals="0" id="ixv-34765" unitRef="usd">172475</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-34766" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c8" decimals="0" id="ixv-34767" unitRef="usd">102825</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-34768" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c8" decimals="0" id="ixv-34769" unitRef="usd">703897</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-34770" unitRef="usd">517429</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <nivf:LoanToASPAC contextRef="c2" decimals="0" id="ixv-34771" unitRef="usd">140000</nivf:LoanToASPAC>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-34772" unitRef="usd">354285</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c8" decimals="0" id="ixv-34773" unitRef="usd">1163306</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-34774" unitRef="usd">1201456</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c8" decimals="0" id="ixv-34775" unitRef="usd">159931</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-34776" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c8" decimals="0" id="ixv-34777" unitRef="usd">272474</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-34778" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c8" decimals="0" id="ixv-34779" unitRef="usd">1056</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c8" decimals="0" id="ixv-34780" unitRef="usd">910</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c8" decimals="0" id="ixv-34781" unitRef="usd">434371</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-34782" unitRef="usd">446004</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c8" decimals="0" id="ixv-34783" unitRef="usd">1597677</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-34784" unitRef="usd">1647460</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c8" decimals="0" id="ixv-34785" unitRef="usd">1940645</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-34786" unitRef="usd">172626</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c8" decimals="0" id="ixv-34787" unitRef="usd">3014988</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34788" unitRef="usd">241613</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c8" decimals="0" id="ixv-34789" unitRef="usd">37592</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34790" unitRef="usd">7937</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c9" decimals="0" id="ixv-34791" unitRef="usd">48997</us-gaap:OtherLiabilitiesCurrent>
    <nivf:DueToShareholders contextRef="c10" decimals="0" id="ixv-34792" unitRef="usd">762206</nivf:DueToShareholders>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c8" decimals="0" id="ixv-34793" unitRef="usd">199297</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34794" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-34795" unitRef="usd">6446</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c8" decimals="0" id="ixv-34796" unitRef="usd">486705</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-34797" unitRef="usd">486706</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c8" decimals="0" id="ixv-34798" unitRef="usd">6490430</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-34799" unitRef="usd">1122456</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c8" decimals="0" id="ixv-34800" unitRef="usd">114096</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-34801" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="c8" decimals="0" id="ixv-34802" unitRef="usd">3383861</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c8" decimals="0" id="ixv-34803" unitRef="usd">3497957</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-34804" unitRef="usd">118979</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c8" decimals="0" id="ixv-34805" unitRef="usd">9988387</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-34806" unitRef="usd">1241435</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c8"
      decimals="2"
      id="ixv-34807"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-34808"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c8"
      decimals="INF"
      id="ixv-34809"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-34810"
      unitRef="shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c8"
      decimals="INF"
      id="ixv-34811"
      unitRef="shares">10149386</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-34812"
      unitRef="shares">10149386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-34813"
      unitRef="shares">698123</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-34814"
      unitRef="shares">698123</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c8" decimals="0" id="ixv-34815" unitRef="usd">101494</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-34816" unitRef="usd">6981</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c8" decimals="0" id="ixv-34817" unitRef="usd">7473791</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c2" decimals="0" id="ixv-34818" unitRef="usd">2967100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c8" decimals="0" id="ixv-34819" unitRef="usd">57821</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" id="ixv-34820" unitRef="usd">4324834</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c8" decimals="0" id="ixv-34821" unitRef="usd">-857894</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-34822" unitRef="usd">-461351</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c8" decimals="0" id="ixv-34823" unitRef="usd">193265</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-34824" unitRef="usd">-7288</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-34825" unitRef="usd">-7979105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-34826" unitRef="usd">896076</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c8" decimals="0" id="ixv-34827" unitRef="usd">-411605</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-34828" unitRef="usd">-490051</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-34829" unitRef="usd">-8390710</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-34830" unitRef="usd">406025</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c8" decimals="0" id="ixv-34831" unitRef="usd">1597677</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-34832" unitRef="usd">1647460</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-34833" unitRef="usd">2686902</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c14" decimals="0" id="ixv-34834" unitRef="usd">2138622</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-34835" unitRef="usd">2047970</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c14" decimals="0" id="ixv-34836" unitRef="usd">1205940</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-34837" unitRef="usd">638932</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c14" decimals="0" id="ixv-34838" unitRef="usd">932682</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-34839" unitRef="usd">56732</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c14" decimals="0" id="ixv-34840" unitRef="usd">2887</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-34841" unitRef="usd">869886</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c14" decimals="0" id="ixv-34842" unitRef="usd">1223284</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-34843" unitRef="usd">926618</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c14" decimals="0" id="ixv-34844" unitRef="usd">1266171</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-34845" unitRef="usd">-287686</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="0" id="ixv-34846" unitRef="usd">-293489</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" id="ixv-34847" unitRef="usd">7146</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c14" decimals="0" id="ixv-34848" unitRef="usd">8528</us-gaap:OtherIncome>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-34849" unitRef="usd">12921</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c14" decimals="0" id="ixv-34850" unitRef="usd">364</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c0" decimals="0" id="ixv-34851" unitRef="usd">120162</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c14" decimals="0" id="ixv-34852" unitRef="usd">10463</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-34853" unitRef="usd">-100095</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c14" decimals="0" id="ixv-34854" unitRef="usd">-1571</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-34855" unitRef="usd">-387781</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-34856" unitRef="usd">-295060</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c14" decimals="0" id="ixv-34857" unitRef="usd">83727</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-34858" unitRef="usd">-387781</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c14" decimals="0" id="ixv-34859" unitRef="usd">-378787</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-34860" unitRef="usd">-8762</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-34861" unitRef="usd">70890</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-34862" unitRef="usd">-396543</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="0" id="ixv-34863" unitRef="usd">-307897</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-34864" unitRef="usd">270236</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c14" decimals="0" id="ixv-34865" unitRef="usd">37894</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c0" decimals="0" id="ixv-34866" unitRef="usd">-117545</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c14" decimals="0" id="ixv-34867" unitRef="usd">-340893</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-34868" unitRef="usd">78445</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-34869" unitRef="usd">-61211</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-34870" unitRef="usd">-195990</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c14" decimals="0" id="ixv-34871" unitRef="usd">279682</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-34872"
      unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-34873"
      unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ixv-34874"
      unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ixv-34875"
      unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-34876"
      unitRef="shares">10149386</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-34877"
      unitRef="shares">10149386</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-34878"
      unitRef="shares">601830</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="INF"
      id="ixv-34879"
      unitRef="shares">601830</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-34880"
      unitRef="shares">601830</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" id="ixv-34881" unitRef="usd">6018</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-34882" unitRef="usd">-319872</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-34883" unitRef="usd">1458941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-34884" unitRef="usd">-591544</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-34885" unitRef="usd">9570</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-34886" unitRef="usd">563113</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-34887" unitRef="usd">-462430</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-34888" unitRef="usd">100683</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c69" decimals="0" id="ixv-34889" unitRef="usd">-307897</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c71" decimals="0" id="ixv-34890" unitRef="usd">-307897</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c72" decimals="0" id="ixv-34891" unitRef="usd">-70890</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c14" decimals="0" id="ixv-34892" unitRef="usd">-378787</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c70" decimals="0" id="ixv-34893" unitRef="usd">28215</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c71" decimals="0" id="ixv-34894" unitRef="usd">28215</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c72" decimals="0" id="ixv-34895" unitRef="usd">9679</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c14" decimals="0" id="ixv-34896" unitRef="usd">37894</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c67" decimals="0" id="ixv-34897" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c71" decimals="0" id="ixv-34898" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable contextRef="c14" decimals="0" id="ixv-34899" unitRef="usd">192308</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c73"
      decimals="INF"
      id="ixv-34900"
      unitRef="shares">601830</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c73" decimals="0" id="ixv-34901" unitRef="usd">6018</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c74" decimals="0" id="ixv-34902" unitRef="usd">-127564</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c75" decimals="0" id="ixv-34903" unitRef="usd">1458941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c76" decimals="0" id="ixv-34904" unitRef="usd">-899441</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c77" decimals="0" id="ixv-34905" unitRef="usd">37785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c78" decimals="0" id="ixv-34906" unitRef="usd">-475739</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c79" decimals="0" id="ixv-34907" unitRef="usd">-523641</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c80" decimals="0" id="ixv-34908" unitRef="usd">-47902</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="INF"
      id="ixv-34909"
      unitRef="shares">698123</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c59" decimals="0" id="ixv-34910" unitRef="usd">6981</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c60" decimals="0" id="ixv-34911" unitRef="usd">-2967100</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c61" decimals="0" id="ixv-34912" unitRef="usd">4324834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c62" decimals="0" id="ixv-34913" unitRef="usd">-461351</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c63" decimals="0" id="ixv-34914" unitRef="usd">-7288</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c64" decimals="0" id="ixv-34915" unitRef="usd">896076</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c65" decimals="0" id="ixv-34916" unitRef="usd">-490051</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-34917" unitRef="usd">406025</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c84" decimals="0" id="ixv-34918" unitRef="usd">-396543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c86" decimals="0" id="ixv-34919" unitRef="usd">-396543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c87" decimals="0" id="ixv-34920" unitRef="usd">8762</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-34921" unitRef="usd">-387781</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c85" decimals="0" id="ixv-34922" unitRef="usd">191791</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c86" decimals="0" id="ixv-34923" unitRef="usd">191791</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c87" decimals="0" id="ixv-34924" unitRef="usd">78445</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-34925" unitRef="usd">270236</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c81"
      decimals="INF"
      id="ixv-34926"
      unitRef="shares">9451263</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c81" decimals="0" id="ixv-34927" unitRef="usd">-94513</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c82" decimals="0" id="ixv-34928" unitRef="usd">4506691</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c83" decimals="0" id="ixv-34929" unitRef="usd">4267013</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c85" decimals="0" id="ixv-34930" unitRef="usd">-8762</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c86" decimals="0" id="ixv-34931" unitRef="usd">8670429</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c87" decimals="0" id="ixv-34932" unitRef="usd">8761</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c0" decimals="0" id="ixv-34933" unitRef="usd">8679190</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c88" decimals="0" id="ixv-34934" unitRef="usd">101494</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c89" decimals="0" id="ixv-34935" unitRef="usd">-7473791</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c90" decimals="0" id="ixv-34936" unitRef="usd">57821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c91" decimals="0" id="ixv-34937" unitRef="usd">-857894</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c92" decimals="0" id="ixv-34938" unitRef="usd">193265</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c93" decimals="0" id="ixv-34939" unitRef="usd">-7979105</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c94" decimals="0" id="ixv-34940" unitRef="usd">-411605</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-34941" unitRef="usd">-8390710</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-34942" unitRef="usd">-387781</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c14" decimals="0" id="ixv-34943" unitRef="usd">-378787</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-34944" unitRef="usd">12619</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c14" decimals="0" id="ixv-34945" unitRef="usd">19461</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" id="ixv-34946" unitRef="usd">4442</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c14" decimals="0" id="ixv-34947" unitRef="usd">84731</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c14" decimals="0" id="ixv-34948" unitRef="usd">612</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-34949" unitRef="usd">165568</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c14" decimals="0" id="ixv-34950" unitRef="usd">81515</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-34951" unitRef="usd">-22128</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c14" decimals="0" id="ixv-34952" unitRef="usd">22451</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c0" decimals="0" id="ixv-34953" unitRef="usd">140000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c14" decimals="0" id="ixv-34954" unitRef="usd">-140000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c0" decimals="0" id="ixv-34955" unitRef="usd">-25137</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c14" decimals="0" id="ixv-34956" unitRef="usd">-1406</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-34957" unitRef="usd">1771406</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c14" decimals="0" id="ixv-34958" unitRef="usd">51054</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-34959" unitRef="usd">2770371</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c14" decimals="0" id="ixv-34960" unitRef="usd">19681</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="0" id="ixv-34961" unitRef="usd">29655</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c14" decimals="0" id="ixv-34962" unitRef="usd">-1250900</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-34963" unitRef="usd">-12714</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c14" decimals="0" id="ixv-34964" unitRef="usd">-89702</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c14" decimals="0" id="ixv-34965" unitRef="usd">83561</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-34966" unitRef="usd">4209695</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="0" id="ixv-34967" unitRef="usd">-1702849</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-34968" unitRef="usd">10393</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="0" id="ixv-34969" unitRef="usd">1056</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-34970" unitRef="usd">-11449</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="0" id="ixv-34971" unitRef="usd">6446</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="0" id="ixv-34972" unitRef="usd">9317</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c0" decimals="0" id="ixv-34973" unitRef="usd">560000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-34974" unitRef="usd">605489</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c14" decimals="0" id="ixv-34975" unitRef="usd">1530872</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <nivf:SubscriptionReceivables contextRef="c0" decimals="0" id="ixv-34976" unitRef="usd">-8892956</nivf:SubscriptionReceivables>
    <nivf:SubscriptionReceivables contextRef="c14" decimals="0" id="ixv-34977" unitRef="usd">192308</nivf:SubscriptionReceivables>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c0" decimals="0" id="ixv-34978" unitRef="usd">3380990</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-34979" unitRef="usd">-4352923</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c14" decimals="0" id="ixv-34980" unitRef="usd">1713863</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-34981" unitRef="usd">-154677</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c14" decimals="0" id="ixv-34982" unitRef="usd">11014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-34983" unitRef="usd">284681</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c14" decimals="0" id="ixv-34984" unitRef="usd">38724</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-34985" unitRef="usd">54104</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-34986" unitRef="usd">27556</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="0" id="ixv-34987" unitRef="usd">184109</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c80" decimals="0" id="ixv-34988" unitRef="usd">77294</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-34989" unitRef="usd">120162</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c14" decimals="0" id="ixv-34990" unitRef="usd">837</us-gaap:InterestPaidNet>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c14" decimals="0" id="ixv-34991" unitRef="usd">675826</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-30615">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 1 &#x2014;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;NewGenIvf Limited (the &#x201c;Company&#x201d;
or the &#x201c;Group&#x201d;) was incorporated under the laws of the Cayman Islands on January&#160;16, 2019 as an investment holding company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following is an organization chart of the
Company and its subsidiaries:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;img alt="" src="fin_002.jpg" style="width: 650px; height: 355px"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of June&#160;30, 2024, the Company&#x2019;s
subsidiaries are detailed in the table as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 22%; padding-right: 3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 39%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NewGenivf Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cayman Islands company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;br/&gt; &#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 23%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Bishkek LLC (&#x201c;FFB&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;br/&gt; &#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Note:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;According to the Foreign
Business Act (the &#x201c;FBA&#x201d;), the majority shareholdings of limited company incorporated in Thailand is required to be owned
by Thai nationals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#x201c;Share Structure&#x201d;) of Med Holdings and
FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have the same rights and
status in all respects except for the distribution of profits by way of dividends with details as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After allocation of dividends
    as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to
    their shareholding ratio;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The holders of preferred
    shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and
    there shall be no cumulative dividends; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends allocated to
    the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall
    be paid to the holders of preferred shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Based upon the management&#x2019;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Group reorganization&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Pursuant to a group reorganization
(the &#x201c;group reorganization&#x201d;) to rationalize the structure of the Company and its subsidiary companies (herein collectively
referred to as the &#x201c;Group&#x201d;) in preparation for the listing of its shares, the Company becomes the holding company of the
Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests were also
ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and comprehensive
income, consolidated statements of changes in shareholders&#x2019; equity and consolidated statements of cash flows are prepared as if
the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023, or since the respective
dates of incorporation/establishment of the relevant entity, where this is a shorter period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The unaudited condensed
consolidated balance sheets as of June&#160;30, 2024 and 2023 present the assets and liabilities of the aforementioned companies now
comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The movement in the Company&#x2019;s
authorized share capital and the number of ordinary shares outstanding and issued in the Company are also detailed in Note&#160;10.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-34992">As of June&#160;30, 2024, the Company&#x2019;s
subsidiaries are detailed in the table as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 22%; padding-right: 3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 39%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NewGenivf Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Cayman Islands company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FFPGS (HK) Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketing and administrative services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Image Limited&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Med Holdings Limited (&#x201c;Med Holdings&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%*&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility PGS Center Limited (&#x201c;FFC&#x201d;) (Note)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;A Thailand company&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"&gt;&#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014&lt;/p&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;74%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Phnom Penh Limited (&#x201c;FFPP&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Cambodia company&lt;br/&gt; &#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision of IVF treatment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 23%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership %&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal activity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Fertility Bishkek LLC (&#x201c;FFB&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company&lt;br/&gt; &#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provision surrogacy and ancillary caring services&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <nivf:SubsidiariesBackground contextRef="c259" id="ixv-30652">&#x25cf;&#160;&#160;&#160;A Cayman Islands company &#x25cf;&#160;&#160;&#160;Incorporated on 16 January, 2019</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c259"
      decimals="2"
      id="ixv-34993"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c259" id="ixv-30660">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c260" id="ixv-30667">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c260"
      decimals="2"
      id="ixv-34994"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c260" id="ixv-30675">Marketing and administrative services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c261" id="ixv-30682">&#x25cf;&#160;&#160;&#160;A Hong&#160;Kong company &#x25cf;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c261"
      decimals="2"
      id="ixv-34995"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c261" id="ixv-30690">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c262" id="ixv-30697">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c262"
      decimals="2"
      id="ix_12_fact"
      unitRef="pure">0.49</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c262" id="ixv-30705">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c263" id="ixv-30712">&#x25cf;&#160;&#160;&#160;A Thailand company &#x25cf;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c263"
      decimals="2"
      id="ixv-34997"
      unitRef="pure">0.74</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c263" id="ixv-30720">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c264" id="ixv-30727">&#x25cf;&#160;&#160;&#160;A Cambodia company &#x25cf;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c264"
      decimals="2"
      id="ixv-34998"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c264" id="ixv-30735">Provision of IVF treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <nivf:SubsidiariesBackground contextRef="c265" id="ixv-30795">&#x25cf;&#160;&#160;&#160;A Kyrgyzstan company &#x25cf;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</nivf:SubsidiariesBackground>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c265"
      decimals="2"
      id="ixv-34999"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c265" id="ixv-30803">Provision surrogacy and ancillary caring services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c258"
      decimals="2"
      id="ixv-35000"
      unitRef="pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PolicyholderDividendsRateOnPolicyEarnings contextRef="c0" decimals="2" id="ixv-35001" unitRef="pure">0.15</us-gaap:PolicyholderDividendsRateOnPolicyEarnings>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-30899">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 2 &#x2014;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of preparation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management has prepared
the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the
United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual
method accounting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant estimates required to be made by management
include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ from those estimates, and as such,
differences may be material to the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#x201c;HK$&#x201d;).
Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom Penh Limited uses Cambodian
riel (&#x201c;KHR&#x201d;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States dollar (&#x201c;USD&#x201d;)
as its functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations and comprehensive income
as other comprehensive income or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The value of foreign currencies
including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36.8454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.3081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.4021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,112.3016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,132.8226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,080.0304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,075.4046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,058.1179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,105.4181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, prepayment, other receivables and
deferred IPO cost, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deposits, prepayment, other
receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;) cost, net primarily include deposits paid to suppliers, prepaid
expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to shareholders&#x2019; equity upon the completion of the Initial Public Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Plant and equipment, net&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Plant and equipment are
stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#x2019;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete
inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes the basis
for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory would not
be reversed if market conditions improve.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s ordinary
shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received, net of issuance cost,
and the par value is recorded in additional paid-in&#160;capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC
Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its contracts
    with customers;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its performance
    obligations under those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine the transaction
    prices of those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate the transaction
    prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize revenue when
    each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the
    client in an amount that reflects the consideration expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company enters into
service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties. All the contracts have
commercial substance, and it is probable that the Company will collect considerations from its customers for service component.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company derives its
revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In vitro fertilization (&#x201c;IVF&#x201d;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. The Company collects payment from customer in advance for IVF treatment.
The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations can be found in Note&#160;8 below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from surrogacy and ancillary caring
services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company.
During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins, supplements
and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where a baby is born,
therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother gives birth. The
Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across pregnancy
period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations can
be found in Note&#160;8 below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract related assets
and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Account receivables, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Expected credit loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;ASU No.&#160;2016-13, Financial
Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of
credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due
to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective
interest rate of the financial asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (the &#x201c;CODM&#x201d;), or decision making group, in making decisions on how to allocate resources and assess performance.
The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing Fund Alfred, the Company&#x2019;s
Chief Executive Officer. Since the Company operates in one operating segment, all required financial segment information can be found
in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers as of June 30, 2024 and 2023
by geographical area are presented in Note&#160;13.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company measured the
lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-155"&gt;twelve&lt;/span&gt;&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, there were $272,474 and $ 283,847 million&#160;right of use (&#x201c;ROU&#x201d;) assets and $313,393 and $326,107
lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#x2019;s management
believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#x201c;BLR&#x201d;)
minus 0.125%&#160;was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the present value of the
lease payments; the rate used by the Company was 6.6% and 5.0% respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the
differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not
realizable or recoverable in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions
in income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company computes earnings
per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is measured as the income or
loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents
the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and
or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive
effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those
that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive
securities that were in-the-money&#160;that were outstanding during the six months ended June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In the normal course of
business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to
a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency
if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of risks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, one and two customers which individually contributed more than 10% of trade receivable, accounted for 15% and
96.3% of the Company&#x2019;s trade receivable respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;None of the customers contributed
more than 10% of revenue for&#160;six months ended June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, one and four suppliers which individually contributed more than 10% of trade payable, accounted for 13.6% and
30.6% of the Company&#x2019;s trade payable respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;For the six months ended
June 30, 2024 and 2023, one and one vendors which contributed more than 10% of total purchases of the Company, accounted for 15.3% and
21.5% of the Company&#x2019;s total purchases respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net,
loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that
approximate their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements and Disclosures&#x201d;
requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial Instruments&#x201d;
defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents,
accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify
as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such
instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;inputs
    to the valuation methodology used quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2014;&#160;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are
    observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s full term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2014;&#160;inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities from Equity&#x201d;
and ASC&#160;815.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting pronouncements adopted &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In April 2019, the FASB
issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,
and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB issued ASU 2019-05,
Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair value option to
be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until December 15,
2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected
credit loss (&#x201c;CECL&#x201d;) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial
asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets
measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures
such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected
to be collected by using an allowance for expected credit losses. The Company already adopted the new standard and the Company recognizes
the full impact of the new standard in these consolidated balance sheets and makes related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In November 2023, the FASB
issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments in ASU 2023-07 improve financial
reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable
investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit
or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources.
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed
under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure requirements. The amendments in ASU
2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December
15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that
the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In December 2023, FASB issued
Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740)&#x201d; (&#x201c;ASU 2023-09&#x201d;). The amendments
in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure
of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations,
to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income
tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain
categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an
annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions,
including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to
or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods
beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update
on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-30904">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management has prepared
the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the
United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;). The Company maintains its general ledger and journals with the accrual
method accounting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-30946">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant estimates required to be made by management
include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ from those estimates, and as such,
differences may be material to the consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-30953">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#x201c;$&#x201d;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#x201c;HK$&#x201d;).
Med Holdings and FFC use Thai baht (&#x201c;THB&#x201d;) as their functional currencies. First Fertility Phnom Penh Limited uses Cambodian
riel (&#x201c;KHR&#x201d;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States dollar (&#x201c;USD&#x201d;)
as its functional currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations and comprehensive income
as other comprehensive income or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The value of foreign currencies
including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#x2019;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36.8454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.3081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.4021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,112.3016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,132.8226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,080.0304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,075.4046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,058.1179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,105.4181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0" id="ixv-35002">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            HK$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.8000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36.8454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.3081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.2265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            THB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.4021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.3864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34.7867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,112.3016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,132.8226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,080.0304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            KHR&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,075.4046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,058.1179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,105.4181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period-end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Period average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$:
                                            RMB&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.0835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c281"
      decimals="4"
      id="ixv-35003"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c282"
      decimals="4"
      id="ixv-35004"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c118"
      decimals="4"
      id="ixv-35005"
      unitRef="pure">7.8</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c281"
      decimals="4"
      id="ixv-35006"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c282"
      decimals="4"
      id="ixv-35007"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c118"
      decimals="4"
      id="ixv-35008"
      unitRef="pure">7.8</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c283"
      decimals="4"
      id="ixv-35009"
      unitRef="pure">36.8454</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c284"
      decimals="4"
      id="ixv-35010"
      unitRef="pure">35.3081</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c121"
      decimals="4"
      id="ixv-35011"
      unitRef="pure">34.2265</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c283"
      decimals="4"
      id="ixv-35012"
      unitRef="pure">34.4021</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c284"
      decimals="4"
      id="ixv-35013"
      unitRef="pure">34.3864</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c121"
      decimals="4"
      id="ixv-35014"
      unitRef="pure">34.7867</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c285"
      decimals="4"
      id="ixv-35015"
      unitRef="pure">4112.3016</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c286"
      decimals="4"
      id="ixv-35016"
      unitRef="pure">4132.8226</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c124"
      decimals="4"
      id="ixv-35017"
      unitRef="pure">4080.0304</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c285"
      decimals="4"
      id="ixv-35018"
      unitRef="pure">4075.4046</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c286"
      decimals="4"
      id="ixv-35019"
      unitRef="pure">4058.1179</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c124"
      decimals="4"
      id="ixv-35020"
      unitRef="pure">4105.4181</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c287"
      decimals="4"
      id="ixv-35021"
      unitRef="pure">7.2674</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c288"
      decimals="4"
      id="ixv-35022"
      unitRef="pure">6.4586</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c127"
      decimals="4"
      id="ixv-35023"
      unitRef="pure">7.0971</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c287"
      decimals="4"
      id="ixv-35024"
      unitRef="pure">7.2142</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c288"
      decimals="4"
      id="ixv-35025"
      unitRef="pure">6.4077</nivf:ForeignCurrencyExchangeRateTranslation>
    <nivf:ForeignCurrencyExchangeRateTranslation
      contextRef="c127"
      decimals="4"
      id="ixv-35026"
      unitRef="pure">7.0835</nivf:ForeignCurrencyExchangeRateTranslation>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-31174">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock contextRef="c0" id="ixv-31181">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Deposits, prepayment, other receivables and
deferred IPO cost, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deposits, prepayment, other
receivables and deferred Initial Public Offering (&#x201c;IPO&#x201d;) cost, net primarily include deposits paid to suppliers, prepaid
expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to shareholders&#x2019; equity upon the completion of the Initial Public Offering.&lt;/p&gt;</nivf:DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-31191">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Plant and equipment are
stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#x2019;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c8" decimals="2" id="ixv-35027" unitRef="pure">0</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment contextRef="c0" id="ixv-35028">The estimated useful lives of the plan and equipment are as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 74%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the lesser of useful life or&#160;term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
    instruments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;10&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Motor
    vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c289" id="ixv-35029">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c290" id="ixv-35030">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c292" id="ixv-35031">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c293" id="ixv-35032">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c294" id="ixv-35033">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c295" id="ixv-35034">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c296" id="ixv-35035">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c297" id="ixv-35036">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-31235">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of&#160;long-lived&#160;assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-31276">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete
inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes the basis
for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory would not
be reversed if market conditions improve.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-31283">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Other borrowings&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c0" id="ixv-31290">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s ordinary
shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received, net of issuance cost,
and the par value is recorded in additional paid-in&#160;capital.&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c8"
      decimals="2"
      id="ixv-35037"
      unitRef="usdPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-31297">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC
Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#x201c;IVF&#x201d;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its contracts
    with customers;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify its performance
    obligations under those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine the transaction
    prices of those contracts;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate the transaction
    prices to its performance obligations in those contracts; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize revenue when
    each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the
    client in an amount that reflects the consideration expected in exchange for those services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company enters into
service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties. All the contracts have
commercial substance, and it is probable that the Company will collect considerations from its customers for service component.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company derives its
revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from IVF treatment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In vitro fertilization (&#x201c;IVF&#x201d;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. The Company collects payment from customer in advance for IVF treatment.
The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations can be found in Note&#160;8 below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from surrogacy and ancillary caring
services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company.
During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins, supplements
and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where a baby is born,
therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother gives birth. The
Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across pregnancy
period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#x2019;s result of operations can
be found in Note&#160;8 below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract related assets
and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Account receivables, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#x2019;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#x2019;s customers&#x2019; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#x2019;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Expected credit loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;ASU No.&#160;2016-13, Financial
Instruments&#160;&#x2014;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of
credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due
to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective
interest rate of the financial asset.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <nivf:RevenueRate contextRef="c8" decimals="2" id="ixv-35038" unitRef="pure">0.40</nivf:RevenueRate>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="c0" id="ixv-31483">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Retirement benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-31490">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Segment information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (the &#x201c;CODM&#x201d;), or decision making group, in making decisions on how to allocate resources and assess performance.
The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing Fund Alfred, the Company&#x2019;s
Chief Executive Officer. Since the Company operates in one operating segment, all required financial segment information can be found
in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers as of June 30, 2024 and 2023
by geographical area are presented in Note&#160;13.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-35039" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c266"
      decimals="0"
      id="ixv-35040"
      unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-31528">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company measured the
lease in accordance to ASU&#160;2016-02, &#x201c;Leases&#x201d; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of &lt;span style="-sec-ix-hidden: hidden-fact-155"&gt;twelve&lt;/span&gt;&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, there were $272,474 and $ 283,847 million&#160;right of use (&#x201c;ROU&#x201d;) assets and $313,393 and $326,107
lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#x2019;s management
believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#x201c;BLR&#x201d;)
minus 0.125%&#160;was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation of the present value of the
lease payments; the rate used by the Company was 6.6% and 5.0% respectively.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c8" decimals="0" id="ixv-35041" unitRef="usd">272474</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-35042" unitRef="usd">283847</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability contextRef="c8" decimals="0" id="ixv-35043" unitRef="usd">313393</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c2" decimals="0" id="ixv-35044" unitRef="usd">326107</us-gaap:FinanceLeaseLiability>
    <us-gaap:SubordinatedBorrowingInterestRate contextRef="c0" decimals="5" id="ixv-35045" unitRef="pure">0.00125</us-gaap:SubordinatedBorrowingInterestRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="c8" decimals="3" id="ixv-35046" unitRef="pure">0.066</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="c2" decimals="3" id="ixv-35047" unitRef="pure">0.05</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-31539">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the
differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not
realizable or recoverable in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions
in income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-31549">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;&lt;i&gt;Comprehensive Income&lt;/i&gt;. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-31588">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company computes earnings
per share (&#x201c;EPS&#x201d;) following ASC Topic&#160;260, &#x201c;Earnings per share&#x201d;. Basic EPS is measured as the income or
loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents
the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and
or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive
effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those
that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive
securities that were in-the-money&#160;that were outstanding during the six months ended June 30, 2024 and 2023.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <nivf:RelatedPartiesPolicyTextBlock contextRef="c0" id="ixv-31595">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/p&gt;</nivf:RelatedPartiesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-31602">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In the normal course of
business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to
a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency
if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <nivf:NonControllingInterestsPolicyTextBlock contextRef="c0" id="ixv-31609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Non-controlling&#160;interests&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.&lt;/p&gt;</nivf:NonControllingInterestsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-31616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Concentration of customers&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, one and two customers which individually contributed more than 10% of trade receivable, accounted for 15% and
96.3% of the Company&#x2019;s trade receivable respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;None of the customers contributed
more than 10% of revenue for&#160;six months ended June 30, 2024 and 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Concentration of suppliers&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, one and four suppliers which individually contributed more than 10% of trade payable, accounted for 13.6% and
30.6% of the Company&#x2019;s trade payable respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;For the six months ended
June 30, 2024 and 2023, one and one vendors which contributed more than 10% of total purchases of the Company, accounted for 15.3% and
21.5% of the Company&#x2019;s total purchases respectively.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c267"
      decimals="2"
      id="ixv-35048"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c268"
      decimals="2"
      id="ixv-35049"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c269"
      decimals="2"
      id="ixv-35050"
      unitRef="pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c270"
      decimals="3"
      id="ixv-35051"
      unitRef="pure">0.963</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c271"
      decimals="2"
      id="ixv-35052"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c272"
      decimals="2"
      id="ixv-35053"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c273"
      decimals="2"
      id="ixv-35054"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c274"
      decimals="2"
      id="ixv-35055"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c275"
      decimals="3"
      id="ixv-35056"
      unitRef="pure">0.136</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c276"
      decimals="3"
      id="ixv-35057"
      unitRef="pure">0.306</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c277"
      decimals="2"
      id="ixv-35058"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c278"
      decimals="2"
      id="ixv-35059"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c279"
      decimals="3"
      id="ixv-35060"
      unitRef="pure">0.153</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c280"
      decimals="3"
      id="ixv-35061"
      unitRef="pure">0.215</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-31690">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net,
loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that
approximate their fair values due to their short maturities. ASC Topic&#160;820, &#x201c;Fair Value Measurements and Disclosures&#x201d;
requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#x201c;Financial Instruments&#x201d;
defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents,
accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify
as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such
instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined
as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2014;&#160;inputs
    to the valuation methodology used quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2014;&#160;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are
    observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#x2019;s full term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2014;&#160;inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#x201c;Distinguishing Liabilities from Equity&#x201d;
and ASC&#160;815.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-31759">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting pronouncements adopted &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In April 2019, the FASB
issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,
and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB issued ASU 2019-05,
Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair value option to
be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until December 15,
2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected
credit loss (&#x201c;CECL&#x201d;) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial
asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets
measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures
such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected
to be collected by using an allowance for expected credit losses. The Company already adopted the new standard and the Company recognizes
the full impact of the new standard in these consolidated balance sheets and makes related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c0" id="ixv-31766">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In November 2023, the FASB
issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments in ASU 2023-07 improve financial
reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable
investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit
or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources.
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed
under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure requirements. The amendments in ASU
2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December
15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that
the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In December 2023, FASB issued
Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (Topic 740)&#x201d; (&#x201c;ASU 2023-09&#x201d;). The amendments
in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure
of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations,
to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income
tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain
categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an
annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions,
including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to
or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods
beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update
on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#x2019;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c0" decimals="2" id="ixv-35062" unitRef="pure">0.05</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-35063" unitRef="pure">0.05</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:AccountsAndNontradeReceivableTextBlock contextRef="c0" id="ixv-31802">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 3 &#x2014;&#160;ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accounts receivable, net consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Within 90&#160;days&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reversal (provision) of provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of currency translation adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-35064">Accounts receivable, net consists of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c8" decimals="0" id="ixv-35065" unitRef="usd">172493</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" id="ixv-35066" unitRef="usd">9393</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c8" decimals="0" id="ixv-35067" unitRef="usd">18</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" id="ixv-35068" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c8" decimals="0" id="ixv-35069" unitRef="usd">172475</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-35070" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0" id="ixv-35071">As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Within 90&#160;days&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,475&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,374&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c298" decimals="0" id="ixv-35072" unitRef="usd">172475</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c139" decimals="0" id="ixv-35073" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c8" decimals="0" id="ixv-35074" unitRef="usd">172475</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-35075" unitRef="usd">9374</us-gaap:AccountsReceivableNetCurrent>
    <nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock contextRef="c0" id="ixv-35076">The movement of allowances for expected credit
loss is as follow:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reversal (provision) of provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of currency translation adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c145" decimals="0" id="ixv-35077" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c141" decimals="0" id="ixv-35078" unitRef="usd">26</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c299" decimals="0" id="ixv-35079" unitRef="usd">1</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c143" decimals="0" id="ixv-35080" unitRef="usd">7</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c300" decimals="0" id="ixv-35081" unitRef="usd">18</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c145" decimals="0" id="ixv-35082" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-31965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 4 &#x2014;&#160;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Inventories consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Medicines, consumables and reagents for clinical and laboratory analyses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;102,825&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102,825&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-35083">Inventories consist of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Medicines, consumables and reagents for clinical and laboratory analyses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;102,825&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102,825&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;126,264&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryGross contextRef="c8" decimals="0" id="ixv-35084" unitRef="usd">102825</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c2" decimals="0" id="ixv-35085" unitRef="usd">126264</us-gaap:InventoryGross>
    <us-gaap:InventoryNet contextRef="c8" decimals="0" id="ixv-35086" unitRef="usd">102825</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-35087" unitRef="usd">126264</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-32035">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 5 &#x2014;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES
AND DEFERRED IPO COST, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;359,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Prepayment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;213,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d; cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;703,897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;517,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reversal of provision (Provision)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of currency translation adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-35088">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;359,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Prepayment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;213,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred initial public offering &#x201c;IPO&#x201d; cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;703,897&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;517,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherReceivables contextRef="c8" decimals="0" id="ixv-35089" unitRef="usd">359035</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c2" decimals="0" id="ixv-35090" unitRef="usd">15910</us-gaap:OtherReceivables>
    <us-gaap:DepositAssets contextRef="c8" decimals="0" id="ixv-35091" unitRef="usd">131111</us-gaap:DepositAssets>
    <us-gaap:DepositAssets contextRef="c2" decimals="0" id="ixv-35092" unitRef="usd">123008</us-gaap:DepositAssets>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c8" decimals="0" id="ixv-35093" unitRef="usd">213765</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-35094" unitRef="usd">4848</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-35095" unitRef="usd">373677</us-gaap:DeferredOfferingCosts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c8" decimals="0" id="ixv-35096" unitRef="usd">14</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts contextRef="c2" decimals="0" id="ixv-35097" unitRef="usd">14</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c8" decimals="0" id="ixv-35098" unitRef="usd">703897</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-35099" unitRef="usd">517429</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock contextRef="c0" id="ixv-35100">The movement of allowances for expected credit
loss is as follow:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reversal of provision (Provision)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of currency translation adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c2" decimals="0" id="ixv-35101" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c80" decimals="0" id="ixv-35102" unitRef="usd">-141</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision contextRef="c301" decimals="0" id="ixv-35103" unitRef="usd">127</nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c8" decimals="0" id="ixv-35104" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <nivf:AllowancesForExpectedCreditLoss contextRef="c2" decimals="0" id="ixv-35105" unitRef="usd">-14</nivf:AllowancesForExpectedCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-32217">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 6 &#x2014;&#160;PLANT AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Plant and equipment, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;At cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Building improvement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;247,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;765,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,379,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,219,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,319,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;159,931&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;162,157&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Depreciation expenses for the&#160;six
months ended June 30, 2024 and 2023 were $12,619 and $19,461, respectively. No loss on disposal of assets for the six months ended June
30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-162"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163"&gt;No&lt;/span&gt;&lt;/span&gt; impairment loss was recorded for the&#160;six
months ended June&#160;30, 2024, and 2023.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-35106">Plant and equipment, net consist of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;At cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Building improvement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;247,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;765,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,379,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,219,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,319,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;159,931&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;162,157&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c302" decimals="0" id="ixv-35107" unitRef="usd">85867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c146" decimals="0" id="ixv-35108" unitRef="usd">92438</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c303" decimals="0" id="ixv-35109" unitRef="usd">247229</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c148" decimals="0" id="ixv-35110" unitRef="usd">250493</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c304" decimals="0" id="ixv-35111" unitRef="usd">765081</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c150" decimals="0" id="ixv-35112" unitRef="usd">844809</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c305" decimals="0" id="ixv-35113" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c152" decimals="0" id="ixv-35114" unitRef="usd">142936</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c306" decimals="0" id="ixv-35115" unitRef="usd">138369</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c154" decimals="0" id="ixv-35116" unitRef="usd">150688</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c8" decimals="0" id="ixv-35117" unitRef="usd">1379482</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-35118" unitRef="usd">1481364</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c8" decimals="0" id="ixv-35119" unitRef="usd">1219551</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-35120" unitRef="usd">1319207</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c8" decimals="0" id="ixv-35121" unitRef="usd">159931</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-35122" unitRef="usd">162157</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-35123" unitRef="usd">12619</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c14" decimals="0" id="ixv-35124" unitRef="usd">19461</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-32362">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 7 &#x2014;&#160;ACCRUED LIABILTIES AND OTHER PAYABLES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued liabilities and other payables consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;183,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Withholding tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Compensation payable (Note&#160;1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued legal and professional fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,699,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;--&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315,696&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;241,613&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-35125">Accrued liabilities and other payables consist
of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;183,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Withholding tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Compensation payable (Note&#160;1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued legal and professional fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,699,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;--&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,616&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315,696&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;241,613&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c8" decimals="0" id="ixv-35126" unitRef="usd">183071</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-35127" unitRef="usd">43633</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c8" decimals="0" id="ixv-35128" unitRef="usd">4168</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="0" id="ixv-35129" unitRef="usd">7349</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c8" decimals="0" id="ix_13_fact" unitRef="usd">14183</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent contextRef="c2" decimals="0" id="ix_14_fact" unitRef="usd">144015</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c8" decimals="0" id="ixv-35132" unitRef="usd">2699292</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c8" decimals="0" id="ixv-35133" unitRef="usd">114274</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="0" id="ixv-35134" unitRef="usd">46616</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c8" decimals="0" id="ixv-35135" unitRef="usd">315696</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c2" decimals="0" id="ixv-35136" unitRef="usd">241613</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-32461">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 8 &#x2014;&#160;CONTRACT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Contract liabilities consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,360,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Recognized to revenue during the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,937&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Refund to customers (Note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,341,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance at end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;37,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c0" id="ixv-35137">Contract liabilities consist of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,360,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Recognized to revenue during the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,937&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Refund to customers (Note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,341,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance at end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;37,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,937&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c2" decimals="0" id="ixv-35138" unitRef="usd">7937</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c3" decimals="0" id="ixv-35139" unitRef="usd">1360168</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c0" decimals="0" id="ixv-35140" unitRef="usd">37592</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination contextRef="c11" decimals="0" id="ixv-35141" unitRef="usd">112006</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c0" decimals="0" id="ixv-35142" unitRef="usd">-7937</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c11" decimals="0" id="ixv-35143" unitRef="usd">-122662</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c2" decimals="0" id="ix_15_fact" unitRef="usd">1341575</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c8" decimals="0" id="ixv-35145" unitRef="usd">37592</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c2" decimals="0" id="ixv-35146" unitRef="usd">7937</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-32573">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 9 &#x2014;&#160;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has various
operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#x2019;s management
believes that the interest rate of 6.6% and 5% was the most indicative rate of the Company&#x2019;s borrowing cost for the calculation
of the present value of the lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of June 30, 2024 and December 31, 2023, the
right-of-use&#160;assets totaled $272,474 and $296,742, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of June&#160;30, 2024 and December 31,2023,
lease liabilities consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,297&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current
    portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;326,107&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Other lease information is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Weighted-average remaining lease term&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.67years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.92years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Short term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The following is a schedule
of future minimum payments under operating leases as of June 30, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Not later than 1 year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,654&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Between 1 to 2&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Between 2 to 3&#160;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total operating lease liabilities, net
    of interest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c307"
      decimals="3"
      id="ixv-35147"
      unitRef="pure">0.066</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c308"
      decimals="2"
      id="ixv-35148"
      unitRef="pure">0.05</us-gaap:LesseeOperatingLeaseDiscountRate>
    <nivf:OperatingLeaseRightOfUseAssets contextRef="c8" decimals="0" id="ixv-35149" unitRef="usd">272474</nivf:OperatingLeaseRightOfUseAssets>
    <nivf:OperatingLeaseRightOfUseAssets contextRef="c2" decimals="0" id="ixv-35150" unitRef="usd">296742</nivf:OperatingLeaseRightOfUseAssets>
    <nivf:ScheduleOfLeaseLiabilitiesTableTextBlock contextRef="c0" id="ixv-35151">As of June&#160;30, 2024 and December 31,2023,
lease liabilities consist of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,297&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Lease liabilities&#160;&#x2013;&#160;non-current
    portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;326,107&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nivf:ScheduleOfLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c8" decimals="0" id="ixv-35152" unitRef="usd">199297</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-35153" unitRef="usd">207128</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c8" decimals="0" id="ixv-35154" unitRef="usd">114096</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-35155" unitRef="usd">118979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c8" decimals="0" id="ixv-35156" unitRef="usd">313393</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-35157" unitRef="usd">326107</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-35158">Other lease information is as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Weighted-average remaining lease term&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.67years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.92years&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Weighted-average discount rate&#160;&#x2013;&#160;operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Short term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;114,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c8" id="ixv-35159">P0Y8M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-35160">P0Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c8" decimals="2" id="ixv-35161" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" id="ixv-35162" unitRef="pure">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="0" id="ixv-35163" unitRef="usd">100009</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c11" decimals="0" id="ixv-35164" unitRef="usd">114937</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-35165">The following is a schedule
of future minimum payments under operating leases as of June 30, 2024:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Not later than 1 year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,654&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Between 1 to 2&#160;years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Between 2 to 3&#160;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total operating lease liabilities, net
    of interest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c8" decimals="0" id="ixv-35166" unitRef="usd">199654</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c8" decimals="0" id="ixv-35167" unitRef="usd">79079</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c8" decimals="0" id="ixv-35168" unitRef="usd">35018</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c8" decimals="0" id="ixv-35169" unitRef="usd">313751</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c8" decimals="0" id="ixv-35170" unitRef="usd">358</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c8" decimals="0" id="ixv-35171" unitRef="usd">313393</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-32757">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 10 &#x2014;&#160;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Ordinary shares&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As at June&#160;30, 2024,
the Company is authorized to issue 5,000,000 ordinary shares. Each ordinary share is entitled to one vote. The holders of ordinary shares
are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On April 3, 2024, the Company
completed the business combination with A SPAC I Acquisition Corp.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The equity of the Company
as of June&#160;30, 2024 and December 31, 2023 represents 10,149,386 and 698,123 ordinary shares amounting to $101,494 and $6,981, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Subscription receivables&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;319,872&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,866,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement
    of subscription receivable &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(219,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Business combination&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,506,691&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,473,791&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,967,100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Additional paid-in capital&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,324,834&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,458,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,865,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Business combination&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,267,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,324,834&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c88"
      decimals="0"
      id="ixv-35172"
      unitRef="shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights contextRef="c0" id="ixv-35173">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c8"
      decimals="0"
      id="ixv-35174"
      unitRef="shares">10149386</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-35175"
      unitRef="shares">698123</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c8" decimals="0" id="ixv-35176" unitRef="usd">101494</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-35177" unitRef="usd">6981</us-gaap:CommonStockValue>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c0" id="ixv-32774">&lt;i&gt;Subscription receivables&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;319,872&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,866,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Settlement
    of subscription receivable &lt;i&gt;(Note 2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(219,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Business combination&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,506,691&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,473,791&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,967,100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 2:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c309" decimals="0" id="ixv-35178" unitRef="usd">2967100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c310" decimals="0" id="ixv-35179" unitRef="usd">319872</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c312"
      decimals="0"
      id="ix_16_fact"
      unitRef="usd">2866856</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c312"
      decimals="0"
      id="ix_17_fact"
      unitRef="usd">219628</nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c311" decimals="0" id="ixv-35182" unitRef="usd">4506691</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c313" decimals="0" id="ixv-35183" unitRef="usd">7473791</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c309" decimals="0" id="ixv-35184" unitRef="usd">2967100</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c158"
      decimals="0"
      id="ixv-35185"
      unitRef="shares">41830</us-gaap:ExcessStockSharesIssued>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c159" decimals="0" id="ixv-35186" unitRef="usd">961538</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OtherBorrowings contextRef="c158" decimals="0" id="ixv-35187" unitRef="usd">641025</us-gaap:OtherBorrowings>
    <us-gaap:OtherBorrowings contextRef="c160" decimals="0" id="ixv-35188" unitRef="usd">641</us-gaap:OtherBorrowings>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c158" decimals="0" id="ixv-35189" unitRef="usd">319872</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:AmountOfRegulatoryAssistanceReceived1 contextRef="c161" decimals="0" id="ixv-35190" unitRef="usd">192308</us-gaap:AmountOfRegulatoryAssistanceReceived1>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c162" decimals="0" id="ixv-35191" unitRef="usd">192308</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c163"
      decimals="0"
      id="ixv-35192"
      unitRef="shares">27293</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c163" decimals="0" id="ixv-35193" unitRef="usd">812573</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c164"
      decimals="0"
      id="ixv-35194"
      unitRef="shares">69000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c165"
      decimals="0"
      id="ixv-35195"
      unitRef="shares">2054283</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c2" decimals="0" id="ixv-35196" unitRef="usd">27320</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock contextRef="c0" id="ixv-32875">&lt;i&gt;Additional paid-in capital&lt;/i&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,324,834&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,458,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    of shares &lt;i&gt;(Note 1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,865,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Business combination&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,267,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57,821&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,324,834&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0%"&gt;&lt;/td&gt; &lt;td style="width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note 1:&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</nivf:ScheduleOfAdditionalPaidinCapitalTableTextBlock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c182" decimals="0" id="ixv-35197" unitRef="usd">4324834</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c314" decimals="0" id="ixv-35198" unitRef="usd">1458941</us-gaap:AdditionalPaidInCapitalCommonStock>
    <nivf:IssuanceOfSharesAdditionalpaidincapital
      contextRef="c316"
      decimals="0"
      id="ix_18_fact"
      unitRef="usd">2865893</nivf:IssuanceOfSharesAdditionalpaidincapital>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="c315" decimals="0" id="ixv-35200" unitRef="usd">4267013</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c317" decimals="0" id="ixv-35201" unitRef="usd">57821</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c182" decimals="0" id="ixv-35202" unitRef="usd">4324834</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c168"
      decimals="0"
      id="ixv-35203"
      unitRef="shares">41830</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:OtherAdditionalCapital contextRef="c158" decimals="0" id="ixv-35204" unitRef="usd">961120</us-gaap:OtherAdditionalCapital>
    <us-gaap:SharesIssued
      contextRef="c163"
      decimals="0"
      id="ixv-35205"
      unitRef="shares">27293</us-gaap:SharesIssued>
    <us-gaap:DebtInstrumentTerm contextRef="c169" id="ixv-35206">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c170" decimals="0" id="ixv-35207" unitRef="usd">812300</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c171"
      decimals="0"
      id="ixv-35208"
      unitRef="shares">69000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:DebtInstrumentTerm contextRef="c172" id="ixv-35209">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c165" decimals="0" id="ixv-35210" unitRef="usd">2053593</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-32955">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 11 &#x2014;&#160;EMPLOYEE BENEFIT PLANS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5% of the employees&#x2019;
basic salaries on monthly basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession had been determined
by the Government which saw the standard amount &lt;span style="-sec-ix-hidden: hidden-fact-173"&gt;THB750&lt;/span&gt; per month per person reduced to &lt;span style="-sec-ix-hidden: hidden-fact-174"&gt;THB450&lt;/span&gt; per month per person.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#x201c;NSSF&#x201d;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Once registered, the business
must pay to the NSSF:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution equivalent to 0.8% of each worker&#x2019;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution equivalent to 2.6% of a worker&#x2019;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between &lt;span style="-sec-ix-hidden: hidden-fact-172"&gt;KHR400,000&lt;/span&gt; (approximately $100) up to &lt;span style="-sec-ix-hidden: hidden-fact-171"&gt;KHR1,200,000&lt;/span&gt; (approximately $300).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15% and 8%, respectively
of the employees&#x2019; basic salaries on monthly basis.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c318"
      decimals="2"
      id="ixv-35211"
      unitRef="pure">0.05</us-gaap:ManagementAndServiceFeesRate>
    <nivf:ContributableWageRate
      contextRef="c320"
      decimals="3"
      id="ixv-35212"
      unitRef="pure">0.008</nivf:ContributableWageRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c321"
      decimals="2"
      id="ixv-35213"
      unitRef="usdPershares">0.4</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c322"
      decimals="2"
      id="ixv-35214"
      unitRef="usdPershares">2.4</us-gaap:SaleOfStockPricePerShare>
    <nivf:ContributableWageRate
      contextRef="c323"
      decimals="3"
      id="ixv-35215"
      unitRef="pure">0.026</nivf:ContributableWageRate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c324"
      decimals="2"
      id="ixv-35216"
      unitRef="usdPershares">1.3</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c325"
      decimals="2"
      id="ixv-35217"
      unitRef="usdPershares">7.8</us-gaap:SaleOfStockPricePerShare>
    <nivf:ContributableWageRate
      contextRef="c326"
      decimals="2"
      id="ixv-35218"
      unitRef="pure">0.02</nivf:ContributableWageRate>
    <nivf:ContributableWageTotalRate
      contextRef="c326"
      decimals="2"
      id="ixv-35219"
      unitRef="pure">0.04</nivf:ContributableWageTotalRate>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c327" decimals="0" id="ixv-35220" unitRef="usd">100</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c328" decimals="0" id="ixv-35221" unitRef="usd">300</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="c329"
      decimals="2"
      id="ixv-35222"
      unitRef="pure">0.15</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:ManagementAndServiceFeesRate contextRef="c0" decimals="2" id="ixv-35223" unitRef="pure">0.08</us-gaap:ManagementAndServiceFeesRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-33046">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 12 &#x2014;&#160;PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cayman Islands&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;HK SAR&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived
from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Accordingly, the HK SAR
profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Thailand&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty (DTT).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cambodia&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The standard rate of corporate
income tax (&#x201c;CIT&#x201d;) for companies and permanent establishments who are classified as medium and large taxpayers is 20%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from 0% to 20%. In
view of the annual turnover of the company, the annual turnover ranges from &lt;span style="-sec-ix-hidden: hidden-fact-185"&gt;KHR1&lt;/span&gt;&#160;billion to &lt;span style="-sec-ix-hidden: hidden-fact-186"&gt;KHR6&lt;/span&gt;&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Kyrgyzstan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Profit tax is calculated
at a rate of 10% of aggregate annual income less allowed deductions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Significant components of
the provisions for income taxes for the six months ended June 30, 2024, and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Late penalty provision Kyrgyzstan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Income/(loss) before taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(387,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(295,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax expenses/(credit) at the effective tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(69,180&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114,645&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(509&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on utilization of tax losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax asset, net&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant components of deferred tax assets,
net were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&#x2013; Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June&#160;30, 2024
and December 31, 2023, the Company had net operating loss carry forward of $164,721 and $164,721. The Company believes it is less likely
than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As
a result, the Company provided 100% allowance on deferred tax assets on net operating loss.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <nivf:ProfitTaxDescription contextRef="c0" id="ixv-35224">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived
from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</nivf:ProfitTaxDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="4" id="ixv-35225" unitRef="pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c330"
      decimals="-6"
      id="ixv-35226"
      unitRef="hkd">2000000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment contextRef="c0" decimals="3" id="ixv-35227" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther contextRef="c0" decimals="2" id="ixv-35228" unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c0" decimals="2" id="ixv-35229" unitRef="pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="2" id="ixv-35230" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal contextRef="c0" decimals="2" id="ixv-35231" unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c331"
      decimals="2"
      id="ixv-35232"
      unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c332"
      decimals="2"
      id="ixv-35233"
      unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther contextRef="c0" decimals="2" id="ixv-35234" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-35235">Significant components of
the provisions for income taxes for the six months ended June 30, 2024, and 2023 were as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Kyrgyzstan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current tax provision Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Late penalty provision Kyrgyzstan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c334" decimals="0" id="ixv-35236" unitRef="usd">83727</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c14" decimals="0" id="ixv-35237" unitRef="usd">83727</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-33213">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Income/(loss) before taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(387,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(295,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax expenses/(credit) at the effective tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(69,180&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114,645&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on non-taxable income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(509&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Tax effect on utilization of tax losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,727&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-35238" unitRef="usd">-387781</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-35239" unitRef="usd">-295060</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="0" id="ixv-35240" unitRef="usd">-69180</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c14" decimals="0" id="ixv-35241" unitRef="usd">-114645</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c0" decimals="0" id="ixv-35242" unitRef="usd">-509</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="0" id="ixv-35243" unitRef="usd">42924</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c14" decimals="0" id="ixv-35244" unitRef="usd">206496</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c0" decimals="0" id="ixv-35245" unitRef="usd">26765</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c14" decimals="0" id="ixv-35246" unitRef="usd">-8124</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c14" decimals="0" id="ixv-35247" unitRef="usd">83727</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-35248">Significant components of deferred tax assets,
net were as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&#x2013; Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c8" decimals="0" id="ixv-35249" unitRef="usd">28441</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-35250" unitRef="usd">28441</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c8" decimals="0" id="ixv-35251" unitRef="usd">28441</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-35252" unitRef="usd">28441</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c8" decimals="0" id="ixv-35253" unitRef="usd">164721</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-35254" unitRef="usd">164721</us-gaap:OperatingLossCarryforwards>
    <nivf:PercentageOfAllowanceOnDeferredTaxAssets contextRef="c0" decimals="2" id="ixv-35255" unitRef="pure">1</nivf:PercentageOfAllowanceOnDeferredTaxAssets>
    <nivf:DissagregattedRevenuesTextBlock contextRef="c0" id="ixv-33360">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 13 &#x2014;&#160;DISAGGREGATED REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s main business operations
are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;IVF treatment service&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,380,576&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,869,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Surrogacy, ancillary caring and other
    services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;306,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,686,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,138,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Geographical information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers originated from&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,426,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;306,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,109,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;441,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,686,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,138,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The revenue information above is based on the
locations where the revenue originated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Long-lived assets located at&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,371&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,004&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.&lt;/p&gt;</nivf:DissagregattedRevenuesTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c0" id="ixv-35256">The Company&#x2019;s main business operations
are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;IVF treatment service&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,380,576&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,869,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Surrogacy, ancillary caring and other
    services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;306,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,686,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,138,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues contextRef="c339" decimals="0" id="ixv-35257" unitRef="usd">2380576</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c340" decimals="0" id="ixv-35258" unitRef="usd">1869987</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c341" decimals="0" id="ixv-35259" unitRef="usd">306326</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c342" decimals="0" id="ixv-35260" unitRef="usd">268635</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-35261" unitRef="usd">2686902</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c14" decimals="0" id="ixv-35262" unitRef="usd">2138622</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-33445">&lt;b&gt;Geographical information&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Six months ended June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Revenue from external customers originated from&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Kyrgyzstan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,426,592&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;306,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,109,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;441,375&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,686,902&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,138,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c343" decimals="0" id="ixv-35263" unitRef="usd">3077</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c329" decimals="0" id="ixv-35264" unitRef="usd">1267983</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c345" decimals="0" id="ixv-35265" unitRef="usd">1426592</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c346" decimals="0" id="ixv-35266" unitRef="usd">306326</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c347" decimals="0" id="ixv-35267" unitRef="usd">270655</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c348" decimals="0" id="ixv-35268" unitRef="usd">1109516</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c349" decimals="0" id="ixv-35269" unitRef="usd">441375</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-35270" unitRef="usd">2686902</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c14" decimals="0" id="ixv-35271" unitRef="usd">2138622</us-gaap:Revenues>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-35272">The revenue information above is based on the
locations where the revenue originated.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Long-lived assets located at&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;HK SAR&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cambodia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thailand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300,575&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,371&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,004&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:AssetsNoncurrent contextRef="c350" decimals="0" id="ixv-35273" unitRef="usd">1169</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c221" decimals="0" id="ixv-35274" unitRef="usd">584</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c351" decimals="0" id="ixv-35275" unitRef="usd">132627</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c226" decimals="0" id="ixv-35276" unitRef="usd">137472</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c319" decimals="0" id="ixv-35277" unitRef="usd">300575</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c184" decimals="0" id="ixv-35278" unitRef="usd">307948</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c8" decimals="0" id="ixv-35279" unitRef="usd">434371</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-35280" unitRef="usd">446004</us-gaap:AssetsNoncurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-33582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 14 &#x2014;&#160;RISKS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"&gt;A. Credit risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of
June 30, 2024 and December&#160;31, 2023 is $&lt;span style="-sec-ix-hidden: hidden-fact-188"&gt;Nil&lt;/span&gt; and $19, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Deposits and other receivables, amount due
from shareholders and loan to A SPAC I&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company assessed the
impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating
and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables,
due from shareholders and loan to A SPAC I as of June 30, 2024 is $14, $&lt;span style="-sec-ix-hidden: hidden-fact-189"&gt;Nil&lt;/span&gt; and $ &lt;span style="-sec-ix-hidden: hidden-fact-190"&gt;Nil&lt;/span&gt;, respectively. The loss allowance for deposits
and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and &lt;span style="-sec-ix-hidden: hidden-fact-191"&gt;Nil&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;B.&#160;Interest
risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Cash flow interest rate risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#x2019;s variable-rates&#160;bank balances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#x2019;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Sensitivity analysis&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#x2019;s assessment of the reasonably possible change
in interest rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;If interest rates had been
1% higher or lower and all other variables were held constant, the Company&#x2019;s net (loss) income for the&#160;six months ended June
30, 2024 and 2023 would have increased or decreased by approximately $1,202 and $773, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Foreign currency risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#x2019;s financial position as a result of a change in foreign
currency exchange rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s monetary
assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional currencies of the relevant
group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company
currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related
foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need arise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;C. Economic and
political risks&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#x2019;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company&#x2019;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#x2019;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"&gt;D. Inflation risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#x2019;s consolidated financial statements; however,
significant increases in the price of labor that cannot be passed to the Company&#x2019;s customers could adversely impact the Company&#x2019;s
results of operations.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="c2" decimals="0" id="ixv-35281" unitRef="usd">19</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c352" decimals="0" id="ixv-35282" unitRef="usd">14</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c6" decimals="0" id="ixv-35283" unitRef="usd">14</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss contextRef="c232" decimals="0" id="ixv-35284" unitRef="usd">17818</us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c0" decimals="2" id="ixv-35285" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <nivf:InterestRateOtherVariablesPercentage contextRef="c0" decimals="2" id="ixv-35286" unitRef="pure">0.01</nivf:InterestRateOtherVariablesPercentage>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c0" decimals="0" id="ixv-35287" unitRef="usd">1202</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:IncreaseDecreaseInPensionPlanObligations contextRef="c14" decimals="0" id="ixv-35288" unitRef="usd">773</us-gaap:IncreaseDecreaseInPensionPlanObligations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-33742">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 15 &#x2014;&#160;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The summary of amount due from and due to related
parties as the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Due from shareholders consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Due to a related party consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The balance due from shareholders consist of
the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Due (to) from shareholders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The movement of allowances for expected credit
loss is as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(759&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Revised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Directors&#x2019; remuneration to Mr.&#160;Siu Wing
    Fung, Alfred&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Directors&#x2019; remuneration to Ms. Fong Hei Yue, Tina&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-35289">The summary of amount due from and due to related
parties as the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Due from shareholders consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Due to a related party consist of the following:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Mr.&#160;Siu Wing Fung, Alfred (&#x201c;Mr.&#160;Siu&#x201d;) and Ms.&#160;Fong Hei Yue, Tina (&#x201c;Ms. Fong&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholders and directors (note 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c354" id="ixv-35290">Shareholders and directors (note 1)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c356" decimals="0" id="ixv-35291" unitRef="usd">354285</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c354" id="ixv-35292">Shareholders and directors (note 1)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c355" decimals="0" id="ixv-35293" unitRef="usd">221203</us-gaap:OtherLiabilitiesCurrent>
    <nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock contextRef="c0" id="ixv-35294">The balance due from shareholders consist of
the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Due (to) from shareholders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(221,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;354,285&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</nivf:ScheduleOfTheBalanceDueFromShareholdersTableTextBlock>
    <nivf:DueFromShareholder contextRef="c8" decimals="0" id="ixv-35295" unitRef="usd">-221203</nivf:DueFromShareholder>
    <nivf:DueFromShareholder contextRef="c2" decimals="0" id="ixv-35296" unitRef="usd">372103</nivf:DueFromShareholder>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent contextRef="c2" decimals="0" id="ixv-35297" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent>
    <nivf:OtherReceivablesNet contextRef="c8" decimals="0" id="ixv-35298" unitRef="usd">-221203</nivf:OtherReceivablesNet>
    <nivf:OtherReceivablesNet contextRef="c2" decimals="0" id="ixv-35299" unitRef="usd">354285</nivf:OtherReceivablesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-35300">The movement of allowances for expected credit
loss is as follow:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at beginning of the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(759&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Revised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(17,818&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-35301" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c80" decimals="0" id="ixv-35302" unitRef="usd">17059</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c301" decimals="0" id="ixv-35303" unitRef="usd">-759</us-gaap:ProvisionForDoubtfulAccounts>
    <nivf:AllowanceForExpectedCreditLossRevised contextRef="c0" decimals="0" id="ixv-35304" unitRef="usd">17818</nivf:AllowanceForExpectedCreditLossRevised>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-35305" unitRef="usd">17818</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0" id="ixv-35306">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Directors&#x2019; remuneration to Mr.&#160;Siu Wing
    Fung, Alfred&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Directors&#x2019; remuneration to Ms. Fong Hei Yue, Tina&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <nivf:TransactionsWithRelatedParties contextRef="c357" decimals="0" id="ixv-35307" unitRef="usd">95000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c358" decimals="0" id="ixv-35308" unitRef="usd">60000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c359" decimals="0" id="ixv-35309" unitRef="usd">95000</nivf:TransactionsWithRelatedParties>
    <nivf:TransactionsWithRelatedParties contextRef="c360" decimals="0" id="ixv-35310" unitRef="usd">60000</nivf:TransactionsWithRelatedParties>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-34042">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 16 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of June 30, 2024 and
2023, the Company was not a party to any legal or administrative proceedings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;First Fertility Bishkek
LLC (&#x201c;FFB&#x201d;), the Company incorporated in Kyrgyzstan, did not report the current year tax &#160;&#160;to the tax authority
till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of June 30, 2024. Since FFB had no profit
for the six months ended June 30, 2024, the tax department may not issue tax return at current tax position. The tax return is not yet
filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible amount of tax penalty.
The contingent tax penalty is reasonably possible and estimated at $486,706. Thus, no provision was made. Except the potential tax issue,
the Company concludes that there was no contingent liability, either individually or in the aggregate, that could have resulted in an
unfavorable outcome with a material adverse effect on the Company&#x2019;s results of operations, consolidated financial condition, or
cash flows.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c8" decimals="0" id="ixv-35311" unitRef="usd">486706</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-34055">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 17 &#x2014;&#160;&lt;span style="text-transform: uppercase"&gt;segment
information&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company uses the management
approach to determine reportable operating segments. The management approach considers the internal organization and reporting used by
the Company&#x2019;s CODM, specifically the Group&#x2019;s CEO and CFO, for making decisions, allocating resources and assessing performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company does not distinguish
revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses by nature as a whole.
Based on the management&#x2019;s assessment, the Group determines that it has only one operating segment and therefore one reportable
segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be found in these
consolidated financial statements.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <nivf:NumberOfOperatingSegment contextRef="c0" decimals="0" id="ixv-35312" unitRef="pure">1</nivf:NumberOfOperatingSegment>
    <us-gaap:NumberOfReportingUnits contextRef="c0" decimals="0" id="ixv-35313" unitRef="pure">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-34068">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;NOTE 18 &#x2014;&#160;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In accordance with ASC Topic
855, &#x201c;Subsequent Events&#x201d;, which establishes general standards of accounting for and disclosure of events that occur after
the balance sheet date but before consolidated financial statements are issued, the Company evaluated all events or transactions that
occurred after June 30, 2024, up through the date the Company&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">F-1/A</dei:DocumentType>
    <nivf:LoanToASPAC
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c6"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:LoanToASPAC
      contextRef="c8"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c8"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c6"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:DueToShareholders
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c8"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c16"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c25"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c27"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c24"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c26"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c24"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c26"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c27"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c29"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c31"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c31"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c38"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c39"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c40"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c42"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c38"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c39"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c40"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c41"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c38"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c39"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c41"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c42"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c44"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c41"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c42"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c44"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c52"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c53"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c54"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c56"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c52"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c53"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c54"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c55"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c52"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c54"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c55"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c56"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c58"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c55"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c56"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c57"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c58"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c11"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c66"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c67"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c68"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c70"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c66"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c67"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c68"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c69"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c66"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c68"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c69"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c70"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c72"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c81"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c82"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c83"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c85"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c81"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c82"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c83"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c84"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c84"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c88"
      decimals="INF"
      id="hidden-fact-86"
      unitRef="shares">10149386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c11"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c13"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseDebt
      contextRef="c12"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseDebt
      contextRef="c13"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c12"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:WaiverOfRelatedPartyBalance
      contextRef="c13"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LegalFees
      contextRef="c12"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LegalFees
      contextRef="c13"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeTaxExpense
      contextRef="c11"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeTaxExpense
      contextRef="c13"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInFinanceReceivables
      contextRef="c11"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="c11"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:ProceedsFromAmountDueFromASPACI
      contextRef="c12"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:ProceedsFromAmountDueFromASPACI
      contextRef="c13"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="c11"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c12"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c13"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:PaymentofInterest
      contextRef="c12"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:PaymentofInterest
      contextRef="c13"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c11"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c2" id="hidden-fact-108">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c108"
      id="hidden-fact-109"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c115"
      id="hidden-fact-110"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="c3"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c3"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment
      contextRef="c11"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c11"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c11"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c12"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="c2"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="c3"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="c174"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c176"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueDirectorsRemuneration
      contextRef="c180"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c193"
      decimals="0"
      id="hidden-fact-122"
      unitRef="kzt">1200000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c192"
      decimals="0"
      id="hidden-fact-123"
      unitRef="kzt">400000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SpecialAssessmentBond
      contextRef="c184"
      decimals="0"
      id="hidden-fact-124"
      unitRef="thb">750</us-gaap:SpecialAssessmentBond>
    <us-gaap:SpecialAssessmentBond
      contextRef="c2"
      decimals="0"
      id="hidden-fact-125"
      unitRef="thb">450</us-gaap:SpecialAssessmentBond>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c198"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c200"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c202"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c12"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c13"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c11"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c11"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c12"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c12"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c13"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="c11"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c3"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c3"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c157"
      decimals="-9"
      id="hidden-fact-143"
      unitRef="khr">1000000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c156"
      decimals="-9"
      id="hidden-fact-144"
      unitRef="khr">1000000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:Revenues
      contextRef="c211"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c212"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="c222"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="c223"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c2"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c3"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c37"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:DueToRelatedParties
      contextRef="c239"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:TransactionsWithRelatedParties
      contextRef="c247"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:TransactionsWithRelatedParties
      contextRef="c248"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c8" id="hidden-fact-155">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c299"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c143"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c8"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AllowancesForExpectedCreditLossReversalOfProvisionProvision
      contextRef="c0"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment
      contextRef="c0"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment
      contextRef="c301"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c0"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c14"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c2"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="c8"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c311"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable
      contextRef="c311"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="c312"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:IssuanceOfSharesAdditionalpaidincapital
      contextRef="c315"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="c316"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c328"
      decimals="0"
      id="hidden-fact-171"
      unitRef="kzt">1200000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c327"
      decimals="0"
      id="hidden-fact-172"
      unitRef="kzt">400000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SpecialAssessmentBond
      contextRef="c319"
      decimals="0"
      id="hidden-fact-173"
      unitRef="thb">750</us-gaap:SpecialAssessmentBond>
    <us-gaap:SpecialAssessmentBond
      contextRef="c8"
      decimals="0"
      id="hidden-fact-174"
      unitRef="thb">450</us-gaap:SpecialAssessmentBond>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c333"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c335"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c336"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c337"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c338"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c14"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c8"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c308"
      decimals="-9"
      id="hidden-fact-185"
      unitRef="khr">1000000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c307"
      decimals="-9"
      id="hidden-fact-186"
      unitRef="khr">6000000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:Revenues
      contextRef="c344"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="c8"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c8"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c353"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss
      contextRef="c2"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="c355"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c356"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="c8"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c0"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <nivf:AllowanceForExpectedCreditLossRevised
      contextRef="c301"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="c8"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-35515">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-35516">0001981662</dei:EntityCentralIndexKey>
    <nivf:PropertyPlantAndEquipmentEstimatedUsefulLive contextRef="c132" id="ixv-35517">the lesser of useful life or term of lease</nivf:PropertyPlantAndEquipmentEstimatedUsefulLive>
    <nivf:PropertyPlantAndEquipmentEstimatedUsefulLive contextRef="c291" id="ixv-35518">the lesser of useful life or term of lease</nivf:PropertyPlantAndEquipmentEstimatedUsefulLive>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-118"
          xlink:label="hidden-fact-118"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-118"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-167"
          xlink:label="hidden-fact-167"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-120"
          xlink:label="hidden-fact-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On January 18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald FAN and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-167"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-120"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-121"
          xlink:label="hidden-fact-121"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-121"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#x201c;FFC&#x201d;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-165"
          xlink:label="hidden-fact-165"
          xlink:type="locator"/>
        <link:footnote id="ix_11_footnote" xlink:label="ix_11_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-165"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-166"
          xlink:label="hidden-fact-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_12_footnote" xlink:label="ix_12_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#x201c;Seazen&#x201d;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-166"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-169"
          xlink:label="hidden-fact-169"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_13_footnote" xlink:label="ix_13_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-169"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898092432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEWGENIVF
GROUP LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment
No. 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001981662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1/F,
Pier 2, Central<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">HK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hong
Kong<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">999077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+1 (212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">537-4406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">122
East 42nd Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">947-7200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Cogency
Global Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">18th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898194256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,109<span></span>
</td>
<td class="nump">$ 54,104<span></span>
</td>
<td class="nump">$ 27,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">172,475<span></span>
</td>
<td class="nump">9,374<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">102,825<span></span>
</td>
<td class="nump">126,264<span></span>
</td>
<td class="nump">46,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits, prepayment and other receivables, net</a></td>
<td class="nump">703,897<span></span>
</td>
<td class="nump">517,429<span></span>
</td>
<td class="nump">70,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_LoanToASPAC', window );">Loan to A SPAC I</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from shareholders</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">354,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,163,306<span></span>
</td>
<td class="nump">1,201,456<span></span>
</td>
<td class="nump">2,398,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant and equipment, net</a></td>
<td class="nump">159,931<span></span>
</td>
<td class="nump">162,157<span></span>
</td>
<td class="nump">122,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">272,474<span></span>
</td>
<td class="nump">283,847<span></span>
</td>
<td class="nump">383,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,056<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Deposits, prepayment and other receivables, net</a></td>
<td class="nump">910<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">434,371<span></span>
</td>
<td class="nump">446,004<span></span>
</td>
<td class="nump">506,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,597,677<span></span>
</td>
<td class="nump">1,647,460<span></span>
</td>
<td class="nump">2,904,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,940,645<span></span>
</td>
<td class="nump">172,626<span></span>
</td>
<td class="nump">104,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">3,014,988<span></span>
</td>
<td class="nump">241,613<span></span>
</td>
<td class="nump">289,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">7,937<span></span>
</td>
<td class="nump">1,360,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">199,297<span></span>
</td>
<td class="nump">207,128<span></span>
</td>
<td class="nump">184,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,446<span></span>
</td>
<td class="nump">18,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">486,705<span></span>
</td>
<td class="nump">486,706<span></span>
</td>
<td class="nump">486,872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,490,430<span></span>
</td>
<td class="nump">1,122,456<span></span>
</td>
<td class="nump">2,555,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">114,096<span></span>
</td>
<td class="nump">118,979<span></span>
</td>
<td class="nump">242,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible promissory note</a></td>
<td class="nump">3,383,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,446<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">3,497,957<span></span>
</td>
<td class="nump">118,979<span></span>
</td>
<td class="nump">248,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,988,387<span></span>
</td>
<td class="nump">1,241,435<span></span>
</td>
<td class="nump">2,804,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="nump">101,494<span></span>
</td>
<td class="nump">6,981<span></span>
</td>
<td class="nump">6,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(7,473,791)<span></span>
</td>
<td class="num">(2,967,100)<span></span>
</td>
<td class="num">(319,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">57,821<span></span>
</td>
<td class="nump">4,324,834<span></span>
</td>
<td class="nump">1,458,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(857,894)<span></span>
</td>
<td class="num">(461,351)<span></span>
</td>
<td class="num">(591,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="nump">193,265<span></span>
</td>
<td class="num">(7,288)<span></span>
</td>
<td class="nump">9,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to the shareholders of the Company</a></td>
<td class="num">(7,979,105)<span></span>
</td>
<td class="nump">896,076<span></span>
</td>
<td class="nump">563,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(411,605)<span></span>
</td>
<td class="num">(490,051)<span></span>
</td>
<td class="num">(462,430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="num">(8,390,710)<span></span>
</td>
<td class="nump">406,025<span></span>
</td>
<td class="nump">100,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">1,597,677<span></span>
</td>
<td class="nump">1,647,460<span></span>
</td>
<td class="nump">2,904,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,285<span></span>
</td>
<td class="nump">2,240,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToShareholders', window );">Due to shareholders</a></td>
<td class="nump">762,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to a related party</a></td>
<td class="nump">$ 48,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 110,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of due to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_LoanToASPAC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of loans to ASPAC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_LoanToASPAC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899012912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">10,149,386<span></span>
</td>
<td class="nump">698,123<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares ,shares outstanding</a></td>
<td class="nump">10,149,386<span></span>
</td>
<td class="nump">698,123<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897850768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,686,902<span></span>
</td>
<td class="nump">$ 2,138,622<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="nump">$ 4,118,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="num">(2,047,970)<span></span>
</td>
<td class="num">(1,205,940)<span></span>
</td>
<td class="num">(3,454,368)<span></span>
</td>
<td class="num">(4,406,421)<span></span>
</td>
<td class="num">(3,093,340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">638,932<span></span>
</td>
<td class="nump">932,682<span></span>
</td>
<td class="nump">1,681,785<span></span>
</td>
<td class="nump">1,537,769<span></span>
</td>
<td class="nump">1,024,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="num">(56,732)<span></span>
</td>
<td class="num">(2,887)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
<td class="num">(36,194)<span></span>
</td>
<td class="num">(24,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(869,886)<span></span>
</td>
<td class="num">(1,223,284)<span></span>
</td>
<td class="num">(1,259,364)<span></span>
</td>
<td class="num">(1,094,962)<span></span>
</td>
<td class="num">(801,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Audit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(362,149)<span></span>
</td>
<td class="num">(7,908)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(926,618)<span></span>
</td>
<td class="num">(1,266,171)<span></span>
</td>
<td class="num">(1,639,543)<span></span>
</td>
<td class="num">(1,139,064)<span></span>
</td>
<td class="num">(826,022)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(287,686)<span></span>
</td>
<td class="num">(293,489)<span></span>
</td>
<td class="nump">42,242<span></span>
</td>
<td class="nump">398,705<span></span>
</td>
<td class="nump">198,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expenses), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income, net</a></td>
<td class="nump">7,146<span></span>
</td>
<td class="nump">8,528<span></span>
</td>
<td class="nump">111,837<span></span>
</td>
<td class="nump">23,019<span></span>
</td>
<td class="nump">45,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">12,921<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Interest expense</a></td>
<td class="num">(120,162)<span></span>
</td>
<td class="num">(10,463)<span></span>
</td>
<td class="num">(46,179)<span></span>
</td>
<td class="num">(77,757)<span></span>
</td>
<td class="num">(88,289)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="num">(100,095)<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="nump">66,176<span></span>
</td>
<td class="num">(54,717)<span></span>
</td>
<td class="num">(42,574)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="num">(387,781)<span></span>
</td>
<td class="num">(295,060)<span></span>
</td>
<td class="nump">108,418<span></span>
</td>
<td class="nump">343,988<span></span>
</td>
<td class="nump">156,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(83,727)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(208,141)<span></span>
</td>
<td class="num">(294,716)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(387,781)<span></span>
</td>
<td class="num">(378,787)<span></span>
</td>
<td class="nump">108,418<span></span>
</td>
<td class="nump">135,847<span></span>
</td>
<td class="num">(138,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to non-controlling interests</a></td>
<td class="num">(8,762)<span></span>
</td>
<td class="nump">70,890<span></span>
</td>
<td class="num">(21,775)<span></span>
</td>
<td class="num">(322,820)<span></span>
</td>
<td class="num">(137,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to the shareholders of the Company</a></td>
<td class="num">(396,543)<span></span>
</td>
<td class="num">(307,897)<span></span>
</td>
<td class="nump">130,193<span></span>
</td>
<td class="nump">458,667<span></span>
</td>
<td class="num">(533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">270,236<span></span>
</td>
<td class="nump">37,894<span></span>
</td>
<td class="num">(22,704)<span></span>
</td>
<td class="num">(1,920)<span></span>
</td>
<td class="nump">7,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Total comprehensive income (loss)</a></td>
<td class="num">(117,545)<span></span>
</td>
<td class="num">(340,893)<span></span>
</td>
<td class="nump">85,714<span></span>
</td>
<td class="nump">133,927<span></span>
</td>
<td class="num">(130,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest', window );">Less: total comprehensive loss attributable to non-controlling interests</a></td>
<td class="nump">78,445<span></span>
</td>
<td class="num">(61,211)<span></span>
</td>
<td class="num">(27,621)<span></span>
</td>
<td class="num">(323,458)<span></span>
</td>
<td class="num">(136,396)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to the shareholders of the Company</a></td>
<td class="num">$ (195,990)<span></span>
</td>
<td class="nump">$ 279,682<span></span>
</td>
<td class="nump">$ 113,335<span></span>
</td>
<td class="nump">$ 457,385<span></span>
</td>
<td class="nump">$ 5,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earning per share &#8211; basic (in Dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earning per share &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (in Shares)</a></td>
<td class="nump">10,149,386<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
<td class="nump">615,135<span></span>
</td>
<td class="nump">575,930<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in Shares)</a></td>
<td class="nump">10,149,386<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
<td class="nump">615,135<span></span>
</td>
<td class="nump">575,930<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818892706592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Subscription receivable</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income/(loss)</div></th>
<th class="th"><div>Total attributable to the shareholders of the Company</div></th>
<th class="th"><div>Non- controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 57,821<span></span>
</td>
<td class="num">$ (1,049,678)<span></span>
</td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="num">$ (981,553)<span></span>
</td>
<td class="num">$ (2,576)<span></span>
</td>
<td class="num">$ (984,129)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="num">(137,999)<span></span>
</td>
<td class="num">(138,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,148<span></span>
</td>
<td class="nump">6,148<span></span>
</td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">7,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueDirectorsRemuneration', window );">Directors&#8217; remuneration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">257,821<span></span>
</td>
<td class="num">(1,050,211)<span></span>
</td>
<td class="nump">10,852<span></span>
</td>
<td class="num">(775,938)<span></span>
</td>
<td class="num">(138,972)<span></span>
</td>
<td class="num">(914,910)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">458,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">458,667<span></span>
</td>
<td class="num">(322,820)<span></span>
</td>
<td class="nump">135,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
<td class="num">(1,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueDirectorsRemuneration', window );">Directors&#8217; remuneration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="num">(319,872)<span></span>
</td>
<td class="nump">961,120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">641,666<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">641,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">41,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 6,018<span></span>
</td>
<td class="num">(319,872)<span></span>
</td>
<td class="nump">1,458,941<span></span>
</td>
<td class="num">(591,544)<span></span>
</td>
<td class="nump">9,570<span></span>
</td>
<td class="nump">563,113<span></span>
</td>
<td class="num">(462,430)<span></span>
</td>
<td class="nump">$ 100,683<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">601,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(307,897)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(307,897)<span></span>
</td>
<td class="num">(70,890)<span></span>
</td>
<td class="num">$ (378,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,215<span></span>
</td>
<td class="nump">28,215<span></span>
</td>
<td class="nump">9,679<span></span>
</td>
<td class="nump">37,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Subscription receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">192,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">192,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">192,308<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 6,018<span></span>
</td>
<td class="num">(127,564)<span></span>
</td>
<td class="nump">1,458,941<span></span>
</td>
<td class="num">(899,441)<span></span>
</td>
<td class="nump">37,785<span></span>
</td>
<td class="num">(475,739)<span></span>
</td>
<td class="num">(523,641)<span></span>
</td>
<td class="num">(47,902)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">601,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 6,018<span></span>
</td>
<td class="num">(319,872)<span></span>
</td>
<td class="nump">1,458,941<span></span>
</td>
<td class="num">(591,544)<span></span>
</td>
<td class="nump">9,570<span></span>
</td>
<td class="nump">563,113<span></span>
</td>
<td class="num">(462,430)<span></span>
</td>
<td class="nump">$ 100,683<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">601,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130,193<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130,193<span></span>
</td>
<td class="num">(21,775)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,858)<span></span>
</td>
<td class="num">(16,858)<span></span>
</td>
<td class="num">(5,846)<span></span>
</td>
<td class="num">(22,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Subscription receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">219,628<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">219,628<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">219,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="num">(2,866,856)<span></span>
</td>
<td class="nump">2,865,893<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">96,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 6,981<span></span>
</td>
<td class="num">(2,967,100)<span></span>
</td>
<td class="nump">4,324,834<span></span>
</td>
<td class="num">(461,351)<span></span>
</td>
<td class="num">(7,288)<span></span>
</td>
<td class="nump">896,076<span></span>
</td>
<td class="num">(490,051)<span></span>
</td>
<td class="nump">$ 406,025<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">698,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,123<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 6,018<span></span>
</td>
<td class="num">(127,564)<span></span>
</td>
<td class="nump">1,458,941<span></span>
</td>
<td class="num">(899,441)<span></span>
</td>
<td class="nump">37,785<span></span>
</td>
<td class="num">(475,739)<span></span>
</td>
<td class="num">(523,641)<span></span>
</td>
<td class="num">$ (47,902)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">601,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 6,981<span></span>
</td>
<td class="num">(2,967,100)<span></span>
</td>
<td class="nump">4,324,834<span></span>
</td>
<td class="num">(461,351)<span></span>
</td>
<td class="num">(7,288)<span></span>
</td>
<td class="nump">896,076<span></span>
</td>
<td class="num">(490,051)<span></span>
</td>
<td class="nump">$ 406,025<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">698,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(396,543)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(396,543)<span></span>
</td>
<td class="nump">8,762<span></span>
</td>
<td class="num">$ (387,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">191,791<span></span>
</td>
<td class="nump">191,791<span></span>
</td>
<td class="nump">78,445<span></span>
</td>
<td class="nump">270,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Business combination</a></td>
<td class="nump">$ 94,513<span></span>
</td>
<td class="num">(4,506,691)<span></span>
</td>
<td class="num">(4,267,013)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,762<span></span>
</td>
<td class="num">(8,670,429)<span></span>
</td>
<td class="num">(8,761)<span></span>
</td>
<td class="num">(8,679,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Business combination (in Shares)</a></td>
<td class="nump">9,451,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 101,494<span></span>
</td>
<td class="num">$ (7,473,791)<span></span>
</td>
<td class="nump">$ 57,821<span></span>
</td>
<td class="num">$ (857,894)<span></span>
</td>
<td class="nump">$ 193,265<span></span>
</td>
<td class="num">$ (7,979,105)<span></span>
</td>
<td class="num">$ (411,605)<span></span>
</td>
<td class="num">$ (8,390,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">10,149,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueDirectorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period to directors&#8217; remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueDirectorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to settlement of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897979568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (387,781)<span></span>
</td>
<td class="num">$ (378,787)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
<td class="nump">$ 135,847<span></span>
</td>
<td class="num">$ (138,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of plant and equipment</a></td>
<td class="nump">12,619<span></span>
</td>
<td class="nump">19,461<span></span>
</td>
<td class="nump">31,173<span></span>
</td>
<td class="nump">100,533<span></span>
</td>
<td class="nump">166,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">84,731<span></span>
</td>
<td class="nump">198,535<span></span>
</td>
<td class="nump">203,411<span></span>
</td>
<td class="nump">175,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">114,013<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Provision of expected credit loss allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">10,777<span></span>
</td>
<td class="nump">6,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,179<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_WaiverOfRelatedPartyBalance', window );">Waiver of related party balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Directors&#8217; remuneration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,320<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeTaxExpense', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">208,141<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(165,568)<span></span>
</td>
<td class="num">(81,515)<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">129,922<span></span>
</td>
<td class="nump">56,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">22,128<span></span>
</td>
<td class="num">(22,451)<span></span>
</td>
<td class="num">(80,665)<span></span>
</td>
<td class="num">(7,219)<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Loan to A SPAC I</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="num">(140,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Deposit, prepayment and other receivables, net</a></td>
<td class="nump">25,137<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Deposit and other receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(448,266)<span></span>
</td>
<td class="num">(15,197)<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,771,406<span></span>
</td>
<td class="nump">51,054<span></span>
</td>
<td class="nump">71,362<span></span>
</td>
<td class="nump">58,752<span></span>
</td>
<td class="num">(60,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="nump">2,770,371<span></span>
</td>
<td class="nump">19,681<span></span>
</td>
<td class="num">(51,167)<span></span>
</td>
<td class="nump">190,689<span></span>
</td>
<td class="nump">79,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">29,655<span></span>
</td>
<td class="num">(1,250,900)<span></span>
</td>
<td class="num">(1,352,231)<span></span>
</td>
<td class="nump">548,010<span></span>
</td>
<td class="nump">812,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(12,714)<span></span>
</td>
<td class="num">(89,702)<span></span>
</td>
<td class="num">(230,433)<span></span>
</td>
<td class="num">(175,132)<span></span>
</td>
<td class="num">(148,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinanceReceivables', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,476)<span></span>
</td>
<td class="num">(19,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,170)<span></span>
</td>
<td class="nump">290,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="nump">4,209,695<span></span>
</td>
<td class="num">(1,702,849)<span></span>
</td>
<td class="num">(1,766,135)<span></span>
</td>
<td class="nump">1,710,901<span></span>
</td>
<td class="nump">1,433,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of plant and equipment</a></td>
<td class="num">(10,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,848)<span></span>
</td>
<td class="num">(94,452)<span></span>
</td>
<td class="num">(16,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(1,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(11,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,848)<span></span>
</td>
<td class="num">(94,452)<span></span>
</td>
<td class="num">(16,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProceedsFromAmountDueFromASPACI', window );">Amount due from A SPAC I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease</a></td>
<td class="num">(6,446)<span></span>
</td>
<td class="num">(9,317)<span></span>
</td>
<td class="num">(9,317)<span></span>
</td>
<td class="num">(19,476)<span></span>
</td>
<td class="num">(17,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Other borrowings, net</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">128,204<span></span>
</td>
<td class="nump">512,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PaymentofInterest', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,704)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Amount with related parties</a></td>
<td class="nump">605,489<span></span>
</td>
<td class="nump">1,530,872<span></span>
</td>
<td class="nump">1,863,206<span></span>
</td>
<td class="num">(1,742,509)<span></span>
</td>
<td class="num">(2,039,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubscriptionReceivables', window );">Subscription receivables</a></td>
<td class="num">(8,892,956)<span></span>
</td>
<td class="nump">192,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="nump">3,380,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="num">(4,352,923)<span></span>
</td>
<td class="nump">1,713,863<span></span>
</td>
<td class="nump">1,881,493<span></span>
</td>
<td class="num">(1,633,781)<span></span>
</td>
<td class="num">(1,544,369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="num">(154,677)<span></span>
</td>
<td class="nump">11,014<span></span>
</td>
<td class="nump">45,510<span></span>
</td>
<td class="num">(17,332)<span></span>
</td>
<td class="num">(127,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency translation on cash and cash equivalents</a></td>
<td class="nump">284,681<span></span>
</td>
<td class="nump">38,724<span></span>
</td>
<td class="num">(18,962)<span></span>
</td>
<td class="nump">16,124<span></span>
</td>
<td class="nump">50,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">54,104<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
<td class="nump">106,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">184,109<span></span>
</td>
<td class="nump">77,294<span></span>
</td>
<td class="nump">54,104<span></span>
</td>
<td class="nump">27,556<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplementary cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,170)<span></span>
</td>
<td class="num">(3,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">$ (120,162)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">$ (24,704)<span></span>
</td>
<td class="num">$ (55,469)<span></span>
</td>
<td class="num">$ (65,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Listing fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PaymentofInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow during the period as interest paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PaymentofInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProceedsFromAmountDueFromASPACI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to A SPAC I.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProceedsFromAmountDueFromASPACI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SubscriptionReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SubscriptionReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_WaiverOfRelatedPartyBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiver of related party balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_WaiverOfRelatedPartyBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinanceReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in outstanding loans including accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinanceReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898996304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND PRINCIPAL ACTIVITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited (the &#8220;Company&#8221;
or the &#8220;Group&#8221;) was incorporated under the laws of the Cayman Islands on January&#160;16, 2019 as an investment holding company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is an organization chart of the
Company and its subsidiaries:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<img alt="" src="fin_002.jpg" style="width: 650px; height: 355px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June&#160;30, 2024, the Company&#8217;s
subsidiaries are detailed in the table as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 22%; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company<br/> &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company<br/> &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to the Foreign
Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required to be owned
by Thai nationals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With reference to the capital
structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;) of Med Holdings and
FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have the same rights and
status in all respects except for the distribution of profits by way of dividends with details as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After allocation of dividends
    as per (a)&#160;above, the rest of the dividends shall be distributed equally amongst the holders of ordinary shares according to
    their shareholding ratio;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of preferred
    shares shall be entitled to dividends only in respect of the&#160;years for which the Company has declared a dividend payment, and
    there shall be no cumulative dividends; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends allocated to
    the holders of preferred shares in each year shall be limited at the rate as stated in (a)&#160;only. No additional dividends shall
    be paid to the holders of preferred shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based upon the management&#8217;s
judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board meeting, the Company accounts
for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings and FFC by exercising its majority
voting power in any board meetings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Group reorganization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to a group reorganization
(the &#8220;group reorganization&#8221;) to rationalize the structure of the Company and its subsidiary companies (herein collectively
referred to as the &#8220;Group&#8221;) in preparation for the listing of its shares, the Company becomes the holding company of the
Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests were also
ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and comprehensive
income, consolidated statements of changes in shareholders&#8217; equity and consolidated statements of cash flows are prepared as if
the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023, or since the respective
dates of incorporation/establishment of the relevant entity, where this is a shorter period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited condensed
consolidated balance sheets as of June&#160;30, 2024 and 2023 present the assets and liabilities of the aforementioned companies now
comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The movement in the Company&#8217;s
authorized share capital and the number of ordinary shares outstanding and issued in the Company are also detailed in Note&#160;10.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 1 &#8212;&#160;ORGANIZATION
AND PRINCIPAL ACTIVITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">NewGenIvf
Limited (the &#8220;Company&#8221; or the &#8220;Group&#8221;) was incorporated under the laws of the Cayman Islands on January&#160;16,
2019 as an investment holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
following is an organization chart of the Company and its subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><img alt="" src="fin_001.jpg"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023, the Company&#8217;s subsidiaries are detailed in the table as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 22%; padding-right: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 23%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">Note:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">According
to the Foreign Business Act (the &#8220;FBA&#8221;), the majority shareholdings of limited company incorporated in Thailand is required
to be owned by Thai nationals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">With
reference to the capital structure and voting rights structure of ordinary shares and preference shares (the &#8220;Share Structure&#8221;)
of Med Holdings and FFC, all the preference share capital is owned by a Thai national. The ordinary shares and preference shares have
the same rights and status in all respects except for the distribution of profits by way of dividends with details as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Dividends from profits of Med Holdings and FFC shall be allocated to the holders of preference shares at a rate fixed from time to time by the board of directors prior to allocating to the holders of ordinary shares. In any event, such dividends to be allocated to the holders of preference shares shall not exceed 15% of the total amount of dividends declared from time to time;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">After
                                            allocation of dividends as per (a)&#160;above, the rest of the dividends shall be distributed
                                            equally amongst the holders of ordinary shares according to their shareholding ratio;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            holders of preferred shares shall be entitled to dividends only in respect of the&#160;years
                                            for which the Company has declared a dividend payment, and there shall be no cumulative dividends;
                                            and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(d)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Dividends
                                            allocated to the holders of preferred shares in each year shall be limited at the rate as
                                            stated in (a)&#160;only. No additional dividends shall be paid to the holders of preferred
                                            shares.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Based
upon the management&#8217;s judgement on the Shares Structure, as the Company is able to exercise majority voting power in any board
meeting, the Company accounts for Med Holdings and FFC as subsidiaries on the ground that the Company is able to control Med Holdings
and FFC by exercising its majority voting power in any board meetings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Group reorganization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Pursuant
to a group reorganization (the &#8220;group reorganization&#8221;) to rationalize the structure of the Company and its subsidiary companies
(herein collectively referred to as the &#8220;Group&#8221;) in preparation for the listing of its shares, the Company becomes the holding
company of the Group on February&#160;2, 2023. As the Group were under same control of the shareholders and their entire equity interests
were also ultimately held by the shareholders immediately prior to the group reorganization, the consolidated statements of income and
comprehensive income, consolidated statements of changes in shareholders&#8217; equity and consolidated statements of cash flows are
prepared as if the current group structure had been in existence throughout the three-year&#160;period ended December&#160;31, 2023,
or since the respective dates of incorporation/establishment of the relevant entity, where this is a shorter period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
consolidated balance sheets as of December&#160;31, 2023 and 2022 present the assets and liabilities of the aforementioned companies
now comprising the Group which had been incorporated/established as of the relevant balance sheet date as if the current group structure
had been in existence at those dates based on the same control aforementioned. The Company eliminates all significant intercompany balances
and transactions in its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
movement in the Company&#8217;s authorized share capital and the number of ordinary shares outstanding and issued in the Company are
also detailed in Note&#160;10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December&#160;31,
2023, the Company had bank balance of $54,104 and may have challenge to settle its obligations when payment become due. The Company is
always closely monitoring the market opportunities and is currently in the process of exercising various fundraising projects with various
potential investors to improve the Company&#8217;s cash flow position for its operation and short-term payables. One fundraising project
was completed on April 3, 2024. As of April 4, 2024, the Company settled $2 million to any payment with respect to accounts payable,
but not, directly or indirectly, for (i) except for expenses relating to the Business Combination, the satisfaction of any indebtedness
of the Company or any of its Subsidiaries, (ii) the redemption or repurchase of any securities of the Company or any of its Subsidiaries,
or (iii) the settlement of any outstanding litigation as at December 31, 2023. The Company secured funding subsequent to year-end with
total of $2 million, and that the Company received $2 million funding to date. Please refer to <i>Note 20 &#8211; Subsequent Events</i>
for further information. The Company can make no assurance that required financings will be available for the amounts needed, or on terms
commercially acceptable to the Company, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient
to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Company and its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899299072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared
the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the
United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant estimates required to be made by management
include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ from those estimates, and as such,
differences may be material to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited uses Cambodian
riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States dollar (&#8220;USD&#8221;)
as its functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations and comprehensive income
as other comprehensive income or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.8454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.3081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.4021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3864</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,112.3016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132.8226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,080.0304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,075.4046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,058.1179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,105.4181</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, prepayment, other receivables and
deferred IPO cost, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, prepayment, other
receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers, prepaid
expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Plant and equipment, net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are
stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete
inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes the basis
for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory would not
be reversed if market conditions improve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received, net of issuance cost,
and the par value is recorded in additional paid-in&#160;capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC
Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts
    with customers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance
    obligations under those contracts;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction
    prices of those contracts;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction
    prices to its performance obligations in those contracts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-indent: -24.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when
    each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the
    client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into
service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties. All the contracts have
commercial substance, and it is probable that the Company will collect considerations from its customers for service component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its
revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. The Company collects payment from customer in advance for IVF treatment.
The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can be found in Note&#160;8 below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company.
During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins, supplements
and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where a baby is born,
therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother gives birth. The
Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across pregnancy
period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can
be found in Note&#160;8 below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets
and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of
credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due
to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective
interest rate of the financial asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources and assess performance.
The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing Fund Alfred, the Company&#8217;s
Chief Executive Officer. Since the Company operates in one operating segment, all required financial segment information can be found
in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers as of June 30, 2024 and 2023
by geographical area are presented in Note&#160;13.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-155">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, there were $272,474 and $ 283,847 million&#160;right of use (&#8220;ROU&#8221;) assets and $313,393 and $326,107
lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s management
believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#8220;BLR&#8221;)
minus 0.125%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present value of the
lease payments; the rate used by the Company was 6.6% and 5.0% respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the
differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not
realizable or recoverable in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions
in income tax expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or
loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents
the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and
or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive
effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those
that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive
securities that were in-the-money&#160;that were outstanding during the six months ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of
business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to
a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency
if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and two customers which individually contributed more than 10% of trade receivable, accounted for 15% and
96.3% of the Company&#8217;s trade receivable respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&#160;six months ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and four suppliers which individually contributed more than 10% of trade payable, accounted for 13.6% and
30.6% of the Company&#8217;s trade payable respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the six months ended
June 30, 2024 and 2023, one and one vendors which contributed more than 10% of total purchases of the Company, accounted for 15.3% and
21.5% of the Company&#8217;s total purchases respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net,
loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that
approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221;
requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221;
defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents,
accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify
as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such
instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs
    to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are
    observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements adopted </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2019, the FASB
issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,
and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB issued ASU 2019-05,
Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair value option to
be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until December 15,
2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected
credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial
asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets
measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures
such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected
to be collected by using an allowance for expected credit losses. The Company already adopted the new standard and the Company recognizes
the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements not yet adopted</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November 2023, the FASB
issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in ASU 2023-07 improve financial
reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable
investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit
or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources.
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed
under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure requirements. The amendments in ASU
2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December
15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that
the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2023, FASB issued
Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU 2023-09&#8221;). The amendments
in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure
of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations,
to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income
tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain
categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an
annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions,
including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to
or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods
beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update
on the Company&#8217;s consolidated financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 2 &#8212;&#160;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Principles of consolidation
and basis of preparation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company&#160;balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Management
has prepared the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted
in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Use of estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates
required to be made by management include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ
from those estimates, and as such, differences may be material to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Foreign currency
translation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency
of the Company. The functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong
dollar (&#8220;HK$&#8221;). Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom
Penh Limited uses Cambodian riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States
dollar (&#8220;USD&#8221;) as its functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial
condition in terms of reporting in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.2265</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.6153</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">33.1964</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.7867</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">35.1428</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">32.1003</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,080.0304</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,114.3335</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,068.9577</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,105.4181</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,083.7043</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,065.8164</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0971</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.9091</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.3551</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0835</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4569</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4368</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Cash and cash equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original
maturities of three&#160;months or less that are readily convertible to known amounts of cash and which are subject to an insignificant
risk of changes in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Deposits, prepayment,
other receivables and deferred IPO cost, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers,
prepaid expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deferred
IPO costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the Initial Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Plant and equipment,
net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Plant
and equipment are stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the
straight-line&#160;method. The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 25%; padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss
are included in the Company&#8217;s results of operations. The costs of maintenance and repairs are expensed as incurred. Significant
renewals and betterments that extend the useful life of an assets are capitalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company evaluates the long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of assets may not be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies,
or if the Company has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present
if the carrying amount of an asset is less than its expected future undiscounted cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">If
an asset is considered impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value
of the asset. Assets to be disposed of are reported lower the carrying amount or fair value less cost to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Inventories</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Inventories
are stated at the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value
is based on the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and
obsolete inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes
the basis for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory
would not be reversed if market conditions improve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Other borrowings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Other
borrowings are recognized initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized
cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements
of operations over the period of the borrowings using the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Ordinary shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s ordinary shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received,
net of issuance cost, and the par value is recorded in additional paid-in&#160;capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenue recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606
had been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its contracts with customers;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its performance obligations under those contracts;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine
                                            the transaction prices of those contracts;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate
                                            the transaction prices to its performance obligations in those contracts; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.2pt; text-align: left; text-indent: -24.1pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize
                                            revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
                                            when promised services are transferred to the client in an amount that reflects the consideration
                                            expected in exchange for those services.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The
agreements also identify the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties.
All the contracts have commercial substance, and it is probable that the Company will collect considerations from its customers for service
component.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company derives its revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary
caring services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
IVF treatment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized
in laboratory to become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the
performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to customer when
embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation. The Company collects
payment from customer in advance for IVF treatment. The amount of revenue recognized from contract liabilities to the Company&#8217;s
result of operations can be found in Note&#160;8 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
surrogacy and ancillary caring services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother
contracted by the Company. During pregnancy period, the Company provides ancillary caring services including regular body check and provision
of vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result
of operations can be found in Note&#160;8 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
related assets and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to
the revenue cycle are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Account receivables,
net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable, net are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected
credit loss is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the
accounts receivable balances, current general economic conditions, future expectations and customer specific quantitative and qualitative
factors that may affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence
for the Company to reasonably estimate the amount of probable loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Contract liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
liabilities represent considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under
the contract. These amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Expected
credit loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">ASU
No.&#160;2016-13, Financial Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments
requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using
this methodology will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to
recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments
of other financial assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates
of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows
due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the
effective interest rate of the financial asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Retirement benefits</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Retirement
benefits in the form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated
to wages as part of cost of revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Segment information</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources
and assess performance. The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing
Fund Alfred, the Company&#8217;s Chief Executive Officer. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers
as of December&#160;31, 2023, 2022 and 2021 by geographical area are presented in Note&#160;13.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company measured the lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the
present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not
have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life
of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease
exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-108">twelve</span>&#160;months or less.
Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense
is recognized on a straight-line&#160;basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2023 and 2022, there were $283,847 and $383,670&#160;million right of use (&#8220;ROU&#8221;) assets and $326,107
and $426,838 lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s
management believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate
(&#8220;BLR&#8221;) minus 0.125%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present
value of the lease payments; the rate used by the Company was 6.6% and 5.0% respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company recognizes deferred income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated
financial statements or tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences
between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will
be in effect when the differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred
tax asset is not realizable or recoverable in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company determines that the tax position is more likely than not to be sustained and records the largest amount of benefit that is more
likely than not to be realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain
tax positions in income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Comprehensive Income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company presents comprehensive income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states
that all items that are required to be recognized under accounting standards as components of comprehensive income be reported in the
consolidated financial statements. The components of comprehensive income were the net income for the&#160;years and the foreign currency
translation adjustments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Earnings per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is
measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period.
Diluted EPS presents the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise
of options and or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the
potentially dilutive effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities
(i.e., those that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially
dilutive securities that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Related parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC&#160;850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Commitments and
contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such
contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments including historical and the specific facts and circumstances of each matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Non-controlling&#160;interests</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Concentration of
risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
credit risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable.
The Company places cash and cash equivalents with financial institutions with high credit ratings and quality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable primarily comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers,
and generally does not require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts
primarily based upon the factors surrounding the credit risk of specific customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
customers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, two and Nil customers which individually contributed more than 10% of trade receivable, accounted
for 96.3% and <span style="-sec-ix-hidden: hidden-fact-109">Nil</span> of the Company&#8217;s trade receivable respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">None
of the customers contributed more than 10% of revenue for&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Concentration
of suppliers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, one and four suppliers which individually contributed more than 10% of trade payable, accounted for
30.6% and 69.8% of the Company&#8217;s trade payable respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">For
the year ended December&#160;31, 2023, 2022 and 2021, Nil, two and two vendors which contributed more than 10% of total purchases of
the Company, accounted for <span style="-sec-ix-hidden: hidden-fact-110">Nil</span>, 55.3% and 35.6% of the Company&#8217;s total purchases respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Financial instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and
deferred IPO cost, net, loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders,
have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements
and Disclosures&#8221; requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial
Instruments&#8221; defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash
and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related
parties each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation
hierarchy are defined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical
                                            assets or liabilities in active markets.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar
                                            assets and liabilities in active markets and information that are observable for the asset
                                            or liability, either directly or indirectly, for substantially the financial instrument&#8217;s
                                            full term</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant
                                            to the fair value measurement.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities
from Equity&#8221; and ASC&#160;815.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements adopted </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements not yet adopted</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in
ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for
all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report
a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions
about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and
depletion expense, to be disclosed under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure
requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective
for years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively.
Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
December 2023, FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements
to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU
2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit)
from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable
statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling
items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires
disclosure of, on an annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state,
and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual
jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective
for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact
of the update on the Company&#8217;s consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Save
for elsewhere disclosed, the Company does not believe other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income
(loss) and statement of cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899725040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAdditionalImprovementsAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNontradeReceivableTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 3 &#8212;&#160;ACCOUNTS RECEIVABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accounts receivable, net consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">172,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,475</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">172,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,374</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,475</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(26</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal (provision) of provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 3 &#8212;&#160;ACCOUNTS
RECEIVABLE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accounts receivable</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">9,393</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">13,026</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: allowance for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(19</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">As
of the end of each of the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based
on the invoice date is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Within 90&#160;days</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(286</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of expected credit losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(19</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNontradeReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/326/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNontradeReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAdditionalImprovementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAdditionalImprovementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899699408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;INVENTORIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Inventories consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">102,825</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">126,264</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,825</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">126,264</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 4 &#8212;&#160;INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Inventories
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Medicines, consumables and reagents for clinical and laboratory
    analyses</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">126,264</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">46,910</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">126,264</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">46,910</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899689328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract', window );"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;DEPOSITS, PREPAYMENT, OTHER RECEIVABLES
AND DEFERRED IPO COST, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">359,035</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Prepayment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,848</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">703,897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">517,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(141</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal of provision (Provision)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 5 &#8212;&#160;DEPOSITS,
PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred IPO cost, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Other receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">15,910</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">30,295</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deposits</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">123,008</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">40,131</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Prepayment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,848</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deferred initial public offering &#8220;IPO&#8221;
    cost</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">373,677</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: allowance for expected
    credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">517,429</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">70,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(115</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of provision (Provision)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">127</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(30</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Effect of currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898830544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;PLANT AND EQUIPMENT, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Plant and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">765,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,809</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,379,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,219,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,319,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">159,931</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">162,157</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation expenses for the&#160;six
months ended June 30, 2024 and 2023 were $12,619 and $19,461, respectively. No loss on disposal of assets for the six months ended June
30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-hidden: hidden-fact-163">No</span></span> impairment loss was recorded for the&#160;six
months ended June&#160;30, 2024, and 2023.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 6 &#8212;&#160;PLANT
AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Plant
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">At cost:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Building improvement</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">92,438</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">72,519</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Furniture and fixtures</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">250,493</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">246,682</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Medical instruments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">844,809</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">791,514</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">142,936</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">142,936</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">150,688</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">146,432</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,481,364</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,400,083</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,319,207</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,277,410</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">162,157</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">122,673</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Depreciation
expenses for the&#160;years ended December&#160;31, 2023 and 2022 were $31,173 and $100,533, respectively. Loss on disposal of assets
for the year ended December&#160;31, 2023 and 2022 was $<span style="-sec-ix-hidden: hidden-fact-114">Nil</span> and $114,013, respectively, due to moving of clinic to new location in First
Fertility PGS Center Limited in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-hidden: hidden-fact-116">No</span></span>
impairment loss was recorded for the&#160;years ended December&#160;31, 2023, and 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899749952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilties and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILTIES AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;ACCRUED LIABILTIES AND OTHER PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities and other payables consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">183,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,633</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued legal and professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,699,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">--</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315,696</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,613</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 7 &#8212;&#160;ACCRUED
LIABILTIES AND OTHER PAYABLES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Accrued
liabilities and other payables consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accrued expenses</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">43,633</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">22,345</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Other tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,180</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Withholding tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7,349</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">82,240</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Compensation payable (Note&#160;1)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">144,015</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">117,935</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">46,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">64,077</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">241,613</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">289,777</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898974096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilitiesAbstract', window );"><strong>Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">CONTRACT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;CONTRACT LIABILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Contract liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,360,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,006</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Recognized to revenue during the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,937</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,341,575</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">37,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,937</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 8 &#8212;&#160;CONTRACT
LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Contract
liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">812,158</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Additions</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">112,006</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Recognized to revenue during the
    year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(122,662</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(812,158</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Refund
    to customers (Note 1)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,341,575</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at
    end of year</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">7,937</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818900018144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has various
operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The Company&#8217;s management
believes that the interest rate of 6.6% and 5% was the most indicative rate of the Company&#8217;s borrowing cost for the calculation
of the present value of the lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024 and December 31, 2023, the
right-of-use&#160;assets totaled $272,474 and $296,742, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June&#160;30, 2024 and December 31,2023,
lease liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,297</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">207,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">326,107</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other lease information is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.67years</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.92years</td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,009</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">114,937</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a schedule
of future minimum payments under operating leases as of June 30, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,654</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,079</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Between 2 to 3&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,751</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities, net
    of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 9 &#8212;&#160;LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has various operating leases for clinics and office spaces. The lease agreements do not specify an explicit interest rate. The
Company&#8217;s management believes that the interest rate of 6.6% and 5% was the most indicative rate of the Company&#8217;s borrowing
cost for the calculation of the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, the right-of-use&#160;assets totaled $283,847, and $383,670, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, lease liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;current
    portion</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">207,128</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">184,651</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">118,979</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">242,187</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">326,107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">426,838</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">Other
lease information is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Short term lease cost</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">114,937</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">89,380</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
following is a schedule of future minimum payments under operating leases as of December&#160;31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Not later than 1 year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">240,835</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between 1 to 2&#160;years</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">111,613</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between
    2 to 3&#160;years</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">10,373</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total lease payments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">362,821</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: imputed
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(36,714</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total operating
    lease liabilities, net of interest</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">326,107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899717680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Ordinary shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As at June&#160;30, 2024,
the Company is authorized to issue 5,000,000 ordinary shares. Each ordinary share is entitled to one vote. The holders of ordinary shares
are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 3, 2024, the Company
completed the business combination with A SPAC I Acquisition Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity of the Company
as of June&#160;30, 2024 and December 31, 2023 represents 10,149,386 and 698,123 ordinary shares amounting to $101,494 and $6,981, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Subscription receivables</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,967,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">319,872</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,866,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,506,691</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,473,791</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,967,100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional paid-in capital</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,324,834</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,458,941</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,865,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,267,013</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">57,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,324,834</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 10 &#8212;&#160;EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Ordinary shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
at December&#160;31, 2023, the Company is authorized to issue 5,000,000 ordinary shares. Each ordinary share is entitled to one vote.
The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
equity of the Company as of December&#160;31, 2023 and 2022 represents 698,123 and 601,830 ordinary shares amounting to $6,981 and $6,018,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Subscription
receivables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,866,856</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(219,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,967,100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0%"></td><td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Additional paid-in
capital</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,458,941</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">257,821</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    remuneration <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">240,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,865,893</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">961,120</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,324,834</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,458,941</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898954816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE BENEFIT PLANS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5% of the employees&#8217;
basic salaries on monthly basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is obliged to
make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession had been determined
by the Government which saw the standard amount <span style="-sec-ix-hidden: hidden-fact-173">THB750</span> per month per person reduced to <span style="-sec-ix-hidden: hidden-fact-174">THB450</span> per month per person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every business employing
one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;) for the Occupational
Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once registered, the business
must pay to the NSSF:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 0.8% of each worker&#8217;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution equivalent to 2.6% of a worker&#8217;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-172">KHR400,000</span> (approximately $100) up to <span style="-sec-ix-hidden: hidden-fact-171">KHR1,200,000</span> (approximately $300).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has a defined
contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed by an independent
fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15% and 8%, respectively
of the employees&#8217; basic salaries on monthly basis.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 11 &#8212;&#160;EMPLOYEE
BENEFIT PLANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>HK SAR</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 5%
of the employees&#8217; basic salaries on monthly basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Thailand</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company is obliged to make social security payments within the first 15&#160;days of the month over which it is accrued. Special concession
had been determined by the Government which saw the standard amount <span style="-sec-ix-hidden: hidden-fact-124">THB750</span> per month per person reduced to <span style="-sec-ix-hidden: hidden-fact-125">THB450</span> per month per person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cambodia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Every
business employing one or more workers must register its business and workers with the National Social Security Fund (the &#8220;NSSF&#8221;)
for the Occupational Risk Scheme (for work-related&#160;accidents and occupational diseases), the Health Care Scheme and the Pension
Scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Once
registered, the business must pay to the NSSF:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution equivalent to 0.8% of each worker&#8217;s monthly average wages (between $0.40 and $2.40 per month per worker) for the Occupational Risk Scheme.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution equivalent to 2.6% of a worker&#8217;s monthly average wages (between $1.30 and $7.80 per month per worker) for the Health Care Scheme.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">A monthly contribution to the compulsory Pension Scheme, which is jointly paid by the employer and the employee at the same rate of 2% (total of 4%) of the contributable wage for the first five&#160;years. The contributable wage for the Pension Scheme ranges from between <span style="-sec-ix-hidden: hidden-fact-123">KHR400,000</span> (approximately $100) up to <span style="-sec-ix-hidden: hidden-fact-122">KHR1,200,000</span> (approximately $300).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company has a defined contribution pension scheme for its qualifying employees. The scheme assets are held under a provident fund managed
by an independent fund manager. The Company and its employees are each required to make contributions to the scheme calculated at 15%
and 8%, respectively of the employees&#8217; basic salaries on monthly basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898974096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Provision for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION FOR INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cayman Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NewGenIvf Limited was incorporated
in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law. In addition, upon payment
of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HK SAR</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived
from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, the HK SAR
profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the remaining estimated
assessable profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Thailand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The companies incorporated
in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from or in consequence of the
business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying on business in Thailand is
subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends, royalties, rentals, and service
fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%, while other rates may apply under
the provisions of a double tax treaty (DTT).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cambodia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard rate of corporate
income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and large taxpayers is 20%. For
companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive rates from 0% to 20%. In
view of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-185">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-186">KHR6</span>&#160;billion for service and commercial
sectors, the company shall consider as the medium-sized&#160;company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Kyrgyzstan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company is subject to
a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying out business activities
through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities of that permanent
establishments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Profit tax is calculated
at a rate of 10% of aggregate annual income less allowed deductions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant components of
the provisions for income taxes for the six months ended June 30, 2024, and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,727</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,727</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Income/(loss) before taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(387,781</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(295,060</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax expenses/(credit) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69,180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114,645</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(509</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Tax effect on utilization of tax losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,765</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,727</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax asset, net</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant components of deferred tax assets,
net were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, the Company had net operating loss carry forward of $164,721 and $164,721. The Company believes it is less likely
than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward. As
a result, the Company provided 100% allowance on deferred tax assets on net operating loss.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 12 &#8212;&#160;PROVISION
FOR INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cayman Islands</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">NewGenIvf
Limited was incorporated in the Cayman Islands and is not subject to tax on income or capital gains under current Cayman Islands law.
In addition, upon payment of dividends by these entities to the shareholders, no Cayman Islands withholding tax will be imposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>HK SAR</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Under
the two-tiered&#160;profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates
regime will continue to be taxed at a flat rate of 16.5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accordingly,
the HK SAR profits tax is calculated at 8.25% on the first HK$2&#160;million of the estimated assessable profits and at 16.5% on the
remaining estimated assessable profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Thailand</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
companies incorporated in Thailand are taxed on worldwide income. A company incorporated abroad is taxed on its profits arising from
or in consequence of the business carried on in Thailand. The corporate income tax (CIT) rate is 20%. A foreign company not carrying
on business in Thailand is subject to a final withholding tax (WHT) on certain types of assessable income (e.g. interest, dividends,
royalties, rentals, and service fees) paid from or in Thailand. The rate of tax is generally 15%, except for dividends, which is 10%,
while other rates may apply under the provisions of a double tax treaty (DTT).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cambodia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">The
standard rate of corporate income tax (&#8220;CIT&#8221;) for companies and permanent establishments who are classified as medium and
large taxpayers is 20%. For companies and permanent establishments who are classified as small taxpayers, the CIT rates are progressive
rates from 0% to 20%. In view of the annual turnover of the company, the annual turnover ranges from <span style="-sec-ix-hidden: hidden-fact-143">KHR1</span>&#160;billion to <span style="-sec-ix-hidden: hidden-fact-144">KHR6</span>&#160;billion
for service and commercial sectors, the company shall consider as the medium-sized&#160;company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Kyrgyzstan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
company is subject to a corporate income tax on their aggregate annual income earned worldwide. Non-resident&#160;legal entities carrying
out business activities through a permanent establishment in Kyrgyzstan are subject to profit tax on the income attributed to the activities
of that permanent establishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Profit
tax is calculated at a rate of 10% of aggregate annual income less allowed deductions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the provisions for income taxes for the year ended December&#160;31, 2023, and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"><td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196,116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208,141</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income before taxes</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">108,418</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">343,988</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">156,184</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax expenses (credit) at the effective
    tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,732</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(124,591</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">36,755</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-taxable income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(39,173</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-deductible expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">369,101</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">114,656</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on late penalty provision</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">145,295</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">28,441</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect
    on utilization of tax losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(36,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,990</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income taxes</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">208,141</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">294,716</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Deferred tax asset,
net</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-size: 10pt">Significant
components of deferred tax assets, net were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred tax assets:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">&#8211; Net operating
    loss carry forward</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">28,441</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, the Company had net operating loss carry forward of $164,721 and $297,207. The Company believes it
is less likely than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry
forward. As a result, the Company provided 100% allowance on deferred tax assets on net operating loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818912291088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesAbstract', window );"><strong>Disaggregated Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DissagregattedRevenuesTextBlock', window );">DISAGGREGATED REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED REVENUES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s main business operations
are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,380,576</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,869,987</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy, ancillary caring and other
    services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268,635</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,686,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,138,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Geographical information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,077</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,426,592</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270,655</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,109,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">441,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,686,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,138,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The revenue information above is based on the
locations where the revenue originated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">584</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,627</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,472</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,371</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,004</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s long-lived&#160;assets consist
of plant and equipment, net and operating leases right-of-use&#160;assets, net.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 13 &#8212;&#160;DISAGGREGATED
REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s main business operations are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the year ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">IVF treatment service</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,819,163</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">3,199,683</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Surrogacy,
    ancillary caring and other services</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">3,125,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">918,437</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,118,120</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>Geographical information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers originated from</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">34,038</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,123,593</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,060,973</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,110,483</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">621,619</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">377,608</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">313,737</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,356,903</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">505,609</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">693,900</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,118,120</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
revenue information above is based on the locations where the revenue originated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 10pt">Long-lived assets located at</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">584</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22,513</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,835</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">137,472</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">229,085</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">332,799</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">307,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">254,745</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">238,744</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">446,004</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">506,343</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">592,378</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s long-lived&#160;assets consist of plant and equipment, net and operating leases right-of-use&#160;assets, net.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisaggregatedRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisaggregatedRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DissagregattedRevenuesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for dissagregatted revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DissagregattedRevenuesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899283296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">RISKS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">A. Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Accounts receivable</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to minimize the
credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover overdue debts. The Company
considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk
on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, the Company compares
the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account receivables as of
June 30, 2024 and December&#160;31, 2023 is $<span style="-sec-ix-hidden: hidden-fact-188">Nil</span> and $19, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cash and cash equivalents</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The credit risk on liquid
funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Deposits and other receivables, amount due
from shareholders and loan to A SPAC I</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company assessed the
impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating
and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition.
Based on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables,
due from shareholders and loan to A SPAC I as of June 30, 2024 is $14, $<span style="-sec-ix-hidden: hidden-fact-189">Nil</span> and $ <span style="-sec-ix-hidden: hidden-fact-190">Nil</span>, respectively. The loss allowance for deposits
and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and <span style="-sec-ix-hidden: hidden-fact-191">Nil</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">B.&#160;Interest
risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cash flow interest rate risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is exposed to
cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sensitivity analysis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably possible change
in interest rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If interest rates had been
1% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;six months ended June
30, 2024 and 2023 would have increased or decreased by approximately $1,202 and $773, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is
the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result of a change in foreign
currency exchange rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s monetary
assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional currencies of the relevant
group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered insignificant. The Company
currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors monitor the related
foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">C. Economic and
political risks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial condition, and results
of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia and Kyrgyzstan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s operations
in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include risks associated with,
among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s results may be adversely
affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad, and rates and methods
of taxation, among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">D. Inflation risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management monitors changes
in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements; however,
significant increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the Company&#8217;s
results of operations.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 14 &#8212;&#160;RISKS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">A.
Credit risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Accounts receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
order to minimize the credit risk, the management of the Company monitors and ensures that follow-up&#160;action is taken to recover
overdue debts. The Company considers the probability of default upon initial recognition of asset and whether there has been a significant
increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit
risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date
of initial recognition. It considers available reasonable and supportive forward-looking&#160;information, such as GDP growth rate and
nominal GDP per capita. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for account
receivables as of December&#160;31, 2023 and 2022 is $19 and $26, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Cash and cash equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating&#160;agencies.
The Company is exposed to concentration of credit risk on liquid funds which are deposited with several banks with high credit ratings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Deposits and
other receivables, amount due from shareholders and loan to A SPAC I</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company assessed the impairment for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on
internal credit rating and ageing of these debtors which, in the opinion of the directors, have no significant increase in credit risk
since initial recognition. Based on the impairment assessment performed by the Company, the directors consider the loss allowance for
deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2023 is $14, $17,818 and <span style="-sec-ix-hidden: hidden-fact-149">Nil</span>, respectively.
The loss allowance for deposits and other receivables, due from shareholders and loan to A SPAC I as of December&#160;31, 2022 is $141,
$17,059 and <span style="-sec-ix-hidden: hidden-fact-150">Nil</span>, respectively. The loss allowance for deposits and other receivables and amount due from shareholders as of December&#160;31,
2021 was $115 and $6,312 and <span style="-sec-ix-hidden: hidden-fact-151">Nil</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">B.&#160;Interest
risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Cash flow interest
rate risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company is exposed to cash flow interest rate risk through the changes in interest rates related mainly to the Company&#8217;s variable-rates&#160;bank
balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company currently does not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest
rate risk. The directors monitor the Company&#8217;s exposures on an ongoing basis and will consider hedging the interest rate should
the need arises.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Sensitivity
analysis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
sensitivity analysis below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period
and had been applied to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is
used when reporting interest rate risk internally to key management personnel and represents management&#8217;s assessment of the reasonably
possible change in interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">If
interest rates had been 1% higher or lower and all other variables were held constant, the Company&#8217;s net (loss) income for the&#160;years
ended December&#160;31, 2023, 2022 and 2021 would have increased or decreased by approximately $541, $275 and $287, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Foreign currency
risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Foreign
currency risk is the risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result
of a change in foreign currency exchange rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s monetary assets and liabilities are mainly denominated in HK$, THB, KHR and RMB which are the same as the functional
currencies of the relevant group entities. Hence, in the opinion of the directors of the Company, the currency risk of US$ is considered
insignificant. The Company currently does not have a foreign currency hedging policy to eliminate currency exposures. However, the directors
monitor the related foreign currency exposure closely and will consider hedging significant foreign currency exposures should the need
arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">C.
Economic and political risks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s operations are mainly conducted in Thailand, Cambodia and Kyrgyzstan. Accordingly, the Company&#8217;s business, financial
condition, and results of operations may be influenced by changes in the political, economic, and legal environments in Thailand, Cambodia
and Kyrgyzstan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s operations in Thailand, Cambodia and Kyrgyzstan are subject to special considerations and significant risks. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s
results may be adversely affected by changes in the political and social conditions in Thailand, Cambodia and Kyrgyzstan, and by changes
in governmental policies with respect to laws and regulations, anti-inflationary&#160;measures, currency conversion, remittances abroad,
and rates and methods of taxation, among other things.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">D.
Inflation risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Management
monitors changes in prices levels. Historically inflation has not materially impacted the Company&#8217;s consolidated financial statements;
however, significant increases in the price of labor that cannot be passed to the Company&#8217;s customers could adversely impact the
Company&#8217;s results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818891094736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED PARTY BALANCES AND TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The summary of amount due from and due to related
parties as the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt">Shareholders and directors (note 1)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">354,285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Shareholders and directors (note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(221,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The balance due from shareholders consist of
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Due (to) from shareholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(221,203</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">372,103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(221,203</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">354,285</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The movement of allowances for expected credit
loss is as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,818</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(759</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Revised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,818</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(17,818</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Mr.&#160;Siu Wing
    Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 15 &#8212;&#160;RELATED
PARTY BALANCES AND TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
summary of amount due from and due to related parties as the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Relationship</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due from shareholders consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><span style="font-size: 10pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Shareholders and directors (note 1)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">354,285</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">2,240,872</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due to a related party consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Harcourt Limited</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">A related company (note&#160;2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-152; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(110,773</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 24pt"><span style="font-size: 10pt">Note</span></td><td style="text-align: left"></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: left; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
balance due from shareholders consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Due from shareholders</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">372,103</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,257,931</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: allowance
    for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(17,818</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">354,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,240,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(6,312</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(759</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(10,747</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(17,818</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
addition to the transactions and balances detailed elsewhere in these consolidated financial statements, the Company had the following
transactions with related parties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Mr.&#160;Siu Wing Fung, Alfred</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">120,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Ms. Fong Hei Yue, Tina</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">120,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Waiver of related party balance
    of Mr. Siu Wing Fung, Alfred</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(88,151</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899285328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to a SPAC I<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loan to a SPAC I [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LOAN TO A SPAC I</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;LOAN
TO A SPAC&#160;I</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">On
June&#160;12, 2023, NewGenIvf Limited (the &#8220;Company&#8221;) and A SPAC&#160;I Acquisition Corp (&#8220;A SPAC&#160;I&#8221;) entered
into a First Amendment to Merger Agreement, pursuant to which the Company agreed to provide non-interest&#160;bearing loans in an aggregate
principal amount of up to $560,000 (the &#8220;Loan&#8221;) to A SPAC&#160;I to fund amounts required to further extend the period of
time available for A SPAC&#160;I to consummate a business combination, and for working capital and payment of professional, administrative
and operational expenses, and other purposes as mutually agreed by A SPAC&#160;I and the Company. The Loan will only become repayable
upon the closing of the Acquisition Merger. As of December 31, 2023, $140,000 was outstanding under the loan. The Company completed the
business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to A SPAC I was eliminated
in the subsequent period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899707712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Covid-19<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ImpactOfCovid19Abstract', window );"><strong>Impact of Covid-19 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ImpactOfCovid19TextBlock', window );">IMPACT OF COVID-19</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;<span style="text-transform: uppercase">IMPACT
OF&#160;</span>COVID-19</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
COVID-19&#160;has negatively impacted the global economy, disrupted consumer spending and global supply chains, and created significant
volatility and disruption of financial markets. The Company experienced some resulting disruptions to the Company&#8217;s business operations,
and the Company expected the COVID-19&#160;pandemic could have a material adverse impact on the Company&#8217;s business and financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Due
to the ongoing recession caused by the COVID-19, the Company&#8217;s business is likely to be adversely impacted. The effects of recession
can also increase economic instability with vendors and customers.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ImpactOfCovid19Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ImpactOfCovid19Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ImpactOfCovid19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure impact of covid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ImpactOfCovid19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898888560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 16 &#8212;&#160;<span style="text-transform: uppercase">CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June 30, 2024 and
2023, the Company was not a party to any legal or administrative proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">First Fertility Bishkek
LLC (&#8220;FFB&#8221;), the Company incorporated in Kyrgyzstan, did not report the current year tax &#160;&#160;to the tax authority
till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of June 30, 2024. Since FFB had no profit
for the six months ended June 30, 2024, the tax department may not issue tax return at current tax position. The tax return is not yet
filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible amount of tax penalty.
The contingent tax penalty is reasonably possible and estimated at $486,706. Thus, no provision was made. Except the potential tax issue,
the Company concludes that there was no contingent liability, either individually or in the aggregate, that could have resulted in an
unfavorable outcome with a material adverse effect on the Company&#8217;s results of operations, consolidated financial condition, or
cash flows.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;<span style="text-transform: uppercase">CONTINGENCIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December 31, 2023 and 2022, the Company was not a party to any legal or administrative proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
Fertility Bishkek LLC (&#8220;FFB&#8221;), the Company incorporated in Kyrgyzstan, did not report the current year tax </span><span style="font-size: 10pt">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">to
the tax authority till the reporting date since 2023. The late tax filing may lead to contingent tax penalty as of December 31, 2023.
Since FFB had no profit for the year ended December 31, 2023, the tax department may not issue tax return at current tax position. The
tax return is not yet filed so it is not possible to give the Company evaluation of the likelihood of the outcome or estimate the possible
amount of tax penalty. The contingent tax penalty is reasonably possible and estimated at $486,706. Thus, no provision was made. Except
the potential tax issue, the Company concludes that there was no contingent liability, either individually or in the aggregate, that
could have resulted in an unfavorable outcome with a material adverse effect on the Company&#8217;s results of operations, consolidated
financial condition, or cash flows.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898964816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 17 &#8212;&#160;<span style="text-transform: uppercase">segment
information</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company uses the management
approach to determine reportable operating segments. The management approach considers the internal organization and reporting used by
the Company&#8217;s CODM, specifically the Group&#8217;s CEO and CFO, for making decisions, allocating resources and assessing performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company does not distinguish
revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses by nature as a whole.
Based on the management&#8217;s assessment, the Group determines that it has only one operating segment and therefore one reportable
segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be found in these
consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration:underline">NOTE 19 &#8212;&#160;<span style="text-transform: uppercase">segment
information</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company uses the management approach to determine reportable operating segments. The management approach considers the internal organization
and reporting used by the Company&#8217;s CODM, specifically the Group&#8217;s CEO and CFO, for making decisions, allocating resources
and assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company does not distinguish revenues, costs and expenses between segments in its internal reporting, but instead reports costs and expenses
by nature as a whole. Based on the management&#8217;s assessment, the Group determines that it has only one operating segment and therefore
one reportable segment as defined by ASC 280. As such, all financial segment information required by the authoritative guidance can be
found in these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898922848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">NOTE 18 &#8212;&#160;SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with ASC Topic
855, &#8220;Subsequent Events&#8221;, which establishes general standards of accounting for and disclosure of events that occur after
the balance sheet date but before consolidated financial statements are issued, the Company evaluated all events or transactions that
occurred after June 30, 2024, up through the date the Company</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">NOTE
20 &#8212;&#160;SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements
were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have
required adjustment or disclosure in the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Convertible note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
February 29, 2024, A SPAC I Acquisition Corp. (&#8220;ASCA&#8221;), A SPAC I Mini Acquisition Corp. (the then name of NewGenIvf Group
Limited), NewGenIvf Limited (&#8220;NewGenIvf&#8221;, the &#8220;Company&#8221;), A SPAC I Mini Sub Acquisition Corp. (the &#8220;Merger
Sub&#8221;), and certain buyers named therein led by JAK Opportunities VI LLC (collectively, the &#8220;Buyers&#8221; or &#8220;JAK&#8221;)
entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;), pursuant to which the NewGenIvf Group
Limited agreed to issue and sell to JAK, in a private placement, an aggregate of up to $3,500,000 principal amount of convertible notes
(the &#8220;Notes&#8221;), consisting of one or more tranches: (i) an initial tranche (the &#8220;Initial Tranche&#8221;) of an aggregate
principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500, and (ii) subsequent
tranches of an aggregate principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, JAK received a certain amount of ordinary shares of the NewGenIvf Group Limited (the &#8220;Commitment Shares&#8221;),
which were converted from the Company ordinary shares issued to JAK in February 2024 and equaled 295,000 ordinary shares of the NewGenIvf
Group Limited, as well as an additional 100,000 ordinary shares of the NewGenIvf Group Limited, which were converted from the Company
ordinary shares transferred by another shareholder of the Company to JAK in March 2024. In addition, a subsequent tranche of the Notes
in the principal amount of $250,000 was issued and sold to JAK shortly after the closing of the Business Combination. As such, as of
April 4, 2024, an aggregate principal amount of Notes of $2,000,000 were issued and sold to JAK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Business combination
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">On
April 3, 2024, the Company completed the business combination with A SPAC I Acquisition Corp. After the combination, the combined company
will be named &#8220;NewGenIvf Group Limited&#8221; (&#8220;NewGenIvf Group&#8221;) and its shares and warrants are expected to begin
trading on the Nasdaq Capital Market under the tickers &#8220;NIVF&#8221;, and &#8220;NIVFW&#8221;, respectively, on April 4, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896841200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation and basis of preparation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Principles of consolidation and basis of preparation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All
inter-company&#160;balances and transactions have been eliminated in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management has prepared
the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted in the
United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Principles of consolidation
and basis of preparation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company&#160;balances and transactions have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Management
has prepared the accompanying consolidated financial statements and these notes in accordance with accounting principles generally accepted
in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;). The Company maintains its general ledger and journals with the accrual
method accounting.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant estimates required to be made by management
include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ from those estimates, and as such,
differences may be material to the consolidated financial statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Use of estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates
required to be made by management include, but are not limited to, contingent tax liability for Kyrgyzstan. Actual results could differ
from those estimates, and as such, differences may be material to the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency translation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency of the Company. The
functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong dollar (&#8220;HK$&#8221;).
Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom Penh Limited uses Cambodian
riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States dollar (&#8220;USD&#8221;)
as its functional currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assets and liabilities denominated
in currencies other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the
balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations and comprehensive income
as other comprehensive income or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Transactions in currencies
other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on the transaction
date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations and comprehensive
income as other income (other expenses).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The value of foreign currencies
including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant variations of the aforementioned
currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial condition in terms of reporting
in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.8454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.3081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.4021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3864</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,112.3016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132.8226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,080.0304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,075.4046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,058.1179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,105.4181</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Foreign currency
translation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
accompanying consolidated financial statements are presented in United&#160;States dollar (&#8220;$&#8221;), which is the reporting currency
of the Company. The functional currency of the Company and its subsidiaries, FFPGS (HK) Limited and Well Image Limited, are Hong&#160;Kong
dollar (&#8220;HK$&#8221;). Med Holdings and FFC use Thai baht (&#8220;THB&#8221;) as their functional currencies. First Fertility Phnom
Penh Limited uses Cambodian riel (&#8220;KHR&#8221;) as its functional currency and First Fertility Bishkek LLC uses United&#160;States
dollar (&#8220;USD&#8221;) as its functional currency.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of operations
and comprehensive income as other comprehensive income or loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Transactions
in currencies other than the reporting currency are measured and recorded in the reporting currency at the exchange rate prevailing on
the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated statements of operations
and comprehensive income as other income (other expenses).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
value of foreign currencies including, the HK$, THB, KHR and RMB, may fluctuate against the United&#160;States dollar. Any significant
variations of the aforementioned currencies relative to the United&#160;States dollar may materially affect the Company&#8217;s financial
condition in terms of reporting in USD.&#160;The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.2265</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.6153</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">33.1964</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.7867</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">35.1428</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">32.1003</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,080.0304</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,114.3335</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,068.9577</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,105.4181</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,083.7043</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,065.8164</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0971</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.9091</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.3551</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0835</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4569</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4368</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and cash equivalents</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original maturities of three&#160;months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Cash and cash equivalents</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term&#160;deposits with original
maturities of three&#160;months or less that are readily convertible to known amounts of cash and which are subject to an insignificant
risk of changes in value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock', window );">Deposits, prepayment, other receivables and deferred IPO cost, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Deposits, prepayment, other receivables and
deferred IPO cost, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deposits, prepayment, other
receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers, prepaid
expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Deposits, prepayment,
other receivables and deferred IPO cost, net</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred Initial Public Offering (&#8220;IPO&#8221;) cost, net primarily include deposits paid to suppliers,
prepaid expenses, the prepaid professional fee which meets the definition of deferred IPO cost, and other deposits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Deferred
IPO costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related
to the Initial Public Offering and that were charged to shareholders&#8217; equity upon the completion of the Initial Public Offering.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Plant and equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Plant and equipment, net</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Plant and equipment are
stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the straight-line&#160;method.
The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment are as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost and related accumulated
depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss are included in the Company&#8217;s
results of operations. The costs of maintenance and repairs are expensed as incurred. Significant renewals and betterments that extend
the useful life of an assets are capitalized.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Plant and equipment,
net</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Plant
and equipment are stated at cost less accumulated depreciation. Depreciation is provided over their estimated useful lives, using the
straight-line&#160;method. The Company typically applies a salvage value of 0%. The estimated useful lives of the plan and equipment
are as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 25%; padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts, and any gain or loss
are included in the Company&#8217;s results of operations. The costs of maintenance and repairs are expensed as incurred. Significant
renewals and betterments that extend the useful life of an assets are capitalized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company evaluates the
long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount of assets may not
be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies, or if the Company
has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present if the carrying
amount of an asset is less than its expected future undiscounted cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an asset is considered
impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the asset. Assets to
be disposed of are reported lower the carrying amount or fair value less cost to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Impairment of&#160;long-lived&#160;assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company evaluates the long-lived&#160;assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of assets may not be recoverable. Impairment may become obsolete from a difference in the industry, introduction of new technologies,
or if the Company has inadequate working capital to utilize the long-lived&#160;assets to generate adequate profits. Impairment is present
if the carrying amount of an asset is less than its expected future undiscounted cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">If
an asset is considered impaired, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value
of the asset. Assets to be disposed of are reported lower the carrying amount or fair value less cost to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Inventories</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Inventories are stated at
the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value is based on
the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and obsolete
inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes the basis
for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory would not
be reversed if market conditions improve.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Inventories</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Inventories
are stated at the lower of cost and net realizable value. Costs are determined on a first-in, first-out&#160;basis. Net realizable value
is based on the estimated selling prices less any estimated costs to be incurred to completion and disposal. A provision for excess and
obsolete inventory will be made based primarily on forecasts of product demand. The excess balance determined by this analysis becomes
the basis for excess inventory charge and the written-down&#160;value of the inventory becomes its cost. Written-down&#160;inventory
would not be reversed if market conditions improve.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Other borrowings</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Other borrowings</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other borrowings are recognized
initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized cost; any difference
between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements of operations
over the period of the borrowings using the effective interest method.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Other borrowings</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Other
borrowings are recognized initially at fair value, net of debt issuance costs incurred. Other borrowings are subsequently stated at amortized
cost; any difference between the proceeds (net of debt issuance costs) and the redemption value is recognized in the consolidated statements
of operations over the period of the borrowings using the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Ordinary shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s ordinary
shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received, net of issuance cost,
and the par value is recorded in additional paid-in&#160;capital.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Ordinary shares</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s ordinary shares are stated at par value of $0.01 per ordinary share. The difference between the consideration received,
net of issuance cost, and the par value is recorded in additional paid-in&#160;capital.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC
Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1, 2017 using
the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606 had
been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its contracts
    with customers;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify its performance
    obligations under those contracts;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine the transaction
    prices of those contracts;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate the transaction
    prices to its performance obligations in those contracts; and</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize revenue when
    each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the
    client in an amount that reflects the consideration expected in exchange for those services.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company enters into
service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify
the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties. All the contracts have
commercial substance, and it is probable that the Company will collect considerations from its customers for service component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company derives its
revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary caring services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from IVF treatment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In vitro fertilization (&#8220;IVF&#8221;)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
and procedures that are not separately distinct and only brings benefits to customer when embryo is successfully implanted, therefore
revenue from IVF treatment is recognized at a point in time when it is completed in clinic. The completion of this treatment is evidenced
by a written IVF report indicating successful embryo implantation. The Company collects payment from customer in advance for IVF treatment.
The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can be found in Note&#160;8 below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue from surrogacy and ancillary caring
services</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company.
During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins, supplements
and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where a baby is born,
therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother gives birth. The
Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across pregnancy
period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result of operations can
be found in Note&#160;8 below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract related assets
and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to the revenue cycle
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Account receivables, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net
are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected credit loss
is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the accounts receivable
balances, current general economic conditions, future expectations and customer specific quantitative and qualitative factors that may
affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence for the Company
to reasonably estimate the amount of probable loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contract liabilities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Contract liabilities represent
considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under the contract. These
amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Expected credit loss</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ASU No.&#160;2016-13, Financial
Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments requires entities
to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology
will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss
until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial
assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates of
credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows due
to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective
interest rate of the financial asset.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenue recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC Topic&#160;606, Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC&#160;606 on April&#160;1,
2017 using the full retrospective method which requires the Company to present the financial statements for all periods as if Topic&#160;606
had been applied to all prior periods. The Company derives revenue principally from provision of In vitro fertilization (&#8220;IVF&#8221;)
treatment and surrogacy and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its contracts with customers;</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify
                                            its performance obligations under those contracts;</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine
                                            the transaction prices of those contracts;</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate
                                            the transaction prices to its performance obligations in those contracts; and</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize
                                            revenue when each performance obligation under those contracts is satisfied. Revenue is recognized
                                            when promised services are transferred to the client in an amount that reflects the consideration
                                            expected in exchange for those services.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company enters into service agreements with its customers that outline the rights, responsibilities, and obligations of each party. The
agreements also identify the scope of services, service fees, and payment terms. Agreements are acknowledged and signed by both parties.
All the contracts have commercial substance, and it is probable that the Company will collect considerations from its customers for service
component.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company derives its revenues from two sources: (1)&#160;revenue from IVF treatment, and (2)&#160;revenue from surrogacy and ancillary
caring services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
IVF treatment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
vitro fertilization (&#8220;IVF&#8221;) treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized
in laboratory to become embryo. Fertilized embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the
performance of a series of medical treatment and procedures that are not separately distinct and only brings benefits to customer when
embryo is successfully implanted, therefore revenue from IVF treatment is recognized at a point in time when it is completed in clinic.
The completion of this treatment is evidenced by a written IVF report indicating successful embryo implantation. The Company collects
payment from customer in advance for IVF treatment. The amount of revenue recognized from contract liabilities to the Company&#8217;s
result of operations can be found in Note&#160;8 below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Revenue from
surrogacy and ancillary caring services</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company provides surrogacy and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother
contracted by the Company. During pregnancy period, the Company provides ancillary caring services including regular body check and provision
of vitamins, supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation
where a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate
mother gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments
across pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company&#8217;s result
of operations can be found in Note&#160;8 below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
related assets and liabilities are classified as current assets and current liabilities. Significant balance sheet accounts related to
the revenue cycle are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Account receivables,
net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable, net are stated at the original amount less an allowance for expected credit loss on such receivables. The allowance for expected
credit loss is estimated based upon the Company&#8217;s assessment of various factors including historical experience, the age of the
accounts receivable balances, current general economic conditions, future expectations and customer specific quantitative and qualitative
factors that may affect the Company&#8217;s customers&#8217; ability to pay. An allowance is also made when there is objective evidence
for the Company to reasonably estimate the amount of probable loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><b><i>Contract liabilities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Contract
liabilities represent considerations received from customers in advance of satisfying the Company&#8217;s performance obligations under
the contract. These amounts are expected to be earned within 12&#160;months and are classified as current liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Expected
credit loss</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">ASU
No.&#160;2016-13, Financial Instruments&#160;&#8212;&#160;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments
requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using
this methodology will result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to
recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments
of other financial assets may be recorded and presented, and that expand disclosures. Expected credit losses are probability-weighted&#160;estimates
of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e., the difference between the cash flows
due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the
effective interest rate of the financial asset.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Retirement benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Retirement benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Retirement benefits in the
form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated to wages
as part of cost of revenues.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Retirement benefits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Retirement
benefits in the form of mandatory government-sponsored&#160;defined contribution plans are charged to either expense as incurred or allocated
to wages as part of cost of revenues.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Segment information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources and assess performance.
The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing Fund Alfred, the Company&#8217;s
Chief Executive Officer. Since the Company operates in one operating segment, all required financial segment information can be found
in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers as of June 30, 2024 and 2023
by geographical area are presented in Note&#160;13.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Segment information</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (the &#8220;CODM&#8221;), or decision making group, in making decisions on how to allocate resources
and assess performance. The Company operates and manages in one operating segment. The Company defines its CODM as Mr.&#160;Siu Wing
Fund Alfred, the Company&#8217;s Chief Executive Officer. Since the Company operates in one operating segment, all required financial
segment information can be found in the consolidated financial statements. The long-lived&#160;assets and revenue from external customers
as of December&#160;31, 2023, 2022 and 2021 by geographical area are presented in Note&#160;13.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Leases</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company measured the
lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the present value of lease
payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty
at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU
assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease exception, therefore
operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-155">twelve</span>&#160;months or less. Its leases generally
do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line&#160;basis
over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, there were $272,474 and $ 283,847 million&#160;right of use (&#8220;ROU&#8221;) assets and $313,393 and $326,107
lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s management
believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate (&#8220;BLR&#8221;)
minus 0.125%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present value of the
lease payments; the rate used by the Company was 6.6% and 5.0% respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Leases</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company measured the lease in accordance to ASU&#160;2016-02, &#8220;Leases&#8221; (Topic&#160;842). Lease terms used to calculate the
present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not
have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life
of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term&#160;lease
exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of <span style="-sec-ix-hidden: hidden-fact-108">twelve</span>&#160;months or less.
Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense
is recognized on a straight-line&#160;basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2023 and 2022, there were $283,847 and $383,670&#160;million right of use (&#8220;ROU&#8221;) assets and $326,107
and $426,838 lease liabilities based on the present value of the future minimum rental payments of leases, respectively. The Company&#8217;s
management believes that using an incremental borrowing rate of the minimum loan rate and the Hong&#160;Kong Dollar Best Lending Rate
(&#8220;BLR&#8221;) minus 0.125%&#160;was the most indicative rate of the Company&#8217;s borrowing cost for the calculation of the present
value of the lease payments; the rate used by the Company was 6.6% and 5.0% respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company recognizes deferred
income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated financial statements or
tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial
reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will be in effect when the
differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred tax asset is not
realizable or recoverable in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company determines that
the tax position is more likely than not to be sustained and records the largest amount of benefit that is more likely than not to be
realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain tax positions
in income tax expense.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company recognizes deferred income tax assets or liabilities for expected future tax consequences of events recognized in the consolidated
financial statements or tax returns. Under this method, deferred income tax assets and liabilities are determined based on the differences
between the financial reporting and income tax bases of assets and liabilities and are measured using the income tax rates that will
be in effect when the differences are expected to reverse. Valuation allowances are provided when it is more likely than not that a deferred
tax asset is not realizable or recoverable in the future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company determines that the tax position is more likely than not to be sustained and records the largest amount of benefit that is more
likely than not to be realized when the tax position is settled. the Company recognizes interest and penalties, if any, related to uncertain
tax positions in income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Comprehensive Income</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company presents comprehensive
income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states that all items that are required
to be recognized under accounting standards as components of comprehensive income be reported in the consolidated financial statements.
The components of comprehensive income were the net income for the&#160;years and the foreign currency translation adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Comprehensive Income</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company presents comprehensive income in accordance with ASC Topic&#160;220,&#160;<i>Comprehensive Income</i>. ASC Topic&#160;220 states
that all items that are required to be recognized under accounting standards as components of comprehensive income be reported in the
consolidated financial statements. The components of comprehensive income were the net income for the&#160;years and the foreign currency
translation adjustments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Earnings per share</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company computes earnings
per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is measured as the income or
loss available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS presents
the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise of options and
or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the potentially dilutive
effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities (i.e., those
that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially dilutive
securities that were in-the-money&#160;that were outstanding during the six months ended June 30, 2024 and 2023.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Earnings per share</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) following ASC Topic&#160;260, &#8220;Earnings per share&#8221;. Basic EPS is
measured as the income or loss available to common shareholders divided by the weighted average common shares outstanding for the period.
Diluted EPS presents the dilutive effect on a per-share&#160;basis from the potential conversion of convertible securities or the exercise
of options and or warrants; the dilutive impacts of potentially convertible securities are calculated using the as-if&#160;method; the
potentially dilutive effect of options or warranties are computed using the treasury stock method. Potentially anti-dilutive&#160;securities
(i.e., those that increase income per share or decrease loss per share) are excluded from diluted EPS calculation. There were no potentially
dilutive securities that were in-the-money&#160;that were outstanding during the&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_RelatedPartiesPolicyTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company adopted ASC&#160;850,
Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company adopted ASC&#160;850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Commitments and contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the normal course of
business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to
a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such contingency
if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider
many factors in making these assessments including historical and the specific facts and circumstances of each matter.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Commitments and
contingencies</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes its liability for such
contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments including historical and the specific facts and circumstances of each matter.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NonControllingInterestsPolicyTextBlock', window );">Non-controlling interests</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Non-controlling&#160;interests</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Non-controlling&#160;interests</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Non-controlling&#160;interests
are presented as a separate component of equity on the consolidated balance sheets and net (loss) income and other comprehensive loss
are attributed to controlling and non-controlling&#160;interests respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of risks</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of risks</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of credit risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable. The Company
places cash and cash equivalents with financial institutions with high credit ratings and quality.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable primarily
comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers, and generally does not
require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts primarily based upon
the factors surrounding the credit risk of specific customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of customers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and two customers which individually contributed more than 10% of trade receivable, accounted for 15% and
96.3% of the Company&#8217;s trade receivable respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of the customers contributed
more than 10% of revenue for&#160;six months ended June 30, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of suppliers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of June&#160;30, 2024
and December 31, 2023, one and four suppliers which individually contributed more than 10% of trade payable, accounted for 13.6% and
30.6% of the Company&#8217;s trade payable respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the six months ended
June 30, 2024 and 2023, one and one vendors which contributed more than 10% of total purchases of the Company, accounted for 15.3% and
21.5% of the Company&#8217;s total purchases respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Concentration of
risks</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
credit risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Financial
instruments that potentially expose us to concentrations of credit risk consist primarily of cash and cash equivalents and account receivable.
The Company places cash and cash equivalents with financial institutions with high credit ratings and quality.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Accounts
receivable primarily comprise of amounts receivable from the service customers. The Company conducts credit evaluations of customers,
and generally does not require collateral or other security from its customers. The Company establishes an allowance for doubtful accounts
primarily based upon the factors surrounding the credit risk of specific customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><i>Concentration of
customers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, two and Nil customers which individually contributed more than 10% of trade receivable, accounted
for 96.3% and <span style="-sec-ix-hidden: hidden-fact-109">Nil</span> of the Company&#8217;s trade receivable respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">None
of the customers contributed more than 10% of revenue for&#160;years ended December&#160;31, 2023, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Concentration
of suppliers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, one and four suppliers which individually contributed more than 10% of trade payable, accounted for
30.6% and 69.8% of the Company&#8217;s trade payable respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">For
the year ended December&#160;31, 2023, 2022 and 2021, Nil, two and two vendors which contributed more than 10% of total purchases of
the Company, accounted for <span style="-sec-ix-hidden: hidden-fact-110">Nil</span>, 55.3% and 35.6% of the Company&#8217;s total purchases respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financial instruments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company&#8217;s financial
instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and deferred IPO cost, net,
loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders, have carrying amounts that
approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements and Disclosures&#8221;
requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial Instruments&#8221;
defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents,
accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related parties each qualify
as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such
instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined
as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8212;&#160;inputs
    to the valuation methodology used quoted prices for identical assets or liabilities in active markets.</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8212;&#160;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets and information that are
    observable for the asset or liability, either directly or indirectly, for substantially the financial instrument&#8217;s full term</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8212;&#160;inputs
    to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company analyzes all
financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities from Equity&#8221;
and ASC&#160;815.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Financial instruments</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivables, net, deposits, other receivables and
deferred IPO cost, net, loan to A SPAC I, accounts payables, accrued liabilities and other payables, and due from (to) shareholders,
have carrying amounts that approximate their fair values due to their short maturities. ASC Topic&#160;820, &#8220;Fair Value Measurements
and Disclosures&#8221; requires disclosing the fair value of financial instruments held by the Company. ASC Topic&#160;825, &#8220;Financial
Instruments&#8221; defines fair value and establishes a three-level&#160;valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for cash
and cash equivalents, accounts and other receivables, accounts and other payables, accrued liabilities and amounts due from (to) related
parties each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between
the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation
hierarchy are defined as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            1&#160;&#8212;&#160;inputs to the valuation methodology used quoted prices for identical
                                            assets or liabilities in active markets.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            2&#160;&#8212;&#160;inputs to the valuation methodology include quoted prices for similar
                                            assets and liabilities in active markets and information that are observable for the asset
                                            or liability, either directly or indirectly, for substantially the financial instrument&#8217;s
                                            full term</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level
                                            3&#160;&#8212;&#160;inputs to the valuation methodology are unobservable and significant
                                            to the fair value measurement.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
Company analyzes all financial instruments with features of both liabilities and equity under ASC&#160;480, &#8220;Distinguishing Liabilities
from Equity&#8221; and ASC&#160;815.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements adopted </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2019, the FASB
issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,
and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB issued ASU 2019-05,
Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair value option to
be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until December 15,
2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected
credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated life of the financial
asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies to financial assets
measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance sheet credit exposures
such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at the net amount expected
to be collected by using an allowance for expected credit losses. The Company already adopted the new standard and the Company recognizes
the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements adopted </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-size: 10pt">In
April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives
and Hedging, and Topic 825, Financial Instruments, which amends and clarifies several provisions of Topic 326. In May 2019, the FASB
issued ASU 2019-05, Financial Instruments-Credit Losses (Topic 326) Targeted Transition Relief, which amends Topic 326 to allow the fair
value option to be elected for certain financial instruments upon adoption. ASU 2019-10 extended the effective date of ASU 2016-13 until
December 15, 2022. This standard replaces the incurred loss methodology with an expected loss methodology that is referred to as the
current expected credit loss (&#8220;CECL&#8221;) methodology. CECL requires an estimate of credit losses for the remaining estimated
life of the financial asset using historical experience, current conditions, and reasonable and supportable forecasts and generally applies
to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities, and some off-balance
sheet credit exposures such as unfunded commitments to extend credit. Financial assets measured at amortized cost will be presented at
the net amount expected to be collected by using an allowance for expected credit losses. The Company already adopted the new standard
and the Company recognizes the full impact of the new standard in these consolidated balance sheets and makes related disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent accounting pronouncements not yet adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recent accounting pronouncements not yet adopted</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November 2023, the FASB
issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in ASU 2023-07 improve financial
reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable
investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit
or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources.
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed
under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure requirements. The amendments in ASU
2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the
quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December
15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that
the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2023, FASB issued
Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU 2023-09&#8221;). The amendments
in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure
of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations,
to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income
tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain
categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an
annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions,
including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to
or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods
beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update
on the Company&#8217;s consolidated financial statements and related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Save for elsewhere disclosed,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income (loss) and statement of cash
flows.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt"><span style="text-decoration:underline">Recent accounting
pronouncements not yet adopted</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;). The amendments in
ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for
all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report
a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions
about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and
depletion expense, to be disclosed under certain circumstances. The amendments in ASU 202307 do not change or remove those disclosure
requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective
for years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively.
Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial
statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">In
December 2023, FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, &#8220;Income Taxes (Topic 740)&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements
to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU
2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit)
from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable
statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling
items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires
disclosure of, on an annual basis, the year to date amount of income taxes paid (net of refunds received) disaggregated by federal, state,
and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual
jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective
for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact
of the update on the Company&#8217;s consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">Save
for elsewhere disclosed, the Company does not believe other recently issued but not yet effective accounting standards, if currently
adopted, would have a material effect on the Company&#8217;s consolidated balance sheet, statement of operations and comprehensive income
(loss) and statement of cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NonControllingInterestsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NonControllingInterestsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for policy related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899333024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Company&#8217;s subsidiaries</a></td>
<td class="text">As of June&#160;30, 2024, the Company&#8217;s
subsidiaries are detailed in the table as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 22%; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NewGenivf Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Cayman Islands company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap">&#160;</td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;A Thailand company</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</p></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company<br/> &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company<br/> &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr></table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">As
of December&#160;31, 2023, the Company&#8217;s subsidiaries are detailed in the table as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 22%; padding-right: 3pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FFPGS (HK) Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and administrative services</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Image Limited</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%*</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Thailand company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Cambodia company</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of IVF treatment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 23%; padding-bottom: 1.5pt"><span style="font-size: 10pt"><b>Name</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership %</b></span></td> <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activity</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Fertility Bishkek LLC (&#8220;FFB&#8221;)</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;A Kyrgyzstan company</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019</span></p></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td> <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision surrogacy and ancillary caring services</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898901520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</a></td>
<td class="text">The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial
statements:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Period-end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            HK$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.8454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.3081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.2265</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            THB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.4021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.3864</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,112.3016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132.8226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,080.0304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            KHR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,075.4046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,058.1179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,105.4181</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Period-end</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Period average</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$:
                                            RMB</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0835</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text">The following table outlines the currency exchange rates that were used in preparing the
accompanying consolidated financial statements:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: HK$</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.8000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.2265</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.6153</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">33.1964</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: THB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">34.7867</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">35.1428</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">32.1003</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,080.0304</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,114.3335</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,068.9577</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: KHR</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,105.4181</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,083.7043</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,065.8164</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period-end</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0971</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.9091</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.3551</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Period average</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-size: 10pt">$: RMB</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7.0835</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4569</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6.4368</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment', window );">Schedule of Estimated Useful Lives of the Plant and Equipment</a></td>
<td class="text">The estimated useful lives of the plan and equipment are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table><span></span>
</td>
<td class="text">The estimated useful lives of the plan and equipment
are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 74%; padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 25%; padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lesser of useful life or&#160;term of lease</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    instruments</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;10&#160;years</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motor
    vehicle</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-bottom: 2.25pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    equipment</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#160;&#8211;&#160;5&#160;years</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818905394736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAdditionalImprovementsAbstract', window );"><strong>Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text">Accounts receivable, net consists of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">172,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,393</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,475</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Accounts
receivable, net consists of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accounts receivable</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">9,393</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">13,026</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: allowance for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(19</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</a></td>
<td class="text">As of the end of each of
the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is
as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Within 90&#160;days</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">172,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,374</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">172,475</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,374</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">As
of the end of each of the financial year, the aging analysis of accounts receivable, net of allowance for expected credit loss, based
on the invoice date is as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Within 90&#160;days</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">9,374</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock', window );">Schedule of movement Allowances for Expected Credit Loss</a></td>
<td class="text">The movement of allowances for expected credit
loss is as follow:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(26</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal (provision) of provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(286</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of expected credit losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(19</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(26</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movement allowances for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAdditionalImprovementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAdditionalImprovementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898825248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text">Inventories consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Medicines, consumables and reagents for clinical and laboratory analyses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">102,825</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">126,264</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102,825</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">126,264</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Inventories
consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Medicines, consumables and reagents for clinical and laboratory
    analyses</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">126,264</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">46,910</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">126,264</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">46,910</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818913960752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract', window );"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</a></td>
<td class="text">Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Other receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">359,035</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Prepayment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,848</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Deferred initial public offering &#8220;IPO&#8221; cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">703,897</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">517,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Deposits,
prepayment, other receivables and deferred IPO cost, net consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Other receivables</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">15,910</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">30,295</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deposits</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">123,008</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">40,131</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Prepayment</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">4,848</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Deferred initial public offering &#8220;IPO&#8221;
    cost</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">373,677</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: allowance for expected
    credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">517,429</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">70,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock', window );">Schedule of Movement of Allowances for Expected Credit Loss</a></td>
<td class="text">The movement of allowances for expected credit
loss is as follow:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(141</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal of provision (Provision)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Balance at beginning of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(115</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Reversal of provision (Provision)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">127</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(30</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Effect of currency translation adjustment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(141</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898816576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Plant and Equipment, Net</a></td>
<td class="text">Plant and equipment, net consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>At cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Building improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,493</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">765,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,809</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,379,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,219,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,319,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">159,931</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">162,157</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Plant
and equipment, net consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0in"><span style="font-size: 10pt">At cost:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Building improvement</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">92,438</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">72,519</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Furniture and fixtures</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">250,493</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">246,682</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Medical instruments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">844,809</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">791,514</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Motor vehicle</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">142,936</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">142,936</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-size: 10pt">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">150,688</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">146,432</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: -0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,481,364</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,400,083</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0in"><span style="font-size: 10pt">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,319,207</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,277,410</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">162,157</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">122,673</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899771792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilties and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities and Other Payables</a></td>
<td class="text">Accrued liabilities and other payables consist
of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">183,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,633</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation payable (Note&#160;1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued legal and professional fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,699,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">--</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315,696</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,613</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Accrued
liabilities and other payables consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-size: 10pt">Accrued expenses</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">43,633</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">22,345</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Other tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,180</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Withholding tax payable</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">7,349</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">82,240</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Compensation payable (Note&#160;1)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">144,015</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">117,935</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Other payables</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">46,616</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">64,077</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">241,613</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">289,777</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899723408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilitiesAbstract', window );"><strong>Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Liabilities</a></td>
<td class="text">Contract liabilities consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,360,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,006</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Recognized to revenue during the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,937</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,662</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Refund to customers (Note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,341,575</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">37,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,937</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Contract
liabilities consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">812,158</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Additions</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">112,006</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Recognized to revenue during the
    year</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(122,662</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(812,158</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Refund
    to customers (Note 1)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,341,575</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at
    end of year</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">7,937</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,360,168</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899671360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfLeaseLiabilitiesTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text">As of June&#160;30, 2024 and December 31,2023,
lease liabilities consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,297</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">207,128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">326,107</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">As
of December&#160;31, 2023 and 2022, lease liabilities consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;current
    portion</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">207,128</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">184,651</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Lease liabilities&#160;&#8211;&#160;non-current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">118,979</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">242,187</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">326,107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">426,838</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Other Lease Information</a></td>
<td class="text">Other lease information is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.67years</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.92years</td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Short term lease cost</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,009</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">114,937</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Other
lease information is as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Weighted-average remaining lease term&#160;&#8211;&#160;operating leases</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91&#160;years</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Weighted-average discount rate&#160;&#8211;&#160;operating leases</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Short term lease cost</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">114,937</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">89,380</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments under Operating Leases</a></td>
<td class="text">The following is a schedule
of future minimum payments under operating leases as of June 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Not later than 1 year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,654</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Between 1 to 2&#160;years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,079</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Between 2 to 3&#160;years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,751</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities, net
    of interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
following is a schedule of future minimum payments under operating leases as of December&#160;31, 2023:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Not later than 1 year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">240,835</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between 1 to 2&#160;years</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">111,613</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Between
    2 to 3&#160;years</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">10,373</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total lease payments</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">362,821</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: imputed
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(36,714</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total operating
    lease liabilities, net of interest</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">326,107</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899013904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Subscription Receivables</a></td>
<td class="text"><i>Subscription receivables</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,967,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">319,872</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,866,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,506,691</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,473,791</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,967,100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt"><i>Subscription
receivables</i></span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,866,856</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of subscription receivable <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(219,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,967,100</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">319,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0%"></td><td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On January&#160;18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald Fan and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock', window );">Schedule of Additional Paid-in Capital</a></td>
<td class="text"><i>Additional paid-in capital</i><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Balance at beginning of period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,324,834</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,458,941</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 1)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,865,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Business combination</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,267,013</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">57,821</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,324,834</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1:</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt"><i>Additional paid-in
capital</i></span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,458,941</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">257,821</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    remuneration <i>(Note 1)</i></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">240,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of shares <i>(Note 2)</i></span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">2,865,893</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">961,120</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,324,834</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">1,458,941</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 1:</span></td><td style="text-align: justify"><span style="font-size: 10pt">The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">Note 2:</span></td><td style="text-align: justify"><span style="font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of schedule of additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899220544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Provision for Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the Provisions for Income Taxes</a></td>
<td class="text">Significant components of
the provisions for income taxes for the six months ended June 30, 2024, and 2023 were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,727</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,727</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><span></span>
</td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the provisions for income taxes for the year ended December&#160;31, 2023, and 2022 were as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"><td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Kyrgyzstan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">196,116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current tax provision Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Late penalty provision Kyrgyzstan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208,141</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Income/(loss) before taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(387,781</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(295,060</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax expenses/(credit) at the effective tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69,180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114,645</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-taxable income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(509</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax effect on non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Tax effect on utilization of tax losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,765</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,727</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income before taxes</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">108,418</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">343,988</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">156,184</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax expenses (credit) at the effective
    tax rates</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">10,732</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(124,591</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">36,755</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-taxable income</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(39,173</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on non-deductible expenses</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">369,101</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">114,656</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect on late penalty provision</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">145,295</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Change in valuation allowance</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">28,441</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Tax effect
    on utilization of tax losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(36,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(1,990</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Income taxes</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">208,141</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">294,716</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text">Significant components of deferred tax assets,
net were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">&#8211; Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,441</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">Significant
components of deferred tax assets, net were as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,
    <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred tax assets:</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">&#8211; Net operating
    loss carry forward</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">28,441</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(28,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Deferred
    tax assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818904879968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesAbstract', window );"><strong>Disaggregated Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Business Operations</a></td>
<td class="text">The Company&#8217;s main business operations
are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring services.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IVF treatment service</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,380,576</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,869,987</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Surrogacy, ancillary caring and other
    services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268,635</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0in">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,686,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,138,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
Company&#8217;s main business operations are to provide: (i)&#160;IVF treatment service; and (ii)&#160;surrogacy and ancillary caring
services.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the year ended<br/> December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">IVF treatment service</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">4,021,696</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,819,163</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">3,199,683</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Surrogacy,
    ancillary caring and other services</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,114,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">3,125,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">918,437</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,118,120</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Geographical Information</a></td>
<td class="text"><b>Geographical information</b><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Revenue from external customers originated from</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,077</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kyrgyzstan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,426,592</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270,655</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,109,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">441,375</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenues</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,686,902</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,138,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt"><b>Geographical information</b></span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">Revenue from external
    customers originated from</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">34,038</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,123,593</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">5,060,973</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">3,110,483</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">621,619</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">377,608</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">313,737</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">1,356,903</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">505,609</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">693,900</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total revenues</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,136,153</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">5,944,190</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">4,118,120</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Information above is Based on the Locations</a></td>
<td class="text">The revenue information above is based on the
locations where the revenue originated.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Long-lived assets located at</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">HK SAR</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">584</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cambodia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,627</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,472</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thailand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,371</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,004</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
revenue information above is based on the locations where the revenue originated.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 10pt">Long-lived assets located at</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">HK SAR</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">584</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Kyrgyzstan</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">22,513</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,835</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Cambodia</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">137,472</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">229,085</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">332,799</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Thailand</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">307,948</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">254,745</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">238,744</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">446,004</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">506,343</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">592,378</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisaggregatedRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisaggregatedRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896933888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Amount Due from and Due to Related Parties</a></td>
<td class="text">The summary of amount due from and due to related
parties as the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Due from shareholders consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt">Shareholders and directors (note 1)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">354,285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Due to a related party consist of the following:</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Shareholders and directors (note 1)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(221,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
summary of amount due from and due to related parties as the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Relationship</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due from shareholders consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td colspan="2" style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><span style="font-size: 10pt">Mr.&#160;Siu Wing Fung, Alfred (&#8220;Mr.&#160;Siu&#8221;) and Ms.&#160;Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; width: 23%; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Shareholders and directors (note 1)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">354,285</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-size: 10pt">2,240,872</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Due to a related party consist of the following:</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-size: 10pt">Harcourt Limited</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">A related company (note&#160;2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-152; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(110,773</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock', window );">Schedule of Balance Due from Shareholders</a></td>
<td class="text">The balance due from shareholders consist of
the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Due (to) from shareholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(221,203</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">372,103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for expected credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(221,203</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">354,285</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
balance due from shareholders consist of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Due from shareholders</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">372,103</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,257,931</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Less: allowance
    for expected credit loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(17,818</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">354,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">2,240,872</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Movement of Allowances for Expected Credit Loss</a></td>
<td class="text">The movement of allowances for expected credit
loss is as follow:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June&#160;30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at beginning of the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,818</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">Provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(759</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Revised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,818</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(17,818</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">The
movement of allowances for expected credit loss is as follow:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Balance at beginning
    of the year</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">(6,312</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(759</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(10,747</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Ending balance</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(17,818</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 10pt">(17,059</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of Consolidated Financial Statements</a></td>
<td class="text">In addition to the transactions
and balances detailed elsewhere in these consolidated financial statements, the Company had the following transactions with related parties:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Mr.&#160;Siu Wing
    Fung, Alfred</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">95,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><span style="font-size: 10pt">In
addition to the transactions and balances detailed elsewhere in these consolidated financial statements, the Company had the following
transactions with related parties:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Mr.&#160;Siu Wing Fung, Alfred</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">120,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Directors&#8217; remuneration
    to Ms. Fong Hei Yue, Tina</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">120,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Waiver of related party balance
    of Mr. Siu Wing Fung, Alfred</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">(88,151</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818891112368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OrganizationandPrincipalActivitiesDetailsLineItems', window );"><strong>Organization and Principal Activities (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyholderDividendsRateOnPolicyEarnings', window );">Dividends percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Bank balance</a></td>
<td class="nump">$ 54,104<span></span>
</td>
<td class="nump">$ 184,109<span></span>
</td>
<td class="nump">$ 54,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSecuredFinancings', window );">Secured funding amount</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Received from secured funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_SubsidiarieMember', window );">Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OrganizationandPrincipalActivitiesDetailsLineItems', window );"><strong>Organization and Principal Activities (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity investment percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OrganizationandPrincipalActivitiesDetailsLineItems', window );"><strong>Organization and Principal Activities (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_OrganizationandPrincipalActivitiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_OrganizationandPrincipalActivitiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSecuredFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Secured financing other than securities sold under agreements to repurchase and securities loaned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 83<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480647/815-10-15-83<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSecuredFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderDividendsRateOnPolicyEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of earnings allocable to participating policyholders based on earnings of such policies for payment of dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(14)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderDividendsRateOnPolicyEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_SubsidiarieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_SubsidiarieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818892961264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Details) - Schedule of Company&#8217;s subsidiaries<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember', window );">FFPGS (HK) Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_WellImageLimitedMember', window );">Well Image Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember', window );">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember', window );">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember', window );">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cambodia company &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cambodia company &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember', window );">First Fertility Bishkek LLC (&#8220;FFB&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Kyrgyzstan company &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Kyrgyzstan company &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision surrogacy and ancillary caring services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision surrogacy and ancillary caring services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SubsidiariesBackground">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Background.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SubsidiariesBackground</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FFPGSHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_WellImageLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_WellImageLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893190816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Salvage value percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_RevenueRate', window );">Contract revenue rate</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets (in Dollars)</a></td>
<td class="nump">$ 272,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,847<span></span>
</td>
<td class="nump">$ 383,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Lease liabilities (in Dollars)</a></td>
<td class="nump">$ 313,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="nump">$ 426,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Borrowing cost rate</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Lease payments rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Lease payments rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SupplierMember', window );">Supplier [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember', window );">Suppliers One [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember', window );">Suppliers One [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersFourMember', window );">Suppliers Four [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersFourMember', window );">Suppliers Four [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_NoVendorsMember', window );">No Vendors [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">21.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_VendorTwoMember', window );">Vendor Two [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.30%<span></span>
</td>
<td class="nump">35.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_OneVendorsMember', window );">One Vendors [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_OneVendorsMember', window );">One Vendors [Member] | Customer Concentration Risk [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other Customer [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember', window );">Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember', window );">Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember', window );">Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_RevenueMember', window );">Revenue [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_RevenueBenchmarkOneMember', window );">Revenue Benchmark One [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_RevenueBenchmarkTwoMember', window );">Revenue Benchmark Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_OneCustomerMember', window );">One Customer [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=nivf_OneCustomerMember', window );">One Customer [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_RevenueRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of revenue rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_RevenueRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_SuppliersFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_NoVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_NoVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_OneVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=nivf_OneVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_RevenueBenchmarkOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_RevenueBenchmarkOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_RevenueBenchmarkTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_RevenueBenchmarkTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nivf_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nivf_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898205104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_HKD', window );">HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_THB', window );">THB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">36.8454<span></span>
</td>
<td class="nump">34.2265<span></span>
</td>
<td class="nump">35.3081<span></span>
</td>
<td class="nump">34.6153<span></span>
</td>
<td class="nump">33.1964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">34.4021<span></span>
</td>
<td class="nump">34.7867<span></span>
</td>
<td class="nump">34.3864<span></span>
</td>
<td class="nump">35.1428<span></span>
</td>
<td class="nump">32.1003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_KHR', window );">KHR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">4,112.3016<span></span>
</td>
<td class="nump">4,080.0304<span></span>
</td>
<td class="nump">4,132.8226<span></span>
</td>
<td class="nump">4,114.3335<span></span>
</td>
<td class="nump">4,068.9577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">4,075.4046<span></span>
</td>
<td class="nump">4,105.4181<span></span>
</td>
<td class="nump">4,058.1179<span></span>
</td>
<td class="nump">4,083.7043<span></span>
</td>
<td class="nump">4,065.8164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.2674<span></span>
</td>
<td class="nump">7.0971<span></span>
</td>
<td class="nump">6.4586<span></span>
</td>
<td class="nump">6.9091<span></span>
</td>
<td class="nump">6.3551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">7.2142<span></span>
</td>
<td class="nump">7.0835<span></span>
</td>
<td class="nump">6.4077<span></span>
</td>
<td class="nump">6.4569<span></span>
</td>
<td class="nump">6.4368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_HKD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_HKD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_THB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_THB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_KHR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_KHR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898945696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PropertyPlantAndEquipmentEstimatedUsefulLive', window );">Estimated useful lives</a></td>
<td class="text">the lesser of useful life or term of lease<span></span>
</td>
<td class="text">the lesser of useful life or term of lease<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PropertyPlantAndEquipmentEstimatedUsefulLive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PropertyPlantAndEquipmentEstimatedUsefulLive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45819110022208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 172,493<span></span>
</td>
<td class="nump">$ 9,393<span></span>
</td>
<td class="nump">$ 13,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893711664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems', window );"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember', window );">Within 90 days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems', window );"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898089392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss - Movement of Allowances [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems', window );"><strong>Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reversal of expected credit losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897207056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - Schedule of Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Medicines, consumables and reagents for clinical and laboratory analyses</a></td>
<td class="nump">$ 102,825<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="nump">$ 46,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, total</a></td>
<td class="nump">$ 102,825<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="nump">$ 46,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898008656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">$ 359,035<span></span>
</td>
<td class="nump">$ 15,910<span></span>
</td>
<td class="nump">$ 30,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">131,111<span></span>
</td>
<td class="nump">123,008<span></span>
</td>
<td class="nump">40,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepayment</a></td>
<td class="nump">213,765<span></span>
</td>
<td class="nump">4,848<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred initial public offering &#8220;IPO&#8221; cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">373,677<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits, prepayment, other receivables and deferred IPO cost, net</a></td>
<td class="nump">$ 703,897<span></span>
</td>
<td class="nump">$ 517,429<span></span>
</td>
<td class="nump">$ 70,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818900035040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract', window );"><strong>Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Balance at beginning of the year</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision', window );">Reversal of provision (Provision)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment', window );">Effect of currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Ending balance</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of allowances for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of effect of currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repressent the amount of reversal of provision (Provision).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899318736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 12,619<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="nump">$ 31,173<span></span>
</td>
<td class="nump">$ 100,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">114,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898081888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 1,379,482<span></span>
</td>
<td class="nump">$ 1,481,364<span></span>
</td>
<td class="nump">$ 1,400,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,219,551)<span></span>
</td>
<td class="num">(1,319,207)<span></span>
</td>
<td class="num">(1,277,410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant and equipment, Net</a></td>
<td class="nump">159,931<span></span>
</td>
<td class="nump">162,157<span></span>
</td>
<td class="nump">122,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">85,867<span></span>
</td>
<td class="nump">92,438<span></span>
</td>
<td class="nump">72,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">247,229<span></span>
</td>
<td class="nump">250,493<span></span>
</td>
<td class="nump">246,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember', window );">Medical instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">765,081<span></span>
</td>
<td class="nump">844,809<span></span>
</td>
<td class="nump">791,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">142,936<span></span>
</td>
<td class="nump">142,936<span></span>
</td>
<td class="nump">142,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 138,369<span></span>
</td>
<td class="nump">$ 150,688<span></span>
</td>
<td class="nump">$ 146,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893920048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 183,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 43,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 22,345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Withholding tax payable</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">82,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Compensation payable (Note 1)</a></td>
<td class="nump">14,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">144,015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">117,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">114,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">46,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued Liabilties and Other Payables</a></td>
<td class="nump">$ 3,014,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 241,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 289,777<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897947520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities (Details) - Schedule of Contract Liabilities - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Schedule of Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions</a></td>
<td class="nump">$ 37,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 112,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized to revenue during the year</a></td>
<td class="num">(7,937)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(122,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(812,158)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Refund to customers</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,341,575)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">812,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="nump">$ 37,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898007488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 272,474<span></span>
</td>
<td class="nump">$ 283,847<span></span>
</td>
<td class="nump">$ 383,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 272,474<span></span>
</td>
<td class="nump">$ 296,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_OperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_OperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898068848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Lease Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Schedule of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities &#8211; current portion</a></td>
<td class="nump">$ 199,297<span></span>
</td>
<td class="nump">$ 207,128<span></span>
</td>
<td class="nump">$ 184,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities &#8211; non-current portion</a></td>
<td class="nump">114,096<span></span>
</td>
<td class="nump">118,979<span></span>
</td>
<td class="nump">242,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 313,393<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="nump">$ 426,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893014048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Other Lease Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Other Lease Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases</a></td>
<td class="text">8 months 1 day<span></span>
</td>
<td class="text">11 months 1 day<span></span>
</td>
<td class="text">1 year 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="nump">$ 100,009<span></span>
</td>
<td class="nump">$ 114,937<span></span>
</td>
<td class="nump">$ 89,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897715792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Future Minimum Payments under Operating Leases - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments under Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Not later than 1 year</a></td>
<td class="nump">$ 199,654<span></span>
</td>
<td class="nump">$ 240,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Between 1 to 2 years</a></td>
<td class="nump">79,079<span></span>
</td>
<td class="nump">111,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Between 2 to 3 years</a></td>
<td class="nump">35,018<span></span>
</td>
<td class="nump">10,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">313,751<span></span>
</td>
<td class="nump">362,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(358)<span></span>
</td>
<td class="num">(36,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities, net of interest</a></td>
<td class="nump">$ 313,393<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="nump">$ 426,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899047072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149,386<span></span>
</td>
<td class="nump">698,123<span></span>
</td>
<td class="nump">601,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,494<span></span>
</td>
<td class="nump">$ 6,981<span></span>
</td>
<td class="nump">$ 6,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional ordinary shares (in Shares)</a></td>
<td class="nump">2,054,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,293<span></span>
</td>
<td class="nump">41,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">$ 2,053,593<span></span>
</td>
<td class="nump">$ 192,308<span></span>
</td>
<td class="nump">$ 812,573<span></span>
</td>
<td class="nump">$ 319,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountOfRegulatoryAssistanceReceived1', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued (in Shares)</a></td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Increase in paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember', window );">Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Remuneration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiMember', window );">Ms. Fong, Hei [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Remuneration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nivf_SeazenResourcesInvestmentLimitedMember', window );">Seazen Resources Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional ordinary shares (in Shares)</a></td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherBorrowings', window );">Other borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Consulting service</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,451,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember', window );">NewGenIvf Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRegulatoryAssistanceReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory assistance received from a federal regulatory agency in conjunction with either an acquisition of a troubled financial institution, transfer of nonperforming assets to a newly-formed entity, or other reorganization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.N)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRegulatoryAssistanceReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAdditionalCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional paid-in capital (APIC) classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAdditionalCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MsFongHeiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nivf_SeazenResourcesInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nivf_SeazenResourcesInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nivf_NewGenIvfLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899296576">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Subscription Receivables - Subscription Receivable including Common Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems', window );"><strong>Equity (Details) - Schedule of Subscription Receivables [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Balance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 319,872<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares (Note 1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,866,856<span></span>
</td>
<td class="nump">319,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Settlement of subscription receivable (Note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(219,628)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,967,100<span></span>
</td>
<td class="nump">$ 319,872<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On January 18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald FAN and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to settlement of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nivf_SubscriptionReceivableIncludingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nivf_SubscriptionReceivableIncludingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818891088448">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Additional Paid-in Capital - Common Stock Including Additional Paid in Capital [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems', window );"><strong>Equity (Details) - Schedule of Additional Paid-in Capital [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Balance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 257,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueDirectorsRemuneration', window );">Directors&#8217; remuneration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_IssuanceOfSharesAdditionalpaidincapital', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,865,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,865,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">961,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 57,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The Company recorded remuneration to its directors, Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina. The remuneration to Mr.&#160;Siu, Wing Fung Alfred and Ms. Fong, Hei Yue Tina was $120,000 and $120,000 for the year ended December&#160;31, 2022, respectively. The directors considered remuneration as a capital injection rather than receiving it in cash, resulting in an $240,000 increase in paid-in capital.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_IssuanceOfSharesAdditionalpaidincapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_IssuanceOfSharesAdditionalpaidincapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueDirectorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period to directors&#8217; remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueDirectorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899508144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>KZT (&#8376;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>KZT (&#8376;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>THB (&#3647;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>THB (&#3647;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SpecialAssessmentBond', window );">Special concession amount (in Baht) | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 450<span></span>
</td>
<td class="nump">&#3647; 450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SpecialAssessmentBond', window );">Special concession amount (in Baht) | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 750<span></span>
</td>
<td class="nump">&#3647; 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">KYRGYZSTAN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Scheme calculated rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member] | Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ContributableWageRate', window );">Contribution equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member] | Cambodia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average wages per share (in Dollars per share)</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_OccupationalRiskSchemeMember', window );">Occupational Risk Scheme [Member] | Cambodia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average wages per share (in Dollars per share)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member] | Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ContributableWageRate', window );">Contribution equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member] | Cambodia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average wages per share (in Dollars per share)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_HealthCareSchemeMember', window );">Health Care Scheme [Member] | Cambodia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average wages per share (in Dollars per share)</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ContributableWageRate', window );">Contribution equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ContributableWageTotalRate', window );">Contribution equivalent total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Cambodia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Contributable wage</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">&#8376; 400,000<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">&#8376; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember', window );">Pension Scheme [Member] | Cambodia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Contributable wage</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">&#8376; 1,200,000<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">&#8376; 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ContributableWageRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributable wage rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ContributableWageRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ContributableWageTotalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributable wage total rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ContributableWageTotalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EmployeeBenefitPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EmployeeBenefitPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementAndServiceFeesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementAndServiceFeesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SpecialAssessmentBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SpecialAssessmentBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nivf_OccupationalRiskSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nivf_OccupationalRiskSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nivf_HealthCareSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nivf_HealthCareSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nivf_PensionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nivf_PensionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896830672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details)<br> $ in Millions, &#6107; in Billions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>KHR (&#6107;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>KHR (&#6107;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsLineItems', window );"><strong>Provision for IncomeTaxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProfitTaxDescription', window );">Profit tax rate description</a></td>
<td class="text">Under the two-tiered&#160;profits
tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits arising in or derived
from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits above HK$2&#160;million
will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates regime will continue to
be taxed at a flat rate of 16.5%.<span></span>
</td>
<td class="text">Under
the two-tiered&#160;profits tax rates regime, Hong&#160;Kong tax residents are subject to Hong&#160;Kong Profits Tax in respect of profits
arising in or derived from Hong&#160;Kong at 8.25% for the first HK$2&#160;million of profits of the qualifying group entity, and profits
above HK$2&#160;million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered&#160;profits tax rates
regime will continue to be taxed at a flat rate of 16.5%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Profit tax percent</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment', window );">Estimated assessable profit rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther', window );">Corporate income tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Rate of tax</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Provisions rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">Corporate income tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">progressive rates</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Profit tax rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PercentageOfAllowanceOnDeferredTaxAssets', window );">Percentage of allowance on deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsLineItems', window );"><strong>Provision for IncomeTaxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">progressive rates</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Annual turnover ranges (in Riels) | &#6107;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsLineItems', window );"><strong>Provision for IncomeTaxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">progressive rates</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Annual turnover ranges (in Riels) | &#6107;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#6107; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HK [Member] | HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsLineItems', window );"><strong>Provision for IncomeTaxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Estimated assessable profits (in Dollars) | $</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PercentageOfAllowanceOnDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of allowance on deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PercentageOfAllowanceOnDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProfitTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit tax Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProfitTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProvisionforIncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProvisionforIncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to investment tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893928560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 208,141<span></span>
</td>
<td class="nump">$ 294,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember', window );">Current tax provision Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember', window );">Current tax provision Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember', window );">Late penalty provision Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899454336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of Income Taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfIncomeTaxesAbstract', window );"><strong>Schedule of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="num">$ (387,781)<span></span>
</td>
<td class="num">$ (295,060)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
<td class="nump">$ 343,988<span></span>
</td>
<td class="nump">$ 156,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax expenses (credit) at the effective tax rates</a></td>
<td class="num">(69,180)<span></span>
</td>
<td class="num">(114,645)<span></span>
</td>
<td class="nump">10,732<span></span>
</td>
<td class="num">(124,591)<span></span>
</td>
<td class="nump">36,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Tax effect on non-taxable income</a></td>
<td class="num">(509)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,173)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Tax effect on non-deductible expenses</a></td>
<td class="nump">42,924<span></span>
</td>
<td class="nump">206,496<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,101<span></span>
</td>
<td class="nump">114,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Tax effect on late penalty provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">145,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,441<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Tax effect on utilization of tax losses</a></td>
<td class="nump">26,765<span></span>
</td>
<td class="num">(8,124)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,369)<span></span>
</td>
<td class="num">(1,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 208,141<span></span>
</td>
<td class="nump">$ 294,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899819952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Schedule of Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">&#8211; Net operating loss carry forward</a></td>
<td class="nump">$ 28,441<span></span>
</td>
<td class="nump">$ 28,441<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(28,441)<span></span>
</td>
<td class="num">(28,441)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818915158128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Business Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,686,902<span></span>
</td>
<td class="nump">$ 2,138,622<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="nump">$ 4,118,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember', window );">IVF treatment service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,380,576<span></span>
</td>
<td class="nump">1,869,987<span></span>
</td>
<td class="nump">4,021,696<span></span>
</td>
<td class="nump">2,819,163<span></span>
</td>
<td class="nump">3,199,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember', window );">Surrogacy, ancillary caring and other services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 306,326<span></span>
</td>
<td class="nump">$ 268,635<span></span>
</td>
<td class="nump">$ 1,114,457<span></span>
</td>
<td class="nump">$ 3,125,027<span></span>
</td>
<td class="nump">$ 918,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893020832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,686,902<span></span>
</td>
<td class="nump">$ 2,138,622<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="nump">$ 4,118,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nivf_HKSARMember', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,038<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,267,983<span></span>
</td>
<td class="nump">1,426,592<span></span>
</td>
<td class="nump">3,123,593<span></span>
</td>
<td class="nump">5,060,973<span></span>
</td>
<td class="nump">3,110,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">306,326<span></span>
</td>
<td class="nump">270,655<span></span>
</td>
<td class="nump">621,619<span></span>
</td>
<td class="nump">377,608<span></span>
</td>
<td class="nump">313,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,109,516<span></span>
</td>
<td class="nump">$ 441,375<span></span>
</td>
<td class="nump">$ 1,356,903<span></span>
</td>
<td class="nump">$ 505,609<span></span>
</td>
<td class="nump">$ 693,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899643328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">$ 434,371<span></span>
</td>
<td class="nump">$ 446,004<span></span>
</td>
<td class="nump">$ 506,343<span></span>
</td>
<td class="nump">$ 592,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nivf_HKSARMember', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,513<span></span>
</td>
<td class="nump">20,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">132,627<span></span>
</td>
<td class="nump">137,472<span></span>
</td>
<td class="nump">229,085<span></span>
</td>
<td class="nump">332,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">$ 300,575<span></span>
</td>
<td class="nump">$ 307,948<span></span>
</td>
<td class="nump">$ 254,745<span></span>
</td>
<td class="nump">$ 238,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893898432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for account receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Allowance for deposits and other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase (decrease) interest risk rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_InterestRateOtherVariablesPercentage', window );">Interest rate other variables, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPensionPlanObligations', window );">Increased (decreased) amount</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Allowance for deposits and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nivf_ASPACIMember', window );">A SPAC I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Allowance for deposits and other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,818<span></span>
</td>
<td class="nump">$ 17,059<span></span>
</td>
<td class="nump">6,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_DepositsAndOtherReceivableMember', window );">Deposits and Other Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Risks [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss', window );">Allowance for deposits and other receivables</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_InterestRateOtherVariablesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate other variables, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_InterestRateOtherVariablesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPensionPlanObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for pension benefits. Includes, but is not limited to, defined benefit or defined contribution plans. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPensionPlanObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nivf_ASPACIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nivf_ASPACIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_DepositsAndOtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_DepositsAndOtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818890995856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseAbstract', window );"><strong>Related Party Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholders', window );">Due from shareholders</a></td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="nump">$ 2,240,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897103248">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember', window );">Mr. Siu Wing Fung, Alfred (&#8220;Mr. Siu&#8221;) and Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholdersConsistOfTheFollowingAbstract', window );"><strong>Due from shareholders consist of the following:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Shareholders and directors (note 1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Shareholders and directors (note 1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToRelatedParties', window );">Due to Related Parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="nump">$ 2,240,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember', window );">Harcourt Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholdersConsistOfTheFollowingAbstract', window );"><strong>Due from shareholders consist of the following:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A related company (note&#160;2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToRelatedParties', window );">Due to Related Parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (110,773)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">The directors and shareholders of Harcourt Limited are Mr.&#160;Siu and Ms. Fong, Harcourt Limited therefore has the common ultimate beneficial owners with the Company.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholdersConsistOfTheFollowingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholdersConsistOfTheFollowingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_HarcourtLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899283984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract', window );"><strong>Schedule of the Balance Due from Shareholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholder', window );">Due from shareholders</a></td>
<td class="num">$ (221,203)<span></span>
</td>
<td class="nump">$ 372,103<span></span>
</td>
<td class="nump">$ 2,257,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent', window );">Less: allowance for expected credit loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17,818)<span></span>
</td>
<td class="num">(17,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss', window );">Total shareholders amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="nump">$ 2,240,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfBalanceDueFromShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893896784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract', window );"><strong>Schedule of the Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
<td class="num">$ (6,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(759)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
<td class="num">(10,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899786592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember', window );">Directors&#8217; remuneration to Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TransactionsWithRelatedParties', window );">Transactions with Related Parties</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember', window );">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TransactionsWithRelatedParties', window );">Transactions with Related Parties</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember', window );">Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TransactionsWithRelatedParties', window );">Transactions with Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,151)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_TransactionsWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_TransactionsWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898926208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to a SPAC I (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loan to a SPAC I [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherShortTermDebt', window );">Loan outstanding</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899693008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Contingent tax penalty</a></td>
<td class="nump">$ 486,706<span></span>
</td>
<td class="nump">$ 486,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896993488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_NumberOfOperatingSegment', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Reportable segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_NumberOfOperatingSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments operated by the entity. A operating segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_NumberOfOperatingSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898216768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 03, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Apr. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Principal amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Ordinary shares (in Shares)</a></td>
<td class="nump">295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional ordinary shares (in Shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nivf_TranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nivf_TranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818897139600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Details) - Schedule of Company&#8217;s Subsidiaries<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_NewGenIvfLimitedMember', window );">NewGenivf Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cayman Islands company &#9679;&#160;&#160;&#160;Incorporated on 16 January, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember', window );">FFPGS (HK) Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on December&#160;19, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Marketing and administrative services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_WellImageLimitedMember', window );">Well Image Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Hong&#160;Kong company &#9679;&#160;&#160;&#160;Incorporated on July&#160;11, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember', window );">Med Holdings Limited (&#8220;Med Holdings&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on January&#160;21, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Investment holding<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember', window );">First Fertility PGS Center Limited (&#8220;FFC&#8221;) (Note) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Thailand company &#9679;&#160;&#160;&#160;Incorporated on March&#160;6, 2014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember', window );">First Fertility Phnom Penh Limited (&#8220;FFPP&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cambodia company &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Cambodia company &#9679;&#160;&#160;&#160;Incorporated on August&#160;10, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision of IVF treatment<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember', window );">First Fertility Bishkek LLC (&#8220;FFB&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SubsidiariesBackground', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;A Kyrgyzstan company &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#9679;&#160;&#160;&#160;A Kyrgyzstan company &#9679;&#160;&#160;&#160;Incorporated on October&#160;11, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal activity</a></td>
<td class="text">Provision surrogacy and ancillary caring services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Provision surrogacy and ancillary caring services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Where less than 50% of the equity of an investee is held, the Company (through its subsidiaries) holds significantly more voting rights than any other vote holder or organized company of vote holders. An assessment has been made, taking into account all the factors relevant to the relationship with the investee, to ascertain control has been established and the investee should be consolidated as a subsidiary of the Company.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SubsidiariesBackground">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Background.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SubsidiariesBackground</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_NewGenIvfLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_NewGenIvfLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FFPGSHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FFPGSHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_WellImageLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_WellImageLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_MedHoldingsLimitedMedHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPGSCenterLimitedFFCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityPhnomPenhLimitedFFPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=nivf_FirstFertilityBishkekLLCFFBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818900004416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_HKD', window );">HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_THB', window );">THB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">36.8454<span></span>
</td>
<td class="nump">34.2265<span></span>
</td>
<td class="nump">35.3081<span></span>
</td>
<td class="nump">34.6153<span></span>
</td>
<td class="nump">33.1964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">34.4021<span></span>
</td>
<td class="nump">34.7867<span></span>
</td>
<td class="nump">34.3864<span></span>
</td>
<td class="nump">35.1428<span></span>
</td>
<td class="nump">32.1003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_KHR', window );">KHR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">4,112.3016<span></span>
</td>
<td class="nump">4,080.0304<span></span>
</td>
<td class="nump">4,132.8226<span></span>
</td>
<td class="nump">4,114.3335<span></span>
</td>
<td class="nump">4,068.9577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">4,075.4046<span></span>
</td>
<td class="nump">4,105.4181<span></span>
</td>
<td class="nump">4,058.1179<span></span>
</td>
<td class="nump">4,083.7043<span></span>
</td>
<td class="nump">4,065.8164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems', window );"><strong>Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates, period-end</a></td>
<td class="nump">7.2674<span></span>
</td>
<td class="nump">7.0971<span></span>
</td>
<td class="nump">6.4586<span></span>
</td>
<td class="nump">6.9091<span></span>
</td>
<td class="nump">6.3551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ForeignCurrencyExchangeRateTranslation', window );">Currency exchange rates, period average</a></td>
<td class="nump">7.2142<span></span>
</td>
<td class="nump">7.0835<span></span>
</td>
<td class="nump">6.4077<span></span>
</td>
<td class="nump">6.4569<span></span>
</td>
<td class="nump">6.4368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_HKD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_HKD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_THB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_THB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_KHR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_KHR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818900005248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_PropertyPlantAndEquipmentEstimatedUsefulLive', window );">Estimated useful lives</a></td>
<td class="text">the lesser of useful life or term of lease<span></span>
</td>
<td class="text">the lesser of useful life or term of lease<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Medical Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_PropertyPlantAndEquipmentEstimatedUsefulLive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_PropertyPlantAndEquipmentEstimatedUsefulLive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899956752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfAccountsReceivableNetAbstract', window );"><strong>Schedule of Accounts Receivable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 172,493<span></span>
</td>
<td class="nump">$ 9,393<span></span>
</td>
<td class="nump">$ 13,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfAccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfAccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896002528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems', window );"><strong>Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember', window );">Within 90 days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems', window );"><strong>Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable , net</a></td>
<td class="nump">$ 172,475<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=nivf_Within90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898043200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss - Movement of Allowances [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems', window );"><strong>Schedule of Movement Allowances for Expected Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reversal (provision) of provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Effect of currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=nivf_MovementOfAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893310320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - Schedule of Inventories - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Medicines, consumables and reagents for clinical and laboratory analyses</a></td>
<td class="nump">$ 102,825<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="nump">$ 46,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, total</a></td>
<td class="nump">$ 102,825<span></span>
</td>
<td class="nump">$ 126,264<span></span>
</td>
<td class="nump">$ 46,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898070416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">$ 359,035<span></span>
</td>
<td class="nump">$ 15,910<span></span>
</td>
<td class="nump">$ 30,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">131,111<span></span>
</td>
<td class="nump">123,008<span></span>
</td>
<td class="nump">40,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepayment</a></td>
<td class="nump">213,765<span></span>
</td>
<td class="nump">4,848<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred initial public offering &#8220;IPO&#8221; cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">373,677<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts', window );">Less: allowance for expected credit loss</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits, prepayment, other receivables and deferred IPO cost, net</a></td>
<td class="nump">$ 703,897<span></span>
</td>
<td class="nump">$ 517,429<span></span>
</td>
<td class="nump">$ 70,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898859200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract', window );"><strong>Schedule of Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Balance at beginning of the year</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision', window );">Reversal of provision (Provision)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment', window );">Effect of currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowancesForExpectedCreditLoss', window );">Ending balance</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of allowances for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of effect of currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repressent the amount of reversal of provision (Provision).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895659376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 1,379,482<span></span>
</td>
<td class="nump">$ 1,481,364<span></span>
</td>
<td class="nump">$ 1,400,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,219,551)<span></span>
</td>
<td class="num">(1,319,207)<span></span>
</td>
<td class="num">(1,277,410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant and equipment, Net</a></td>
<td class="nump">159,931<span></span>
</td>
<td class="nump">162,157<span></span>
</td>
<td class="nump">122,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">85,867<span></span>
</td>
<td class="nump">92,438<span></span>
</td>
<td class="nump">72,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">247,229<span></span>
</td>
<td class="nump">250,493<span></span>
</td>
<td class="nump">246,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember', window );">Medical instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">765,081<span></span>
</td>
<td class="nump">844,809<span></span>
</td>
<td class="nump">791,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">142,936<span></span>
</td>
<td class="nump">142,936<span></span>
</td>
<td class="nump">142,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>At cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Plant and equipment, Gross</a></td>
<td class="nump">$ 138,369<span></span>
</td>
<td class="nump">$ 150,688<span></span>
</td>
<td class="nump">$ 146,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nivf_MedicalInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818898996304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 183,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 43,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 22,345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Withholding tax payable</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">82,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Compensation payable (Note 1)</a></td>
<td class="nump">14,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">144,015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">117,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">2,699,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">114,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">46,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 64,077<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued Liabilties and Other Payables</a></td>
<td class="nump">$ 315,696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 241,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Compensation payable represented a claim relating to an employee of First Fertility PGS Center Limited (&#8220;FFC&#8221;). On April 23, 2023, the compensation agreement is finalized with the employee and the compensation is payable in 12 instalments within one year from 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895689120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities (Details) - Schedule of Contract Liabilities - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Schedule of Contract Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions</a></td>
<td class="nump">$ 37,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 112,006<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized to revenue during the period</a></td>
<td class="num">(7,937)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(122,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(812,158)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Refund to customers</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,341,575)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">812,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="nump">$ 37,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,360,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Refund of the deposits received from customer for services not rendered during 2023. China-based clients who prepaid for surrogacy and ancillary caring services requested refund of fees so such clients can appoint their own surrogate mothers in countries in which the Company does not conduct business. The Company sent the funds to accounts dictated by the clients and terminated service contract with those clients.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818896930832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Lease Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Schedule of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities &#8211; current portion</a></td>
<td class="nump">$ 199,297<span></span>
</td>
<td class="nump">$ 207,128<span></span>
</td>
<td class="nump">$ 184,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities &#8211; non-current portion</a></td>
<td class="nump">114,096<span></span>
</td>
<td class="nump">118,979<span></span>
</td>
<td class="nump">242,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 313,393<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="nump">$ 426,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895689984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Other Lease Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Other Lease Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases</a></td>
<td class="text">8 months 1 day<span></span>
</td>
<td class="text">11 months 1 day<span></span>
</td>
<td class="text">1 year 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8211; operating leases</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="nump">$ 100,009<span></span>
</td>
<td class="nump">$ 114,937<span></span>
</td>
<td class="nump">$ 89,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899520016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Future Minimum Payments under Operating Leases - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments under Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Not later than 1 year</a></td>
<td class="nump">$ 199,654<span></span>
</td>
<td class="nump">$ 240,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Between 1 to 2 years</a></td>
<td class="nump">79,079<span></span>
</td>
<td class="nump">111,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Between 2 to 3 years</a></td>
<td class="nump">35,018<span></span>
</td>
<td class="nump">10,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">313,751<span></span>
</td>
<td class="nump">362,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(358)<span></span>
</td>
<td class="num">(36,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities, net of interest</a></td>
<td class="nump">$ 313,393<span></span>
</td>
<td class="nump">$ 326,107<span></span>
</td>
<td class="nump">$ 426,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818915924608">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Subscription Receivables - Subscription Receivable including Common Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems', window );"><strong>Equity (Details) - Schedule of Subscription Receivables [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Balance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,967,100<span></span>
</td>
<td class="nump">$ 319,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,866,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable', window );">Settlement of subscription receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(219,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,506,691<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,473,791<span></span>
</td>
<td class="nump">$ 2,967,100<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&#160;15, 2022, the Company issued and allotted additional 41,830 ordinary shares to Seazen Resources Investment Limited (&#8220;Seazen&#8221;) at the consideration of $961,538, of which other borrowings of $641,025 and $641 settlement was offset with consideration as partial settlement and $319,872 was subscription receivable due from Seazen.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On January 18, 2023, the Company received $192,308 from Seazen, reducing the subscription receivable by $192,308. On January 10, 2023, the Company issued and allotted additional 27,293 ordinary shares to Tung Donald FAN and Hok Lun Alan Lau at the consideration of $812,573. On December 4, 2023, the Company issued and allotted additional 69,000 shares to DoubleClick Services Limited at $2,054,283. Among the subscription receivable during the year, $27,320 was settled by the professional consulting service rendered during the year ended December 31, 2023.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to settlement of subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nivf_SubscriptionReceivableIncludingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nivf_SubscriptionReceivableIncludingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895654896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of Additional Paid-in Capital - Common Stock Including Additional Paid in Capital [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems', window );"><strong>Equity (Details) - Schedule of Additional Paid-in Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Balance at beginning of year</a></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 257,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_IssuanceOfSharesAdditionalpaidincapital', window );">Issuance of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,865,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,865,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">961,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Business combination</a></td>
<td class="num">(4,267,013)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Total</a></td>
<td class="nump">$ 57,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,324,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,458,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">On August 15, 2022, the Company issued 41,830 ordinary shares to Seazen, increasing the additional paid-in capital by $961,120. On January 10, 2023, the Company issued 27,293 ordinary shares to professional party for consulting service of 10 years, increasing the additional paid-in capital by $812,300. On December 4, 2023, the Company issued additional 69,000 shares to DoubleClick Services Limited for consulting service of 10 years, increasing the additional paid-in capital by $2,053,593.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_IssuanceOfSharesAdditionalpaidincapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_IssuanceOfSharesAdditionalpaidincapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899389696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 208,141<span></span>
</td>
<td class="nump">$ 294,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember', window );">Current tax provision Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember', window );">Current tax provision Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember', window );">Late penalty provision Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems', window );"><strong>Schedule of the Provisions for Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_CurrentTaxProvisionCambodiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=nivf_LatePenaltyProvisionKyrgyzstanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895656112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of Income Taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfIncomeTaxesAbstract', window );"><strong>Schedule of Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income/(loss) before taxes</a></td>
<td class="num">$ (387,781)<span></span>
</td>
<td class="num">$ (295,060)<span></span>
</td>
<td class="nump">$ 108,418<span></span>
</td>
<td class="nump">$ 343,988<span></span>
</td>
<td class="nump">$ 156,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax expenses/(credit) at the effective tax rates</a></td>
<td class="num">(69,180)<span></span>
</td>
<td class="num">(114,645)<span></span>
</td>
<td class="nump">10,732<span></span>
</td>
<td class="num">(124,591)<span></span>
</td>
<td class="nump">36,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Tax effect on non-taxable income</a></td>
<td class="num">(509)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,173)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Tax effect on non-deductible expenses</a></td>
<td class="nump">42,924<span></span>
</td>
<td class="nump">206,496<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,101<span></span>
</td>
<td class="nump">114,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Tax effect on utilization of tax losses</a></td>
<td class="nump">26,765<span></span>
</td>
<td class="num">(8,124)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,369)<span></span>
</td>
<td class="num">(1,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 208,141<span></span>
</td>
<td class="nump">$ 294,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818913398560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">&#8211; Net operating loss carry forward</a></td>
<td class="nump">$ 28,441<span></span>
</td>
<td class="nump">$ 28,441<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(28,441)<span></span>
</td>
<td class="num">(28,441)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899894960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Business Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,686,902<span></span>
</td>
<td class="nump">$ 2,138,622<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="nump">$ 4,118,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember', window );">IVF treatment service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,380,576<span></span>
</td>
<td class="nump">1,869,987<span></span>
</td>
<td class="nump">4,021,696<span></span>
</td>
<td class="nump">2,819,163<span></span>
</td>
<td class="nump">3,199,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember', window );">Surrogacy, ancillary caring and other services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Schedule of Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 306,326<span></span>
</td>
<td class="nump">$ 268,635<span></span>
</td>
<td class="nump">$ 1,114,457<span></span>
</td>
<td class="nump">$ 3,125,027<span></span>
</td>
<td class="nump">$ 918,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_IVFTreatmentServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nivf_SurrogacyAncillaryCaringAndOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895532768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,686,902<span></span>
</td>
<td class="nump">$ 2,138,622<span></span>
</td>
<td class="nump">$ 5,136,153<span></span>
</td>
<td class="nump">$ 5,944,190<span></span>
</td>
<td class="nump">$ 4,118,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nivf_HKSARMember', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">34,038<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KG', window );">Kyrgyzstan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,267,983<span></span>
</td>
<td class="nump">1,426,592<span></span>
</td>
<td class="nump">3,123,593<span></span>
</td>
<td class="nump">5,060,973<span></span>
</td>
<td class="nump">3,110,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">306,326<span></span>
</td>
<td class="nump">270,655<span></span>
</td>
<td class="nump">621,619<span></span>
</td>
<td class="nump">377,608<span></span>
</td>
<td class="nump">313,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems', window );"><strong>Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,109,516<span></span>
</td>
<td class="nump">$ 441,375<span></span>
</td>
<td class="nump">$ 1,356,903<span></span>
</td>
<td class="nump">$ 505,609<span></span>
</td>
<td class="nump">$ 693,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818893086800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">$ 434,371<span></span>
</td>
<td class="nump">$ 446,004<span></span>
</td>
<td class="nump">$ 506,343<span></span>
</td>
<td class="nump">$ 592,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=nivf_HKSARMember', window );">HK SAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KH', window );">Cambodia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">132,627<span></span>
</td>
<td class="nump">137,472<span></span>
</td>
<td class="nump">229,085<span></span>
</td>
<td class="nump">332,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TH', window );">Thailand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Revenue Information above is Based on the Locations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-lived assets</a></td>
<td class="nump">$ 300,575<span></span>
</td>
<td class="nump">$ 307,948<span></span>
</td>
<td class="nump">$ 254,745<span></span>
</td>
<td class="nump">$ 238,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nivf_HKSARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nivf_HKSARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818917236576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties - Mr. Siu Wing Fung, Alfred (&#8220;Mr. Siu&#8221;) and Ms. Fong Hei Yue, Tina (&#8220;Ms. Fong&#8221;) [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholdersConsistOfTheFollowingAbstract0', window );"><strong>Due from shareholders consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Due from shareholders, Relationship</a></td>
<td class="text">Shareholders and directors (note 1)<span></span>
</td>
<td colspan="2" class="text">Shareholders and directors (note 1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from shareholders</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0', window );"><strong>Due to a related party consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Due to a related party, Relationship</a></td>
<td class="text">Shareholders and directors (note 1)<span></span>
</td>
<td colspan="2" class="text">Shareholders and directors (note 1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to a related party</a></td>
<td class="num">$ (221,203)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Ms. Fong is the spouse of Mr.&#160;Siu. As of December 31, 2023 and 2022, the due from shareholders balance was $354,285 and $2,240,872, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholdersConsistOfTheFollowingAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholdersConsistOfTheFollowingAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nivf_MrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895293856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract', window );"><strong>Schedule of the Balance Due from Shareholders [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_DueFromShareholder', window );">Due from shareholders</a></td>
<td class="num">$ (221,203)<span></span>
</td>
<td class="nump">$ 372,103<span></span>
</td>
<td class="nump">$ 2,257,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent', window );">Less: allowance for expected credit loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_OtherReceivablesNet', window );">Total shareholders amount</a></td>
<td class="num">$ (221,203)<span></span>
</td>
<td class="nump">$ 354,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_DueFromShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_DueFromShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_OtherReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_OtherReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfBalanceDueFromShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfBalanceDueFromShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818899919616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract', window );"><strong>Schedule of the Movement of Allowances for Expected Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the year</a></td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
<td class="num">$ (6,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(759)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
<td class="num">(10,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_AllowanceForExpectedCreditLossRevised', window );">Revised</a></td>
<td class="nump">17,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,818)<span></span>
</td>
<td class="num">$ (17,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_AllowanceForExpectedCreditLossRevised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for expected credit loss/revised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_AllowanceForExpectedCreditLossRevised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45818895961104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember', window );">Directors&#8217; remuneration to Mr. Siu Wing Fung, Alfred [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TransactionsWithRelatedParties', window );">Transactions with Related Parties</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember', window );">Directors&#8217; remuneration to Ms. Fong Hei Yue, Tina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nivf_TransactionsWithRelatedParties', window );">Transactions with Related Parties</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nivf_TransactionsWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nivf_TransactionsWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nivf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nivf_DirectorsRemunerationToMsFongHeiYueTinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>361</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Unaudited Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Unaudited Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Changes in Shareholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Principal Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivities</Role>
      <ShortName>Organization and Principal Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PlantandEquipmentNet</Role>
      <ShortName>Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accrued Liabilties and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables</Role>
      <ShortName>Accrued Liabilties and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Contract Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ContractLiabilities</Role>
      <ShortName>Contract Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Provision for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxes</Role>
      <ShortName>Provision for Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Disaggregated Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisaggregatedRevenues</Role>
      <ShortName>Disaggregated Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Risks</Role>
      <ShortName>Risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Related Party Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions</Role>
      <ShortName>Related Party Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Loan to a SPAC I</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LoantoaSPACI</Role>
      <ShortName>Loan to a SPAC I</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Impact of Covid-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ImpactofCovid19</Role>
      <ShortName>Impact of Covid-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization and Principal Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</Role>
      <ShortName>Organization and Principal Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Inventories</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PlantandEquipmentNetTables</Role>
      <ShortName>Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PlantandEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables</Role>
      <ShortName>Accrued Liabilties and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Contract Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ContractLiabilitiesTables</Role>
      <ShortName>Contract Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ContractLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Equity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Provision for Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</Role>
      <ShortName>Provision for Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Disaggregated Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</Role>
      <ShortName>Disaggregated Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenues</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Related Party Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</Role>
      <ShortName>Related Party Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Organization and Principal Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails</Role>
      <ShortName>Organization and Principal Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company???s subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable</Role>
      <ShortName>Organization and Principal Activities (Details) - Schedule of Company???s subsidiaries</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Inventories (Details) - Schedule of Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofInventoriesTable</Role>
      <ShortName>Inventories (Details) - Schedule of Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/InventoriesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/PlantandEquipmentNetDetails</Role>
      <ShortName>Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PlantandEquipmentNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable</Role>
      <ShortName>Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PlantandEquipmentNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable</Role>
      <ShortName>Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable</Role>
      <ShortName>Contract Liabilities (Details) - Schedule of Contract Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ContractLiabilitiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Leases (Details) - Schedule of Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Leases (Details) - Schedule of Other Lease Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable</Role>
      <ShortName>Leases (Details) - Schedule of Other Lease Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable</Role>
      <ShortName>Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Equity (Details) - Schedule of Subscription Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable</Role>
      <ShortName>Equity (Details) - Schedule of Subscription Receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable</Role>
      <ShortName>Equity (Details) - Schedule of Additional Paid-in Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails</Role>
      <ShortName>Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Business Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Geographical Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RisksDetails</Role>
      <ShortName>Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Risks</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Related Party Balances and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails</Role>
      <ShortName>Related Party Balances and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Loan to a SPAC I (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/LoantoaSPACIDetails</Role>
      <ShortName>Loan to a SPAC I (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LoantoaSPACI</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/Contingencies</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SegmentInformation</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company???s Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable</Role>
      <ShortName>Organization and Principal Activities (Details) - Schedule of Company???s Subsidiaries</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Inventories (Details) - Schedule of Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofInventoriesTable0</Role>
      <ShortName>Inventories (Details) - Schedule of Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/InventoriesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1</Role>
      <ShortName>Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0</Role>
      <ShortName>Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/PlantandEquipmentNetTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996064 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0</Role>
      <ShortName>Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0</Role>
      <ShortName>Contract Liabilities (Details) - Schedule of Contract Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ContractLiabilitiesTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996066 - Disclosure - Leases (Details) - Schedule of Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0</Role>
      <ShortName>Leases (Details) - Schedule of Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Leases (Details) - Schedule of Other Lease Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0</Role>
      <ShortName>Leases (Details) - Schedule of Other Lease Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996068 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0</Role>
      <ShortName>Leases (Details) - Schedule of Future Minimum Payments under Operating Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/LeasesTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996069 - Disclosure - Equity (Details) - Schedule of Subscription Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0</Role>
      <ShortName>Equity (Details) - Schedule of Subscription Receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996070 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0</Role>
      <ShortName>Equity (Details) - Schedule of Additional Paid-in Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/EquityTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996071 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996072 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>996073 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0</Role>
      <ShortName>Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>996074 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Business Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Geographical Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>996076 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0</Role>
      <ShortName>Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/DisaggregatedRevenuesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>996077 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>996078 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>996079 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="ea0219447-f1a4_newgen.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>996080 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0</Role>
      <ShortName>Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="F-1/A" isDefinitelyFs="true" isUsgaap="true" original="ea0219447-f1a4_newgen.htm">ea0219447-f1a4_newgen.htm</File>
    <File>nivf-20240630.xsd</File>
    <File>nivf-20240630_cal.xml</File>
    <File>nivf-20240630_def.xml</File>
    <File>nivf-20240630_lab.xml</File>
    <File>nivf-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>fin_002.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1372">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>251
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0219447-f1a4_newgen.htm": {
   "nsprefix": "nivf",
   "nsuri": "http://www.newgenivf.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "ea0219447-f1a4_newgen.htm"
     ]
    },
    "schema": {
     "local": [
      "nivf-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nivf-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nivf-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nivf-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nivf-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 282,
   "keyCustom": 40,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 35,
   "memberCustom": 43,
   "hidden": {
    "total": 202,
    "http://fasb.org/us-gaap/2024": 156,
    "http://www.newgenivf.com/20240630": 43,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 361,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 575,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1372,
    "http://xbrl.sec.gov/dei/2024": 22,
    "http://fasb.org/srt/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://www.newgenivf.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "nivf:LoanToASPAC",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss)",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations And Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.newgenivf.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit)",
     "shortName": "Unaudited Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c15",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c15",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.newgenivf.com/role/ConsolidatedCashFlow",
     "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivities",
     "longName": "006 - Disclosure - Organization and Principal Activities",
     "shortName": "Organization and Principal Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.newgenivf.com/role/AccountsReceivableNet",
     "longName": "008 - Disclosure - Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.newgenivf.com/role/Inventories",
     "longName": "009 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet",
     "longName": "010 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.newgenivf.com/role/PlantandEquipmentNet",
     "longName": "011 - Disclosure - Plant and Equipment, Net",
     "shortName": "Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables",
     "longName": "012 - Disclosure - Accrued Liabilties and Other Payables",
     "shortName": "Accrued Liabilties and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.newgenivf.com/role/ContractLiabilities",
     "longName": "013 - Disclosure - Contract Liabilities",
     "shortName": "Contract Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.newgenivf.com/role/Leases",
     "longName": "014 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.newgenivf.com/role/Equity",
     "longName": "015 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.newgenivf.com/role/EmployeeBenefitPlans",
     "longName": "016 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxes",
     "longName": "017 - Disclosure - Provision for Income Taxes",
     "shortName": "Provision for Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.newgenivf.com/role/DisaggregatedRevenues",
     "longName": "018 - Disclosure - Disaggregated Revenues",
     "shortName": "Disaggregated Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:DissagregattedRevenuesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:DissagregattedRevenuesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.newgenivf.com/role/Risks",
     "longName": "019 - Disclosure - Risks",
     "shortName": "Risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions",
     "longName": "020 - Disclosure - Related Party Balances and Transactions",
     "shortName": "Related Party Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.newgenivf.com/role/LoantoaSPACI",
     "longName": "021 - Disclosure - Loan to a SPAC I",
     "shortName": "Loan to a SPAC I",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.newgenivf.com/role/ImpactofCovid19",
     "longName": "022 - Disclosure - Impact of Covid-19",
     "shortName": "Impact of Covid-19",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "nivf:ImpactOfCovid19TextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "nivf:ImpactOfCovid19TextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.newgenivf.com/role/Contingencies",
     "longName": "023 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.newgenivf.com/role/SegmentInformation",
     "longName": "024 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.newgenivf.com/role/SubsequentEvents",
     "longName": "025 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.newgenivf.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables",
     "longName": "996001 - Disclosure - Organization and Principal Activities (Tables)",
     "shortName": "Organization and Principal Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.newgenivf.com/role/AccountsReceivableNetTables",
     "longName": "996003 - Disclosure - Accounts Receivable, Net (Tables)",
     "shortName": "Accounts Receivable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.newgenivf.com/role/InventoriesTables",
     "longName": "996004 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables",
     "longName": "996005 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.newgenivf.com/role/PlantandEquipmentNetTables",
     "longName": "996006 - Disclosure - Plant and Equipment, Net (Tables)",
     "shortName": "Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables",
     "longName": "996007 - Disclosure - Accrued Liabilties and Other Payables (Tables)",
     "shortName": "Accrued Liabilties and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.newgenivf.com/role/ContractLiabilitiesTables",
     "longName": "996008 - Disclosure - Contract Liabilities (Tables)",
     "shortName": "Contract Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.newgenivf.com/role/LeasesTables",
     "longName": "996009 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:ScheduleOfLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:ScheduleOfLeaseLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.newgenivf.com/role/EquityTables",
     "longName": "996010 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables",
     "longName": "996011 - Disclosure - Provision for Income Taxes (Tables)",
     "shortName": "Provision for Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.newgenivf.com/role/DisaggregatedRevenuesTables",
     "longName": "996012 - Disclosure - Disaggregated Revenues (Tables)",
     "shortName": "Disaggregated Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "nivf:DissagregattedRevenuesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "nivf:DissagregattedRevenuesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables",
     "longName": "996013 - Disclosure - Related Party Balances and Transactions (Tables)",
     "shortName": "Related Party Balances and Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
     "longName": "996014 - Disclosure - Organization and Principal Activities (Details)",
     "shortName": "Organization and Principal Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:PolicyholderDividendsRateOnPolicyEarnings",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:PolicyholderDividendsRateOnPolicyEarnings",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable",
     "longName": "996015 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company\u2019s subsidiaries",
     "shortName": "Organization and Principal Activities (Details) - Schedule of Company\u2019s subsidiaries",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c260",
      "name": "nivf:SubsidiariesBackground",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c281",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c289",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
     "longName": "996019 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
     "longName": "996020 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
     "longName": "996021 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c145",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.newgenivf.com/role/ScheduleofInventoriesTable",
     "longName": "996022 - Disclosure - Inventories (Details) - Schedule of Inventories",
     "shortName": "Inventories (Details) - Schedule of Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:InventoryGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
     "longName": "996023 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable",
     "longName": "996024 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "nivf:AllowancesForExpectedCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.newgenivf.com/role/PlantandEquipmentNetDetails",
     "longName": "996025 - Disclosure - Plant and Equipment, Net (Details)",
     "shortName": "Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
     "longName": "996026 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net",
     "shortName": "Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
     "longName": "996027 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables",
     "shortName": "Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
     "longName": "996028 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities",
     "shortName": "Contract Liabilities (Details) - Schedule of Contract Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.newgenivf.com/role/LeasesDetails",
     "longName": "996029 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "nivf:OperatingLeaseRightOfUseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable",
     "longName": "996030 - Disclosure - Leases (Details) - Schedule of Lease Liabilities",
     "shortName": "Leases (Details) - Schedule of Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable",
     "longName": "996031 - Disclosure - Leases (Details) - Schedule of Other Lease Information",
     "shortName": "Leases (Details) - Schedule of Other Lease Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
     "longName": "996032 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases",
     "shortName": "Leases (Details) - Schedule of Future Minimum Payments under Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.newgenivf.com/role/EquityDetails",
     "longName": "996033 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
     "longName": "996034 - Disclosure - Equity (Details) - Schedule of Subscription Receivables",
     "shortName": "Equity (Details) - Schedule of Subscription Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c173",
      "name": "us-gaap:StockholdersEquityNoteSubscriptionsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c175",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
     "longName": "996035 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital",
     "shortName": "Equity (Details) - Schedule of Additional Paid-in Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c182",
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c181",
      "name": "nivf:StockIssuedDuringPeriodValueDirectorsRemuneration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
     "longName": "996036 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ManagementAndServiceFeesRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c320",
      "name": "nivf:ContributableWageRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
     "longName": "996037 - Disclosure - Provision for Income Taxes (Details)",
     "shortName": "Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:ProfitTaxDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:ProfitTaxDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
     "longName": "996038 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes",
     "shortName": "Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
     "longName": "996039 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes",
     "shortName": "Provision for Income Taxes (Details) - Schedule of Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:IncomeTaxReconciliationOtherAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable",
     "longName": "996040 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets",
     "shortName": "Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
     "longName": "996041 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
     "longName": "996042 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Geographical Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
     "longName": "996043 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c224",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.newgenivf.com/role/RisksDetails",
     "longName": "996044 - Disclosure - Risks (Details)",
     "shortName": "Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails",
     "longName": "996045 - Disclosure - Related Party Balances and Transactions (Details)",
     "shortName": "Related Party Balances and Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "nivf:DueFromShareholders",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "nivf:DueFromShareholders",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
     "longName": "996046 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c354",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c237",
      "name": "nivf:DueToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable",
     "longName": "996047 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "nivf:DueFromShareholder",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0",
     "longName": "996048 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
     "longName": "996049 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c357",
      "name": "nivf:TransactionsWithRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c246",
      "name": "nivf:TransactionsWithRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.newgenivf.com/role/LoantoaSPACIDetails",
     "longName": "996050 - Disclosure - Loan to a SPAC I (Details)",
     "shortName": "Loan to a SPAC I (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c249",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c249",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.newgenivf.com/role/ContingenciesDetails",
     "longName": "996051 - Disclosure - Contingencies (Details)",
     "shortName": "Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.newgenivf.com/role/SegmentInformationDetails",
     "longName": "996052 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nivf:NumberOfOperatingSegment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:NumberOfOperatingSegment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.newgenivf.com/role/SubsequentEventsDetails",
     "longName": "996053 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c256",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c256",
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
     "longName": "996054 - Disclosure - Organization and Principal Activities (Details) - Schedule of Company\u2019s Subsidiaries",
     "shortName": "Organization and Principal Activities (Details) - Schedule of Company\u2019s Subsidiaries",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c259",
      "name": "nivf:SubsidiariesBackground",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c259",
      "name": "nivf:SubsidiariesBackground",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0",
     "longName": "996055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c281",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R83": {
     "role": "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
     "longName": "996056 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c289",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0",
     "longName": "996057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0",
     "longName": "996058 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0",
     "longName": "996059 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c145",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://www.newgenivf.com/role/ScheduleofInventoriesTable0",
     "longName": "996060 - Disclosure - Inventories (Details) - Schedule of Inventories",
     "shortName": "Inventories (Details) - Schedule of Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:InventoryGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0",
     "longName": "996061 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1",
     "longName": "996062 - Disclosure - Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "shortName": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "nivf:AllowancesForExpectedCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0",
     "longName": "996063 - Disclosure - Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net",
     "shortName": "Plant and Equipment, Net (Details) - Schedule of Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0",
     "longName": "996064 - Disclosure - Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables",
     "shortName": "Accrued Liabilties and Other Payables (Details) - Schedule of Accrued Liabilities and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0",
     "longName": "996065 - Disclosure - Contract Liabilities (Details) - Schedule of Contract Liabilities",
     "shortName": "Contract Liabilities (Details) - Schedule of Contract Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0",
     "longName": "996066 - Disclosure - Leases (Details) - Schedule of Lease Liabilities",
     "shortName": "Leases (Details) - Schedule of Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R94": {
     "role": "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0",
     "longName": "996067 - Disclosure - Leases (Details) - Schedule of Other Lease Information",
     "shortName": "Leases (Details) - Schedule of Other Lease Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0",
     "longName": "996068 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments under Operating Leases",
     "shortName": "Leases (Details) - Schedule of Future Minimum Payments under Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0",
     "longName": "996069 - Disclosure - Equity (Details) - Schedule of Subscription Receivables",
     "shortName": "Equity (Details) - Schedule of Subscription Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c309",
      "name": "us-gaap:StockholdersEquityNoteSubscriptionsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c310",
      "name": "us-gaap:StockholdersEquityNoteSubscriptionsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0",
     "longName": "996070 - Disclosure - Equity (Details) - Schedule of Additional Paid-in Capital",
     "shortName": "Equity (Details) - Schedule of Additional Paid-in Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c182",
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c315",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0",
     "longName": "996071 - Disclosure - Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes",
     "shortName": "Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R99": {
     "role": "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0",
     "longName": "996072 - Disclosure - Provision for Income Taxes (Details) - Schedule of Income Taxes",
     "shortName": "Provision for Income Taxes (Details) - Schedule of Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0",
     "longName": "996073 - Disclosure - Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets",
     "shortName": "Provision for Income Taxes (Details) - Schedule of Components of Deferred Tax Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R101": {
     "role": "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0",
     "longName": "996074 - Disclosure - Disaggregated Revenues (Details) - Schedule of Business Operations",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R102": {
     "role": "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
     "longName": "996075 - Disclosure - Disaggregated Revenues (Details) - Schedule of Geographical Information",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Geographical Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0",
     "longName": "996076 - Disclosure - Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations",
     "shortName": "Disaggregated Revenues (Details) - Schedule of Revenue Information above is Based on the Locations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R104": {
     "role": "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0",
     "longName": "996077 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Amount Due from and Due to Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c354",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c356",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0",
     "longName": "996078 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Balance Due from Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "nivf:DueFromShareholder",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "nivf:OtherReceivablesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2",
     "longName": "996079 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Movement of Allowances for Expected Credit Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nivf:AllowanceForExpectedCreditLossRevised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0",
     "longName": "996080 - Disclosure - Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements",
     "shortName": "Related Party Balances and Transactions (Details) - Schedule of Consolidated Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c357",
      "name": "nivf:TransactionsWithRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0219447-f1a4_newgen.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "nivf_ASPACIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ASPACIMember",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A SPAC I [Member]",
        "label": "ASPACIMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shareholders amount",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AccountsAndNontradeReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndNontradeReceivableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS RECEIVABLE, NET",
        "label": "Accounts and Nontrade Receivable [Text Block]",
        "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r296"
     ]
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net [Abstract]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r882"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r71"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED LIABILTIES AND OTHER PAYABLES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilties and Other Payables",
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r805"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable [Member]",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r293",
      "r757"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivable [Member]",
        "verboseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movement Allowances for Expected Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts receivable net",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable , net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]",
        "terseLabel": "Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AccountsReceivableNetDetailsScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net of Allowance for Expected Credit Loss [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss [Line Items]",
        "terseLabel": "Schedule of Movement Allowances for Expected Credit Loss [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AccountsReceivableNetDetailsScheduleofMovementAllowancesforExpectedCreditLossTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net (Details) - Schedule of Movement Allowances for Expected Credit Loss [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax payable",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r758",
      "r933"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withholding tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r118"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilties and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r187",
      "r602"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r77",
      "r192",
      "r596",
      "r628",
      "r632"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income/(loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16",
      "r21",
      "r487",
      "r490",
      "r535",
      "r623",
      "r624",
      "r855",
      "r856",
      "r857",
      "r866",
      "r867",
      "r868",
      "r871"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Total",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r866",
      "r867",
      "r868",
      "r871",
      "r948",
      "r1009"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for account receivables",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Balance at beginning of the year",
        "negatedPeriodEndLabel": "Ending balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r294",
      "r303",
      "r304",
      "r306",
      "r974"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r294",
      "r303"
     ]
    },
    "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulOtherReceivablesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable",
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit loss",
        "label": "Allowance for Credit Loss, Receivable, Other, Current",
        "documentation": "Amount of allowance for credit loss on receivable, classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "nivf_AllowanceForExpectedCreditLossRevised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AllowanceForExpectedCreditLossRevised",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revised",
        "documentation": "Allowance for expected credit loss/revised.",
        "label": "Allowance For Expected Credit Loss Revised"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AllowancesForExpectedCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AllowancesForExpectedCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Ending balance",
        "documentation": "Represent the amount of allowances for expected credit loss.",
        "label": "Allowances For Expected Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AllowancesForExpectedCreditLossEffectOfCurrencyTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of currency translation adjustment",
        "documentation": "Represent the amount of effect of currency translation adjustment.",
        "label": "Allowances For Expected Credit Loss Effect Of Currency Translation Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_AllowancesForExpectedCreditLossReversalOfProvisionProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "AllowancesForExpectedCreditLossReversalOfProvisionProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of provision (Provision)",
        "documentation": "Repressent the amount of reversal of provision (Provision).",
        "label": "Allowances For Expected Credit Loss Reversal Of Provision Provision"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmountOfRegulatoryAssistanceReceived1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmountOfRegulatoryAssistanceReceived1",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount received",
        "label": "Amount of Regulatory Assistance Received",
        "documentation": "Amount of regulatory assistance received from a federal regulatory agency in conjunction with either an acquisition of a troubled financial institution, transfer of nonperforming assets to a newly-formed entity, or other reorganization."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r944"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration amount",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r945",
      "r946",
      "r947"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r944"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r128",
      "r188",
      "r219",
      "r255",
      "r261",
      "r278",
      "r281",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r480",
      "r484",
      "r500",
      "r592",
      "r678",
      "r769",
      "r770",
      "r805",
      "r832",
      "r901",
      "r902",
      "r963"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r196",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r480",
      "r484",
      "r500",
      "r805",
      "r901",
      "r902",
      "r963"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Total Long-lived assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r480",
      "r484",
      "r500",
      "r901",
      "r902",
      "r963"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building improvement [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r14"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business combination",
        "label": "Business Combination, Consideration Transferred, Other",
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835"
     ]
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CNY",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RMB [Member]",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Bank balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r185",
      "r755"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r88",
      "r215"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease)/increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r88"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r323",
      "r324",
      "r739",
      "r893",
      "r898"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r740"
     ]
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Including Additional Paid in Capital [Member]",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829",
      "r866",
      "r867",
      "r871",
      "r948",
      "r1006",
      "r1009"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary share, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable",
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r672",
      "r717"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "verboseLabel": "Ordinary shares, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r664"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares, shares issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares ,shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r63",
      "r664",
      "r684",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r594",
      "r805"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT PLANS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income attributable to the shareholders of the Company",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r198",
      "r200",
      "r206",
      "r588",
      "r609",
      "r610"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r47",
      "r48",
      "r289",
      "r738"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r47",
      "r48",
      "r289",
      "r634",
      "r738"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r47",
      "r48",
      "r289",
      "r738",
      "r840"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r136"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Risks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RISKS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r47",
      "r48",
      "r289"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r47",
      "r48",
      "r289",
      "r738"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Consolidated Financial Statements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r171",
      "r172",
      "r173",
      "r223",
      "r838"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation and basis of preparation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r759"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ContractLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r402"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r402"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized to revenue during the year",
        "verboseLabel": "Recognized to revenue during the period",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerReceivableAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for deposits and other receivables",
        "label": "Contract with Customer, Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r384"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofContractLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Refund to customers",
        "label": "Contract with Customer, Refund Liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "nivf_ContributableWageRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ContributableWageRate",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution equivalent",
        "documentation": "Contributable wage rate.",
        "label": "Contributable Wage Rate"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ContributableWageTotalRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ContributableWageTotalRate",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution equivalent total",
        "documentation": "Contributable wage total rate.",
        "label": "Contributable Wage Total Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Convertible Debt, Noncurrent",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r500",
      "r769",
      "r901"
     ]
    },
    "us-gaap_CreditLossAdditionalImprovementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossAdditionalImprovementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "nivf_CurrentTaxProvisionCambodiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "CurrentTaxProvisionCambodiaMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision Cambodia [Member]",
        "label": "Current Tax Provision Cambodia Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_CurrentTaxProvisionKyrgyzstanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "CurrentTaxProvisionKyrgyzstanMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision Kyrgyzstan [Member]",
        "label": "Current Tax Provision Kyrgyzstan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r289"
     ]
    },
    "nivf_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two [Member]",
        "label": "Customer Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan to a SPAC I [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACI"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOAN TO A SPAC I",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r217",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r331",
      "r332",
      "r342",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r358",
      "r365",
      "r366",
      "r367",
      "r514"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual turnover ranges (in Riels)",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r54",
      "r55",
      "r117",
      "r119",
      "r223",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r862",
      "r894",
      "r895",
      "r896",
      "r953",
      "r954"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold rate",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) interest risk rate",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r223",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r862",
      "r894",
      "r895",
      "r896",
      "r953",
      "r954"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting service",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred initial public offering \u201cIPO\u201d cost",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable",
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable",
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2013 Net operating loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable",
      "http://www.newgenivf.com/role/ScheduleofComponentsofDeferredTaxAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposit Assets",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_DepositContractsLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositContractsLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsAndOtherReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DepositsAndOtherReceivableMember",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and Other Receivable [Member]",
        "label": "Deposits And Other Receivable Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DepositsPrepaymentOtherReceivablesAndDeferredIPOCostNetPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits, prepayment, other receivables and deferred IPO cost, net",
        "documentation": "Disclosure of accounting policy for deposits, prepayment, other receivables and deferred ipo cost, net.",
        "label": "Deposits Prepayment Other Receivables And Deferred IPOCost Net Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/PlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of plant and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r255",
      "r265",
      "r281",
      "r769",
      "r770"
     ]
    },
    "nivf_DirectorsRemunerationToMrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DirectorsRemunerationToMrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration to Mr. Siu Wing Fung, Alfred [Member]",
        "label": "Directors Remuneration To Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DirectorsRemunerationToMsFongHeiYueTinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DirectorsRemunerationToMsFongHeiYueTinaMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration to Ms. Fong Hei Yue, Tina [Member]",
        "label": "Directors Remuneration To Ms Fong Hei Yue Tina Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisaggregatedRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DisaggregatedRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregated Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DisaggregatedRevenuesDetailsScheduleofGeographicalInformationLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregated Revenues (Details) - Schedule of Geographical Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DisaggregatedRevenuesDetailsScheduleofGeographicalInformationTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregated Revenues (Details) - Schedule of Geographical Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue Information above is Based on the Locations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Information above is Based on the Locations",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "nivf_DissagregattedRevenuesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DissagregattedRevenuesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISAGGREGATED REVENUES",
        "documentation": "The entire disclosure for dissagregatted revenues.",
        "label": "Dissagregatted Revenues Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromShareholder": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueFromShareholder",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable",
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders",
        "documentation": "Due from shareholders.",
        "label": "Due From Shareholder"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueFromShareholders",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders",
        "documentation": "Due from shareholders.",
        "label": "Due From Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromShareholdersConsistOfTheFollowingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueFromShareholdersConsistOfTheFollowingAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders consist of the following:",
        "label": "Due From Shareholders Consist Of The Following Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueFromShareholdersConsistOfTheFollowingAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueFromShareholdersConsistOfTheFollowingAbstract0",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders consist of the following:",
        "label": "Due From Shareholders Consist Of The Following Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueToARelatedPartyConsistOfTheFollowingAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueToARelatedPartyConsistOfTheFollowingAbstract0",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to a related party consist of the following:",
        "label": "Due To ARelated Party Consist Of The Following Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueToRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due to Related Parties",
        "documentation": "Due to related parties.",
        "label": "Due To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_DueToShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "DueToShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to shareholders",
        "documentation": "The amount of due to shareholders.",
        "label": "Due To Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earning per share \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r246",
      "r248",
      "r250",
      "r251",
      "r252",
      "r254",
      "r475",
      "r478",
      "r497",
      "r498",
      "r589",
      "r611",
      "r761"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earning per share \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r248",
      "r250",
      "r251",
      "r252",
      "r254",
      "r475",
      "r478",
      "r497",
      "r498",
      "r589",
      "r611",
      "r761"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r253"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency translation on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax percentage",
        "verboseLabel": "progressive rates",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r793"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r934",
      "r935"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of tax",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r934",
      "r935"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions rate",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r864",
      "r934",
      "r935"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit tax percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r450",
      "r864",
      "r934"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated assessable profit rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to investment tax credit."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r934",
      "r936"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsOther",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r934",
      "r935"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r934",
      "r935"
     ]
    },
    "nivf_EmployeeBenefitPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EmployeeBenefitPlansDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r178",
      "r202",
      "r203",
      "r204",
      "r224",
      "r225",
      "r226",
      "r230",
      "r238",
      "r241",
      "r243",
      "r256",
      "r297",
      "r302",
      "r317",
      "r381",
      "r463",
      "r464",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r496",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r516",
      "r519",
      "r535",
      "r608",
      "r623",
      "r624",
      "r625",
      "r648",
      "r709"
     ]
    },
    "nivf_EquityDetailsScheduleofAdditionalPaidinCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EquityDetailsScheduleofAdditionalPaidinCapitalLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Additional Paid-in Capital [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EquityDetailsScheduleofAdditionalPaidinCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EquityDetailsScheduleofAdditionalPaidinCapitalTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Additional Paid-in Capital [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EquityDetailsScheduleofSubscriptionReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EquityDetailsScheduleofSubscriptionReceivablesLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Subscription Receivables [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EquityDetailsScheduleofSubscriptionReceivablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EquityDetailsScheduleofSubscriptionReceivablesTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of Subscription Receivables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional ordinary shares (in Shares)",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FFPGSHKLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "FFPGSHKLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FFPGS (HK) Limited [Member]",
        "label": "FFPGSHKLimited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities (in Dollars)",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, current",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, non-current",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance lease",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Axis]",
        "documentation": "Information by period in which financial asset is past due or not past due."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r307",
      "r776"
     ]
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Asset, Aging [Domain]",
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r307",
      "r776"
     ]
    },
    "nivf_FirstFertilityBishkekLLCFFBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "FirstFertilityBishkekLLCFFBMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility Bishkek LLC (\u201cFFB\u201d) [Member]",
        "label": "First Fertility Bishkek LLCFFBMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FirstFertilityPGSCenterLimitedFFCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "FirstFertilityPGSCenterLimitedFFCMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility PGS Center Limited (\u201cFFC\u201d) (Note) [Member]",
        "label": "First Fertility PGSCenter Limited FFCMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_FirstFertilityPhnomPenhLimitedFFPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "FirstFertilityPhnomPenhLimitedFFPPMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Fertility Phnom Penh Limited (\u201cFFPP\u201d) [Member]",
        "label": "First Fertility Phnom Penh Limited FFPPMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ForeignCurrencyExchangeRateTranslation": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ForeignCurrencyExchangeRateTranslation",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rates, period average",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate Translation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rates, period-end",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/PlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r689"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r127",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r500",
      "r763",
      "r769",
      "r872",
      "r874",
      "r875",
      "r876",
      "r877",
      "r901"
     ]
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "HK",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK SAR [Member]",
        "verboseLabel": "HK [Member]",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "currency_HKD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "HKD",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK [Member]",
        "label": "Hong Kong, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HKSARMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "HKSARMember",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HK SAR [Member]",
        "label": "HKSARMember"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HarcourtLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "HarcourtLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Harcourt Limited [Member]",
        "label": "Harcourt Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_HealthCareSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "HealthCareSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Scheme [Member]",
        "label": "Health Care Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_IVFTreatmentServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "IVFTreatmentServiceMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IVF treatment service [Member]",
        "label": "IVFTreatment Service Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ImpactOfCovid19Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ImpactOfCovid19Abstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of Covid-19 [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ImpactOfCovid19TextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ImpactOfCovid19TextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ImpactofCovid19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMPACT OF COVID-19",
        "documentation": "The entire disclosure impact of covid.",
        "label": "Impact Of Covid19 Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/PlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98",
      "r797"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r100"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before taxes",
        "terseLabel": "Income before taxes",
        "verboseLabel": "Income/(loss) before taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r123",
      "r127",
      "r590",
      "r604",
      "r763",
      "r769",
      "r872",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r443",
      "r444",
      "r454",
      "r460",
      "r793",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r443",
      "r444",
      "r454",
      "r460",
      "r793",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r941"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROVISION FOR INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r438",
      "r443",
      "r451",
      "r452",
      "r453",
      "r455",
      "r459",
      "r465",
      "r467",
      "r468",
      "r469",
      "r642",
      "r793"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Total provision for income taxes",
        "verboseLabel": "Income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r142",
      "r242",
      "r243",
      "r255",
      "r266",
      "r281",
      "r442",
      "r443",
      "r466",
      "r613",
      "r793"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r440",
      "r441",
      "r455",
      "r456",
      "r458",
      "r462",
      "r639"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r793",
      "r934"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expenses (credit) at the effective tax rates",
        "verboseLabel": "Tax expenses/(credit) at the effective tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r443",
      "r446",
      "r793"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r934"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on non-taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r934",
      "r936"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on late penalty provision",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r934",
      "r935"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleofIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect on utilization of tax losses",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r935"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated assessable profits (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r450",
      "r934"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r90",
      "r861",
      "r939",
      "r940"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposit, prepayment and other receivables, net",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r859"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to A SPAC I",
        "label": "Increase (Decrease) in Due to Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInFinanceReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInFinanceReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance lease liabilities",
        "label": "Increase (Decrease) in Finance Receivables",
        "documentation": "The increase (decrease) during the reporting period in outstanding loans including accrued interest."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r859"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposit and other receivables, net",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPensionPlanObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPensionPlanObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increased (decreased) amount",
        "label": "Increase (Decrease) in Obligation, Pension Benefits",
        "documentation": "Amount of increase (decrease) in obligation for pension benefits. Includes, but is not limited to, defined benefit or defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r891",
      "r892"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r362",
      "r368",
      "r781",
      "r782"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r212",
      "r213"
     ]
    },
    "nivf_InterestRateOtherVariablesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "InterestRateOtherVariablesPercentage",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate other variables, percentage",
        "documentation": "Interest rate other variables, percentage.",
        "label": "Interest Rate Other Variables Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORIES",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable0": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable",
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicines, consumables and reagents for clinical and laboratory analyses",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable",
      "http://www.newgenivf.com/role/ScheduleofInventoriesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventories, total",
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r756",
      "r805"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r184",
      "r194",
      "r308",
      "r309",
      "r310",
      "r553",
      "r760"
     ]
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issue discount",
        "label": "Investment Income, Amortization of Discount",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r264",
      "r281",
      "r769",
      "r858"
     ]
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r830",
      "r975"
     ]
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACIDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Principal amount",
        "label": "Investment Owned, Balance, Principal Amount",
        "documentation": "Amount of principal of investment owned."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r654",
      "r720",
      "r726",
      "r729",
      "r824"
     ]
    },
    "nivf_IssuanceOfSharesAdditionalpaidincapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "IssuanceOfSharesAdditionalpaidincapital",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "documentation": "Represent the amount of issuance of shares.",
        "label": "Issuance Of Shares Additionalpaidincapital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (Note 1)",
        "verboseLabel": "Issuance of shares",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "country_KG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "KG",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kyrgyzstan [Member]",
        "verboseLabel": "KYRGYZSTAN [Member]",
        "label": "KYRGYZSTAN"
       }
      }
     },
     "auth_ref": []
    },
    "country_KH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "KH",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambodia [Member]",
        "label": "CAMBODIA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_KHR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "KHR",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KHR [Member]",
        "label": "Cambodia, Riels"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_LatePenaltyProvisionKyrgyzstanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "LatePenaltyProvisionKyrgyzstanMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Late penalty provision Kyrgyzstan [Member]",
        "label": "Late Penalty Provision Kyrgyzstan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Lease Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r530"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and professional fee",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments rate",
        "label": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments under Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not later than 1 year",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 2 to 3 years",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 1 to 2 years",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r481",
      "r484",
      "r485",
      "r500",
      "r663",
      "r762",
      "r832",
      "r901",
      "r963",
      "r964"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r121",
      "r599",
      "r805",
      "r863",
      "r883",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r183",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r481",
      "r484",
      "r485",
      "r500",
      "r805",
      "r901",
      "r963",
      "r964"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r57",
      "r58",
      "r59",
      "r60",
      "r219",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r481",
      "r484",
      "r485",
      "r500",
      "r901",
      "r963",
      "r964"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_LoanToASPAC": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "LoanToASPAC",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to A SPAC I",
        "documentation": "Represents amount of loans to ASPAC.",
        "label": "Loan To ASPAC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.newgenivf.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent tax penalty",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r329",
      "r330",
      "r436",
      "r777"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r787",
      "r815",
      "r819",
      "r905",
      "r976",
      "r977",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_MajorityShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MajorityShareholderMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders",
        "label": "Majority Shareholder [Member]",
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementAndServiceFeesRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManagementAndServiceFeesRate",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheme calculated rate",
        "label": "Management and Service Fees, Rate",
        "documentation": "Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r176",
      "r177",
      "r325",
      "r326",
      "r327",
      "r328",
      "r408",
      "r436",
      "r499",
      "r551",
      "r621",
      "r622",
      "r633",
      "r655",
      "r656",
      "r719",
      "r722",
      "r724",
      "r725",
      "r728",
      "r750",
      "r751",
      "r775",
      "r783",
      "r792",
      "r798",
      "r799",
      "r800",
      "r801",
      "r816",
      "r903",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "nivf_MedHoldingsLimitedMedHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MedHoldingsLimitedMedHoldingsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Med Holdings Limited (\u201cMed Holdings\u201d) (Note) [Member]",
        "label": "Med Holdings Limited Med Holdings Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MedicalInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MedicalInstrumentsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Instruments [Member]",
        "verboseLabel": "Medical instruments [Member]",
        "label": "Medical Instruments Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r176",
      "r177",
      "r325",
      "r326",
      "r327",
      "r328",
      "r408",
      "r436",
      "r499",
      "r551",
      "r621",
      "r622",
      "r633",
      "r655",
      "r656",
      "r719",
      "r722",
      "r724",
      "r725",
      "r728",
      "r750",
      "r751",
      "r775",
      "r783",
      "r792",
      "r798",
      "r799",
      "r800",
      "r816",
      "r903",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r120",
      "r219",
      "r295",
      "r333",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r500",
      "r598",
      "r666"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles [Member]",
        "label": "Motor Vehicles Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MovementOfAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MovementOfAllowancesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement of Allowances [Member]",
        "label": "Movement Of Allowances Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Siu Wing Fung, Alfred (\u201cMr. Siu\u201d) and Ms. Fong Hei Yue, Tina (\u201cMs. Fong\u201d) [Member]",
        "verboseLabel": "Mr. Siu Wing Fung, Alfred [Member]",
        "label": "Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_MsFongHeiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "MsFongHeiMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ms. Fong, Hei [Member]",
        "label": "Ms Fong Hei Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r787",
      "r815",
      "r819",
      "r905",
      "r976",
      "r977",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to the shareholders of the Company",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r91",
      "r124",
      "r181",
      "r197",
      "r199",
      "r204",
      "r219",
      "r229",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r242",
      "r243",
      "r249",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r475",
      "r478",
      "r498",
      "r500",
      "r607",
      "r686",
      "r707",
      "r708",
      "r830",
      "r901"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: net loss attributable to non-controlling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r111",
      "r197",
      "r199",
      "r238",
      "r242",
      "r243",
      "r606",
      "r857"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements not yet adopted",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r180",
      "r227",
      "r228",
      "r231",
      "r232",
      "r244",
      "r245",
      "r290",
      "r298",
      "r299",
      "r473",
      "r474",
      "r476",
      "r478",
      "r491",
      "r495",
      "r533",
      "r536",
      "r537",
      "r555",
      "r556",
      "r557",
      "r627",
      "r628",
      "r629",
      "r630",
      "r632"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NewGenIvfLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "NewGenIvfLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NewGenivf Limited [Member]",
        "verboseLabel": "NewGenIvf Limited [Member]",
        "label": "New Gen Ivf Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NoVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "NoVendorsMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Vendors [Member]",
        "label": "No Vendors Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_NonControllingInterestsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "NonControllingInterestsPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "documentation": "Disclosure of accounting policy for non-controlling interests.",
        "label": "Non Controlling Interests Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r381",
      "r866",
      "r867",
      "r868",
      "r871",
      "r1009"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "nivf_NumberOfOperatingSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "NumberOfOperatingSegment",
     "presentation": [
      "http://www.newgenivf.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "documentation": "Number of segments operated by the entity. A operating segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number Of Operating Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r873"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.newgenivf.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OccupationalRiskSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OccupationalRiskSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Occupational Risk Scheme [Member]",
        "label": "Occupational Risk Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment [Member]",
        "verboseLabel": "Office equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Customer [Member]",
        "label": "One Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OneVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OneVendorsMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Vendors [Member]",
        "label": "One Vendors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r763",
      "r872",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments under Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable",
      "http://www.newgenivf.com/role/ScheduleofFutureMinimumPaymentsunderOperatingLeasesTable0",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total operating lease liabilities, net of interest",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Lease liabilities \u2013 current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable",
      "http://www.newgenivf.com/role/ScheduleofLeaseLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Lease liabilities \u2013 non-current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right-of-use assets (in Dollars)",
        "netLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "nivf_OperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "documentation": "The amount of operating lease right of use assets.",
        "label": "Operating Lease Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable",
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate \u2013 operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r804"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable",
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term \u2013 operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r804"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carry forward (in Dollars)",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND PRINCIPAL ACTIVITIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r109",
      "r635",
      "r636"
     ]
    },
    "nivf_OrganizationandPrincipalActivitiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OrganizationandPrincipalActivitiesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_OrganizationandPrincipalActivitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OrganizationandPrincipalActivitiesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilties and Other Payables",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherAdditionalCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAdditionalCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in paid-in capital",
        "label": "Other Additional Capital",
        "documentation": "Amount of additional paid-in capital (APIC) classified as other."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r595"
     ]
    },
    "us-gaap_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other Borrowings",
        "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r119"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r16",
      "r110"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r75",
      "r76",
      "r77",
      "r502",
      "r503",
      "r505"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: total comprehensive loss attributable to non-controlling interests",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r16",
      "r110"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r608"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND DEFERRED IPO COST, NET",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCustomerMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Customer [Member]",
        "label": "Other Customer [Member]",
        "documentation": "Customer classified as other."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1003"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r687",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expenses), net",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to a related party",
        "negatedLabel": "Due to a related party",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r805"
     ]
    },
    "us-gaap_OtherNoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Other Noncash Income Tax Expense",
        "documentation": "The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r889"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r673",
      "r770",
      "r973"
     ]
    },
    "nivf_OtherReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "OtherReceivablesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBalanceDuefromShareholdersTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shareholders amount",
        "documentation": "The amount of other receivables.",
        "label": "Other Receivables Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from shareholders",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSecuredFinancings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSecuredFinancings",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured funding amount",
        "label": "Other Secured Financings",
        "documentation": "Secured financing other than securities sold under agreements to repurchase and securities loaned."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total attributable to the shareholders of the Company",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listing fee paid",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "nivf_PaymentofInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "PaymentofInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "documentation": "Cash outflow during the period as interest paid.",
        "label": "Paymentof Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "nivf_PensionSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "PensionSchemeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Scheme [Member]",
        "label": "Pension Scheme Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_PercentageOfAllowanceOnDeferredTaxAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "PercentageOfAllowanceOnDeferredTaxAssets",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of allowance on deferred tax assets",
        "documentation": "Percentage of allowance on deferred tax assets.",
        "label": "Percentage Of Allowance On Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_PolicyholderDividendsRateOnPolicyEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyholderDividendsRateOnPolicyEarnings",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends percentage",
        "label": "Policyholder Dividends, Rate on Policy Earnings",
        "documentation": "The percentage of earnings allocable to participating policyholders based on earnings of such policies for payment of dividends."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement benefits",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_PreferredStockRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remuneration amount",
        "label": "Preferred Stock, Redemption Amount",
        "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r61"
     ]
    },
    "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for expected credit loss",
        "label": "Premium Receivable, Allowance for Credit Loss",
        "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r881",
      "r887",
      "r888",
      "r974"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable",
      "http://www.newgenivf.com/role/ScheduleofDepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deposits, prepayment, other receivables and deferred IPO cost, net",
        "terseLabel": "Deposits, prepayment and other receivables, net",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits, prepayment and other receivables, net",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r851"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProceedsFromAmountDueFromASPACI": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProceedsFromAmountDueFromASPACI",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amount due from A SPAC I",
        "documentation": "The cash outflow paid to A SPAC I.",
        "label": "Proceeds From Amount Due From ASPACI"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings, net",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received from secured funding",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount with related parties",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r174",
      "r285",
      "r554",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r753",
      "r785",
      "r814",
      "r816",
      "r817",
      "r820",
      "r821",
      "r849",
      "r899",
      "r900",
      "r905",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r174",
      "r285",
      "r554",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r753",
      "r785",
      "r814",
      "r816",
      "r817",
      "r820",
      "r821",
      "r849",
      "r899",
      "r900",
      "r905",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Audit fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r830",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow",
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r197",
      "r199",
      "r210",
      "r219",
      "r229",
      "r238",
      "r242",
      "r243",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r475",
      "r478",
      "r479",
      "r482",
      "r483",
      "r498",
      "r500",
      "r590",
      "r605",
      "r647",
      "r686",
      "r707",
      "r708",
      "r795",
      "r796",
      "r831",
      "r857",
      "r901"
     ]
    },
    "nivf_ProfitTaxDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProfitTaxDescription",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit tax rate description",
        "documentation": "Profit tax Description.",
        "label": "Profit Tax Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r530"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/PlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLANT AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r137",
      "r140",
      "r141"
     ]
    },
    "nivf_PropertyPlantAndEquipmentEstimatedUsefulLive": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLive",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "documentation": "Description of property plant and equipment estimated useful lives.",
        "label": "Property Plant And Equipment Estimated Useful Live"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r186",
      "r603"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Plant and equipment, Net",
        "terseLabel": "Plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r530",
      "r591",
      "r603",
      "r805"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant and Equipment, Net [Abstract]",
        "terseLabel": "At cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r137",
      "r140",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salvage value percentage",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/PlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r530"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofMovementAllowancesforExpectedCreditLossTable0",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable0",
      "http://www.newgenivf.com/role/ScheduleofMovementofAllowancesforExpectedCreditLossTable2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of expected credit losses",
        "verboseLabel": "Provision",
        "netLabel": "Reversal (provision) of provision",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r305"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision of expected credit loss allowance",
        "label": "Provision for Other Credit Losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r122"
     ]
    },
    "nivf_ProvisionforIncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProvisionforIncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for IncomeTaxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Significant Components of the Provisions for Income Taxes [Line Items]",
        "terseLabel": "Schedule of the Provisions for Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProvisionforIncomeTaxesDetailsScheduleoftheProvisionsforIncomeTaxesTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable",
      "http://www.newgenivf.com/role/ScheduleoftheProvisionsforIncomeTaxesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes (Details) - Schedule of the Provisions for Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ProvisionforIncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ProvisionforIncomeTaxesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r176",
      "r177",
      "r325",
      "r326",
      "r327",
      "r328",
      "r406",
      "r408",
      "r432",
      "r433",
      "r434",
      "r436",
      "r499",
      "r549",
      "r550",
      "r551",
      "r621",
      "r622",
      "r633",
      "r655",
      "r656",
      "r719",
      "r722",
      "r724",
      "r725",
      "r728",
      "r750",
      "r751",
      "r775",
      "r783",
      "r792",
      "r798",
      "r799",
      "r800",
      "r801",
      "r816",
      "r824",
      "r897",
      "r903",
      "r950",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/LeasesDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0",
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r176",
      "r177",
      "r325",
      "r326",
      "r327",
      "r328",
      "r406",
      "r408",
      "r432",
      "r433",
      "r434",
      "r436",
      "r499",
      "r549",
      "r550",
      "r551",
      "r621",
      "r622",
      "r633",
      "r655",
      "r656",
      "r719",
      "r722",
      "r724",
      "r725",
      "r728",
      "r750",
      "r751",
      "r775",
      "r783",
      "r792",
      "r798",
      "r799",
      "r800",
      "r801",
      "r816",
      "r824",
      "r897",
      "r903",
      "r950",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r71"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RelatedPartiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RelatedPartiesPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Disclosure of accounting policy for policy related parties.",
        "label": "Related Parties Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r407",
      "r541",
      "r542",
      "r593",
      "r600",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r718"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party",
        "verboseLabel": "Related Party",
        "netLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r541",
      "r542",
      "r543",
      "r544",
      "r593",
      "r600",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r718"
     ]
    },
    "us-gaap_RelatedPartyTaxExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTaxExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Balances and Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r962"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship",
        "verboseLabel": "Due from shareholders, Relationship",
        "netLabel": "Due to a related party, Relationship",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r189",
      "r529",
      "r531",
      "r532",
      "r540"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amount Due from and Due to Related Parties [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r690",
      "r691",
      "r694"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/RisksDetails",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r407",
      "r541",
      "r542",
      "r593",
      "r600",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r718",
      "r962"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY BALANCES AND TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r542",
      "r545",
      "r643",
      "r644",
      "r645",
      "r692",
      "r693",
      "r694",
      "r714",
      "r716"
     ]
    },
    "us-gaap_RepaymentsOfOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfOtherShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/LoantoaSPACIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan outstanding",
        "label": "Repayments of Other Short-Term Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r179",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r254",
      "r300",
      "r301",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r494",
      "r496",
      "r497",
      "r498",
      "r515",
      "r517",
      "r534",
      "r535",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r878"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r179",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r254",
      "r300",
      "r301",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r494",
      "r496",
      "r497",
      "r498",
      "r515",
      "r517",
      "r534",
      "r535",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r878"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r104",
      "r597",
      "r627",
      "r632",
      "r641",
      "r665",
      "r805"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r224",
      "r225",
      "r226",
      "r230",
      "r238",
      "r241",
      "r243",
      "r297",
      "r302",
      "r317",
      "r463",
      "r464",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478",
      "r486",
      "r488",
      "r489",
      "r492",
      "r496",
      "r516",
      "r519",
      "r623",
      "r625",
      "r648",
      "r1009"
     ]
    },
    "nivf_RevenueBenchmarkOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RevenueBenchmarkOneMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark One [Member]",
        "label": "Revenue Benchmark One Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RevenueBenchmarkTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RevenueBenchmarkTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark Two [Member]",
        "label": "Revenue Benchmark Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Contract Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r752"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ContractLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTRACT LIABILITIES",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r404"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Geographical Information",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "nivf_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue [Member]",
        "label": "Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RevenueRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RevenueRate",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract revenue rate",
        "documentation": "The percentage of revenue rate.",
        "label": "Revenue Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r205",
      "r219",
      "r255",
      "r262",
      "r263",
      "r277",
      "r281",
      "r285",
      "r287",
      "r289",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r500",
      "r590",
      "r769",
      "r901"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_RisksDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "RisksDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributable wage",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average wages per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r847",
      "r870"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported [Member]",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r224",
      "r226",
      "r229",
      "r230",
      "r233",
      "r234",
      "r243",
      "r254",
      "r471",
      "r475",
      "r476",
      "r477",
      "r478",
      "r494",
      "r496",
      "r497",
      "r515",
      "r517",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r841",
      "r843",
      "r844",
      "r845",
      "r869",
      "r878",
      "r884",
      "r885",
      "r949",
      "r959",
      "r960"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r244",
      "r409",
      "r837",
      "r870"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r71",
      "r293",
      "r882"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccruedLiabiltiesandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities and Other Payables",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfAccountsReceivableNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Receivable, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfAccountsReceivableNetOfAllowanceForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Receivable Net Of Allowance For Expected Credit Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAdditionalPaidInCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfAdditionalPaidInCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Paid-in Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAdditionalPaidinCapitalTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfAdditionalPaidinCapitalTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Paid-in Capital",
        "documentation": "Tabular disclosure of schedule of additional paid-in capital.",
        "label": "Schedule Of Additional Paidin Capital Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfAmountDueFromAndDueToRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amount Due From And Due To Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfBalanceDueFromShareholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfBalanceDueFromShareholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Balance Due from Shareholders [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfBusinessOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfBusinessOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Business Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfCompanySSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfCompanySSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SSubsidiaries Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Provisions for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r173",
      "r223",
      "r838"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Financial Statements",
        "label": "Condensed Financial Statements [Table Text Block]",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r865"
     ]
    },
    "nivf_ScheduleOfConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Currency Exchange Rates That Were Used In Preparing The Accompanying Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfCurrencyExchangeRatesThatWereUsedInPreparingTheAccompanyingConsolidatedFinancialStatementsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r793",
      "r934"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DisaggregatedRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Operations",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipment",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of the Plant and Equipment",
        "documentation": "Tabular disclosure of estimated useful lives of plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of The Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfEstimatedUsefulLivesOfThePlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of The Plant And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "nivf_ScheduleOfIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfIncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r72",
      "r73",
      "r74"
     ]
    },
    "nivf_ScheduleOfLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Liabilities",
        "documentation": "Tabular disclosure of schedule of lease liabilities.",
        "label": "Schedule Of Lease Liabilities Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementAllowancesForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfMovementAllowancesForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement Allowances For Expected Credit Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfMovementAllowancesForExpectedCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of movement Allowances for Expected Credit Loss",
        "documentation": "Tabular disclosure of movement allowances for expected credit loss.",
        "label": "Schedule Of Movement Allowances For Expected Credit Loss Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfMovementOfAllowancesForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movement of Allowances for Expected Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfMovementOfAllowancesForExpectedCreditLossTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement of Allowances for Expected Credit Loss",
        "label": "Schedule Of Movement Of Allowances For Expected Credit Loss Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/DepositsPrepaymentOtherReceivablesandDeferredIPOCostNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deposits, Prepayment, Other Receivables and Deferred IPO Cost, Net",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r530"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable",
      "http://www.newgenivf.com/role/ScheduleofAmountDuefromandDuetoRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r690",
      "r691",
      "r694"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount Due from and Due to Related Parties",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfRevenueInformationAboveIsBasedOnTheLocationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue Information Above Is Based On The Locations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Subscription Receivables",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "nivf_ScheduleOfSubscriptionReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfSubscriptionReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subscription Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s subsidiaries",
        "verboseLabel": "Schedule of Company\u2019s Subsidiaries",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTheBalanceDueFromShareholdersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfTheBalanceDueFromShareholdersTableTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Due from Shareholders",
        "documentation": "Tabular disclosure of balance due from shareholders.",
        "label": "Schedule Of The Balance Due From Shareholders Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfTheMovementOfAllowancesForExpectedCreditLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Movement of Allowances for Expected Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_ScheduleOfTheProvisionsForIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "ScheduleOfTheProvisionsForIncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Provisions For Income Taxes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SeazenResourcesInvestmentLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SeazenResourcesInvestmentLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seazen Resources Investment Limited [Member]",
        "label": "Seazen Resources Investment Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r152",
      "r154",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r287",
      "r288",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r651",
      "r652",
      "r653",
      "r721",
      "r723",
      "r727",
      "r733",
      "r737",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r754",
      "r786",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r824",
      "r905",
      "r976",
      "r977",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r267",
      "r268",
      "r269",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r289",
      "r764",
      "r767",
      "r768",
      "r769",
      "r771",
      "r773",
      "r774"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r284",
      "r287",
      "r765",
      "r766",
      "r772"
     ]
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentsGeographicalAreasAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Geographical Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement amount",
        "label": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.newgenivf.com/role/RisksDetails",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable",
      "http://www.newgenivf.com/role/ScheduleofOtherLeaseInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r804"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r216"
     ]
    },
    "us-gaap_SpecialAssessmentBond": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SpecialAssessmentBond",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special concession amount (in Baht)",
        "label": "Special Assessment Bond",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r54",
      "r972"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable0",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r63",
      "r68",
      "r69",
      "r178",
      "r202",
      "r203",
      "r204",
      "r224",
      "r225",
      "r226",
      "r230",
      "r238",
      "r241",
      "r243",
      "r256",
      "r297",
      "r302",
      "r317",
      "r381",
      "r463",
      "r464",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r496",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r516",
      "r519",
      "r535",
      "r608",
      "r623",
      "r624",
      "r625",
      "r648",
      "r709"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ProvisionforIncomeTaxesDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r152",
      "r154",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r287",
      "r288",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r651",
      "r652",
      "r653",
      "r721",
      "r723",
      "r727",
      "r733",
      "r737",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r754",
      "r786",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r824",
      "r905",
      "r976",
      "r977",
      "r978",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r256",
      "r519",
      "r554",
      "r638",
      "r649",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r825"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r244",
      "r409",
      "r837",
      "r839",
      "r870"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r256",
      "r292",
      "r519",
      "r554",
      "r638",
      "r649",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r825"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination (in Shares)",
        "verboseLabel": "Shares issued (in Shares)",
        "netLabel": "Ordinary shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r104"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r62",
      "r63",
      "r104",
      "r640",
      "r709",
      "r734"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business combination",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r63",
      "r68",
      "r69",
      "r104"
     ]
    },
    "nivf_StockIssuedDuringPeriodValueDirectorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "StockIssuedDuringPeriodValueDirectorsRemuneration",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAdditionalPaidinCapitalTable",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 remuneration",
        "documentation": "Value of shares of stock issued during the period to directors\u2019 remuneration.",
        "label": "Stock Issued During Period Value Directors Remuneration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r62",
      "r63",
      "r104",
      "r648",
      "r709",
      "r734",
      "r831"
     ]
    },
    "nivf_StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "StockIssuedDuringPeriodValueSettlementOfSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivables",
        "negatedLabel": "Settlement of subscription receivable (Note 2)",
        "negatedTerseLabel": "Settlement of subscription receivable",
        "documentation": "Value of shares issued during the period to settlement of subscription receivable.",
        "label": "Stock Issued During Period Value Settlement Of Subscription Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity attributable to the shareholders of the Company",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r69",
      "r96",
      "r666",
      "r684",
      "r710",
      "r711",
      "r805",
      "r832",
      "r863",
      "r883",
      "r951",
      "r1009"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r45",
      "r178",
      "r179",
      "r203",
      "r224",
      "r225",
      "r226",
      "r230",
      "r238",
      "r241",
      "r297",
      "r302",
      "r317",
      "r381",
      "r463",
      "r464",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r496",
      "r506",
      "r507",
      "r511",
      "r517",
      "r535",
      "r624",
      "r625",
      "r646",
      "r666",
      "r684",
      "r710",
      "r711",
      "r735",
      "r831",
      "r863",
      "r883",
      "r951",
      "r1009"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r218",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r493",
      "r712",
      "r715",
      "r736"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Total",
        "negatedLabel": "Subscription receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r62",
      "r63",
      "r68",
      "r717"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r713"
     ]
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubordinatedBorrowingInterestRate",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing cost rate",
        "label": "Subordinated Borrowing, Interest Rate",
        "documentation": "Stated interest rate of the subordinated debt."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SubscriptionReceivableIncludingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SubscriptionReceivableIncludingCommonStockMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable",
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Receivable including Common Stock [Member]",
        "label": "Subscription Receivable Including Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SubscriptionReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SubscriptionReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivables",
        "documentation": "Subscription receivables.",
        "label": "Subscription Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r548"
     ]
    },
    "nivf_SubsidiarieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SubsidiarieMember",
     "presentation": [
      "http://www.newgenivf.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [Member]",
        "label": "Subsidiarie Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SubsidiariesBackground": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SubsidiariesBackground",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background",
        "documentation": "Background.",
        "label": "Subsidiaries Background"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal activity",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose",
        "documentation": "Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership %",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofSubscriptionReceivablesTable0",
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.newgenivf.com/role/RelatedPartyBalancesandTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement of Allowances for Expected Credit Loss",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates that were Used in Preparing the Accompanying Consolidated Financial Statements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable",
      "http://www.newgenivf.com/role/ScheduleofEstimatedUsefulLivesofthePlantandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of the Plant and Equipment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary cash flow information:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SupplierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SupplierMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Member]",
        "label": "Supplier Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SuppliersFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SuppliersFourMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers Four [Member]",
        "label": "Suppliers Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SuppliersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SuppliersOneMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers One [Member]",
        "label": "Suppliers One Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_SurrogacyAncillaryCaringAndOtherServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "SurrogacyAncillaryCaringAndOtherServicesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable",
      "http://www.newgenivf.com/role/ScheduleofBusinessOperationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surrogacy, ancillary caring and other services [Member]",
        "label": "Surrogacy Ancillary Caring And Other Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_TH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "TH",
     "presentation": [
      "http://www.newgenivf.com/role/EmployeeBenefitPlansDetails",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable",
      "http://www.newgenivf.com/role/ScheduleofGeographicalInformationTable0",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable",
      "http://www.newgenivf.com/role/ScheduleofRevenueInformationaboveisBasedontheLocationsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thailand [Member]",
        "label": "THAILAND"
       }
      }
     },
     "auth_ref": []
    },
    "currency_THB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "THB",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofCurrencyExchangeRatesthatwereUsedinPreparingtheAccompanyingConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THB [Member]",
        "label": "Thailand, Baht"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.newgenivf.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r961"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_TranchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "TranchesMember",
     "presentation": [
      "http://www.newgenivf.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranches [Member]",
        "label": "Tranches Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_TransactionsWithRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "TransactionsWithRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with Related Parties",
        "documentation": "Transactions with related parties.",
        "label": "Transactions With Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.newgenivf.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r134",
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable",
      "http://www.newgenivf.com/role/ScheduleofPlantandEquipmentNetTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicle [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "nivf_VendorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "VendorTwoMember",
     "presentation": [
      "http://www.newgenivf.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor Two [Member]",
        "label": "Vendor Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WaiverOfRelatedPartyBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "WaiverOfRelatedPartyBalance",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Waiver of related party balance",
        "documentation": "Waiver of related party balance.",
        "label": "Waiver Of Related Party Balance"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "WaiverOfRelatedPartyBalanceOfMrSiuWingFungAlfredMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofConsolidatedFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver of related party balance of Mr. Siu Wing Fung, Alfred [Member]",
        "label": "Waiver Of Related Party Balance Of Mr Siu Wing Fung Alfred Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average shares outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r252"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.newgenivf.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average shares outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r252"
     ]
    },
    "nivf_WellImageLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "WellImageLimitedMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofCompanysSubsidiariesTable",
      "http://www.newgenivf.com/role/ScheduleofCompanyssubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Well Image Limited [Member]",
        "label": "Well Image Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "nivf_Within90DaysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.newgenivf.com/20240630",
     "localname": "Within90DaysMember",
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable",
      "http://www.newgenivf.com/role/ScheduleofAccountsReceivableNetofAllowanceforExpectedCreditLossTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 90 days [Member]",
        "label": "Within90 Days Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0": {
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
      "http://www.newgenivf.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation payable (Note 1)",
        "label": "Workers' Compensation Liability, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.N)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-5"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310/tableOfContent"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/326/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(14)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
